NCT Number,Study Title,Study URL,Study Status,Conditions,Interventions,Sponsor,Collaborators,Study Type
NCT07018752,"A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS",https://clinicaltrials.gov/study/NCT07018752,NOT_YET_RECRUITING,Peripheral T Cells Lymphoma (PTCL),DRUG: roginolisib|DRUG: Golcadomide|DRUG: azacitidine,The Lymphoma Academic Research Organisation,iOnctura|AbbVie|Bristol-Myers Squibb,INTERVENTIONAL
NCT06495723,Polyspecific Antibodies in Lymphoproliferative T-cell Disorders,https://clinicaltrials.gov/study/NCT06495723,RECRUITING,Peripheral T Cells Lymphoma (PTCL),DRUG: LIS1,Xenothera SAS,,INTERVENTIONAL
NCT05013372,CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05013372,UNKNOWN,T-cell Non-Hodgkin's Lymphoma,DRUG: CD147- CAR T cells,Peking University People's Hospital,,INTERVENTIONAL
NCT02520908,Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis,https://clinicaltrials.gov/study/NCT02520908,ACTIVE_NOT_RECRUITING,Epidermotropic T-cell Lymphomas,PROCEDURE: HSCT|OTHER: Standard Care,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT06176027,Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT06176027,RECRUITING,Relapsed Peripheral T-Cell Lymphomas|Refractory Peripheral T-Cell Lymphomas,DRUG: Azacytidine plus CAOLD regimen,"Navy General Hospital, Beijing",Chinese PLA General Hospital,INTERVENTIONAL
NCT02520219,Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study,https://clinicaltrials.gov/study/NCT02520219,UNKNOWN,Peripheral T-cell Lymphomas,DRUG: GDP|BIOLOGICAL: Endostar,"Nanjing NingQi Medicine Science and Technology Co., Ltd.",Jiangsu Cancer Institute & Hospital,INTERVENTIONAL
NCT02987244,Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02987244,UNKNOWN,T Cell Non-Hodgkin's Lymphoma,DRUG: Chidamide|DRUG: Cyclophosphamide|DRUG: Epirubicin|DRUG: Vindesine|DRUG: Etoposide|DRUG: Prednisone,Peking Union Medical College Hospital,Chinese PLA General Hospital|Peking University First Hospital|Peking University Third Hospital|Peking University Cancer Hospital & Institute|Tianjin Medical University Cancer Institute and Hospital,INTERVENTIONAL
NCT05105412,Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas,https://clinicaltrials.gov/study/NCT05105412,TERMINATED,Peripheral T-cell Lymphomas (PTCL),DRUG: Lenalidomide and Gemcitabine (Dose level 11)|DRUG: Lenalidomide and Gemcitabine (Dose level 21)|DRUG: Lenalidomide and Gemcitabine (Dose level 31)|DRUG: Lenalidomide and Gemcitabine (Dose level 41),"National Health Research Institutes, Taiwan",National Taiwan University Hospital|Chang Gung Memorial Hospital|National Cheng-Kung University Hospital|China Medical University Hospital,INTERVENTIONAL
NCT00972842,"Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)",https://clinicaltrials.gov/study/NCT00972842,TERMINATED,Peripheral T-Cell Non-Hodgkin's Lymphoma,"DRUG: Vorinostat, Lenalidomide",Arbeitsgemeinschaft medikamentoese Tumortherapie,Merck Sharp & Dohme LLC|Celgene Corporation,INTERVENTIONAL
NCT05316246,Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05316246,UNKNOWN,NK/T Cell Lymphoma Nos,DRUG: Brentuximab Vedotin in Combination with Tislelizumab,Shanghai Zhongshan Hospital,Takeda|BeiGene,INTERVENTIONAL
NCT00453427,Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00453427,COMPLETED,Peripheral T-cell Lymphomas,DRUG: Alemtuzumab (Campath-1H),Ontario Clinical Oncology Group (OCOG),"Sunnybrook Health Sciences Centre|Genzyme, a Sanofi Company",INTERVENTIONAL
NCT04484506,Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04484506,RECRUITING,NK/T Cell Lymphoma Nos,"DRUG: pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone",Peking University,Peking University Cancer Hospital & Institute|Peking University International Hospital|Hebei Medical University Fourth Hospital|Jiangxi Provincial Cancer Hospital,INTERVENTIONAL
NCT04231370,Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04231370,UNKNOWN,NK/T Cell Lymphoma Nos,DRUG: Sintilimab|DRUG: Lenalidomide,Beijing Tongren Hospital,,INTERVENTIONAL
NCT00655668,A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00655668,TERMINATED,T-cell Non-Hodgkin's Lymphoma,DRUG: Lenalidomide,Celgene,,INTERVENTIONAL
NCT00840385,"Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL)",https://clinicaltrials.gov/study/NCT00840385,UNKNOWN,T-Cell Lymphomas|Chemotherapy,DRUG: FAD,Fudan University,,INTERVENTIONAL
NCT04365036,"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)",https://clinicaltrials.gov/study/NCT04365036,RECRUITING,NK/T Cell Lymphoma Nos,DRUG: Toripalimab|DRUG: Pegaspargase|DRUG: Gemcitabine|DRUG: Oxaliplatin|RADIATION: Definitive intensity-modulated radiotherapy (IMRT),Sun Yat-sen University,,INTERVENTIONAL
NCT04127227,"Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type",https://clinicaltrials.gov/study/NCT04127227,RECRUITING,NK/T Cell Lymphoma Nos,"DRUG: sintilimab,pegaspargase,gemcitabine,oxaliplatin",Sun Yat-sen University,,INTERVENTIONAL
NCT03617224,Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome,https://clinicaltrials.gov/study/NCT03617224,WITHDRAWN,Cutaneous T-Cell Lymphomas,RADIATION: TSEBT|DRUG: TSEBT and pembrolizumab,University of Texas Southwestern Medical Center,,INTERVENTIONAL
NCT06224049,Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T,https://clinicaltrials.gov/study/NCT06224049,RECRUITING,T-cell Lymphoma,BIOLOGICAL: hNeo-T|DRUG: Cyclophosphamide|DRUG: Fludarabine,"BGI, China",Shenzhen University General Hospital,INTERVENTIONAL
NCT01878708,A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01878708,TERMINATED,T-Cell Lymphoma|Relapsed T-Cell Lymphoma|Refractory T-Cell Lymphoma,DRUG: PEG-L-asparaginase|DRUG: Dexamethasone acetate,Dana-Farber Cancer Institute,"Leadiant Biosciences, Inc.",INTERVENTIONAL
NCT05996185,Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma,https://clinicaltrials.gov/study/NCT05996185,RECRUITING,T Cell Lymphoma,DRUG: Mogamulizumab|DRUG: DA-EPOCH Protocol,Yale University,"Kyowa Kirin, Inc.",INTERVENTIONAL
NCT06756308,A Study of Enasidenib in People With T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06756308,RECRUITING,T-cell Lymphoma,DRUG: Enasidenib|DRUG: Rituximab,Memorial Sloan Kettering Cancer Center,Bristol-Myers Squibb|The Leukemia and Lymphoma Society,INTERVENTIONAL
NCT05313243,Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05313243,RECRUITING,T-Cell Lymphoma,DRUG: Brentuximab vedotin|DRUG: Pembrolizumab,Yale University,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT04502446,A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM),https://clinicaltrials.gov/study/NCT04502446,TERMINATED,T Cell Lymphoma,BIOLOGICAL: CTX130,CRISPR Therapeutics AG,,INTERVENTIONAL
NCT05367856,Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05367856,UNKNOWN,T Cell Lymphoma,DRUG: Chidamide combined with BEAM,Ruijin Hospital,,INTERVENTIONAL
NCT05886478,A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin,https://clinicaltrials.gov/study/NCT05886478,COMPLETED,T-Cell Lymphoma,DRUG: No intervention,Takeda,,OBSERVATIONAL
NCT04840875,Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma,https://clinicaltrials.gov/study/NCT04840875,COMPLETED,T Cell Lymphoma|T-cell Leukemia,BIOLOGICAL: chimeric antigen receptor T cell treatment,Beijing Boren Hospital,,INTERVENTIONAL
NCT05230680,Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS),https://clinicaltrials.gov/study/NCT05230680,RECRUITING,T Cell Lymphoma,DRUG: ACHOP,Won Seog Kim,,INTERVENTIONAL
NCT05010005,A Study of Ruxolitinib and Duvelisib in People With Lymphoma,https://clinicaltrials.gov/study/NCT05010005,RECRUITING,T-cell Lymphomas|NK-Cell Lymphomas|T-cell Prolymphocytic Leukemia|T-cell Large Granular Lymphocyte Leukemia,DRUG: Ruxolitinib|DRUG: Duvelisib,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT04331119,Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT04331119,ACTIVE_NOT_RECRUITING,T-Cell Lymphoma,DRUG: Duvelisib|PROCEDURE: Peripheral blood draw,Washington University School of Medicine,SecuraBio,INTERVENTIONAL
NCT05983965,Study of Tazemetostat in Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT05983965,RECRUITING,T-cell Lymphoma,DRUG: Tazemetostat,University of Alabama at Birmingham,,INTERVENTIONAL
NCT05442554,A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05442554,COMPLETED,T-Cell Lymphoma,DRUG: Brentuximab vedotin,Takeda,,INTERVENTIONAL
NCT06534060,MB-105 in Patients With CD5 Positive T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06534060,RECRUITING,"Lymphoma, T-Cell",BIOLOGICAL: Genetic: MB-105,March Biosciences Inc,,INTERVENTIONAL
NCT04928105,Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma,https://clinicaltrials.gov/study/NCT04928105,UNKNOWN,"Lymphoma, T-Cell",BIOLOGICAL: Senl-T7,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT04334174,Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas,https://clinicaltrials.gov/study/NCT04334174,WITHDRAWN,T Cell Lymphoma,DRUG: Brentuximab Vedotin,University of Kansas Medical Center,Seagen Inc.,INTERVENTIONAL
NCT05075460,"Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT05075460,RECRUITING,T-cell Lymphoma,"DRUG: Tucidinostat, Azacitidine combined with CHOP",Peking Union Medical College Hospital,,INTERVENTIONAL
NCT04712864,Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04712864,ACTIVE_NOT_RECRUITING,T-Cell Lymphoma|Peripheral T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Refractory|Cutaneous T-Cell Lymphoma Recurrent|Peripheral T-Cell Lymphoma Recurrent,BIOLOGICAL: LB1901,Legend Biotech USA Inc,,INTERVENTIONAL
NCT03952078,A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03952078,ACTIVE_NOT_RECRUITING,T-cell Lymphoma,DRUG: CPI-818,"Corvus Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT06362148,Circulating Tumor DNA in Peripheral T-cell Lymphomas,https://clinicaltrials.gov/study/NCT06362148,RECRUITING,Peripheral T-cell Lymphoma|NK/T-Cell Lymphoma,"DIAGNOSTIC_TEST: Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay|DIAGNOSTIC_TEST: 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)",University of Aarhus,Aarhus University Hospital,OBSERVATIONAL
NCT03770000,Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03770000,COMPLETED,T Cell Lymphoma,DRUG: Tenalisib|DRUG: Romidepsin,Rhizen Pharmaceuticals SA,,INTERVENTIONAL
NCT00161239,LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00161239,TERMINATED,T-Cell Lymphoma,"DRUG: Doxil, Methotrexate, L-Asparaginase, Prednisone",University of Medicine and Dentistry of New Jersey,"Ortho Biotech, Inc.",INTERVENTIONAL
NCT02274584,CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273),https://clinicaltrials.gov/study/NCT02274584,UNKNOWN,Lymphomas,GENETIC: Anti-CD30 CAR T cells,Peking University,University of Florida,INTERVENTIONAL
NCT01561833,A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT01561833,COMPLETED,T Cell Lymphoma,DRUG: Sorafenib,Yale University,,INTERVENTIONAL
NCT02676778,Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02676778,COMPLETED,Peripheral T-cell Lymphoma|Cutaneous T-cell Lymphoma,DRUG: E7777,"Eisai Co., Ltd.",,INTERVENTIONAL
NCT03207789,T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients,https://clinicaltrials.gov/study/NCT03207789,UNKNOWN,T-cell Lymphoma|NK-Cell Lymphoma|T-cell Lymphoma Adults,,Grupo de Estudos Multicentricos em Onco-Hematologia,Takeda,OBSERVATIONAL
NCT00959686,Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00959686,COMPLETED,T-cell Lymphoma,DRUG: Bendamustine,French Innovative Leukemia Organisation,Mundipharma Pte Ltd.,INTERVENTIONAL
NCT05137847,A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study),https://clinicaltrials.gov/study/NCT05137847,COMPLETED,"Lymphoma, T-cell, Peripheral|Lymphoma, T-cell, Cutaneous",DRUG: Remitoro,Eisai Inc.,,OBSERVATIONAL
NCT00798096,Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00798096,COMPLETED,T Cell Lymphoma,DRUG: Fostamatinib Disodium,Rigel Pharmaceuticals,,INTERVENTIONAL
NCT04973527,LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor,https://clinicaltrials.gov/study/NCT04973527,TERMINATED,T Cell Lymphoma|T-cell Leukemia,DRUG: Efficacy of LCAR-T2C CAR-T cells,Beijing Boren Hospital,Nanjing Legend Biotech Co.,INTERVENTIONAL
NCT03552692,Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03552692,TERMINATED,T-Cell Lymphoma Relapsed|T-Cell Lymphoma Refractory,DRUG: Venetoclax,Fondazione Italiana Linfomi - ETS,,INTERVENTIONAL
NCT06035497,"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)",https://clinicaltrials.gov/study/NCT06035497,RECRUITING,Relapsed or Refractory T-cell Lymphomas,DRUG: BMS-986369,Bristol-Myers Squibb,,INTERVENTIONAL
NCT04045470,A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04045470,RECRUITING,Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma,DEVICE: Microdevices|OTHER: Standard of care therapy|OTHER: Standard of care systemic therapy,Dana-Farber Cancer Institute,,INTERVENTIONAL
NCT06692452,Tazemetostat Plus CHOP in 1L T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06692452,RECRUITING,Lymphoma|Peripheral T Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma,DRUG: Tazemetostat|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Cytoxan|DRUG: Carmustine|DRUG: Etoposide|DRUG: Cytarabine|DRUG: Melphalan,"Eric Jacobsen, MD",Ipsen,INTERVENTIONAL
NCT00974324,Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT00974324,UNKNOWN,T Cell Lymphoma,DRUG: endostar and CHOP,Fudan University,,INTERVENTIONAL
NCT04162340,CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies,https://clinicaltrials.gov/study/NCT04162340,UNKNOWN,T Cell Lymphoma in Relapse|Refractory T-Cell Lymphoma,BIOLOGICAL: CD4 CAR T cells,iCell Gene Therapeutics,iCAR Bio Therapeutics Ltd.|Peking University Shenzhen Hospital,INTERVENTIONAL
NCT02424045,"Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT02424045,COMPLETED,T-cell Lymphoma,"DRUG: BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)",Samsung Medical Center,,INTERVENTIONAL
NCT01430013,Trial of Endostar Combined With CHOPT for T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01430013,UNKNOWN,T Cell Lymphoma,DRUG: Endostar and CHOPT,Tianjin Medical University Cancer Institute and Hospital,"Simcere Pharmaceutical Co., Ltd",INTERVENTIONAL
NCT01553786,Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL),https://clinicaltrials.gov/study/NCT01553786,COMPLETED,T-cell Lymphoma,DRUG: Lenalidomide,The Lymphoma Academic Research Organisation,,INTERVENTIONAL
NCT04233697,Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04233697,WITHDRAWN,"Lymphoma, T-Cell",DRUG: Copanlisib|DRUG: Romidepsin,Columbia University,Bayer,INTERVENTIONAL
NCT04264078,Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies,https://clinicaltrials.gov/study/NCT04264078,UNKNOWN,T-cell Leukemia|T-cell Lymphoma,BIOLOGICAL: CD7 UCAR-T cells|DRUG: Fludarabine|DRUG: Cytoxan|DRUG: Melphalan,Xinqiao Hospital of Chongqing,"Gracell Biotechnologies (Shanghai) Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Second Affiliated Hospital of Chongqing Medical University|The Affiliated Hospital Of Guizhou Medical University|Central South University|First Affiliated Hospital of Kunming Medical University|The General Hospital of Western Theater Command|Second Affiliated Hospital of Xi'an Jiaotong University|Nanfang Hospital, Southern Medical University|Fujian Medical University Union Hospital|The First Affiliated Hospital of Anhui Medical University|Tang-Du Hospital",INTERVENTIONAL
NCT00322985,A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00322985,COMPLETED,T-cell Lymphoma,DRUG: Lenalidomide,AHS Cancer Control Alberta,Celgene Corporation|Alberta Cancer Foundation,INTERVENTIONAL
NCT05772728,Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL),https://clinicaltrials.gov/study/NCT05772728,UNKNOWN,T Cell Lymphoma,DRUG: Cidapenem combined with azacitidine and mitoxantrone liposome (CAM) regimen,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT03829540,CD4CAR for CD4+ Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT03829540,RECRUITING,T-cell Lymphoma|T-cell Leukemia,BIOLOGICAL: CD4CAR,Huda Salman,iCell Gene Therapeutics,INTERVENTIONAL
NCT03703375,Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03703375,ACTIVE_NOT_RECRUITING,"Lymphoma, T-Cell",DRUG: Azacitidine|DRUG: Romidepsin|DRUG: Gemcitabine,Celgene,,INTERVENTIONAL
NCT06151106,Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06151106,RECRUITING,Peripheral T Cell Lymphoma|Relapsed Peripheral T-Cell Lymphoma|Refractory T-Cell Lymphoma,DRUG: Chidamide combined with Duvillisib,The First Affiliated Hospital of Xiamen University,Fujian Cancer Hospital|Zhangzhou Affiliated Hospital of Fujian Medical University|Dongguan People's Hospital|Huizhou Municipal Central Hospital|The First Affiliated Hospital with Nanjing Medical University|Sun Yat-sen University|Shanxi Province Cancer Hospital,INTERVENTIONAL
NCT03046953,Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03046953,COMPLETED,T-Cell Lymphoma Relapsed|T-Cell Lymphoma Refractory,DRUG: Avelumab,University of Birmingham,Bloodwise|Pfizer,INTERVENTIONAL
NCT02588651,A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL),https://clinicaltrials.gov/study/NCT02588651,COMPLETED,T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepato-splenic T-cell Lymphoma|Adult T-cell Leukemia/Lymphoma|Enteropathy Associated T-cell Lymphoma|NK T-cell Lymphoma,DRUG: Brentuximab vedotin,Deepa Jagadeesh,,INTERVENTIONAL
NCT04251065,"Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH",https://clinicaltrials.gov/study/NCT04251065,TERMINATED,Refractory T-Cell Lymphoma|Relapsed T-Cell Lymphoma,DRUG: Daratumumab,Fondazione Italiana Linfomi - ETS,,INTERVENTIONAL
NCT00877656,HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00877656,COMPLETED,T Cell Lymphoma,BIOLOGICAL: HuMax-CD4,Emergent BioSolutions,,INTERVENTIONAL
NCT03672084,Allo-HSCT as First-line Consolidation in High-risk PTCL,https://clinicaltrials.gov/study/NCT03672084,UNKNOWN,T Cell Lymphoma,,Peking University People's Hospital,,OBSERVATIONAL
NCT02158975,"Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas",https://clinicaltrials.gov/study/NCT02158975,COMPLETED,"Lymphoma, T-Cell",DRUG: MLN9708,University of Michigan Rogel Cancer Center,,INTERVENTIONAL
NCT04425070,A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04425070,ACTIVE_NOT_RECRUITING,Peripheral T-cell Lymphoma|NK/T-cell Lymphoma,COMBINATION_PRODUCT: ICE [ifosfamide+carboplatin+etoposide]|COMBINATION_PRODUCT: GEMOX [gemcitabine+oxaliplatin]|COMBINATION_PRODUCT: Tislelizumab,Antengene Corporation,,INTERVENTIONAL
NCT00893516,CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma,https://clinicaltrials.gov/study/NCT00893516,TERMINATED,T-cell Lymphoma,BIOLOGICAL: CHOP + CD4|DRUG: CHOP,Emergent BioSolutions,,INTERVENTIONAL
NCT00418535,Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00418535,COMPLETED,"Lymphoma, T-Cell","DRUG: Concurrent Radiotherapy (RT)/cisplatin, VIPD",Samsung Medical Center,Korea University Anam Hospital|Asan Medical Center|Gyeongsang National University Hospital,INTERVENTIONAL
NCT05773040,A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas,https://clinicaltrials.gov/study/NCT05773040,RECRUITING,Lymphomas|B-cell Lymphomas,DRUG: JV-213|PROCEDURE: Leukapheresis,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT00007345,Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00007345,COMPLETED,Cutaneous T Cell Lymphoma|Peripheral T Cell Lymphoma,DRUG: Romidepsin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01854112,Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01854112,UNKNOWN,T-cell Lymphoma,,Far Eastern Memorial Hospital,,OBSERVATIONAL
NCT06699771,"Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies",https://clinicaltrials.gov/study/NCT06699771,RECRUITING,"Lymphoma, T-Cell",DRUG: GCC2005|DRUG: Cyclophosphamide|DRUG: Fludarabine,GC Cell Corporation,"Artiva Biotherapeutics, Inc.",INTERVENTIONAL
NCT02341014,"Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas",https://clinicaltrials.gov/study/NCT02341014,COMPLETED,T-cell Lymphomas|Relapsed or Refractory,DRUG: Carfilzomib|DRUG: Romidepsin|DRUG: Lenalidomide,Memorial Sloan Kettering Cancer Center,University of Nebraska,INTERVENTIONAL
NCT04083495,CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04083495,RECRUITING,Peripheral T Cell Lymphoma,BIOLOGICAL: ATLCAR.CD30 T cells|DRUG: Bendamustine|DRUG: Fludarabine|DRUG: Cyclophosphamide,UNC Lineberger Comprehensive Cancer Center,,INTERVENTIONAL
NCT06698003,A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1,https://clinicaltrials.gov/study/NCT06698003,RECRUITING,"T-Cell Leukemia/Lymphoma, Adult|T-cell Leukemia/Lymphoma|T-cell Leukemia|Lymphoma",DRUG: Mogamulizumab,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT06647329,CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors,https://clinicaltrials.gov/study/NCT06647329,NOT_YET_RECRUITING,CAR-T Cell Therapy|Lymphomas,BIOLOGICAL: CAR-T Therapy,Mingzhi Zhang,,INTERVENTIONAL
NCT02567656,Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02567656,COMPLETED,"Lymphoma, T-Cell, Peripheral|Lymphoma, T-Cell, Cutaneous",DRUG: RP6530,Rhizen Pharmaceuticals SA,,INTERVENTIONAL
NCT00069238,Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00069238,COMPLETED,"Lymphoma, T-Cell|Lymphoma, Extranodal NK-T-Cell",BIOLOGICAL: Alemtuzumab (Campath)|DRUG: EPOCH,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06633341,Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma,https://clinicaltrials.gov/study/NCT06633341,RECRUITING,T-lymphoblastic Lymphoma,BIOLOGICAL: CD5 CAR T-cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT06089941,Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas,https://clinicaltrials.gov/study/NCT06089941,NOT_YET_RECRUITING,Peripheral T Cell Lymphoma,OTHER: circulating tumoral DNA detection,Centre Henri Becquerel,,OBSERVATIONAL
NCT02783625,Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,https://clinicaltrials.gov/study/NCT02783625,ACTIVE_NOT_RECRUITING,Lymphoma|Relapsed/Refractory T-cell Lymphomas,DRUG: Romidepsin|DRUG: Bortezomib|DRUG: duvelisib,Memorial Sloan Kettering Cancer Center,Dana-Farber Cancer Institute|Stanford University,INTERVENTIONAL
NCT05463263,A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT05463263,RECRUITING,"Lymphoma, B-Cell|Lymphoma, T-Cell",DRUG: STP938,"Step Pharma, SAS",,INTERVENTIONAL
NCT05444712,Transplantation After Complete Response In Patients With T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05444712,RECRUITING,Peripheral T Cell Lymphoma,PROCEDURE: Chemotherapy + follow up|PROCEDURE: Chemotherapy + ASCT + follow up,Hospices Civils de Lyon,,INTERVENTIONAL
NCT04828174,Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies,https://clinicaltrials.gov/study/NCT04828174,SUSPENDED,Peripheral T Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Lymphoma|Acute T Cell Leukemia|T-lymphoblastic Lymphoma,DRUG: anti-TRBC1 CAR-T cell therapy,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT04234048,Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04234048,RECRUITING,"T-cell Lymphoma|Cutaneous/Peripheral T-Cell Lymphoma|Peripheral T-cell Lymphoma|Peripheral T-Cell Lymphoma, Not Classified|Primary Cutaneous T-cell Lymphoma|Cutaneous T-Cell Lymphoma, Unspecified|Cutaneous T-cell Lymphoma|Follicular T-Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Sézary's Disease|Mycosis Fungoides",DRUG: Fenretinide,"SciTech Development, Inc.",,INTERVENTIONAL
NCT05934864,"Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)",https://clinicaltrials.gov/study/NCT05934864,RECRUITING,Peripheral T Cell Lymphoma,GENETIC: 84-gene penal,Ruijin Hospital,"West China Hospital|Shandong Provincial Hospital|RenJi Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Tianjin Medical University Cancer Institute and Hospital",OBSERVATIONAL
NCT06433362,CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06433362,RECRUITING,Peripheral T Cell Lymphoma,DRUG: CMOEP,Tianjin Medical University Cancer Institute and Hospital,,INTERVENTIONAL
NCT07000617,"A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma",https://clinicaltrials.gov/study/NCT07000617,RECRUITING,NK/T Cell Lymphoma,DRUG: DAPT regimen plus radiotherapy,Peking University Cancer Hospital & Institute,Peking University International Hospital|Chinese Academy of Medical Sciences,INTERVENTIONAL
NCT06712173,Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT06712173,NOT_YET_RECRUITING,Peripheral T Cell Lymphoma,DRUG: linperlisib and SHR2554,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT06561048,"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma",https://clinicaltrials.gov/study/NCT06561048,RECRUITING,"Peripheral T-Cell Lymphoma, Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Follicular T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Systemic Anaplastic Large Cell Lymphoma|Lymphoma, T-Cell, Peripheral|Lymphoma, T-Cell",DRUG: Soquelitinib|DRUG: Belinostat|DRUG: Pralatrexate,"Corvus Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT05398614,SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies,https://clinicaltrials.gov/study/NCT05398614,UNKNOWN,"T-ALL|Lymphoma, T-Cell",BIOLOGICAL: SENL101,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT03302728,Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT03302728,COMPLETED,"Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Hodgkin Lymphoma",DRUG: Lenalidomide 15mg|DRUG: Brentuximab Vedotin 1.8 mg/Kg,"Peter MacCallum Cancer Centre, Australia",,INTERVENTIONAL
NCT04899414,"Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma",https://clinicaltrials.gov/study/NCT04899414,UNKNOWN,NK/T Cell Lymphoma,"DRUG: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab",Peking University,Peking University Cancer Hospital & Institute,INTERVENTIONAL
NCT05900089,Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma,https://clinicaltrials.gov/study/NCT05900089,NOT_YET_RECRUITING,Peripheral T Cell Lymphoma,DRUG: SHR0302,Henan Cancer Hospital,,INTERVENTIONAL
NCT06757387,Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06757387,NOT_YET_RECRUITING,Peripheral T-cell Lymphoma,DRUG: chidamide and golidocitinib,Peking University Cancer Hospital & Institute,,INTERVENTIONAL
NCT06385522,"A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System",https://clinicaltrials.gov/study/NCT06385522,NOT_YET_RECRUITING,NHL|Cutaneous T Cell Lymphoma|Peripheral T-cell Lymphoma,BIOLOGICAL: BITR2101,Boston Immune Technologies and Therapeutics,,INTERVENTIONAL
NCT03021057,Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas,https://clinicaltrials.gov/study/NCT03021057,UNKNOWN,T-Cell Lymphoma|NK-Cell Lymphoma,DRUG: pembrolizumab,The University of Hong Kong,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT00880867,Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma,https://clinicaltrials.gov/study/NCT00880867,TERMINATED,B Cell Lymphoma|T Cell Lymphoma,DRUG: Poly-ICLC,Nevada Cancer Institute,CLL Topics,INTERVENTIONAL
NCT05179213,Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05179213,UNKNOWN,Angioimmunoblastic T-cell Lymphoma,DRUG: Azacitidine|DRUG: Chidamide,Peking Union Medical College Hospital,Beijing Longfu Hospital,INTERVENTIONAL
NCT06422247,Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy,https://clinicaltrials.gov/study/NCT06422247,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Systemic therapy,Bristol-Myers Squibb,,OBSERVATIONAL
NCT05979792,Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT05979792,NOT_YET_RECRUITING,Peripheral T Cell Lymphoma,DRUG: CAR-T Therapy,Zhao Weili,,INTERVENTIONAL
NCT02247609,Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas,https://clinicaltrials.gov/study/NCT02247609,UNKNOWN,B-cell Lymphomas,GENETIC: Anti-CD19 CAR T cells,Peking University,University of Florida,INTERVENTIONAL
NCT06511895,AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27),https://clinicaltrials.gov/study/NCT06511895,RECRUITING,Peripheral T Cell Lymphoma,DRUG: AZD4205,Dizal Pharmaceuticals,,INTERVENTIONAL
NCT04040491,"PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT04040491,UNKNOWN,Peripheral T-cell Lymphoma,"DRUG: PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine",Mingzhi Zhang,,INTERVENTIONAL
NCT02309580,Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02309580,COMPLETED,T-cell Lymphoma|Relapsed and Refractory T-cell Lymphoma,DRUG: Ibrutinib,Memorial Sloan Kettering Cancer Center,"Ohio State University|Pharmacyclics LLC.|Janssen Biotech, Inc.",INTERVENTIONAL
NCT05083208,PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05083208,TERMINATED,Peripheral T-Cell Lymphoma,DRUG: Parsaclisib|DRUG: Chidamide,Henan Cancer Hospital,,INTERVENTIONAL
NCT03964480,Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.,https://clinicaltrials.gov/study/NCT03964480,RECRUITING,Peripheral T-Cell Lymphoma,,Associazione Angela Serra per la ricerca sul cancro,,OBSERVATIONAL
NCT06149390,ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06149390,COMPLETED,T-cell Lymphoma Adults,DRUG: consolidation with ASCT,Huazhong University of Science and Technology,Peking University People's Hospital|Ruijin Hospital|West China Hospital,OBSERVATIONAL
NCT06511869,AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26),https://clinicaltrials.gov/study/NCT06511869,ACTIVE_NOT_RECRUITING,Peripheral T-cell Lymphoma,DRUG: AZD4205,Dizal Pharmaceuticals,,INTERVENTIONAL
NCT06382844,Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL,https://clinicaltrials.gov/study/NCT06382844,RECRUITING,Cutaneous T-Cell Lymphoma,DIAGNOSTIC_TEST: Detection and quantitation of (blood) tumor cells in patients with mycosis fungoides (MF) / Sézary syndrome (SS).,Instituto de Investigación Biomédica de Salamanca,Carlos III Health Institute,OBSERVATIONAL
NCT06160843,Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06160843,RECRUITING,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,"DRUG: Pembrolizumab IV infusion Q3W, with daily oral Olaparib.","National Cancer Centre, Singapore","Merck Sharp & Dohme LLC|National Medical Research Council (NMRC), Singapore",INTERVENTIONAL
NCT03161223,"Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",https://clinicaltrials.gov/study/NCT03161223,UNKNOWN,"Lymphoma, T-Cell",DRUG: Durvalumab|DRUG: Pralatrexate|DRUG: Romidepsin|DRUG: 5-Azacitidine,University of Virginia,,INTERVENTIONAL
NCT04512534,Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04512534,RECRUITING,Peripheral T-cell Lymphoma,DRUG: PD-1 antibody+ HDAC inhibitor,Fudan University,,INTERVENTIONAL
NCT00699296,Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT00699296,TERMINATED,"Cutaneous T-Cell Lymphoma|Leukemia-Lymphoma, Adult T-Cell",DRUG: Panobinostat (LBH589),Novartis Pharmaceuticals,,INTERVENTIONAL
NCT04480099,Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04480099,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: CHOP|DRUG: CHOP+X,Ruijin Hospital,,INTERVENTIONAL
NCT06550336,A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).,https://clinicaltrials.gov/study/NCT06550336,ACTIVE_NOT_RECRUITING,Peripheral T Cell Lymphoma,DRUG: Chidamide,The First Hospital of Jilin University,,INTERVENTIONAL
NCT01169298,"A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT01169298,COMPLETED,Adult T-cell Leukemia-Lymphoma|Peripheral T-cell Lymphoma,DRUG: Lenalidomide,Celgene,,INTERVENTIONAL
NCT06173999,A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06173999,RECRUITING,Peripheral T-cell Lymphoma,DRUG: SHR2554/CHOP|DRUG: SHR2554/CHOEP,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL
NCT05495100,"A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT05495100,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: Mitoxantrone liposome、Chidamide、Azacitidine,"Second Affiliated Hospital, School of Medicine, Zhejiang University",Ningbo No. 1 Hospital|Jinhua Central Hospital|Huizhou Municipal Central Hospital,INTERVENTIONAL
NCT06436677,A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06436677,RECRUITING,Cutaneous T-Cell Lymphoma/Mycosis Fungoides|Cutaneous T Cell Lymphoma,OTHER: molecular subtype based treatment,Peking University First Hospital,Peking University Third Hospital|Peking University Cancer Hospital & Institute,OBSERVATIONAL
NCT05458180,CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05458180,UNKNOWN,Peripheral T-cell Lymphoma,"DRUG: Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)",Tianjin Medical University Cancer Institute and Hospital,"CSPC Ouyi Pharmaceutical Co., Ltd.",INTERVENTIONAL
NCT04296786,Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study,https://clinicaltrials.gov/study/NCT04296786,UNKNOWN,Cutaneous T-cell Lymphoma,DRUG: Sintilimab|DRUG: Chidamide,Peking Union Medical College Hospital,"Peking University Third Hospital|Beijing Longfu Hospital|Dongzhimen Hospital, Beijing",INTERVENTIONAL
NCT01663571,STAT3 in T Cells: At The Crossroads of Inflammation and Cancer,https://clinicaltrials.gov/study/NCT01663571,TERMINATED,Cutaneous T Cell Lymphoma,,NYU Langone Health,,OBSERVATIONAL
NCT04880746,Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study,https://clinicaltrials.gov/study/NCT04880746,RECRUITING,Peripheral T-cell Lymphoma,DRUG: BEAC|DRUG: Cladribine combined with BEAC,Ruijin Hospital,"Xinqiao Hospital of Chongqing|The First Affiliated Hospital of Anhui Medical University|Harbin Hematology and Oncology Institute|The Affiliated Zhongshan Hospital of Dalian University|Qilu Hospital of Shandong University|Fujian Medical University Union Hospital|Shanxi Province Cancer Hospital|RenJi Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Huashan Hospital",INTERVENTIONAL
NCT04038411,"PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma",https://clinicaltrials.gov/study/NCT04038411,UNKNOWN,NK/T Cell Lymphoma,"DRUG: PD-1 Antibody, chidamide, lenalidomide and etoposide",Mingzhi Zhang,,INTERVENTIONAL
NCT06665490,Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash,https://clinicaltrials.gov/study/NCT06665490,NOT_YET_RECRUITING,Cutaneous T Cell Lymphoma,OTHER: CLn Body Wash,Northwestern University,,OBSERVATIONAL
NCT03932279,Characterization of the Microbiome in Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03932279,RECRUITING,Cutaneous T Cell Lymphoma,,Northwestern University,,OBSERVATIONAL
NCT04489264,The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04489264,RECRUITING,Peripheral T Cell Lymphoma,"DRUG: Transplant, Autologous",Peking University,,OBSERVATIONAL
NCT05662540,PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05662540,RECRUITING,NK/T-cell Lymphoma,DEVICE: Positron Emission Tomography/Magnetic Resonance (PET/MR),Ruijin Hospital,,INTERVENTIONAL
NCT04653649,CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.,https://clinicaltrials.gov/study/NCT04653649,UNKNOWN,"Hodgkin Lymphoma, Adult|T Cell Lymphoma",BIOLOGICAL: HSP-CAR30,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,Josep Carreras Leukaemia Research Institute|Instituto de Salud Carlos III,INTERVENTIONAL
NCT06548347,A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT06548347,NOT_YET_RECRUITING,Peripheral T Cell Lymphoma,DRUG: Linperlisib,Shanghai YingLi Pharmaceutical Co. Ltd.,,INTERVENTIONAL
NCT06420076,Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells,https://clinicaltrials.gov/study/NCT06420076,RECRUITING,T Cell Lymphoma|T Cell Leukemia|T-cell Acute Lymphoblastic Leukemia|T-Cell Lymphoma of CNS|T Cell Prolymphocytic Leukemia|T Cell Childhood ALL,BIOLOGICAL: CD5/CD7 CAR-T,Essen Biotech,,INTERVENTIONAL
NCT06083701,"Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study",https://clinicaltrials.gov/study/NCT06083701,RECRUITING,Peripheral T Cell Lymphoma,DRUG: Linperlisib in combined with Chidamide,Peking Union Medical College Hospital,,INTERVENTIONAL
NCT06037239,"Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study",https://clinicaltrials.gov/study/NCT06037239,RECRUITING,Cutaneous T-cell Lymphoma,DRUG: Linperlisib in combined with Chidamide,Peking Union Medical College Hospital,,INTERVENTIONAL
NCT04008394,Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies,https://clinicaltrials.gov/study/NCT04008394,UNKNOWN,Adult T-Cell Lymphoma/Leukaemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|NK/T-cell Lymphoma|Peripheral T Cell Lymphoma|Hodgkin Lymphoma,GENETIC: Anti-CD30 CAR T cells,"Wuhan Union Hospital, China","Wuhan Bio-Raid Biotechnology Co, Ltd. China",INTERVENTIONAL
NCT06698822,"A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA",https://clinicaltrials.gov/study/NCT06698822,RECRUITING,Cutaneous T-Cell Lymphoma,DRUG: tofacitinib 2% cream,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT06947967,Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype,https://clinicaltrials.gov/study/NCT06947967,NOT_YET_RECRUITING,"Lymphoma, T-Cell, Peripheral","DRUG: CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|DRUG: Tucidinostat|DRUG: Placebo","Chipscreen Biosciences, Ltd.",,INTERVENTIONAL
NCT03553537,Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03553537,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: Decitabine|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone,"Southwest Hospital, China",,INTERVENTIONAL
NCT06509945,Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL,https://clinicaltrials.gov/study/NCT06509945,RECRUITING,Peripheral T Cell Lymphoma,OTHER: allogeneic peripheral blood stem cell transplantation,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT03553914,PLM60 for Peripheral T Cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT03553914,WITHDRAWN,Peripheral T Cell Lymphoma,DRUG: PLM60,"Conjupro Biotherapeutics, Inc.","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INTERVENTIONAL
NCT05949944,Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05949944,RECRUITING,Peripheral T-cell Lymphoma,DRUG: Linperlisib in combination with CHOP,Sun Yat-sen University,,INTERVENTIONAL
NCT03372057,A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT03372057,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Duvelisib|DRUG: Duvelisib|DRUG: Duvelisib,SecuraBio,,INTERVENTIONAL
NCT06630091,"A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study",https://clinicaltrials.gov/study/NCT06630091,RECRUITING,Peripheral T Cell Lymphoma,DRUG: Golidocitinib|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03023358,Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT03023358,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: chidamide|DRUG: cyclophosphamide|DRUG: liposomal doxorubicin|DRUG: vincristine|DRUG: prednisone,"Nanfang Hospital, Southern Medical University",,INTERVENTIONAL
NCT05321147,Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2,https://clinicaltrials.gov/study/NCT05321147,COMPLETED,Peripheral T Cell Lymphoma,BIOLOGICAL: lacutamab,Innate Pharma,,INTERVENTIONAL
NCT05728879,Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution,https://clinicaltrials.gov/study/NCT05728879,NOT_YET_RECRUITING,Cutaneous T Cell Lymphoma,COMBINATION_PRODUCT: APR-TD011 (RLF-TD011),Northwestern University,,INTERVENTIONAL
NCT06671717,Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06671717,NOT_YET_RECRUITING,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,OTHER: Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation,Peking University People's Hospital,Ruijin Hospital|Wuhan TongJi Hospital|West China Hospital,INTERVENTIONAL
NCT06588868,Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06588868,RECRUITING,Cutaneous T Cell Lymphoma|Cutaneous T-Cell Lymphoma/Mycosis Fungoides|Cutaneous T-Cell Lymphoma/Sezary Syndrome,,Fondazione Italiana Linfomi - ETS,Takeda,OBSERVATIONAL
NCT03321890,Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT03321890,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: Chidamide|DRUG: prednisone|DRUG: Cyclophosphamide|DRUG: etoposide|DRUG: Methotrexate,Sun Yat-sen University,,INTERVENTIONAL
NCT01664975,Treatment of Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01664975,COMPLETED,Peripheral T-cell Lymphoma,DRUG: GDPT regimen|DRUG: CHOP regimen,Mingzhi Zhang,Zhengzhou University,INTERVENTIONAL
NCT04490590,A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04490590,UNKNOWN,NK/T-Cell Lymphoma,DRUG: Chidamide+ Etoposide,Mingzhi Zhang,,INTERVENTIONAL
NCT01445535,Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas,https://clinicaltrials.gov/study/NCT01445535,COMPLETED,T-Cell Peripheral Lymphoma|Gamma Delta Hepatosplenic T-Cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|NK T-Cell Lymphoma,BIOLOGICAL: Rituximab|DRUG: Etoposide|BIOLOGICAL: Siplizumab|DRUG: Prednisone|DRUG: Vincristine|DRUG: Cyclophosphamide|DRUG: Doxorubicin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02809573,Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT02809573,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Chidamide|DRUG: cyclophosphamide|DRUG: adriacin|DRUG: vincristine|DRUG: prednisone,"Chipscreen Biosciences, Ltd.",,INTERVENTIONAL
NCT06468267,RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.,https://clinicaltrials.gov/study/NCT06468267,RECRUITING,Peripheral T Cell Lymphoma,DRUG: Thiotepa,"Xianmin Song, MD",,INTERVENTIONAL
NCT03586999,Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas,https://clinicaltrials.gov/study/NCT03586999,COMPLETED,Peripheral T Cell Lymphoma,DRUG: Nivolumab|DRUG: Etoposide|DRUG: Prednisolone|DRUG: Oncovin|DRUG: Cyclophosphamide|DRUG: Hydroxydaunorubicin,"University of Colorado, Denver",Bristol-Myers Squibb,INTERVENTIONAL
NCT04061772,A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04061772,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: Bortezomib|DRUG: Etoposide|DRUG: Cyclophosphamide|DRUG: Pharmorubicin|DRUG: Prednisone,Zhejiang Cancer Hospital,,INTERVENTIONAL
NCT04615468,A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma（PTCL）,https://clinicaltrials.gov/study/NCT04615468,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: TQ-B3525,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,INTERVENTIONAL
NCT01226472,Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001,https://clinicaltrials.gov/study/NCT01226472,COMPLETED,Peripheral T-cell Lymphoma|Cutaneous T-cell Lymphoma,BIOLOGICAL: KW-0761,"Kyowa Kirin Co., Ltd.","Kyowa Hakko Kirin Pharma, Inc.",INTERVENTIONAL
NCT04470141,A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04470141,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: SHC014748M treatment,"Nanjing Sanhome Pharmaceutical, Co., Ltd.",,INTERVENTIONAL
NCT01806337,CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01806337,COMPLETED,Peripheral T-Cell Lymphoma,DRUG: Alemtuzumab,University of Göttingen,,INTERVENTIONAL
NCT03292406,"A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)",https://clinicaltrials.gov/study/NCT03292406,COMPLETED,Cutaneous T Cell Lymphoma,DRUG: Placebo|DRUG: CD11301 0.03%|DRUG: CD11301 0.06%,Galderma R&D,,INTERVENTIONAL
NCT06925464,CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas,https://clinicaltrials.gov/study/NCT06925464,RECRUITING,T-Cell Non-Hodgkin Lymphoma|T-cell Lymphoma (PTCL and CTCL),DRUG: CD7 CAR-T cells infusion,Beijing GoBroad Hospital,Ruijin Hospital|Shanghai Liquan Hospital,INTERVENTIONAL
NCT01841021,Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30,https://clinicaltrials.gov/study/NCT01841021,TERMINATED,Peripheral T-Cell Lymphoma,DRUG: Brentuximab vedotin,H. Lee Moffitt Cancer Center and Research Institute,Seagen Inc.,INTERVENTIONAL
NCT03297697,Minimal Residual Disease in Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03297697,COMPLETED,Peripheral T Cell Lymphoma,PROCEDURE: Tumor biopsy|PROCEDURE: Peripheral blood draw|PROCEDURE: Lymphotrack TCR clonality assay,Washington University School of Medicine,"Invivoscribe, Inc.|National Cancer Institute (NCI)|T-Cell Leukemia Lymphoma Foundation",OBSERVATIONAL
NCT03349333,A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL,https://clinicaltrials.gov/study/NCT03349333,COMPLETED,Refractory Peripheral T-Cell Lymphoma|Relapsed T-Cell Lymphoma,DRUG: pralatrexate|DIETARY_SUPPLEMENT: Vitamin B12 and folic acid,Mundipharma (China) Pharmaceutical Co. Ltd,,INTERVENTIONAL
NCT04444141,A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04444141,TERMINATED,Peripheral T-cell Lymphoma,BIOLOGICAL: AK104,Akeso,"Akeso Pharmaceuticals, Inc.",INTERVENTIONAL
NCT04230330,Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04230330,WITHDRAWN,NK/T Cell Lymphoma,DRUG: IV Nivolumab|DRUG: IV Nivolumab|DRUG: IV Gemcitabine|DRUG: IV Cisplatin|DRUG: IV/PO Dexamethasone|DRUG: IV L-asparaginase,"National Cancer Centre, Singapore",Bristol-Myers Squibb,INTERVENTIONAL
NCT05554575,Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL,https://clinicaltrials.gov/study/NCT05554575,UNKNOWN,T Cell Lymphoblastic Lymphoma,BIOLOGICAL: BT-007 CD7 CAR-T cells,"Bioceltech Therapeutics, Ltd.",,INTERVENTIONAL
NCT02999633,Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02999633,TERMINATED,T-cell Type Acute Leukemia-Precursor|T-lymphoblastic Lymphoma/Leukaemia,DRUG: Isatuximab SAR650984|DRUG: dexamethasone|DRUG: dexamethasone|DRUG: acetaminophen|DRUG: ranitidine|DRUG: diphenhydramine,Sanofi,,INTERVENTIONAL
NCT02944812,Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT02944812,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: Chidamide,Guangdong Provincial People's Hospital,,INTERVENTIONAL
NCT04457830,The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).,https://clinicaltrials.gov/study/NCT04457830,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: F520,"Shandong New Time Pharmaceutical Co., LTD",,INTERVENTIONAL
NCT02192021,Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT02192021,COMPLETED,Cutaneous T Cell Lymphoma,DRUG: Micro needle array-Doxorubicin (MNA-D),"Falo, Louis, MD",,INTERVENTIONAL
NCT01660568,Gemcitabine in NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01660568,COMPLETED,NK/T Cell Lymphoma,,Samsung Medical Center,,OBSERVATIONAL
NCT00969085,Trial of Curcumin in Cutaneous T-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT00969085,WITHDRAWN,Cutaneous T-cell Lymphoma,DRUG: Curcumin (Turmeric)|BEHAVIORAL: Questionnaires|OTHER: Photos,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03235869,Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03235869,WITHDRAWN,Cutaneous T Cell Lymphoma,DRUG: Durvalumab|RADIATION: Radiation Therapy,University of Michigan Rogel Cancer Center,,INTERVENTIONAL
NCT01822886,Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT01822886,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Romidepsin + Gemcitabine,Fondazione Italiana Linfomi - ETS,,INTERVENTIONAL
NCT03927105,Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03927105,COMPLETED,Peripheral T Cell Lymphoma,DRUG: Nivolumab|DRUG: cabiralizumab,University of Michigan Rogel Cancer Center,Bristol-Myers Squibb,INTERVENTIONAL
NCT06113081,Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06113081,RECRUITING,Cutaneous T Cell Lymphoma|Cutaneous T-Cell Lymphoma/Mycosis Fungoides|Cutaneous T-Cell Lymphoma/Sezary Syndrome,,Fondazione Italiana Linfomi - ETS,,OBSERVATIONAL
NCT03952572,Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03952572,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: Cyclophosphamide|DRUG: pegylated liposomal doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Doxorubicin,Peking University,,INTERVENTIONAL
NCT02856997,Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT02856997,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: Chidamide with ICE regimen,Yuankai Shi,,INTERVENTIONAL
NCT03742921,ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03742921,COMPLETED,"Lymphoma, T-Cell, Peripheral",DRUG: Istodax,Celgene,,OBSERVATIONAL
NCT05675813,Genotype-guided Treatment in Newly Diagnosed PTCL,https://clinicaltrials.gov/study/NCT05675813,RECRUITING,Peripheral T Cell Lymphoma,DRUG: CHOP+selinexor+5-Azacitidine|DRUG: CHOP+duvelisib+5-Azacitidine|DRUG: CHOP+chidamide+tislelizumab|DRUG: standard CHOP,Ruijin Hospital,"The First Affiliated Hospital of Nanchang University|Peking University Third Hospital|Wuhan TongJi Hospital|West China Hospital|Nanfang Hospital, Southern Medical University|Anhui Provincial Cancer Hospital|The First Affiliated Hospital of Soochow University|The Second Affiliated Hospital of Harbin Medical University|The First Affiliated Hospital of Xiamen University|The First Affiliated Hospital of Zhengzhou University|Beijing Tongren Hospital|Peking University People's Hospital|Sun Yat-sen University|The First Affiliated Hospital of Anhui Medical University|The First Hospital of Jilin University",INTERVENTIONAL
NCT01336933,Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01336933,COMPLETED,Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma,DRUG: prednisone|DRUG: cyclophosphamide|DRUG: etoposide|DRUG: Vincristine|DRUG: pralatrexate|OTHER: laboratory biomarker analysis|GENETIC: comparative genomic hybridization|GENETIC: gene expression analysis|GENETIC: nucleic acid sequencing|GENETIC: mutation analysis|OTHER: immunohistochemistry staining method|GENETIC: microarray analysis|GENETIC: RNA analysis,University of Nebraska,"National Cancer Institute (NCI)|Spectrum Pharmaceuticals, Inc",INTERVENTIONAL
NCT03742804,Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03742804,WITHDRAWN,"Lymphoma, T-Cell, Cutaneous",BIOLOGICAL: Intratumoral G100,Yale University,,INTERVENTIONAL
NCT00865969,Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00865969,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Belinostat,"Spectrum Pharmaceuticals, Inc",Valerio Therapeutics,INTERVENTIONAL
NCT01401530,E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01401530,COMPLETED,Peripheral T-Cell Lymphoma,BIOLOGICAL: denileukin diftitox (E7777),"Eisai Co., Ltd.",,INTERVENTIONAL
NCT02593045,Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL),https://clinicaltrials.gov/study/NCT02593045,COMPLETED,Cutaneous T-Cell Lymphoma,BIOLOGICAL: IPH4102,Innate Pharma,,INTERVENTIONAL
NCT02314247,Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02314247,TERMINATED,Peripheral T-cell Lymphoma (PTCL)|Cutaneous T-cell Lymphoma (CTCL),DRUG: Selinexor,Karyopharm Therapeutics Inc,,INTERVENTIONAL
NCT06739265,Golidocitinib Plus CHOP in Newly Diagnosed PTCL,https://clinicaltrials.gov/study/NCT06739265,RECRUITING,Peripheral T-cell Lymphoma,DRUG: Golidocitinib plus CHOP,Peking Union Medical College Hospital,,INTERVENTIONAL
NCT01110733,Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry,https://clinicaltrials.gov/study/NCT01110733,COMPLETED,Peripheral T-cell Lymphoma,,Acrotech Biopharma Inc.,,OBSERVATIONAL
NCT01611142,Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT01611142,COMPLETED,Peripheral T-Cell Lymphoma,BIOLOGICAL: KW-0761 (mogamulizumab),"Kyowa Kirin Co., Ltd.","Kyowa Hakko Kirin Pharma, Inc.",INTERVENTIONAL
NCT01132989,Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01132989,UNKNOWN,Cutaneous T Cell Lymphoma,DRUG: Lenalidomide,Florida Academic Dermatology Centers,Celgene Corporation,INTERVENTIONAL
NCT03268889,"Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)",https://clinicaltrials.gov/study/NCT03268889,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: Chidamide,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT03502629,Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226),https://clinicaltrials.gov/study/NCT03502629,UNKNOWN,Peripheral T Cell Lymphoma,BIOLOGICAL: GB226,"Genor Biopharma Co., Ltd.",,INTERVENTIONAL
NCT01902225,Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01902225,COMPLETED,Lymphoma|T-Cell Lymphoma|Cutaneous Lymphoma,DRUG: Istodax|DRUG: Doxil,Weiyun Ai,Celgene Corporation,INTERVENTIONAL
NCT03049449,T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas,https://clinicaltrials.gov/study/NCT03049449,COMPLETED,"Lymphoma, Large-Cell, Anaplastic|Enteropathy-Associated T-Cell Lymphoma|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Extranodal NK-T-Cell|Lymphoma, T-Cell, Peripheral",BIOLOGICAL: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03273452,"Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)",https://clinicaltrials.gov/study/NCT03273452,UNKNOWN,Angioimmunoblastic T-cell Lymphoma,DRUG: Chidamide,Qingdao University,,INTERVENTIONAL
NCT02495415,Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas,https://clinicaltrials.gov/study/NCT02495415,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: Fenretinide,"CerRx, Inc.",,INTERVENTIONAL
NCT04217317,CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04217317,TERMINATED,Relapsed T-Cell Lymphoma|Refractory T-Cell Lymphoma|Non Hodgkin Lymphoma,DRUG: CPI 613|DRUG: Bendamustine,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT01420679,Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT01420679,TERMINATED,Peripheral T-cell Lymphoma,DRUG: Pralatrexate Injection,"Spectrum Pharmaceuticals, Inc",,INTERVENTIONAL
NCT02753543,Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02753543,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: Chidamide,Ruijin Hospital,,INTERVENTIONAL
NCT01637090,Everolimus in Treating Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01637090,TERMINATED,Cutaneous T-Cell Lymphoma,DRUG: Everolimus,Adam Lerner,Novartis,INTERVENTIONAL
NCT00863395,Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00863395,TERMINATED,Cutaneous T-Cell Lymphoma,PROCEDURE: skin biopsy,University of Minnesota,,INTERVENTIONAL
NCT02788916,"A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas",https://clinicaltrials.gov/study/NCT02788916,COMPLETED,"Lymphoma, T-Cell, Peripheral",OTHER: No Intervention,Takeda,,OBSERVATIONAL
NCT05620680,CD7 CAR-T Cells in T-cell Lymphoma/Leukemia,https://clinicaltrials.gov/study/NCT05620680,RECRUITING,T Lymphoblastic Leukemia/Lymphoma,BIOLOGICAL: CD7 CAR-T cells,Shenzhen University General Hospital,,INTERVENTIONAL
NCT03853044,Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03853044,UNKNOWN,Angioimmunoblastic T-cell Lymphoma,DRUG: Chidamide|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone,Ruijin Hospital,,INTERVENTIONAL
NCT05852028,A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05852028,RECRUITING,Lymphoma|DLBCL|T Cell Lymphoma,DRUG: Selinexor,Ruijin Hospital,,OBSERVATIONAL
NCT03051581,18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03051581,UNKNOWN,"Lymphoma, T-Cell, Peripheral",DEVICE: 18F-FDG PET/ CT,Peking University Cancer Hospital & Institute,Beijing Municipal Administration of Hospitals,INTERVENTIONAL
NCT00888927,Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00888927,COMPLETED,Peripheral T-Cell Lymphoma,BIOLOGICAL: KW-0761,"Kyowa Kirin Co., Ltd.","Kyowa Hakko Kirin Pharma, Inc.",INTERVENTIONAL
NCT00426764,A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00426764,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Romidepsin,Celgene,,INTERVENTIONAL
NCT05290155,Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies,https://clinicaltrials.gov/study/NCT05290155,COMPLETED,T Lymphoblastic Leukemia/Lymphoma|T-cell Acute Lymphoblastic Leukemia|Peripheral T Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma,DRUG: anti-CD7 CAR-T cells,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT02061449,"Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma",https://clinicaltrials.gov/study/NCT02061449,TERMINATED,Cutaneous T-cell Lymphoma,DRUG: Romidepsin|DRUG: Poly ICLC|RADIATION: Focal lesional radiation,NYU Langone Health,Ludwig Institute for Cancer Research,INTERVENTIONAL
NCT00554827,Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00554827,COMPLETED,Cutaneous T-cell Lymphoma,DIETARY_SUPPLEMENT: Vitamin B12|DIETARY_SUPPLEMENT: Folic Acid|DRUG: Pralatrexate,Acrotech Biopharma Inc.,,INTERVENTIONAL
NCT06421948,Linperlisib Combined With Chidamide in Patients With PTCL,https://clinicaltrials.gov/study/NCT06421948,RECRUITING,Peripheral T-cell Lymphoma,"DRUG: Linperlisib and chidamide|DRUG: cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone",Yanyan Liu,,INTERVENTIONAL
NCT03141203,Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT03141203,COMPLETED,Peripheral T Cell Lymphoma,DRUG: Romidepsin|DRUG: Carfilzomib,University of Birmingham,Bloodwise|Celgene|Amgen,INTERVENTIONAL
NCT00425555,Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00425555,COMPLETED,Cutaneous T-Cell Lymphoma,DRUG: Panobinostat,Novartis Pharmaceuticals,,INTERVENTIONAL
NCT04480125,Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy,https://clinicaltrials.gov/study/NCT04480125,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: Azacitidine|DRUG: Chidamide,Ruijin Hospital,,INTERVENTIONAL
NCT05559008,A Umbrella Study in R/R PTCL Guided by Molecular Subtypes,https://clinicaltrials.gov/study/NCT05559008,RECRUITING,Peripheral T Cell Lymphoma,DRUG: Azacitidine Injection|DRUG: Dasatinib|DRUG: Linperlisib|DRUG: Tucidinostat|DRUG: SHR2554|DRUG: Camrelizumab|DRUG: Apatinib,Ruijin Hospital,,INTERVENTIONAL
NCT01142674,T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01142674,COMPLETED,"Lymphoma, T-Cell, Peripheral",,Associazione Angela Serra per la ricerca sul cancro,Fondazione Italiana Linfomi - ETS|INTERNATIONAL T-CELL NON-HODGKIN'S LYMPHOMA STUDY GROUP,OBSERVATIONAL
NCT03547700,Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT03547700,ACTIVE_NOT_RECRUITING,"Lymphoma, T-Cell, Peripheral",DRUG: Romidepsin|DRUG: Ixazomib,Ryan Wilcox,University of Michigan Rogel Cancer Center|Takeda,INTERVENTIONAL
NCT00136565,Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00136565,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Velcade|DRUG: Doxorubicin|DRUG: Prednisone|DRUG: Cyclophosphamide|DRUG: Vindesine|DRUG: Bleomycin,Lymphoma Study Association,Janssen-Cilag International NV,INTERVENTIONAL
NCT02859402,"Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas",https://clinicaltrials.gov/study/NCT02859402,RECRUITING,"T-cell Non-Hodgkin Lymphoma|Lymphoma, Extranodal NK-T-Cell",DRUG: Busulfan|DRUG: Fludarabine,Keimyung University Dongsan Medical Center,"Otsuka Pharmaceutical Co., Ltd.",INTERVENTIONAL
NCT03071822,"Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas",https://clinicaltrials.gov/study/NCT03071822,UNKNOWN,Peripheral T Cell Lymphoma,DRUG: cisplatin|DRUG: ifosfamide|DRUG: gemcitabine|DRUG: L-asparaginase|DRUG: etoposide|DRUG: dexamethasone,The University of Hong Kong,,INTERVENTIONAL
NCT02546440,Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT02546440,COMPLETED,Cutaneous T Cell Lymphoma,DRUG: Dimethyl fumarate,Universitätsmedizin Mannheim,Klinikum Minden|Klinikum Krefeld|Wuerzburg University Hospital|KKS Netzwerk|Klinikum Ludwigshafen|Universitätsklinikum Kiel,INTERVENTIONAL
NCT03212937,"Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT03212937,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Selinexor|DRUG: ICE Chemotherapy,"National Cancer Centre, Singapore",,INTERVENTIONAL
NCT02653976,A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT02653976,COMPLETED,Peripheral T-Cell Lymphoma,DRUG: SP-02L (darinaparsin for injection),Solasia Pharma K.K.,,INTERVENTIONAL
NCT00274651,A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00274651,TERMINATED,Cutaneous T-Cell Lymphoma|Peripheral T-Cell Lymphoma|Non-Hodgkin's Lymphoma,DRUG: belinostat,Valerio Therapeutics,,INTERVENTIONAL
NCT03701022,PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03701022,UNKNOWN,NK/T-cell Lymphoma,DRUG: SHR1210,Peking University,,INTERVENTIONAL
NCT04639843,"Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma",https://clinicaltrials.gov/study/NCT04639843,WITHDRAWN,"Adult T-cell Leukemia/Lymphoma|Extranodal NK-/T-cell Lymphoma, Nasal Type|Enteropathy-Associated T-Cell Lymphoma|Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma|Hepatosplenic T-cell Lymphoma",DRUG: CC-486 (5-azacitidine)|DRUG: Duvelisib|DRUG: Romidepsin|DRUG: Doxorubicin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00705809,T-Cell Project: Epidemiologic Component,https://clinicaltrials.gov/study/NCT00705809,COMPLETED,Peripheral T-Cell Lymphoma,,National Cancer Institute (NCI),,OBSERVATIONAL
NCT06224842,Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL,https://clinicaltrials.gov/study/NCT06224842,RECRUITING,Angioimmunoblastic T-cell Lymphoma,DRUG: mitoxantrone liposome 16 and azacitidine|DRUG: mitoxantrone liposome 18 and azacitidine|DRUG: mitoxantrone liposome 20 and azacitidine,Huijing Wu,Beijing Xisike Clinical Oncology Research Foundation|CSPC Pharmaceutical Group,INTERVENTIONAL
NCT05963347,Go-CHOP as the Frontline Therapy for PTCL,https://clinicaltrials.gov/study/NCT05963347,RECRUITING,Peripheral T Cell Lymphoma,DRUG: Golidocitinib|DRUG: CHOP Regimen,Henan Cancer Hospital,,INTERVENTIONAL
NCT00080535,Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00080535,COMPLETED,Lymphoma|T-Cell|Cutaneous,BIOLOGICAL: LMB-2,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01941680,High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant,https://clinicaltrials.gov/study/NCT01941680,COMPLETED,T-cell Lymphoma|Leukaemia,,University Hospital Center of Martinique,,OBSERVATIONAL
NCT02013362,Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02013362,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Pralatrexate injection|DIETARY_SUPPLEMENT: Vitamin B12|DIETARY_SUPPLEMENT: Folic Acid,Mundipharma K.K.,,INTERVENTIONAL
NCT00431912,A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00431912,COMPLETED,Cutaneous T-cell Lymphoma,DRUG: APO866,Valerio Therapeutics,,INTERVENTIONAL
NCT03051568,Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03051568,UNKNOWN,"Lymphoma, T-Cell, Peripheral",DEVICE: 18F-FDG PET/CT,Peking University Cancer Hospital & Institute,Beijing Municipal Administration of Hospitals,INTERVENTIONAL
NCT06072131,To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL,https://clinicaltrials.gov/study/NCT06072131,RECRUITING,Peripheral T Cell Lymphoma,DRUG: Belinostat Injection|DRUG: Pralatrexate Injection|DRUG: CHOP|DRUG: COP,Acrotech Biopharma Inc.,,INTERVENTIONAL
NCT00731536,Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands,https://clinicaltrials.gov/study/NCT00731536,COMPLETED,Hepatosplenic T-cell Lymphoma,OTHER: No intervention,"Centocor Ortho Biotech Services, L.L.C.",,OBSERVATIONAL
NCT00490776,Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT00490776,TERMINATED,Cutaneous T-Cell Lymphoma,DRUG: Panobinostat,Novartis Pharmaceuticals,,INTERVENTIONAL
NCT01676831,Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT01676831,COMPLETED,Cutaneous T Cell Lymphoma,DRUG: Topical resiquimod 0.06%|DRUG: topical resiquimod 0.03%,Abramson Cancer Center at Penn Medicine,,INTERVENTIONAL
NCT00646854,Alemtuzumab and CHOP in T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00646854,COMPLETED,"Lymphoma, T-Cell, Peripheral","DRUG: CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|DRUG: CHOP14 chemotherapy (see specification under Arm B) plus G-CSF",Aarhus University Hospital,"GCP-unit at Aarhus University Hospital, Aarhus, Denmark",INTERVENTIONAL
NCT05296304,A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05296304,RECRUITING,Cutaneous T-cell Lymphoma,DRUG: Bexarotene|RADIATION: Total Skin Electron Beam (TSEB),Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT00364923,Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00364923,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Pralatrexate Injection,Acrotech Biopharma Inc.,,INTERVENTIONAL
NCT04219319,LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04219319,TERMINATED,CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia),DRUG: Efficacy of LCAR-T2C CAR-T cells,The First Affiliated Hospital with Nanjing Medical University,Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west district；The First Affiliated Hospital of the Air Force Medical University,INTERVENTIONAL
NCT01280526,A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT01280526,COMPLETED,Peripheral T Cell Lymphoma,DRUG: Romidepsin and CHOP|DRUG: Romidepsin and CHOP|DRUG: Romidepsin and CHOP|DRUG: Romidepsin and CHOP,The Lymphoma Academic Research Organisation,,INTERVENTIONAL
NCT00001249,Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac,https://clinicaltrials.gov/study/NCT00001249,COMPLETED,"Leukemia, T-Cell|Lymphoma, T-Cell, Cutaneous",DRUG: Yttrium-90 radiolabeled anti-Tac antibody,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00744991,A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00744991,COMPLETED,Cutaneous T-Cell Lymphoma,DRUG: Enzastaurin,Eli Lilly and Company,,INTERVENTIONAL
NCT00779896,Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study,https://clinicaltrials.gov/study/NCT00779896,UNKNOWN,Cutaneous T-Cell Lymphoma,DRUG: Tazarotene,McGill University,,INTERVENTIONAL
NCT01839097,Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT01839097,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Belinostat|DRUG: CHOP,Acrotech Biopharma Inc.,,INTERVENTIONAL
NCT01796002,Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01796002,COMPLETED,Peripheral T-cell Lymphoma,DRUG: Romidepsin + CHOP|DRUG: CHOP,The Lymphoma Academic Research Organisation,,INTERVENTIONAL
NCT01435863,A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT01435863,COMPLETED,Peripheral T-cell Lymphoma,DRUG: SP-02L (darinaparsin for injection)|DRUG: SP-02L (darinaparsin for injection)|DRUG: SP-02L (darinaparsin for injection),Solasia Pharma K.K.,,INTERVENTIONAL
NCT00970385,Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT00970385,COMPLETED,Peripheral T Cell Lymphoma,DRUG: CHOP21|DRUG: VIP/ABVD|RADIATION: Radiotherapy consolidation,"University Hospital, Grenoble",French Innovative Leukemia Organisation,INTERVENTIONAL
NCT01689220,A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea,https://clinicaltrials.gov/study/NCT01689220,COMPLETED,Peripheral T-cell Lymphoma,DRUG: SP-02L (darinaparsin for injection)|DRUG: SP-02L (darinaparsin for injection),Solasia Pharma K.K.,Synex Consulting Korea Ltd.,INTERVENTIONAL
NCT03379493,Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT03379493,TERMINATED,Lymphomas Non-Hodgkin's B-Cell,BIOLOGICAL: ET190L1 ARTEMIS™ T cells,Eureka Therapeutics Inc.,Duke University|Duke Clinical Research Institute,INTERVENTIONAL
NCT05239910,"Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL",https://clinicaltrials.gov/study/NCT05239910,WITHDRAWN,Peripheral T Cell Lymphoma,DRUG: Tenalisib,Rhizen Pharmaceuticals SA,,INTERVENTIONAL
NCT02448381,FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides),https://clinicaltrials.gov/study/NCT02448381,COMPLETED,Cutaneous T-Cell Lymphoma,DRUG: SGX301 (synthetic hypericin)|DRUG: Placebo,Soligenix,,INTERVENTIONAL
NCT00211198,Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT00211198,COMPLETED,"Lymphoma, T-Cell, Cutaneous","DRUG: ONTAK (denileukin difitox, DAB389IL-2)",Eisai Inc.,Tufts Medical Center|National Cancer Institute (NCI)|Ligand Pharmaceuticals,INTERVENTIONAL
NCT04934774,Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances,https://clinicaltrials.gov/study/NCT04934774,UNKNOWN,T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|T-cell Non-Hodgkin Lymphoma,BIOLOGICAL: CD7 CAR T cells,iCell Gene Therapeutics,iCAR Bio Therapeutics Ltd.|Peking University Shenzhen Hospital,INTERVENTIONAL
NCT01804166,A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL),https://clinicaltrials.gov/study/NCT01804166,COMPLETED,Hepatosplenic T-Cell Lymphoma,DRUG: Infliximab|DRUG: Golimumab,"Janssen Scientific Affairs, LLC",,INTERVENTIONAL
NCT00374699,Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas,https://clinicaltrials.gov/study/NCT00374699,COMPLETED,Peripheral T-Cell Lymphomas|Non-Hodgkin Lymphoma,DRUG: Velcade,Samsung Medical Center,Janssen Medical Affairs,INTERVENTIONAL
NCT01198665,RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas,https://clinicaltrials.gov/study/NCT01198665,COMPLETED,"Peripheral T Cell Lymphoma Unspecified|Anaplastic Large Cell Lymphoma, ALK-negative|Angioimmunoblastic T Cell Lymphoma|Cutaneous T Cell Lymphoma",DRUG: RAD001 (Everolimus),Samsung Medical Center,"Asan Medical Center|Yonsei University|National Cancer Center, Korea|Korea Cancer Center Hospital",INTERVENTIONAL
NCT00306969,Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00306969,COMPLETED,Cutaneous T-Cell Lymphoma,DRUG: bexarotene|DEVICE: photopheresis,Boston University,Ligand Pharmaceuticals,INTERVENTIONAL
NCT01486277,A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01486277,COMPLETED,"Lymphoma, T-Cell, Cutaneous","DRUG: Quisinostat, 12 mg","Janssen Research & Development, LLC",,INTERVENTIONAL
NCT04569032,A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression,https://clinicaltrials.gov/study/NCT04569032,ACTIVE_NOT_RECRUITING,Peripheral T-cell Lymphoma,DRUG: brentuximab vedotin|DRUG: cyclophosphamide|DRUG: doxorubicin|DRUG: prednisone,"Seagen, a wholly owned subsidiary of Pfizer",,INTERVENTIONAL
NCT04831710,Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL,https://clinicaltrials.gov/study/NCT04831710,UNKNOWN,Angioimmunoblastic T-cell Lymphoma,DRUG: Sintilimab|DRUG: Chidamide,Sun Yat-sen University,,INTERVENTIONAL
NCT01355783,A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01355783,WITHDRAWN,Peripheral T-Cell Lymphoma,DRUG: E7777,Eisai Inc.,,INTERVENTIONAL
NCT01433731,"Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)",https://clinicaltrials.gov/study/NCT01433731,COMPLETED,"Lymphoma, T-Cell, Cutaneous",DRUG: placebo for SHAPE (SHP-141)|DRUG: SHAPE (SHP-141) 0.1% BID|DRUG: SHAPE (SHP-141) 0.5% BID|DRUG: SHAPE (SHP-141) 1.0% BID,TetraLogic Pharmaceuticals,"The Leukemia and Lymphoma Society|Therapeutics, Inc.|Veristat, Inc.|PPD Development, LP",INTERVENTIONAL
NCT00930605,The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT00930605,COMPLETED,Peripheral T-cell Lymphoma,DRUG: CHOP regimen alternate with ESHAP regimen|DRUG: Alemtuzumab,King Chulalongkorn Memorial Hospital,Bayer,INTERVENTIONAL
NCT05827107,Skin Barrier and Microbiome of CTCL Patients,https://clinicaltrials.gov/study/NCT05827107,UNKNOWN,"Lymphoma, T-Cell, Cutaneous",,"Centre for Human Drug Research, Netherlands",Leiden University Medical Center|Micreos,OBSERVATIONAL
NCT05377827,Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05377827,ACTIVE_NOT_RECRUITING,T-Cell Non-Hodgkin Lymphoma|Acute Myeloid Leukemia|Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Peripheral T Cell Lymphoma|Anaplastic Large Cell Lymphoma|Adult T Cell Leukemia|Adult T Cell Lymphoma|T Cell Prolymphocytic Leukemia|Extranodal NK/T-cell Lymphoma|Transformed Mycosis Fungoides|Sezary Syndrome|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Hepatosplenic T-cell Lymphoma,BIOLOGICAL: WU-CART-007,Washington University School of Medicine,"Wugen, Inc.",INTERVENTIONAL
NCT02689453,Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL),https://clinicaltrials.gov/study/NCT02689453,COMPLETED,T-Cell Lymphoma Relapsed|Adult T-Cell Leukemia (ATL)|Peripheral T-Cell Lymphoma (PTCL)|Cutaneous T Cell Lymphoma (CTCL)|T-Cell Prolymphocytic Leukemia,BIOLOGICAL: IL-15 plus|BIOLOGICAL: alemtuzumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01470066,Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas,https://clinicaltrials.gov/study/NCT01470066,UNKNOWN,Peripheral T Cell Lymphoma,,Chonnam National University Hospital,Kyungpook National University Hospital,OBSERVATIONAL
NCT00071084,"Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.",https://clinicaltrials.gov/study/NCT00071084,COMPLETED,Cutaneous T-Cell Lymphoma,DRUG: HuMax-CD4|DRUG: HuMax-CD4,Genmab,,INTERVENTIONAL
NCT05006664,Brentuximab Vedotin in Combination With CHEP in Patient With PTCL,https://clinicaltrials.gov/study/NCT05006664,UNKNOWN,"Lymphoma, T-Cell, Peripheral",DRUG: Adcetris 50 MG Injection|DRUG: Endoxan|DRUG: Doxorubicin|DRUG: Etoposide|DRUG: Prednisone tablet,Czech Lymphoma Study Group,,INTERVENTIONAL
NCT00082017,UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00082017,TERMINATED,"Lymphoma, Large-Cell, Ki-1|Lymphoma, T-Cell",DRUG: UCN-01 (7-hydroxystaurosporine),National Cancer Institute (NCI),,INTERVENTIONAL
NCT00106431,"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)",https://clinicaltrials.gov/study/NCT00106431,COMPLETED,Cutaneous T-cell Lymphoma,"DRUG: romidepsin (depsipeptide, FK228)",Celgene,Celgene Corporation,INTERVENTIONAL
NCT06285370,A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy,https://clinicaltrials.gov/study/NCT06285370,RECRUITING,Cutaneous T-Cell Lymphoma,DRUG: Mogamulizumab,"Kyowa Kirin China Pharmaceutical Co., Ltd.",,INTERVENTIONAL
NCT01679860,Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma,https://clinicaltrials.gov/study/NCT01679860,COMPLETED,"Lymphoma, T-Cell, Peripheral",PROCEDURE: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|DRUG: Clin B (CHOP- CAMPATH) Chemo-immunotherapy,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",,INTERVENTIONAL
NCT00071071,"Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.",https://clinicaltrials.gov/study/NCT00071071,COMPLETED,Cutaneous T-Cell Lymphoma,DRUG: HuMax-CD4|DRUG: HuMax-CD4,Genmab,,INTERVENTIONAL
NCT02039895,Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma,https://clinicaltrials.gov/study/NCT02039895,UNKNOWN,Cutaneous T-cell Lymphoma,RADIATION: HITS,Far Eastern Memorial Hospital,,INTERVENTIONAL
NCT01728805,Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL,https://clinicaltrials.gov/study/NCT01728805,COMPLETED,Cutaneous T-Cell Lymphoma,BIOLOGICAL: KW-0761|DRUG: Vorinostat,"Kyowa Kirin, Inc.",,INTERVENTIONAL
NCT04668690,Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL,https://clinicaltrials.gov/study/NCT04668690,ACTIVE_NOT_RECRUITING,Peripheral T Cell Lymphoma,DRUG: Mitoxantrone Hydrochloride Liposome Injection|DRUG: Chidamide,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,INTERVENTIONAL
NCT03192202,AFM13 in Relapsed/Refractory Cutaneous Lymphomas,https://clinicaltrials.gov/study/NCT03192202,COMPLETED,"Lymphoma, T-Cell, Cutaneous",DRUG: AFM13,Ahmed Sawas,,INTERVENTIONAL
NCT00043420,CPG 7909 in Patients With Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00043420,COMPLETED,"Lymphoma, T-Cell, Cutaneous",DRUG: PF-3512676|DRUG: PF-3512676|DRUG: PF-3512676|DRUG: PF-3512676|DRUG: PF-3512676|DRUG: PF-3512676|DRUG: PF-3512676|DRUG: PF-3512676,Pfizer,,INTERVENTIONAL
NCT05681260,Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children with Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL),https://clinicaltrials.gov/study/NCT05681260,RECRUITING,T-cell Lymphoblastic Lymphoma,"DRUG: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|DRUG: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin|DRUG: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide","Children's Cancer Group, China",Shanghai Children's Medical Center|Beijing Children's Hospital|Children's Hospital of Scow University|West China Second University Hospital|Nanjing Children's Hospital|Qilu Hospital of Shandong University|Tianjin Medical University Cancer Institute and Hospital|Tongji Hospital|Xiangya Hospital of Central South University|The First Affiliated Hospital of Zhengzhou University|Cancer hospital of Shandong Province|Shenzhen Children's Hospital|Wuhan Children's Hospital|Zhejiang University School of Medicine Children's Hospital|Shanghai Children's Hospital|Ruijin Hospital|Second Affiliated Hospital of Anhui Medical University|Children's Hospital of Hebei Province|Cancer Hospital of Henan Province|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Qilu Children's Hospital,INTERVENTIONAL
NCT03355768,Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL,https://clinicaltrials.gov/study/NCT03355768,WITHDRAWN,"Lymphoma, T-Cell, Peripheral",DRUG: Romidepsin|DRUG: Pralatrexate,Jennifer Amengual,Columbia University,INTERVENTIONAL
NCT00337987,A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00337987,COMPLETED,Peripheral T-Cell Lymphoma,"DRUG: Ontak|DRUG: CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy",Yale University,Eisai Inc.,INTERVENTIONAL
NCT05627856,"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL",https://clinicaltrials.gov/study/NCT05627856,RECRUITING,NK/T Cell Lymphoma|Vascular Immunomother T Cell Lymphoma|Non-Hodgkin Lymphoma,DRUG: GNC-038,"Sichuan Baili Pharmaceutical Co., Ltd.","SystImmune Inc.|Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.",INTERVENTIONAL
NCT02535247,Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT02535247,TERMINATED,"Lymphoma, T-Cell, Peripheral",DRUG: MK-3475|DRUG: Copanlisib,Fox Chase Cancer Center,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT06747299,"The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study",https://clinicaltrials.gov/study/NCT06747299,NOT_YET_RECRUITING,T-NK Cell Lymphoma,,Ruijin Hospital,West China Hospital,OBSERVATIONAL
NCT00542919,A Study for Patients With Non-Hodgkin's Lymphomas,https://clinicaltrials.gov/study/NCT00542919,COMPLETED,T-Cell Lymphoma|B-Cell Lymphoma,DRUG: enzastaurin,Eli Lilly and Company,,INTERVENTIONAL
NCT04052659,Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL,https://clinicaltrials.gov/study/NCT04052659,NOT_YET_RECRUITING,Peripheral T-cell Lymphoma,DRUG: Sintilimab|DRUG: Chidamide|DRUG: Azacidine,Peking University,,INTERVENTIONAL
NCT03496779,Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine,https://clinicaltrials.gov/study/NCT03496779,COMPLETED,Refractory Peripheral T-Cell Lymphoma|Relapsed Peripheral T-Cell Lymphoma,DRUG: Brentuximab Vedotin - induction|DRUG: Gemcitabine|DRUG: Brentuximab Vedotin - maintenance|PROCEDURE: autologous or allogeneic stem cell transplantation,The Lymphoma Academic Research Organisation,,INTERVENTIONAL
NCT00611208,A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT00611208,COMPLETED,T-cell Lymphomas|T-cell Leukemia|Sezary Syndrome|Mycosis Fungoides|Cutaneous T-cell Lymphoma (CTCL),BIOLOGICAL: A-dmDT390-bisFv(UCHT1),Angimmune LLC,James Graham Brown Cancer Center|M.D. Anderson Cancer Center|Scott and White Hospital & Clinic|University of Texas Southwestern Medical Center|Yale University,INTERVENTIONAL
NCT06863441,The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma,https://clinicaltrials.gov/study/NCT06863441,NOT_YET_RECRUITING,T-NK Cell Lymphoma,,Ruijin Hospital,,OBSERVATIONAL
NCT02445404,Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL,https://clinicaltrials.gov/study/NCT02445404,UNKNOWN,Peripheral T-cell Lymphoma,DRUG: CHOP|DRUG: fractionated ICED,Samsung Medical Center,,INTERVENTIONAL
NCT02650999,Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas,https://clinicaltrials.gov/study/NCT02650999,COMPLETED,CD19+ Diffuse Large B-cell Lymphomas|Follicular Lymphomas|Mantle Cell Lymphomas,DRUG: Pembrolizumab,Abramson Cancer Center at Penn Medicine,,INTERVENTIONAL
NCT02017613,Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies,https://clinicaltrials.gov/study/NCT02017613,COMPLETED,"Lymphoma, B-Cell|T-Cell Lymphoma",DRUG: RP6530,Rhizen Pharmaceuticals SA,,INTERVENTIONAL
NCT04803201,Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04803201,RECRUITING,"Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Follicular T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Peripheral T-Cell Lymphoma, Not Otherwise Specified",DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DRUG: Etoposide|DRUG: Duvelisib|DRUG: Oral azacitidine,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT06420089,CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL),https://clinicaltrials.gov/study/NCT06420089,RECRUITING,T Cell Non-Hodgkin Lymphoma,DRUG: Senza5 CART5,Vittoria Biotherapeutics,University of Pennsylvania,INTERVENTIONAL
NCT00419367,Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042),https://clinicaltrials.gov/study/NCT00419367,NO_LONGER_AVAILABLE,"Lymphoma, T-Cell, Cutaneous",DRUG: Comparator: vorinostat,Merck Sharp & Dohme LLC,,EXPANDED_ACCESS
NCT00211185,"A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00211185,COMPLETED,"Lymphoma, T-Cell, Peripheral",DRUG: Denileukin diftitox|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|OTHER: Pegfilgrastim,Eisai Inc.,,INTERVENTIONAL
NCT04447027,"Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies",https://clinicaltrials.gov/study/NCT04447027,ACTIVE_NOT_RECRUITING,Cutaneous T-Cell Lymphoma|Mature T-cell Malignancies|Peripheral T-Cell Lymphoma|Relapsed/ Refractory T-cell Malignancies,DRUG: Romidepsin|DRUG: Lenalidomide|DRUG: CC-486 (5-azacitidine)|DRUG: Dexamethasone|DIAGNOSTIC_TEST: EKG|PROCEDURE: Bone Marrow Aspiration/Biopsy|DIAGNOSTIC_TEST: MRI|PROCEDURE: Lumbar Puncture|DIAGNOSTIC_TEST: TTE,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01482962,Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01482962,COMPLETED,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,DRUG: Alisertib|DRUG: Pralatrexate|DRUG: Gemcitabine|DRUG: Romidepsin,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT04745234,Mogamulizumab Q4week Dosing in Participants With R/R CTCL,https://clinicaltrials.gov/study/NCT04745234,ACTIVE_NOT_RECRUITING,"Cutaneous T-Cell Lymphoma, Relapsed|Cutaneous T-Cell Lymphoma Refractory",DRUG: Mogamulizumab,"Kyowa Kirin, Inc.",,INTERVENTIONAL
NCT04004637,"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT04004637,UNKNOWN,T-lymphoblastic Lymphoma|NK/T Cell Lymphoma|Acute Lymphocytic Leukemia,DRUG: CD7 CAR-T cells infusion,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",The First Affiliated Hospital of Zhengzhou University,INTERVENTIONAL
NCT01036399,Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients,https://clinicaltrials.gov/study/NCT01036399,TERMINATED,Peripheral T-cell Lymphoma,DRUG: Lenalidomide,University of Bologna,,INTERVENTIONAL
NCT01456039,"A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)",https://clinicaltrials.gov/study/NCT01456039,COMPLETED,"Lymphoma, T-cell, Peripheral",DRUG: Romidepsin,Celgene,,INTERVENTIONAL
NCT00791947,A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT,https://clinicaltrials.gov/study/NCT00791947,COMPLETED,Peripheral T-Cell Lymphoma,DRUG: CHOEP + G-CSF followed by BEAM,University of Aarhus,Nordic Lymphoma Group,INTERVENTIONAL
NCT05821192,Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.,https://clinicaltrials.gov/study/NCT05821192,UNKNOWN,"Peripheral T-Cell Lymphoma, Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma",DRUG: Rituximab|DRUG: Gemcitabine|DRUG: Dexamethasone|DRUG: Cisplatin|DRUG: PD-1 monoclonal antibody,"Ou Bai, MD/PHD","Second Hospital of Jilin University|China-Japan Union Hospital, Jilin University",INTERVENTIONAL
NCT02650414,CD22 Redirected Autologous T Cells for ALL,https://clinicaltrials.gov/study/NCT02650414,RECRUITING,B Cell Leukemias|B Cell Lymphomas,BIOLOGICAL: Cohort 1|BIOLOGICAL: Cohorts 2|BIOLOGICAL: Cohort 3,University of Pennsylvania,Children's Hospital of Philadelphia,INTERVENTIONAL
NCT02296398,Long-term Use of Romidepsin in Patients With CTCL,https://clinicaltrials.gov/study/NCT02296398,COMPLETED,Cutaneous T-cell Lymphoma,DRUG: Romidepsin,Northwestern University,,OBSERVATIONAL
NCT02512497,Romidepsin Maintenance After Allogeneic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT02512497,ACTIVE_NOT_RECRUITING,Cutaneous T-cell Lymphoma|T-Prolymphocytic Leukemia|T-Large Granulocytic Leukemia|T-Lymphoblastic Leukemia/Lymphoma|Peripheral T-Cell Lymphoma,DRUG: Romidepsin|DRUG: Busulfan|DRUG: Fludarabine|PROCEDURE: Stem Cell Transplant|DRUG: Thymoglobulin,Ohio State University Comprehensive Cancer Center,Celgene Corporation,INTERVENTIONAL
NCT06701344,Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT06701344,NOT_YET_RECRUITING,Enteropathy Associated T Cell Lymphoma,"DRUG: Go-CHOP (Golidocitinib plus Cyclophosphamide, vincristine, doxorubicin and prednisone)|DRUG: Golidocitinib",Ruijin Hospital,,INTERVENTIONAL
NCT00441025,The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL,https://clinicaltrials.gov/study/NCT00441025,TERMINATED,Peripheral T-Cell Lymphoma,DRUG: Alemtuzumab,Mahidol University,Bayer,INTERVENTIONAL
NCT03029338,CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma,https://clinicaltrials.gov/study/NCT03029338,COMPLETED,Lymphomas Non-Hodgkin's B-Cell|Relapse,BIOLOGICAL: CD19 CAR T cells,"Institute of Hematology & Blood Diseases Hospital, China",Juventas Cell Therapy Ltd.,INTERVENTIONAL
NCT01579318,Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma,https://clinicaltrials.gov/study/NCT01579318,TERMINATED,Cutaneous T Cell Lymphomas (CTCL)|Mycosis Fungoides (MF),BIOLOGICAL: Tavokinogene Telseplasmid (tavo)|DEVICE: OncoSec Medical System (OMS),OncoSec Medical Incorporated,,INTERVENTIONAL
NCT01719835,"CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study",https://clinicaltrials.gov/study/NCT01719835,UNKNOWN,"Peripheral T-cell Lymphoma NOS|Anaplastic Large Cell Lymphoma, ALK-Negative|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic Gamma/ Delta T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma",DRUG: Cyclophosphamide|DRUG: Gemcitabine|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisolone|DRUG: methylprednisolone|DRUG: Cisplatin,Royal Marsden NHS Foundation Trust,Cancer Research UK,INTERVENTIONAL
NCT00632827,Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak),https://clinicaltrials.gov/study/NCT00632827,TERMINATED,Peripheral T-Cell Lymphoma,DRUG: Gemcitabine|DRUG: Navelbine|DRUG: Doxorubicin Hydrochloride Liposome Injection|DRUG: Granulocyte-colony stimulating factor (G-CSF)|DRUG: Pegfilgrastim|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Leucovorin|DRUG: Methotrexate|DRUG: Doxorubicin Hydrochloride|DRUG: Cytarabine|DRUG: Etoposide|DRUG: Carmustine|DRUG: Denileukin diftitox,"University of California, San Francisco",Eisai Inc.|Washington University School of Medicine,INTERVENTIONAL
NCT03590574,Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03590574,COMPLETED,"T Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma",BIOLOGICAL: AUTO4,Autolus Limited,,INTERVENTIONAL
NCT02539472,Early Diagnosis of Mycosis Fungoides,https://clinicaltrials.gov/study/NCT02539472,UNKNOWN,Cutaneous T Cell Lymphoma,OTHER: Blood sampling,Assistance Publique - Hôpitaux de Paris,,INTERVENTIONAL
NCT01378871,A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT01378871,TERMINATED,Adult T Cell Leukemia|Adult T Cell Lymphoma,DRUG: IMTOX-25,Amit Verma,,INTERVENTIONAL
NCT00161590,"Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00161590,COMPLETED,"T-Cell Lymphoma|Lymphoma, Non-Hodgkin's",DRUG: CHOP and alemtuzumab,Weill Medical College of Cornell University,Bayer,INTERVENTIONAL
NCT02404571,GDP in Frontline Chemotherapy for Patients With PTCL-NOS,https://clinicaltrials.gov/study/NCT02404571,UNKNOWN,"Lymphoma, T-Cell, Peripheral",DRUG: GDP chemotherapy,Chinese Academy of Medical Sciences,,INTERVENTIONAL
NCT03593018,Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL,https://clinicaltrials.gov/study/NCT03593018,ACTIVE_NOT_RECRUITING,Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma,DRUG: Oral azacitidine|DRUG: Romidepsin|DRUG: Bendamustine|DRUG: Gemcitabine,The Lymphoma Academic Research Organisation,Celgene,INTERVENTIONAL
NCT00398372,Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment,https://clinicaltrials.gov/study/NCT00398372,COMPLETED,"Lymphoma, Non-Hodgkin|Lymphomas: Non-Hodgkin|Lymphomas: Non-Hodgkin Cutaneous Lymphoma|Lymphomas: Non-Hodgkin Diffuse Large B-Cell|Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell|Lymphomas: Non-Hodgkin Mantle Cell|Lymphomas: Non-Hodgkin Marginal Zone|Lymphomas: Non-Hodgkin Peripheral T-Cell|Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia",DRUG: Rituximab|DRUG: Epratuzumab,Stanford University,Amgen|National Institutes of Health (NIH),INTERVENTIONAL
NCT06810778,Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT06810778,NOT_YET_RECRUITING,T-cell-prolymphocytic Leukemia|Cutaneous T-Cell Lymphoma Refractory,DRUG: Duvelisib|DRUG: Venetoclax,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL
NCT06941688,"Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT06941688,TERMINATED,Peripheral T-cell Lymphoma (PTCL),DRUG: Decitabine with GemOx|DRUG: GemOx,Seoul National University Hospital,,INTERVENTIONAL
NCT04703192,"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)",https://clinicaltrials.gov/study/NCT04703192,ACTIVE_NOT_RECRUITING,Relapsed/Refractory Peripheral T-Cell Lymphoma|Adult T Cell Leukemia/Lymphoma,DRUG: Valemetostat Tosylate,Daiichi Sankyo,,INTERVENTIONAL
NCT01948180,Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma,https://clinicaltrials.gov/study/NCT01948180,TERMINATED,"Lymphoma, Extranodal NK-T-Cell|EBV",BIOLOGICAL: baltaleucel-T,Cell Medica Ltd,,INTERVENTIONAL
NCT06963632,A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06963632,NOT_YET_RECRUITING,Peripheral T-cell Lymphoma (PTCL),,Ruijin Hospital,,OBSERVATIONAL
NCT05991973,Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas,https://clinicaltrials.gov/study/NCT05991973,RECRUITING,T Lymphoblastic Leukemia/Lymphoma,DRUG: Chidamide,Zhejiang University,,INTERVENTIONAL
NCT06069830,PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT06069830,RECRUITING,"NK-T-Cell Lymphoma, Extranodal","DRUG: 4 cycles of ESA regimen with sandwiched radiotherapy|DRUG: 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase|DRUG: 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase",Ruijin Hospital,,INTERVENTIONAL
NCT06824883,"Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT06824883,RECRUITING,Extranodal NK/T-cell Lymphoma,DRUG: Immunochemotherapy,Peking Union Medical College Hospital,,INTERVENTIONAL
NCT01336920,Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01336920,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma,DRUG: carfilzomib,University of Nebraska,National Cancer Institute (NCI)|Amgen,INTERVENTIONAL
NCT01746173,CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01746173,TERMINATED,T-cell Non-Hodgkin Lymphoma,DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Etoposide|DRUG: Prednisone|DRUG: Filgrastim|DRUG: Plerixafor|PROCEDURE: Stem Cell Collection|DRUG: Palifermin|DRUG: Gemcitabine|DRUG: Busulfan|DRUG: Melphalan|PROCEDURE: Stem Cell Transplant,Dana-Farber Cancer Institute,Massachusetts General Hospital|Beth Israel Deaconess Medical Center,INTERVENTIONAL
NCT04554511,Prognostic Nomogram of Extranodal NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04554511,UNKNOWN,Extranodal NK/T-cell Lymphoma,,Sun Yat-sen University,,OBSERVATIONAL
NCT00704691,"Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas",https://clinicaltrials.gov/study/NCT00704691,TERMINATED,Peripheral T-cell Lymphomas|Adult T-cell Leukemia|Adult T-cell Lymphoma|Peripheral T-cell Lymphoma Unspecified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|T/Null Cell Systemic Type|Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease,DRUG: Lenalidomide,University of Alabama at Birmingham,,INTERVENTIONAL
NCT06741813,Allo-HSCT vs ASCT in Adult T-LBL,https://clinicaltrials.gov/study/NCT06741813,NOT_YET_RECRUITING,T Lymphoblastic Lymphoma,PROCEDURE: ASCT|PROCEDURE: Allo-HSCT,Peking University People's Hospital,,INTERVENTIONAL
NCT04279379,Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04279379,UNKNOWN,Extranodal NK/T-cell Lymphoma,DRUG: Sintilimab|DRUG: Decitabine,Beijing Tongren Hospital,,INTERVENTIONAL
NCT04763616,Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy,https://clinicaltrials.gov/study/NCT04763616,RECRUITING,Natural Killer/T-cell Lymphoma|Relapsed Natural Killer/T-cell Lymphoma|Refractory Natural Killer/T-cell Lymphoma,DRUG: Isatuximab|DRUG: Cemiplimab,Won Seog Kim,Sanofi,INTERVENTIONAL
NCT04795869,Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04795869,WITHDRAWN,"Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Follicular T-Cell Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Follicular T-Cell Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma",DRUG: Brentuximab Vedotin|BIOLOGICAL: Pembrolizumab,Northwestern University,National Cancer Institute (NCI)|Merck Sharp & Dohme LLC|Seagen Inc.,INTERVENTIONAL
NCT05138458,A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL,https://clinicaltrials.gov/study/NCT05138458,SUSPENDED,"Lymphoma, T-Cell, Peripheral|Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides|Adoptive Cellular Immunotherapy|Cell Therapy",BIOLOGICAL: MT-101|OTHER: MT-101 + Conditioning (Lymphodepleting) Chemotherapy,Myeloid Therapeutics,,INTERVENTIONAL
NCT01746992,CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01746992,UNKNOWN,"ALK-negative Anaplastic Large Cell Lymphoma|Peripherial T Cell Lymphoma,Not Otherwise Specified|Angioimmunoblastic T Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Hepatosplenic T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma",DRUG: Cyclophosphamide 750mg/m2|DRUG: Vincristine 1.4mg/m2|DRUG: Doxorubicin 50mg/m2|DRUG: prednisone 60mg/m2|DRUG: ifosfamide 2000mg/m2|DRUG: pirarubicin 50mg/m2|DRUG: pirarubicin 25mg/m2|DRUG: Etoposide phosphate 100mg/m2|DRUG: methotrexate 1500mg/m2,Ruijin Hospital,,INTERVENTIONAL
NCT02691351,Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study,https://clinicaltrials.gov/study/NCT02691351,COMPLETED,Non-Hodgkin T-cell Lymphoma,OTHER: Prospective Registry,Samsung Medical Center,,OBSERVATIONAL
NCT04594135,Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies,https://clinicaltrials.gov/study/NCT04594135,UNKNOWN,T-cell Acute Lymphoblastic Leukemia|T-cell Non-Hodgkin Lymphoma,DRUG: anti-CD5 CAR T cells,iCell Gene Therapeutics,iCAR Bio Therapeutics Ltd.|Peking University Shenzhen Hospital,INTERVENTIONAL
NCT01843998,Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT01843998,WITHDRAWN,Cutaneous T-cell Lymphoma (CTCL),DRUG: Sirolimus 0.1% Ointment,Stefan Schieke MD,,INTERVENTIONAL
NCT05156229,A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).,https://clinicaltrials.gov/study/NCT05156229,TERMINATED,Cutaneous T-cell Lymphoma (CTCL),BIOLOGICAL: CDK-003,Codiak BioSciences,,INTERVENTIONAL
NCT04917250,GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04917250,UNKNOWN,Extranodal NK/T-cell Lymphoma,DRUG: Gemcitabine|DRUG: Pegaspargase|DRUG: Etoposide|DRUG: Dexamethasone,Beijing Tongren Hospital,,INTERVENTIONAL
NCT04423536,Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04423536,UNKNOWN,Natural Killer T-cell Lymphoma,,Sun Yat-sen University,,OBSERVATIONAL
NCT03902184,IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03902184,ACTIVE_NOT_RECRUITING,"Lymphoma, T-Cell|Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides/Sezary Syndrome",BIOLOGICAL: IPH4102,Innate Pharma,,INTERVENTIONAL
NCT05700448,Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05700448,NOT_YET_RECRUITING,Extranodal NK/T-cell Lymphoma,BIOLOGICAL: Sugemalimab|DRUG: Placebo|DRUG: Pegaspargase|DRUG: Gemcitabine|DRUG: Oxaliplatin,CStone Pharmaceuticals,,INTERVENTIONAL
NCT03690011,Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells,https://clinicaltrials.gov/study/NCT03690011,RECRUITING,T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Leukemia,GENETIC: CD7.CAR/28zeta CAR T cells,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine|The Leukemia and Lymphoma Society|Cancer Prevention Research Institute of Texas",INTERVENTIONAL
NCT06406556,Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL,https://clinicaltrials.gov/study/NCT06406556,RECRUITING,Extranodal NK/T-cell Lymphoma,COMBINATION_PRODUCT: Pegaspargase combined with concurrent radiotherapy.,Sun Yat-sen University,,INTERVENTIONAL
NCT05208853,An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma,https://clinicaltrials.gov/study/NCT05208853,UNKNOWN,"Hodgkin Lymphoma|NK/T Cell Lymphoma|Peripheral T Cell Lymphoma, Unspecified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Diffuse Large B Cell Lymphoma|Mediastinal B-Cell Diffuse Large Cell Lymphoma|Gray Zone Lymphoma",BIOLOGICAL: Anti CD30 CAR-T Cell Injection,Zhejiang University,"Shanghai First Song Therapeutics Co., Ltd",INTERVENTIONAL
NCT02594267,A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT02594267,COMPLETED,Peripheral T-Cell Lymphoma (PTCL),DRUG: Pralatrexate Injection,Acrotech Biopharma Inc.,Axis Clinicals Limited,INTERVENTIONAL
NCT01933282,MESA Treatment for NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01933282,UNKNOWN,"Lymphoma, Extranodal NK-T-Cell",DRUG: MESA chemotherapy|DRUG: MESA,"Air Force Military Medical University, China",,INTERVENTIONAL
NCT02742727,CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT02742727,UNKNOWN,"Acute Myeloid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-cell Prolymphocytic Leukemia|T-cell Large Granular Lymphocytic Leukemia|Peripheral T-cell Lymphoma, NOS|Angioimmunoblastic T-cell Lymphoma|Extranodal NK/T-cell Lymphoma, Nasal Type|Enteropathy-type Intestinal T-cell Lymphoma|Hepatosplenic T-cell Lymphoma",BIOLOGICAL: anti-CD7 CAR-pNK cells,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",The First People's Hospital of Hefei|Hefei Binhu Hospital,INTERVENTIONAL
NCT06909474,Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06909474,RECRUITING,T-ALL/Lymphoma,BIOLOGICAL: Anti-CD5 CAR NK cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT05131438,An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL),https://clinicaltrials.gov/study/NCT05131438,NO_LONGER_AVAILABLE,Extranodal NK/T-cell Lymphoma,DRUG: sugemalimab,"EQRx International, Inc.",,EXPANDED_ACCESS
NCT00501735,Forodesine in the Treatment of Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00501735,COMPLETED,"Cutaneous T-cell Lymphoma (CTCL),",DRUG: Forodesine 200 mg,BioCryst Pharmaceuticals,,INTERVENTIONAL
NCT02955589,Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL),https://clinicaltrials.gov/study/NCT02955589,COMPLETED,Adult T-Cell Lymphoma (ATL),DRUG: HBI-8000,"HUYABIO International, LLC.",Iqvia Pty Ltd,INTERVENTIONAL
NCT05774028,"Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma",https://clinicaltrials.gov/study/NCT05774028,UNKNOWN,"NK-T-Cell Lymphoma, Extranodal","DRUG: Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) regimen",The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT02533323,P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens,https://clinicaltrials.gov/study/NCT02533323,TERMINATED,"Lymphoma, Extranodal NK-T-Cell",DRUG: gemcitabine|DRUG: oxaliplatin|DRUG: pegaspargase,Sun Yat-sen University,,INTERVENTIONAL
NCT02213861,"Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma",https://clinicaltrials.gov/study/NCT02213861,UNKNOWN,Cutaneous T-Cell Lymphoma (CTCL),DRUG: SHAPE,TetraLogic Pharmaceuticals,,INTERVENTIONAL
NCT03116659,CTCL Directed Therapy,https://clinicaltrials.gov/study/NCT03116659,UNKNOWN,"Lymphoma, T-Cell, Cutaneous",DRUG: Doxycycline|DRUG: Imiquimod,James J. Peters Veterans Affairs Medical Center,,INTERVENTIONAL
NCT03246750,B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03246750,COMPLETED,Extranodal NK/T-cell Lymphoma,DRUG: B-MAD chemotherapy,The Thai Lymphoma Study Group,Takeda,INTERVENTIONAL
NCT03493451,Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms,https://clinicaltrials.gov/study/NCT03493451,COMPLETED,"Peripheral T Cell Lymphoma|PTCL|Extranodal NK/T-cell Lymphoma|Extranodal NK/T-cell Lymphoma, Nasal Type|Extranodal NK T Cell Lymphoma|Extranodal NK T Cell Lymphoma, Nasal|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma Recurrent|Angioimmunoblastic T-Cell Lymphoma Refractory|Peripheral T-cell Lymphoma NOS|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Peripheral T-Cell Lymphoma Refractory|Anaplastic Large Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Large Cell Lymphoma, ALK-negative|ALK-negative Anaplastic Large Cell Lymphoma|ALK-Positive Anaplastic Large Cell Lymphoma|Cutaneous T-cell Lymphoma",DRUG: Tislelizumab,BeiGene,,INTERVENTIONAL
NCT02533700,CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL,https://clinicaltrials.gov/study/NCT02533700,UNKNOWN,"Peripheral T-Cell Lymphoma, Not Otherwise Specified|Angioimmunoblastic T Cell Lymphoma|ALK-negative Anaplastic Large Cell Lymphoma|Enteropathy Associated T Cell Lymphoma|Subcutaneous Panniculitis Like T Cell Lymphoma|Hepatosplenic T-cell Lymphoma",DRUG: CEOP/IVE/GDP chemotherapy regimen|DRUG: CEOP chemotherapy regimen for 6 cycles,Shandong Provincial Hospital,,INTERVENTIONAL
NCT03671850,VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT03671850,UNKNOWN,Extranodal NK/T-cell Lymphoma,BIOLOGICAL: VT-EBV-N|OTHER: Placebo,ViGenCell Inc.,,INTERVENTIONAL
NCT04417166,Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04417166,RECRUITING,"Lymphoma, Extranodal NK-T-Cell",DRUG: Pembrolizumab|RADIATION: Involved Field Radiation Therapy,International Extranodal Lymphoma Study Group (IELSG),Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT03922724,Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03922724,RECRUITING,Peripheral T-cell Lymphomas|Lymphoproliferative Disorders|Immune System Diseases,DRUG: ATL-RIC|DRUG: mRIC|PROCEDURE: allo HCT|DRUG: RIC|DRUG: GVHD prophylaxis|DRUG: IOC,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01007448,Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT01007448,COMPLETED,Refractory Cutaneous T-cell Lymphoma,DRUG: Bexarotene,"Bausch Health Americas, Inc.",,INTERVENTIONAL
NCT02106650,Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies,https://clinicaltrials.gov/study/NCT02106650,COMPLETED,Relapsed Peripheral T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma,DRUG: Folotyn and Leucovorin|DRUG: Folic Acid|DRUG: Vitamin B12,Acrotech Biopharma Inc.,Axis Clinicals Limited,INTERVENTIONAL
NCT03081910,Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen,https://clinicaltrials.gov/study/NCT03081910,RECRUITING,T-cell Acute Lymphoblastic Lymphoma|T-non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Leukemia,GENETIC: Autologous CD5.CAR/28zeta CAR T cells|GENETIC: Allogeneic CD5.CAR/28zeta CAR T cells,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute|National Cancer Institute (NCI)",INTERVENTIONAL
NCT02808091,"Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma",https://clinicaltrials.gov/study/NCT02808091,TERMINATED,Extranodal NK-T-CELL LYMPHOMA,DRUG: GIFOX-Bortezomib|DRUG: GIFOX-Bortezomib|RADIATION: IMRT,"National Cancer Centre, Singapore",,INTERVENTIONAL
NCT06914037,A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT06914037,RECRUITING,Peripheral T-cell Lymphoma|Cutaneous T-cell Lymphoma (CTCL)|NHL (Non-Hodgkin Lymphoma),DRUG: CHT101,Tianjin Medical University Cancer Institute and Hospital,"Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.",INTERVENTIONAL
NCT00958074,Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00958074,TERMINATED,Cutaneous T-cell Lymphoma Stage I|Cutaneous T-cell Lymphoma Stage II|Cutaneous T-cell Lymphoma Stage III|Cutaneous T-cell Lymphoma Stage IV,DRUG: vorinostat|OTHER: flow cytometry|OTHER: laboratory biomarker analysis,University of Washington,National Cancer Institute (NCI),INTERVENTIONAL
NCT02953652,Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT02953652,COMPLETED,Peripheral T-Cell Lymphoma (PTCL),DRUG: HBI-8000,"HUYABIO International, LLC.",Iqvia Pty Ltd,INTERVENTIONAL
NCT02616965,A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02616965,COMPLETED,Cutaneous T-cell Lymphoma (CTCL),DRUG: Romidepsin|DRUG: Brentuximab vedotin,Fox Chase Cancer Center,Seagen Inc.|Celgene Corporation,INTERVENTIONAL
NCT03051555,18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03051555,UNKNOWN,"Lymphoma, Extranodal NK-T-Cell",DEVICE: 18F-FDG PET/ CT,Peking University Cancer Hospital & Institute,Beijing Municipal Administration of Hospitals,INTERVENTIONAL
NCT06953739,A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.,https://clinicaltrials.gov/study/NCT06953739,NOT_YET_RECRUITING,"NK-T-Cell Lymphoma, Extranodal",DRUG: P-GEMD|DRUG: P-Gemox,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT01341119,Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01341119,COMPLETED,Extranodal NK/T Cell Lymphoma,,Samsung Medical Center,,OBSERVATIONAL
NCT06733051,Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50),https://clinicaltrials.gov/study/NCT06733051,RECRUITING,Natural Killer T-cell Lymphoma,DRUG: Golidocitinib|DRUG: Benmelstobart,Sun Yat-sen University,,INTERVENTIONAL
NCT00684411,Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00684411,COMPLETED,T Cell Non-Hodgkin Lymphoma,DRUG: Imatinib mesylate,Dana-Farber Cancer Institute,Brigham and Women's Hospital|Novartis,INTERVENTIONAL
NCT02678299,"Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study",https://clinicaltrials.gov/study/NCT02678299,ACTIVE_NOT_RECRUITING,Malignant Lymphoma,DRUG: PREBEN,University of Aarhus,,INTERVENTIONAL
NCT04480788,CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study,https://clinicaltrials.gov/study/NCT04480788,UNKNOWN,"T Lymphoblastic Leukemia/Lymphoma|Extramedullary NK-T-cell Lymphoma, Nasal Type|Peripheral T-cell Lymphoma, Nonspecific|Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-negative|T-cell Lymphoblastic Leukemia",BIOLOGICAL: T cell injection targeting CD7 chimeric antigen receptor,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",The First Affiliated Hospital of Zhengzhou University,INTERVENTIONAL
NCT03439501,Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY],https://clinicaltrials.gov/study/NCT03439501,UNKNOWN,"Lymphoma, Extranodal NK-T-Cell",DRUG: avelumab,Samsung Medical Center,"Merck KGaA, Darmstadt, Germany",INTERVENTIONAL
NCT04337593,Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL,https://clinicaltrials.gov/study/NCT04337593,UNKNOWN,Extranodal NK/T-cell Lymphoma,DRUG: Basiliximab|DRUG: Pegaspargase,Beijing Tongren Hospital,,INTERVENTIONAL
NCT06573138,"Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL",https://clinicaltrials.gov/study/NCT06573138,NOT_YET_RECRUITING,"Lymphoma, Extranodal NK-T-Cell","DRUG: Selinexor, anti-PD-1 antibody plus Golidocitinib",Ruijin Hospital,,INTERVENTIONAL
NCT00412997,LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00412997,COMPLETED,Tumors|Cutaneous T-Cell Lymphoma,DRUG: LBH589,Novartis,,INTERVENTIONAL
NCT02544425,"VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)",https://clinicaltrials.gov/study/NCT02544425,UNKNOWN,Extranodal NK-T-Cell Lymphoma,DRUG: Etoposide|DRUG: Ifosfamide|DRUG: Dexamethasone|DRUG: L-asparaginase|DRUG: Busulfan|DRUG: Melphalan,Samsung Medical Center,,INTERVENTIONAL
NCT03051542,Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03051542,UNKNOWN,"Lymphoma, Extranodal NK-T-Cell",DEVICE: 18F-FDG PET/CT,Peking University Cancer Hospital & Institute,Beijing Municipal Administration of Hospitals,INTERVENTIONAL
NCT05426824,The Whole-course Management of Pegaspargase in ENKTL,https://clinicaltrials.gov/study/NCT05426824,NOT_YET_RECRUITING,Extranodal NK/T Cell Lymphoma,DRUG: Pegaspargase（P-GOD）|DRUG: Pegaspargase（PEMD）,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT06210243,C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06210243,TERMINATED,"Lymphoma, B-Cell|CAR-T",BIOLOGICAL: C752,920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,"Shanghai PerHum Therapeutics Co., Ltd.",INTERVENTIONAL
NCT05441761,Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL,https://clinicaltrials.gov/study/NCT05441761,UNKNOWN,Treatment|Peripheral T-cell Lymphoma,"DRUG: liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin",Peking Union Medical College Hospital,"CSPC Ouyi Pharmaceutical Co., Ltd.",INTERVENTIONAL
NCT05679895,Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL,https://clinicaltrials.gov/study/NCT05679895,RECRUITING,T-cell Acute Lymphoblastic Leukemia|Lymphoblastic T-Cell Lymphoma,BIOLOGICAL: CD1a-CAR T,OneChain Immunotherapeutics,BioClever 2005 S.L.|Hospital Clinic of Barcelona|Hospital Sant Joan de Deu,INTERVENTIONAL
NCT01569724,Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01569724,COMPLETED,Hypertriglyceridemia|Cutaneous T Cell Lymphoma,OTHER: oral glucose tolerance test (OGTT),Rennes University Hospital,,INTERVENTIONAL
NCT06530550,PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas,https://clinicaltrials.gov/study/NCT06530550,RECRUITING,"Lymphoma, T-Cell|NK-LGL Leukemia|T-LGL Leukemia",DRUG: PI3K inhibitor,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT03154918,GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03154918,UNKNOWN,"Lymphoma, Extranodal NK-T-Cell",DRUG: GLIDE,Sichuan University,,INTERVENTIONAL
NCT06934382,Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT06934382,RECRUITING,T-Cell Acute Lymphoblastic Leukemia/Lymphoma,BIOLOGICAL: Allogeneic anti-CD7 CAR-T cells (BEAM-201),Stephan Grupp MD PhD,Beam Therapeutics Inc.,INTERVENTIONAL
NCT02867553,Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions,https://clinicaltrials.gov/study/NCT02867553,UNKNOWN,Indolent Cutaneous B Cell Lymphomas,DRUG: rituximab|RADIATION: Multi-fields radiotherapy,CHU de Reims,,INTERVENTIONAL
NCT01187446,Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT01187446,TERMINATED,Cutaneous Lymphoma|Cutaneous T-cell Lymphoma,RADIATION: Total skin electron beam therapy (TSEBT)|DRUG: Vorinostat,Stanford University,,INTERVENTIONAL
NCT00476554,A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00476554,TERMINATED,Cutaneous T-cell Lymphoma (CTCL),DRUG: Sapacitabine,"Cyclacel Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT03988582,Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies,https://clinicaltrials.gov/study/NCT03988582,WITHDRAWN,EBV Lymphomas|EBV-associated Malignancies,BIOLOGICAL: EBV-specific T-cells,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT05127135,Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies,https://clinicaltrials.gov/study/NCT05127135,UNKNOWN,T-Acute Lymphoblastic Leukemia|T-cell Non-Hodgkin Lymphoma|T-cell Acute Lymphoblastic Lymphoma,BIOLOGICAL: ThisCART7 cells,"Fundamenta Therapeutics, Ltd.",The First Affiliated Hospital of University of Science and Technology of China,INTERVENTIONAL
NCT04414163,"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type",https://clinicaltrials.gov/study/NCT04414163,ACTIVE_NOT_RECRUITING,"Extranodal NK/T-cell Lymphoma, Nasal Type|Extranodal NK/T-cell Lymphoma",DRUG: IMC-001,ImmuneOncia Therapeutics Inc.,,INTERVENTIONAL
NCT06600568,Novel Therapeutic Approach for Human T-cell Malignancies,https://clinicaltrials.gov/study/NCT06600568,RECRUITING,"T-Cell Leukemia/Lymphoma, Adult",OTHER: Translation analysis,Istituto Oncologico Veneto IRCCS,Istituto Nazionale Tumori IRCSS-Fondazione G.Pascale,OBSERVATIONAL
NCT03776279,A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03776279,UNKNOWN,Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma,DRUG: Mitoxantrone Hydrochloride Liposome Injection,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,INTERVENTIONAL
NCT00038025,A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT00038025,COMPLETED,Peripheral T-cell Lymphoma|Cutaneous T-cell Lymphoma|Chronic Lymphocytic Leukemia,DRUG: Deoxycoformycin (DCF),M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT01908777,A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01908777,ACTIVE_NOT_RECRUITING,T Cell Non-Hodgkin Lymphoma,OTHER: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin,Memorial Sloan Kettering Cancer Center,University of Washington|Weill Medical College of Cornell University|H. Lee Moffitt Cancer Center and Research Institute,INTERVENTIONAL
NCT06492304,A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06492304,RECRUITING,T Cell Lymphoma|B Cell Lymphoma|Acute Myeloid Leukemia,BIOLOGICAL: CTX131,CRISPR Therapeutics,,INTERVENTIONAL
NCT06988085,Impact of Lymphodepletion Regimen on the Response to CAR T-cells in Patients With With Relapsed/Refractory Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06988085,NOT_YET_RECRUITING,Large B Cell Lymphoma|CAR T Cell,OTHER: Blood sampling,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT00725231,Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP,https://clinicaltrials.gov/study/NCT00725231,UNKNOWN,"Peripheral T Cell Lymphoma, Unspecified|Angioimmunoblastic Lymphadenopathy|Extranodal NK/T-cell Lymphoma",BIOLOGICAL: alemtuzumab|DRUG: chemotherapy,University of Göttingen,German High-Grade Non-Hodgkin's Lymphoma Study Group|Nordic Lymphoma Group,INTERVENTIONAL
NCT01309789,A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms,https://clinicaltrials.gov/study/NCT01309789,COMPLETED,"Lymphoma, Large-Cell, Anaplastic|Lymphoma, NK-cell|Lymphoma, T-cell",DRUG: brentuximab vedotin|DRUG: cyclophosphamide|DRUG: brentuximab vedotin|DRUG: prednisone|DRUG: cyclophosphamide|DRUG: doxorubicin|DRUG: doxorubicin|DRUG: prednisone|DRUG: vincristine,Seagen Inc.,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT06610344,BHB & CAR-T for Lymphomas,https://clinicaltrials.gov/study/NCT06610344,RECRUITING,Large B-cell Lymphoma,"DIETARY_SUPPLEMENT: R-1,3-Butanediol",Abramson Cancer Center at Penn Medicine,,INTERVENTIONAL
NCT06136364,CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study,https://clinicaltrials.gov/study/NCT06136364,RECRUITING,T-lymphoblastic Lymphoma|T-ALL,BIOLOGICAL: CAR-T,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT06485219,A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06485219,RECRUITING,Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|Cutaneous T-cell Lymphoma (CTCL),DRUG: 11.2 mg/m2 Purinostat Mesylate|DRUG: 15 mg/m2 Purinostat Mesylate,"Chengdu Zenitar Biomedical Technology Co., Ltd",,INTERVENTIONAL
NCT04213209,"Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion ""Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma""",https://clinicaltrials.gov/study/NCT04213209,COMPLETED,Peripheral T Cell Lymphoma|Pediatric Hodgkin Lymphoma,DRUG: Brentuximab Vedotin (Genetical Recombination),Takeda,,OBSERVATIONAL
NCT02547948,CD19-targeting CAR T Cells for B Cell Lymphoma,https://clinicaltrials.gov/study/NCT02547948,WITHDRAWN,B Cell Lymphoma,BIOLOGICAL: CD19-targeting CAR T Cells infusion,"Fuda Cancer Hospital, Guangzhou",,INTERVENTIONAL
NCT03921879,Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma,https://clinicaltrials.gov/study/NCT03921879,UNKNOWN,"Lymphoma|Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Lymphoma, T-Cell|Lymphoma, Follicular|Lymphoma, Peripheral T-Cell|Lymphoma, Hodgkin",DRUG: OT-82 Dose Escalation|DRUG: OT-82 Dose Expansion,"Oncotartis, Inc.",,INTERVENTIONAL
NCT05557903,Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL,https://clinicaltrials.gov/study/NCT05557903,UNKNOWN,"Lymphoma, Non-Hodgkin|Lymphoma, T-Cell",BIOLOGICAL: Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection,"Lanzhou Institute of Biological Products Co., Ltd",,INTERVENTIONAL
NCT04916860,Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT04916860,UNKNOWN,SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,BIOLOGICAL: Senl-T7,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT02359162,Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage,https://clinicaltrials.gov/study/NCT02359162,TERMINATED,"Lymphoma, Extranodal NK-T-Cell",DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Pegaspargase|DRUG: Etoposide|DRUG: Vincristine|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Prednisone|RADIATION: IMRT,Sun Yat-sen University,,INTERVENTIONAL
NCT05466318,ChiCGB vs BEAM in High-risk or R/R Lymphomas,https://clinicaltrials.gov/study/NCT05466318,RECRUITING,"Lymphoma, Large B-Cell, Diffuse|Lymphoma, T-Cell",DRUG: Chidamide|DRUG: Cladribine|DRUG: Gemcitabine|DRUG: Busulfan|DRUG: Carmustine|DRUG: Etoposide|DRUG: Cytarabine|DRUG: Melphalan|PROCEDURE: Autologous hematopoietic stem cell transplant,Sichuan University,,INTERVENTIONAL
NCT03947255,A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03947255,TERMINATED,Hodgkin Lymphoma|Peripheral T Cell Lymphoma|Anaplastic Large Cell Lymphoma,DRUG: brentuximab vedotin,Seagen Inc.,,INTERVENTIONAL
NCT06561074,"A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)",https://clinicaltrials.gov/study/NCT06561074,NOT_YET_RECRUITING,T-cell Acute Lymphoblastic Leukemia|T-Cell Lymphoblastic Lymphoma,DRUG: Decitabine|DRUG: Venetoclax|DRUG: Calaspargase pegol-mknl,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03598959,Tofacitinib Combined With Chidamide in R/R ENKTCL,https://clinicaltrials.gov/study/NCT03598959,UNKNOWN,Extranodal NK/T-cell Lymphoma,DRUG: tofacitinib|DRUG: chidamide,Sichuan University,,INTERVENTIONAL
NCT04362007,A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04362007,TERMINATED,"Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)",DRUG: ASTX660|DRUG: ASTX660|DRUG: ASTX660,"Otsuka Pharmaceutical Co., Ltd.",,INTERVENTIONAL
NCT00985140,Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00985140,TERMINATED,Mycosis Fungoides|Lymphomas: Non-Hodgkin|Lymphomas: Non-Hodgkin Peripheral T-Cell|Lymphomas: Non-Hodgkin Cutaneous Lymphoma,RADIATION: Total Skin Electron Beam Therapy (TSEBT),Stanford University,,OBSERVATIONAL
NCT04823091,Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies,https://clinicaltrials.gov/study/NCT04823091,UNKNOWN,T-Cell Lymphocytic Leukemia|T-Cell Chronic Lymphocytic Leukemia|T Cell Non-Hodgkin Lymphoma,DRUG: Fludarabine + Cyclophosphamide + CAR7-T Cells,"Wuhan Union Hospital, China","Beijing GoBroad Hospital Management Co.,Ltd|Yake Biotechnology Ltd.",INTERVENTIONAL
NCT05059912,CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma,https://clinicaltrials.gov/study/NCT05059912,UNKNOWN,Refractory and Relapsed T Cell Lymphoma,BIOLOGICAL: Humanized CD7 CAR-T cells,The First Affiliated Hospital of Soochow University,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Affiliated Hospital of Jiangnan University|The Affiliated Zhongshan Hospital of Dalian University|The First Affiliated Hospital of Dalian Medical University",INTERVENTIONAL
NCT05509855,A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007,https://clinicaltrials.gov/study/NCT05509855,ENROLLING_BY_INVITATION,T-cell Acute Lymphoblastic Leukemia|T-cell Lymphoblastic Lymphoma,GENETIC: Genetic: WU-CART-007,"Wugen, Inc.",,OBSERVATIONAL
NCT01590732,"Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT01590732,COMPLETED,"Mycosis Fungoides|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",DRUG: Carboplatin|DRUG: Etoposide|DRUG: Ifosfamide|DRUG: Romidepsin,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03719105,Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT03719105,RECRUITING,NK-Cell Lymphoma|NK-Cell Leukemia|Peripheral T Cell Lymphoma,"DRUG: Methotrexate|DRUG: pralatraxate,|DRUG: Ifosfamide|DRUG: Dexamethasone|DRUG: Etoposide|DRUG: calaspargase pegol|DRUG: cyclophosphamide|DRUG: Doxorubicin|DRUG: Prednisone|DRUG: Brentuximab Vedotin",New York Medical College,University of Alabama at Birmingham,INTERVENTIONAL
NCT03217643,CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.,https://clinicaltrials.gov/study/NCT03217643,COMPLETED,Enteropathy Associated T-cell Lymphoma,DRUG: Brentuximab Vedotin,Imagine Institute,Takeda,INTERVENTIONAL
NCT01777152,ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas,https://clinicaltrials.gov/study/NCT01777152,COMPLETED,Anaplastic Large-Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Lymphoma,DRUG: brentuximab vedotin|DRUG: doxorubicin|DRUG: prednisone|DRUG: vincristine|DRUG: cyclophosphamide,Seagen Inc.,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT06793956,Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT06793956,RECRUITING,Extranodal Natural Killer/T Cell Lymphoma,DRUG: Sintilimab and Linperlisib Combination Treatment,Sun Yat-sen University,,INTERVENTIONAL
NCT02631746,Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT02631746,COMPLETED,Acute Adult T-Cell Leukemia/Lymphoma|Adult T-Cell Leukemia/Lymphoma|Chronic Adult T-Cell Leukemia/Lymphoma|HTLV-1 Infection|Lymphomatous Adult T-Cell Leukemia/Lymphoma|Smoldering Adult T-Cell Leukemia/Lymphoma,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|OTHER: Pharmacogenomic Study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01192984,Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma,https://clinicaltrials.gov/study/NCT01192984,COMPLETED,Peripheral T/NK-cell Lymphoma,BIOLOGICAL: KW-0761,"Kyowa Kirin Co., Ltd.",,INTERVENTIONAL
NCT04848064,Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT04848064,RECRUITING,Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Adult T-Cell Leukemia/Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Mogamulizumab|BIOLOGICAL: Natural Killer Cell Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,John Reneau,,INTERVENTIONAL
NCT02597153,Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas,https://clinicaltrials.gov/study/NCT02597153,TERMINATED,Relapsed Cutaneous T Cell Lymphom,DRUG: Mitoxantrone HCL Liposome Injection,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,INTERVENTIONAL
NCT04196205,Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas,https://clinicaltrials.gov/study/NCT04196205,UNKNOWN,"Acute Lymphoblastic Leukemia ,Lymphomas",BIOLOGICAL: Anti-CD19 CAR-T,The First Affiliated Hospital of Nanchang University,,INTERVENTIONAL
NCT04984837,Study of Lacutamab in Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04984837,RECRUITING,Peripheral T Cell Lymphoma|Relapse/Recurrence,DRUG: Lacutamab|DRUG: Gemcitabine|DRUG: Oxaliplatine,The Lymphoma Academic Research Organisation,Innate Pharma,INTERVENTIONAL
NCT02561273,Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT02561273,COMPLETED,"Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Hepatosplenic T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Stage II Angioimmunoblastic T-cell Lymphoma|Stage II Enteropathy-Associated T-Cell Lymphoma|Stage III Angioimmunoblastic T-cell Lymphoma|Stage III Enteropathy-Associated T-Cell Lymphoma|Stage IV Angioimmunoblastic T-cell Lymphoma|Stage IV Enteropathy-Associated T-Cell Lymphoma",PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|OTHER: Laboratory Biomarker Analysis|DRUG: Lenalidomide|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Prednisone|DRUG: Vincristine Sulfate,University of Nebraska,National Cancer Institute (NCI),INTERVENTIONAL
NCT04102150,Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT04102150,COMPLETED,Adult T-cell Leukemia/Lymphoma,DRUG: Valemetostat Tosylate,"Daiichi Sankyo Co., Ltd.",,INTERVENTIONAL
NCT05976997,"Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)",https://clinicaltrials.gov/study/NCT05976997,RECRUITING,Newly Diagnosed Peripheral T-cell Lymphoma,"DRUG: Duvelisib, Chidamide",Liling Zhang,"CSPC Ouyi Pharmaceutical Co., Ltd.",INTERVENTIONAL
NCT06210750,Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL),https://clinicaltrials.gov/study/NCT06210750,WITHDRAWN,T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|DRUG: Calaspargase Pegol|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin|DRUG: Dexamethasone|DRUG: Doxorubicin|PROCEDURE: Echocardiography|PROCEDURE: Lumbar Puncture|DRUG: Mercaptopurine|DRUG: Methotrexate|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Navitoclax|DRUG: Nelarabine|DRUG: Pegaspargase|PROCEDURE: Positron Emission Tomography|DRUG: Thioguanine|DRUG: Venetoclax|DRUG: Vincristine|PROCEDURE: X-Ray Imaging,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04860817,A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL,https://clinicaltrials.gov/study/NCT04860817,WITHDRAWN,T-cell Acute Lymphoblastic Leukemia|T-lymphoblastic Lymphoma,BIOLOGICAL: Target CD7 CAR-T cells,920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,,INTERVENTIONAL
NCT01626664,KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL),https://clinicaltrials.gov/study/NCT01626664,COMPLETED,Adult T-cell Leukemia-Lymphoma,BIOLOGICAL: KW-0761|DRUG: Pralatrexate|DRUG: gemcitabine plus oxaliplatin|DRUG: DHAP,"Kyowa Kirin, Inc.",,INTERVENTIONAL
NCT03283111,Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma,https://clinicaltrials.gov/study/NCT03283111,UNKNOWN,Lymphoma,BIOLOGICAL: autologous stem cell transplantation,Peking University,,INTERVENTIONAL
NCT04136275,CAR-37 T Cells in Hematologic Malignancies,https://clinicaltrials.gov/study/NCT04136275,COMPLETED,"Hematologic Malignancy|Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, T-Cell|Lymphoma, Non-Hodgkin",BIOLOGICAL: CAR-37 T cells,"Marcela V. Maus, M.D.,Ph.D.",,INTERVENTIONAL
NCT04014374,Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab,https://clinicaltrials.gov/study/NCT04014374,RECRUITING,Leukemia/Lymphoma|Cutaneous T Cell Lymphoma|ATLL,,"Kyowa Kirin, Inc.",,OBSERVATIONAL
NCT00082225,"LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)",https://clinicaltrials.gov/study/NCT00082225,TERMINATED,Lymphoma,BIOLOGICAL: CD45 antibodies|BIOLOGICAL: EBV specific T cells,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT00438802,Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00438802,COMPLETED,Lymphoma,DRUG: Alefacept,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT03631862,Treatment of Newly Diagnosed Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03631862,UNKNOWN,Newly Diagnosed Peripheral T-cell Lymphoma,DRUG: Apatinib|DRUG: CHOP Regimen,Zhengzhou University,,INTERVENTIONAL
NCT06702605,To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT06702605,NOT_YET_RECRUITING,Relapsed/Refractory Peripheral T Cell Lymphoma,DRUG: XNW5004 tablets,Evopoint Biosciences Inc.,,INTERVENTIONAL
NCT05532761,"Multidimensional Assessment of Quality of Life, Social and Professional Life and Care Utilization in Patients With Diffuse Large Cell B-cell Lymphoma Treated With CAR-T Cells",https://clinicaltrials.gov/study/NCT05532761,UNKNOWN,Diffuse Large B-cell Lymphoma (DLBCL)|CAR-T Cells Treatment,OTHER: self-administered questionnaires,Hospices Civils de Lyon,,OBSERVATIONAL
NCT03542266,CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03542266,COMPLETED,Previously Untreated Peripheral T-cell Lymphoma,DRUG: CC-486 Administration|DRUG: CHOP Administration,Weill Medical College of Cornell University,Celgene Corporation,INTERVENTIONAL
NCT03576807,The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma,https://clinicaltrials.gov/study/NCT03576807,UNKNOWN,Relapsed or Refractory B-cell Lymphomas,DRUG: CD20 CAR-T cells,Xin Wang,,INTERVENTIONAL
NCT01846390,"Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma",https://clinicaltrials.gov/study/NCT01846390,COMPLETED,Peripheral T-Cell Lymphoma|Diffuse Large B-Cell Lymphoma,DRUG: Gemcitabine|DRUG: Dexamethasone|DRUG: Cisplatin|DRUG: Romidepsin,Canadian Cancer Trials Group,Celgene,INTERVENTIONAL
NCT02264613,ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas,https://clinicaltrials.gov/study/NCT02264613,COMPLETED,Solid Tumor|Lymphoma|Peripheral T-Cell Lymphoma,DRUG: ALRN-6924,"Aileron Therapeutics, Inc.",,INTERVENTIONAL
NCT01466881,Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01466881,COMPLETED,Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma,DRUG: Alisertib|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06519526,Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT06519526,RECRUITING,Relapsed/Refractory Peripheral T Cell Lymphoma,DRUG: SHR-0302|DRUG: SHR-2554,Fudan University,,INTERVENTIONAL
NCT03598998,Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT03598998,ACTIVE_NOT_RECRUITING,"Anaplastic Large Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hepatosplenic T-Cell Lymphoma|Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Hepatosplenic T-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Subcutaneous Panniculitis-Like T-Cell Lymphoma",BIOLOGICAL: Pembrolizumab|DRUG: Pralatrexate,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00061048,Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT00061048,COMPLETED,Acute T-Cell Leukemia-Lymphoma,BIOLOGICAL: Alemtuzumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01804335,CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT01804335,COMPLETED,Lymphoma,DRUG: CD5789 0.01% Cream,M.D. Anderson Cancer Center,Galderma R&D,INTERVENTIONAL
NCT06776952,"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma",https://clinicaltrials.gov/study/NCT06776952,NOT_YET_RECRUITING,Relapsed/Refractory Peripheral T Cell Lymphoma,DRUG: XNW5004 ; Chidamide placebo|DRUG: XNW5004 placebo; Chidamide,Evopoint Biosciences Inc.,,INTERVENTIONAL
NCT04572308,Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells,https://clinicaltrials.gov/study/NCT04572308,COMPLETED,T-cell Acute Lymphoblastic Leukemia/Lymphoma,BIOLOGICAL: CD7 CAR-T,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT05896813,CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05896813,UNKNOWN,Newly Diagnosed Peripheral T-cell Lymphoma,DRUG: CMOP+Chidamide,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT00131937,Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00131937,COMPLETED,Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma,DRUG: sorafenib tosylate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00020072,Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells,https://clinicaltrials.gov/study/NCT00020072,COMPLETED,Lymphoma,OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02080234,Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL,https://clinicaltrials.gov/study/NCT02080234,UNKNOWN,"Lymphoma, Extranodal NK-T-Cell",DRUG: GELOX|RADIATION: IFRT,Sun Yat-sen University,,INTERVENTIONAL
NCT00299351,"A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.",https://clinicaltrials.gov/study/NCT00299351,UNKNOWN,Peripheral T Cell Lymphoma (PTCL),DRUG: Depsipeptide,Royal Marsden NHS Foundation Trust,,INTERVENTIONAL
NCT05464433,Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT05464433,ACTIVE_NOT_RECRUITING,Extranodal Natural Killer T Cell Lymphoma,DRUG: Tislelizumab combined with Liposomal mitoxantrone hydrochloride|DRUG: Maintenance of tislelizumab,Sun Yat-sen University,,INTERVENTIONAL
NCT04723914,Dual Target CAR-T Cells in B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04723914,UNKNOWN,"Lymphoma, B-Cell|Relapse/Recurrence|Refractory Lymphoma|Dual-target CAR-T Cells",BIOLOGICAL: dual target CAR-T cell therapy,YuLi,,INTERVENTIONAL
NCT05958719,"Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma",https://clinicaltrials.gov/study/NCT05958719,RECRUITING,Peripheral T Cell Lymphoma|Epigenetic Repression,DRUG: Chidamide|DRUG: Azacitidine|DRUG: liposomal mitoxantrone|DRUG: prednisone,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT06716658,JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/refractory Indolent T/NK-cell Lymphomas,https://clinicaltrials.gov/study/NCT06716658,RECRUITING,"Lymphoma, T-Cell|NK-LGL Leukemia|T-LGL Leukemia|Cutaneous T Cell Lymphoma|Cutaneous T Cell Lymphoma (CTCL)|Large Granular Lymphocyte Leukemia|Large Granular Lymphocytic Leukemia|Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract|Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma|Mycosis Fungoides",DRUG: JAK1 Inhibitor,"Institute of Hematology & Blood Diseases Hospital, China",Tianjin First Central Hospital|The First Affiliated Hospital of Air Force Medicial University|The First Hospital of Jilin University|The First Affiliated Hospital of Nanchang University|Henan Cancer Hospital|Second Xiangya Hospital of Central South University|Tongji Hospital,INTERVENTIONAL
NCT01000285,EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma,https://clinicaltrials.gov/study/NCT01000285,COMPLETED,"Leukemia-Lymphoma, Adult T-Cell",DRUG: Bortezomib|DRUG: Etoposide|DRUG: Vincristine|DRUG: Doxorubicin|DRUG: Prednisone|DRUG: Cyclophosphamide|DRUG: Raltegravir,Washington University School of Medicine,,INTERVENTIONAL
NCT04696705,Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients,https://clinicaltrials.gov/study/NCT04696705,UNKNOWN,Non-Hodgkin's Lymphoma (NHL)|Peripheral T Cell Lymphoma (PTCL),BIOLOGICAL: Ex-vivo expanded allogeneic γδT cells,"Institute of Hematology & Blood Diseases Hospital, China","Beijing GD Initiative Cell Therapy Technology Co., Ltd.|Chinese Academy of Medical Sciences",INTERVENTIONAL
NCT06482684,CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma,https://clinicaltrials.gov/study/NCT06482684,RECRUITING,Mantle Cell Lymphoma,DRUG: KTE-X19|DRUG: Ibrutinib,"Christian Schmidt, MD",Johannes Gutenberg University Mainz,INTERVENTIONAL
NCT06244368,GVM±R in Patients With Relapsed or Refractory Aggressive NHL.,https://clinicaltrials.gov/study/NCT06244368,RECRUITING,Peripheral T Cell Lymphoma|Diffuse Large B-cell Lymphoma,DRUG: GVM±R regimen,"Institute of Hematology & Blood Diseases Hospital, China","First Hospital of China Medical University|Hebei Medical University Fourth Hospital|Chengdu Shangjin Nanfu Hospital|Affiliated Cancer Hospital & Institute of Guangzhou Medical University|Xuanwu Hospital, Beijing|The Affiliated Ganzhou Hospital of Nanchang University|Beijing Tongren Hospital|The First Affiliated Hospital of Dalian Medical University|The First Hospital of Jilin University|People's Hospital of Zhengzhou University|The First Affiliated Hospital of Bengbu Medical University|The Second Affiliated Hospital of Kunming Medical University|The First Affiliated Hospital of Nanchang University|The Second Affiliated Hospital of Harbin Medical University|Shengjing Hospital|Peking University Third Hospital|First Affiliated Hospital of Harbin Medical University|China-Japan Friendship Hospital",INTERVENTIONAL
NCT04689659,"Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma",https://clinicaltrials.gov/study/NCT04689659,COMPLETED,T-cell Leukemia/Lymphoma|Refractory T Lymphoblastic Leukemia/Lymphoma|Relapse/Recurrence,BIOLOGICAL: chimeric antigen receptor T cell treatment,Beijing Boren Hospital,,INTERVENTIONAL
NCT00920790,Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma,https://clinicaltrials.gov/study/NCT00920790,COMPLETED,Adult T-cell Leukemia-lymphoma,BIOLOGICAL: KW-0761,"Kyowa Kirin Co., Ltd.",,INTERVENTIONAL
NCT06724237,Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy,https://clinicaltrials.gov/study/NCT06724237,NOT_YET_RECRUITING,"Anaplastic Large Cell Lymphoma, ALK-Negative|Follicular Helper T-Cell Lymphoma|Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type|Peripheral T-Cell Lymphoma, Not Otherwise Specified",PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|OTHER: Best Practice|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: High Dose Chemotherapy|PROCEDURE: Leukapheresis|PROCEDURE: Positron Emission Tomography|DRUG: Stem Cell Mobilization Therapy,Eastern Cooperative Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT05343377,A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT05343377,NOT_YET_RECRUITING,Extranodal Natural Killer/T-cell Lymphoma,DIAGNOSTIC_TEST: circulate free methylated EBV DNA,The First Affiliated Hospital with Nanjing Medical University,Zhenjiang First People's Hospital|Changzhou First People's Hospital|Changzhou Second People's Hospital|Wuxi People's Hospital|Second Affiliated Hospital of Soochow University|The First Affiliated Hospital of Nantong University|Huaian first people's hospital|Yancheng First People's Hospital,INTERVENTIONAL
NCT01724177,A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma,https://clinicaltrials.gov/study/NCT01724177,COMPLETED,Adult T-Cell Leukemia-Lymphoma,DRUG: Lenalidomide,Celgene,,INTERVENTIONAL
NCT00002635,Aminocamptothecin in Treating Patients With T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00002635,COMPLETED,Lymphoma,BIOLOGICAL: filgrastim|DRUG: aminocamptothecin,Yale University,National Cancer Institute (NCI),INTERVENTIONAL
NCT05387226,Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05387226,UNKNOWN,T-cell Lymphoma|Virus|Intravenous Injection,BIOLOGICAL: Oncolytic Virus Injection(RT-01),The First Affiliated Hospital of Bengbu Medical University,,INTERVENTIONAL
NCT05540340,A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant,https://clinicaltrials.gov/study/NCT05540340,RECRUITING,"Lymphoma|Lymphoma, B-Cell|Lymphoma, T-Cell|Lymphoma, Hodgkin|Lymphoma, Non-Hodgkin",OTHER: Pharmacokinetics|OTHER: Pharmacokinetics,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT05079282,Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma,https://clinicaltrials.gov/study/NCT05079282,RECRUITING,Relapsed or Refractory T Cell Lymphoma,DRUG: ONO-4685,Ono Pharmaceutical Co. Ltd,,INTERVENTIONAL
NCT05182957,Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05182957,UNKNOWN,Relapsed/Refractory Peripheral T-cell Lymphoma,DRUG: Anti-PD-1 monoclonal antibody|DRUG: Lenalidomide|DRUG: Azacitidine,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT01274533,Lenalidomide in HTLV-1 Adult T-Cell Leukemia,https://clinicaltrials.gov/study/NCT01274533,COMPLETED,Adult T Cell Leukemia/Lymphoma,DRUG: Lenalidomide,Columbia University,Celgene Corporation,INTERVENTIONAL
NCT05833893,Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05833893,RECRUITING,nk/T-cell Lymphoma|Newly Diagnosed|Advanced Lymphoma,DRUG: XPO1 inhibitor,Chinese PLA General Hospital,,INTERVENTIONAL
NCT02875002,Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,https://clinicaltrials.gov/study/NCT02875002,WITHDRAWN,Relapsed and Refractory Aggressive B- and T-cell Lymphomas|Lymphoma,DRUG: volasertib|DRUG: belinostat,Yale University,Massey Cancer Center|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,INTERVENTIONAL
NCT05934838,A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas,https://clinicaltrials.gov/study/NCT05934838,RECRUITING,Follicular Lymphoma|B-Cell Lymphoma|Mantle Cell Lymphoma|Diffuse Large B Cell Lymphoma,DRUG: Tazemetostat Pill,Weill Medical College of Cornell University,"Epizyme, Inc.|Applebaum Foundation|American Society of Clinical Oncology",INTERVENTIONAL
NCT02362997,"Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL",https://clinicaltrials.gov/study/NCT02362997,COMPLETED,Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Peripheral T-Cell Lymphoma,DRUG: Pembrolizumab,Dana-Farber Cancer Institute,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT00901147,Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00901147,COMPLETED,Peripheral T-cell Lymphoma (Not Otherwise Specified)|Angioimmunoblastic T-cell Lymphoma|Extranodal NK/T-cell Lymphoma Nasal Type|Enteropathy- Type T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)|Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant,DRUG: panobinostat and bortezomib,Singapore General Hospital,,INTERVENTIONAL
NCT06850285,CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma,https://clinicaltrials.gov/study/NCT06850285,RECRUITING,"Lymphoma, B-Cell",DRUG: chimeric antigen receptor gene modified T cells,Shanxi Bethune Hospital,,INTERVENTIONAL
NCT00408005,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT00408005,COMPLETED,T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma,DRUG: Asparaginase|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin Hydrochloride|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Leucovorin Calcium|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Nelarabine|DRUG: Pegaspargase|DRUG: Prednisone|RADIATION: Radiation Therapy|DRUG: Thioguanine|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00145002,A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL),https://clinicaltrials.gov/study/NCT00145002,COMPLETED,Adult T-cell Leukemia|Lymphoma,DRUG: VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|DRUG: biweekly-CHOP with G-CSF and intrathecal prophylaxis,Japan Clinical Oncology Group,"Ministry of Health, Labour and Welfare, Japan",INTERVENTIONAL
NCT06255795,"The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT06255795,NOT_YET_RECRUITING,Extranodal Natural Killer T Cell Lymphoma,"DRUG: chidamide, anti-PD1 antibody, and pegaspargase|DRUG: DDGP",Ruijin Hospital,,INTERVENTIONAL
NCT05572983,Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype,https://clinicaltrials.gov/study/NCT05572983,RECRUITING,Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype,DRUG: Chidamide combined with CHOP|DRUG: Chidamide,Sun Yat-sen University,,INTERVENTIONAL
NCT05403450,A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL),https://clinicaltrials.gov/study/NCT05403450,ACTIVE_NOT_RECRUITING,Relapsed/Refractory Peripheral T-cell Lymphoma,DRUG: Tolinapant|DRUG: Decitabine + Cedazuridine,"Taiho Oncology, Inc.",,INTERVENTIONAL
NCT04922567,Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04922567,RECRUITING,Peripheral T-Cell Lymphoma|Lenalidomide|CHOP,DRUG: Lenalidomide|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone,"Second Affiliated Hospital, School of Medicine, Zhejiang University","Ruijin Hospital|Xinqiao Hospital of Chongqing|Union hospital of Fujian Medical University|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Southern Medical University, China|Shandong Provincial Hospital|Huashan Hospital|First Hospital of China Medical University|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Henan Provincial People's Hospital|First Affiliated Hospital Xi'an Jiaotong University|Changhai Hospital|The Affiliated Hospital of Xuzhou Medical University|Wuhan Union Hospital, China|RenJi Hospital|Zhongda Hospital|The First Affiliated Hospital of Anhui Medical University|Hunan Cancer Hospital|First Affiliated Hospital of Harbin Medical University|Xiangya Hospital of Central South University|The First Affiliated Hospital of Dalian Medical University|Jilin Provincial Tumor Hospital|Shanxi Province Cancer Hospital|Zhongshan Hospital Xiamen University",INTERVENTIONAL
NCT04718883,CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT04718883,ACTIVE_NOT_RECRUITING,Mantle Cell Lymphoma,BIOLOGICAL: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells,"Shanghai Ming Ju Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT02917083,"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)",https://clinicaltrials.gov/study/NCT02917083,RECRUITING,Hodgkin's Lymphoma|Non-Hodgkin Lymphoma,GENETIC: CAR T Cells,Baylor College of Medicine,The Methodist Hospital Research Institute,INTERVENTIONAL
NCT02323659,Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas,https://clinicaltrials.gov/study/NCT02323659,TERMINATED,"Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides",DRUG: Methotrexate|DRUG: Interferon Alfa-2b,Polish Lymphoma Research Group,,INTERVENTIONAL
NCT02879526,"Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma",https://clinicaltrials.gov/study/NCT02879526,UNKNOWN,Relapse/Refratory Peripheral T Cell Lymphoma,DRUG: C-CPT,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT02364466,Cohort of Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT02364466,UNKNOWN,"Lymphoma, T-Cell, Peripheral|Febrile Neutropenia",,Korea Cancer Center Hospital,"Samsung Medical Center|Asan Medical Center|Keimyung University Dongsan Medical Center|Kosin University Gospel Hospital|Dankook University|Soonchunhyang University Hospital|Ajou University School of Medicine|Yeungnam University Hospital|Ulsan University Hospital|Inje University|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|Hallym University Medical Center|Hanyang University Seoul Hospital|Seoul National University Hospital|Pusan National University Hospital|National Health Insurance Service Ilsan Hospital|Hanyang University",OBSERVATIONAL
NCT06733441,A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06733441,RECRUITING,Lymphoma,DRUG: TLN-254|DRUG: TLN-254,"Treeline Biosciences, Inc.",,INTERVENTIONAL
NCT00169156,A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma,https://clinicaltrials.gov/study/NCT00169156,COMPLETED,Untreated T-cell Angioimmunoblastic Lymphoma,DRUG: Rituximab|DRUG: Prednisone|DRUG: Doxorubicine|DRUG: Cyclophosphamide|DRUG: Vincristine,Lymphoma Study Association,Hoffmann-La Roche,INTERVENTIONAL
NCT04702503,Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT04702503,COMPLETED,Cutaneous T-Cell Lymphoma/Mycosis Fungoides,DRUG: WP1220,"Moleculin Biotech, Inc.",,INTERVENTIONAL
NCT03823365,Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT03823365,UNKNOWN,Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia,BIOLOGICAL: Blinatumomab Expanded T-cells (BET),A.O. Ospedale Papa Giovanni XXIII,,INTERVENTIONAL
NCT05626400,Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL,https://clinicaltrials.gov/study/NCT05626400,RECRUITING,T-cell Acute Lymphoblastic Leukemia/Lymphoma,BIOLOGICAL: Senl-T7,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT04556266,A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies,https://clinicaltrials.gov/study/NCT04556266,WITHDRAWN,"Leukemia|Lymphoma|Lymphoma, B-Cell",BIOLOGICAL: CAR T-Cell Infusion,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT00968760,CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT00968760,COMPLETED,Lymphoma|B-cell Lymphoma,PROCEDURE: Leukapheresis|PROCEDURE: Stem Cell Transplant|PROCEDURE: CD19-specific T Cell Infusion|DRUG: IL-2|DRUG: Carmustine|DRUG: Etoposide|DRUG: Cytarabine|DRUG: Melphalan,M.D. Anderson Cancer Center,National Cancer Institute (NCI)|Alaunos Therapeutics|Intrexon Corporation,INTERVENTIONAL
NCT03595657,A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL),https://clinicaltrials.gov/study/NCT03595657,COMPLETED,Extranodal Natural Killer/T-Cell Lymphoma,BIOLOGICAL: CS1001,CStone Pharmaceuticals,,INTERVENTIONAL
NCT04301076,"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (""EPOCH"") for Adult T-Cell Leukemia-Lymphoma (ATLL)",https://clinicaltrials.gov/study/NCT04301076,RECRUITING,Acute Adult T-Cell Leukemia/Lymphoma|Adult T-Cell Leukemia/Lymphoma|Chronic Adult T-Cell Leukemia/Lymphoma|HTLV-1 Infection,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|DRUG: Lenalidomide|PROCEDURE: Positron Emission Tomography|DRUG: Prednisone|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03843294,Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma,https://clinicaltrials.gov/study/NCT03843294,ACTIVE_NOT_RECRUITING,Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma,BIOLOGICAL: TAA-T cells|DRUG: Nivolumab,Catherine Bollard,,INTERVENTIONAL
NCT00787527,SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00787527,COMPLETED,Lymphoma,DRUG: Zolinza (vorinostat)|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone,M.D. Anderson Cancer Center,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT02181218,"Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",https://clinicaltrials.gov/study/NCT02181218,COMPLETED,"Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Hodgkin Disease|Lymphoma, Large B-Cell, Diffuse",DRUG: Romidepsin|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Dexamethasone|DRUG: Pegfilgrastim,Washington University School of Medicine,Celgene,INTERVENTIONAL
NCT06874946,Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL,https://clinicaltrials.gov/study/NCT06874946,RECRUITING,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,BIOLOGICAL: CD5-targeted CAR-T cells,Peking University People's Hospital,"Hebei Senlang Biotechnology Inc., Ltd.",INTERVENTIONAL
NCT03150602,A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy,https://clinicaltrials.gov/study/NCT03150602,UNKNOWN,"Peripheral T Cell Lymphoma|Progression, Disease",DRUG: Pralatrexate,Taiwan Mundipharma Pharmaceuticals Ltd.,,INTERVENTIONAL
NCT06002659,CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study),https://clinicaltrials.gov/study/NCT06002659,RECRUITING,B-cell Lymphoma,BIOLOGICAL: CAR20(NAP)-T|DRUG: Cyclophosphamide|DRUG: Fludarabine,Uppsala University,Elicera Therapeutics|Uppsala University Hospital|Karolinska University Hospital,INTERVENTIONAL
NCT03558412,A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT03558412,UNKNOWN,T-lymphoblastic Lymphoma,COMBINATION_PRODUCT: CODOX-M/IVAC|DRUG: Decitabine,Mingzhi Zhang,,INTERVENTIONAL
NCT05755828,Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05755828,UNKNOWN,B-cell Lymphoma,BIOLOGICAL: ASCT+CAR-T Cell Infusion,The Affiliated Hospital of Xuzhou Medical University,,INTERVENTIONAL
NCT05941156,Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia,https://clinicaltrials.gov/study/NCT05941156,RECRUITING,Extranodal NK T Cell Lymphoma|NK-Cell Leukemia,BIOLOGICAL: Anti-CD56 CAR T,The Affiliated Hospital of Xuzhou Medical University,,INTERVENTIONAL
NCT02518113,A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,https://clinicaltrials.gov/study/NCT02518113,COMPLETED,T-cell Acute Lymphoblastic Leukemia|T-cell Lymphoblastic Lymphoma,DRUG: LY3039478|DRUG: Dexamethasone|DRUG: Placebo,Eli Lilly and Company,,INTERVENTIONAL
NCT04526834,Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04526834,ACTIVE_NOT_RECRUITING,Anaplastic Large Cell Lymphoma|Peripheral T Cell Lymphoma|Extranodal NK/T-cell Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL),DRUG: CD30.CAR-T,Tessa Therapeutics,,INTERVENTIONAL
NCT03880279,Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03880279,WITHDRAWN,"Lymphoma, B-Cell",BIOLOGICAL: TAC01-CD19,"Triumvira Immunologics, Inc.",,INTERVENTIONAL
NCT04052061,QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04052061,WITHDRAWN,"Diffuse Large B Cell Lymphoma|Large-cell Lymphoma|Lymphoma, B-Cell|Lymphoma",BIOLOGICAL: CD19 t-haNK,"ImmunityBio, Inc.",,INTERVENTIONAL
NCT02842138,Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT02842138,UNKNOWN,B-cell Lymphoma,BIOLOGICAL: autologous anti-CD19 CAR T cells,Peking University,"Marino Biotechnology Co., Ltd.",INTERVENTIONAL
NCT03079947,Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients,https://clinicaltrials.gov/study/NCT03079947,UNKNOWN,Diffuse Large B Cell Lymphoma|Peripheral T Cell Lymphoma,,Peking Union Medical College Hospital,,OBSERVATIONAL
NCT00430053,Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00430053,COMPLETED,Lymphoma,GENETIC: gene rearrangement analysis|GENETIC: polymerase chain reaction|GENETIC: proteomic profiling|OTHER: flow cytometry|OTHER: immunohistochemistry staining method|PROCEDURE: biopsy,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),OBSERVATIONAL
NCT05978141,A Registry for People With T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05978141,RECRUITING,"T-cell Lymphoma|NK-Cell Lymphoma|T-cell Prolymphocytic Leukemia|T-cell Large Granular Lymphocytic Leukemia|Chronic Lymphoproliferative Disorder of NK Cells|Aggressive NK-cell Leukemia|Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder)|Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood|Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Adult T-cell Leukemia/Lymphoma|Extranodal NK/T-cell Lymphoma, Nasal Type|Enteropathy-associated T-cell Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Intestinal T-Cell Lymphoma, Not Otherwise Specified|Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract|Hepatosplenic T-cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Mycosis Fungoides|Sezary Syndrome|Primary Cutaneous Anaplastic Large Cell Lymphoma|Primary Cutaneous T-cell Lymphoma|Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma|Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Follicular T-Cell Lymphoma|Nodal Peripheral T-Cell Lymphoma With TFH Phenotype|Anaplastic Large Cell Lymphoma, ALK-Positive|Anaplastic Large Cell Lymphoma, ALK-negative|Breast Implant-Associated Anaplastic Large Cell Lymphoma",OTHER: Optional Blood Sample and Nail Sample,Memorial Sloan Kettering Cancer Center,,OBSERVATIONAL
NCT05948033,CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma,https://clinicaltrials.gov/study/NCT05948033,RECRUITING,Lymphoma,BIOLOGICAL: CD70-targeting CAR-T cells,Chinese PLA General Hospital,UTC Therapeutics Inc.,INTERVENTIONAL
NCT06912529,Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06912529,RECRUITING,B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent,PROCEDURE: Leukapheresis|DRUG: Bridging Therapy|DRUG: Lymphodepletion|GENETIC: Axicabtagene Ciloleucel,Universität Münster,"Kite, A Gilead Company",INTERVENTIONAL
NCT04429438,Multi-CAR-T Cells Targeting B Cell Lymphomas,https://clinicaltrials.gov/study/NCT04429438,UNKNOWN,B Cell Lymphoma (BCL),BIOLOGICAL: 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2,Shenzhen Geno-Immune Medical Institute,The Seventh Affiliated Hospital of Sun Yat-sen University|Shenzhen Children's Hospital,INTERVENTIONAL
NCT03154710,Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response,https://clinicaltrials.gov/study/NCT03154710,TERMINATED,"Lymphoma, T-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Hodgkin",DEVICE: MOOVCARE,Weprom,Sivan Innovation Ltd.|Takeda,INTERVENTIONAL
NCT01716806,A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT01716806,COMPLETED,Hodgkin Disease|Peripheral T Cell Lymphoma,DRUG: brentuximab vedotin|DRUG: bendamustine|DRUG: dacarbazine|DRUG: nivolumab,Seagen Inc.,Bristol-Myers Squibb,INTERVENTIONAL
NCT06508463,Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06508463,RECRUITING,"Peripheral T Cell Lymphoma|Relapsed Peripheral T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Relapsed Anaplastic Large Cell Lymphoma|Relapsed Mycosis Fungoides",PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|PROCEDURE: Single Photon Emission Computed Tomography|BIOLOGICAL: Cemiplimab|BIOLOGICAL: Ipilimumab,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT00001582,Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer,https://clinicaltrials.gov/study/NCT00001582,COMPLETED,T-cell Lymphoma|B-Cell Lymphoma|ATL|Myeloma,,National Cancer Institute (NCI),,OBSERVATIONAL
NCT05487495,Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT05487495,WITHDRAWN,T-Cell Acute Lymphoblastic Leukemia/Lymphoma,BIOLOGICAL: CD5 CAR T (CT125B),Beijing Boren Hospital,,INTERVENTIONAL
NCT05134740,(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).,https://clinicaltrials.gov/study/NCT05134740,WITHDRAWN,Hodgkins Lymphoma|Non Hodgkins Lymphoma,BIOLOGICAL: TAA-specific CTLs,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT06026319,CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06026319,RECRUITING,Non-hodgkin Lymphoma|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|High-grade B-cell Lymphoma|Grade 3b Follicular Lymphoma|Mantle Cell Lymphoma,DRUG: CD79b-19 CAR T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,"Marcela V. Maus, M.D.,Ph.D.",,INTERVENTIONAL
NCT05380635,PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05380635,COMPLETED,Cutaneous T-Cell Lymphoma/Mycosis Fungoides,DRUG: Hypericin,Soligenix,,INTERVENTIONAL
NCT00355472,Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL,https://clinicaltrials.gov/study/NCT00355472,COMPLETED,Adult T-Cell Leukemia and Lymphoma (ATL)|Adult Peripheral T-Cell Lymphoma (PTCL),DRUG: KW-0761,"Kyowa Kirin Co., Ltd.",,INTERVENTIONAL
NCT06211881,Chi-GVM Regimen for the Treatment of R/R PTCL,https://clinicaltrials.gov/study/NCT06211881,RECRUITING,Relapsed/Refractory Peripheral T-cell Lymphoma,DRUG: Chi-GVM,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT04972942,Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma,https://clinicaltrials.gov/study/NCT04972942,RECRUITING,T-cell Acute Lymphoblastic Leukemia|T-Cell Acute Lymphoblastic Lymphoma,DRUG: Daratumumab,New York Medical College,,INTERVENTIONAL
NCT05931263,A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL,https://clinicaltrials.gov/study/NCT05931263,RECRUITING,Newly Diagnosed Peripheral T-cell Lymphoma,DRUG: C-BEAM Regimen|DRUG: BEAM Regimen,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT05678933,AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH,https://clinicaltrials.gov/study/NCT05678933,ENROLLING_BY_INVITATION,Peripheral T-cell Lymphoma Targeted Therapy,DRUG: Azacitidine|DRUG: Chidamide|DRUG: Cyclophosphamide|DRUG: Epirubicin|DRUG: Vincristine|DRUG: Prednisone,Tianjin Medical University Cancer Institute and Hospital,,INTERVENTIONAL
NCT01173887,"Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15",https://clinicaltrials.gov/study/NCT01173887,COMPLETED,Adult T-cell Leukemia-Lymphoma,DRUG: VCAP/AMP/VECP(mLSG15)|BIOLOGICAL: KW-0761,"Kyowa Kirin Co., Ltd.",,INTERVENTIONAL
NCT03837457,PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study,https://clinicaltrials.gov/study/NCT03837457,TERMINATED,Cutaneous T-Cell Lymphoma/Mycosis Fungoides,DRUG: Cobomarsen,"miRagen Therapeutics, Inc.",,INTERVENTIONAL
NCT05414500,Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05414500,RECRUITING,Cutaneous T Cell Lymphoma|Mycosis Fungoides,DRUG: Mogamulizumab|DRUG: Brentuximab vedotin,University of Alabama at Birmingham,"Seagen Inc.|Kyowa Kirin, Inc.",INTERVENTIONAL
NCT03713320,SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT03713320,TERMINATED,Cutaneous T-Cell Lymphoma/Mycosis Fungoides,DRUG: Cobomarsen|DRUG: Vorinostat,"miRagen Therapeutics, Inc.",,INTERVENTIONAL
NCT01129180,Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01129180,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Small Intestine Lymphoma|T-cell Large Granular Lymphocyte Leukemia,DRUG: azacitidine|DRUG: bortezomib|PROCEDURE: Correlative studies,Pierluigi Porcu,"Millennium Pharmaceuticals, Inc.|Celgene Corporation",INTERVENTIONAL
NCT00505921,Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00505921,TERMINATED,Lymphoma,DRUG: Campath-1H|DRUG: G-CSF|DRUG: GM-CSF|DRUG: BCNU|DRUG: Stem Cell Transplant|DRUG: Preparative Regimen for Allogenic Stem Cell Transplantation|DRUG: Cytarabine|DRUG: Etoposide|DRUG: Melphalan|DRUG: Campath|DRUG: Fludarabine|DRUG: Cyclophosphamide|RADIATION: Low dose total body irradiation,M.D. Anderson Cancer Center,Bayer,INTERVENTIONAL
NCT01742793,"An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)",https://clinicaltrials.gov/study/NCT01742793,TERMINATED,Hodgkin's Lymphoma|Mature T-cell Lymphoma|Multiple Myeloma,DRUG: lenalidomide (Revlimid) and romidepsin (Istodax),Yale University,"Peter MacCallum Cancer Centre, Australia",INTERVENTIONAL
NCT05872854,Treatment of Mycosis Fungoides with Hypericin Ointment and Visible Light,https://clinicaltrials.gov/study/NCT05872854,RECRUITING,Cutaneous T Cell Lymphoma|Mycosis Fungoides,DRUG: Hypericin|OTHER: Visible Light,"Ellen Kim, MD",Soligenix,INTERVENTIONAL
NCT02223208,Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas,https://clinicaltrials.gov/study/NCT02223208,ACTIVE_NOT_RECRUITING,Peripheral T-cell Lymphomas (PTCL)|PTCL-NOS|Angioimmunoblastic T-cell Lymphoma (AITL)|ALK- Anaplastic Large Cell Lymphoma (ALCL)|Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin,DRUG: Ro-CHOEP-21 (PHASE I)|DRUG: Ro-CHOEP-21 (PHASE II),Fondazione Italiana Linfomi - ETS,,INTERVENTIONAL
NCT04036019,A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy,https://clinicaltrials.gov/study/NCT04036019,COMPLETED,B Cell Lymphoma,BIOLOGICAL: CD20-directed CAR-T cells with CliniMACS Prodigy® system,"Shanghai Tongji Hospital, Tongji University School of Medicine",Shanghai AbelZeta Ltd.,INTERVENTIONAL
NCT03118180,CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03118180,UNKNOWN,Lymphoma,BIOLOGICAL: CD19 targeted chimeric antigen receptor T cells,Zhejiang University,"Innovative Cellular Therapeutics Co., Ltd.",INTERVENTIONAL
NCT04999878,A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.,https://clinicaltrials.gov/study/NCT04999878,UNKNOWN,Hemophagocytic Syndrome|T/NK-Cell Lymphoma,"DRUG: Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum",Zhengzhou University,,INTERVENTIONAL
NCT06376721,Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06376721,RECRUITING,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type|T-lymphoblastic Lymphoma",DRUG: Linperlisib|DRUG: Camrelizumab|DRUG: Pegaspargase|DRUG: Dexamethasone,Beijing Tongren Hospital,,INTERVENTIONAL
NCT04260932,CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT04260932,COMPLETED,B-cell Lymphoma,BIOLOGICAL: CD19/CD20 Dual-CAR-T cells,Hebei Yanda Ludaopei Hospital,"China Immunotech (Beijing) Biotechnology Co., Ltd.",INTERVENTIONAL
NCT07009002,BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma,https://clinicaltrials.gov/study/NCT07009002,NOT_YET_RECRUITING,B Cell Lymphoma,BIOLOGICAL: CAR19TIF cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,Chinese PLA General Hospital,,INTERVENTIONAL
NCT00061880,BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00061880,COMPLETED,Lymphoma,DRUG: forodesine hydrochloride,BioCryst Pharmaceuticals,,INTERVENTIONAL
NCT05885464,A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL),https://clinicaltrials.gov/study/NCT05885464,ACTIVE_NOT_RECRUITING,Lymphoblastic Lymphoma|T-Cell Lymphoblastic Leukemia/Lymphoma|Lymphoblastic Leukemia,BIOLOGICAL: BEAM-201,Beam Therapeutics Inc.,,INTERVENTIONAL
NCT00099255,Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00099255,COMPLETED,Large Cell Lymphoma,DRUG: SGN-30,Seagen Inc.,,INTERVENTIONAL
NCT06149247,HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL,https://clinicaltrials.gov/study/NCT06149247,COMPLETED,Cutaneous T-Cell Lymphoma/Mycosis Fungoides,DRUG: Hypericin|DRUG: Mechlorethamine Topical Gel,Soligenix,,INTERVENTIONAL
NCT01390597,Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms,https://clinicaltrials.gov/study/NCT01390597,COMPLETED,Lymphoma,GENETIC: DNA analysis|GENETIC: cytogenetic analysis|GENETIC: gene mapping|GENETIC: mutation analysis|GENETIC: polymerase chain reaction|OTHER: laboratory biomarker analysis,Eastern Cooperative Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT06347653,Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL),https://clinicaltrials.gov/study/NCT06347653,RECRUITING,Nodal T-follicular Helper Cell Lymphoma,DRUG: linperlisib combined with CHOP regimen,Peking University,,INTERVENTIONAL
NCT03728972,"Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type",https://clinicaltrials.gov/study/NCT03728972,ACTIVE_NOT_RECRUITING,NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)|NK/T-Cell Lymphoma of Nasopharynx (Diagnosis),DRUG: Pembrolizumab,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT04548700,"Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL",https://clinicaltrials.gov/study/NCT04548700,TERMINATED,Treatment-naïve|Peripheral T Cell Lymphoma,"DRUG: Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone|DRUG: Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,INTERVENTIONAL
NCT05680558,Photopheresis in Early-stage Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05680558,RECRUITING,Cutaneous T Cell Lymphoma|Mycosis Fungoides,DRUG: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis|DEVICE: THERAKOS® CELLEX photopheresis system,Columbia University,"Mallinckrodt, Inc.",INTERVENTIONAL
NCT03075553,Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03075553,TERMINATED,"Blastic Plasmacytoid Dendritic Cell Neoplasm|Hepatosplenic T-Cell Lymphoma|HTLV-1 Infection|NK-Cell Lymphoma, Unclassifiable|Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-cell Lymphoma|Recurrent Enteropathy-Associated T-Cell Lymphoma|Recurrent Mycosis Fungoides|Refractory Adult T-Cell Leukemia/Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma|Refractory Enteropathy-Associated T-Cell Lymphoma|Refractory Mycosis Fungoides|Refractory Nasal Type Extranodal NK/T-Cell Lymphoma|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT04715217,Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04715217,RECRUITING,"Lymphoma, B-Cell",BIOLOGICAL: CD19-CD22 CAR-T cells,Shanxi Province Cancer Hospital,"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.",INTERVENTIONAL
NCT00667017,RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00667017,TERMINATED,Lymphoma,BIOLOGICAL: RFT5-dgA immunotoxin|OTHER: fluorescence activated cell sorting|OTHER: immunohistochemistry staining method,University of Texas Southwestern Medical Center,,INTERVENTIONAL
NCT05205902,TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05205902,NOT_YET_RECRUITING,Mycosis Fungoides|Cutaneous T Cell Lymphoma,OTHER: Low-dose total-skin electron-beam therapy|OTHER: Phototherapy,Assistance Publique - Hôpitaux de Paris,,INTERVENTIONAL
NCT00298467,MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00298467,WITHDRAWN,"Lymphoma, Large-Cell",DRUG: MDX-060,Bristol-Myers Squibb,,INTERVENTIONAL
NCT03258047,Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03258047,UNKNOWN,B Cell Lymphoma,COMBINATION_PRODUCT: CAR-T,First Affiliated Hospital of Zhejiang University,,INTERVENTIONAL
NCT00030849,Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00030849,COMPLETED,Lymphoma,BIOLOGICAL: recombinant interferon alfa|DRUG: bexarotene,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01363817,Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT01363817,COMPLETED,"Lymphoblastic Leukemia, Acute T-cell|Precursor T-Cell Lymphoblastic Lymphoma",DRUG: BMS-906024|DRUG: Dexamethasone,Bristol-Myers Squibb,,INTERVENTIONAL
NCT00099593,Immunization Against Tumor Cells in Sezary Syndrome,https://clinicaltrials.gov/study/NCT00099593,COMPLETED,Cutaneous T-cell Lymphoma|Sezary Syndrome,BIOLOGICAL: Autologous Dendritic Cell Vaccine,University of Pittsburgh,,INTERVENTIONAL
NCT06522737,A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype,https://clinicaltrials.gov/study/NCT06522737,RECRUITING,Lymphoma,DRUG: Duvelisib|DRUG: Gemcitabine|DRUG: Bendamustine,SecuraBio,,INTERVENTIONAL
NCT06004167,Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T),https://clinicaltrials.gov/study/NCT06004167,RECRUITING,"Lymphoma, B-Cell|Relapsed Cancer|Refractory Lymphoma|Diffuse Large B Cell Lymphoma|Mediastinal Large B-cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma",RADIATION: Adaptive Bridging Radiation Therapy (ABRT),Massachusetts General Hospital,Varian Medical Systems,INTERVENTIONAL
NCT06434467,The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT06434467,NOT_YET_RECRUITING,T-lymphoblastic Leukemia|T-lymphoblastic Lymphoma,DRUG: Nelarabine injection,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,INTERVENTIONAL
NCT00221039,"Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A",https://clinicaltrials.gov/study/NCT00221039,COMPLETED,Cutaneous T Cell Lymphoma|Mycosis Fungoides,DRUG: Methoxsalen+ECP,M.D. Anderson Cancer Center,Boston Medical Center|University of Pittsburgh|Case Western Reserve University|Vanderbilt University Medical Center|University of Minnesota|Rush University Medical Center|Mallinckrodt,INTERVENTIONAL
NCT00182637,Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00182637,COMPLETED,Lymphoma,DRUG: bortezomib,Jonsson Comprehensive Cancer Center,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT06390319,Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL),https://clinicaltrials.gov/study/NCT06390319,RECRUITING,T-cell Acute Lymphoblastic Leukemia|T-cell Lymphoma|Mixed Phenotype Acute Leukemia,DRUG: Dexamethasone|DRUG: Vincristine|DRUG: Daunorubicin|DRUG: Calaspargase pegol|DRUG: Dasatinib|DRUG: Venetoclax|DRUG: Bortezomib|DRUG: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Mercaptopurine|DRUG: Nelarabine|DRUG: Methotrexate|DRUG: Thioguanine,St. Jude Children's Research Hospital,AbbVie,INTERVENTIONAL
NCT00292695,A Phase II Study of Nasal NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00292695,COMPLETED,Lymphoma,"OTHER: VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT","National Health Research Institutes, Taiwan","Mackay Memorial Hospital|National Cheng-Kung University Hospital|Taichung Veterans General Hospital|Taipei Veterans General Hospital, Taiwan|Kaohsiung Veterans General Hospital.|National Taiwan University Hospital|Tri-Service General Hospital|Chi Mei Medical Hospital|Kaohsiung Medical University|Changhua Christian Hospital|Buddhist Tzu Chi General Hospital",INTERVENTIONAL
NCT00030589,Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00030589,UNKNOWN,Lymphoma,DRUG: bexarotene|DRUG: methoxsalen|PROCEDURE: UV light therapy,Millennix,,INTERVENTIONAL
NCT03264131,BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT03264131,ACTIVE_NOT_RECRUITING,Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases,DRUG: Brentuximab Vedotin|DRUG: CHEP,UNC Lineberger Comprehensive Cancer Center,Seagen Inc.,INTERVENTIONAL
NCT02737046,Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,https://clinicaltrials.gov/study/NCT02737046,ACTIVE_NOT_RECRUITING,Adult T-cell Leukemia-Lymphoma|ATLL,DRUG: Belinostat|DRUG: Zidovudine|DRUG: Interferon-Alfa-2b|DRUG: Pegylated Interferon-Alfa-2b,University of Miami,,INTERVENTIONAL
NCT05477264,"Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type",https://clinicaltrials.gov/study/NCT05477264,RECRUITING,Lymphoma,DRUG: Tislelizumab,Won Seog Kim,,INTERVENTIONAL
NCT02992834,Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma,https://clinicaltrials.gov/study/NCT02992834,UNKNOWN,"Lymphoma, B Cell",BIOLOGICAL: IL-2 pre-treated CD19 cells|BIOLOGICAL: IL-7/IL-15 pre-treated CD19 cells,jiangjingting,,INTERVENTIONAL
NCT04338282,Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04338282,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: toripalimab,Beijing Tongren Hospital,,INTERVENTIONAL
NCT01926665,"Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)",https://clinicaltrials.gov/study/NCT01926665,COMPLETED,Lymphoma,DRUG: Carfilzomib|DRUG: Dexamethasone,M.D. Anderson Cancer Center,Amgen,INTERVENTIONAL
NCT00255801,Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00255801,COMPLETED,Lymphoma,DRUG: Targretin® (bexarotene)|DRUG: pegylated liposomal doxorubicin hydrochloride,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI)|Tibotec Pharmaceutical Limited|M.D. Anderson Cancer Center|NYU Langone Health|Hackensack Meridian Health|Roswell Park Cancer Institute,INTERVENTIONAL
NCT06340737,AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas,https://clinicaltrials.gov/study/NCT06340737,RECRUITING,Follicular Lymphoma|Mantle Cell Lymphoma|Hairy Cell Leukemia|Lymphoplasmacytic Lymphoma|Burkitt Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,DRUG: CD22CART Infusion,Stanford University,The Leukemia and Lymphoma Society,INTERVENTIONAL
NCT00182650,Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00182650,COMPLETED,Lymphoma,BIOLOGICAL: aldesleukin|BIOLOGICAL: rituximab|BIOLOGICAL: therapeutic autologous lymphocytes|DRUG: fludarabine phosphate,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04889716,CAR-T Followed by Bispecific Antibodies,https://clinicaltrials.gov/study/NCT04889716,RECRUITING,Large B-cell Lymphoma|DLBCL - Diffuse Large B Cell Lymphoma,DRUG: mosunetuzumab|DRUG: glofitamab|DRUG: obinutuzumab,Abramson Cancer Center at Penn Medicine,"Genentech, Inc.",INTERVENTIONAL
NCT00501826,Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT00501826,RECRUITING,T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma,DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Nelarabine|DRUG: Pegaspargase|DRUG: Prednisone|DRUG: Venetoclax|DRUG: Vincristine Sulfate,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00578461,"T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE",https://clinicaltrials.gov/study/NCT00578461,TERMINATED,"Leukemia|Cancer|Lymphoma|Lymphoma, Hodgkin|Lymphoma, Non-Hodgkin",DRUG: Ara C|DRUG: Mesna|DRUG: Cyclophosphamide|RADIATION: TBI-Total Body Irradiation,Baylor College of Medicine,,INTERVENTIONAL
NCT05833724,Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL),https://clinicaltrials.gov/study/NCT05833724,RECRUITING,Relapsed or Refractory Peripheral T-cell Lymphoma,DRUG: Chidamide,Great Novel Therapeutics Biotech & Medicals Corporation,,INTERVENTIONAL
NCT05990465,"LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",https://clinicaltrials.gov/study/NCT05990465,RECRUITING,Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Burkitt Lymphoma,DRUG: Pirtobrutinib|DRUG: LV20.19 CAR T cells,Medical College of Wisconsin,,INTERVENTIONAL
NCT03409432,Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03409432,ACTIVE_NOT_RECRUITING,Lymphomatoid Papulosis|Primary Cutaneous Anaplastic Large Cell Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma,DRUG: Brentuximab Vedotin|OTHER: Laboratory Biomarker Analysis|DRUG: Lenalidomide,John Reneau,,INTERVENTIONAL
NCT06106776,CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study,https://clinicaltrials.gov/study/NCT06106776,NOT_YET_RECRUITING,Lymphoma,DRUG: Chimeric Antigen Receptor,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,OBSERVATIONAL
NCT06067347,A Global Study of the PETAL Consortium,https://clinicaltrials.gov/study/NCT06067347,RECRUITING,T-Cell and NK-Cell Neoplasm,,Massachusetts General Hospital,,OBSERVATIONAL
NCT03383965,CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas,https://clinicaltrials.gov/study/NCT03383965,RECRUITING,Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma,BIOLOGICAL: ICAR30 T cells,"Immune Cell, Inc.",Weifang People's Hospital,INTERVENTIONAL
NCT02881749,Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT02881749,UNKNOWN,Mycosis Fungoides|Cutaneous T-cell Lymphoma,RADIATION: Total skin electron beam therapy (TSEBT)|DRUG: mechlorethamine gel 0.016%,Thomas Jefferson University,Actelion,INTERVENTIONAL
NCT02386813,International Extranodal NK/T-cell Lymphoma Project,https://clinicaltrials.gov/study/NCT02386813,COMPLETED,"Extranodal NK/T-cell Lymphoma, Nasal Type",,Samsung Medical Center,Seok Jin Kim|Consortium for Improving Survival of Lymphoma|Asia Lymphoma Study Group|Lymphoma Study Association|Dok Hyun Yoon|Arnaud Jaccard|Wee Joo Chng|Soon Thye Lim|Huangming Hong|Yong Park|Kian Meng Chang|Yoshinobu Maeda|Fumihiro Ishida|Dong-Yeop Shin|Jin Seok Kim|Seong Hyun Jeong|Deok-Hwan Yang|Jae-Cheol Jo|Gyeong-Won Lee|Chul Won Choi|Won-Sik Lee|Tsai-Yun Chen|Kiyeun Kim|Sin-Ho Jung|Tohru Murayama|Yasuhiro Oki|Ranjana Advani|Francesco d'Amore|Norbert Schmitz|Cheolwon Suh|Ritsuro Suzuki|Yok Lam Kwong|Tong-Yu Lin,OBSERVATIONAL
NCT06180174,Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT06180174,RECRUITING,B Cell Lymphoma|Non Hodgkin Lymphoma,BIOLOGICAL: MC-1-50,"Chongqing Precision Biotech Co., Ltd",Peking University Cancer Hospital & Institute,INTERVENTIONAL
NCT06120504,A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers,https://clinicaltrials.gov/study/NCT06120504,RECRUITING,"Lymphoma, T-Cell, Cutaneous|Hodgkin Disease|Lymphoma, T-Cell, Peripheral|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin",DRUG: PF-08046045,"Seagen, a wholly owned subsidiary of Pfizer",,INTERVENTIONAL
NCT00003423,Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00003423,UNKNOWN,Lymphoma,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: etoposide|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: prednisolone|DRUG: thioguanine|DRUG: vincristine sulfate,United Kingdom Children's Cancer Study Group,,INTERVENTIONAL
NCT03586024,"Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas",https://clinicaltrials.gov/study/NCT03586024,WITHDRAWN,Lymphoma,DRUG: Pembrolizumab,Abramson Cancer Center at Penn Medicine,,INTERVENTIONAL
NCT03629873,Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects,https://clinicaltrials.gov/study/NCT03629873,UNKNOWN,"Lymphoma, Large B-Cell, Diffuse|Mantle Cell Lymphoma|Peripheral T Cell Lymphoma|Double-hit Lymphoma",DRUG: Chidamide,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT04128072,Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04128072,RECRUITING,Stage IB-IIB Cutaneous T-Cell Lymphoma,DRUG: Mogamulizumab|RADIATION: Total Skin Electron Beam Therapy (TSEB)|DRUG: Mogamulizumab (subsequent cycles post TSEB),European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT03040206,Risk Stratification of Nodal PTCL,https://clinicaltrials.gov/study/NCT03040206,COMPLETED,"Peripheral T-Cell Lymphoma, Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-negative",,Chonbuk National University Hospital,Chonnam National University Hospital|Kyungpook National University Hospital|Keimyung University Dongsan Medical Center|Korea University Anam Hospital|Korea University Guro Hospital|Dong-A University Hospital|Pusan National University Hospital|Yeungnam University Hospital|Inje University|Chungnam National University Hospital|Samsung Medical Center,OBSERVATIONAL
NCT00070291,Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00070291,TERMINATED,Lymphoma,DRUG: cyclosporine,Eastern Cooperative Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT00933673,"New Combination Regimen of L-asparaginase, Dexamethasone, Ifosfamide, Cisplatin and Etoposide in NK/T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00933673,UNKNOWN,Lymphoma,"DRUG: L-asp, DXM, IFO, VP-16, DDP",Fudan University,,INTERVENTIONAL
NCT03356678,Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03356678,COMPLETED,Relapsed or Refractory Peripheral T-cell Lymphoma,DRUG: Pralatrexate,Samsung Medical Center,,OBSERVATIONAL
NCT01555892,"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE",https://clinicaltrials.gov/study/NCT01555892,RECRUITING,Hodgkin's Disease|Non-Hodgkin's Lymphoma|Lymphoproliferative Disease|Lymphoma,BIOLOGICAL: EBV-specific T cells: A|BIOLOGICAL: EBV-specific T cells: B,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine|National Institutes of Health (NIH)|National Cancer Institute (NCI)",INTERVENTIONAL
NCT06064903,CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL,https://clinicaltrials.gov/study/NCT06064903,RECRUITING,T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma,BIOLOGICAL: CD7-CART01,Bambino Gesù Hospital and Research Institute,,INTERVENTIONAL
NCT04096690,Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04096690,UNKNOWN,Nasal Type Extranodal NK/T-Cell Lymphoma,DRUG: Pegaspargase|DRUG: Anti-PD-1 monoclonal antibody,Ruijin Hospital,,INTERVENTIONAL
NCT00290433,Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00290433,COMPLETED,Lymphoma,DRUG: Cyclophosphamide|DRUG: Mesna|DRUG: Vincristine|DRUG: Methotrexate|DRUG: Ara-C|DRUG: Dexamethasone|DRUG: G-CSF|DRUG: Doxil,M.D. Anderson Cancer Center,"Ortho Biotech, Inc.",INTERVENTIONAL
NCT00568607,Study on the Combination Regimen of Dexamethasone Ifosfamide Cisplatin Etoposide in Patients With NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT00568607,UNKNOWN,Lymphoma,"DRUG: IFO, VP-16, DDP, DXM",Fudan University,,INTERVENTIONAL
NCT01871727,A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01871727,COMPLETED,Persistent or Recurrent Cutaneous T-Cell Lymphoma,DRUG: E7777 9 mcg/kg,Eisai Inc.,"Dr. Reddy's Laboratories Limited|Citius Pharmaceuticals, Inc.",INTERVENTIONAL
NCT01667302,Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01667302,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: Radiotherapy followed by chemotherapy,Fudan University,,INTERVENTIONAL
NCT05909527,A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma,https://clinicaltrials.gov/study/NCT05909527,ACTIVE_NOT_RECRUITING,T-Cell Acute Lymphocytic Leukemia,BIOLOGICAL: CD7 CAR-T,"Guangzhou Bio-gene Technology Co., Ltd",,INTERVENTIONAL
NCT02464228,Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy,https://clinicaltrials.gov/study/NCT02464228,COMPLETED,Relapsed or Refractory Peripheral T-Cell Lymphoma,DRUG: Tipifarnib,"Kura Oncology, Inc.",,INTERVENTIONAL
NCT05527275,A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05527275,UNKNOWN,Relapsed and Refractory Peripheral T-cell Lymphoma,DRUG: Mitoxantrone liposome combine with Chidamide,Sun Yat-sen University,,INTERVENTIONAL
NCT01445340,Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01445340,TERMINATED,Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms,DRUG: Romidepsin (FR901228),National Cancer Institute (NCI),,INTERVENTIONAL
NCT03000738,The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas,https://clinicaltrials.gov/study/NCT03000738,UNKNOWN,"Lymphoma,Non-Hodgkin|Diffuse Large B Cell Lymphoma|Peripheral T-Cell Lymphoma",,Peking Union Medical College Hospital,,OBSERVATIONAL
NCT04329130,Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04329130,UNKNOWN,Relapsed or Refractory Peripheral T-cell Lymphoma,"DRUG: Chidamide, Lenalidomide",Sun Yat-sen University,,INTERVENTIONAL
NCT05757700,Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05757700,ACTIVE_NOT_RECRUITING,"B-Cell Lymphoma|Large B-cell Lymphoma|DLBCL, Nos Genetic Subtypes|High-grade B Cell Lymphoma|Mediastinal Large B-cell Lymphoma",BIOLOGICAL: 19(T2)28z1xx TRAC T cell,Memorial Sloan Kettering Cancer Center,Takeda,INTERVENTIONAL
NCT04101331,Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides,https://clinicaltrials.gov/study/NCT04101331,COMPLETED,Peripheral T Cell Lymphoma|Transformed Mycosis Fungoides,DRUG: AFM13,Affimed GmbH,,INTERVENTIONAL
NCT04303247,CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL,https://clinicaltrials.gov/study/NCT04303247,UNKNOWN,B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent,BIOLOGICAL: CD19 and CD22 targeted CAR-T cells,Xinqiao Hospital of Chongqing,"Gracell Biotechnologies (Shanghai) Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Affiliated Hospital Of Guizhou Medical University|Tang-Du Hospital|The General Hospital of Western Theater Command|Chongqing University Cancer Hospital",INTERVENTIONAL
NCT02342782,Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT02342782,COMPLETED,Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Yttrium Y 90 Basiliximab|DRUG: Carmustine|DRUG: Etoposide|DRUG: Cytarabine|DRUG: Melphalan|PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00660231,"Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT00660231,COMPLETED,Lymphoma,DRUG: bexarotene|DRUG: gemcitabine hydrochloride,"University College, London",,INTERVENTIONAL
NCT04911478,Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells,https://clinicaltrials.gov/study/NCT04911478,ENROLLING_BY_INVITATION,"Lymphoma, Follicular|Lymphoma, Mantle-Cell|Marginal Zone Lymphoma|Primary Mediastinal B-cell Lymphoma|Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin",GENETIC: ADI-001,Adicet Therapeutics,,OBSERVATIONAL
NCT05312801,Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05312801,RECRUITING,"Lymphoma, Non-Hodgkin Lymphoma, B-Cell",DRUG: BAFF CAR-T,Luminary Therapeutics,Case Comprehensive Cancer Center,INTERVENTIONAL
NCT01667289,Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01667289,TERMINATED,"Extranodal NK/T-cell Lymphoma, Nasal Type",RADIATION: Radiotherapy alone|DRUG: Concurrent chemoradiation,Fudan University,,INTERVENTIONAL
NCT03999658,A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies,https://clinicaltrials.gov/study/NCT03999658,WITHDRAWN,"Peripheral T Cell Lymphoma|Diffuse Large B Cell Lymphoma|Biliary Tract Cancer|Extranodal NK T Cell Lymphoma, Nasal",BIOLOGICAL: STI-3031,"Sorrento Therapeutics, Inc.",,INTERVENTIONAL
NCT04108325,A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04108325,UNKNOWN,Relapsed or Refractory Peripheral T-Cell Lymphoma,DRUG: YY-20394,Shanghai YingLi Pharmaceutical Co. Ltd.,,INTERVENTIONAL
NCT04484012,Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT04484012,RECRUITING,Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,DRUG: Acalabrutinib|BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04679506,the Efficacy and Safety of CLAE in R/R T-ALL/LBL,https://clinicaltrials.gov/study/NCT04679506,UNKNOWN,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,DRUG: Cladribine,Peking University Third Hospital,,OBSERVATIONAL
NCT05015972,UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05015972,WITHDRAWN,B-cell Lymphoma,BIOLOGICAL: CTA30X UCAR-T injection,920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,"Nanjing Bioheng Biotech Co., Ltd.",INTERVENTIONAL
NCT03646422,AEDV Registry of Primary Cutaneous Lymphoma,https://clinicaltrials.gov/study/NCT03646422,UNKNOWN,"Lymphoma, T-Cell, Cutaneous|Lymphoma, B-Cell, Marginal Zone|Lymphoma, Large B-Cell, Diffuse|Sezary Syndrome|Lymphoma, Extranodal NK-T-Cell|Lymphoma, B-Cell",OTHER: Registry of patients (exposure is Cutaneous Lymphoma),Fundación Academia Española de Dermatología,,OBSERVATIONAL
NCT01921790,Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01921790,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",BIOLOGICAL: Avastin|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Pegaspargase|DRUG: Dexamethasone,Sun Yat-sen University,Hoffmann-La Roche|Eli Lilly and Company,INTERVENTIONAL
NCT05673785,"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)",https://clinicaltrials.gov/study/NCT05673785,ACTIVE_NOT_RECRUITING,Lymphoma,DRUG: Brentuximab Vedotin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Prednisone,Takeda,,INTERVENTIONAL
NCT01007526,Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01007526,COMPLETED,NK/T-cell Lymphoma of Nasal Cavity,OTHER: CCRT followed by VIDL chemotherapy,Samsung Medical Center,"Asan Medical Center|National Cancer Center, Korea|Severance Hospital",INTERVENTIONAL
NCT00003613,O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00003613,TERMINATED,Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma,DRUG: O6-benzylguanine|DRUG: carmustine|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02963038,CAR T Cells for Refractory B Cell Malignancy,https://clinicaltrials.gov/study/NCT02963038,UNKNOWN,B-Cell Leukemia|B-Cell Lymphoma,BIOLOGICAL: Autologous CD19-targeting CAR T cells,"Hebei Senlang Biotechnology Inc., Ltd.",The Second Hospital of Hebei Medical University,INTERVENTIONAL
NCT00771472,Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1),https://clinicaltrials.gov/study/NCT00771472,COMPLETED,Lymphoma,DRUG: vorinostat,Merck Sharp & Dohme LLC,,INTERVENTIONAL
NCT05651100,Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT05651100,NOT_YET_RECRUITING,"Lymphoma, B-Cell",BIOLOGICAL: CD19 and CD22 targeted CAR-T cells,Kecellitics Biotech Company Ltd,Hebei Yanda Ludaopei Hospital,INTERVENTIONAL
NCT02825147,Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT02825147,COMPLETED,Nasal Type Extranodal NK/T-Cell Lymphoma,DRUG: Pegaspargase|DRUG: Methotrexate|DRUG: Dexamethasone|DRUG: Etoposide|RADIATION: radiotherapy,Ruijin Hospital,,INTERVENTIONAL
NCT05436223,Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05436223,RECRUITING,B-cell Non-Hodgkin's Lymphoma,DRUG: Human CD19Targeted T Cells Injection,"Hrain Biotechnology Co., Ltd.",Shanghai Zhongshan Hospital,INTERVENTIONAL
NCT05631912,TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL,https://clinicaltrials.gov/study/NCT05631912,RECRUITING,"Non-hodgkin Lymphoma,B Cell",BIOLOGICAL: Autologous CD19-STAR-T cell|DRUG: Fludarabine|DRUG: Cyclophosphamide,Chinese PLA General Hospital,,INTERVENTIONAL
NCT04602065,Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial,https://clinicaltrials.gov/study/NCT04602065,TERMINATED,"Extranodal NK/T Cell Lymphoma, Nasal Type",DRUG: IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody),Innovent Biologics (Suzhou) Co. Ltd.,,INTERVENTIONAL
NCT06339255,Italian Observational Study on CAR-T Therapy for Lymphoma,https://clinicaltrials.gov/study/NCT06339255,RECRUITING,Diffuse Low Grade B-Cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Mantle Cell Lymphoma|Follicular Lymphoma,,Paolo Corradini,Annalisa Chiappella|Cristiana Carniti|Anna Dodero,OBSERVATIONAL
NCT06712121,Venetoclax and Decitabine in R/R T-ALL,https://clinicaltrials.gov/study/NCT06712121,NOT_YET_RECRUITING,T Lymphoblastic Leukemia/Lymphoma,DRUG: decitabine plus venetoclax,Seoul National University Hospital,Korean Society of Hematology,INTERVENTIONAL
NCT00630903,PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00630903,TERMINATED,Cutaneous T-Cell Lymphoma (Mycosis Fungoides),DRUG: PUVA (8MOP + UVA) + IFN|DRUG: PUVA (8-MOP + UVA),Madrilenian Group of Cutaneous Lymphomas,,INTERVENTIONAL
NCT03052933,Copanlisib and Gemcitabine in Relapsed/Refractory PTCL,https://clinicaltrials.gov/study/NCT03052933,COMPLETED,Mature T-Cell and NK-Cell Neoplasm,DRUG: Copanlisib|DRUG: Gemcitabine,Chonnam National University Hospital,Bayer|Consortium for Improving Survival of Lymphoma,INTERVENTIONAL
NCT03932955,MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03932955,UNKNOWN,Lymphoma,BIOLOGICAL: MC-19PD1 CAR-T cells,Peking University,,INTERVENTIONAL
NCT06532643,Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma,https://clinicaltrials.gov/study/NCT06532643,RECRUITING,Relapsed/Refractory Lymphoma,GENETIC: anti-CD20/CD30-CAR-T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Shanghai First Song Biotechnology Co., LTD",,INTERVENTIONAL
NCT02776813,Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT02776813,COMPLETED,Lymphoma,BIOLOGICAL: ACTR087|BIOLOGICAL: rituximab,"Cogent Biosciences, Inc.",,INTERVENTIONAL
NCT01991158,GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT01991158,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: High dose of methotrexate|DRUG: Gemcitabine|DRUG: Pegaspargase|DRUG: Dexamethasone,Sun Yat-sen University,Eli Lilly and Company,INTERVENTIONAL
NCT03363555,SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03363555,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: SHR-1210,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL
NCT04620655,RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL,https://clinicaltrials.gov/study/NCT04620655,UNKNOWN,T Acute Lymphoblastic Leukemia|T-lymphoblastic Lymphoma,DRUG: RD13-01 cell infusion,Min Xiang,,INTERVENTIONAL
NCT03054532,Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03054532,UNKNOWN,LYMPHOMA,DRUG: Durvalumab|DRUG: Lenali,Singapore General Hospital,Celgene,INTERVENTIONAL
NCT01421667,A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01421667,COMPLETED,"Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell",DRUG: brentuximab vedotin|DRUG: rituximab,Seagen Inc.,,INTERVENTIONAL
NCT05883449,Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL,https://clinicaltrials.gov/study/NCT05883449,RECRUITING,Relapsed or Refractory Hodgkin Lymphoma|Peripheral T Cell Lymphoma,DRUG: AFM13|DRUG: AB-101|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Interleukin-2,Affimed GmbH,"Artiva Biotherapeutics, Inc.",INTERVENTIONAL
NCT05239676,Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma,https://clinicaltrials.gov/study/NCT05239676,UNKNOWN,Lymphoma,BIOLOGICAL: Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT06176690,Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas,https://clinicaltrials.gov/study/NCT06176690,NOT_YET_RECRUITING,"CD30-Positive Diffuse Large B-Cell Lymphoma|Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type|Anaplastic Large Cell Lymphoma, ALK-Positive|Peripheral T-cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-negative|Non-Hodgkin Lymphoma|Hodgkin Lymphoma",BIOLOGICAL: C7R.CD30.CAR-EBVST cells,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT04121507,ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy,https://clinicaltrials.gov/study/NCT04121507,COMPLETED,"Aggressive Non-hodgkin Lymphoma (aNHL)|Lymphoma, B-Cell|Lymphoma, T-Cell",DRUG: High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|PROCEDURE: Bone marrow histology|DIAGNOSTIC_TEST: clinical and laboratory parameters|DIAGNOSTIC_TEST: PET-CT or CT,GWT-TUD GmbH,,INTERVENTIONAL
NCT00854425,L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT00854425,COMPLETED,Lymphoma,DRUG: L-asparaginase,Fudan University,,INTERVENTIONAL
NCT04747093,Induced-T Cell Like NK Cells for B Cell Malignancies,https://clinicaltrials.gov/study/NCT04747093,UNKNOWN,B Cell Leukemia|B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory,BIOLOGICAL: CAR-ITNK cells,"Nanfang Hospital, Southern Medical University",,INTERVENTIONAL
NCT05176275,PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t Cells,https://clinicaltrials.gov/study/NCT05176275,UNKNOWN,Lymphoma,DIAGNOSTIC_TEST: 68Ga-NOTA-RP25,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT03929107,Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.,https://clinicaltrials.gov/study/NCT03929107,UNKNOWN,B Cell Lymphoma,BIOLOGICAL: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells,Wenbin Qian,Zhejiang Provincial Tongde Hospital,INTERVENTIONAL
NCT02764281,MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02764281,COMPLETED,"Extranodal NK-T-Cell Lymphoma, Nasal Type",DRUG: MEDA|PROCEDURE: Auto-HSCT,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT04890236,"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study",https://clinicaltrials.gov/study/NCT04890236,COMPLETED,Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,DRUG: Duvelisib|BIOLOGICAL: Tisagenlecleucel,Emory University,"National Cancer Institute (NCI)|Secura Bio, Inc.|Novartis",INTERVENTIONAL
NCT00779337,Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas,https://clinicaltrials.gov/study/NCT00779337,COMPLETED,Lymphoma,BIOLOGICAL: Autologous AdE1- Latent Membrane Protein CTLs,Queensland Institute of Medical Research,"The Atlantic Philanthropies|Australian Department of Industry, Tourism and Resources|British Society for Haematology|National Health and Medical Research Council, Australia",INTERVENTIONAL
NCT04782193,a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04782193,UNKNOWN,B Cell Lymphoma,BIOLOGICAL: CD19 and CD22 targeted prime CAR- T cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT06494371,A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT06494371,RECRUITING,Hodgkin's Lymphoma|Anaplastic Large Cell Lymphoma,BIOLOGICAL: LCAR-HL30 cells,Ruijin Hospital,Nanjing Legend Biotech Co.,INTERVENTIONAL
NCT06458439,Epcoritamab-CAR T Cells for Large B-cell Lymphomas,https://clinicaltrials.gov/study/NCT06458439,RECRUITING,"Lymphoma, Non-Hodgkin|Relapsed Diffuse Large B Cell Lymphoma|Refractory Diffuse Large B-cell Lymphoma|High-grade B-cell Lymphoma|Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",DRUG: Epcoritamab,Abramson Cancer Center at Penn Medicine,Genmab,INTERVENTIONAL
NCT04033302,Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies,https://clinicaltrials.gov/study/NCT04033302,UNKNOWN,T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|Acute Myeloid Leukemia|NK Cell Lymphoma,BIOLOGICAL: CD7-specific CAR gene-engineered T cells,Shenzhen Geno-Immune Medical Institute,,INTERVENTIONAL
NCT02878278,"Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation",https://clinicaltrials.gov/study/NCT02878278,UNKNOWN,"Lymphoma, Extranodal NK-T-Cell|EBV",DRUG: Chidamide BIW|DRUG: Chidamide QD,Huiqiang Huang,,INTERVENTIONAL
NCT01316146,Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30),https://clinicaltrials.gov/study/NCT01316146,WITHDRAWN,Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma,DRUG: CAR.CD30 T cells,UNC Lineberger Comprehensive Cancer Center,"The Methodist Hospital Research Institute|Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT00924326,CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma,https://clinicaltrials.gov/study/NCT00924326,COMPLETED,"Primary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle Cell",DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Anti-cluster of differentiation 19 (CD19)-CAR PBL|DRUG: Aldesleukin|DRUG: Fludarabine|DRUG: Cyclophosphamide,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02631239,MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02631239,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: Methotrexate|DRUG: Etoposide|DRUG: Dexamethasone|DRUG: Pegaspargase|RADIATION: Radiotherapy,Ruijin Hospital,,INTERVENTIONAL
NCT02659943,T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies,https://clinicaltrials.gov/study/NCT02659943,COMPLETED,"Lymphoma, B-Cell|Lymphoma, Non-hodgkins",BIOLOGICAL: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01787409,Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency,https://clinicaltrials.gov/study/NCT01787409,RECRUITING,"Aggressive Non-Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Mediastinal (Thymic) Large B-Cell Lymphoma|Nasal Type Extranodal NK/T-Cell Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Primary Cutaneous Anaplastic Large Cell Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Small Lymphocytic Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma",DIETARY_SUPPLEMENT: Cholecalciferol|OTHER: Laboratory Biomarker Analysis,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT04511351,Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT04511351,UNKNOWN,Lymphoma,DRUG: Chidamide,Chinese Academy of Medical Sciences,,INTERVENTIONAL
NCT04300998,Study of CAR-T Therapy in Older Patients,https://clinicaltrials.gov/study/NCT04300998,ACTIVE_NOT_RECRUITING,"Lymphoma|Refractory B-Cell Lymphoma|Lymphoma, B-Cell|DLBCL NOS|High-grade B-cell Lymphoma|Multiple Myeloma",BEHAVIORAL: Activities of Daily Living/ADLs|BEHAVIORAL: Instrumental Activity of Daily Living|BEHAVIORAL: Timed Up and Go|BEHAVIORAL: Cognition|BEHAVIORAL: Geriatric Depression Scale|BEHAVIORAL: Social Support|BEHAVIORAL: Brief Test of Attention|BEHAVIORAL: Trail Making Test|BEHAVIORAL: Controlled Oral Word Association Test|BEHAVIORAL: Hopkins Verbal Learning Test-Revised|OTHER: Blood draw,Memorial Sloan Kettering Cancer Center,,OBSERVATIONAL
NCT05404048,PD-L1 PET-imaging During CAR T-cell Therapy,https://clinicaltrials.gov/study/NCT05404048,RECRUITING,Large B-cell Lymphoma,OTHER: 89Zr-atezolizumab PET-imaging,University Medical Center Groningen,,INTERVENTIONAL
NCT01366170,Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT01366170,COMPLETED,Lymphoma,GENETIC: microarray analysis|GENETIC: protein expression analysis|GENETIC: western blotting|OTHER: flow cytometry|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis|OTHER: mass spectrometry,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT04774068,Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT04774068,COMPLETED,Recurrent Anaplastic Large Cell Lymphoma|Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Mycosis Fungoides|Refractory Anaplastic Large Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Transformed Mycosis Fungoides|T-Cell Non-Hodgkin Lymphoma,DRUG: Parsaclisib|DRUG: Romidepsin,Walter Hanel,,INTERVENTIONAL
NCT00003837,506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT00003837,COMPLETED,Leukemia|Lymphoma,DRUG: nelarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04984356,A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL,https://clinicaltrials.gov/study/NCT04984356,COMPLETED,T-cell Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,BIOLOGICAL: WU-CART-007,"Wugen, Inc.",,INTERVENTIONAL
NCT04998331,A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin,https://clinicaltrials.gov/study/NCT04998331,COMPLETED,"Hodgkin Disease|Lymphoma, T-Cell, Cutaneous",OTHER: No Intervention,Takeda,,OBSERVATIONAL
NCT01497184,Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood,https://clinicaltrials.gov/study/NCT01497184,COMPLETED,Leukemia|Lymphoma,PROCEDURE: HSCT|GENETIC: DLI,M.D. Anderson Cancer Center,Ziopharm Oncology,INTERVENTIONAL
NCT04405375,GPED Regimen for Relapsed/Refractory or Advanced ENKTCL,https://clinicaltrials.gov/study/NCT04405375,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: gemcitabin|DRUG: Pegaspargase|DRUG: Etoposide|DRUG: Dexamethasone,Beijing Tongren Hospital,,INTERVENTIONAL
NCT02733458,GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02733458,COMPLETED,"Extranodal NK-T-Cell Lymphoma, Nasal Type",DRUG: GELAD|RADIATION: Radiotherapy,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT07008872,CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia,https://clinicaltrials.gov/study/NCT07008872,NOT_YET_RECRUITING,CD7+ Lymphoma|CD7+ Acute Leukemia,BIOLOGICAL: CD7 CART,Qi deng,"Hebei Taihe Chunyu Biotechnology Co., Ltd",INTERVENTIONAL
NCT05385263,Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion,https://clinicaltrials.gov/study/NCT05385263,UNKNOWN,B Cell Lymphoma,DRUG: Nivolumab Injection [Opdivo],Tel-Aviv Sourasky Medical Center,,INTERVENTIONAL
NCT03789864,Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT03789864,TERMINATED,"Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides",DIAGNOSTIC_TEST: Biodynamic imaging (BDI) of mycosis fungoides,Indiana University,Purdue University,INTERVENTIONAL
NCT04021082,CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT04021082,WITHDRAWN,"Peripheral T-Cell Lymphoma (PTCL NOS)|Nodal Lymphomas of T Follicular Helper (TFH)|Follicular T-cell Lymphoma (FTCL)|AITL|ALCL|HSTCL|EATL I,II|MEITL, EATL Type II|Nasal Lymphoma",DRUG: Cerdulatinib,Portola Pharmaceuticals,,INTERVENTIONAL
NCT00810576,Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00810576,TERMINATED,Lymphoma,DRUG: Vorinostat|DRUG: Bortezomib,M.D. Anderson Cancer Center,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT04014894,ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT04014894,UNKNOWN,Leukemia|Lymphoma,DRUG: ET019003-T Cells,"Wuhan Union Hospital, China","Eureka(Beijing) Biotechnology Co., Ltd.",INTERVENTIONAL
NCT03792256,Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL),https://clinicaltrials.gov/study/NCT03792256,COMPLETED,"Leukemia, Lymphocytic|Lymphoblastic Lymphoma|T-cell Lymphoma|T-cell Leukemia|Recurrent Disease|Acute Leukemia",DRUG: Palbociclib|DRUG: Cytarabine|DRUG: Methotrexate|DRUG: Hydrocortisone|DRUG: Doxorubicin|DRUG: Prednisolone|DRUG: Vincristine|DRUG: Pegaspargase|DRUG: Hydrocortisone|DRUG: Prednisone,Children's Oncology Group,,INTERVENTIONAL
NCT03113500,Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03113500,ACTIVE_NOT_RECRUITING,"Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Angioimmunoblastic T-Cell Lymphoma|Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Hepatosplenic T-Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified",DRUG: Brentuximab Vedotin|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|DRUG: Etoposide Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Prednisone,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05956041,"Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas",https://clinicaltrials.gov/study/NCT05956041,RECRUITING,Cutaneous T Cell Lymphoma|Fungoides Mycosis Sezary Syndrome,DRUG: Pembrolizumab|DRUG: Mogamulizumab,University of Michigan Rogel Cancer Center,Merck Sharp & Dohme LLC|Hoosier Cancer Research Network,INTERVENTIONAL
NCT02142530,Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,https://clinicaltrials.gov/study/NCT02142530,COMPLETED,Non-Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Peripheral T-cell Lymphoma,DRUG: Carfilzomib|DRUG: Belinostat,Massachusetts General Hospital,National Comprehensive Cancer Network,INTERVENTIONAL
NCT06479356,CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06479356,RECRUITING,Non-Hodgkin Lymphoma|Large B-cell Lymphoma,BIOLOGICAL: Relma-cel,"Shanghai Ming Ju Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT03070964,A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03070964,TERMINATED,Lymphoma,DRUG: plitidepsin,PharmaMar,,INTERVENTIONAL
NCT06378190,Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology,https://clinicaltrials.gov/study/NCT06378190,RECRUITING,Refractory B-Cell Lymphoma|B-cell Lymphoma Recurrent,BIOLOGICAL: CAR-T cells therapy,Instituto de Investigación Biomédica de Salamanca,Spanish Clinical Research Network - SCReN|Fundación Canaria de Investigación Sanitaria|Fundación para la Investigación Biomédica del Hospital 12 de Octubre,INTERVENTIONAL
NCT04320992,"A Multicenter Prospective Study of ""High Risk"" Molecular Typing in Patients With Adult T Lymphoblastic Lymphoma",https://clinicaltrials.gov/study/NCT04320992,UNKNOWN,T-Lymphoblastic Lymphoma/Leukemia,,Sun Yat-sen University,,OBSERVATIONAL
NCT05995028,Universal 4SCAR7U Targeting CD7-positive Malignancies,https://clinicaltrials.gov/study/NCT05995028,RECRUITING,T-cell Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Lymphoma|Acute Myeloid Leukemia|NK Cell Lymphoma,BIOLOGICAL: Universal CD7-specific CAR gene-engineered T cells,Shenzhen Geno-Immune Medical Institute,,INTERVENTIONAL
NCT00217425,Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms,https://clinicaltrials.gov/study/NCT00217425,COMPLETED,Lymphoma,BIOLOGICAL: bevacizumab|DRUG: cyclophosphamide|DRUG: doxorubicin|DRUG: prednisone|DRUG: vincristine,Eastern Cooperative Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT02663297,Administration of T Lymphocytes for Prevention of Relapse of Lymphomas,https://clinicaltrials.gov/study/NCT02663297,ACTIVE_NOT_RECRUITING,"Hodgkin Disease|Lymphoma|Lymphoma, Non-Hodgkin|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Neoplasms by Histologic Type",DRUG: ATLCAR.CD30 cells,UNC Lineberger Comprehensive Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL
NCT03720457,Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.,https://clinicaltrials.gov/study/NCT03720457,UNKNOWN,CD19-positive|Diffuse Large B-cell Lymphoma|Follicular Lymphoma,DRUG: Human CD19 targeted T Cells Injection,"Hrain Biotechnology Co., Ltd.",Shanghai Zhongshan Hospital,INTERVENTIONAL
NCT00981799,"Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL",https://clinicaltrials.gov/study/NCT00981799,TERMINATED,Relapsed T-Cell Acute Lymphoblastic Leukemia|Relapsed T-Cell Lymphoblastic Lymphoma,DRUG: Nelarabine|DRUG: Etoposide|DRUG: Cyclophosphamide|DRUG: Methotrexate|DRUG: Filgrastim,Therapeutic Advances in Childhood Leukemia Consortium,GlaxoSmithKline|Novartis,INTERVENTIONAL
NCT04545762,Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04545762,RECRUITING,Refractory Non-Hodgkin Lymphoma|Burkitt Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Diffuse Large B Cell Lymphoma|Small Lymphocytic Lymphoma|Transformed Lymphoma,DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: anti-CD19 CAR-T cells,C. Babis Andreadis,"University of California, Davis",INTERVENTIONAL
NCT03262298,Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies,https://clinicaltrials.gov/study/NCT03262298,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: Anti-CD22-CAR-transduced T cells,Affiliated Hospital to Academy of Military Medical Sciences,,INTERVENTIONAL
NCT02836886,VircapSeq Virus Detection in Sézary Syndrome,https://clinicaltrials.gov/study/NCT02836886,COMPLETED,"Lymphoma, T-Cell, Cutaneous|Sézary Syndrome",,Columbia University,,OBSERVATIONAL
NCT03534180,Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03534180,COMPLETED,Anaplastic Large Cell Lymphoma|Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,OTHER: Laboratory Biomarker Analysis|DRUG: Romidepsin|DRUG: Venetoclax,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02423915,Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,https://clinicaltrials.gov/study/NCT02423915,COMPLETED,Leukemia|Lymphoma,DRUG: Rituximab|DRUG: Fludarabine|DRUG: Cyclophosphamide|RADIATION: Total Body Radiation|PROCEDURE: Fucosylated Regulatory T Cells|PROCEDURE: Cord Blood Infusions|DRUG: Mycophenolate mofetil|DRUG: Sirolimus|PROCEDURE: Bone Marrow Aspiration|DRUG: G-CSF|PROCEDURE: Non-Fucosylated Regulatory T Cells,M.D. Anderson Cancer Center,National Cancer Institute (NCI)|Cancer Prevention Research Institute of Texas,INTERVENTIONAL
NCT06514794,"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma",https://clinicaltrials.gov/study/NCT06514794,ACTIVE_NOT_RECRUITING,T-cell Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,BIOLOGICAL: WU-CART-007,"Wugen, Inc.",,INTERVENTIONAL
NCT02229682,Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy,https://clinicaltrials.gov/study/NCT02229682,UNKNOWN,"Lymphoma,|Non-Hodgkin Lymphoma,|Extranodal NK/T-cell Lymphoma,Nasal-type,",RADIATION: Mild-dose IMRT,Sun Yat-sen University,,INTERVENTIONAL
NCT02965157,Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma,https://clinicaltrials.gov/study/NCT02965157,UNKNOWN,"Lymphoma, B-Cell",BIOLOGICAL: CART20,"Beijing Biohealthcare Biotechnology Co.,Ltd",,INTERVENTIONAL
NCT06550141,Emapalumab Prevention of CAR-T Cell Associated Toxicities,https://clinicaltrials.gov/study/NCT06550141,RECRUITING,Large B-cell Lymphoma|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma,DRUG: Emapalumab|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|DRUG: Axicabtagene Ciloleucel,"Marcela V. Maus, M.D.,Ph.D.",Swedish Orphan Biovitrum,INTERVENTIONAL
NCT02652910,Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma,https://clinicaltrials.gov/study/NCT02652910,UNKNOWN,Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,DRUG: CD19.CAR-T cells,Xinqiao Hospital of Chongqing,"Xuzhou Medical University|Hrain Biotechnology Co., Ltd.|Shanghai Changzheng Hospital",INTERVENTIONAL
NCT00963274,Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,https://clinicaltrials.gov/study/NCT00963274,COMPLETED,Leukemia|Lymphoma,DRUG: Bortezomib|DRUG: Romidepsin,Virginia Commonwealth University,National Cancer Institute (NCI),INTERVENTIONAL
NCT04676789,Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL,https://clinicaltrials.gov/study/NCT04676789,UNKNOWN,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: Pegaspargase|DRUG: Anti-PD-1 monoclonal antibody|RADIATION: Definitive intensity-modulated radiotherapy (IMRT),Sun Yat-sen University,,INTERVENTIONAL
NCT00684619,506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL),https://clinicaltrials.gov/study/NCT00684619,COMPLETED,"T-ALL, T-NHL (Lymphoblastic)",DRUG: Nelarabine,Goethe University,,INTERVENTIONAL
NCT02974647,Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma,https://clinicaltrials.gov/study/NCT02974647,RECRUITING,Lymphoma,DRUG: Ruxolitinib,Memorial Sloan Kettering Cancer Center,Cornell University|Dana-Farber Cancer Institute|Thomas Jefferson University,INTERVENTIONAL
NCT00098332,"Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00098332,COMPLETED,Lymphoma,DRUG: forodesine hydrochloride,BioCryst Pharmaceuticals,,INTERVENTIONAL
NCT01871675,Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01871675,COMPLETED,Lymphoma|Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma|T-cell Lymphoma,DRUG: IPI-145|DRUG: Rituximab|DRUG: Bendamustine,"SCRI Development Innovations, LLC","Infinity Pharmaceuticals, Inc.",INTERVENTIONAL
NCT05020392,Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma,https://clinicaltrials.gov/study/NCT05020392,RECRUITING,Diffuse Large B Cell Lymphoma|Burkitt Lymphoma|Follicular Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma,DRUG: BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells|DRUG: Fludarabine-based chemotherapy + CAR-T-CD19 Cells,"Wuhan Union Hospital, China","Wuhan Si'an Medical Technology Co., Ltd",INTERVENTIONAL
NCT04107285,Looking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T Therapy,https://clinicaltrials.gov/study/NCT04107285,RECRUITING,Lymphoma Receiving CAR-T Therapy,BEHAVIORAL: neurocognitive evaluations|DIAGNOSTIC_TEST: brain MRIs|OTHER: Blood samples,Memorial Sloan Kettering Cancer Center,,OBSERVATIONAL
NCT02341209,Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT02341209,TERMINATED,Cutaneous T-cell Lymphoma|Mycosis Fungoides|Sezary Syndrome,DRUG: Doxycycline monohydrate,Rochester General Hospital,,INTERVENTIONAL
NCT00369629,Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome,https://clinicaltrials.gov/study/NCT00369629,TERMINATED,Lymphoma,DRUG: Gemcitabine|DRUG: Pemetrexed,Northwestern University,National Cancer Institute (NCI)|Eli Lilly and Company,INTERVENTIONAL
NCT04105010,"Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)",https://clinicaltrials.gov/study/NCT04105010,COMPLETED,Relapsed or Refractory Peripheral T Cell Lymphoma,DRUG: golidocitinib,Dizal Pharmaceuticals,,INTERVENTIONAL
NCT05781386,A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors,https://clinicaltrials.gov/study/NCT05781386,RECRUITING,Advanced Solid Tumor|Cutaneous T Cell Lymphoma,DRUG: SIM1811-03 or in combination with Sintilimab injectiont,"Jiangsu Simcere Biologics Co., Ltd",,INTERVENTIONAL
NCT04491825,Diagnostic Classifier for Cutaneous T-cell Lymphomas,https://clinicaltrials.gov/study/NCT04491825,UNKNOWN,CTCL/ Mycosis Fungoides,DIAGNOSTIC_TEST: Skin suction blistering and skin biopsies,Medical University of Vienna,,OBSERVATIONAL
NCT04089215,CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma,https://clinicaltrials.gov/study/NCT04089215,ACTIVE_NOT_RECRUITING,"Lymphoma, Non-Hodgkin|Diffuse Large B Cell Lymphoma|Follicular Lymphoma",BIOLOGICAL: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells,"Shanghai Ming Ju Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT05269940,"A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies",https://clinicaltrials.gov/study/NCT05269940,COMPLETED,Non Hodgkin Lymphoma|Peripheral T Cell Lymphoma|CLL/SLL,DRUG: ZX-101A,Nanjing Zenshine Pharmaceuticals,,INTERVENTIONAL
NCT00958854,"Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00958854,UNKNOWN,Lymphoma,DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: thalidomide|OTHER: laboratory biomarker analysis,Cancer Research UK,,INTERVENTIONAL
NCT06648889,Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06648889,RECRUITING,T-ALL,DRUG: Isatuximab|DRUG: Isatuximab,Goethe University,Sanofi,INTERVENTIONAL
NCT05475925,A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas,https://clinicaltrials.gov/study/NCT05475925,RECRUITING,"LGLL - Large Granular Lymphocytic Leukemia|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma|Hepatosplenic T-cell Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Aggressive NK Cell Leukemia|Systemic EBV1 T-cell Lymphoma, if CD8 Positive|Hydroa Vacciniforme-Like Lymphoproliferative Disorder|Extranodal NK/T Cell Lymphoma, Nasal Type|Enteropathy-Associated T-Cell Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)|Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)",DRUG: DR-01,Dren Bio,Novotech Health Holdings Pte. Ltd.,INTERVENTIONAL
NCT06617286,CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06617286,NOT_YET_RECRUITING,Classical Hodgkin Lymphoma,BIOLOGICAL: CD30 CAR T-cell,New York Medical College,University of North Carolina,INTERVENTIONAL
NCT03623087,SIMPLE Chemotherapy for NK Lymphoma/Leukaemia,https://clinicaltrials.gov/study/NCT03623087,UNKNOWN,"Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin T-cell Lymphoma|Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Etoposide (VP-16)|DEVICE: Ifosfamide|DRUG: Dexamethasone|DRUG: L-asparaginase,The University of Hong Kong,,INTERVENTIONAL
NCT05432635,Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05432635,RECRUITING,B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Transformed Non-Hodgkin Lymphoma,BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes|PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|PROCEDURE: Myeloablative Conditioning,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT07003295,"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy",https://clinicaltrials.gov/study/NCT07003295,NOT_YET_RECRUITING,Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Glofitamab|BIOLOGICAL: Obinutuzumab|PROCEDURE: Positron Emission Tomography,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00041327,Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT00041327,COMPLETED,Lymphoma,BIOLOGICAL: filgrastim|BIOLOGICAL: recombinant interferon alfa|DRUG: Etoposide|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: lamivudine|DRUG: prednisone|DRUG: vincristine sulfate|DRUG: zidovudine,AIDS Malignancy Consortium,National Cancer Institute (NCI),INTERVENTIONAL
NCT01593696,Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT01593696,COMPLETED,ALL|B Cell Lymphoma|Leukemia|Large Cell Lymphoma|Non-Hodgkin Lymphoma,BIOLOGICAL: Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR),National Cancer Institute (NCI),,INTERVENTIONAL
NCT00127101,An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED),https://clinicaltrials.gov/study/NCT00127101,TERMINATED,Lymphoma,DRUG: vorinostat|DRUG: Comparator: bexarotene,Merck Sharp & Dohme LLC,,INTERVENTIONAL
NCT06633354,Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL,https://clinicaltrials.gov/study/NCT06633354,RECRUITING,T-Acute Lymphoblastic Leukemia,BIOLOGICAL: CD5 CAR T-cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT05863871,Real World Study of Linperlisib for Lymphoma Treatment,https://clinicaltrials.gov/study/NCT05863871,NOT_YET_RECRUITING,Focus on the Lymphoma Including B/T-cell Lymphoma,DRUG: Linperlisib,Ruijin Hospital,Tianjin Medical University Cancer Institute and Hospital,OBSERVATIONAL
NCT05929716,"An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma",https://clinicaltrials.gov/study/NCT05929716,WITHDRAWN,Large B-cell Lymphoma|B-cell Lymphoma,DRUG: Magrolimab|DRUG: Rituximab|DRUG: CAR T leukapheresis|DRUG: Radiation,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT00338494,Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00338494,COMPLETED,B-Cell Lymphoma,DRUG: Clofarabine,Yale University,"Genzyme, a Sanofi Company",INTERVENTIONAL
NCT05749549,Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers,https://clinicaltrials.gov/study/NCT05749549,ACTIVE_NOT_RECRUITING,Advanced Cancer|Follicular Lymphoma|Peripheral T Cell Lymphoma|Diffuse Large B Cell Lymphoma,DRUG: BR1733,"Shanghai Blueray Biopharma Co., Ltd.",,INTERVENTIONAL
NCT04509466,Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL,https://clinicaltrials.gov/study/NCT04509466,TERMINATED,"Extranodal NK/T-cell Lymphoma, Nasal Type",DRUG: Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase|DRUG: Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase|DRUG: Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,INTERVENTIONAL
NCT00066664,"Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin",https://clinicaltrials.gov/study/NCT00066664,COMPLETED,Lymphoma,GENETIC: proteomic profiling,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT06742463,VHAG in Treating R/R T-ALL/LBL,https://clinicaltrials.gov/study/NCT06742463,RECRUITING,Acute T Lymphpblastic Leukemia/Lymphoma,DRUG: Venetoclax|DRUG: homoharringtonine|DRUG: Cytarabine (Ara-C)|DRUG: G-CSF,First Affiliated Hospital of Zhejiang University,,INTERVENTIONAL
NCT06321289,Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL,https://clinicaltrials.gov/study/NCT06321289,RECRUITING,"Non-hodgkin Lymphoma,B Cell",BIOLOGICAL: Allogeneic CD19-STAR T cell|DRUG: Fludarabine|DRUG: Cyclophosphamide,Chinese PLA General Hospital,,INTERVENTIONAL
NCT04163575,"Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL",https://clinicaltrials.gov/study/NCT04163575,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: :Anti-CD22-CAR,Kecellitics Biotech Company Ltd,Hebei Yanda Ludaopei Hospital,INTERVENTIONAL
NCT00466921,Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome,https://clinicaltrials.gov/study/NCT00466921,COMPLETED,Lymphoma,DRUG: lenalidomide,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT03079544,Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients,https://clinicaltrials.gov/study/NCT03079544,COMPLETED,"Extranodal NK-T-Cell Lymphoma, Nasal Type",COMBINATION_PRODUCT: L-Asparaginase or or Pegaspargase containing chemotherapy,Rong Tao,,OBSERVATIONAL
NCT00807495,Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00807495,COMPLETED,"Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Burkitt's Lymphoma|T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma|Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component",DRUG: Alisertib,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT03271515,"Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL",https://clinicaltrials.gov/study/NCT03271515,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: anti-CD19 anti-CD20 Bispecific CAR-T,"Beijing Doing Biomedical Co., Ltd.",,INTERVENTIONAL
NCT04231747,"A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT04231747,COMPLETED,Lymphoma Non-Hodgkin|Agressive Lymphoma|Diffuse-large B-cell Lymphoma (DLBCL),BIOLOGICAL: CC-97540,"Juno Therapeutics, a Subsidiary of Celgene",,INTERVENTIONAL
NCT05362331,Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy,https://clinicaltrials.gov/study/NCT05362331,WITHDRAWN,Lymphoma|Leukemia|Plasma Cell Dyscrasia,OTHER: Web Application,"University of California, San Francisco",,INTERVENTIONAL
NCT00317408,Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00317408,UNKNOWN,Lymphoma,BIOLOGICAL: anti-thymocyte globulin|DRUG: busulfan|DRUG: carboplatin|DRUG: carmustine|DRUG: cyclosporine|DRUG: cytarabine|DRUG: dexamethasone|DRUG: etoposide phosphate|DRUG: idarubicin|DRUG: ifosfamide|DRUG: leucovorin calcium|DRUG: lomustine|DRUG: melphalan|DRUG: methotrexate|DRUG: mitoxantrone hydrochloride|DRUG: prednisolone|DRUG: thiotepa|DRUG: vinblastine sulfate|DRUG: vindesine|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: autologous hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: total-body irradiation,European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma,,INTERVENTIONAL
NCT02846935,p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT02846935,COMPLETED,T-cell Lymphoma|Aggressive B-cell Lymphoma|Non-Hodgkin's Lymphomas|Indolent B-cell Lymphoma,DRUG: Decitabine|DRUG: Tetrahydrouridine,Yogen Saunthararajah,,INTERVENTIONAL
NCT03189836,Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03189836,TERMINATED,Lymphoma,BIOLOGICAL: ACTR707|BIOLOGICAL: rituximab,"Cogent Biosciences, Inc.",,INTERVENTIONAL
NCT01712659,Ruxolitinib for Adult T-Cell Leukemia,https://clinicaltrials.gov/study/NCT01712659,TERMINATED,"T Cell Leukemia, Adult|Leukemia, Adult T-Cell|T Cell Leukemia, HTLV I Associated",DRUG: Ruxolitinib|DRUG: Ruxolitinib|DRUG: Ruxolitinib|DRUG: Ruxolitinib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02546739,"Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL",https://clinicaltrials.gov/study/NCT02546739,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: Anti-CD19-CAR,"Beijing Doing Biomedical Co., Ltd.",The First Hospital of Jilin University|Hebei Yanda Ludaopei Hospital,INTERVENTIONAL
NCT04975698,HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903,https://clinicaltrials.gov/study/NCT04975698,ACTIVE_NOT_RECRUITING,HIV Associated Lymphoma,BIOLOGICAL: HST-NEETs|BIOLOGICAL: Bone Marrow Transplant,Catherine Bollard,"National Heart, Lung, and Blood Institute (NHLBI)|Blood and Marrow Transplant Clinical Trials Network|National Cancer Institute (NCI)|National Marrow Donor Program|Children's National Research Institute",INTERVENTIONAL
NCT04877080,CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL,https://clinicaltrials.gov/study/NCT04877080,WITHDRAWN,B-cell Lymphoma,BIOLOGICAL: Fast Dual CAR-T Injection,920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,,INTERVENTIONAL
NCT06290622,"PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL",https://clinicaltrials.gov/study/NCT06290622,WITHDRAWN,"Diffuse Large B Cell Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular","DRUG: Retifanlimab, INCAGN02385, INCAGN02390",University of Alabama at Birmingham,,INTERVENTIONAL
NCT01644253,Phase 1b Safety and Efficacy Study of TRU-016,https://clinicaltrials.gov/study/NCT01644253,TERMINATED,Chronic Lymphocytic Leukemia|Peripheral T-cell Lymphoma,BIOLOGICAL: 20 mg/kg TRU-016 + Rituximab|BIOLOGICAL: 10 mg/kg TRU-016 + Rituximab|BIOLOGICAL: TRU-016 20 mg/kg + Obinutuzumab|BIOLOGICAL: TRU-016 6-20 mg/kg + idelalisib + rituximab|BIOLOGICAL: TRU-016 10-20 mg/kg + ibrutinib|BIOLOGICAL: TRU-016 10-20 mg/kg + bendamustine,Aptevo Therapeutics,,INTERVENTIONAL
NCT05225584,"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors",https://clinicaltrials.gov/study/NCT05225584,COMPLETED,Non Hodgkin Lymphoma (NHL)|Peripheral T-cell Lymphoma (PTCL)|Cutaneous T-Cell Lymphoma (CTCL)|Large Granular Lymphocytic Leukemia (LGL-L)|T-cell Prolymphocytic Leukemia (T-PLL)|Solid Tumors,DRUG: KT-333,"Kymera Therapeutics, Inc.",,INTERVENTIONAL
NCT02081937,CART-19 Immunotherapy in Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT02081937,UNKNOWN,"Hematopoietic/Lymphoid Cancer|Non-hodgkin Lymphoma,B Cell|Mantle Cell Lymphoma",BIOLOGICAL: anti-CD19-CAR vector-transduced T cells,Chinese PLA General Hospital,,INTERVENTIONAL
NCT05038644,XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05038644,TERMINATED,Acute Myeloid Leukemia|T Cell Acute Lymphoblastic Leukemia|T Cell Lymphoblastic Lymphoma,DRUG: XmAb18968 - Dose level -1|DRUG: XmAb18968 - Dose level 0 (starting dose)|DRUG: XmAb18968 - Dose level 1|DRUG: XmAb18968 - Dose level 2|DRUG: XmAb18968 - Dose level 3,Ehab L Atallah,,INTERVENTIONAL
NCT03811457,Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT03811457,COMPLETED,Lymphoma Leukemia,GENETIC: Welgenaleucel,UWELL Biopharma,Liaocheng People's Hospital,INTERVENTIONAL
NCT05143112,Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05143112,UNKNOWN,"Non-hodgkin Lymphoma,B Cell",BIOLOGICAL: Allogeneic CD19 CR-T cell,Shenzhen University General Hospital,,INTERVENTIONAL
NCT02210065,Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation,https://clinicaltrials.gov/study/NCT02210065,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs),M.D. Anderson Cancer Center,Miltenyi Biotec B.V. & Co. KG,INTERVENTIONAL
NCT00038376,Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies,https://clinicaltrials.gov/study/NCT00038376,COMPLETED,"Lymphoma, T-Cell|Mycosis Fungoides|Hematologic Neoplasms",DRUG: Isotretinoin (Accutane)|DRUG: Interferon Alpha,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03601819,Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders,https://clinicaltrials.gov/study/NCT03601819,TERMINATED,"Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Chronic Lymphocytic Leukemia|Lymphoproliferative Disorders|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma",DRUG: Pacritinib,University of Michigan Rogel Cancer Center,,INTERVENTIONAL
NCT05569057,A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05569057,UNKNOWN,Advanced Solid Tumor|Cutaneous T-cell Lymphoma (CTCL),DRUG: SIM1811-03,"Jiangsu Simcere Pharmaceutical Co., Ltd.",,INTERVENTIONAL
NCT01501149,Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ,https://clinicaltrials.gov/study/NCT01501149,UNKNOWN,Nasal and Nasal-type NK/T-cell Lymphoma,"DRUG: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DRUG: Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）",Mingzhi Zhang,"Second Hospital of Shanxi Medical University|Shanxi Province Cancer Hospital|Wuhan University|Wuhan TongJi Hospital|Wuhan Union Hospital, China|Qingdao University|Cancer Hospital of Guizhou Province|Xinyang Central Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine",INTERVENTIONAL
NCT01501136,Treatment of Natural Killer/T Cell Lymphoma-I/II,https://clinicaltrials.gov/study/NCT01501136,UNKNOWN,Nasal and Nasal-type NK/T-cell Lymphoma,"OTHER: DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|OTHER: VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|OTHER: gemcitabine,pegaspargase,cisplatin,dexamethasone|OTHER: cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|RADIATION: Radiotherapy",Mingzhi Zhang,"Second Hospital of Shanxi Medical University|Shanxi Province Cancer Hospital|Wuhan University|Wuhan TongJi Hospital|Wuhan Union Hospital, China|Qingdao University|Cancer Hospital of Guizhou Province|Xinyang Central Hospital|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine",INTERVENTIONAL
NCT04156243,CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT04156243,UNKNOWN,B Cell Lymphoma|B Cell Leukemia,BIOLOGICAL: CD19 CARvac T cells,iCell Gene Therapeutics,Peking University Shenzhen Hospital|Chengdu Military General Hospital|iCAR Bio Therapeutics Ltd.,INTERVENTIONAL
NCT05464719,A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy,https://clinicaltrials.gov/study/NCT05464719,RECRUITING,Large B-cell Lymphoma|Lymphoma,DRUG: Loncastuximab Tesirine,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT00453193,Alemtuzumab and Pentostatin In T-cell Neoplasms,https://clinicaltrials.gov/study/NCT00453193,TERMINATED,Lymphoma|Leukemia,DRUG: Pentostatin|DRUG: Alemtuzumab,M.D. Anderson Cancer Center,"Astex Pharmaceuticals, Inc.|Bayer",INTERVENTIONAL
NCT03905135,Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies,https://clinicaltrials.gov/study/NCT03905135,COMPLETED,Peripheral T-cell Lymphoma NOS|Mycosis Fungoides|Sezary Syndrome|Anaplastic Large Cell Lymphoma,DRUG: rhIL-15|DRUG: rhIL-15|BIOLOGICAL: Avelumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05934513,A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),https://clinicaltrials.gov/study/NCT05934513,RECRUITING,Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),DRUG: GFH009,Genfleet Therapeutics (Shanghai) Inc.,,INTERVENTIONAL
NCT00896493,Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT00896493,COMPLETED,"Mycoses|Sezary Syndrome|Lymphoma, T-Cell, Cutaneous|Bone Marrow Transplant Failure|Lymphoma, Non-Hodgkin|Cutaneous T-cell Lymphoma",DRUG: anti-thymocyte globulin|DRUG: cyclosporine|RADIATION: Lymphoid radiation,Stanford University,,INTERVENTIONAL
NCT00006100,"Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00006100,UNKNOWN,Lymphoma,BIOLOGICAL: aldesleukin|BIOLOGICAL: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|DRUG: fludarabine phosphate|PROCEDURE: peripheral blood stem cell transplantation,Milton S. Hershey Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00339638,Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1,https://clinicaltrials.gov/study/NCT00339638,COMPLETED,Human T-Lymphoma Virus Type I,,National Cancer Institute (NCI),,OBSERVATIONAL
NCT06343311,T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL),https://clinicaltrials.gov/study/NCT06343311,RECRUITING,"B-Cell Non-Hodgkin's Lymphoma (NHL)|Lymphoma, Non-Hodgkins|Lymphomas Non-Hodgkin's B-Cell|Non-Hodgkin Lymphoma|Non-Hodgkin's Lymphoma|Large B-Cell Lymphoma|Lymphoma, Non-Hodgkin's, Adult|Lymphoma|Refractory Non-Hodgkin Lymphoma|Relapsed Non-Hodgkin Lymphoma|Lymphoma, Non-Hodgkin|HIV Associated Lymphoma|CNS Lymphoma|High-grade B-cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma",BIOLOGICAL: EB103,"Estrella Biopharma, Inc.",Eureka Therapeutics Inc.,INTERVENTIONAL
NCT03278782,Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,https://clinicaltrials.gov/study/NCT03278782,ACTIVE_NOT_RECRUITING,"Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma",BIOLOGICAL: Pembrolizumab|DRUG: Romidepsin,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02168140,CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT02168140,COMPLETED,Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia,"DRUG: 6,8-bis(benzylthio)octanoic acid|DRUG: bendamustine hydrochloride",Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT04726787,RadiothErapy priMIng for CAR-T,https://clinicaltrials.gov/study/NCT04726787,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma,RADIATION: Bridging Radiotherapy,"University College, London",Novartis Pharmaceuticals,INTERVENTIONAL
NCT06248086,A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas,https://clinicaltrials.gov/study/NCT06248086,TERMINATED,B-cell Lymphoma,DRUG: ASP2802|DRUG: MA-20,"Astellas Pharma Global Development, Inc.",,INTERVENTIONAL
NCT02631044,Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001),https://clinicaltrials.gov/study/NCT02631044,COMPLETED,Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle-cell Lymphoma|Primary Mediastinal B-cell Lymphoma,BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) single-dose schedule|BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) 2-dose schedule,"Juno Therapeutics, a Subsidiary of Celgene",,INTERVENTIONAL
NCT05421663,A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05421663,RECRUITING,"Lymphoma, Non-Hodgkin|Lymphoma, B-Cell",BIOLOGICAL: JNJ-90014496,"Janssen Research & Development, LLC",,INTERVENTIONAL
NCT02927925,"A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type",https://clinicaltrials.gov/study/NCT02927925,COMPLETED,Lymphoma,DRUG: Daratumumab,"Janssen Research & Development, LLC",,INTERVENTIONAL
NCT04735471,A Phase 1 Study of ADI-001 in B Cell Malignancies,https://clinicaltrials.gov/study/NCT04735471,ACTIVE_NOT_RECRUITING,"Lymphoma, Follicular|Lymphoma, Mantle-Cell|Marginal Zone Lymphoma|Primary Mediastinal B-cell Lymphoma|Diffuse Large B Cell Lymphoma|Lymphoma, Non-Hodgkin",GENETIC: ADI-001|DRUG: Fludarabine|DRUG: Cyclophosphamide,Adicet Therapeutics,,INTERVENTIONAL
NCT01196208,A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001,https://clinicaltrials.gov/study/NCT01196208,NO_LONGER_AVAILABLE,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Cutaneous",DRUG: brentuximab vedotin,Seagen Inc.,"Millennium Pharmaceuticals, Inc.",EXPANDED_ACCESS
NCT05619861,CAR-T Cells in the Treatment of Malignant Hematological Tumors,https://clinicaltrials.gov/study/NCT05619861,UNKNOWN,"Lymphoma, B-Cell|Leukemia, B-cell|Leukemia, T-Cell|Multiple Myeloma",BIOLOGICAL: CAR-T,"Hebei Senlang Biotechnology Inc., Ltd.",Cangzhou People's Hospital,INTERVENTIONAL
NCT03488160,CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma,https://clinicaltrials.gov/study/NCT03488160,UNKNOWN,Lymphoma,BIOLOGICAL: CD19-targeted CAR-T cells,"Sinobioway Cell Therapy Co., Ltd.",,INTERVENTIONAL
NCT01657331,Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL),https://clinicaltrials.gov/study/NCT01657331,COMPLETED,Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma,DRUG: Brentuximab Vedotin|DRUG: Bendamustine|DRUG: Neulasta,Columbia University,,INTERVENTIONAL
NCT01950364,A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT01950364,COMPLETED,Hodgkin Lymphoma|Anaplastic Large-cell Lymphoma,DRUG: brentuximab vedotin|DRUG: Brentuximab vedotin and rifampicin,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT01788137,A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT01788137,UNKNOWN,T-cell Lymphoma Adults|Previously Untreated|High Risk,DRUG: chemotherapy (CHOP)|DRUG: chemotherapy(c-ATT),Sun Yat-sen University,Chinese Academy of Medical Sciences|Fudan University|Tianjin Medical University Cancer Institute and Hospital,INTERVENTIONAL
NCT02057445,3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma,https://clinicaltrials.gov/study/NCT02057445,COMPLETED,Non-Hodgkins Lymphoma|Hodgkins Lymphoma|Lymphoproliferative Disorder,DRUG: EBV CTL's|OTHER: Peripheral Blood Donor,New York Medical College,Children's National Research Institute|Baylor College of Medicine|M.D. Anderson Cancer Center|University of Michigan|University of Utah|City of Hope Medical Center|Ohio University|Johns Hopkins University,INTERVENTIONAL
NCT03068416,"CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy",https://clinicaltrials.gov/study/NCT03068416,COMPLETED,B-cell Leukemia|B-Cell Lymphoma,BIOLOGICAL: CAR T cells,Uppsala University,Uppsala University Hospital|AFA Insurance,INTERVENTIONAL
NCT06045910,A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies,https://clinicaltrials.gov/study/NCT06045910,RECRUITING,"Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Mantle-Cell|Lymphoma, Follicular|Lymphoma, B-Cell|Large B-cell Lymphoma",DRUG: ALETA-001,Cancer Research UK,Aleta BioTherapeutics,INTERVENTIONAL
NCT06541327,Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection,https://clinicaltrials.gov/study/NCT06541327,RECRUITING,"Lymphoma, Non-Hodgkin",DRUG: Chimeric Antigen Receptor,Ruijin Hospital,,OBSERVATIONAL
NCT05907447,A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types,https://clinicaltrials.gov/study/NCT05907447,UNKNOWN,"Lymphoma|Extranodal Lymphoma|Diffuse Large B Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Marginal Zone Lymphoma|Mucosa-Associated Lymphoid Tissue Lymphoma|NK/T-Cell Lymphoma, Nasal and Nasal-Type|Intravascular Large B-Cell Lymphoma",OTHER: No interventions need to be specified for this study,Ruijin Hospital,"Nanfang Hospital, Southern Medical University|Fujian Medical University Union Hospital|Peking University Third Hospital|Peking University People's Hospital|Peking Union Medical College Hospital|Beijing Hospital|The Second Affiliated Hospital of Dalian Medical University|The First Affiliated Hospital of Guangzhou Medical University|Henan Provincial People's Hospital|Hunan Cancer Hospital|Henan Cancer Hospital|The First Hospital of Jilin University|Wuhan Union Hospital, China|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Affiliated Hospital of Nantong University|The First Affiliated Hospital of Xiamen University|Shandong Provincial Hospital|Shanxi Province Cancer Hospital|RenJi Hospital|Beijing Friendship Hospital|West China Hospital|The First Affiliated Hospital of Soochow University|Tongji Hospital|Second Affiliated Hospital, School of Medicine, Zhejiang University|Sun Yat-sen University|Chongqing University Cancer Hospital|Anhui Provincial Cancer Hospital|The General Hospital of Northern Theater Command|Qilu Hospital of Shandong University|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|The Affiliated Hospital Of Guizhou Medical University|Wuhan TongJi Hospital|General Hospital of Ningxia Medical University|The First Affiliated Hospital of Nanchang University|The First Affiliated Hospital with Nanjing Medical University|Anshan Central Hospital|Hainan Cancer Hospital|Fifth Affiliated Hospital of Guangzhou Medical University|The First Affiliated Hospital of Anhui Medical University|The Affiliated Hospital of Xuzhou Medical University|First Affiliated Hospital of Harbin Medical University|Zhujiang Hospital",OBSERVATIONAL
NCT04844086,RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT04844086,TERMINATED,"B-cell Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory|Primary Mediastinal Large B Cell Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|High-grade B-cell Lymphoma",BIOLOGICAL: RPM CD19-mbIL15-CAR-T cells,Eden BioCell Ltd.,National Taiwan University Hospital,INTERVENTIONAL
NCT05108805,Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting,https://clinicaltrials.gov/study/NCT05108805,COMPLETED,Large B-cell Lymphoma|Diffuse Large B-cell Lymphoma,PROCEDURE: Telemedicine Visit|PROCEDURE: Vital sign measurements|PROCEDURE: Out-Patient Clinic Visit|PROCEDURE: Blood pressure and pulse oximeter|BIOLOGICAL: Axicabtagene Ciloleucel|DRUG: Cyclophosphamide|DRUG: Fludarabine,Vanderbilt-Ingram Cancer Center,"Kite, A Gilead Company",INTERVENTIONAL
NCT04745559,Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy,https://clinicaltrials.gov/study/NCT04745559,ACTIVE_NOT_RECRUITING,Diffuse Large-Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|High-grade B-cell Lymphoma (HGBCL)|Follicular Lymphoma,BIOLOGICAL: Pneumococcal conjugate vaccine (PCV13)|BIOLOGICAL: CD19 targeted CAR T Cell Therapy,H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL
NCT06662227,Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors,https://clinicaltrials.gov/study/NCT06662227,RECRUITING,B Cell Lymphoma|B Cell Leukemia|B Cell Malignancy,BIOLOGICAL: Single dose injection of certain dose of UWD-19,Wondercel Biotech (ShenZhen),HeFei Parasol Biotech,INTERVENTIONAL
NCT00513188,Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00513188,WITHDRAWN,Lymphoma,BIOLOGICAL: denileukin diftitox|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: doxorubicin hydrochloride|DRUG: leucovorin calcium|DRUG: methotrexate|DRUG: prednisone|DRUG: vincristine sulfate|GENETIC: protein expression analysis|OTHER: flow cytometry|OTHER: laboratory biomarker analysis,University of Miami,,INTERVENTIONAL
NCT05326243,Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05326243,RECRUITING,Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Large B-cell Lymphoma|Follicular Lymphoma Grade 3A|Follicular Lymphoma Grade 3B,BIOLOGICAL: CD19-targeted chimeric antigen receptor T-cell,"Pell Bio-Med Technology Co., Ltd.",,INTERVENTIONAL
NCT04648475,Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT04648475,UNKNOWN,"Leukemia, B-cell|Lymphoma, B-Cell",BIOLOGICAL: CD19 and CD22 targeted CAR-T cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT03602157,Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL,https://clinicaltrials.gov/study/NCT03602157,RECRUITING,Lymphoma|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Cutaneous Lymphoma|Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Sezary Syndrome|Lymphomatoid Papulosis|Cutaneous T Cell Lymphoma|Gray Zone Lymphoma,BIOLOGICAL: ATLCAR.CD30.CCR4 cells|BIOLOGICAL: ALTCAR.CD30 cells|DRUG: Bendamustine|DRUG: Fludarabine,UNC Lineberger Comprehensive Cancer Center,Stand Up To Cancer|National Cancer Institute (NCI),INTERVENTIONAL
NCT06391814,Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01),https://clinicaltrials.gov/study/NCT06391814,RECRUITING,EBV Associated Lymphoma,BIOLOGICAL: EBV-specific T cells,Ciusss de L'Est de l'Île de Montréal,,INTERVENTIONAL
NCT01823718,Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes,https://clinicaltrials.gov/study/NCT01823718,UNKNOWN,EBV Associated Lymphoma,BIOLOGICAL: Injection of allogenic CTL EBV specific,Nantes University Hospital,,INTERVENTIONAL
NCT02844881,Study of Apatinib and MASCT in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02844881,UNKNOWN,Advanced Solid Tumors|Excluding T Cell Lymphoma,DRUG: Apatinib|BIOLOGICAL: MASCT,The First People's Hospital of Lianyungang,"Hengrui Yuanzheng Bio-Technology Co., Ltd.",INTERVENTIONAL
NCT00004907,"Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00004907,COMPLETED,Lymphoma,DRUG: busulfan|DRUG: cyclophosphamide|DRUG: etoposide|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: bone marrow ablation with stem cell support|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT02537977,CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy,https://clinicaltrials.gov/study/NCT02537977,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: CD19-directed CAR-T cells,"Shanghai Tongji Hospital, Tongji University School of Medicine",,INTERVENTIONAL
NCT05032599,Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05032599,TERMINATED,T-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CD5 CART,Beijing Boren Hospital,,INTERVENTIONAL
NCT03383952,A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia,https://clinicaltrials.gov/study/NCT03383952,RECRUITING,B Cell Leukemia|B Cell Lymphoma,BIOLOGICAL: ICAR19 CAR-T cells,"Immune Cell, Inc.",Weifang People's Hospital,INTERVENTIONAL
NCT04914091,Quality Of Life and Drug Use in Patients With CAR-T Cells,https://clinicaltrials.gov/study/NCT04914091,UNKNOWN,Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells,OTHER: Semi-structured interviews and self-administered questionnaires,Hospices Civils de Lyon,,OBSERVATIONAL
NCT03881774,Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies,https://clinicaltrials.gov/study/NCT03881774,UNKNOWN,Refractory|Relapsed|B Cell Lymphoma|B Cell Leukemia,BIOLOGICAL: CAR-T cells,Henan Cancer Hospital,Henan Hualong Biotechnology Company,INTERVENTIONAL
NCT03487133,Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03487133,COMPLETED,Relapsed and/or Refractory Cutaneous T-cell Lymphoma,DRUG: bortezomib/dexamethasone,Samsung Medical Center,,INTERVENTIONAL
NCT00578539,"T-Reg Cell Kinetics, Stem Cell Transplant, REGALE",https://clinicaltrials.gov/study/NCT00578539,TERMINATED,Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma|Myeloproliferative Disorders,DRUG: ARA C|DRUG: Cyclophosphamide|DRUG: MESNA|RADIATION: Total Body Irradiation (TBI)|BIOLOGICAL: Campath-1h|PROCEDURE: Stem Cell Infusion,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT03613428,Ruxolitinib Plus LVP in Patients With R/R ETP-ALL,https://clinicaltrials.gov/study/NCT03613428,UNKNOWN,Acute T Cell Leukemia,DRUG: Ruxolitinib|DRUG: Vincristine|DRUG: Prednisone,Sichuan University,,INTERVENTIONAL
NCT01460914,Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment,https://clinicaltrials.gov/study/NCT01460914,COMPLETED,Cutaneous T Cell Lymphoma|Graft Versus Host Disease,,Dartmouth-Hitchcock Medical Center,,OBSERVATIONAL
NCT00109928,"S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00109928,COMPLETED,Lymphoma,DRUG: cisplatin|DRUG: etoposide|DRUG: gemcitabine|DRUG: methylprednisolone,SWOG Cancer Research Network,National Cancer Institute (NCI),INTERVENTIONAL
NCT02813837,Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies,https://clinicaltrials.gov/study/NCT02813837,UNKNOWN,"Leukemia, B-Cell|Lymphoma, B-Cell",BIOLOGICAL: CD19CART,"Innovative Cellular Therapeutics Co., Ltd.",,INTERVENTIONAL
NCT07001384,A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL),https://clinicaltrials.gov/study/NCT07001384,NOT_YET_RECRUITING,Anaplastic Lymphoma Kinase|Anaplastic Large Cell Lymphoma,DRUG: Alectinib|DRUG: Duvelisib,Memorial Sloan Kettering Cancer Center,"Genentech, Inc.|Secura Bio, Inc.",INTERVENTIONAL
NCT03098355,Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies,https://clinicaltrials.gov/study/NCT03098355,WITHDRAWN,B-Cell Leukemia|B-Cell Lymphoma,BIOLOGICAL: 4SCAR19/22 T cells|DRUG: Interleukin-2,Zhujiang Hospital,Shenzhen Geno-Immune Medical Institute,INTERVENTIONAL
NCT04833504,Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04833504,COMPLETED,Diffuse Large B-cell Lymphoma|Mantle Cell Lymphoma|Transformed Follicular Lymphoma|Primary Mediastinal Large B-cell Lymphoma,BIOLOGICAL: CD19 CAR-T Expressing IL7 and CCL19,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,OBSERVATIONAL
NCT03375619,Long-term Follow-up Study of Patients Receiving CAR-T Cells,https://clinicaltrials.gov/study/NCT03375619,RECRUITING,"Chronic Lymphocytic Leukemia|Lymphomas Non-Hodgkin's B-Cell|Lymphoma, Small Lymphocytic|Mantle Cell Lymphoma|Central Nervous System Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma|Multiple Myeloma",OTHER: Long-Term Follow-Up of Participants who Received CAR-T cells,Medical College of Wisconsin,,OBSERVATIONAL
NCT05472610,Study of Efficacy of BZ019 in Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05472610,UNKNOWN,Large B-cell Lymphoma,BIOLOGICAL: BZ019,Shanghai Mengchao Cancer Hospital,"Shanghai Cell Therapy Group Co.,Ltd",INTERVENTIONAL
NCT03259503,Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant,https://clinicaltrials.gov/study/NCT03259503,ACTIVE_NOT_RECRUITING,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma,DRUG: Busulfan|DRUG: Gemcitabine|DRUG: Melphalan|DRUG: Olaparib|PROCEDURE: Peripheral Blood Stem Cell Transplantation|OTHER: Pharmacokinetic Study|BIOLOGICAL: Rituximab|DRUG: Vorinostat,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04257578,Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04257578,RECRUITING,"B-Cell Non-Hodgkin Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3a Follicular Lymphoma",DRUG: Acalabrutinib|BIOLOGICAL: Axicabtagene Ciloleucel,University of Washington,AstraZeneca,INTERVENTIONAL
NCT04697290,CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.,https://clinicaltrials.gov/study/NCT04697290,SUSPENDED,B-cell Non-Hodgkin's Lymphoma,BIOLOGICAL: CD19/CD20 Dual-CAR-T cells,Beijing Tsinghua Chang Gung Hospital,China Immunotech Pharmaceuticals Co.Ltd.,INTERVENTIONAL
NCT06696846,CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT06696846,NOT_YET_RECRUITING,Relapsed/refractory T-cell Lymphoma|Relapsed/refractory Acute Myeloid Leukemia,BIOLOGICAL: CD70 CAR-NK,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,INTERVENTIONAL
NCT04067414,Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04067414,UNKNOWN,Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Transformed Lymphoma|Primary Mediastinal Large B Cell Lymphoma,BIOLOGICAL: BZ019,"Institute of Hematology & Blood Diseases Hospital, China","Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.",INTERVENTIONAL
NCT05081479,A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma,https://clinicaltrials.gov/study/NCT05081479,ACTIVE_NOT_RECRUITING,Lymphoma,DRUG: N-Acetylcysteine,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT04812691,CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04812691,COMPLETED,Diffuse Large B Cell Lymphoma,BIOLOGICAL: JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells),"Shanghai Ming Ju Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT04148430,A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy,https://clinicaltrials.gov/study/NCT04148430,ACTIVE_NOT_RECRUITING,B Cell ALL|B-Cell Lymphoma|B-cell Non Hodgkin Lymphoma,DRUG: Anakinra,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT05277753,NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL,https://clinicaltrials.gov/study/NCT05277753,RECRUITING,T-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Antigen-specific T cells CAR-T/CTL and DCvac,Shenzhen Geno-Immune Medical Institute,,INTERVENTIONAL
NCT01578499,A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study),https://clinicaltrials.gov/study/NCT01578499,COMPLETED,Primary Cutaneous Anaplastic Large Cell Lymphoma|Mycosis Fungoides|Cutaneous T-Cell Lymphoma,DRUG: Brentuximab Vedotin|DRUG: Methotrexate|DRUG: Bexarotene,"Millennium Pharmaceuticals, Inc.",Seagen Inc.,INTERVENTIONAL
NCT00003650,Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00003650,COMPLETED,Lymphoma,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: etoposide|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: mitoxantrone hydrochloride|DRUG: prednisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,UNICANCER,,INTERVENTIONAL
NCT00244946,"Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00244946,COMPLETED,Lymphoma,BIOLOGICAL: therapeutic autologous lymphocytes|DRUG: carmustine|DRUG: cytarabine|DRUG: etoposide|DRUG: melphalan|PROCEDURE: peripheral blood stem cell transplantation (PBSCT),Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT04638270,Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL,https://clinicaltrials.gov/study/NCT04638270,UNKNOWN,"Lymphoma, Non-Hodgkin",BIOLOGICAL: anti-CD19 FasT CAR-T cells,Xinqiao Hospital of Chongqing,"Gracell Biotechnologies (Shanghai) Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Second Affiliated Hospital of Chongqing Medical University|The Affiliated Hospital Of Guizhou Medical University|The Second Affiliated Hospital of Kunming Medical University|Chongqing University Cancer Hospital",INTERVENTIONAL
NCT00006455,Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99),https://clinicaltrials.gov/study/NCT00006455,COMPLETED,Lymphoma,DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: ifosfamide|DRUG: leucovorin calcium|DRUG: methotrexate|DRUG: therapeutic hydrocortisone|DRUG: vinblastine sulfate,"Gustave Roussy, Cancer Campus, Grand Paris",,INTERVENTIONAL
NCT06911710,The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors,https://clinicaltrials.gov/study/NCT06911710,RECRUITING,"Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)|AML (Acute Myelogenous Leukemia)|Myeloma Multiple|B-ALL|T-ALL/Lymphoma|T-lymphocyte Lymphoma","DRUG: CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）",Tianjin Medical University General Hospital,"Hebei Taihe Chunyu Biotechnology Co., Ltd",INTERVENTIONAL
NCT00606645,Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00606645,COMPLETED,Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma,BIOLOGICAL: XmAb2513,"Xencor, Inc.",,INTERVENTIONAL
NCT02933775,CD19-redirected Autologous Cells (CAR-CD19 T Cells),https://clinicaltrials.gov/study/NCT02933775,UNKNOWN,CD19 Positive Malignant B-cell Leukemia and Lymphoma,GENETIC: CAR-CD19 T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,RenJi Hospital,"CARsgen Therapeutics Co., Ltd.",INTERVENTIONAL
NCT06149169,CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06149169,ACTIVE_NOT_RECRUITING,"Lymphoma, Non-Hodgkin|Diffuse Large B Cell Lymphoma",BIOLOGICAL: CD19-targeted Chimeric Antigen Receptor(CAR) T Cells,"Shanghai Ming Ju Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT05731375,Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage,https://clinicaltrials.gov/study/NCT05731375,NOT_YET_RECRUITING,Doxorubicin Induced Cardiomyopathy|Chemotherapeutic Toxicity|B-cell Lymphoma|T-cell Lymphoma,DIAGNOSTIC_TEST: 31-MRS at 7 Tesla (T),UMC Utrecht,Julius Clinical,OBSERVATIONAL
NCT04186520,CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT04186520,RECRUITING,Non Hodgkin Lymphoma (NHL)|Mantle Cell Lymphoma (MCL)|Chronic Lymphocytic Leukemia (CLL)|Follicular Lymphoma|Marginal Zone Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Central Nervous System Lymphoma,BIOLOGICAL: 8/12-Day Production of Car-T Cells|BIOLOGICAL: 8/12-Day Production of Cryopreserved Car-T Cells|BIOLOGICAL: 12-Day Production of Car-T Cells,Medical College of Wisconsin,,INTERVENTIONAL
NCT04649983,CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT04649983,UNKNOWN,"Leukemia, B-cell|Lymphoma, B-Cell",BIOLOGICAL: CD19 and CD22 targeted CAR-T cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT03684889,CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT03684889,ACTIVE_NOT_RECRUITING,Leukemia|Lymphoma,BIOLOGICAL: SCRI-huCAR19v1|BIOLOGICAL: SCRI-huCAR19v2,Seattle Children's Hospital,,INTERVENTIONAL
NCT03385226,"A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)",https://clinicaltrials.gov/study/NCT03385226,ACTIVE_NOT_RECRUITING,Cutaneous T Cell Lymphoma|Mycosis Fungoides/Sezary Syndrome,DRUG: Pembrolizumab|RADIATION: Radiotherapy,"University College, London",Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT06167785,A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T,https://clinicaltrials.gov/study/NCT06167785,RECRUITING,Large B-cell Lymphoma,DRUG: Tislelizumab|DRUG: Zanubrutinib|DRUG: Tislelizumab + Zanubrutinib,"University Health Network, Toronto",,INTERVENTIONAL
NCT02560441,"Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type",https://clinicaltrials.gov/study/NCT02560441,UNKNOWN,"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type",OTHER: chemotherapy followed by radiotherapy|OTHER: radiotherapy followed by chemotherapy|DRUG: IPGDP regimen chemotherapy,Chinese Academy of Medical Sciences,"307 Hospital of PLA|Tianjin Medical University Cancer Institute and Hospital|First Hospital of China Medical University|The Second Affiliated Hospital of Dalian Medical University|Hebei Medical University Fourth Hospital|Qilu Hospital of Shandong University|Shandong Cancer Hospital and Institute|Nanfang Hospital, Southern Medical University|Guangdong Provincial People's Hospital|People's Hospital of Guangxi Zhuang Autonomous Region|Xuzhou Medical University|Shanxi Province Cancer Hospital|Shanxi Dayi Hospital|Zhangzhou Municipal Hospital of Fujian Province",INTERVENTIONAL
NCT05745181,Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT05745181,RECRUITING,Acute T-lymphoblastic Leukemia|Acute T-lymphoblastic Lymphoma,BIOLOGICAL: CAR-T Cell Infusion,The Affiliated Hospital of Xuzhou Medical University,,INTERVENTIONAL
NCT00644189,Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00644189,COMPLETED,"Follicular Lymphoma|Marginal Zone Lymphoma|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Low Grade B-cell Lymphoma, Not Otherwise Specified|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large-cell Lymphoma",DRUG: Clofarabine,Massachusetts General Hospital,"Dana-Farber Cancer Institute|Brigham and Women's Hospital|Genzyme, a Sanofi Company",INTERVENTIONAL
NCT04703686,Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy,https://clinicaltrials.gov/study/NCT04703686,ACTIVE_NOT_RECRUITING,Diffuse Large B-Cell Lymphoma Refractory|Refractory Indolent Adult Non-Hodgkin Lymphoma|Refractory Transformed B-cell Non-Hodgkin Lymphoma|Refractory Primary Mediastinal Large B-Cell Cell Lymphoma|Refractory Mantle Cell Lymphoma,DRUG: Obinutuzumab|DRUG: RO7082859,The Lymphoma Academic Research Organisation,,INTERVENTIONAL
NCT04323657,TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04323657,COMPLETED,Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma,DRUG: TC-110 T Cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,TCR2 Therapeutics,,INTERVENTIONAL
NCT04809233,Expanded Access to Tipifarnib,https://clinicaltrials.gov/study/NCT04809233,AVAILABLE,HRAS Mutations or Peripheral T Cell Lymphoma (PTCL),DRUG: Tipifarnib,"Kura Oncology, Inc.",,EXPANDED_ACCESS
NCT05206045,Evolution of the SURvival of Patients With SEzary Syndrome (SS) Over the 1998-2020 Period and Its Association With the Early Use of Therapeutic Monoclonal Antibodies,https://clinicaltrials.gov/study/NCT05206045,UNKNOWN,Sezary Syndrome|Cutaneous T Lymphoma,OTHER: Standard of care,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT02276248,Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02276248,COMPLETED,Stage I/II Extranodal NK/T-cell Lymphoma,RADIATION: Intensity-modulated radiation therapy|DRUG: GDP chemotherapy,Chinese Academy of Medical Sciences,,INTERVENTIONAL
NCT00002590,Combination Chemotherapy in Treating Children With Lymphoma,https://clinicaltrials.gov/study/NCT00002590,COMPLETED,Lymphoma,BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: leucovorin calcium|DRUG: methotrexate|DRUG: pegaspargase|DRUG: prednisone|DRUG: thioguanine|DRUG: vincristine sulfate|RADIATION: radiation therapy,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT05757219,Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy,https://clinicaltrials.gov/study/NCT05757219,RECRUITING,Diffuse Large B Cell Lymphoma,DRUG: Itacitinib|BIOLOGICAL: Chimeric antigen receptor (CAR) T-cell therapy,H. Lee Moffitt Cancer Center and Research Institute,Incyte Corporation,INTERVENTIONAL
NCT00363090,"Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00363090,UNKNOWN,Lymphoma,BIOLOGICAL: alemtuzumab|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: prednisone|DRUG: vincristine sulfate|OTHER: flow cytometry|OTHER: pharmacological study,Toronto Sunnybrook Regional Cancer Centre,,INTERVENTIONAL
NCT06909877,Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06909877,RECRUITING,Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL),DRUG: HH2853 Tablets,"Haihe Biopharma Co., Ltd.",,INTERVENTIONAL
NCT06071871,"A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma",https://clinicaltrials.gov/study/NCT06071871,RECRUITING,Large B-cell Lymphoma,DRUG: Glofitamab|DRUG: Polatuzumab vedotin|DRUG: Obinutuzumab,"University College, London",Hoffmann-La Roche,INTERVENTIONAL
NCT04250324,Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04250324,UNKNOWN,Large B-cell Lymphoma,BIOLOGICAL: BZ019,"Shanghai Cell Therapy Group Co.,Ltd","Institute of Hematology & Blood Diseases Hospital, China|Tianjin Medical University Cancer Institute and Hospital",INTERVENTIONAL
NCT06142188,Relmacabtagene Autoleucel in Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06142188,NOT_YET_RECRUITING,"Lymphoma, B-Cell|Large B-cell Lymphoma|Follicular Lymphoma",BIOLOGICAL: Relmacabtagene Autoleucel,"Shanghai Ming Ju Biotechnology Co., Ltd.",,OBSERVATIONAL
NCT06254495,A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers,https://clinicaltrials.gov/study/NCT06254495,RECRUITING,"Hodgkin Disease|Lymphoma, T-Cell, Peripheral|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Large-Cell, Anaplastic",DRUG: PF-08046044/SGN-35C,"Seagen, a wholly owned subsidiary of Pfizer",,INTERVENTIONAL
NCT03019055,Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell,https://clinicaltrials.gov/study/NCT03019055,COMPLETED,"Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma",BIOLOGICAL: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|BIOLOGICAL: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|BIOLOGICAL: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|BIOLOGICAL: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg),Medical College of Wisconsin,"Children's Hospital and Health System Foundation, Wisconsin",INTERVENTIONAL
NCT06464861,Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma,https://clinicaltrials.gov/study/NCT06464861,RECRUITING,Primary Mediastinal B-cell Lymphoma (PMBCL)|Mantle Cell Lymphoma (MCL)|Diffuse Large B Cell Lymphoma( DLBCL),BIOLOGICAL: CD19-CAR-NK/T,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,INTERVENTIONAL
NCT06462248,Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies,https://clinicaltrials.gov/study/NCT06462248,RECRUITING,"Lymphoma, Nonhodgkin|Leukemia, Lymphocytic",DRUG: CUCART19,Chi Kong Li,Hong Kong Children's Hospital,INTERVENTIONAL
NCT03107962,Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03107962,UNKNOWN,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: Pembrolizumab (PD-1 Blocking Antibody),Mingzhi Zhang,,INTERVENTIONAL
NCT02132624,CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.,https://clinicaltrials.gov/study/NCT02132624,COMPLETED,B Cell Lymphoma|B Cell Leukemia,BIOLOGICAL: Autologous 3rd generation CD19-targeting CAR T cells,Uppsala University,Uppsala University Hospital|Karolinska University Hospital|AFA Insurance|Swedish Cancer Society,INTERVENTIONAL
NCT05274997,A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma,https://clinicaltrials.gov/study/NCT05274997,UNKNOWN,Peripheral T/NK Cell Lymphoma (R/R PTCL),DRUG: YY-20394,Shanghai YingLi Pharmaceutical Co. Ltd.,,INTERVENTIONAL
NCT04156178,CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT04156178,UNKNOWN,B Cell Lymphoma|B Cell Leukemia,BIOLOGICAL: CD20-CD19 cCAR T cells,iCell Gene Therapeutics,Peking University Shenzhen Hospital|Chengdu Military General Hospital|iCAR Bio Therapeutics Ltd.,INTERVENTIONAL
NCT04697940,Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL,https://clinicaltrials.gov/study/NCT04697940,RECRUITING,Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma|Decitabine-primed Tandem CD19/CD20 CAR T Cells,BIOLOGICAL: Decitabine-primed Tandem CAR19/20 engineered T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,Han weidong,,INTERVENTIONAL
NCT03869619,REal World Data in LYmphoma and Survival in Adults,https://clinicaltrials.gov/study/NCT03869619,RECRUITING,Diffuse Large B Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL)|Marginal Zone Lymphoma (MZL)|T-cell Lymphoma (T-NHL)|Hodgkin's Lymphoma (HL)|Burkitt Lymphoma (BL)),OTHER: Real-life epidemiological platform of lymphoma in France,Hospices Civils de Lyon,The Lymphoma Academic Research Organisation,OBSERVATIONAL
NCT05800067,Axi-cel Retreatment in Relapsed/Refractory LBCL,https://clinicaltrials.gov/study/NCT05800067,UNKNOWN,CAR-T Retreatment,DRUG: axi-cel,Ruijin Hospital,,INTERVENTIONAL
NCT03086954,Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma,https://clinicaltrials.gov/study/NCT03086954,UNKNOWN,Lymphoma,BIOLOGICAL: The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T),"Sinobioway Cell Therapy Co., Ltd.",Jiangsu Cancer Institute & Hospital,INTERVENTIONAL
NCT05544968,CD30biAb-AATC for CD30+ Malignancies,https://clinicaltrials.gov/study/NCT05544968,NOT_YET_RECRUITING,Hodgkin Disease|CD30-Positive Diffuse Large B-Cell Lymphoma|CD30+ Anaplastic Large Cell Lymphoma|CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma|CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma|Leukemia|Lymphoma,DRUG: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)|DRUG: GM-CSF,Medical College of Wisconsin,,INTERVENTIONAL
NCT05688241,EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases,https://clinicaltrials.gov/study/NCT05688241,NOT_YET_RECRUITING,EBV Lymphoma|Post-transplant Lymphoproliferative Disease (PTLD),DRUG: Donor-derived ex-vivo expanded EBV Tscm CTL,"University Hospital, Basel, Switzerland",,INTERVENTIONAL
NCT05058755,Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05058755,COMPLETED,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","DRUG: tislelizumab, azacytidine, lenalidomide|DRUG: tislelizumab, etoposide, pegaspargase","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT04952584,Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas,https://clinicaltrials.gov/study/NCT04952584,WITHDRAWN,"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|Classical Hodgkin Lymphoma",BIOLOGICAL: CD30.CAR-EBVST cells,Baylor College of Medicine,The Methodist Hospital Research Institute,INTERVENTIONAL
NCT00881920,"Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL",https://clinicaltrials.gov/study/NCT00881920,RECRUITING,Lymphoma|Myeloma|Leukemia,BIOLOGICAL: Kappa CD28 T cells,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT05114837,Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL,https://clinicaltrials.gov/study/NCT05114837,WITHDRAWN,Lymphoma Leukemia,DRUG: allogeneic CAR19 regulatory T cells (CAR19-tTreg)|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00254332,Effect of Denileukin Diftitox on Immune System in CTCL Patients,https://clinicaltrials.gov/study/NCT00254332,COMPLETED,Cutaneous T-cell Lymphoma|Sezary Syndrome|Mycosis Fungoides,,University of Pittsburgh,,OBSERVATIONAL
NCT02763384,BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT02763384,TERMINATED,T-Acute Lymphoblastic Leukemia|Adult T Lymphoblastic Lymphoma,DRUG: BL-8040|DRUG: Nelarabine,Washington University School of Medicine,The Leukemia and Lymphoma Society|National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL
NCT05814718,Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT,https://clinicaltrials.gov/study/NCT05814718,NOT_YET_RECRUITING,Autologous Stem Cell Transplantation|Conditioning,DRUG: modified BEAM|DRUG: BEAM,First Affiliated Hospital Xi'an Jiaotong University,,INTERVENTIONAL
NCT06503094,CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors,https://clinicaltrials.gov/study/NCT06503094,RECRUITING,B-Cell Lymphoblastic Leukemia/Lymphoma,DRUG: CD19&CD20 bispecific CAR-T cells,"Wuhan Union Hospital, China","Hebei Taihe Chunyu Biotechnology Co., Ltd|Zhujiang Hospital|Jingzhou Central Hospital|Shiyan People's Hospital|Xiangyang Central Hospital|Yichang Central People's Hospital",INTERVENTIONAL
NCT01909934,Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT01909934,COMPLETED,Lymphoma,DRUG: Brentuximab vedotin,Takeda,"Takeda Development Center Americas, Inc.",INTERVENTIONAL
NCT02030834,Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas,https://clinicaltrials.gov/study/NCT02030834,COMPLETED,"Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas",BIOLOGICAL: CART-19,University of Pennsylvania,,INTERVENTIONAL
NCT01087294,Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT01087294,COMPLETED,"Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell",PROCEDURE: Allogeneic stem cell transplant|BIOLOGICAL: Anti-CD19-chimeric-antigen-receptor-transduced T cells|PROCEDURE: Leukapheresis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03999697,A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies,https://clinicaltrials.gov/study/NCT03999697,UNKNOWN,Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Primary Cutaneous Follicle Centre Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Mantle Cell Lymphoma|Plasma Cell Neoplasm|B Cell Lymphoma,DRUG: Autologous chimeric antigen receptor T cell transfusing agent targeting CD22,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",Anhui Provincial Hospital,INTERVENTIONAL
NCT03287817,CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03287817,COMPLETED,Diffuse Large B Cell Lymphoma|Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|DLBCL,BIOLOGICAL: AUTO3,Autolus Limited,,INTERVENTIONAL
NCT06446128,A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL),https://clinicaltrials.gov/study/NCT06446128,ACTIVE_NOT_RECRUITING,"Non-Hodgkin Lymphoma, B-cell",BIOLOGICAL: CD19/CD20/BCMA CAR T cells,"Shanghai Cell Therapy Group Co.,Ltd",,INTERVENTIONAL
NCT02728882,Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma,https://clinicaltrials.gov/study/NCT02728882,UNKNOWN,Lymphoma,BIOLOGICAL: CD19-targeted CAR-T cells,"Sinobioway Cell Therapy Co., Ltd.",The First Affiliated Hospital of Anhui Medical University,INTERVENTIONAL
NCT00156013,Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL),https://clinicaltrials.gov/study/NCT00156013,COMPLETED,"Lymphoma, B-Cell|Lymphoma, Non-Hodgkin",DRUG: CLOFARABINE,"Oncology Specialists, S.C.","Genzyme, a Sanofi Company",INTERVENTIONAL
NCT00091559,Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001),https://clinicaltrials.gov/study/NCT00091559,COMPLETED,Cutaneous T-cell Lymphoma|Sezary Syndrome|Mycosis Fungoides,"DRUG: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months",Merck Sharp & Dohme LLC,,INTERVENTIONAL
NCT00117845,Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia,https://clinicaltrials.gov/study/NCT00117845,TERMINATED,"Leukemia, Adult T-Cell",BIOLOGICAL: Denileukin diftitox (Ontak),National Cancer Institute (NCI),,INTERVENTIONAL
NCT06966154,A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL,https://clinicaltrials.gov/study/NCT06966154,RECRUITING,Natural Killer/T-cell Lymphoma|Relapsed or Refractory Lymphoma Including ENKL,DRUG: tislezumab|DRUG: golidocitinib|DRUG: Selinexor,Fudan University,,INTERVENTIONAL
NCT06593145,CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms,https://clinicaltrials.gov/study/NCT06593145,RECRUITING,Acute Lymphoblastic Leukemia (ALL)|Mantle Cell Lymphoma (MCL)|Large B-cell Lymphoma,BIOLOGICAL: FCTX-CL19-1 (Tarcidomgen Kimleucel),FamiCordTx,,INTERVENTIONAL
NCT06589089,Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy,https://clinicaltrials.gov/study/NCT06589089,RECRUITING,Diffuse Large B Cell Lymphoma,DRUG: autologous hematopoietic stem cell,Ruijin Hospital,,INTERVENTIONAL
NCT04447547,Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04447547,UNKNOWN,Non-hodgkin's Lymphoma,BIOLOGICAL: CD19 CAR-T,"Hebei Senlang Biotechnology Inc., Ltd.",Beijing Lu Daopei Hospital|Hebei Yanda Ludaopei Hospital,INTERVENTIONAL
NCT02431988,Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation,https://clinicaltrials.gov/study/NCT02431988,COMPLETED,Diffuse Large B-Cell Lymphoma,PROCEDURE: Leukapheresis|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: CAR19 T-Cells,"University College, London",,INTERVENTIONAL
NCT00365274,SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00365274,TERMINATED,Anaplastic Large Cell Lymphoma,DRUG: Cyclophosphamide|DRUG: Doxorubicin hydrochloride|DRUG: vincristine sulfate|DRUG: prednisone|DRUG: SGN-30,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05801913,Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05801913,RECRUITING,High Grade B-Cell Non-Hodgkin's Lymphoma|Intermediate Grade B-Cell Non-Hodgkin's Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Leukapheresis|PROCEDURE: Lymphodepletion Therapy|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|PROCEDURE: Positron Emission Tomography|PROCEDURE: X-Ray Imaging,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05691153,ThisCART19A for B-NHL Relapsed After Auto-CAR T,https://clinicaltrials.gov/study/NCT05691153,RECRUITING,CAR|B Cell Lymphoma|Relapsed Non-Hodgkin Lymphoma,DRUG: ThisCART19A with Dose Level 1|DRUG: ThisCART19A with Dose Level 2,The First Affiliated Hospital of Soochow University,"Fundamenta Therapeutics, Ltd.",INTERVENTIONAL
NCT05206071,Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05206071,UNKNOWN,Non-hodgkin's Lymphoma,BIOLOGICAL: CD19+22 CAR-T cells,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT02051257,Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT02051257,ACTIVE_NOT_RECRUITING,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma,BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|OTHER: Laboratory Biomarker Analysis,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04088864,CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies,https://clinicaltrials.gov/study/NCT04088864,ACTIVE_NOT_RECRUITING,"B Cell Lymphoma|Acute Lymphoblastic Leukemia, Pediatric|Lymphoma",DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Autologous CD22 CAR T,Stanford University,,INTERVENTIONAL
NCT01685606,Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT01685606,TERMINATED,Mantle Cell Lymphoma|Diffuse Large Cell Lymphoma|Burkitts Lymphoma|T Cell Lymphomas|Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia,BIOLOGICAL: cellular immunotherapy,Brown University,,INTERVENTIONAL
NCT03593109,"A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma",https://clinicaltrials.gov/study/NCT03593109,TERMINATED,"Lymphoma, B-Cell",DRUG: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy,Second Affiliated Hospital of Xi'an Jiaotong University,Nanjing Legend Biotech Co.,INTERVENTIONAL
NCT03098589,Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL),https://clinicaltrials.gov/study/NCT03098589,COMPLETED,Lymphoma,DRUG: Revlimid,Celgene,,OBSERVATIONAL
NCT06735495,CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors,https://clinicaltrials.gov/study/NCT06735495,RECRUITING,B-Cell Lymphoblastic Leukemia/Lymphoma,DRUG: CD19&CD22 bispecific CAR-T cells,"Wuhan Union Hospital, China","Hebei Taihe Chunyu Biotechnology Co., Ltd",INTERVENTIONAL
NCT06090864,ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells,https://clinicaltrials.gov/study/NCT06090864,RECRUITING,Hodgkin Lymphoma|Relapse|Refractory,DRUG: Chemotherapy|BIOLOGICAL: Cell infusion,UNC Lineberger Comprehensive Cancer Center,,INTERVENTIONAL
NCT06567366,CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors,https://clinicaltrials.gov/study/NCT06567366,NOT_YET_RECRUITING,Large B-cell Lymphoma,BIOLOGICAL: CAR T-cell therapy|DRUG: Glofitamab|DRUG: Obinutuzumab,Ruijin Hospital,,INTERVENTIONAL
NCT02763254,Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas,https://clinicaltrials.gov/study/NCT02763254,TERMINATED,"Hodgkin Lymphoma|Lymphoma, Large B-Cell, Diffuse|Post-transplant Lymphoproliferative Disorder",BIOLOGICAL: baltaleucel-T,Cell Medica Ltd,,INTERVENTIONAL
NCT03468153,Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma,https://clinicaltrials.gov/study/NCT03468153,UNKNOWN,Lymphoma,BIOLOGICAL: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy,Ruijin Hospital,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",INTERVENTIONAL
NCT02349698,A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT02349698,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: Chimeric Antigen Receptor Modified T cells Targeting CD19,"Southwest Hospital, China",,INTERVENTIONAL
NCT05574114,A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma,https://clinicaltrials.gov/study/NCT05574114,ACTIVE_NOT_RECRUITING,"Non-Hodgkin Lymphoma|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory",RADIATION: Bridging radiotherapy (BRT)|DRUG: Conditioning chemotherapy|BIOLOGICAL: CAR T-cell product,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT05665062,Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05665062,ACTIVE_NOT_RECRUITING,CLL/SLL|NHL|Mantle Cell Lymphoma|Follicular Lymphoma|Large B-cell Lymphoma|Indolent B-Cell Non-Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma,DRUG: SYNCAR-001|DRUG: STK-009|DRUG: Cyclophosphamide|DRUG: Fludarabine,Synthekine,,INTERVENTIONAL
NCT00724061,Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL,https://clinicaltrials.gov/study/NCT00724061,TERMINATED,Lymphoma,BIOLOGICAL: Pegylated interferon α-2b|OTHER: Psoralens with ultraviolet light A|OTHER: Narrowband-ultraviolet light B,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003741,Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00003741,COMPLETED,Lymphoma,BIOLOGICAL: monoclonal antibody HeFi-1,Beth Israel Deaconess Medical Center,,INTERVENTIONAL
NCT04512716,Iomab-ACT: a Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT04512716,RECRUITING,"B-ALL|DLBCL|B ALL|Dlbcl-Ci|DLBCL Unclassifiable|DLBCL, Nos Genetic Subtypes|DLBCL Activated B-Cell Type|DLBCL Germinal Center B-Cell Type|Diffuse Large B-cell Lymphoma|HGBL|HGBL, Nos",DRUG: 131-I Apamistamab|BIOLOGICAL: CAR T-cell,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT03434769,AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT03434769,ACTIVE_NOT_RECRUITING,Non-Hodgkin Lymphoma,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: CAR-T Cells,Benjamin Tomlinson,,INTERVENTIONAL
NCT06716164,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research,https://clinicaltrials.gov/study/NCT06716164,RECRUITING,"Non-hodgkin Lymphoma,B Cell",DRUG: Metabolically Armed CD19 CAR-T cells,Zhejiang University,"Leman Biotech Co., Ltd.",INTERVENTIONAL
NCT01389427,"Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).",https://clinicaltrials.gov/study/NCT01389427,COMPLETED,Mantle Cell Lymphoma Refractory,DRUG: Torisel dose 15 mg and R-CHOP|DRUG: Torisel dose 15 mg and R-FC|DRUG: Torisel dose 15 mg and R-DHA|DRUG: Torisel dose 25 mg and R-CHOP|DRUG: Torisel dose 50 mg and R-CHOP|DRUG: Torisel dose 75 mg and R-CHOP|DRUG: Torisel dose 25 mg and R-FC|DRUG: Torisel dose 50 mg and R-FC|DRUG: Torisel dose 75 mg and R-FC|DRUG: Torisel dose 25 mg and R-DHA|DRUG: Torisel dose 50 mg and R-DHA|DRUG: Torisel 75 mg and R-DHA,The Lymphoma Academic Research Organisation,French Innovative Leukemia Organisation,INTERVENTIONAL
NCT04312841,Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab,https://clinicaltrials.gov/study/NCT04312841,COMPLETED,B-Cell Prolymphocytic Leukemia|Chronic Lymphocytic Leukemia|Peripheral T-Cell Lymphoma|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|T-Cell Prolymphocytic Leukemia,DRUG: Letermovir,Ohio State University Comprehensive Cancer Center,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT00079755,Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00079755,COMPLETED,Anaplastic Large-Cell Lymphoma,DRUG: SGN-30 (anti-CD30 mAb),Seagen Inc.,,INTERVENTIONAL
NCT06120166,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research,https://clinicaltrials.gov/study/NCT06120166,RECRUITING,Diffuse Large B-cell Lymphoma,DRUG: Metabolically Armed CD19 CAR-T cells,He Huang,"Leman Biotech Co., Ltd.",INTERVENTIONAL
NCT05784415,Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell,https://clinicaltrials.gov/study/NCT05784415,ACTIVE_NOT_RECRUITING,"Leukemia|Leukemia, Lymphoblastic|Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Non-Hodgkin|HIV Infections|HIV Associated Lymphoma|HIV Disease; Lymphoma",,AIDS Malignancy Consortium,Center for International Blood and Marrow Transplant Research,OBSERVATIONAL
NCT04319601,Rituximab Combined With Chidamide and Lenalidomide for r/r AITL,https://clinicaltrials.gov/study/NCT04319601,UNKNOWN,Angioimmunoblastic T-cell Lymphoma|Chemotherapy Effect|Chemotherapeutic Toxicity,DRUG: Rituximab,Zhejiang Cancer Hospital,,INTERVENTIONAL
NCT04661020,CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT04661020,RECRUITING,"Non-hodgkin Lymphoma,B Cell",DRUG: CD19 CAR-T cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT05596266,CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05596266,RECRUITING,T-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CD5 CAR-T,"Xuanwu Hospital, Beijing",Baoding Children's Hospital,INTERVENTIONAL
NCT04134325,Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04134325,ACTIVE_NOT_RECRUITING,Relapsed Hodgkin Lymphoma|Refractory Hodgkin Lymphoma,BIOLOGICAL: Nivolumab|BIOLOGICAL: Pembrolizumab,UNC Lineberger Comprehensive Cancer Center,American Society of Clinical Oncology,INTERVENTIONAL
NCT02840747,Tissue Repository: CTCL Collection Protocol,https://clinicaltrials.gov/study/NCT02840747,RECRUITING,"Lymphoma, T-Cell, Cutaneous|Lymphomatoid Papulosis|Sézary Syndrome",,Columbia University,,OBSERVATIONAL
NCT04288726,Allogeneic CD30.CAR-EBVSTs in Patients with Relapsed or Refractory CD30-Positive Lymphomas,https://clinicaltrials.gov/study/NCT04288726,RECRUITING,"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|Classical Hodgkin Lymphoma",BIOLOGICAL: CD30.CAR-EBVST cells,Baylor College of Medicine,The Methodist Hospital Research Institute,INTERVENTIONAL
NCT06849401,The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06849401,NOT_YET_RECRUITING,T-ALL,BIOLOGICAL: VGO-Cs01p,Shanghai Jiao Tong University School of Medicine,"Shanghai Vitalgen BioPharma Co., Ltd.",INTERVENTIONAL
NCT04752826,BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20),https://clinicaltrials.gov/study/NCT04752826,RECRUITING,Advanced Malignancies|Ovarian Cancer|T-cell Lymphoma|Melanoma,DRUG: BI-1808|DRUG: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection,BioInvent International AB,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT02721407,Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients,https://clinicaltrials.gov/study/NCT02721407,UNKNOWN,Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III/IV Adult Diffuse Large Cell Lymphoma|Stage III/IV Follicular Lymphoma|Stage III/IV Mantle Cell Lymphoma,DRUG: Retroviral vector-transduced autologous T cells to express CD22-specific CARs,Xinqiao Hospital of Chongqing,Xuzhou Medical University,INTERVENTIONAL
NCT04503538,Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity,https://clinicaltrials.gov/study/NCT04503538,WITHDRAWN,Large B-cell Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma,OTHER: Telemedicine visit,Wake Forest University Health Sciences,,INTERVENTIONAL
NCT05715606,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research,https://clinicaltrials.gov/study/NCT05715606,UNKNOWN,Diffuse Large B-cell Lymphoma,DRUG: Metabolically Armed CD19 CAR-T cells,Anhui Provincial Hospital,"Leman Biotech Co., Ltd.",INTERVENTIONAL
NCT01614197,A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,https://clinicaltrials.gov/study/NCT01614197,COMPLETED,"Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Lymphoma|Peripheral T-cell Lymphoma",DRUG: Temsirolimus|DRUG: Etoposide|DRUG: Cyclophosphamide|DRUG: Methotrexate|DRUG: Hydrocortisone|DRUG: Cytarabine,Therapeutic Advances in Childhood Leukemia Consortium,Pfizer,INTERVENTIONAL
NCT00002557,Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00002557,UNKNOWN,Lymphoma,DRUG: CHOP regimen|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: leucovorin calcium|DRUG: methotrexate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04664179,EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma,https://clinicaltrials.gov/study/NCT04664179,RECRUITING,EBV-Related Hodgkin Lymphoma|EBV-Related Lymphoproliferative Disorder|EBV Related Non-Hodgkin's Lymphoma,BIOLOGICAL: Dose Level 1A: 2 x 10^7 cells/m2|BIOLOGICAL: Dose Level 2A: 6 x 10^7 cells/m2|BIOLOGICAL: Dose Level 2B: 6 x 10^7 cells/m2|BIOLOGICAL: Dose Level 3B: 2 x 10^8 cells/m2|BIOLOGICAL: Dose Level 3A: 2 x 10^8 cells/m2,Baylor College of Medicine,The Methodist Hospital Research Institute|National Cancer Institute (NCI),INTERVENTIONAL
NCT00002479,Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome,https://clinicaltrials.gov/study/NCT00002479,COMPLETED,Lymphoma,DRUG: tretinoin,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00051597,A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00051597,COMPLETED,"Hodgkin Disease|Lymphoma, Large-Cell|Sarcoma, Kaposi|Lymphoma, T-Cell, Cutaneous|Lymphoma, B-Cell",DRUG: SGN-30 (monoclonal antibody),Seagen Inc.,,INTERVENTIONAL
NCT03540303,Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03540303,UNKNOWN,Relapsed Non Hodgkin Lymphoma,DRUG: CAR19 T cells carrying cytoplasmic activated PD-1,Henan Cancer Hospital,"The Pregene (ShenZhen) Biotechnology Company, Ltd.",INTERVENTIONAL
NCT04637763,CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER),https://clinicaltrials.gov/study/NCT04637763,RECRUITING,"Lymphoma, Non-Hodgkin|Relapsed Non Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma|Lymphoma|B Cell Lymphoma|B Cell Non-Hodgkin's Lymphoma",GENETIC: CB-010|DRUG: Cyclophosphamide|DRUG: Fludarabine,"Caribou Biosciences, Inc.",,INTERVENTIONAL
NCT05064787,Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy,https://clinicaltrials.gov/study/NCT05064787,COMPLETED,"Lymphoma|Lymphoma, B-Cell|Leukemia|Multiple Myeloma|Mantle Cell Lymphoma|Follicular Lymphoma|Leukemia, Acute Lymphoblastic",BEHAVIORAL: Digital Health Coaching,Pack Health,M.D. Anderson Cancer Center|Bristol-Myers Squibb,INTERVENTIONAL
NCT04316624,A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy,https://clinicaltrials.gov/study/NCT04316624,COMPLETED,Diffuse Large B Cell Lymphoma,DRUG: C-CAR066,"Institute of Hematology & Blood Diseases Hospital, China",Shanghai AbelZeta Ltd.,INTERVENTIONAL
NCT04410900,Vaccine Responsiveness After CAR-T Cell Therapy,https://clinicaltrials.gov/study/NCT04410900,ACTIVE_NOT_RECRUITING,B-Cell Neoplasm,BIOLOGICAL: Wistar Rabies Virus Strain PM-1503-3M Vaccine|PROCEDURE: Biospecimen Collection,Fred Hutchinson Cancer Center,,INTERVENTIONAL
NCT04214886,CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT04214886,ACTIVE_NOT_RECRUITING,"B-Cell Acute Lymphoblastic Leukemia, Adult|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent",DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: CD19-CD34 CAR transduced T cells,Loyola University,Leukemia Research Foundation,INTERVENTIONAL
NCT03618238,Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03618238,COMPLETED,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: Anlotinib,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT00368082,"Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)",https://clinicaltrials.gov/study/NCT00368082,ACTIVE_NOT_RECRUITING,"Lymphoma|Hodgkin's Disease|Relapse|Lymphoma, Non-Hodgkin",BIOLOGICAL: TGFbeta resistant LMP-specific CTLs,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT03579888,CD19-Specific T Cells Post AlloSCT,https://clinicaltrials.gov/study/NCT03579888,TERMINATED,"B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Ph-Like Acute Lymphoblastic Leukemia|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Ph-Like Acute Lymphoblastic Leukemia|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma",BIOLOGICAL: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,M.D. Anderson Cancer Center,Ziopharm Oncology,INTERVENTIONAL
NCT00177190,In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT00177190,COMPLETED,Cutaneous T-cell Lymphoma|Sezary Syndrome|Mycosis Fungoides,,University of Pittsburgh,,OBSERVATIONAL
NCT01098656,Lenalidomide Maintenance Post-debulking in Advanced CTCL,https://clinicaltrials.gov/study/NCT01098656,TERMINATED,Lymphoma,DRUG: lenalidomide,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT06651203,"Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study",https://clinicaltrials.gov/study/NCT06651203,NOT_YET_RECRUITING,Mycosis Fungoides/Sezary Syndrome|Cutaneous T Cell Lymphoma,OTHER: Follow-up,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT04049513,ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy),https://clinicaltrials.gov/study/NCT04049513,ACTIVE_NOT_RECRUITING,Lymphomas Non-Hodgkin's B-Cell|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (TFL)|Follicular Lymphoma (FL)|Mantle Cell Lymphoma (MCL),BIOLOGICAL: WZTL002-1 (1928T2z CAR-T cells)|DRUG: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy,Malaghan Institute of Medical Research,Wellington Zhaotai Therapies Limited,INTERVENTIONAL
NCT02576496,"Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",https://clinicaltrials.gov/study/NCT02576496,COMPLETED,Hematological Malignancies|Multiple Myeloma|Hodgkin's Lymphoma|Cutaneous T Cell Lymphoma,DRUG: Tinostamustine,Mundipharma Research Limited,,INTERVENTIONAL
NCT05130489,CAR T Cell Therapy Related Cardiovascular Outcomes,https://clinicaltrials.gov/study/NCT05130489,COMPLETED,Cardiovascular Diseases|B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Diffuse Large B Cell Lymphoma|Cardiotoxicity|Cardiovascular Complication,,University College London Hospitals,,OBSERVATIONAL
NCT05098613,Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients,https://clinicaltrials.gov/study/NCT05098613,RECRUITING,Non-Hodgkin Lymphoma,DRUG: CD19x22 CAR T Cells,"University of Colorado, Denver",,INTERVENTIONAL
NCT05641428,Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL,https://clinicaltrials.gov/study/NCT05641428,RECRUITING,NHL|DLBCL - Diffuse Large B Cell Lymphoma,DRUG: ARI-0001|DRUG: Axi-cel,University Medical Center Groningen,Stichting Hemato-Oncologie voor Volwassenen Nederland,INTERVENTIONAL
NCT04004572,"Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma",https://clinicaltrials.gov/study/NCT04004572,UNKNOWN,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: LEAP regimen,Rong Tao,,INTERVENTIONAL
NCT05281809,Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05281809,RECRUITING,B-Cell Lymphoma|B Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Lymphoplasmacytic Lymphoma|Chronic Lymphocytic Leukemia|Transformed Lymphoma,DRUG: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous),John Lister,"Lentigen Technology, Inc.|Miltenyi Biotec, Inc.|Allegheny Health Network",INTERVENTIONAL
NCT00074087,"Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides",https://clinicaltrials.gov/study/NCT00074087,COMPLETED,Lymphoma,DRUG: pegylated liposomal doxorubicin hydrochloride,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT01181271,Tandem Auto-Allo Transplant for Lymphoma,https://clinicaltrials.gov/study/NCT01181271,COMPLETED,"Diffuse, Large B-Cell, Lymphoma|Lymphoma, Low-Grade|T-Cell Lymphoma|Mantle-Cell Lymphoma|Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic",DRUG: Busulfan (conditioning for AUTO transplant)|DRUG: Etoposide (conditioning for AUTO transplant)|DRUG: Cyclophosphamide (conditioning for AUTO transplant)|DRUG: Mesna (prior to AUTO transplant)|OTHER: autologous (auto) peripheral blood stem cell transplantation|DRUG: Neupogen|DRUG: Fludarabine (conditioning for ALLO Transplant)|DRUG: Busulfan (conditioning for ALLO Transplant)|OTHER: non-myeloablative allogeneic (allo) transplant|DRUG: Tacrolimus|DRUG: Sirolimus|DRUG: Methotrexate,Massachusetts General Hospital,Dana-Farber Cancer Institute,INTERVENTIONAL
NCT00002687,Interleukin-2 in Treating Patients With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00002687,COMPLETED,Lymphoma,BIOLOGICAL: aldesleukin,University of Washington,,INTERVENTIONAL
NCT06486051,A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06486051,RECRUITING,"Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Transformed Non-Hodgkin Lymphoma",DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: WZTL-002 CAR T-cells,Malaghan Institute of Medical Research,BioOra Limited|Wellington Zhaotai Therapies Limited,INTERVENTIONAL
NCT06314334,Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06314334,RECRUITING,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: Sintilimab+Pegaspargase|DRUG: P-GemOx|DRUG: GELAD|RADIATION: IMRT,Fudan University,,INTERVENTIONAL
NCT00290706,A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00290706,TERMINATED,Lymphoma,DRUG: bortezomib|DRUG: gemcitabine hydrochloride,Northwestern University,"Eli Lilly and Company|Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT06271057,Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse,https://clinicaltrials.gov/study/NCT06271057,RECRUITING,Diffuse Large B-cell Lymphoma Refractory|Refractory Primary Mediastinal Large B-Cell Lymphoma|Refractory Transformed B-cell Non-Hodgkin Lymphoma|Refractory High Grade B-Cell Lymphoma,DRUG: golcadomide,The Lymphoma Academic Research Organisation,Lymphoma Study Association,INTERVENTIONAL
NCT03357224,PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT03357224,TERMINATED,"Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides/Sezary Syndrome",DRUG: Atezolizumab,European Organisation for Research and Treatment of Cancer - EORTC,Hoffmann-La Roche,INTERVENTIONAL
NCT00866047,A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00866047,COMPLETED,"Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",DRUG: brentuximab vedotin,Seagen Inc.,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT06784726,Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T,https://clinicaltrials.gov/study/NCT06784726,NOT_YET_RECRUITING,"Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal Large B-Cell Lymphoma|Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal Large B-Cell Lymphoma|Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",BIOLOGICAL: Odronextamab|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|PROCEDURE: Computed Tomography|PROCEDURE: Leukapheresis|PROCEDURE: Lumbar Puncture|PROCEDURE: Positron Emission Tomography|OTHER: Questionnaire Administration|PROCEDURE: Biopsy,University of Washington,Regeneron Pharmaceuticals,INTERVENTIONAL
NCT04464200,19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers,https://clinicaltrials.gov/study/NCT04464200,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma|Chronic Lymphocytic Leukemia|Indolent Non-Hodgkin Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Burkitt's Lymphoma|Primary CNS Lymphoma,DRUG: 19(T2)28z1xx CAR T cells,Memorial Sloan Kettering Cancer Center,Takeda,INTERVENTIONAL
NCT06866873,CD-19 CAR-T Cell for Pediatric ALL or Lymphoma,https://clinicaltrials.gov/study/NCT06866873,RECRUITING,"Lymphoma, B-Cell|Acute Lymphoblastic Leukemia, Pediatric",BIOLOGICAL: CAR-T,Hong Kong Children's Hospital,,INTERVENTIONAL
NCT06381830,Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT06381830,RECRUITING,"Lymphoma, B-Cell|Autologous Stem Cell Transplantation",OTHER: Apheresis|OTHER: Autologous Stem Cell Transplantation|DRUG: CAR-T Cell Therapy,The First Affiliated Hospital of Soochow University,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|Suzhou Hongci Hematology Hospital, Suzhou, China",INTERVENTIONAL
NCT00275106,Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT00275106,TERMINATED,Lymphoma,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: leucovorin calcium|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: prednisolone|DRUG: thioguanine|DRUG: vincristine sulfate|PROCEDURE: radiation therapy,Children's Cancer and Leukaemia Group,European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma,INTERVENTIONAL
NCT00117988,"17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00117988,COMPLETED,Anaplastic Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma,DRUG: tanespimycin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05094206,"CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies",https://clinicaltrials.gov/study/NCT05094206,TERMINATED,B-cell Non Hodgkin Lymphoma|B-cell Chronic Lymphocytic Leukemia,BIOLOGICAL: 0.75x10^6 cells/kg CAR20.19.22 cells|BIOLOGICAL: 1x10^6 cells/kg CAR20.19.22 cells|BIOLOGICAL: 2.5x10^6 cells/kg CAR20.19.22 cells|BIOLOGICAL: 5x10^6 cells/kg CAR20.19.22 cells|BIOLOGICAL: Dose expansion: The maximum tolerated dose of CAR20.19.22 cells,Medical College of Wisconsin,"Miltenyi Biotec, Inc.",INTERVENTIONAL
NCT06081478,CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06081478,RECRUITING,B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma|Diffuse Large B Cell Lymphoma,DRUG: CD19/CD22-bispecific CAR-T cells,Beijing Tongren Hospital,,INTERVENTIONAL
NCT06003179,Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah,https://clinicaltrials.gov/study/NCT06003179,WITHDRAWN,"Lymphoma, Large B-Cell, Diffuse",DRUG: Cyclophosphamide|RADIATION: TLI|DRUG: Fludarabine,"University Health Network, Toronto",,INTERVENTIONAL
NCT06583083,Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT06583083,RECRUITING,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: Sintilimab with P-GEMOX Regimen|DRUG: P-GEMOX Regimen,Sun Yat-sen University,,INTERVENTIONAL
NCT00669812,High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00669812,UNKNOWN,Lymphoma|Small Intestine Cancer,DRUG: carmustine|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: doxorubicin hydrochloride|DRUG: epirubicin hydrochloride|DRUG: etoposide|DRUG: ifosfamide|DRUG: melphalan|DRUG: methotrexate|DRUG: prednisolone|DRUG: vincristine sulfate|PROCEDURE: autologous hematopoietic stem cell transplantation|PROCEDURE: biopsy|PROCEDURE: peripheral blood stem cell transplantation,Cancer Research UK,,INTERVENTIONAL
NCT00178841,Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL,https://clinicaltrials.gov/study/NCT00178841,COMPLETED,Cutaneous T-cell Lymphoma|Mycosis Fungoides|Sezary Syndrome,DRUG: Rosiglitazone and Bexarotene,Vanderbilt University,,INTERVENTIONAL
NCT04955340,"A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat",https://clinicaltrials.gov/study/NCT04955340,COMPLETED,Cutaneous T Cell Lymphoma|Mycosis Fungoides|Sezary Syndrome,DRUG: [14C]-resminostat,4SC AG,,INTERVENTIONAL
NCT06156774,SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project,https://clinicaltrials.gov/study/NCT06156774,RECRUITING,"Non-hodgkin Lymphoma,B Cell",OTHER: Chimeric Antigen Receptor T-cells (CAR-T) therapy,Fondazione Italiana Linfomi - ETS,"Kite, A Gilead Company",OBSERVATIONAL
NCT05871684,A Combination Study of CAR-T Therapy in r/r B-NHL,https://clinicaltrials.gov/study/NCT05871684,RECRUITING,Diffuse Large B Cell Lymphoma,DRUG: BTK inhibitor|DRUG: PD-1 inhibitor,Ruijin Hospital,,INTERVENTIONAL
NCT00050999,Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients,https://clinicaltrials.gov/study/NCT00050999,COMPLETED,"Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides|Sezary Syndrome",DRUG: ONTAK,Eisai Inc.,,INTERVENTIONAL
NCT03730740,Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03730740,UNKNOWN,Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma,DRUG: Lenalidomide 25mg,Samsung Medical Center,,INTERVENTIONAL
NCT01362452,Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells,https://clinicaltrials.gov/study/NCT01362452,COMPLETED,Leukemia|Lymphoma,GENETIC: T-Cell Infusion|PROCEDURE: Cord Blood Infusion,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT00860171,Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00860171,TERMINATED,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|RADIATION: Iodine I 131 Monoclonal Antibody BC8|OTHER: Laboratory Biomarker Analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02840110,Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product,https://clinicaltrials.gov/study/NCT02840110,TERMINATED,B Cell Lymphomas|Multiple Myeloma|Solid Tumor|HER-2 Protein Overexpression,OTHER: ACTR T Cell Product,"Cogent Biosciences, Inc.",,OBSERVATIONAL
NCT01087333,"Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment",https://clinicaltrials.gov/study/NCT01087333,RECRUITING,Hairy Cell Leukemia (HCL)|Chronic Lymphocytic Leukemia (CLL)|Non-Hodgkins Lymphoma (NHL)|Cutaneous T Cell Lymphoma (CTCL)|Adult T Cell Lymphoma (ATL),,National Cancer Institute (NCI),,OBSERVATIONAL
NCT04443829,Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma,https://clinicaltrials.gov/study/NCT04443829,ACTIVE_NOT_RECRUITING,Primary CNS Lymphoma,BIOLOGICAL: CD19CAR T-cells,"University College, London",,INTERVENTIONAL
NCT04169932,The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04169932,UNKNOWN,Relapsed and Refractory B Cell Lymphoma|Non-Hodgkin Lymphoma,BIOLOGICAL: CD20 CAR-T,"Shanghai Longyao Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT02935153,A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies,https://clinicaltrials.gov/study/NCT02935153,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: Anti-CD22-CAR-transduced T cells,"Southwest Hospital, China",,INTERVENTIONAL
NCT06598722,BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.,https://clinicaltrials.gov/study/NCT06598722,RECRUITING,"Lymphoblastic Lymphoma, Adult|Lymphoblastic Leukemia, Acute T-cell",DRUG: BCL-2 inhibitors combined with the HyperCVAD regimen|OTHER: Propensity score matching historical data,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT05675982,Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells,https://clinicaltrials.gov/study/NCT05675982,NOT_YET_RECRUITING,Diffuse Large B Cell Lymphoma,OTHER: CAR-T cells monitoring,Centre Henri Becquerel,,INTERVENTIONAL
NCT00051012,Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT00051012,COMPLETED,"Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides|Sezary Syndrome",DRUG: ONTAK,Eisai Inc.,,INTERVENTIONAL
NCT02710149,A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies,https://clinicaltrials.gov/study/NCT02710149,UNKNOWN,Leukemia|Lymphoma,BIOLOGICAL: Anti-CD20-CAR-transduced T cells,"Southwest Hospital, China",,INTERVENTIONAL
NCT03895944,"ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma",https://clinicaltrials.gov/study/NCT03895944,UNKNOWN,"CD19+ Lymphoma, B-Cell|CD19+ Leukemia, B-Cell",BIOLOGICAL: ET190L1-ARTEMIS™ T cells -iv low dose|BIOLOGICAL: ET190L1-ARTEMIS™ T cells -iv middle dose|BIOLOGICAL: ET190L1-ARTEMIS™ T cells - iv high dose,First Affiliated Hospital Xi'an Jiaotong University,Eureka Therapeutics Inc.,INTERVENTIONAL
NCT03174808,Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT03174808,TERMINATED,Anxiety|Quality of Life,BEHAVIORAL: Mindfulness-Based Stress Reduction (MBSR),Yale University,The Wallace Foundation,INTERVENTIONAL
NCT04419909,Retreatment With CTL019/CTL119,https://clinicaltrials.gov/study/NCT04419909,NOT_YET_RECRUITING,"Lymphoma, B-Cell",DRUG: CD19 redirected autologous T cells (CTL019 or CTL119 cells),University of Pennsylvania,,INTERVENTIONAL
NCT05289687,Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL,https://clinicaltrials.gov/study/NCT05289687,RECRUITING,T-cell Acute Lymphoblastic Leukemia,DRUG: Daratumumab / Hyaluronidase Injection|DRUG: Daratumumab / Hyaluronidase Injection|DRUG: Daratumumab / Hyaluronidase Injection|DRUG: Daratumumab / Hyaluronidase Injection,Eastern Cooperative Oncology Group,"Janssen, LP",INTERVENTIONAL
NCT06784167,Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment,https://clinicaltrials.gov/study/NCT06784167,RECRUITING,Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Multiple Myeloma|Primary Mediastinal Large B-Cell Lymphoma|Small Lymphocytic Lymphoma,OTHER: Non-Interventional Study,OHSU Knight Cancer Institute,Oregon Health and Science University,OBSERVATIONAL
NCT06552572,Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy,https://clinicaltrials.gov/study/NCT06552572,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma,DRUG: Glofitamab,Samsung Medical Center,,INTERVENTIONAL
NCT00896922,"S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911",https://clinicaltrials.gov/study/NCT00896922,COMPLETED,Lymphoma,GENETIC: microarray analysis|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis,SWOG Cancer Research Network,National Cancer Institute (NCI),OBSERVATIONAL
NCT00059839,Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00059839,COMPLETED,Lymphoma,DRUG: doxorubicin hydrochloride|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: prednisone|DRUG: vinblastine sulfate|DRUG: vincristine sulfate,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT06227026,Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies,https://clinicaltrials.gov/study/NCT06227026,RECRUITING,Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma,BIOLOGICAL: Anti-CD19 CAR-T cells,University of Utah,,INTERVENTIONAL
NCT06285422,Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID),https://clinicaltrials.gov/study/NCT06285422,RECRUITING,Non Hodgkin's Lymphoma|Large B-cell Lymphoma,DRUG: SC262,Sana Biotechnology,,INTERVENTIONAL
NCT03630731,Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT03630731,UNKNOWN,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: chidamide,Chinese Academy of Medical Sciences,,INTERVENTIONAL
NCT01950286,Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.,https://clinicaltrials.gov/study/NCT01950286,COMPLETED,T-cell Acute Lymphoblastic Leukemia,,Region Örebro County,,OBSERVATIONAL
NCT03790891,Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy,https://clinicaltrials.gov/study/NCT03790891,UNKNOWN,Non-Hodgkin Lymphoma,BIOLOGICAL: CD19-TriCAR-T/SILK,Timmune Biotech Inc.,,INTERVENTIONAL
NCT05140382,AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL,https://clinicaltrials.gov/study/NCT05140382,COMPLETED,Relapsed/Refractory Peripheral T-cell Lymphoma|Relapsed/Refractory Classical Hodgkins Lymphoma,DRUG: AZD4573,AstraZeneca,,INTERVENTIONAL
NCT04264039,Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies,https://clinicaltrials.gov/study/NCT04264039,UNKNOWN,B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma,BIOLOGICAL: anti-CD19 UCAR-T cells|DRUG: Fludarabine|DRUG: Cytoxan|DRUG: Melphalan,Xinqiao Hospital of Chongqing,"Gracell Biotechnologies (Shanghai) Co., Ltd.|920th Hospital of Joint Logistics Support Force of People's Liberation Army of China|The Second Affiliated Hospital of Chongqing Medical University|The Affiliated Hospital Of Guizhou Medical University|Central South University|First Affiliated Hospital of Kunming Medical University|The General Hospital of Western Theater Command|Second Affiliated Hospital of Xi'an Jiaotong University|Nanfang Hospital, Southern Medical University|Fujian Medical University Union Hospital|The First Affiliated Hospital of Anhui Medical University|Tang-Du Hospital",INTERVENTIONAL
NCT02973113,"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)",https://clinicaltrials.gov/study/NCT02973113,COMPLETED,NonHodgkin Lymphoma|Lymphoproliferative Disorders|EBV Related Lymphoma|EBV-Related PTLD|Hodgkin Lymphoma|EBV Related Non-Hodgkin's Lymphoma|EBV Related Hodgkin's Lymphoma,BIOLOGICAL: EBVST Cells|BIOLOGICAL: Nivolumab,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT03398967,A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT03398967,UNKNOWN,B Cell Leukemia|B Cell Lymphoma,BIOLOGICAL: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells,Chinese PLA General Hospital,,INTERVENTIONAL
NCT02624258,"Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT02624258,TERMINATED,Hodgkin Lymphoma,BIOLOGICAL: CD19 RNA redirected autologous T-cells (RNA CART19 cells),University of Pennsylvania,Children's Hospital of Philadelphia,INTERVENTIONAL
NCT04271410,CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT04271410,UNKNOWN,"Leukemia|Lymphoma, Large B-Cell, Diffuse|Leukemia, B-cell|Lymphoma, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell",BIOLOGICAL: CD19 CAR-T cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT00278382,Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00278382,COMPLETED,Anaplastic Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma,DRUG: sorafenib tosylate|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04571138,A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT04571138,RECRUITING,Leukemia|Lymphoma,BIOLOGICAL: SCRI-CAR22v2,Seattle Children's Hospital,,INTERVENTIONAL
NCT03454945,Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides,https://clinicaltrials.gov/study/NCT03454945,UNKNOWN,Lymphoma,DRUG: Vibramycin|DEVICE: Phototherapy,Cairo University,,INTERVENTIONAL
NCT00473551,Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT00473551,TERMINATED,Leukemia|Lymphoma|Myeloma,DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Mesna|RADIATION: Radiation Treatment|PROCEDURE: Stem Cell Transplantation (SCT)|DRUG: Sirolimus|PROCEDURE: Anti-third Party Cytolytic T-lymphocytes (CTL),M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT05934448,Pembro Plus CAR T-cell Therapy in R/R in PMBCL,https://clinicaltrials.gov/study/NCT05934448,RECRUITING,Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Primary Mediastinal Large B Cell Lymphoma|Primary Mediastinal Large B-Cell Lymphoma Refractory|Primary Mediastinal Large B-Cell Lymphoma Recurrent|Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma,DRUG: Pembrolizumab|DRUG: Lymphodepletion Chemotherapy|DRUG: Chimeric Antigen Receptor (CAR) Therapy Infusion|PROCEDURE: Leukapheresis,"Jennifer Crombie, MD",Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT00057967,Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome,https://clinicaltrials.gov/study/NCT00057967,COMPLETED,Lymphoma,BIOLOGICAL: alemtuzumab,Northwestern University,"Millennium Pharmaceuticals, Inc.|Genzyme, a Sanofi Company",INTERVENTIONAL
NCT00005788,Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome,https://clinicaltrials.gov/study/NCT00005788,TERMINATED,Lymphoma,BIOLOGICAL: aldesleukin,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00004106,Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome,https://clinicaltrials.gov/study/NCT00004106,TERMINATED,Lymphoma,DRUG: temozolomide,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT03536039,RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor,https://clinicaltrials.gov/study/NCT03536039,COMPLETED,"Lymphoma, Large B-Cell, Diffuse",DRUG: NGR-hTNF|OTHER: RITUXIMAB|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Prednisone,Andres J. M. Ferreri,AGC Biologics S.p.A.,INTERVENTIONAL
NCT01686165,Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL,https://clinicaltrials.gov/study/NCT01686165,COMPLETED,Anaplastic Large Cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma,DRUG: belinostat|BIOLOGICAL: rituximab|RADIATION: yttrium Y 90 ibritumomab tiuxetan,University of Arizona,National Cancer Institute (NCI),INTERVENTIONAL
NCT01238159,Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01238159,COMPLETED,"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type",RADIATION: CCRT+MIDLE chemotherapy,Samsung Medical Center,Asan Medical Center|Yonsei University|Seoul National University|Chonnam National University,INTERVENTIONAL
NCT06918912,Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure,https://clinicaltrials.gov/study/NCT06918912,RECRUITING,Diffuse Large B-Cell Lymphoma|High-grade B-cell Lymphoma (HGBCL)|B-Cell Lymphoma Treatment|Relapsed or Refractory Lymphoma,DRUG: Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate),Istituto Clinico Humanitas,,INTERVENTIONAL
NCT06352242,Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?,https://clinicaltrials.gov/study/NCT06352242,RECRUITING,Diffuse Large B Cell Lymphoma,OTHER: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients|OTHER: Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers,"University Hospital, Montpellier",,INTERVENTIONAL
NCT04163302,Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04163302,UNKNOWN,"Lymphoma, B-Cell",BIOLOGICAL: CD19-PD1-CART Cell,Chinese PLA General Hospital,,INTERVENTIONAL
NCT00081783,Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients,https://clinicaltrials.gov/study/NCT00081783,UNKNOWN,Non-Hodgkin's Lymphoma,DRUG: Xcellerated T Cells,Xcyte Therapies,,INTERVENTIONAL
NCT00521261,"Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00521261,WITHDRAWN,Lymphoma,BIOLOGICAL: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00992446,Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00992446,COMPLETED,Adult Diffuse Large B-Cell Lymphoma|B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin Lymphoma|T-Cell Non-Hodgkin Lymphoma,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Bortezomib|DRUG: Carmustine|DRUG: Cytarabine|DRUG: Etoposide|DRUG: Melphalan|DRUG: Rituximab|DRUG: Vorinostat,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05643742,A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies,https://clinicaltrials.gov/study/NCT05643742,RECRUITING,B-cell Lymphoma|Non-Hodgkin Lymphoma|B-cell Malignancy|Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Large B-cell Lymphoma,BIOLOGICAL: CTX112,CRISPR Therapeutics AG,,INTERVENTIONAL
NCT02938741,ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors,https://clinicaltrials.gov/study/NCT02938741,UNKNOWN,Lymphoblastic Lymphoma,DRUG: Anti-human Thymoglobulin|DRUG: Placebo,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT02542124,NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT),https://clinicaltrials.gov/study/NCT02542124,UNKNOWN,Cutaneous T Cell Lymphoma (CTCL)|Mycosis Fungoides|Sézary Syndrome,BIOLOGICAL: NM-IL-12 and TSEBT,Neumedicines Inc.,National Cancer Institute (NCI),INTERVENTIONAL
NCT04390737,Evaluate the Safety and Clinical Activity of HH2853,https://clinicaltrials.gov/study/NCT04390737,RECRUITING,FL Lymphoma|Epithelioid Sarcoma|Peripheral T Cell Lymphoma|Advanced Solid Tumor,DRUG: HH2853 Tablets,"Haihe Biopharma Co., Ltd.",,INTERVENTIONAL
NCT01793233,Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas,https://clinicaltrials.gov/study/NCT01793233,COMPLETED,Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Lymphoma,OTHER: Laboratory Biomarker Analysis|OTHER: Questionnaire Administration,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT01767766,Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01767766,COMPLETED,Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Peripheral T-Cell Lymphoma|Hodgkin's Lymphoma,DRUG: TGR-1202,"TG Therapeutics, Inc.","SCRI Development Innovations, LLC",INTERVENTIONAL
NCT01921387,Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT01921387,COMPLETED,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Carmustine|DRUG: Cytarabine|DRUG: Etoposide|OTHER: Laboratory Biomarker Analysis|DRUG: Melphalan|PROCEDURE: Peripheral Blood Stem Cell Transplantation|RADIATION: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT06464185,A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06464185,RECRUITING,B-cell Non-Hodgkin Lymphoma,DRUG: Bispecific antibody-based combined with CAR-T cell therapy,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT04366128,"Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL",https://clinicaltrials.gov/study/NCT04366128,UNKNOWN,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: CAPA indution immunotherapy,Rong Tao,,INTERVENTIONAL
NCT06209619,CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT06209619,RECRUITING,B-Cell Non-Hodgkin Lymphoma-Recurrent|Diffuse Large B-Cell Lymphoma-Recurrent|Follicular Lymphoma-Recurrent|High Grade B-Cell Lymphoma-Recurrent|Primary Mediastinal Large B-Cell Lymphoma-Recurrent|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent|B-Cell Non-Hodgkin Lymphoma-Refractory|Diffuse Large B-Cell Lymphoma-Refractory|Follicular Lymphoma-Refractory|High Grade B-Cell Lymphoma-Refractory|Primary Mediastinal Large B-Cell Lymphoma-Refractory|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Golcadomide|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab,Nathan Denlinger,Bristol-Myers Squibb,INTERVENTIONAL
NCT05725720,Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy,https://clinicaltrials.gov/study/NCT05725720,RECRUITING,Diffuse Large B Cell Lymphoma,OTHER: Gut microbiome analysis,University of Bologna,Associazione Italiana per la Ricerca sul Cancro|IRCCS Azienda Ospedaliero-Universitaria di Bologna,OBSERVATIONAL
NCT03436771,Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product,https://clinicaltrials.gov/study/NCT03436771,TERMINATED,Non Hodgkin Lymphoma|Multiple Myeloma|Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma,GENETIC: JCAR017|GENETIC: JCARH125,"Juno Therapeutics, a Subsidiary of Celgene",,OBSERVATIONAL
NCT00199030,Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath,https://clinicaltrials.gov/study/NCT00199030,COMPLETED,"Adult Acute Lymphocytic Leukemia T-cell|Lymphoma, Lymphoblastic",DRUG: Alemtuzumab (MabCampath)|DRUG: Cladribine,Goethe University,,INTERVENTIONAL
NCT00697346,Study of MLN8237 in Participants With Advanced Hematological Malignancies,https://clinicaltrials.gov/study/NCT00697346,COMPLETED,B-cell Follicular Lymphoma|B-cell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma|B-Cell Chronic Lymphocytic Leukemia|Multiple Myeloma|Waldenstrom's Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified|Angioimmunoblastic T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma|NK Lymphoma,DRUG: Alisertib,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT03872180,"Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma",https://clinicaltrials.gov/study/NCT03872180,ACTIVE_NOT_RECRUITING,CCND1 Positive|Mantle Cell Lymphoma|t(11;14) Positive,DRUG: Bendamustine|BIOLOGICAL: Obinutuzumab|DRUG: Venetoclax,Emory University,"Genentech, Inc.|National Cancer Institute (NCI)|National Institutes of Health (NIH)",INTERVENTIONAL
NCT00060385,Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00060385,TERMINATED,Lymphoma,DRUG: CHOP regimen|DRUG: EPOCH regimen|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: prednisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT05625594,Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma,https://clinicaltrials.gov/study/NCT05625594,RECRUITING,Central Nervous System Lymphoma,PROCEDURE: Aspiration|PROCEDURE: Biospecimen Collection|PROCEDURE: Catheterization|BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Fludarabine|PROCEDURE: Leukapheresis|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04205838,Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04205838,RECRUITING,"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma|Progressive Disease|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",BIOLOGICAL: Anakinra|BIOLOGICAL: Axicabtagene Ciloleucel|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Fludarabine Phosphate,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL
NCT02487316,A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib,https://clinicaltrials.gov/study/NCT02487316,WITHDRAWN,Systemic Anaplastic Large-Cell Lymphoma,DRUG: crizotinib,Jun Zhu,"Peking University First Hospital|Peking University People's Hospital|Peking University Third Hospital|Peking Union Medical College Hospital|Beijing Hospital|Chinese PLA General Hospital|First Hospitals affiliated to the China PLA General Hospital|Air Force General Hospital of the PLA|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Anhui Provincial Hospital|Zhejiang University",INTERVENTIONAL
NCT00323323,CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas,https://clinicaltrials.gov/study/NCT00323323,COMPLETED,Non-Hodgkin's Lymphoma,DRUG: CHOP|DRUG: Alemtuzumab|PROCEDURE: Plasma Samples,Ohio State University Comprehensive Cancer Center,Bayer,INTERVENTIONAL
NCT05613348,CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT05613348,WITHDRAWN,"B-cell Acute Lymphoblastic Leukemia|B-Cell Lymphoma, Unspecified",BIOLOGICAL: CD19 CAR T-Cell(CAT19T2),Zhujiang Hospital,"Guangdong Zhaotai Cell Bio-tech Co., LTD",INTERVENTIONAL
NCT04496349,A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL,https://clinicaltrials.gov/study/NCT04496349,RECRUITING,T-Prolymphocytic Leukemia|Non-Hodgkins Lymphoma,DRUG: APG-115|DRUG: APG-2575,Ascentage Pharma Group Inc.,,INTERVENTIONAL
NCT01560117,"Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma",https://clinicaltrials.gov/study/NCT01560117,COMPLETED,Follicular T-NHL Lymphoma|Rituximab Maintenance,DRUG: Rituximab,Arbeitsgemeinschaft medikamentoese Tumortherapie,,INTERVENTIONAL
NCT00801918,Denileukine Diftitox for Relapsed ALCL,https://clinicaltrials.gov/study/NCT00801918,WITHDRAWN,Anaplastic Large-Cell Lymphoma,"DRUG: Denileukin Diftitox|DRUG: Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide",Columbia University,,INTERVENTIONAL
NCT04412174,A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL,https://clinicaltrials.gov/study/NCT04412174,UNKNOWN,B-cell Non Hodgkin Lymphoma,BIOLOGICAL: GC022F,Hebei Yanda Ludaopei Hospital,Gracell Biotechnology Ltd.,INTERVENTIONAL
NCT03497533,Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19,https://clinicaltrials.gov/study/NCT03497533,UNKNOWN,"Non-hodgkin Lymphoma,B Cell",BIOLOGICAL: TriCAR-T-CD19,Timmune Biotech Inc.,Hunan Provincial People's Hospital,INTERVENTIONAL
NCT02087878,"A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT02087878,WITHDRAWN,Crohn's Disease|Ulcerative Colitis (UC)|Hepatosplenic T-Cell Lymphoma,,AbbVie,,OBSERVATIONAL
NCT01431209,Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01431209,COMPLETED,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,OTHER: Laboratory Biomarker Analysis|DRUG: Ruxolitinib Phosphate,University of Nebraska,National Cancer Institute (NCI),INTERVENTIONAL
NCT04185220,Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome,https://clinicaltrials.gov/study/NCT04185220,COMPLETED,Adult T-Cell Lymphoma/Leukemia|Sezary Syndrome|Mycosis Fungoides,DRUG: Recombinant human Interleukin-15 (rhIL-15)|BIOLOGICAL: Mogamulizumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05744037,Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells,https://clinicaltrials.gov/study/NCT05744037,UNKNOWN,B-cell Non Hodgkin Lymphoma,BIOLOGICAL: regimen with BTK inhibitor +Anti-CD19 CAR T cells,The Affiliated Hospital of Xuzhou Medical University,,INTERVENTIONAL
NCT02085655,PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma,https://clinicaltrials.gov/study/NCT02085655,UNKNOWN,"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: pegaspargase|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Methotrexate|DRUG: Dexamethasone|DRUG: Thalidomide,Huiqiang Huang,Sun Yat-sen University,INTERVENTIONAL
NCT06855823,A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL,https://clinicaltrials.gov/study/NCT06855823,RECRUITING,Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL),DRUG: Golicitinib combined with Pomadomide,Sun Yat-sen University,,INTERVENTIONAL
NCT06345027,Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY),https://clinicaltrials.gov/study/NCT06345027,NOT_YET_RECRUITING,"Leukemia, Myeloid, Acute|Leukemia, B-cell|Leukemia, T-Cell|Lymphoma",BIOLOGICAL: Treatment Arm A,Baylor College of Medicine,,INTERVENTIONAL
NCT03501576,Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma,https://clinicaltrials.gov/study/NCT03501576,RECRUITING,Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Inactivated Influenza Vaccine,Emory University,,OBSERVATIONAL
NCT02811783,Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL,https://clinicaltrials.gov/study/NCT02811783,TERMINATED,"Mycosis Fungoides|Lymphoma, T-Cell, Cutaneous|Sézary Syndrome","DRUG: Naloxone Hydrochloride Lotion, 0.5%|DRUG: Placebo Lotion","Elorac, Inc.",,INTERVENTIONAL
NCT06573151,"Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL",https://clinicaltrials.gov/study/NCT06573151,NOT_YET_RECRUITING,Lymphoma,"DRUG: Selinexor, anti-PD-1 antibody and P-GemOx",Ruijin Hospital,,INTERVENTIONAL
NCT04381741,CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04381741,UNKNOWN,Diffuse Large B-cell Lymphoma,BIOLOGICAL: CD19-7×19 CAR-T plus PD1 monoclonal antibody,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,INTERVENTIONAL
NCT04072458,A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT04072458,ACTIVE_NOT_RECRUITING,Mantle Cell Lymphoma|Peripheral T-cell Lymphoma (PTCL)|Cutaneous T-cell Lymphoma (CTCL)|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Follicular Lymphoma|Marginal Zone Lymphoma|Hodgkin Lymphoma|Waldenstrom Macroglobulinemia|DLBCL,DRUG: L-Bcl-2 antisense oligonucleotide,"Bio-Path Holdings, Inc.",,INTERVENTIONAL
NCT03881761,CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03881761,UNKNOWN,B-Cell Lymphoma Stage I|Refractory|Relapsed,BIOLOGICAL: CD19/CD20 bispecific CAR-T cells,Henan Cancer Hospital,Henan Hualong Biotechnology Company,INTERVENTIONAL
NCT01897012,Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT01897012,COMPLETED,MYC Positive|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory Hodgkin Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma,DRUG: Alisertib|OTHER: Laboratory Biomarker Analysis|DRUG: Romidepsin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02737085,the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL),https://clinicaltrials.gov/study/NCT02737085,UNKNOWN,"Lymphoma, Large B-Cell, Diffuse",BIOLOGICAL: Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells,"Southwest Hospital, China",,INTERVENTIONAL
NCT06208735,CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT06208735,RECRUITING,B-Cell Leukemia|Non-Hodgkin's Lymphoma|B-cell Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Mantle Cell Lymphoma|B-cell Lymphoma,BIOLOGICAL: CLIC-2201,British Columbia Cancer Agency,,INTERVENTIONAL
NCT05989204,TmCD19-IL18 in CD19+ Cancers,https://clinicaltrials.gov/study/NCT05989204,RECRUITING,Non Hodgkin Lymphoma,BIOLOGICAL: TmCD19-IL18,University of Pennsylvania,"Kite, A Gilead Company",INTERVENTIONAL
NCT05887167,Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT05887167,RECRUITING,Hematologic Malignancy|Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Mantle Cell Lymphoma|Multiple Myeloma|Diffuse Large B Cell Lymphoma,BIOLOGICAL: autologous hematopoietic stem cells added to planned CAR T,"Joshua Sasine, MD, PhD",,INTERVENTIONAL
NCT00742495,Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.,https://clinicaltrials.gov/study/NCT00742495,TERMINATED,Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia|B-cell Precursor Acute Lymphoblastic Leukaemia|T-cell Non-Hodgkin's Lymphoma,DRUG: Forodesine,Mundipharma Research Limited,Innovative Therapies For Children with Cancer Consortium,INTERVENTIONAL
NCT04881838,CCCG-ALCL-2020 for Chinese Children and Adolescents with Newly Diagnosed High-risk ALCL,https://clinicaltrials.gov/study/NCT04881838,RECRUITING,Pediatric Anaplastic Large Cell Lymphoma,DRUG: P regimen|DRUG: Course A1 + Vin|DRUG: Course B1 +Vin|DRUG: Course A2 + Vin|DRUG: Course B2 +Vin|DRUG: Course A3 + Vin|DRUG: Course B3 +Vin|DRUG: Maintenance therapy,"Children's Cancer Group, China",Shanghai Children's Medical Center|Nanjing Children's Hospital|Qilu Hospital of Shandong University|Tianjin Cancer Hospital|West China Second University Hospital|Xiangya Hospital|1st Affiliated Hospital of Zhengzhou University|Shenzhen Children's Hospital|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,INTERVENTIONAL
NCT05984147,A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1),https://clinicaltrials.gov/study/NCT05984147,RECRUITING,Relapsed Advanced Lymphomas,DRUG: AUR108,Aurigene Discovery Technologies Limited,,INTERVENTIONAL
NCT01134341,Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01134341,COMPLETED,Cutaneous T-cell Lymphoma|Mycosis Fungoides|Sezary Syndrome|Primary Cutaneous Anaplastic Large Cell Lymphoma,DRUG: Pralatrexate Injection|DRUG: Bexarotene Capsules|DIETARY_SUPPLEMENT: Vitamin B12|DIETARY_SUPPLEMENT: Folic Acid,Acrotech Biopharma Inc.,,INTERVENTIONAL
NCT03208556,Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT03208556,UNKNOWN,Relapsed or Refractory B-cell Lymphoma,BIOLOGICAL: iPD1 CD19 eCAR T cells|DRUG: Fludarabine and cyclophosphamide,Peking University,"Marino Biotechnology Co., Ltd.",INTERVENTIONAL
NCT05659628,CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL,https://clinicaltrials.gov/study/NCT05659628,RECRUITING,Diffuse Large B-cell Lymphoma,COMBINATION_PRODUCT: CD19-7×19 CAR-T combined with Tislelizumab,Ningbo No. 1 Hospital,Zhejiang University,INTERVENTIONAL
NCT01073267,Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis Fungoides,https://clinicaltrials.gov/study/NCT01073267,COMPLETED,Lymphoma,RADIATION: TSEBT,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03854994,CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03854994,UNKNOWN,B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Anti-CD19 CAR-T Cells Injection,Yan'an Affiliated Hospital of Kunming Medical University,KAEDI,INTERVENTIONAL
NCT00012207,Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00012207,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: aldesleukin|BIOLOGICAL: therapeutic autologous lymphocytes|DRUG: cyclophosphamide|DRUG: prednisone|DRUG: vincristine sulfate|PROCEDURE: adjuvant therapy,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01520246,Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01520246,COMPLETED,Leukemia|Lymphoma,GENETIC: gene expression analysis|OTHER: laboratory biomarker analysis,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT03504644,Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03504644,ACTIVE_NOT_RECRUITING,Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Acute Lymphoblastic Leukemia|Recurrent T Lymphoblastic Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia|Refractory T Lymphoblastic Lymphoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Lumbar Puncture|PROCEDURE: Positron Emission Tomography|DRUG: Venetoclax|DRUG: Vincristine Liposomal|DRUG: Vincristine Sulfate,ECOG-ACRIN Cancer Research Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT04605666,CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies,https://clinicaltrials.gov/study/NCT04605666,COMPLETED,B Cell Leukemia|B Cell Lymphoma,BIOLOGICAL: CD19-CAR-T2 Cells,"Nanfang Hospital, Southern Medical University",,INTERVENTIONAL
NCT02652715,Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT02652715,COMPLETED,"Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult T-Cell Leukemia/Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|B Lymphoblastic Leukemia/Lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Burkitt Leukemia|Central Nervous System Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Diffuse Large B-Cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3 Follicular Lymphoma|Hepatosplenic T-Cell Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Mediastinal (Thymic) Large B-Cell Lymphoma|Mycosis Fungoides|Nasal Type Extranodal NK/T-Cell Lymphoma|Nodal Marginal Zone Lymphoma|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Post-Transplant Lymphoproliferative Disorder|Primary Cutaneous Anaplastic Large Cell Lymphoma|Primary Effusion Lymphoma|Sezary Syndrome|Splenic Marginal Zone Lymphoma|Subcutaneous Panniculitis-Like T-Cell Lymphoma|Systemic Anaplastic Large Cell Lymphoma|T Lymphoblastic Leukemia/Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma",OTHER: Laboratory Biomarker Analysis|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|DIETARY_SUPPLEMENT: Salvia hispanica Seed,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT02953301,Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS),https://clinicaltrials.gov/study/NCT02953301,COMPLETED,"Mycosis Fungoides|Sezary Syndrome|Lymphoma, T-Cell, Cutaneous",DRUG: resminostat|DRUG: Placebo,4SC AG,,INTERVENTIONAL
NCT04206943,Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL,https://clinicaltrials.gov/study/NCT04206943,UNKNOWN,Acute Lymphoblastic Leukemia|Non Hodgkin Lymphoma,BIOLOGICAL: Car-T Cell Therapy,Acibadem University,Acıbadem Atunizade Hospital|The Scientific and Technological Research Council of Turkey|Acıbadem Labcell,INTERVENTIONAL
NCT02419287,Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas,https://clinicaltrials.gov/study/NCT02419287,COMPLETED,"Anaplastic Large Cell Lymphoma, ALK-Positive",DRUG: crizotinib,University of Milano Bicocca,,INTERVENTIONAL
NCT05333302,Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT05333302,RECRUITING,B-cell Acute Lymphoblastic Leukemia|Lymphoblastic B-Cell Lymphoma,BIOLOGICAL: CD19 CAR-T-cells|DRUG: Tocilizumab,"Belarusian Research Center for Pediatric Oncology, Hematology and Immunology",,INTERVENTIONAL
NCT04473937,Radiation Post-CAR T in Refractory Lymphoma,https://clinicaltrials.gov/study/NCT04473937,TERMINATED,Hematologic Malignancy|Refractory Lymphoma,RADIATION: Radiotherapy,Massachusetts General Hospital,,INTERVENTIONAL
NCT00005080,506U78 in Treating Patients With Lymphoma,https://clinicaltrials.gov/study/NCT00005080,COMPLETED,Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Small Intestine Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome,DRUG: nelarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00924170,"Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia",https://clinicaltrials.gov/study/NCT00924170,COMPLETED,Adult T-Cell Leukemia (ATL),DRUG: LMB-2|DRUG: Fludarabine|DRUG: Cyclophosphamide,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06935136,Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06935136,NOT_YET_RECRUITING,CAR-T Cell Therapy|High-risk Large B-cell Lymphoma (LBCL),DRUG: Axicabtagene Ciloleucel,Ruijin Hospital,,INTERVENTIONAL
NCT04037566,CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.,https://clinicaltrials.gov/study/NCT04037566,UNKNOWN,"Leukemia Lymphocytic Acute (ALL) in Relapse|Leukemia Lymphocytic Acute (All) Refractory|Lymphoma, B-Cell|CD19 Positive",GENETIC: XYF19 CAR-T cell|DRUG: Cyclophosphamide|DRUG: Fludarabine,Xijing Hospital,"Xi'An Yufan Biotechnology Co.,Ltd",INTERVENTIONAL
NCT06585124,Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas,https://clinicaltrials.gov/study/NCT06585124,RECRUITING,Lymphoma|Hemophagocytic Lymphohistiocytoses,DIAGNOSTIC_TEST: Flow Cytometry,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,OBSERVATIONAL
NCT03166878,A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT03166878,UNKNOWN,B Cell Leukemia|B Cell Lymphoma,BIOLOGICAL: UCART019,Chinese PLA General Hospital,,INTERVENTIONAL
NCT00354107,"Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma",https://clinicaltrials.gov/study/NCT00354107,TERMINATED,Anaplastic Large Cell Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma,BIOLOGICAL: monoclonal antibody SGN-30|DRUG: therapeutic hydrocortisone|DRUG: ifosfamide|DRUG: carboplatin|DRUG: etoposide|DRUG: methotrexate|DRUG: cytarabine|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05149391,A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05149391,UNKNOWN,B Cell Non-Hodgkin's Lymphoma,BIOLOGICAL: CD19/CD20-directed Chimeric Antigen Receptor T Cells,Peking University,Peking University Cancer Hospital & Institute,INTERVENTIONAL
NCT05918809,Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings,https://clinicaltrials.gov/study/NCT05918809,COMPLETED,Diffuse Large B-cell Lymphoma,,Novartis Pharmaceuticals,,OBSERVATIONAL
NCT03443128,Vinorelbine for Recurrent ALCL-2017,https://clinicaltrials.gov/study/NCT03443128,COMPLETED,Anaplastic Large Cell Lymphoma|Vinorelbine,DRUG: Vinorelbine,"Children's Cancer Group, China",,INTERVENTIONAL
NCT00056056,Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00056056,TERMINATED,Lymphoma,DRUG: bexarotene|DRUG: methoxypsoralen|PROCEDURE: UV light therapy,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT03397953,Vinorelbine for Recurrent ACLC,https://clinicaltrials.gov/study/NCT03397953,COMPLETED,Anaplastic Large Cell Lymphoma|Vinorelbine,DRUG: Vinorelbine,"Children's Cancer Group, China",,INTERVENTIONAL
NCT06768905,Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06768905,RECRUITING,Non Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma,DRUG: Iomab-B|DRUG: CAR-T cell,University of Texas Southwestern Medical Center,Actinium Pharmaceuticals,INTERVENTIONAL
NCT06976437,A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors,https://clinicaltrials.gov/study/NCT06976437,NOT_YET_RECRUITING,B Cell Lymphoma|Multiple Myeloma,DRUG: RN1101 injection,YANRU WANG,"Rui Therapeutics Co., Ltd|AlloRunning Therapeutics Co., Ltd.",INTERVENTIONAL
NCT00536978,Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT00536978,COMPLETED,Lymphoma|Leukemia,DRUG: ARA-C|DRUG: BCNU|DRUG: Campath-1H|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Rituximab|OTHER: Allogeneic Stem Cell Transplantation|RADIATION: Total body radiation (TBI)|DRUG: Methotrexate|DRUG: Tacrolimus|PROCEDURE: Adback NK or T Cell,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT06756321,A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy,https://clinicaltrials.gov/study/NCT06756321,RECRUITING,Relapsed/refractory Lymphoma|Relapsed/Refractory Leukemia,"BIOLOGICAL: anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells|DRUG: Fludarabine|DRUG: Cyclophosphamide",Affiliated Hospital of Nantong University,"Shanghai First Song Biotechnology Co., LTD",INTERVENTIONAL
NCT02277522,CD19 Redirected Autologous T Cells for Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT02277522,TERMINATED,Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis,BIOLOGICAL: RNA anti-CD19 CAR T cells,University of Pennsylvania,,INTERVENTIONAL
NCT03017820,"A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma",https://clinicaltrials.gov/study/NCT03017820,RECRUITING,"B-Cell Non-Hodgkin Lymphoma|Histiocytic and Dendritic Cell Neoplasm|Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Angioimmunoblastic T-Cell Lymphoma|Recurrent Mycosis Fungoides|Recurrent Plasma Cell Myeloma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Acute Myeloid Leukemia|Refractory Anaplastic Large Cell Lymphoma|Refractory Angioimmunoblastic T-Cell Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Plasma Cell Myeloma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma",PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter|PROCEDURE: Single Photon Emission Computed Tomography|BIOLOGICAL: Cemiplimab|DRUG: Ruxolitinib,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT02918747,PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage,https://clinicaltrials.gov/study/NCT02918747,UNKNOWN,Lymphoma,DRUG: pegaspargase|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Dexamethasone|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|RADIATION: IMRT,Hunan Cancer Hospital,,INTERVENTIONAL
NCT02274506,"Infusion of Allogeneic, 3rd Party CD19-specific T Cells",https://clinicaltrials.gov/study/NCT02274506,WITHDRAWN,Blood And Marrow Transplantation|Leukemia|Lymphoma,DRUG: Cyclophosphamide|DRUG: Fludarabine|PROCEDURE: T-Cell Infusion,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT00002956,Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants,https://clinicaltrials.gov/study/NCT00002956,WITHDRAWN,Leukemia|Lymphoma,BIOLOGICAL: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes,University of Alabama at Birmingham,,INTERVENTIONAL
NCT03011814,Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,https://clinicaltrials.gov/study/NCT03011814,ACTIVE_NOT_RECRUITING,"Folliculotropic Mycosis Fungoides|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified|Sezary Syndrome|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma",BIOLOGICAL: Durvalumab|OTHER: Laboratory Biomarker Analysis|DRUG: Lenalidomide,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00972101,Infusion of Expanded Cord Blood T Cells,https://clinicaltrials.gov/study/NCT00972101,WITHDRAWN,Stem Cell Transplantation|Leukemia|Lymphoma|Pediatric Disorders,RADIATION: Total Body Irradiation (TBI)|DRUG: Melphalan|DRUG: Thiotepa|DRUG: Fludarabine|DRUG: Rituximab|DRUG: Etoposide|DRUG: Anti-thymocyte globulin (ATG)|DRUG: Mycophenolate Mofetil (MMF)|DRUG: Tacrolimus|PROCEDURE: Cord Blood Infusion|DRUG: G-CSF|PROCEDURE: Ex vivo expanded T cell Infusion,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT05189782,Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05189782,UNKNOWN,Diffuse Large B Cell Lymphoma,,Ruijin Hospital,,OBSERVATIONAL
NCT03642626,MT2017-45: CAR-T Cell Therapy for Heme Malignancies,https://clinicaltrials.gov/study/NCT03642626,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Large B-cell Lymphoma,"DRUG: KYMRIAH|DRUG: YESCARTA|DRUG: Fludarabine 30mg/m2 4 doses|DRUG: Cyclophosphamide 500 mg/m2; 2 doses|DRUG: Fludarabine 30mg/m2 3 doses|DRUG: Cyclophosphamide 500 mg/m2; 3 doses|DRUG: Fludarabine 25mg/m2 3 days|DRUG: Cyclophosphamide 250 mg/m2; 3 days|DRUG: Tecartus|DRUG: Abecma, Intravenous Suspension|DRUG: Cyclophosphamide 900 mg/m2; 1 day|DRUG: Breyanzi Injectable Product","Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT04486872,An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection,https://clinicaltrials.gov/study/NCT04486872,UNKNOWN,Diffuse Large B Cell Lymphoma,BIOLOGICAL: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells,First Affiliated Hospital of Zhejiang University,,INTERVENTIONAL
NCT05349266,Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy,https://clinicaltrials.gov/study/NCT05349266,UNKNOWN,Non-Hodgkin's Lymphoma,BIOLOGICAL: ThisCART19A,Zhejiang University,,INTERVENTIONAL
NCT05932173,A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies,https://clinicaltrials.gov/study/NCT05932173,RECRUITING,B-Cell Leukemia|B-Cell Lymphoma|B-cell Tumors,BIOLOGICAL: Anti-CD19 Autologous CAR-T Cell Infusion,920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,,INTERVENTIONAL
NCT04134117,Tisagenlecleucel in Primary CNS Lymphoma,https://clinicaltrials.gov/study/NCT04134117,COMPLETED,Primary CNS Lymphoma|Refractory Primary CNS Lymphoma|Relapsed Primary CNS Lymphoma,BIOLOGICAL: Tisagenlecleucel,"Matthew J. Frigault, M.D.",Novartis,INTERVENTIONAL
NCT00005950,506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00005950,TERMINATED,Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,DRUG: nelarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04446130,"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients",https://clinicaltrials.gov/study/NCT04446130,UNKNOWN,Induction Chemotherapy|Acute T-Lymphocytic Leukemia|T-cell Lymphoblastic Lymphoma Leukemia|T-cell/Myeloid Mixed Phenotype Acute Leukemia,DRUG: Decitabine combined with HAAG Regimen,The First Affiliated Hospital of Soochow University,Henan Cancer Hospital|Shandong Provincial Hospital|Shenzhen People's Hospital|The First Affiliated Hospital of Anhui Medical University|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Changzhou No.2 People's Hospital|The Second People's Hospital of Huai'an,INTERVENTIONAL
NCT03696784,Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma,https://clinicaltrials.gov/study/NCT03696784,RECRUITING,"Lymphoma|Lymphoma, B-Cell|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases",BIOLOGICAL: iC9-CAR19 T cells|DRUG: Bendamustine|DRUG: Fludarabine|DRUG: AP1903|DRUG: Cyclophosphamide,UNC Lineberger Comprehensive Cancer Center,UNC Chapel Hill University Cancer Research Fund|The V Foundation|M.D. Anderson Cancer Center,INTERVENTIONAL
NCT05400109,Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas,https://clinicaltrials.gov/study/NCT05400109,RECRUITING,Non Hodgkin Lymphoma,BIOLOGICAL: UF-KURE19 CAR-T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,David Wald,,INTERVENTIONAL
NCT04608487,Axi-cel in CNS Lymphoma,https://clinicaltrials.gov/study/NCT04608487,ACTIVE_NOT_RECRUITING,Lymphoma|Lymphoma Cns,DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Axicabtagene Ciloleucel,Dana-Farber Cancer Institute,"Kite, A Gilead Company",INTERVENTIONAL
NCT02520791,Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02520791,ACTIVE_NOT_RECRUITING,"Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma|Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type|Refractory Grade 1 Follicular Lymphoma|Refractory Grade 2 Follicular Lymphoma|Refractory Grade 3a Follicular Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Stage IB Mycosis Fungoides AJCC v7|Stage II Mycosis Fungoides AJCC v7|Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Mycosis Fungoides AJCC v7|Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Mycosis Fungoides AJCC v7",BIOLOGICAL: Anti-ICOS Monoclonal Antibody MEDI-570|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06686108,Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention,https://clinicaltrials.gov/study/NCT06686108,RECRUITING,T-cell Acute Lymphoblastic Leukemia|ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION|Relapse,DRUG: Azacitidine (AZA) Days 1 - 5|DRUG: Decitabine (DAC)|DRUG: Venetoclax,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT00039351,Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00039351,COMPLETED,Lymphoma,DRUG: cyclophosphamide|DRUG: prednisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT05312476,Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05312476,UNKNOWN,Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,DRUG: Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT03281551,Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03281551,UNKNOWN,B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma,DRUG: PZ01 CAR-T cells,Pinze Lifetechnology Co. Ltd.,"Chinese Academy of Sciences|Navy General Hospital, Beijing",INTERVENTIONAL
NCT05420493,Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05420493,RECRUITING,Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Non Hodgkin Lymphoma,BIOLOGICAL: CAR-T cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT04289220,Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04289220,UNKNOWN,B Cell Lymphoma|B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Anti-CD19 CAR-T Cells Injection,Yan'an Affiliated Hospital of Kunming Medical University,,INTERVENTIONAL
NCT04539444,A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04539444,UNKNOWN,Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma,BIOLOGICAL: CD19/22 CART|DRUG: Tislelizumab,The First Affiliated Hospital of Soochow University,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",INTERVENTIONAL
NCT04464889,HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT04464889,WITHDRAWN,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorders|Chronic Myeloid Leukemia|Myelofibrosis|Multiple Myeloma|Malignant Lymphoma,DRUG: MDG1021 dose 1|DRUG: MDG1021 dose 2|DRUG: MDG1021 dose 3|DRUG: MDG1021 optimal dose,Medigene AG,,INTERVENTIONAL
NCT03615105,Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors,https://clinicaltrials.gov/study/NCT03615105,TERMINATED,Acute Lymphoid Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Chronic Myeloid Leukemia (CML)|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia,RADIATION: Hyperfractionated total body irradiation|DRUG: Thiotepa|DRUG: Cyclophosphamide|DRUG: Busulfan|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Clofarabine|PROCEDURE: HPC(A) stem cell allograft|DRUG: Rituximab|DEVICE: Rabbit antithymocyte globulin,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT06142175,Relmacabtagene Autoleucel in Patients With LBCL,https://clinicaltrials.gov/study/NCT06142175,RECRUITING,Large B-cell Lymphoma,BIOLOGICAL: Relmacabtagene Autoleucel,"Shanghai Ming Ju Biotechnology Co., Ltd.",,OBSERVATIONAL
NCT00406809,A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT00406809,COMPLETED,Chronic Lymphoid Leukemia|Lymphoid Malignancies|Non-Hodgkin's Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Peripheral T-cell Lymphoma,DRUG: ABT-263,"AbbVie (prior sponsor, Abbott)",,INTERVENTIONAL
NCT00283985,Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00283985,COMPLETED,"Lymphoma, Non-Hodgkin",DRUG: Kidrolase|DRUG: Methotrexate|DRUG: Dexamethasone|DRUG: Erwinase,"University Hospital, Limoges",,INTERVENTIONAL
NCT06343376,Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06343376,SUSPENDED,Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Echocardiography|BIOLOGICAL: EGFRt/19-28z/IL-12 CAR T-lymphocytes|DRUG: Fludarabine Phosphate|PROCEDURE: Leukapheresis|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Positron Emission Tomography,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT02572453,"Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL",https://clinicaltrials.gov/study/NCT02572453,TERMINATED,Recurrent Anaplastic Large Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma,DRUG: Onalespib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00506129,Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00506129,COMPLETED,Lymphoma|Disorder Related to Bone Marrow Transplantation,DRUG: Fludarabine|DRUG: Melphalan|PROCEDURE: Allogeneic Transplant|DRUG: Thymoglobulin,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT04160195,T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04160195,TERMINATED,"Lymphoma, B-Cell|Lymphoma, Non-hodgkins|Chronic Lymphocytic Leukemia|B-Cell Chronic Lymphocytic Leukemia",BIOLOGICAL: Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04520529,Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas,https://clinicaltrials.gov/study/NCT04520529,NOT_YET_RECRUITING,Cutaneous Lymphoma,OTHER: Biologic Samples,Assistance Publique - Hôpitaux de Paris,,INTERVENTIONAL
NCT06875063,GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL,https://clinicaltrials.gov/study/NCT06875063,RECRUITING,"Non-hodgkin Lymphoma,B Cell|Relapsed Non-Hodgkin Lymphoma|Refractory Lymphoma|Chimeric Antigen Receptor T-cell",DRUG: GB5005 CART,The First Affiliated Hospital of Xiamen University,,INTERVENTIONAL
NCT06014762,P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies,https://clinicaltrials.gov/study/NCT06014762,RECRUITING,"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High-grade B-cell Lymphoma|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Transformed Follicular Lymphoma (tFL)|Follicular Lymphoma Grade 3B|DLBCL|DLBCL - Diffuse Large B Cell Lymphoma|DLBCL Arising From Follicular Lymphoma|DLBCL, Diffused Large B Cell Lymphoma|DLBCL NOS",BIOLOGICAL: P-CD19CD20-ALLO1|DRUG: Rimiducid,"Poseida Therapeutics, Inc.",Roche-Genentech,INTERVENTIONAL
NCT02819583,CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT02819583,UNKNOWN,Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|B-cell Prolymphocytic Leukemia|Diffuse Large Cell Lymphoma,BIOLOGICAL: PCAR-019 (anti-CD19 CAR-T cells),"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",The First People's Hospital of Hefei|Hefei Binhu Hospital|Anhui Provincial Hospital,INTERVENTIONAL
NCT02050347,"Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)",https://clinicaltrials.gov/study/NCT02050347,ACTIVE_NOT_RECRUITING,Non-Hodgkin's Lymphoma|B-Cell ALL|B-Cell CLL,GENETIC: CD19.CAR-CD28Z T Cells - dose escalation 2|GENETIC: CD19.CAR-CD28Z T Cells - dose escalation 1,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",INTERVENTIONAL
NCT06104592,Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL,https://clinicaltrials.gov/study/NCT06104592,RECRUITING,Large B-cell Lymphoma|Relapsed Non-Hodgkin Lymphoma,RADIATION: Comprehensive Ablative Bridging Irradiation (CABI)|BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy,H. Lee Moffitt Cancer Center and Research Institute,"Kite, A Gilead Company",INTERVENTIONAL
NCT01626495,Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT01626495,COMPLETED,B Cell Leukemia|B Cell Lymphoma,BIOLOGICAL: CART-19,University of Pennsylvania,,INTERVENTIONAL
NCT00038883,Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT00038883,TERMINATED,"Leukemia, Lymphocytic, Chronic|Leukemia, Lymphocytic, Acute|Lymphoma, Low-Grade|Lymphoma, T-Cell|Lymphoma, B-Cell",DRUG: Campath-1H,M.D. Anderson Cancer Center,Leudosite,INTERVENTIONAL
NCT00199017,German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults,https://clinicaltrials.gov/study/NCT00199017,COMPLETED,"Lymphoma, Lymphoblastic",DRUG: Dexamethasone/Prednisolone|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Daunorubicin|DRUG: Asparaginase|DRUG: G-CSF|DRUG: Mercaptopurine|DRUG: Cytarabine|DRUG: Methotrexate|DRUG: VP16|DRUG: Vindesine|DRUG: Adriamycin|DRUG: Thioguanine|DRUG: HDARAC|PROCEDURE: CNS irradiation|PROCEDURE: Mediastinal irradiation|DRUG: Cladribine,Johann Wolfgang Goethe University Hospital,,INTERVENTIONAL
NCT02323867,Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT02323867,ACTIVE_NOT_RECRUITING,Leukemia|Lymphoma|Myelodysplasia,DEVICE: Alpha Beta T cell depletion,Children's Hospital of Philadelphia,,INTERVENTIONAL
NCT05333367,MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy,https://clinicaltrials.gov/study/NCT05333367,RECRUITING,Cutaneous T-Cell Lymphoma|Graft Vs Host Disease|Graft Rejection,OTHER: Samples collection,Centre Hospitalier Universitaire de Besancon,,INTERVENTIONAL
NCT05798897,Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma,https://clinicaltrials.gov/study/NCT05798897,RECRUITING,"Non-Hodgkin Lymphoma, Adult|Non-Hodgkin Lymphoma, Refractory|Non-Hodgkin Lymphoma, Relapsed|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Hodgkin Lymphoma, Adult|Hodgkin's Lymphoma, Relapsed, Adult",DRUG: MT-601,"Marker Therapeutics, Inc.",,INTERVENTIONAL
NCT01163201,T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01163201,WITHDRAWN,"Hematologic Malignancy|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia in Blast Crisis|Anemia, Refractory, With Excess of Blasts|Chronic Myeloproliferative Disease|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Lymphoma|Large Cell Non-Hodgkin's Lymphoma|Lymphoblastic Lymphoma|Burkitt's Lymphoma|High Grade Non-Hodgkin's Lymphoma",BIOLOGICAL: Treg cells|BIOLOGICAL: CD3+ Teff cells|DRUG: Fludarabine|DRUG: Cyclophosphamide|RADIATION: Total body irradiation|BIOLOGICAL: Umbilical cord blood transplantation,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT06782854,"Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the ""Off the Beaten Track"" Liquid Biopsy",https://clinicaltrials.gov/study/NCT06782854,COMPLETED,Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma(MZL)|Mycosis Fungoides|Chronic Lymphocytic Leukemia|Hairy Cell Leukemia (HCL)|T Cell Lymphoma|Multiple Mieloma,,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,OBSERVATIONAL
NCT04488354,Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T,https://clinicaltrials.gov/study/NCT04488354,ENROLLING_BY_INVITATION,Relapsed/Refractory B-cell Lymphomas|Diffuse Large B-Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Chronic Lymphocytic Leukemia (CLL)|Marginal Zone Lymphoma (MZL)|Mantle Cell Lymphoma (MCL)|Small Lymphocytic Lymphoma (SLL)|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Burkitt Lymphoma,COMBINATION_PRODUCT: CLBR001 and SWI019,"Calibr, a division of Scripps Research",,INTERVENTIONAL
NCT05149378,Venetoclax Based Regimen for R/R T-ALL,https://clinicaltrials.gov/study/NCT05149378,COMPLETED,Acute T-Lymphocytic Leukemia,DRUG: Venetoclax combined with azacitidine regimen,The First Affiliated Hospital of Soochow University,"Jining Medical University|The Second People's Hospital of Huai'an|The First Affiliated Hospital of Bengbu Medical University|Affiliated Hospital of Nantong University|Suzhou Hospital of Traditional Chinese Medicine|The First Affiliated Hospital of Anhui Medical University|Southern Medical University, China|Nanyang Central Hospital of Henan Province|Canglang Hospital of Suzhou",INTERVENTIONAL
NCT03766516,Registry of BrentuximabVedotinin Patients With R/R Anaplastic Large Cell Lymphoma or Classical HL,https://clinicaltrials.gov/study/NCT03766516,COMPLETED,Relapsed or Refractory Anaplastic Large Cell Lymphoma & Hodgkin Lymphoma,,Samsung Medical Center,,OBSERVATIONAL
NCT05366569,Bio-CAR-T BS Study,https://clinicaltrials.gov/study/NCT05366569,RECRUITING,Diffuse Large B Cell Lymphoma (DLBCL)|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Acute Lymphoblastic Leukemia (ALL),,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,,OBSERVATIONAL
NCT04432506,Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04432506,COMPLETED,Hematopoietic and Lymphoid Cell Neoplasm|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,BIOLOGICAL: Anakinra|BIOLOGICAL: Axicabtagene Ciloleucel|DRUG: Cyclophosphamide|DRUG: Fludarabine,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04836507,Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT04836507,RECRUITING,Relapsed Large B-cell Lymphoma|Refractory Large B-cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|Primary Mediastinal Large B-Cell Lymphoma (PMBCL)|High-grade B-cell Lymphoma|Transformed Follicular Lymphoma (TFL),BIOLOGICAL: CRC01|DRUG: Fludarabine|DRUG: Cyclophosphamide,Curocell Inc.,,INTERVENTIONAL
NCT04670874,Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29,https://clinicaltrials.gov/study/NCT04670874,RECRUITING,Cutaneous Lymphoma,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT05052528,Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05052528,RECRUITING,Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|BIOLOGICAL: Rituximab,"Mehrdad Abedi, MD",National Cancer Institute (NCI),INTERVENTIONAL
NCT03205891,"Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas",https://clinicaltrials.gov/study/NCT03205891,WITHDRAWN,Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Classical Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|CD30+ Peripheral T-cell Lymphoma,DRUG: Brentuximab Vedotin|DRUG: TAK228|DEVICE: Glucose Monitor,M.D. Anderson Cancer Center,Takeda,INTERVENTIONAL
NCT04088890,Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT04088890,COMPLETED,B-ALL|B-cell Non Hodgkin Lymphoma|DLBCL|Follicular Lymphoma Grade 3B,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: CD22 CAR,Stanford University,National Cancer Institute (NCI)|The Leukemia and Lymphoma Society|American Society of Hematology,INTERVENTIONAL
NCT04007029,Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT04007029,ACTIVE_NOT_RECRUITING,CD19 Positive|CD20 Positive|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|BIOLOGICAL: Tocilizumab,Jonsson Comprehensive Cancer Center,Parker Institute for Cancer Immunotherapy,INTERVENTIONAL
NCT04028440,γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL),https://clinicaltrials.gov/study/NCT04028440,UNKNOWN,Non-Hodgkin's Lymphoma|Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma|Chronic Lymphoblastic Leukemia|Peripheral T Cell Lymphoma,BIOLOGICAL: Autologous γδT cells,"Institute of Hematology & Blood Diseases Hospital, China","Beijing GD Initiative Cell Therapy Technology Co., Ltd.|Chinese Academy of Medical Sciences",INTERVENTIONAL
NCT01556828,Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing,https://clinicaltrials.gov/study/NCT01556828,TERMINATED,Cutaneous Lymphoma|Other Skin Disorders|Mycosis Fungoides|Cutaneous T-cell Lymphoma,,Stanford University,,OBSERVATIONAL
NCT01333046,Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL,https://clinicaltrials.gov/study/NCT01333046,ACTIVE_NOT_RECRUITING,Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Hodgkin Disease,BIOLOGICAL: Antigen-Escalation Stage|BIOLOGICAL: Dose-Escalation Stage|BIOLOGICAL: azacytidine and multiTAA T cells Stage|BIOLOGICAL: Pediatric multiTAA T cells Stage,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute|National Cancer Institute (NCI)",INTERVENTIONAL
NCT04787263,CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML,https://clinicaltrials.gov/study/NCT04787263,RECRUITING,Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Primary Mediastinal Lymphoma,BIOLOGICAL: CD19-CAR_Lenti T cell,Bambino Gesù Hospital and Research Institute,,INTERVENTIONAL
NCT05075603,Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy,https://clinicaltrials.gov/study/NCT05075603,RECRUITING,"Refractory Diffuse Large B-cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",DRUG: Efineptakin alfa|DRUG: Tisagenlecleucel|DRUG: Axicabtagene ciloleucel|DRUG: Lisocabtagene Maraleucel,NeoImmuneTech,,INTERVENTIONAL
NCT03563040,Study of Photopheresis in the Treatment of Erythrodermic MF and SS,https://clinicaltrials.gov/study/NCT03563040,WITHDRAWN,"Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides/Sezary Syndrome",DRUG: Methoxsalen|DEVICE: THERAKOS CELLEX Photopheresis System,European Organisation for Research and Treatment of Cancer - EORTC,Mallinckrodt,INTERVENTIONAL
NCT03939026,Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma,https://clinicaltrials.gov/study/NCT03939026,ACTIVE_NOT_RECRUITING,Relapsed/Refractory Large B Cell Lymphoma|Relapsed/Refractory Follicular Lymphoma,GENETIC: ALLO-501|BIOLOGICAL: ALLO-647|DRUG: Fludarabine|DRUG: Cyclophosphamide,Allogene Therapeutics,,INTERVENTIONAL
NCT00383097,Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00383097,TERMINATED,Hodgkins Lymphoma|Non-Hodgkin Lymphoma,GENETIC: LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|GENETIC: LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES,Baylor College of Medicine,The Methodist Hospital Research Institute,INTERVENTIONAL
NCT01701986,"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01701986,COMPLETED,Hematopoietic Cell Transplantation Recipient|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma,PROCEDURE: Allogeneic Bone Marrow Transplantation|PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Anti-Thymocyte Globulin|DRUG: Busulfan|DRUG: Clofarabine|DRUG: Gemcitabine Hydrochloride|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|OTHER: Pharmacological Study|BIOLOGICAL: Rituximab|DRUG: Tacrolimus,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01178658,"Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma",https://clinicaltrials.gov/study/NCT01178658,UNKNOWN,Non-Hodgkin Lymphoma,"DRUG: Busulfan, etoposide, cytarabine, and melphalan",Seoul National University Hospital,Inje University|Severance Hospital|Asan Medical Center|Ulsan University Hospital,INTERVENTIONAL
NCT06547528,A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL,https://clinicaltrials.gov/study/NCT06547528,RECRUITING,Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,DRUG: ONO-4685,Ono Pharmaceutical Co. Ltd,,INTERVENTIONAL
NCT00481871,Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies,https://clinicaltrials.gov/study/NCT00481871,COMPLETED,Relapsed or Refractory Lymphoproliferative Malignancies|Hodgkin's Lymphoma|Peripheral T-cell Lymphoma|B-cell Lymphoma|Waldenstrom's Macroglobulinemia,DRUG: Pralatrexate Injection|DRUG: Gemcitabine Hydrochloride|DIETARY_SUPPLEMENT: Vitamin B12|DIETARY_SUPPLEMENT: Folic Acid,Acrotech Biopharma Inc.,,INTERVENTIONAL
NCT06544265,SynKIR-310 for Relapsed/Refractory B-NHL,https://clinicaltrials.gov/study/NCT06544265,RECRUITING,"B Cell Lymphoma|NHL, Adult|Mantle Cell Lymphoma|Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Aggressive B-Cell Non-Hodgkin Lymphoma|Indolent B-Cell Non-Hodgkin Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|DLBCL - Diffuse Large B Cell Lymphoma|HGBL With MYC and BCL2 and/or BCL6 Rearrangements|High-grade B-cell Lymphoma|Diffuse Large B Cell Lymphoma|Large B-cell Lymphoma|T-Cell/Histiocyte Rich Lymphoma|Non-hodgkin Lymphoma,B Cell|Primary Mediastinal Large B-cell Lymphoma (PMBCL)|Epstein-Barr Virus Positive DLBCL, Nos|Follicular Lymphoma Grade 3B|DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation|High Grade B-Cell Lymphoma, Not Otherwise Specified|Follicular Lymphoma Grade 3|Marginal Zone Splenic Lymphoma|DLBCL",BIOLOGICAL: SynKIR-310,Verismo Therapeutics,,INTERVENTIONAL
NCT04220008,Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04220008,WITHDRAWN,Recurrent Aggressive Non-Hodgkin Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Busulfan|DRUG: Clofarabine|DRUG: Cyclophosphamide|DRUG: Gemcitabine|DRUG: Mycophenolate Mofetil|BIOLOGICAL: Rituximab|DRUG: Tacrolimus|DRUG: Vorinostat,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT06854159,Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy,https://clinicaltrials.gov/study/NCT06854159,NOT_YET_RECRUITING,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|BIOLOGICAL: Odronextamab,"University of California, Davis",National Cancer Institute (NCI),INTERVENTIONAL
NCT06822868,A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06822868,RECRUITING,B-Cell Non-Hodgkin Lymphoma,DRUG: CAR T cells,Kai Hu,,INTERVENTIONAL
NCT04035434,A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON),https://clinicaltrials.gov/study/NCT04035434,TERMINATED,B-cell Malignancy|Non-Hodgkin Lymphoma|B-cell Lymphoma|Adult B Cell ALL,BIOLOGICAL: CTX110,CRISPR Therapeutics AG,,INTERVENTIONAL
NCT01386398,"Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT01386398,WITHDRAWN,Lymphoma,DRUG: bortezomib|DRUG: vorinostat|OTHER: laboratory biomarker analysis,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT05826535,Study of LYL314 in Aggressive Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05826535,RECRUITING,Relapsed Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Large B-cell Lymphoma,DRUG: LYL314|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Lyell Immunopharma, Inc.",,INTERVENTIONAL
NCT05322330,Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05322330,UNKNOWN,Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,DRUG: Selinexor|DRUG: Flu|DRUG: CTX|DRUG: CAR-T,The First Affiliated Hospital of Soochow University,West China Hospital|The General Hospital of Western Theater Command|The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Yixing People's Hospital|Affiliated Hospital of Jiangnan University|Wuxi Second People's Hospital,INTERVENTIONAL
NCT06734871,A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06734871,RECRUITING,B-Cell Non-Hodgkin Lymphoma,DRUG: CAR T cells,Aibin Liang，MD，Ph.D.,,INTERVENTIONAL
NCT05934045,Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma,https://clinicaltrials.gov/study/NCT05934045,ACTIVE_NOT_RECRUITING,ALK-Positive Anaplastic Large Cell Lymphoma,BIOLOGICAL: RNAseq,"University Hospital, Toulouse","Institut National de la Santé Et de la Recherche Médicale, France",OBSERVATIONAL
NCT01944982,Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma,https://clinicaltrials.gov/study/NCT01944982,TERMINATED,Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma,BIOLOGICAL: Expanded haploidentical natural killer cells (NKAEs),"Hospital Infantil Universitario Niño Jesús, Madrid, Spain",,INTERVENTIONAL
NCT03559439,CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies,https://clinicaltrials.gov/study/NCT03559439,UNKNOWN,B-cell Malignancy|B-cell Lymphoma|B-Cell Acute Lymphoblastic Leukaemia,BIOLOGICAL: CD19 CAR T,Shanghai Tong Ren Hospital,Gracell Biotechnology Ltd.,INTERVENTIONAL
NCT04223765,Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.,https://clinicaltrials.gov/study/NCT04223765,RECRUITING,Mantle Cell Lymphoma|Follicular Lymphoma|Splenic Marginal Zone Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Indolent Non-hodgkin Lymphoma,DRUG: CAR.k.28|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Bendamustine,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04184414,The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies,https://clinicaltrials.gov/study/NCT04184414,UNKNOWN,B Acute Lymphoblastic Leukemia|Mantle Cell Lymphoma|Follicular Lymphoma,DRUG: CD19-CART,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",Second Affiliated Hospital of Suzhou University,INTERVENTIONAL
NCT02476734,FDG-PET/CT Imaging as Early Predictor of DP,https://clinicaltrials.gov/study/NCT02476734,COMPLETED,Lymphoma,OTHER: There is no intervention,Abramson Cancer Center at Penn Medicine,,OBSERVATIONAL
NCT04058470,Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04058470,RECRUITING,"Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma","DRUG: Toripalimab, Rituximab|DRUG: R-CHOP Protocol",Huiqiang Huang,,INTERVENTIONAL
NCT04240808,Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL),https://clinicaltrials.gov/study/NCT04240808,COMPLETED,Non Hodgkin Lymphoma,BIOLOGICAL: UCD19 CAR T Cells,"University of Colorado, Denver",,INTERVENTIONAL
NCT05397184,Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7),https://clinicaltrials.gov/study/NCT05397184,UNKNOWN,Relapsed/Refractory T-cell Acute Lymphoid Leukaemia,BIOLOGICAL: Cryopreserved BE CAR7 T cells (BE752TBCCLCAR7PBL),Great Ormond Street Hospital for Children NHS Foundation Trust,UCL Great Ormond Street Institute of Child Health|Medical Research Council,INTERVENTIONAL
NCT03277729,A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas,https://clinicaltrials.gov/study/NCT03277729,ACTIVE_NOT_RECRUITING,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Marginal Zone Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Recurrent Central Nervous System Lymphoma|Refractory Central Nervous System Lymphoma,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Cyclophosphamide|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis|DRUG: Fludarabine Phosphate,Fred Hutchinson Cancer Center,Mustang Bio,INTERVENTIONAL
NCT06895538,Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy,https://clinicaltrials.gov/study/NCT06895538,RECRUITING,Leukemia|MDS|Lymphoma,DRUG: Rabbit Anti-Human T-Lymphocyte Immunoglobulin (ATLG),Peking University First Hospital,,OBSERVATIONAL
NCT06365671,CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors,https://clinicaltrials.gov/study/NCT06365671,RECRUITING,B-cell Non Hodgkin Lymphoma,OTHER: autologous stem-cell transplantation|DRUG: Relmacabtagene autoleucel (relma-cel),Ruijin Hospital,,INTERVENTIONAL
NCT05800405,Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05800405,RECRUITING,Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|PROCEDURE: Computed Tomography|RADIATION: External Beam Radiation Therapy|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT06323525,TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma,https://clinicaltrials.gov/study/NCT06323525,RECRUITING,Non-hodgkin Lymphoma,BIOLOGICAL: TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T)|DRUG: Fludarabine|DRUG: Cyclophosphamide,Chinese PLA General Hospital,,INTERVENTIONAL
NCT05376111,Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients,https://clinicaltrials.gov/study/NCT05376111,RECRUITING,T-cell Acute Lymphoblastic Leukemia|Recruiting,"DRUG: Venetoclax, Azacitidine",The First Affiliated Hospital of Soochow University,Jining Medical University|The Second People's Hospital of Huai'an|The First Affiliated Hospital of Bengbu Medical University|Northern Jiangsu People's Hospital|Affiliated Hospital of Nantong University|Suzhou Hospital of Traditional Chinese Medicine,INTERVENTIONAL
NCT00709033,"T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL",https://clinicaltrials.gov/study/NCT00709033,ACTIVE_NOT_RECRUITING,Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia,BIOLOGICAL: autologous or syngeneic PBTLs and EBV-CTLs,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",INTERVENTIONAL
NCT03132584,Cyclophosphamide and Alemtuzumab In Lymphoma,https://clinicaltrials.gov/study/NCT03132584,TERMINATED,Non Hodgkin Lymphoma|High-grade B-cell Lymphoma|Diffuse Large B Cell Lymphoma,DRUG: Cyclophosphamide|DRUG: Alemtuzumab,Dana-Farber Cancer Institute,"Genzyme, a Sanofi Company|Sanofi",INTERVENTIONAL
NCT05627245,Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment,https://clinicaltrials.gov/study/NCT05627245,RECRUITING,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Recurrent Follicular Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Refractory Follicular Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma,DRUG: Belinostat|PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|OTHER: Pharmacokinetic Study|PROCEDURE: Positron Emission Tomography and Computed Tomography Scan|DRUG: Tazemetostat,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02729961,Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT02729961,WITHDRAWN,"Anaplastic Large Cell Lymphoma, ALK-Positive|CD30-Positive Neoplastic Cells Present|Systemic Anaplastic Large Cell Lymphoma",DRUG: Brentuximab Vedotin|DRUG: Ceritinib|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study,University of Washington,National Cancer Institute (NCI),INTERVENTIONAL
NCT00538096,"A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma",https://clinicaltrials.gov/study/NCT00538096,WITHDRAWN,"Lymphoma, B-Cell|Lymphoma, Non-Hodgkin",DRUG: MEDI-538|DRUG: MEDI-538|DRUG: MEDI-538,MedImmune LLC,,INTERVENTIONAL
NCT04626739,CAR-T Cells in Treating Patients With Relapsed or Refractory NHL,https://clinicaltrials.gov/study/NCT04626739,UNKNOWN,Refractory Indolent Adult Non-Hodgkin Lymphoma,DRUG: CD19 CAR-T|DRUG: CD22 CAR-T|DRUG: CD19+CD22 CAR-T|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT06139406,A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer,https://clinicaltrials.gov/study/NCT06139406,RECRUITING,"Lymphoma, Non-Hodgkin",DRUG: JNJ-87801493|DRUG: JNJ-80948543|DRUG: JNJ-75348780,"Janssen Research & Development, LLC",,INTERVENTIONAL
NCT05653271,ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies,https://clinicaltrials.gov/study/NCT05653271,RECRUITING,B-cell Lymphoma|Non Hodgkin Lymphoma|DLBCL|Primary Mediastinal Large B Cell Lymphoma|Marginal Zone Lymphoma|Follicular Lymphoma,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: ACE1831|DRUG: Obinutuzumab,"Acepodia Biotech, Inc.",,INTERVENTIONAL
NCT06760936,Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients,https://clinicaltrials.gov/study/NCT06760936,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma (DLBCL),,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,OBSERVATIONAL
NCT04008251,Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies,https://clinicaltrials.gov/study/NCT04008251,UNKNOWN,Acute Lymphoblastic Leukemia|B Cell Lymphoma,GENETIC: Second generation humanized CAR-T cells,"Wuhan Sian Medical Technology Co., Ltd","Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People Hospital Of Yichang",INTERVENTIONAL
NCT02965092,CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies,https://clinicaltrials.gov/study/NCT02965092,UNKNOWN,Acute Lymphoblastic Leukemia|B Cell Lymphoma,GENETIC: Second generation CAR-T cells,"Wuhan Sian Medical Technology Co., Ltd","Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People Hospital Of Yichang",INTERVENTIONAL
NCT06213636,Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).,https://clinicaltrials.gov/study/NCT06213636,RECRUITING,"Acute Lymphoblastic Leukemia, Adult B-Cell|Acute Lymphoblastic Leukemia, in Relapse|Non-Hodgkin Lymphoma, B-cell|Diffuse Large B Cell Lymphoma|Central Nervous System Lymphoma|Lymphoma, Follicular|MCL",BIOLOGICAL: CD19/CD22-CAR T cells,Essen Biotech,,INTERVENTIONAL
NCT05633615,Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05633615,RECRUITING,Diffuse Large B-Cell Lymphoma|Grade 3b Follicular Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Transformed Follic Lymph to Diff Large B-Cell Lymphoma|Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma,BIOLOGICAL: Axicabtagene Ciloleucel|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Lisocabtagene Maraleucel|BIOLOGICAL: Mosunetuzumab|OTHER: Patient Observation|DRUG: Polatuzumab Vedotin|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Tisagenlecleucel,SWOG Cancer Research Network,"National Cancer Institute (NCI)|Genentech, Inc.",INTERVENTIONAL
NCT05651178,Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients,https://clinicaltrials.gov/study/NCT05651178,RECRUITING,Central Nervous System Lymphoma,DRUG: Human CD19-CD22 Targeted T Cells Injection,"Hrain Biotechnology Co., Ltd.",Second Affiliated Hospital of Nanchang University,INTERVENTIONAL
NCT06898905,Hyperfractionated Dual Equivalent Fractionated Radiation Therapy,https://clinicaltrials.gov/study/NCT06898905,RECRUITING,Diffuse Large B-Cell Lymphoma,OTHER: Bridging Radiation Therapy,Yale University,"American Cancer Society, Inc.",INTERVENTIONAL
NCT02518750,Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT02518750,TERMINATED,"Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin's|Leukemia, T-Cell|Leukemia, B-Cell",DRUG: Dexamethasone|DRUG: Panobinostat|DRUG: Liposomal vincristine|DRUG: Mitoxantrone|DRUG: Peg-asparaginase|DRUG: Bortezomib|DRUG: Intrathecal Triples|DRUG: High-dose methotrexate|DRUG: 6-Mercaptopurine|DRUG: High-dose cytarabine|DRUG: Nelarabine|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Clofarabine,St. Jude Children's Research Hospital,"Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc",INTERVENTIONAL
NCT05487651,Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies,https://clinicaltrials.gov/study/NCT05487651,UNKNOWN,"NHL, Relapsed, Adult|B-cell Lymphoma|B-cell Leukemia|DLBCL - Diffuse Large B Cell Lymphoma|ALL, Adult B Cell|ALL, Childhood|CLL/SLL",GENETIC: KUR-502,"Athenex, Inc.",,INTERVENTIONAL
NCT06660563,A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL),https://clinicaltrials.gov/study/NCT06660563,RECRUITING,"Lymphoma, Non-Hodgkin",DRUG: JNJ-80948543|DRUG: JNJ-75348780,"Janssen Research & Development, LLC",,INTERVENTIONAL
NCT05416554,"Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford",https://clinicaltrials.gov/study/NCT05416554,NOT_YET_RECRUITING,Non Hodgkin Lymphoma,BEHAVIORAL: Neuropsychological testing,Stanford University,,INTERVENTIONAL
NCT01075321,Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01075321,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,DRUG: everolimus|DRUG: lenalidomide|OTHER: laboratory biomarker analysis|GENETIC: polymorphism analysis|OTHER: immunohistochemistry staining method|GENETIC: microarray analysis|GENETIC: fluorescence in situ hybridization,Mayo Clinic,,INTERVENTIONAL
NCT04933617,Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas,https://clinicaltrials.gov/study/NCT04933617,TERMINATED,Burkitt Lymphoma|High-grade B-cell Lymphoma|T-cell/Histocyte-rich Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma (DLBCL)|Germinal Center B-cell Type (GCB),BIOLOGICAL: Rituximab|DRUG: Etoposide|BIOLOGICAL: Copanlisib|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisone|DIAGNOSTIC_TEST: ECHO|DIAGNOSTIC_TEST: EKG|DIAGNOSTIC_TEST: MRI Brain|DIAGNOSTIC_TEST: 18F-FDG - PET|DIAGNOSTIC_TEST: CT Scan|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|DIAGNOSTIC_TEST: Lumbar Puncture (LP),National Cancer Institute (NCI),,INTERVENTIONAL
NCT05923502,(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL),https://clinicaltrials.gov/study/NCT05923502,NOT_YET_RECRUITING,Follicular Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Richter Syndrome|Marginal Zone Lymphoma|Peripheral T Cell Lymphoma|Diffuse Large B Cell Lymphoma,DRUG: Duvelisib,Ruijin Hospital,,OBSERVATIONAL
NCT05212584,CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma,https://clinicaltrials.gov/study/NCT05212584,UNKNOWN,"Relapsed/Refractory, High Risk Hematologic Malignancies|T-ALL/Lymphoma",BIOLOGICAL: CD7CAR T cells,iCell Gene Therapeutics,iCar Bio Therapeutics,INTERVENTIONAL
NCT03994913,Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03994913,COMPLETED,Refractory B-Cell Non-Hodgkin Lymphoma|Relapsed B-cell Non-Hodgkin Lymphoma,BIOLOGICAL: CAR-CD19 T Cells,"CARsgen Therapeutics Co., Ltd.",First Affiliated Hospital of Zhejiang University|RenJi Hospital,INTERVENTIONAL
NCT06242834,Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT06242834,ACTIVE_NOT_RECRUITING,B-Cell Non-Hodgkin Lymphoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography|DRUG: Tazemetostat,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT04582487,Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL,https://clinicaltrials.gov/study/NCT04582487,RECRUITING,T Acute Lymphoblastic Leukemia|Early T Acute Lymphoblastic Leukemia|T-lymphoblastic Lymphoma|Etp All,OTHER: bone marrow and/or peripheral blood samples withdrawal,Gruppo Italiano Malattie EMatologiche dell'Adulto,,INTERVENTIONAL
NCT05106192,Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.,https://clinicaltrials.gov/study/NCT05106192,WITHDRAWN,"Mycosis Fungoides of Skin (Diagnosis)|Cutaneous T-cell Lymphoma|Non Hodgkin Lymphoma|Lymphomatoid Papulosis|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Follicular",DEVICE: Med-Jet Injector|DRUG: Triamcinolone Acetonide|DRUG: Bexarotene 1% Top Gel|DRUG: Nitrogen Mustard|DEVICE: Conventional syringe,Case Comprehensive Cancer Center,,INTERVENTIONAL
NCT01919619,Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT01919619,COMPLETED,B-Cell Non-Hodgkin Lymphoma|Hematopoietic and Lymphoid Cell Neoplasm|Leukemia|Lymphoma|Plasma Cell Myeloma|T-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Ipilimumab|DRUG: Lenalidomide,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02462538,Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL,https://clinicaltrials.gov/study/NCT02462538,TERMINATED,ALK+ Anaplastic Large Cell Lymphoma,DRUG: Brentuximab vedotin|DRUG: Imatinib,Arbeitsgemeinschaft medikamentoese Tumortherapie,,INTERVENTIONAL
NCT03719898,Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT03719898,WITHDRAWN,"Anaplastic Large Cell Lymphoma, ALK-Positive",DRUG: Brigatinib,Fox Chase Cancer Center,,INTERVENTIONAL
NCT05366257,Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL),https://clinicaltrials.gov/study/NCT05366257,COMPLETED,Diffuse Large B-cell Lymphoma (DLBCL),OTHER: CAR-T|OTHER: Allo-HSCT cohort,Novartis Pharmaceuticals,,OBSERVATIONAL
NCT02205333,A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,https://clinicaltrials.gov/study/NCT02205333,TERMINATED,Advanced Solid Tumors|Aggressive B-cell Lymphomas,BIOLOGICAL: MEDI6469 Monotherapy|BIOLOGICAL: MEDI6469 Plus Tremelimumab|BIOLOGICAL: MEDI6469 Plus Durvalumab|BIOLOGICAL: MEDI6469 plus Rituximab,MedImmune LLC,,INTERVENTIONAL
NCT06439173,Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment,https://clinicaltrials.gov/study/NCT06439173,RECRUITING,Diffuse Large B Cell Lymphoma,BIOLOGICAL: CAR-T cell therapy,Instituto de Investigación Biomédica de Salamanca,Carlos III Health Institute,OBSERVATIONAL
NCT04870853,Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy,https://clinicaltrials.gov/study/NCT04870853,RECRUITING,Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Aggressive B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,OTHER: Electronic Health Record Review,M.D. Anderson Cancer Center,,OBSERVATIONAL
NCT02846584,a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies,https://clinicaltrials.gov/study/NCT02846584,UNKNOWN,"Lymphoma, Large B-Cell, Diffuse|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma，Malignant",BIOLOGICAL: CD19 or CD20 CAR T cells briging HSCT,"Southwest Hospital, China",,INTERVENTIONAL
NCT00562068,"Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT00562068,UNKNOWN,Lymphoma|Small Intestine Cancer,BIOLOGICAL: alemtuzumab|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: prednisolone|DRUG: vincristine sulfate|GENETIC: polymerase chain reaction|OTHER: flow cytometry|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,Cancer Research UK,,INTERVENTIONAL
NCT00001337,Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00001337,COMPLETED,Diffuse Large B-Cell Lymphoma (DLBCL)|Primary Mediastinal Large B-cell Lymphoma|Burkitt Lymphoma|Anaplastic Large-Cell Lymphoma|Gray Zone Lymphoma,DRUG: Etoposide|BIOLOGICAL: Rituximab|DRUG: Prednisone|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Doxorubicin|DIAGNOSTIC_TEST: MRI|DIAGNOSTIC_TEST: CT|PROCEDURE: Biopsy|DIAGNOSTIC_TEST: PET scan|PROCEDURE: Laparotomy|OTHER: Ondansetron|OTHER: Prochlorperazine|OTHER: Omeprazole|OTHER: Docusate Sodium + Sennosides|OTHER: Lactulose,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06238648,Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy,https://clinicaltrials.gov/study/NCT06238648,RECRUITING,"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal Large B-Cell Lymphoma|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Epcoritamab|PROCEDURE: Magnetic Resonance Imaging|OTHER: Patient Observation|PROCEDURE: Positron Emission Tomography,Academic and Community Cancer Research United,National Cancer Institute (NCI),INTERVENTIONAL
NCT02273739,"Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",https://clinicaltrials.gov/study/NCT02273739,COMPLETED,Solid Tumor|Glioma|Angioimmunoblastic T-cell Lymphoma|Intrahepatic Cholangiocarcinoma|Chondrosarcoma,DRUG: Enasidenib,Celgene,Celgene Corporation,INTERVENTIONAL
NCT01493453,A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy,https://clinicaltrials.gov/study/NCT01493453,TERMINATED,CD19 Positive Non-Hodgkin Lymphoma,"GENETIC: aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine",The Christie NHS Foundation Trust,,INTERVENTIONAL
NCT04191941,Treatment of Hematological Malignancy With Novel CAR-T Cells.,https://clinicaltrials.gov/study/NCT04191941,UNKNOWN,B-cell Non Hodgkin Lymphoma|B-cell Acute Lymphoblastic Leukemia|Multiple Myeloma,BIOLOGICAL: Novel CAR-T,Timmune Biotech Inc.,Hunan Provincial People's Hospital,INTERVENTIONAL
NCT01261247,Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01261247,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,DRUG: panobinostat|OTHER: laboratory biomarker analysis|GENETIC: western blotting|GENETIC: DNA analysis|OTHER: flow cytometry|OTHER: pharmacological study|OTHER: immunohistochemistry staining method,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT06834529,CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT06834529,RECRUITING,Relapsed or Refractory B Cell Leukemia and Lymphoma,GENETIC: CAR2219-T cells,Affiliated Hospital to Academy of Military Medical Sciences,,INTERVENTIONAL
NCT04476459,Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL,https://clinicaltrials.gov/study/NCT04476459,UNKNOWN,"Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma",DRUG: Camrelizumab|DRUG: Apatinib,Huiqiang Huang,,INTERVENTIONAL
NCT00035022,Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas,https://clinicaltrials.gov/study/NCT00035022,COMPLETED,"Leukemia, Lymphocytic|Lymphoma",DRUG: BCX-1777,BioCryst Pharmaceuticals,,INTERVENTIONAL
NCT05044039,Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy,https://clinicaltrials.gov/study/NCT05044039,ACTIVE_NOT_RECRUITING,Non-hodgkin Lymphoma|Acute Lymphocytic Leukemia,DRUG: Duvelisib,Washington University School of Medicine,SecuraBio|The Foundation for Barnes-Jewish Hospital|National Cancer Institute (NCI),INTERVENTIONAL
NCT06346912,CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL,https://clinicaltrials.gov/study/NCT06346912,RECRUITING,"Acute Lymphoblastic Leukemia,B-Cell|Non-hodgkin Lymphoma,B Cell",BIOLOGICAL: CD19-BAFF Targeted CAR T-cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT06470451,Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL,https://clinicaltrials.gov/study/NCT06470451,RECRUITING,CTCL/ Mycosis Fungoides|CTCL|Mycosis Fungoides|Cutaneous T Cell Lymphoma,DRUG: Hypericin|DRUG: Placebo,Soligenix,,INTERVENTIONAL
NCT00310128,Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00310128,WITHDRAWN,AIDS-related Lymphoma|Adult Non-Hodgkin's Lymphoma|Anaplastic Large Cell Lymphoma,DRUG: cisplatin|DRUG: cytarabine|DRUG: etoposide|DRUG: methylprednisolone|DRUG: rituximab|DRUG: yttrium Y 90 ibritumomab tiuxetan|PROCEDURE: antibody therapy|PROCEDURE: biological therapy|PROCEDURE: chemotherapy|PROCEDURE: monoclonal antibody therapy|PROCEDURE: radiation therapy|PROCEDURE: radioimmunotherapy|PROCEDURE: radioisotope therapy,AIDS Malignancy Consortium,National Cancer Institute (NCI),INTERVENTIONAL
NCT05714345,Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy,https://clinicaltrials.gov/study/NCT05714345,ACTIVE_NOT_RECRUITING,Relapsed/Refractory Large B Cell Lymphoma,BIOLOGICAL: ALLO-647|DRUG: Fludarabine|DRUG: Cyclophosphamide|GENETIC: ALLO-501A,Allogene Therapeutics,,INTERVENTIONAL
NCT02112916,Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT02112916,ACTIVE_NOT_RECRUITING,Adult T Acute Lymphoblastic Leukemia|Ann Arbor Stage II Adult Lymphoblastic Lymphoma|Ann Arbor Stage II Childhood Lymphoblastic Lymphoma|Ann Arbor Stage III Adult Lymphoblastic Lymphoma|Ann Arbor Stage III Childhood Lymphoblastic Lymphoma|Ann Arbor Stage IV Adult Lymphoblastic Lymphoma|Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma|Childhood T Acute Lymphoblastic Leukemia,DRUG: Bortezomib|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin|DRUG: Daunorubicin Hydrochloride|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|DRUG: Hydrocortisone Sodium Succinate|DRUG: Ifosfamide|DRUG: Leucovorin Calcium|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Pegaspargase|RADIATION: Radiation Therapy|DRUG: Thioguanine|DRUG: Vincristine|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06761677,A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06761677,RECRUITING,Relapsed or Refractory Lymphoma Including ENKL,DRUG: Brincidofovir,SymBio Pharmaceuticals,,INTERVENTIONAL
NCT00586391,"CD19 Chimeric Receptor Expressing T Lymphocytes in B-Cell Non Hodgkin's Lymphoma, ALL & CLL",https://clinicaltrials.gov/study/NCT00586391,ACTIVE_NOT_RECRUITING,B Cell Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia,GENETIC: CD19CAR-28-zeta T cells|DRUG: Ipilimumab,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT03720496,Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy,https://clinicaltrials.gov/study/NCT03720496,UNKNOWN,"Non-hodgkin Lymphoma,B Cell",BIOLOGICAL: CD19-TriCAR-T,Timmune Biotech Inc.,,INTERVENTIONAL
NCT01645293,Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides,https://clinicaltrials.gov/study/NCT01645293,UNKNOWN,CD30 Positive Cutaneous T Cell Lymphoma|CD30 Positive Transformed Mycosis Fungoides,GENETIC: Genetically modified T cells # 1138,University of Cologne,,INTERVENTIONAL
NCT04290000,Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies,https://clinicaltrials.gov/study/NCT04290000,RECRUITING,Lymphoma and Acute Lymphoblastic Leukemia,OTHER: additional biological samples during CAR-T CELL treatment,"University Hospital, Montpellier",,OBSERVATIONAL
NCT05950802,Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta,https://clinicaltrials.gov/study/NCT05950802,RECRUITING,DLBCL - Diffuse Large B Cell Lymphoma,DRUG: Cyclophosphamide|RADIATION: TLI,"University Health Network, Toronto",,INTERVENTIONAL
NCT04166838,The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL),https://clinicaltrials.gov/study/NCT04166838,UNKNOWN,B-cell Acute Lymphoblastic Leukemia (B-ALL)|Safety and Efficacy of CD19 UCAR-T Cells,BIOLOGICAL: CD19 UCARTcells,"Shanghai Longyao Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT00683046,T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00683046,COMPLETED,"Acute Myelogenous Leukemia|Lymphoid Leukemia|Chronic Myelogenous Leukemia|Malignant Lymphoma|Hodgkin's Disease|Chronic Lymphocytic Leukemia|Myeloproliferative Disorder|Anemia, Aplastic|Myelodysplastic Syndromes",DRUG: Fludarabine|DRUG: Melphalan|DRUG: Stem cells|DRUG: Campath,University of Chicago,,INTERVENTIONAL
NCT05359211,NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05359211,RECRUITING,"Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent Primary Mediastinal Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory Primary Mediastinal Large B-Cell Lymphoma|Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Lisocabtagene Maraleucel|DRUG: Polymer-conjugated IL-15 Receptor Agonist NKTR-255|PROCEDURE: X-Ray Imaging|PROCEDURE: Echocardiography|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Lumbar Puncture|PROCEDURE: Computed Tomography|PROCEDURE: Positron Emission Tomography|PROCEDURE: Biospecimen Collection|PROCEDURE: Biopsy,Fred Hutchinson Cancer Center,Nektar Therapeutics,INTERVENTIONAL
NCT05645744,Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.,https://clinicaltrials.gov/study/NCT05645744,TERMINATED,"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Chronic Lymphocytic Leukemia in Relapse|Small Lymphocytic Lymphoma, Relapsed|Waldenstrom's Macroglobulinemia Recurrent|Follicular B-cell Non-Hodgkin's Lymphoma|B-cell Lymphoma Refractory|Mantle Cell Lymphoma Recurrent|Hairy Cell Leukemia|Diffuse Large B Cell Lymphoma|Waldenstrom's Macroglobulinemia Refractory|Mantle Cell Lymphoma Refractory",BIOLOGICAL: Prior MB-102 CAR-T cell investigational product.|BIOLOGICAL: Prior MB-106 CAR-T cell investigational product.,Mustang Bio,,OBSERVATIONAL
NCT05370430,BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-NHL,https://clinicaltrials.gov/study/NCT05370430,RECRUITING,Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,BIOLOGICAL: BAFFR-CAR T cells,"PeproMene Bio, Inc.",City of Hope Medical Center,INTERVENTIONAL
NCT05096234,18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma,https://clinicaltrials.gov/study/NCT05096234,TERMINATED,Non-Hodgkin's Lymphoma,DRUG: [ 18F]F-AraG PET,Stanford University,"CellSight Technologies, Inc.",INTERVENTIONAL
NCT04409314,Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy,https://clinicaltrials.gov/study/NCT04409314,COMPLETED,Recurrent Aggressive Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Malignant Neoplasm|Recurrent Plasma Cell Myeloma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Aggressive Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma,DRUG: Fluorine F 18-fluoroazomycin Arabinoside|PROCEDURE: Positron Emission Tomography,"University of California, San Francisco",,OBSERVATIONAL
NCT00943319,Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00943319,COMPLETED,Leukemia|Lymphoma|Myeloma,DRUG: Busulfan|DRUG: Fludarabine|DRUG: Campath|PROCEDURE: Stem Cell Transplant,University of Chicago,,INTERVENTIONAL
NCT03553238,Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL,https://clinicaltrials.gov/study/NCT03553238,UNKNOWN,"Leukemia, Acute|Leukemia, T Cell|Leukemia, Lymphoblastic",DRUG: Chidamide|DRUG: Dexamethasone|DRUG: vincristine|DRUG: Cyclophosphamide|DRUG: Idarubicin|DRUG: Pegaspargase|DRUG: Adriamycin|DRUG: Methotrexate|DRUG: 6-Mercaptopurine|DRUG: Etoposide|DRUG: Cytarabine|PROCEDURE: Bone marrow aspiration|PROCEDURE: Intrathecal injection|RADIATION: Radiation therapy|GENETIC: NGS|PROCEDURE: allogeneic hematopoietic stem cell transplantation|DIAGNOSTIC_TEST: Flow-MRD|DIAGNOSTIC_TEST: FISH|DIAGNOSTIC_TEST: Flow immunophenotyping|DIAGNOSTIC_TEST: Karyotyping,"Nanfang Hospital, Southern Medical University",,INTERVENTIONAL
NCT05510596,Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome,https://clinicaltrials.gov/study/NCT05510596,COMPLETED,"Lymphoma, B-Cell|Neurotoxicity",OTHER: Magnetic Resonance Imaging with contrast injection|OTHER: Blood withdrawal|OTHER: Neuropsychological tests,"University Hospital, Montpellier",,INTERVENTIONAL
NCT06005649,Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT06005649,NOT_YET_RECRUITING,Non-hodgkin Lymphoma,BIOLOGICAL: HY004,Juventas Cell Therapy Ltd.,,INTERVENTIONAL
NCT06350994,Early Assessment of Cardiac Function After Treatment With CAR-T Cells,https://clinicaltrials.gov/study/NCT06350994,NOT_YET_RECRUITING,"Car T- Cell|Hematologic Malignancy|Acute Lymphoblastic Leukemia|Lymphoma, B-Cell|Multiple Myeloma",,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT02580552,"Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL",https://clinicaltrials.gov/study/NCT02580552,COMPLETED,"Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides (MF)|Chronic Lymphocytic Leukemia (CLL)|Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype|Adult T-Cell Leukemia/Lymphoma (ATLL)",DRUG: Cobomarsen,"miRagen Therapeutics, Inc.",,INTERVENTIONAL
NCT05075681,Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT05075681,UNKNOWN,Peripheral Blood Stem Cell Transplantation,DRUG: Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide,Chinese PLA General Hospital,,INTERVENTIONAL
NCT05664217,NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05664217,TERMINATED,Non-Hodgkin Lymphoma|Relapsed/Refractory Diffuse Large B-cell Lymphoma,DRUG: NKTR-255 at 1.5 µg/kg|DRUG: NKTR-255 at 3.0 μg/kg|DRUG: NKTR-255 at 3.0/6.0 μg/kg|OTHER: Placebo Comparator,Nektar Therapeutics,,INTERVENTIONAL
NCT02619630,Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old),https://clinicaltrials.gov/study/NCT02619630,RECRUITING,T-cell Adult Acute Lymphoblastic Leukemia,DRUG: nelarabine,Assistance Publique - Hôpitaux de Paris,,INTERVENTIONAL
NCT01815749,Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01815749,ACTIVE_NOT_RECRUITING,Adult Grade III Lymphomatoid Granulomatosis|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|PROCEDURE: autologous hematopoietic stem cell transplantation|OTHER: laboratory biomarker analysis,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04923789,A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04923789,UNKNOWN,Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma,,The First Affiliated Hospital of Soochow University,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",OBSERVATIONAL
NCT06703892,A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies,https://clinicaltrials.gov/study/NCT06703892,RECRUITING,Diffuse Large B Cell Lymphoma Relapsed|Diffuse Large B Cell Lymphoma Refractory|Follicular Lymphoma ( FL)|Primary Mediastinal Large B-Cell Lymphoma-Refractory|Primary Mediastinal Large B-Cell Lymphoma-Recurrent|High-grade B-cell Lymphoma (HGBCL),BIOLOGICAL: GF-CART01|BIOLOGICAL: GF-CART01|BIOLOGICAL: GF-CART01,"GenomeFrontier Therapeutics TW Co., Ltd.",,INTERVENTIONAL
NCT00081874,"RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma",https://clinicaltrials.gov/study/NCT00081874,COMPLETED,Leukemia|Mantle Cell Lymphoma|Myelofibrosis,DRUG: RAD001,M.D. Anderson Cancer Center,Novartis,INTERVENTIONAL
NCT05585996,Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05585996,RECRUITING,Relapsed and Refractory B-cell Lymphoma,BIOLOGICAL: CD19 CAR-T and CD19 CAR-DC,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,INTERVENTIONAL
NCT04690192,CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04690192,COMPLETED,Large B-cell Lymphoma,BIOLOGICAL: CNCT19|DRUG: Gemcitabine Injection|DRUG: busulfan|DRUG: Melphalan Injection,"Institute of Hematology & Blood Diseases Hospital, China",Juventas Cell Therapy Ltd.,INTERVENTIONAL
NCT03144583,Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy,https://clinicaltrials.gov/study/NCT03144583,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: Adult differentiated autologous T-cells,Sara V. Latorre,Instituto de Salud Carlos III,INTERVENTIONAL
NCT06767956,Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy,https://clinicaltrials.gov/study/NCT06767956,NOT_YET_RECRUITING,Non Hodgkin Lymphoma,DRUG: GOLCADOMIDE|DRUG: Nivolumab,Natalie Galanina,Bristol-Myers Squibb,INTERVENTIONAL
NCT01956084,Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma,https://clinicaltrials.gov/study/NCT01956084,COMPLETED,Hodgkin Disease|Non Hodgkin Lymphoma|Lymphoepithelioma|Severe Chronic Active EBV Infection Syndrome (SCAEBV)|Leiomyosarcoma,DRUG: LMP1/2 CTLs (Group A)|DRUG: LMP1/2 CTLs (Group B),Catherine Bollard,,INTERVENTIONAL
NCT03483103,Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006),https://clinicaltrials.gov/study/NCT03483103,COMPLETED,"Lymphoma, Non-Hodgkin|Lymphoma, Nonhodgkin|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse",BIOLOGICAL: lisocabtagene maraleucel,"Juno Therapeutics, a Subsidiary of Celgene",,INTERVENTIONAL
NCT01035463,Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01035463,COMPLETED,"Anaplastic Large Cell Lymphoma, ALK-Negative|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma",PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Carmustine|DRUG: Cytarabine|DRUG: Etoposide|DRUG: Lenalidomide|DRUG: Melphalan|BIOLOGICAL: Rituximab,University of Nebraska,National Cancer Institute (NCI),INTERVENTIONAL
NCT05763563,Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy,https://clinicaltrials.gov/study/NCT05763563,ACTIVE_NOT_RECRUITING,Lymphoma|Leukemia|Myeloma,BEHAVIORAL: Resistance Training|BEHAVIORAL: Aerobic Exercise|BEHAVIORAL: Optional Aerobic Exercise Procedure|RADIATION: Optional In-Person Exercise Sessions,H. Lee Moffitt Cancer Center and Research Institute,Cancer and Aging Research Group,INTERVENTIONAL
NCT06985576,Long-term Study to Evaluate Safety and Persistence of GF-CART01,https://clinicaltrials.gov/study/NCT06985576,NOT_YET_RECRUITING,DLBCL - Diffuse Large B Cell Lymphoma|Follicular Lymphoma (FL)|Primary Mediastinal Large B-Cell Lymphoma|High Grade B Cell Lymphoma,,"GenomeFrontier Therapeutics TW Co., Ltd.",,OBSERVATIONAL
NCT02053545,Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion,https://clinicaltrials.gov/study/NCT02053545,WITHDRAWN,Leukemia|Lymphoma|MDS,DRUG: Conditioning Regimen & GVHD Prophylaxis,Ann & Robert H Lurie Children's Hospital of Chicago,,INTERVENTIONAL
NCT06131801,Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution,https://clinicaltrials.gov/study/NCT06131801,RECRUITING,Hematologic Malignancy|Leukemia|Lymphoma|Acute Lymphocytic Leukemia|ALL|Acute Myelogenous Leukemia|AML|Chronic Myelogenous Leukemia|CML|Myeloproliferative Neoplasm|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Burkitt Lymphoma|T-cell Lymphoma|B Cell Lymphoma|Peripheral T Cell Lymphoma|Cutaneous B-Cell Lymphoma,"OTHER: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.","Children's Hospital Medical Center, Cincinnati",,OBSERVATIONAL
NCT04171791,A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL),https://clinicaltrials.gov/study/NCT04171791,COMPLETED,CTCL,DRUG: ABT-199 (venetoclax),Yale University,,INTERVENTIONAL
NCT02396043,Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT02396043,UNKNOWN,"Lymphoma, Lymphoblastic",DRUG: induction phase1|DRUG: induction phase2|DRUG: protocol M|DRUG: maintenance therapy|DRUG: reinduction phase1|DRUG: reinduction phase2|DRUG: Intrathecal (IT),Sun Yat-sen University,,INTERVENTIONAL
NCT06646666,ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT,https://clinicaltrials.gov/study/NCT06646666,NOT_YET_RECRUITING,B-cell Non Hodgkin Lymphoma,DRUG: All-trans retinoic acid|DRUG: zanubrutinib|RADIATION: radiotherapy|DRUG: CAR-T|DRUG: PD-1 inhibitor,Ruijin Hospital,,INTERVENTIONAL
NCT03125642,Auto Stem Cell Transplant for Lymphoma Patients,https://clinicaltrials.gov/study/NCT03125642,RECRUITING,Non-Hodgkin Lymphoma|Hodgkin Lymphoma,DRUG: Etoposide|DRUG: BCNU|DRUG: AraC|DRUG: Melphalan|PROCEDURE: Peripheral blood stem cell transplantation|BIOLOGICAL: G-CSF|DRUG: Cyclophosphamide|RADIATION: Total Body Irradiation,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT05077527,Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05077527,RECRUITING,AIDS-Related Diffuse Large B-cell Lymphoma|AIDS-Related Non-Hodgkin Lymphoma|HIV Infection|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Axicabtagene Ciloleucel|DRUG: Cyclophosphamide|DRUG: Fludarabine,AIDS Malignancy Consortium,National Cancer Institute (NCI)|Memorial Sloan Kettering Cancer Center,INTERVENTIONAL
NCT05518851,TreAtments and outComes in paTients With prImary CutAneous Lymphoma,https://clinicaltrials.gov/study/NCT05518851,RECRUITING,Primary Cutaneous Lymphoma,,Peking University First Hospital,,OBSERVATIONAL
NCT07013565,Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL,https://clinicaltrials.gov/study/NCT07013565,NOT_YET_RECRUITING,"Anaplastic Large Cell Lymphoma, ALK-Positive",DRUG: Vinblastine (Velban)|DRUG: Brentuximab vedotin (Adcetris)|DRUG: Nivolumab (Opdivo),New York Medical College,University of Alabama at Birmingham|Helen DeVos Children's Hospital|Nationwide Children's Hospital|Memorial Sloan Kettering Cancer Center|University of Utah|Ohio State University,INTERVENTIONAL
NCT04601831,'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL,https://clinicaltrials.gov/study/NCT04601831,ACTIVE_NOT_RECRUITING,Non-Hodgkin Lymphoma,RADIATION: Focal radiation therapy (RT),University of Texas Southwestern Medical Center,,INTERVENTIONAL
NCT00406757,Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT00406757,COMPLETED,"Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic",DRUG: Nelarabine injection 400mg/m2|DRUG: Nelarabine injection 650mg/m2|DRUG: Nelarabine injection 1000mg/m2|DRUG: Nelarabine injection 1500mg/m2,GlaxoSmithKline,,INTERVENTIONAL
NCT06994169,Glofitamab in Real Life,https://clinicaltrials.gov/study/NCT06994169,NOT_YET_RECRUITING,Large B-cell Lymphoma,DRUG: Glofitamab,The Lymphoma Academic Research Organisation,,OBSERVATIONAL
NCT00416351,Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment,https://clinicaltrials.gov/study/NCT00416351,COMPLETED,Leukemia|Lymphoma|Small Intestine Cancer,DRUG: clofarabine,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI)|University of Rochester|The Cleveland Clinic,INTERVENTIONAL
NCT06093841,Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL,https://clinicaltrials.gov/study/NCT06093841,ACTIVE_NOT_RECRUITING,"Lymphoma, Large B-Cell, Diffuse|Follicular Lymphoma Grade 3B|High-grade B-cell Lymphoma|Mediastinal B-Cell Diffuse Large Cell Lymphoma",BIOLOGICAL: Relmacabtagene Autoleucel|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Shanghai Ming Ju Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT03366350,Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies,https://clinicaltrials.gov/study/NCT03366350,UNKNOWN,Acute Lymphoblastic Leukemia|B Cell Lymphoma,PROCEDURE: Allogeneic hematological stem cell transplantation,"Wuhan Sian Medical Technology Co., Ltd","Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|People Hospital Of Yichang",INTERVENTIONAL
NCT01840566,High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01840566,ACTIVE_NOT_RECRUITING,Non-Hodgkin's Lymphoma,DRUG: Carmustine|DRUG: Etoposide|DRUG: Cytarabine|DRUG: Melphalan|BIOLOGICAL: Pegfilgrastim|BIOLOGICAL: 19-28z T CELLS|PROCEDURE: Autologous Stem Cell Transplantation,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT04074746,Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas,https://clinicaltrials.gov/study/NCT04074746,ACTIVE_NOT_RECRUITING,"Recurrent Anaplastic Large Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Classic Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified|Refractory Anaplastic Large Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Classic Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",BIOLOGICAL: Anti-CD30/CD16A Monoclonal Antibody AFM13|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Fludarabine Phosphate|BIOLOGICAL: Genetically Engineered Lymphocyte Therapy,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03564977,CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT03564977,UNKNOWN,"Lymphoma, B-Cell|Leukemia, B-Cell|Minimal Disease, Residual",BIOLOGICAL: CD19-targeted CAR-T cells,Qingdao Central Hospital,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT06720701,Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.,https://clinicaltrials.gov/study/NCT06720701,NOT_YET_RECRUITING,Non-Hodgkin Lymphoma,,IRCCS Azienda Ospedaliero-Universitaria di Bologna,,OBSERVATIONAL
NCT06880913,Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL,https://clinicaltrials.gov/study/NCT06880913,RECRUITING,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,BIOLOGICAL: Nanobody-Based CD19/CD22 Tandem Dual CAR-T,Peking University People's Hospital,"Hebei Senlang Biotechnology Inc., Ltd.",INTERVENTIONAL
NCT02954445,A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies,https://clinicaltrials.gov/study/NCT02954445,UNKNOWN,Leukemia|Lymphoma|Multiple Myeloma,BIOLOGICAL: Anti-BCMA-CAR-transduced T cells,"Southwest Hospital, China",,INTERVENTIONAL
NCT00968864,T-cell Depleted Alternative Donor Transplantation,https://clinicaltrials.gov/study/NCT00968864,TERMINATED,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Lymphomas|Bone Marrow Failure|Hemoglobinopathy|Immune Deficiency|Osteopetrosis,DEVICE: CliniMACS® (T cell depletion),Wake Forest University Health Sciences,,INTERVENTIONAL
NCT02883517,Cell-free Circulating DNA in Primary Cutaneous Lymphomas,https://clinicaltrials.gov/study/NCT02883517,COMPLETED,"Mycosis Fungoides|Lymphoma, Large B-cell, Diffuse",GENETIC: Cytogenetic and molecular studies,"University Hospital, Bordeaux",,OBSERVATIONAL
NCT00016094,S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00016094,COMPLETED,Anaplastic Large Cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma,BIOLOGICAL: bevacizumab|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04359784,Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy,https://clinicaltrials.gov/study/NCT04359784,COMPLETED,B-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Anakinra|PROCEDURE: X-Ray Imaging|PROCEDURE: Positron Emission Tomography|PROCEDURE: Computed Tomography|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Lumbar Puncture|PROCEDURE: Biospecimen Collection,Fred Hutchinson Cancer Center,Swedish Orphan Biovitrum,INTERVENTIONAL
NCT02939014,Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),https://clinicaltrials.gov/study/NCT02939014,COMPLETED,"Hodgkin Disease|Lymphoma, Large-Cell, Anaplastic",DRUG: Brentuximab Vedotin,Takeda,,INTERVENTIONAL
NCT03366324,Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies,https://clinicaltrials.gov/study/NCT03366324,UNKNOWN,Acute Lymphoblastic Leukemia|B Cell Lymphoma,GENETIC: Second generation CAR-T cells|PROCEDURE: Hematological stem cell transplantation,"Wuhan Sian Medical Technology Co., Ltd","Wuhan Union Hospital, China|Jingzhou Central Hospital|Xiangyang Central Hospital|The First People's Hospital of Yuhang District",INTERVENTIONAL
NCT02440685,A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT02440685,TERMINATED,"Lymphoma, Large B-Cell, Diffuse|Lymphoma, Mantle-Cell|Lymphoma, Follicular|Cancer|Neoplasm|Tumor|Lymphoma, Malignant|Lymphoma, B-cell|Lymphoma, Non-Hodgkin|B-Cell Chronic Lymphocytic Leukemia|B-Cell Leukemia, Chronic|B-Lymphocytic Leukemia, Chronic|Chronic Lymphocytic Leukemia|Leukemia, Lymphocytic, Chronic|Leukemia, Lymphocytic, Chronic, B Cell|Myelofibrosis|Chronic Idiopathic Myelofibrosis|Idiopathic Myelofibrosis|Lymphoma, T Cell, Peripheral|Peripheral T-Cell Lymphoma|T-Cell Lymphoma, Peripheral",DRUG: ASN002 Dose Escalation|DRUG: ASN002 RD,Asana BioSciences,,INTERVENTIONAL
NCT05936229,Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy,https://clinicaltrials.gov/study/NCT05936229,WITHDRAWN,Recurrent B Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,BIOLOGICAL: Interferon Beta-1A|PROCEDURE: X-Ray Imaging|PROCEDURE: Echocardiography|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Computed Tomography|PROCEDURE: Positron Emission Tomography|PROCEDURE: Lumbar Puncture|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Biopsy,Fred Hutchinson Cancer Center,Faron Pharmaceuticals Ltd,INTERVENTIONAL
NCT00514722,Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies,https://clinicaltrials.gov/study/NCT00514722,TERMINATED,"Acute Myeloid Leukemia|Myelodysplasia|Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Multiple Myeloma|Lymphoma, Large-Cell, Diffuse|Lymphoma, Mantle-Cell|Lymphoma, T-Cell, Peripheral|T-NK Cell Lymphoma|Hodgkin Disease",OTHER: umbilical cord stem cells,"University of California, San Francisco",,INTERVENTIONAL
NCT06316856,CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects with Relapsed or Refractory T-cell Malignancies,https://clinicaltrials.gov/study/NCT06316856,RECRUITING,"T-Cell Acute Lymphocytic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia|T-cell Malignancies",DRUG: Autologous CD5 CAR T-cells|DRUG: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells|DRUG: Newly matched donor-derived CD5 CAR T-cells,Beijing GoBroad Hospital,"The General Hospital of Western Theater Command|Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai|Shanghai Liquan Hospital",INTERVENTIONAL
NCT03815682,RPTR-147 in Patients With Selected Solid Tumors and Lymphomas,https://clinicaltrials.gov/study/NCT03815682,TERMINATED,Solid Tumor|Lymphoma,BIOLOGICAL: Arm A: RPTR-147:1|BIOLOGICAL: Arm B: RPTR-147:1 and Pembrolizumab|BIOLOGICAL: Arm C: RPTR-147:2,Repertoire Immune Medicines,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT06445803,CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL,https://clinicaltrials.gov/study/NCT06445803,RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia With Failed Remission|B-cell Lymphoma Refractory|B-cell Lymphoma Recurrent",BIOLOGICAL: KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）,Rong Tao,"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.",INTERVENTIONAL
NCT06026644,Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life,https://clinicaltrials.gov/study/NCT06026644,ACTIVE_NOT_RECRUITING,DLBCL - Diffuse Large B Cell Lymphoma,,Gruppo Italiano Malattie EMatologiche dell'Adulto,,OBSERVATIONAL
NCT06313957,A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06313957,RECRUITING,Relapsed B-cell Non-Hodgkin Lymphoma|Refractory B-cell Non-Hodgkin Lymphoma,BIOLOGICAL: LUCAR-20SP cells,Peking University Cancer Hospital & Institute,Nanjing Legend Biotech Co.|Beijing Boren Hospital|Henan Cancer Hospital,INTERVENTIONAL
NCT05237986,Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy,https://clinicaltrials.gov/study/NCT05237986,RECRUITING,Lymphoma|Leukemia,,National Cancer Institute (NCI),,OBSERVATIONAL
NCT00062868,LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma,https://clinicaltrials.gov/study/NCT00062868,COMPLETED,Hodgkin Disease|Non Hodgkin Lymphoma|Lymphoepithelioma|Leiomyosarcoma,BIOLOGICAL: LMP1/2 CTLs (ALCI - Group A)|BIOLOGICAL: LMP1/2 CTLs (ALCI - Group B)|BIOLOGICAL: LMP1/2 CTLs (ALCI - Group C)|BIOLOGICAL: LMP2 CTLs (ALSCER - Group A)|BIOLOGICAL: LMP2 CTLs (ALSCER - Group B)|BIOLOGICAL: LMP2 CTLs (ALSCER - Group C)|BIOLOGICAL: LMP1/2 CTLs (ALCI - Expansion - Group A)|BIOLOGICAL: LMP1/2 CTLs (ALCI - Expansion Group B)|BIOLOGICAL: LMP1/2 CTLs (ALCI - Expansion Group C),Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT06860880,Combating Cancer-Related Fatigue: A Personalized Supportive Care Program,https://clinicaltrials.gov/study/NCT06860880,NOT_YET_RECRUITING,Indolent Lymphomas|Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Lymphoplasmacytic Lymphoma|Waldenstrom Macroglobulinemia|Cutaneous T Cell Lymphoma,OTHER: Exercise|OTHER: Diet,UNC Lineberger Comprehensive Cancer Center,CLL Society,INTERVENTIONAL
NCT06220097,Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies,https://clinicaltrials.gov/study/NCT06220097,RECRUITING,B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma Refractory,DRUG: Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells,"Wuhan Union Hospital, China",CSPC Pharmaceutical Group Limited,INTERVENTIONAL
NCT04315324,Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL),https://clinicaltrials.gov/study/NCT04315324,RECRUITING,Recurrent T Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia,DRUG: AKR1C3-activated Prodrug OBI-3424,SWOG Cancer Research Network,National Cancer Institute (NCI),INTERVENTIONAL
NCT01418430,Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab),https://clinicaltrials.gov/study/NCT01418430,COMPLETED,HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL),DRUG: CHOP-daclizumab,King's College Hospital NHS Trust,,INTERVENTIONAL
NCT05528887,Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT05528887,RECRUITING,Relapsed/Refractory Hematological Malignancies|Lymphoma|Myeloma|Leukemia,BIOLOGICAL: Autologous CAR-T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,The Affiliated People's Hospital of Ningbo University,UTC Therapeutics Inc.,INTERVENTIONAL
NCT04296461,Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04296461,UNKNOWN,B-cell Non-Hodgkin Lymphoma,GENETIC: Welgenaleucel,UWELL Biopharma,Tri-Service General Hospital,INTERVENTIONAL
NCT01682226,Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies,https://clinicaltrials.gov/study/NCT01682226,COMPLETED,Leukemia|Myelodysplastic Syndrome|Lymphoma,DEVICE: CliniMACS Fractionation system (Arm A)|DEVICE: CliniMACS Fractionation system (Arm B)|BIOLOGICAL: Haploidentical donor CD34+ cells,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT03330691,A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia,https://clinicaltrials.gov/study/NCT03330691,ACTIVE_NOT_RECRUITING,Leukemia|Lymphoma,BIOLOGICAL: Patient-derived CD19- and CD22 specific CAR,Seattle Children's Hospital,,INTERVENTIONAL
NCT04853277,Patient Reported Outcomes and Patient Education in Cellular Therapy Patients,https://clinicaltrials.gov/study/NCT04853277,COMPLETED,Stem Cell Transplant|CAR T-Cell Transplant|CAR T-Cell Therapy|Cellular Therapy|Hematopoietic Stem Cell Transplant|HSCT|Multiple Myeloma|Leukemia|Lymphoma,BEHAVIORAL: Education,Dartmouth-Hitchcock Medical Center,,INTERVENTIONAL
NCT01913119,A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma,https://clinicaltrials.gov/study/NCT01913119,COMPLETED,Histologically Proven Extranodal NKTcell Lymphoma,DRUG: Romidepsin,Samsung Medical Center,Celgene Corporation,INTERVENTIONAL
NCT05797233,Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies,https://clinicaltrials.gov/study/NCT05797233,ACTIVE_NOT_RECRUITING,"Chronic Lymphocytic Leukemia|B-Cell Chronic Lymphocytic Leukemia|Lymphoma, B-Cell",BIOLOGICAL: Anti-CD19 and anti-CD20 bicistronic CAR T- cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05338931,"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT05338931,RECRUITING,B-cell Non Hodgkin Lymphoma,DRUG: AT101(Anti-CD19 Chimeric Antigen Receptor T cell),AbClon,,INTERVENTIONAL
NCT03373305,Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas,https://clinicaltrials.gov/study/NCT03373305,WITHDRAWN,CD30-Positive Neoplastic Cells Present|Folliculotropic Mycosis Fungoides|Recurrent Mycosis Fungoides|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome,DRUG: Brentuximab Vedotin|DRUG: Lenalidomide|OTHER: Laboratory Biomarker Analysis,City of Hope Medical Center,,INTERVENTIONAL
NCT01026233,Cardiac Safety Study of Brentuximab Vedotin (SGN-35),https://clinicaltrials.gov/study/NCT01026233,COMPLETED,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",DRUG: brentuximab vedotin,Seagen Inc.,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT00880815,"Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",https://clinicaltrials.gov/study/NCT00880815,COMPLETED,CD20 Positive|Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Anti-Thymocyte Globulin|DRUG: Bendamustine|BIOLOGICAL: Filgrastim|DRUG: Fludarabine|DRUG: Methotrexate|BIOLOGICAL: Rituximab|DRUG: Tacrolimus,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01155817,Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease,https://clinicaltrials.gov/study/NCT01155817,COMPLETED,"Bone Marrow Transplant Failure|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Peripheral",DRUG: Nilotinib,Stanford University,Novartis,INTERVENTIONAL
NCT05091541,A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05091541,NOT_YET_RECRUITING,B-cell Non-Hodgkin's Lymphoma,DRUG: Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection,"Nanjing IASO Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT06996132,Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06996132,RECRUITING,Relapsed or Refractory Aggressive B-cell Lymphoma,DRUG: Glofitamab|DRUG: Chimeric Antigen Receptor T Cells (CAR-T),"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT04858568,Immune Responses to COVID-19 Vaccination in Lymphoma Patients,https://clinicaltrials.gov/study/NCT04858568,COMPLETED,Classical Hodgkin Lymphoma|Diffuse Large B Cell Lymphoma|Primary Mediastinal B Cell Lymphoma|High-grade B-cell Lymphoma|Burkitt Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma|Nodular Lymphocyte Predominant Hodgkin Lymphoma|Peripheral T-cell Lymphoma,,University Hospital Southampton NHS Foundation Trust,,OBSERVATIONAL
NCT06758713,Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06758713,RECRUITING,Multiple Myeloma|B-cell Lymphoma|Hematological Malignancy,BIOLOGICAL: CAR-T,The Third Affiliated Hospital of Southern Medical University,,INTERVENTIONAL
NCT03707847,Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL,https://clinicaltrials.gov/study/NCT03707847,UNKNOWN,ALK-Positive Anaplastic Large Cell Lymphoma,DRUG: Crizotinib|DRUG: Etoposide Capsule|PROCEDURE: Auto-HSCT,Mingzhi Zhang,,INTERVENTIONAL
NCT00649584,A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies,https://clinicaltrials.gov/study/NCT00649584,TERMINATED,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",DRUG: SGN-35|DRUG: gemcitabine,Seagen Inc.,,INTERVENTIONAL
NCT05155215,Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT05155215,UNKNOWN,"Lymphoma|Lymphoma, Mantle-Cell|Neoplasms by Histologic Type|Neoplasms|Lymphoproliferative Disorders",BIOLOGICAL: IM19 CAR-T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,"Beijing Immunochina Medical Science & Technology Co., Ltd.",,INTERVENTIONAL
NCT02538926,"Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",https://clinicaltrials.gov/study/NCT02538926,WITHDRAWN,B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma,DRUG: Asparaginase|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|DRUG: Imatinib Mesylate|OTHER: Laboratory Biomarker Analysis|DRUG: Prednisone|BIOLOGICAL: Rituximab|DRUG: Vincristine Sulfate,University of Washington,National Cancer Institute (NCI),INTERVENTIONAL
NCT04723901,Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04723901,UNKNOWN,Dual-target CAR-T Cells|B ALL|Relapse|Refractory B Acute Lymphoblastic Leukemia,BIOLOGICAL: Dual target CAR-T cell therapy,Shenzhen University General Hospital,,INTERVENTIONAL
NCT00005982,506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT00005982,TERMINATED,Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome,DRUG: nelarabine|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03505554,A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma,https://clinicaltrials.gov/study/NCT03505554,RECRUITING,"Anaplastic Large Cell Lymphoma, ALK-Positive",DRUG: Lorlatinib,University of Milano Bicocca,Pfizer,INTERVENTIONAL
NCT03603847,Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma,https://clinicaltrials.gov/study/NCT03603847,COMPLETED,"Anaplastic Large Cell Lymphoma, ALK-Positive",,The Lymphoma Academic Research Organisation,Hôpital Necker-Enfants Malades|Fondation ARC|Pfizer|Takeda,OBSERVATIONAL
NCT06052826,"Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study",https://clinicaltrials.gov/study/NCT06052826,RECRUITING,B-Cell Non-Hodgkin Lymphoma|Multiple Myeloma,OTHER: Best Practice|OTHER: Cognitive Intervention|OTHER: Comprehensive Geriatric Assessment|OTHER: Nutritional Intervention|PROCEDURE: Physical Therapy|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT07012447,Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations,https://clinicaltrials.gov/study/NCT07012447,RECRUITING,"Early T Acute Lymphoblastic Leukemia|T-Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia, T/Myeloid, Nos",DRUG: Venetoclax|DRUG: Azacitidine|DRUG: Cytarabine,yuejun Liu,,INTERVENTIONAL
NCT05716113,CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL,https://clinicaltrials.gov/study/NCT05716113,COMPLETED,Neoplasms|Hematologic Neoplasms|Neoplasms by Site|Hematologic Diseases,DRUG: RD13-02 cell infusion,He Huang,"Nanjing Bioheng Biotech Co., Ltd.",INTERVENTIONAL
NCT04319237,Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes,https://clinicaltrials.gov/study/NCT04319237,COMPLETED,Diffuse Large B Cell Lymphoma|Transformed Lymphoma,OTHER: Handgrip strength test|BEHAVIORAL: Neuropsychological Assessment - Wechsler Test of Adult Reading (WTAR)|BEHAVIORAL: Neuropsychological Assessment - Repeatable Battery for the Assessment of Status (RBANS)|BEHAVIORAL: Neuropsychological Assessment - Color Trails|BEHAVIORAL: Neuropsychological Assessment -Stroop Color and Word Test|BEHAVIORAL: Patient Reported Outcomes Measurement Information System-29 (PROMIS-29) Questionnaire|BEHAVIORAL: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire|BEHAVIORAL: Quality of Life (EQ-5D-5L) Questionnaire|BEHAVIORAL: PROMIS Cognitive Function 4a Questionnaire|BEHAVIORAL: Comprehensive Score for Financial Toxicity (COST) measure,H. Lee Moffitt Cancer Center and Research Institute,"Kite, A Gilead Company",OBSERVATIONAL
NCT01430390,In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies,https://clinicaltrials.gov/study/NCT01430390,ACTIVE_NOT_RECRUITING,Acute Lymphocytic Leukemia|Lymphoma,BIOLOGICAL: Biological/Genetically Modified T cells|DRUG: Cyclophosphamide-based chemotherapy,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT02134262,Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes,https://clinicaltrials.gov/study/NCT02134262,UNKNOWN,Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,DRUG: Cyclophosphamide or Bendamustine|GENETIC: Dose Level -1|GENETIC: Dose Level 1|GENETIC: Dose Level 2|GENETIC: Dose Level 3,Jichi Medical University,Takara Bio Inc.,INTERVENTIONAL
NCT06014073,TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL,https://clinicaltrials.gov/study/NCT06014073,RECRUITING,Non Hodgkin's Lymphoma,BIOLOGICAL: TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)|DRUG: Fludarabine|DRUG: Cyclophosphamide,Chinese PLA General Hospital,Peking University|EdiGene Inc.,INTERVENTIONAL
NCT03483688,A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects,https://clinicaltrials.gov/study/NCT03483688,COMPLETED,B-cell Non-Hodgkin Lymphoma,BIOLOGICAL: CD19-directed CAR-T cells,Peking Union Medical College Hospital,Shanghai AbelZeta Ltd.,INTERVENTIONAL
NCT03458117,T-VEC in Non-melanoma Skin Cancer,https://clinicaltrials.gov/study/NCT03458117,COMPLETED,Non-melanoma Skin Cancer|Basal Cell Carcinoma|Squamous Cell Carcinoma|Cutaneous Lymphoma|Merkel Cell Carcinoma,GENETIC: Talimogene Laherparepvec (T-VEC),University of Zurich,,INTERVENTIONAL
NCT04470947,Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies,https://clinicaltrials.gov/study/NCT04470947,RECRUITING,Advanced Lymphoma|Refractory Lymphoma|Refractory Leukemia|Refractory Acute Myeloid Leukemia|Refractory T-Cell Lymphoma,DIAGNOSTIC_TEST: Next generation functional drug screening|DIAGNOSTIC_TEST: Comprehensive genomic profiling,Medical University of Vienna,Roche Pharma AG|Allcyte GmbH,OBSERVATIONAL
NCT05776407,"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma",https://clinicaltrials.gov/study/NCT05776407,UNKNOWN,Refractory or Relapsed B Cell Lymphoma,DRUG: ThisCART19A|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Etoposide,Chongqing University Cancer Hospital,"Fundamenta Therapeutics, Ltd.",INTERVENTIONAL
NCT01741792,Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),https://clinicaltrials.gov/study/NCT01741792,COMPLETED,Diffuse Large B-cell Lymphoma,DRUG: Blinatumomab,Amgen Research (Munich) GmbH,,INTERVENTIONAL
NCT02153580,"Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",https://clinicaltrials.gov/study/NCT02153580,ACTIVE_NOT_RECRUITING,"B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|B-Cell Prolymphocytic Leukemia|High Grade B-Cell Lymphoma, Not Otherwise Specified|Post-Transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Hairy Cell Leukemia|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma",BIOLOGICAL: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|DRUG: Bendamustine Hydrochloride|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Fludarabine Phosphate,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01678443,Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT01678443,TERMINATED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: indium In 111 anti-CD45 monoclonal antibody BC8|RADIATION: yttrium Y 90 anti-CD45 monoclonal antibody BC8|PROCEDURE: peripheral blood stem cell transplantation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04796857,Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL,https://clinicaltrials.gov/study/NCT04796857,UNKNOWN,"Non-GCB/ABC Diffuse Large B-Cell Lymphoma|High-grade B-cell Lymphoma|Follicular Lymphoma Grade IIIb|Transformed Lymphoma|EBV-Positive DLBCL, Nos|ALK-Positive Anaplastic Large Cell Lymphoma",DRUG: PD-1 Antibody|DRUG: Lenalidomide,Huiqiang Huang,,INTERVENTIONAL
NCT04855253,Study of E7777 Prior to Kymriah for R/R DLBCL,https://clinicaltrials.gov/study/NCT04855253,RECRUITING,DLBCL|Diffuse Large B Cell Lymphoma|High-grade B-cell Lymphoma|DLBCL Arising From Follicular Lymphoma,DRUG: E7777,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT03942263,A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation,https://clinicaltrials.gov/study/NCT03942263,COMPLETED,"Hodgkin Disease|Lymphoma, Large-cell, Anaplastic",,Takeda,,OBSERVATIONAL
NCT05303480,"Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides",https://clinicaltrials.gov/study/NCT05303480,COMPLETED,Mycosis Fungoides,DRUG: Chlormethine,"Centre for Human Drug Research, Netherlands",Recordati Rare Diseases,INTERVENTIONAL
NCT06027957,CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06027957,RECRUITING,B-Cell Non Hodgkin Lymphoma|B-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: anti-CD19 CAR T-cells,Vinmec Research Institute of Stem Cell and Gene Technology,"National Institute of Hematology and Blood Transfusion, Vietnam",INTERVENTIONAL
NCT04696432,A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT04696432,COMPLETED,Non-Hodgkin's B-cell Lymphoma,BIOLOGICAL: Prizloncabtagene autoleucel,Tianjin Medical University Cancer Institute and Hospital,Shanghai AbelZeta Ltd.,INTERVENTIONAL
NCT00947856,A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study,https://clinicaltrials.gov/study/NCT00947856,COMPLETED,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",DRUG: brentuximab vedotin,Seagen Inc.,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT04007978,Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies,https://clinicaltrials.gov/study/NCT04007978,UNKNOWN,B Cell Lymphoma|Acute Lymphoblastic Leukemia,GENETIC: Third generation CAR-T cells,"Wuhan Union Hospital, China","Wuhan Bio-Raid Biotechnology Co., Ltd.",INTERVENTIONAL
NCT04271800,Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT04271800,UNKNOWN,"Leukemia|Lymphoma|Leukemia, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell",BIOLOGICAL: CD19 CAR-T cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT04655677,A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT04655677,COMPLETED,B-cell Non-Hodgkin's Lymphoma,BIOLOGICAL: Prizloncabtagene Autoleucel,Peking Union Medical College Hospital,Shanghai AbelZeta Ltd.,INTERVENTIONAL
NCT01258998,Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma,https://clinicaltrials.gov/study/NCT01258998,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: Akt inhibitor MK2206|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06408194,Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies,https://clinicaltrials.gov/study/NCT06408194,RECRUITING,Leukemia|Acute Lymphoblastic Leukemia,DRUG: CD22CART infusion|DRUG: Tisagenlecleucel,Stanford University,,INTERVENTIONAL
NCT06834373,Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy,https://clinicaltrials.gov/study/NCT06834373,RECRUITING,"Large B-Cell Lymphoma With IRF4 Rearrangement|Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma|Recurrent ALK-Positive Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements|Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent Intravascular Large B-Cell Lymphoma|Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Recurrent Primary Mediastinal Large B-Cell Lymphoma|Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Refractory Aggressive B-Cell Non-Hodgkin Lymphoma|Refractory ALK-Positive Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements|Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified|Refractory Intravascular Large B-Cell Lymphoma|Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Refractory Primary Mediastinal Large B-Cell Lymphoma|Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Refractory Transformed Non-Hodgkin Lymphoma",PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|PROCEDURE: Computed Tomography|DRUG: Golcadomide|PROCEDURE: Leukapheresis|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab,Mayo Clinic,,INTERVENTIONAL
NCT06253637,Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program,https://clinicaltrials.gov/study/NCT06253637,RECRUITING,"T-Lymphocytic Leukemia, Acute",DRUG: Daratumumab plus chemotherapy according to the national treatment program,Gruppo Italiano Malattie EMatologiche dell'Adulto,,INTERVENTIONAL
NCT02424968,CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT02424968,COMPLETED,Acute Myeloid Leukemia|B-Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Hodgkin Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|T-Cell Non-Hodgkin Lymphoma,BIOLOGICAL: Anti-Thymocyte Globulin|DRUG: Cyclosporine|DRUG: Mycophenolate Mofetil|PROCEDURE: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant|BIOLOGICAL: Allogeneic Cluster of Differentiation 8 (CD8)+ Memory T-cells|RADIATION: Total Nodal Irradiation,Robert Lowsky,National Cancer Institute (NCI),INTERVENTIONAL
NCT06916767,Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Substudy B: CLL Patients,https://clinicaltrials.gov/study/NCT06916767,NOT_YET_RECRUITING,Relapsed CLL|Refractory CLL|Refractory Lymphoma,DRUG: BAFF CAR-T|DRUG: Obinutuzumab|DRUG: Cyclophosphamide|DRUG: Fludarabine,"Paolo Caimi, MD",The Leukemia and Lymphoma Society,INTERVENTIONAL
NCT00058617,"Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL",https://clinicaltrials.gov/study/NCT00058617,COMPLETED,Epstein-Barr Virus-Related Hodgkin Lymphoma|Epstein-Barr Virus-Related Non-Hodgkin Lymphoma|EBV Positive Plasma Cell Neoplasm,BIOLOGICAL: Injection of EBV Specific CTLs,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT05260957,"CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).",https://clinicaltrials.gov/study/NCT05260957,RECRUITING,Refractory Non-Hodgkin Lymphoma|Relapsed Non Hodgkin Lymphoma|Aggressive Non-Hodgkin Lymphoma,DRUG: Mosunetuzumab|DRUG: Polatuzumab|BIOLOGICAL: CAR-T Cell Therapy,Lazaros Lekakis,"Genentech, Inc.",INTERVENTIONAL
NCT06698484,To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL),https://clinicaltrials.gov/study/NCT06698484,RECRUITING,Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma,DRUG: CAR-T cells,National University of Malaysia,Plutonet Sdn Bhd,INTERVENTIONAL
NCT03298828,CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT03298828,UNKNOWN,Acute Lymphoblastic Leukemia|Burkitt Lymphoma,BIOLOGICAL: CD19 CAR and PD-1 knock out engineered T-cells|BIOLOGICAL: CD19 CAR T-cells,Third Military Medical University,,INTERVENTIONAL
NCT05514327,A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL,https://clinicaltrials.gov/study/NCT05514327,RECRUITING,Diffuse Large B Cell Lymphoma|CAR-T|Radiotherapy|Bridging Therapy,RADIATION: ultra-fraction radiotherapy,Peking Union Medical College Hospital,,INTERVENTIONAL
NCT04018248,BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I),https://clinicaltrials.gov/study/NCT04018248,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Leukemia|B Cell Lymphoma|Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia|Peripheral T Cell Lymphoma,DRUG: BR101801 (Phase Ia)|DRUG: BR101801 (Phase Ib),"Boryung Pharmaceutical Co., Ltd",,INTERVENTIONAL
NCT04306887,A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL),https://clinicaltrials.gov/study/NCT04306887,UNKNOWN,Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL),DRUG: TQ-B3101 capsule,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,INTERVENTIONAL
NCT01318317,"Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01318317,ACTIVE_NOT_RECRUITING,Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Filgrastim|BIOLOGICAL: Genetically Engineered Lymphocyte Therapy|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Plerixafor|BIOLOGICAL: Rituximab,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02685670,Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT02685670,UNKNOWN,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,BIOLOGICAL: anti-CD19 CAR-T|DRUG: Fludarabine|DRUG: Cyclophosphamide,The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine,Xinqiao Hospital of Chongqing|Xuzhou Medical University,INTERVENTIONAL
NCT02786485,Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,https://clinicaltrials.gov/study/NCT02786485,WITHDRAWN,Leukemia|Myelodysplastic Syndromes|Lymphomas|Multiple Myeloma|Other High-risk Hematological Malignancies,BIOLOGICAL: rivogenlecleucel|DRUG: Rimiducid,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT06101381,CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT06101381,RECRUITING,"Leukemia, Acute Lymphoblastic|Lymphoma, Non-Hodgkin",BIOLOGICAL: CART-19,University of Sao Paulo,Blood Center of Ribeirao Preto|Hospital das Clínicas de Ribeirão Preto,INTERVENTIONAL
NCT04792489,DALY II USA/ MB-CART2019.1 for DLBCL,https://clinicaltrials.gov/study/NCT04792489,RECRUITING,Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Relapsed Diffuse Large B Cell Lymphoma|High Grade B-cell Lymphoma (HGBCL)|Primary Mediastinal B-cell Lymphoma (PMBCL)|Transformed Lymphoma|Central Nervous System Lymphoma|Mantle Cell Lymphoma (MCL)|Richter Transformation,BIOLOGICAL: zamtocabtagene autoleucel (MB-CART2019.1)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Bendamustine,Miltenyi Biomedicine GmbH,,INTERVENTIONAL
NCT01419795,"Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",https://clinicaltrials.gov/study/NCT01419795,TERMINATED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: lenalidomide|BIOLOGICAL: rituximab|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05149170,Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL,https://clinicaltrials.gov/study/NCT05149170,UNKNOWN,"Early-stage|Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type",DRUG: Anti-PD-1 monoclonal antibody,Chinese Academy of Medical Sciences,Peking University Cancer Hospital & Institute|The First Hospital of Jilin University|Affiliated Cancer Hospital & Institute of Guangzhou Medical University,INTERVENTIONAL
NCT03936452,"Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma",https://clinicaltrials.gov/study/NCT03936452,COMPLETED,"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type|Early Stage|Anlotinib|Peg-aspargase|Sintilimab|Phase Two|Open|Radiotherapy",DRUG: Sintilimab,Sun Yat-sen University,,INTERVENTIONAL
NCT05800977,A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05800977,RECRUITING,Relapsed/Refractory Large B-Cell Lymphoma,BIOLOGICAL: Prizloncabtagene autoleucel,Shanghai AbelZeta Ltd.,,INTERVENTIONAL
NCT01839916,Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01839916,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: therapeutic allogeneic lymphocytes|OTHER: laboratory biomarker analysis,University of Chicago,National Cancer Institute (NCI),INTERVENTIONAL
NCT05202782,Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05202782,ACTIVE_NOT_RECRUITING,"Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma, Not Otherwise Specified|Large B-Cell Lymphoma With IRF4 Rearrangement|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent Intravascular Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Recurrent Transformed B-Cell Non-Hodgkin Lymphoma|Refractory Aggressive B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory Intravascular Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Refractory Transformed B-Cell Non-Hodgkin Lymphoma",BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|DRUG: Zanubrutinib,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT06890091,"Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT06890091,NOT_YET_RECRUITING,Fatigue Symptom|Lymphoma Non-Hodgkin|Chimeric Antigen Receptor T-cell Therapy|Adverse Events,OTHER: Fatigue assessment,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT06047197,Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06047197,RECRUITING,Recurrent Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-cell Lymphoma,BIOLOGICAL: RC19D2 cell injection,Beijing Yongtai Ruike Biotechnology Company Ltd,,INTERVENTIONAL
NCT03676504,Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR,https://clinicaltrials.gov/study/NCT03676504,RECRUITING,"Acute Lymphoblastic Leukemia, Adult|Acute Lymphoblastic Leukemia, Pediatric|Chronic Lymphocytic Leukemia|Diffuse Large B Cell Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma",BIOLOGICAL: CD19.CAR T Cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,University Hospital Heidelberg,,INTERVENTIONAL
NCT06517004,"An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma",https://clinicaltrials.gov/study/NCT06517004,RECRUITING,Diffuse Large B Cell Lymphoma,BIOLOGICAL: JWCAR201,Fudan University,,INTERVENTIONAL
NCT03312205,CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT03312205,UNKNOWN,Leukemia|Lymphoma|Multiple Myeloma of Bone (Diagnosis),BIOLOGICAL: Autologous CAR-T cells,"Hebei Senlang Biotechnology Inc., Ltd.",Hebei Yanda Ludaopei Hospital|Beijing Lu Daopei Hospital,INTERVENTIONAL
NCT05422521,Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05422521,RECRUITING,Refractory or Relapsed Non-Hodgkin's Lymphoma,OTHER: blood samples and 18FDG PET-CT exams,Centre Hospitalier Universitaire de Nice,,INTERVENTIONAL
NCT06500273,Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL,https://clinicaltrials.gov/study/NCT06500273,RECRUITING,Large B-cell Lymphoma,"GENETIC: cemacabtagene ansegedleucel|BIOLOGICAL: ALLO-647|DRUG: Fludarabine|DRUG: Cyclophosphamide|DEVICE: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™",Allogene Therapeutics,"Foresight Diagnostics, Inc.",INTERVENTIONAL
NCT03355859,Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT03355859,UNKNOWN,Non Hodgkin Lymphoma,BIOLOGICAL: JWCAR029,Zhao Weili,"Shanghai Mingju Biotechnology Co., Ltd.",INTERVENTIONAL
NCT03344367,Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT03344367,UNKNOWN,Non Hodgkin Lymphoma,BIOLOGICAL: JWCAR029,Peking University,"Shanghai Mingju Biotechnology Co., Ltd.",INTERVENTIONAL
NCT02139592,"Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) ""Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma""",https://clinicaltrials.gov/study/NCT02139592,COMPLETED,Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma,DRUG: Brentuximab vedotin (recombinant),Takeda,,OBSERVATIONAL
NCT03097770,Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20,https://clinicaltrials.gov/study/NCT03097770,COMPLETED,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,BIOLOGICAL: anti-CD19/20-CAR vector-transduced T cells,Chinese PLA General Hospital,,INTERVENTIONAL
NCT00601718,"Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",https://clinicaltrials.gov/study/NCT00601718,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Waldenström Macroglobulinemia,DRUG: vorinostat|BIOLOGICAL: rituximab|DRUG: ifosfamide|DRUG: carboplatin|DRUG: etoposide|OTHER: pharmacological study|OTHER: laboratory biomarker analysis|GENETIC: gene expression analysis,University of Washington,National Cancer Institute (NCI),INTERVENTIONAL
NCT05741359,The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05741359,RECRUITING,"Non-hodgkin Lymphoma,B Cell",DRUG: CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection,Bioray Laboratories,"Chinese Academy of Medical Sciences|Zhejiang University|Wuhan Union Hospital, China",INTERVENTIONAL
NCT06492629,Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06492629,ACTIVE_NOT_RECRUITING,PTCL,DRUG: Toripalimab|DRUG: chidamide,"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",,INTERVENTIONAL
NCT03196830,CAR-T for R/R B-NHL,https://clinicaltrials.gov/study/NCT03196830,UNKNOWN,Relapsed Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|CAR - T CD19/CD20/CD22/CD30,BIOLOGICAL: CAR-T,The First Affiliated Hospital of Soochow University,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",INTERVENTIONAL
NCT01184885,A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy,https://clinicaltrials.gov/study/NCT01184885,COMPLETED,Lymphoid Malignancies (New or Relapsed)|Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Lymphoblastic Lymphoma|Mantle Cell Lymphoma|Adult T-cell Leukemia/Lymphoma,DRUG: Hyper-CVAD|DRUG: Sirolimus,Sidney Kimmel Cancer Center at Thomas Jefferson University,American Society of Clinical Oncology,INTERVENTIONAL
NCT06559189,CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL,https://clinicaltrials.gov/study/NCT06559189,RECRUITING,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19x22 CAR T,"University of Colorado, Denver",,INTERVENTIONAL
NCT06870487,A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.,https://clinicaltrials.gov/study/NCT06870487,RECRUITING,Peripheral T Cell Lymphoma|Diffuse Large B-cell Lymphoma|Classical Hodgkin Lymphoma|Head and Neck Squamous Cell Carcinoma|Melanoma|Non-Small Cell Lung Cancer,DRUG: PF-08046032|DRUG: Sasanlimab,Pfizer,,INTERVENTIONAL
NCT05349201,CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI),https://clinicaltrials.gov/study/NCT05349201,COMPLETED,Diffuse Large B-Cell Lymphoma (DLBCL)|Acute Lymphoblastic Leukemia (ALL),OTHER: KYMRIAH|OTHER: YESCARTA,Novartis Pharmaceuticals,,OBSERVATIONAL
NCT01396070,Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level,https://clinicaltrials.gov/study/NCT01396070,COMPLETED,Non-Hodgkin Lymphoma (NHL)|Cutaneous Lymphoma|Cutaneous T-cell Lymphoma (CTCL)|Mycosis Fungoides|Sezary Syndrome,DRUG: Brentuximab vedotin,Youn Kim,Seagen Inc.,INTERVENTIONAL
NCT05169489,A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL),https://clinicaltrials.gov/study/NCT05169489,ACTIVE_NOT_RECRUITING,Diffuse Large B Cell Lymphoma (DLBCL),BIOLOGICAL: bbT369,Regeneron Pharmaceuticals,,INTERVENTIONAL
NCT00058019,Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00058019,COMPLETED,Anaplastic Large Cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma,DRUG: ixabepilone,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00621452,"Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT00621452,COMPLETED,B-cell Chronic Lymphocytic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: therapeutic autologous lymphocytes|DRUG: cyclophosphamide|BIOLOGICAL: aldesleukin|GENETIC: polymerase chain reaction|GENETIC: gene rearrangement analysis|PROCEDURE: lymph node biopsy|BIOLOGICAL: genetically engineered lymphocyte therapy|PROCEDURE: bone marrow aspiration|OTHER: flow cytometry|OTHER: laboratory biomarker analysis|OTHER: enzyme-linked immunosorbent assay,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04205409,"Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",https://clinicaltrials.gov/study/NCT04205409,ACTIVE_NOT_RECRUITING,Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Grade 3a Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma,BIOLOGICAL: Nivolumab,University of Washington,Bristol-Myers Squibb,INTERVENTIONAL
NCT02086591,A Phase II Study of Doxycycline in Relapsed NHL,https://clinicaltrials.gov/study/NCT02086591,TERMINATED,"Adult Diffuse Large B-Cell Lymphoma|Mantle Cell Lymphoma Recurrent|Lymphoma, Follicular|Marginal Zone B-Cell Lymphoma|Malignant Lymphoma - Lymphoplasmacytic|Waldenstrom Macroglobulinemia|Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia (CLL)|T-Cell Lymphoma",DRUG: Doxycycline,University of Rochester,,INTERVENTIONAL
NCT03240211,Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL,https://clinicaltrials.gov/study/NCT03240211,RECRUITING,PTCL|CTCL,DRUG: Pembrolizumab|DRUG: Pralatrexate|DRUG: Decitabine,University of Virginia,"Merck Sharp & Dohme LLC|Otsuka Pharmaceutical Development & Commercialization, Inc.",INTERVENTIONAL
NCT04234061,Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT04234061,ACTIVE_NOT_RECRUITING,Mantle Cell Lymphoma Recurrent,COMBINATION_PRODUCT: ibrutinib and Tisagenlecleucel,"Peter MacCallum Cancer Centre, Australia",Novartis,INTERVENTIONAL
NCT06058858,"Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis",https://clinicaltrials.gov/study/NCT06058858,RECRUITING,Cytomegalovirus Infections|Acute Leukemia|B Cell Lymphoma,,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT00854581,"Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma",https://clinicaltrials.gov/study/NCT00854581,TERMINATED,Lymphoma|Precancerous/Nonmalignant Condition,BIOLOGICAL: PEG-interferon alfa-2b|BIOLOGICAL: Interferon alfa-2b|DRUG: Valproic Acid|DRUG: Zidovudine,University of Miami,National Cancer Institute (NCI),INTERVENTIONAL
NCT05269914,"Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL",https://clinicaltrials.gov/study/NCT05269914,UNKNOWN,Diffuse Large B Cell Lymphoma,OTHER: Autologous anti-CD19 CAR-T cell injection,The Affiliated Hospital of Qingdao University,,INTERVENTIONAL
NCT06191887,B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06191887,RECRUITING,B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia,BIOLOGICAL: Autologous BAFFR-targeting CAR T Cells|DRUG: Bendamustine|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration and Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Echocardiography|DRUG: Fludarabine|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,Mayo Clinic,,INTERVENTIONAL
NCT03384654,A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT03384654,COMPLETED,Precursor Cell Lymphoblastic Leukemia-Lymphoma,DRUG: Daratumumab|DRUG: Vincristine|DRUG: Prednisone|DRUG: Doxorubicin|BIOLOGICAL: Peg-asparaginase|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: 6-mercaptopurine|DRUG: Methotrexate,"Janssen Research & Development, LLC",,INTERVENTIONAL
NCT02732275,DS-3201b in Participants With Lymphomas,https://clinicaltrials.gov/study/NCT02732275,ACTIVE_NOT_RECRUITING,"Lymphoma, Malignant|Non-hodgkin Lymphoma",DRUG: DS-3201b|DRUG: DS-3201b,"Daiichi Sankyo Co., Ltd.",Daiichi Sankyo,INTERVENTIONAL
NCT01609816,"Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01609816,TERMINATED,Non-Hodgkin's Lymphoma|Multiple|Mycosis Fungoides|Hodgkin's Lymphoma|Multiple Myeloma,DRUG: Dasatinib,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT01769222,Ipilimumab and Local Radiation for Selected Solid Tumors,https://clinicaltrials.gov/study/NCT01769222,TERMINATED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Colon Cancer|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Melanoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Rectal Cancer|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: Ipilimumab|RADIATION: Radiation therapy,Stanford University,,INTERVENTIONAL
NCT04920617,"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma",https://clinicaltrials.gov/study/NCT04920617,RECRUITING,Relapsed Diffuse Large B-cell Lymphoma|Refractory Diffuse Large B-cell Lymphoma,DRUG: DPX-Survivac|DRUG: Pembrolizumab|DRUG: CPA,"ImmunoVaccine Technologies, Inc. (IMV Inc.)",Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT02456350,Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies,https://clinicaltrials.gov/study/NCT02456350,UNKNOWN,Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia|Lymphoma,DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Anti-CD19-CAR transduced T cells,Shenzhen Second People's Hospital,Shenzhen Institute for Innovation and Translational Medicine,INTERVENTIONAL
NCT04762485,Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia,https://clinicaltrials.gov/study/NCT04762485,UNKNOWN,T Lymphoblastic Leukemia/Lymphoma|Mixed Phenotype Acute Leukemia|Acute Myeloid Leukemia,BIOLOGICAL: Humanized CD7 CAR-T cells,The First Affiliated Hospital of Soochow University,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",INTERVENTIONAL
NCT03617432,Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT03617432,UNKNOWN,Experimental Tumor,DRUG: Chidamide|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Etoposide|DRUG: Prednisone,Peking University,Peking University International Hospital|Shandong Tumor Hospital|Jiangxi Provincial Cancer Hospital,INTERVENTIONAL
NCT03774654,CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR),https://clinicaltrials.gov/study/NCT03774654,ACTIVE_NOT_RECRUITING,Refractory B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Small Lymphocytic Lymphoma|Relapsed Adult ALL|Relapsed CLL|Relapsed Non Hodgkin Lymphoma,GENETIC: CD19.CAR-aNKT cells,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute|National Cancer Institute (NCI)",INTERVENTIONAL
NCT06049381,Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research,https://clinicaltrials.gov/study/NCT06049381,NOT_YET_RECRUITING,Relapsed Non-Hodgkin Lymphoma,,Ruijin Hospital,,OBSERVATIONAL
NCT01567709,"Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma",https://clinicaltrials.gov/study/NCT01567709,COMPLETED,Adult B Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia,DRUG: Alisertib|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Vorinostat,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00019227,Monoclonal Antibody Therapy in Treating Patients With Leukemia,https://clinicaltrials.gov/study/NCT00019227,COMPLETED,Lymphoma|Radiation Toxicity,DRUG: pentetic acid calcium|RADIATION: yttrium Y 90 daclizumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05598593,Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL,https://clinicaltrials.gov/study/NCT05598593,RECRUITING,Cytarabine+Thiotepa + Fludarabine + Busulfan|T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma,DRUG: cytarabine+thiotepa+ fludarabine + busulfan,First Affiliated Hospital of Zhejiang University,,INTERVENTIONAL
NCT02290132,ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors,https://clinicaltrials.gov/study/NCT02290132,UNKNOWN,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,DRUG: Rabbit Anti-human Thymocyte Globulin (ATG),"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",Tang-Du Hospital|The First Affiliated Hospital of Soochow University|The First Affiliated Hospital with Nanjing Medical University,OBSERVATIONAL
NCT03210662,Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT03210662,ACTIVE_NOT_RECRUITING,Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Aggressive Non-Hodgkin Lymphoma|Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Aggressive Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory T-Cell Non-Hodgkin Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma,RADIATION: External Beam Radiation Therapy|BIOLOGICAL: Pembrolizumab,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01947140,Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT01947140,COMPLETED,Lymphoid Malignancies|Multiple Myeloma|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma,DRUG: Pralatrexate|DRUG: Romidepsin,Jennifer Amengual,,INTERVENTIONAL
NCT00113646,Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00113646,TERMINATED,Lymphoma|Leukemia|Multiple Myeloma|Myelodysplastic Syndrome,DRUG: MEDI-507|PROCEDURE: Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant,Massachusetts General Hospital,Dana-Farber Cancer Institute,INTERVENTIONAL
NCT06519344,An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.,https://clinicaltrials.gov/study/NCT06519344,NOT_YET_RECRUITING,B Cell Malignancies,BIOLOGICAL: anti-CD20/CD30-CAR-T Cells,"Shanghai Tongji Hospital, Tongji University School of Medicine",,INTERVENTIONAL
NCT00113828,Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00113828,TERMINATED,Lymphoma|Leukemia|Multiple Myeloma|Myelodysplastic Syndrome,PROCEDURE: Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|PROCEDURE: T-cell depleted peripheral blood stem cell transplant,Massachusetts General Hospital,Dana-Farber Cancer Institute,INTERVENTIONAL
NCT00078949,Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00078949,COMPLETED,Lymphoma,BIOLOGICAL: rituximab|DRUG: cisplatin|DRUG: cytarabine|DRUG: dexamethasone|DRUG: gemcitabine hydrochloride,NCIC Clinical Trials Group,,INTERVENTIONAL
NCT04544592,UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL,https://clinicaltrials.gov/study/NCT04544592,RECRUITING,B-cell Acute Lymphoblastic Leukemia|B-cell Non Hodgkin Lymphoma,DRUG: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells,"University of Colorado, Denver",Children's Hospital Colorado,INTERVENTIONAL
NCT05972720,A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT05972720,TERMINATED,Cancer|Relapsed/Refractory Large B-cell Lymphoma (LBCL),DRUG: Fludarabine (Conditional therapy)|DRUG: Cyclophosphamide Monohydrate (Conditional therapy)|DRUG: firi-cel (Experimental drug),CARGO Therapeutics,,INTERVENTIONAL
NCT00430846,Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00430846,COMPLETED,"Lymphoma, Non-Hodgkin|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic",DRUG: SGN-35,Seagen Inc.,,INTERVENTIONAL
NCT01352520,"SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)",https://clinicaltrials.gov/study/NCT01352520,ACTIVE_NOT_RECRUITING,"CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma|Lymphoma, Primary Cutaneous Anaplastic Large Cell|Lymphomatoid Papulosis|Mycosis Fungoides|Skin Lymphoma|Cutaneous Lymphomas|Lymphoma|Hematologic Disorder",DRUG: SGN-35,M.D. Anderson Cancer Center,Seagen Inc.,INTERVENTIONAL
NCT03777085,Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL),https://clinicaltrials.gov/study/NCT03777085,UNKNOWN,Diffuse Large B-cell Lymphoma,DRUG: TQB2303|DRUG: Rituximab,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",,INTERVENTIONAL
NCT00185965,CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas,https://clinicaltrials.gov/study/NCT00185965,COMPLETED,Non-Hodgkin Lymphoma|Mycosis Fungoides,DRUG: CPG 7909,Ronald Levy,Lymphoma Research Foundation|American Society of Clinical Oncology,INTERVENTIONAL
NCT00101205,"Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma",https://clinicaltrials.gov/study/NCT00101205,TERMINATED,"Angioimmunoblastic T-cell Lymphoma|B-cell Childhood Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|T-cell Childhood Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: oxaliplatin|DRUG: etoposide,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00400556,ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells,https://clinicaltrials.gov/study/NCT00400556,COMPLETED,Multiple Myeloma|Cutaneous Lymphoma,"DRUG: ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination","Peter MacCallum Cancer Centre, Australia",The Leukemia and Lymphoma Society,INTERVENTIONAL
NCT06316427,Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies,https://clinicaltrials.gov/study/NCT06316427,RECRUITING,"T-cell Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia|T-cell Malignancies",DRUG: Autologous CD7 CAR T-cell|DRUG: Prior-HSCT donor-derived CD7 CAR T-cell|DRUG: New donor-derived CD7 CAR T-cell,Beijing GoBroad Hospital,"The General Hospital of Western Theater Command|Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai|Shanghai Liquan Hospital|Central People's Hospital of Zhanjiang",INTERVENTIONAL
NCT00177268,"Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research",https://clinicaltrials.gov/study/NCT00177268,RECRUITING,Cutaneous T-cell Lymphoma|Sezary Syndrome|Mycosis Fungoides|Eczema|Atopic Dermatitis,"OTHER: Blood draw, skin biopsy or urine collection",University of Pittsburgh,,OBSERVATIONAL
NCT03185494,Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22,https://clinicaltrials.gov/study/NCT03185494,UNKNOWN,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,BIOLOGICAL: anti-CD19/22-CAR vector-transduced T cells,Chinese PLA General Hospital,,INTERVENTIONAL
NCT01904175,Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01904175,COMPLETED,Hodgkin's Disease|Non Hodgkin's Lymphoma|Myeloma|Leukemia|Myelodysplasia,,Duke University,,OBSERVATIONAL
NCT01492088,Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01492088,COMPLETED,Relapsed or Refractory Hodgkin Lymphoma|Relapsed or Refractory Anaplastic Large-cell Lymphoma,DRUG: Brentuximab vedotin,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT00597714,Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00597714,COMPLETED,Hodgkin's Disease|Non Hodgkin's Lymphoma|Myeloma|Leukemia|Myelodysplasia,DRUG: Non-myeloablative Stem Cell Transplantation,"David Rizzieri, MD",,INTERVENTIONAL
NCT04767308,Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies,https://clinicaltrials.gov/study/NCT04767308,UNKNOWN,CD5+ Relapsed/Refractory Hematopoietic Malignancies|Chronic Lymphocytic Leukemia (CLL)|Mantle Cell Lymphoma (MCL)|Diffuse Large B-cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Peripheral T-cell Lymphomas (PTCL),"BIOLOGICAL: CT125A cells|DRUG: Cyclophosphamide, fludarabine",Huazhong University of Science and Technology,"Shanghai IASO Biotechnology Co., Ltd",INTERVENTIONAL
NCT06855810,Newly-diagnosed Pediatric T-cell ALL Protocol,https://clinicaltrials.gov/study/NCT06855810,NOT_YET_RECRUITING,"Acute Lymphoblastic Leukemia|Childhood Leukemia, Acute Lymphoblastic|T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma",DRUG: Venetoclax|DRUG: Dasatinib|DRUG: homoharringtonine,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT03109353,Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease,https://clinicaltrials.gov/study/NCT03109353,COMPLETED,"Cutaneous T-Cell Lymphoma, Unspecified|Chronic Graft Versus Host Disease in Skin",DRUG: ECP with 5-aminolevulinic acid,St. Olavs Hospital,Norwegian University of Science and Technology|Oslo University Hospital,INTERVENTIONAL
NCT04150913,A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity,https://clinicaltrials.gov/study/NCT04150913,COMPLETED,Non Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Relapsed Non Hodgkin Lymphoma|Neurotoxicity|Neurotoxicity Syndromes|Cytokine Release Syndrome,DRUG: Anakinra|DRUG: Axicabtagene Ciloleucel,"Marcela V. Maus, M.D.,Ph.D.","Kite, A Gilead Company",INTERVENTIONAL
NCT03462095,De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL),https://clinicaltrials.gov/study/NCT03462095,UNKNOWN,Precursor Cell Lymphoblastic Leukemia-Lymphoma,PROCEDURE: Autologous HSCT,"National Research Center for Hematology, Russia",,INTERVENTIONAL
NCT04509804,"Target Gene Sequencing for Advanced Stage, Relapsed or Refractory Natural Killer/T-cell Lymphoma",https://clinicaltrials.gov/study/NCT04509804,COMPLETED,Lymphoid Neoplasm,OTHER: non-interventional,Chinese Academy of Medical Sciences,,OBSERVATIONAL
NCT02232516,Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT02232516,ACTIVE_NOT_RECRUITING,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Peripheral T-cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome,DRUG: romidepsin|DRUG: lenalidomide|OTHER: laboratory biomarker analysis,Northwestern University,Celgene|National Cancer Institute (NCI),INTERVENTIONAL
NCT05674175,Co-administration of CART22-65s and huCART19 for B-ALL,https://clinicaltrials.gov/study/NCT05674175,RECRUITING,B-cell Acute Lymphoblastic Leukemia|B Lineage Lymphoblastic Lymphoma,"BIOLOGICAL: Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)|BIOLOGICAL: Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)",Stephan Grupp MD PhD,University of Pennsylvania,INTERVENTIONAL
NCT06392763,Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data,https://clinicaltrials.gov/study/NCT06392763,COMPLETED,Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia (ALL),,Novartis Pharmaceuticals,,OBSERVATIONAL
NCT00005803,Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma,https://clinicaltrials.gov/study/NCT00005803,COMPLETED,Prolymphocytic Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|PROCEDURE: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|DRUG: Carmustine|DRUG: Cyclophosphamide|DRUG: Cyclosporine|DRUG: Cytarabine|DRUG: Etoposide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Melphalan|DRUG: Mycophenolate Mofetil|PROCEDURE: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Peripheral Blood Stem Cell Transplantation|BIOLOGICAL: Therapeutic Autologous Lymphocytes|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00006451,Bone Marrow Transplantation in Treating Patients With Leukemia,https://clinicaltrials.gov/study/NCT00006451,WITHDRAWN,Graft Versus Host Disease|Leukemia|Lymphoma,DRUG: anti-thymocyte globulin|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: methotrexate|DRUG: methylprednisolone|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: in vitro-treated bone marrow transplantation|PROCEDURE: radiation therapy,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00006009,Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma,https://clinicaltrials.gov/study/NCT00006009,COMPLETED,Lymphoma|Small Intestine Cancer,BIOLOGICAL: visilizumab,Stanford University,National Cancer Institute (NCI),INTERVENTIONAL
NCT05797948,GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05797948,UNKNOWN,Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,DRUG: Obinutuzumab|DRUG: Zanubrutinib|DRUG: Lenalidomide|DRUG: CD19/CD22 CAR-T|DRUG: Azacitidine For Injection|DRUG: Fludarabine|DRUG: Cyclophosphamide,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT00341939,Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data,https://clinicaltrials.gov/study/NCT00341939,COMPLETED,Prostate Cancer|Breast Cancer|Cutaneous T-Cell Lymphoma|Lung Cancer|Melanoma,,National Cancer Institute (NCI),,OBSERVATIONAL
NCT02706405,JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT02706405,TERMINATED,"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma",BIOLOGICAL: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|DRUG: Cyclophosphamide|BIOLOGICAL: Durvalumab|DRUG: Fludarabine,Fred Hutchinson Cancer Center,"AstraZeneca|Juno Therapeutics, Inc., a Bristol-Myers Squibb Company|MedImmune LLC|National Cancer Institute (NCI)",INTERVENTIONAL
NCT03310619,A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies,https://clinicaltrials.gov/study/NCT03310619,COMPLETED,"Lymphoma, Non-Hodgkin|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular",BIOLOGICAL: JCAR017|DRUG: Durvalumab|DRUG: CC-122|DRUG: Ibrutinib|DRUG: CC-220|DRUG: Relatlimab|DRUG: Nivolumab|DRUG: CC-99282,Celgene,,INTERVENTIONAL
NCT06643221,Exercise as an Immune Adjuvant for Allogeneic Cell Therapies,https://clinicaltrials.gov/study/NCT06643221,RECRUITING,Leukemia|Hematopoetic Stem Cell Transplantation|Donor Lymphocyte Infusion|CAR T-Cell Therapy|Lymphoma|Cell Therapy,"BEHAVIORAL: Exercise|DRUG: Isoproterenol|DRUG: Placebo|DRUG: Bisoprolol Fumarate Tablet 10 mg|DRUG: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|DRUG: Carvedilol 50 mg|DRUG: Roflumilast 500 Mcg Oral Tablet",University of Arizona,National Cancer Institute (NCI),INTERVENTIONAL
NCT01943682,Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT01943682,COMPLETED,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Diffuse Large Cell Lymphoma|Gray Zone Lymphoma|Lymphoblastic Lymphoma|Anaplastic Large Cell Lymphoma|Hodgkin Lymphoma,DRUG: CPX-351,"Children's Hospital Medical Center, Cincinnati",Jazz Pharmaceuticals,INTERVENTIONAL
NCT00025662,"Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS",https://clinicaltrials.gov/study/NCT00025662,COMPLETED,"Graft vs Host Disease|Myelodysplastic Syndromes|Leukemia|Leukemia, Myeloid|Leukemia, Myelomonocytic, Chronic|Leukemia, Lymphocytic|Lymphoma|Lymphoma, Mantle-cell|Lymphoma, Non-Hodgkin|Hodgkin Disease",DRUG: RFT5-SMPT-dgA|DRUG: Isolex system,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT06355739,CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+,https://clinicaltrials.gov/study/NCT06355739,RECRUITING,B Lymphocytic Leukemia|B Lymphoblastic Lymphoma,DEVICE: CAR T cell injection,Zhu Xiaofan,,INTERVENTIONAL
NCT02301494,Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT02301494,WITHDRAWN,Mycosis Fungoides,DRUG: 3.75% Imiquimod Cream|DRUG: 0.1% Fluocinonide Cream,Rochester General Hospital,"Bausch Health Americas, Inc.|Rochester Skin Lymphoma Medical Group, PLLC",INTERVENTIONAL
NCT00072514,"Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",https://clinicaltrials.gov/study/NCT00072514,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,DRUG: gemcitabine hydrochloride|DRUG: carboplatin|DRUG: dexamethasone|BIOLOGICAL: rituximab,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01408043,"Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01408043,TERMINATED,Adult Acute Lymphoblastic Leukemia in Remission|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: plerixafor|BIOLOGICAL: filgrastim|DRUG: etoposide|PROCEDURE: leukapheresis,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00031668,Radiation Therapy in Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00031668,COMPLETED,Lymphoma,RADIATION: radiation therapy,NCIC Clinical Trials Group,,INTERVENTIONAL
NCT01116154,Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01116154,TERMINATED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-Cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,DRUG: lenalidomide|DRUG: vorinostat|OTHER: laboratory biomarker analysis,City of Hope Medical Center,,INTERVENTIONAL
NCT03076437,Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies,https://clinicaltrials.gov/study/NCT03076437,COMPLETED,Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Lymphoma,COMBINATION_PRODUCT: Drugs and Anti-CD19-CAR transduced T cells,Shenzhen Institute for Innovation and Translational Medicine,Dongguan People's Hospital,INTERVENTIONAL
NCT00006345,Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00006345,COMPLETED,Drug/Agent Toxicity by Tissue/Organ|Lymphoma,BIOLOGICAL: denileukin diftitox|DRUG: dexamethasone,Ligand Pharmaceuticals,,INTERVENTIONAL
NCT00274742,Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL,https://clinicaltrials.gov/study/NCT00274742,COMPLETED,"Non-Hodgkin's Lymphoma, Relapsed",BIOLOGICAL: Blinatumomab (MT103),Amgen Research (Munich) GmbH,,INTERVENTIONAL
NCT03191773,A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies,https://clinicaltrials.gov/study/NCT03191773,UNKNOWN,Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|Lymphoma,COMBINATION_PRODUCT: Drugs and anti-CD19 CAR transduced T cells,Second Affiliated Hospital of Guangzhou Medical University,Shenzhen Institute for Innovation and Translational Medicine|Guangzhou First People's Hospital|First People's Hospital of Foshan|Dongguan People's Hospital|The First Affiliated Hospital of Guangdong Pharmaceutical University,INTERVENTIONAL
NCT06788964,Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06788964,NOT_YET_RECRUITING,Relapsed or Refractory Large B-cell Lymphoma,DRUG: Loncastuximab Tesirine|DRUG: Rituximab,University of Utah,ADC Therapeutics S.A.,INTERVENTIONAL
NCT04220970,Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry,https://clinicaltrials.gov/study/NCT04220970,RECRUITING,Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL),OTHER: BIA-ALCL,The Lymphoma Academic Research Organisation,,OBSERVATIONAL
NCT01769911,Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01769911,WITHDRAWN,Adult Nasal Type Extranodal NK/T-cell Lymphoma|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I AIDS-related Lymphoma|Stage II AIDS-related Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: carmustine|DRUG: cytarabine|DRUG: melphalan|DRUG: etoposide|DRUG: O6-benzylguanine|PROCEDURE: autologous hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04888741,Methods of T Cell Depletion Trial (MoTD),https://clinicaltrials.gov/study/NCT04888741,RECRUITING,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndromes|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Chronic Myelogenous Leukemia|Myelofibrosis,DRUG: Thymoglobulin|DRUG: Cyclophosphamide|DRUG: Cyclosporine|DRUG: Sirolimus|DRUG: Mycophenolate Mofetil,University of Birmingham,"IMPACT (funded by NHS Blood & Transplant, Anthony Nolan and Leukaemia UK)",INTERVENTIONAL
NCT04684472,Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies,https://clinicaltrials.gov/study/NCT04684472,UNKNOWN,Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Leukemia,BIOLOGICAL: Modified anti-CD19 CAR T cells,Liqun Zou,,INTERVENTIONAL
NCT05702853,"Metabolically Fit CD19 CAR T-cell Therapy with CD34 Selection in Patients with CD19+ Relapsed/Refractory NHL, CLL/SLL",https://clinicaltrials.gov/study/NCT05702853,RECRUITING,B-cell Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia,DRUG: Cyclophosphamide injection|DRUG: Fludarabine Injection|BIOLOGICAL: CD19-CD34t metabolically programmed CAR transduced T-cells,Medical University of South Carolina,,INTERVENTIONAL
NCT06732492,RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies,https://clinicaltrials.gov/study/NCT06732492,RECRUITING,NK T-Cell Lymphoma|CART Therapy|CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies,DRUG: RD13-02 cell infusion,"Wuhan Union Hospital, China","Nanjing Bioheng Biotech Co., Ltd.",INTERVENTIONAL
NCT01744223,Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01744223,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Lymphoma|Myelodysplastic Syndromes,BIOLOGICAL: BPX-501 dose 1|DRUG: Rimiducid|BIOLOGICAL: BPX-501 dose 2|BIOLOGICAL: BPX-501 dose 3|BIOLOGICAL: BPX-501 dose 4|PROCEDURE: SCT,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT04237428,CD19-CART in the Treatment of R/R CD19 Positive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT04237428,UNKNOWN,Non Hodgkin Lymphoma,BIOLOGICAL: CD19 CAR-T cells infusion,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",The First Affiliated Hospital of Zhengzhou University,INTERVENTIONAL
NCT00419081,Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens,https://clinicaltrials.gov/study/NCT00419081,TERMINATED,Leukemia|Lymphoma,"DRUG: Forodesine Hydrochloride Sterile Solution, 5 mg/mL|DRUG: Forodesine Hydrochloride Capsules (100 mg)",BioCryst Pharmaceuticals,,INTERVENTIONAL
NCT05665725,Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05665725,COMPLETED,Non-Hodgkin Lymphoma,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Siltuximab,Timothy Voorhees,,INTERVENTIONAL
NCT02374333,Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy,https://clinicaltrials.gov/study/NCT02374333,COMPLETED,Acute Lymphocytic Leukemia|Diffuse Large Cell Lymphoma,BIOLOGICAL: huCART19,University of Pennsylvania,,INTERVENTIONAL
NCT02976857,A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects,https://clinicaltrials.gov/study/NCT02976857,COMPLETED,Refractory Diffuse Large B-Cell Lymphoma,BIOLOGICAL: C-CAR-011,Shanghai AbelZeta Ltd.,The First Affiliated Hospital with Nanjing Medical University,INTERVENTIONAL
NCT04898985,The Leukemia and Lymphoma Society (LLS) T-cells in Blood Cancer and COVID-19,https://clinicaltrials.gov/study/NCT04898985,SUSPENDED,Covid-19,DIAGNOSTIC_TEST: ImmunoSEQ,"Larry Saltzman, MD",,OBSERVATIONAL
NCT03789617,"A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies",https://clinicaltrials.gov/study/NCT03789617,UNKNOWN,EBV Associated Extranodal NK/T-cell Lymphoma|EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma,BIOLOGICAL: EBViNT Cell,Eutilex,,INTERVENTIONAL
NCT04532203,A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies,https://clinicaltrials.gov/study/NCT04532203,RECRUITING,Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma,DRUG: CAR-T cells|PROCEDURE: Ommaya Reservoir,Zhejiang University,,INTERVENTIONAL
NCT04218825,REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL),https://clinicaltrials.gov/study/NCT04218825,TERMINATED,Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL) (Stage IA-IB),DRUG: chlormethine gel,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT02935257,"Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19",https://clinicaltrials.gov/study/NCT02935257,RECRUITING,"Leukemia, Lymphoblastic, Acute, Lymphoma",BIOLOGICAL: CD19CAT-41BBZ CAR T-cells,"University College, London",,INTERVENTIONAL
NCT06902012,Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma,https://clinicaltrials.gov/study/NCT06902012,RECRUITING,Relapsed/Refractory Diffuse Large B-cell Lymphoma,DRUG: Infusion of Axicabtagene Ciloleucel,Zhujiang Hospital,,INTERVENTIONAL
NCT04532268,A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL,https://clinicaltrials.gov/study/NCT04532268,RECRUITING,"Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma,B Cell",DRUG: Humanized CD19 CAR-T cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT05190653,Early Integration of Palliative and Supportive Care in Cellular Therapy,https://clinicaltrials.gov/study/NCT05190653,RECRUITING,Leukemia|Lymphoma|Multiple Myeloma|Blood Cancer|Stem Cell Transplant Complications|Chimeric Antigen Receptor T-cell Therapy,OTHER: Early palliative and supportive care,"Alberta Health Services, Calgary",Alberta Cancer Foundation|University of Victoria,INTERVENTIONAL
NCT00003545,506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT00003545,COMPLETED,Leukemia|Lymphoma,DRUG: nelarabine,National Cancer Institute (NCI),SWOG Cancer Research Network,INTERVENTIONAL
NCT01386619,NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT),https://clinicaltrials.gov/study/NCT01386619,COMPLETED,"Leukemia, Myeloid, Acute|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndromes|Lymphoma|Neuroblastoma|Rhabdomyosarcoma",BIOLOGICAL: CD3-depleted/CD56+ selected natural killer cells collected from apheresis products,"University Hospital, Basel, Switzerland",,INTERVENTIONAL
NCT04414969,Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04414969,RECRUITING,Immune Checkpoint Inhibitor|Chemotherapy Effect|Epigenetic Disorder|NK/T-cell Lymphoma of Nasal Cavity,DRUG: Anti-PD-1 antibody+Peg-Asparaginase+Chidamide,Hunan Cancer Hospital,,INTERVENTIONAL
NCT03910842,Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy,https://clinicaltrials.gov/study/NCT03910842,UNKNOWN,Non-Hodgkin Lymphoma of Intestine|Leukemia,BIOLOGICAL: CD19-TriCAR-T/SILK,Timmune Biotech Inc.,Hunan Provincial People's Hospital,INTERVENTIONAL
NCT01636388,Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma,https://clinicaltrials.gov/study/NCT01636388,TERMINATED,Hodgkins Lymphoma,BIOLOGICAL: allogeneic donor derived LMP specific cytotoxic T-lymphocyte,New York Medical College,Children's National Research Institute|Baylor College of Medicine|M.D. Anderson Cancer Center|City of Hope Medical Center|Johns Hopkins University|Ohio State University|University of Utah|University of Michigan,INTERVENTIONAL
NCT01026415,Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35),https://clinicaltrials.gov/study/NCT01026415,COMPLETED,"Carcinomas|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Neoplasms",DRUG: brentuximab vedotin|DRUG: rifampin|DRUG: midazolam|DRUG: ketoconazole|DRUG: brentuximab vedotin,Seagen Inc.,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT05800210,Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases,https://clinicaltrials.gov/study/NCT05800210,RECRUITING,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndromes|Chronic Myeloid Leukemia|Lymphoma, Non-Hodgkin|Lymphoma, Hodgkin",DEVICE: Miltenyi CliniMACS Prodigy ® system,University of Florida,Florida Department of Health|Ocala Royal Dames for Cancer Research,INTERVENTIONAL
NCT04892277,CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT04892277,RECRUITING,Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia,BIOLOGICAL: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563|DRUG: Bendamustine|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Fludarabine|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,Mayo Clinic,,INTERVENTIONAL
NCT00058773,Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease,https://clinicaltrials.gov/study/NCT00058773,TERMINATED,Hodgkin Disease|Non-Hodgkins Lymphoma,DRUG: Infusion of EBV Specific Cytotoxic T-Lymphocytes,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT03685786,CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT,https://clinicaltrials.gov/study/NCT03685786,UNKNOWN,"Leukemia, Lymphocytic, Acute, B-Cell|Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, B-Cell",BIOLOGICAL: CART19 cell and auto-HSCT,Shenzhen Second People's Hospital,,INTERVENTIONAL
NCT06561425,A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06561425,RECRUITING,Relapsed/Refractory B-cell Non-Hodgkin Lymphoma|Lymphomas Non-Hodgkin&#39;s B-Cell,GENETIC: GLPG5101,Galapagos NV,,INTERVENTIONAL
NCT01800838,Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01800838,COMPLETED,Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome,DRUG: silicon phthalocyanine 4|DRUG: photodynamic therapy|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,Kevin Cooper MD,National Cancer Institute (NCI),INTERVENTIONAL
NCT04026737,Cardiovascular Effects of CART Cell Therapy,https://clinicaltrials.gov/study/NCT04026737,COMPLETED,"Leukemia|Lymphoma|Cardiotoxicity|Risk Factor, Cardiovascular|Immunotherapy",,Abramson Cancer Center at Penn Medicine,,OBSERVATIONAL
NCT04676087,Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides,https://clinicaltrials.gov/study/NCT04676087,TERMINATED,Mycosis Fungoides|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome,PROCEDURE: Extracorporeal Photopheresis|BIOLOGICAL: Mogamulizumab|OTHER: Quality-of-Life Assessment,Emory University,National Cancer Institute (NCI),INTERVENTIONAL
NCT02701517,Cyclosporine Plus Methotrexate or Alemtuzumab,https://clinicaltrials.gov/study/NCT02701517,TERMINATED,Unrecognized Condition: Mature B or T-cell Neoplasm,DRUG: Cyclosporine + METHOTREXATE|DRUG: Cyclosporine + CAMPATH-1H,Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea,,INTERVENTIONAL
NCT00306332,T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00306332,TERMINATED,"Leukemia, Myeloid|Leukemia, Lymphocytic|Myelodysplastic Syndrome|Leukemia, Myeloid, Chronic|Lymphoma",PROCEDURE: T-cell and B-cell depletion,Radboud University Medical Center,,INTERVENTIONAL
NCT01300026,AMG 319 Lymphoid Malignancy FIH,https://clinicaltrials.gov/study/NCT01300026,COMPLETED,Cancer|Chronic Lymphocytic Leukemia|Diffuse Large Cell Lymphoma|Hematologic Malignancies|Hematology|Leukemia|Low Grade Lymphoma|Lymphoma|Mantle Cell Lymphoma|Non-Hodgkin's Lymphoma|Oncology|Oncology Patients|T Cell Lymphoma|Tumors,DRUG: AMG 319,Amgen,,INTERVENTIONAL
NCT01475058,CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant,https://clinicaltrials.gov/study/NCT01475058,COMPLETED,Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia,BIOLOGICAL: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02194374,Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL),https://clinicaltrials.gov/study/NCT02194374,WITHDRAWN,Leukemia,PROCEDURE: ROR1R-CAR-T Cell Infusion|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Rituximab|DRUG: Bendamustine,M.D. Anderson Cancer Center,CLL Global Research Foundation Alliance,INTERVENTIONAL
NCT03834584,A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma,https://clinicaltrials.gov/study/NCT03834584,TERMINATED,Lymphoma,DRUG: AG-636,"Agios Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT04450069,CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies,https://clinicaltrials.gov/study/NCT04450069,COMPLETED,Relapsed/Refractory B-cell Lymphomas|Diffuse Large B Cell Lymphoma (DLBCL)|Follicular Lymphoma (FL)|Chronic Lymphocytic Leukemia (CLL)|Marginal Zone Lymphoma (MZL)|Mantle Cell Lymphoma|Small Lymphocytic Lymphoma (SLL)|Primary Mediastinal Large B Cell Lymphoma|Transformed Follicular Lymphoma|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Burkitt Lymphoma,COMBINATION_PRODUCT: CLBR001 and SWI019,"Calibr, a division of Scripps Research",,INTERVENTIONAL
NCT02315118,Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies,https://clinicaltrials.gov/study/NCT02315118,UNKNOWN,B-Cell Chronic Lymphocytic Leukemia|Non-Hodgkin's Lymphoma,DRUG: T-cell therapy + Rituximab + IL-2,"National University Hospital, Singapore",National University of Singapore,INTERVENTIONAL
NCT05237245,Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS),https://clinicaltrials.gov/study/NCT05237245,RECRUITING,Lymphoproliferation Induced by HTLV-1|HTLV-1 Adult T-cell Lymphoma / Leukemia|HTLV-1 Infection,,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT01979536,Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT01979536,COMPLETED,"Anaplastic Large Cell Lymphoma, ALK-Positive|Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma",DRUG: Brentuximab Vedotin|DRUG: Crizotinib|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|DRUG: Ifosfamide|DRUG: Methotrexate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05909059,CAR T-cell Therapy in Patients With Renal Dysfunction,https://clinicaltrials.gov/study/NCT05909059,RECRUITING,"Non-hodgkin Lymphoma,B Cell|Multiple Myeloma|Acute Lymphoblastic Leukemia, Adult",DRUG: Fludarabine|DRUG: Cyclophosphamide,"Northside Hospital, Inc.",Blood and Marrow Transplant Group of Georgia,INTERVENTIONAL
NCT01748721,MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT01748721,COMPLETED,"Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",BIOLOGICAL: anti-endosialin/TEM1 monoclonal antibody MORAb-004|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,Morphotek,National Cancer Institute (NCI)|Children's Oncology Group,INTERVENTIONAL
NCT05364424,"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma",https://clinicaltrials.gov/study/NCT05364424,ACTIVE_NOT_RECRUITING,Diffuse Large B-Cell Lymphoma (DLBCL),DRUG: Glofitamab|DRUG: Obinutuzumab|DRUG: Tocilizumab|DRUG: Rituximab|DRUG: Ifosfamide|DRUG: Carboplatin|DRUG: Etoposide,Hoffmann-La Roche,,INTERVENTIONAL
NCT03528421,Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients,https://clinicaltrials.gov/study/NCT03528421,UNKNOWN,Non Hodgkin Lymphoma,BIOLOGICAL: IM19|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Beijing Immunochina Medical Science & Technology Co., Ltd.",Peking University Cancer Hospital & Institute,INTERVENTIONAL
NCT01776411,Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT01776411,COMPLETED,Recurrent or Refractory PTCL,DRUG: forodesine hydrochloride,Mundipharma K.K.,,INTERVENTIONAL
NCT05418088,Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT05418088,RECRUITING,Recurrent Acute Lymphoblastic Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent B-Cell Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent High Grade B-Cell Lymphoma|Recurrent Indolent Non-Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Transformed Chronic Lymphocytic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory B-Cell Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory High Grade B-Cell Lymphoma|Refractory Indolent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Chronic Lymphocytic Leukemia|Refactory Childhood Acute Lymphoblastic Leukemia|Refractory Childhood Non-Hodgkin Lymphoma,BIOLOGICAL: Anti-CD19/CD20/CD22 CAR T-Cells|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|PROCEDURE: Echocardiography|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Biopsy|PROCEDURE: Pheresis|PROCEDURE: Bone Marrow Aspiration and Biopsy|PROCEDURE: Biospecimen Collection,Sumithira Vasu,National Cancer Institute (NCI),INTERVENTIONAL
NCT05576532,Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia,https://clinicaltrials.gov/study/NCT05576532,RECRUITING,"T-lymphoblastic Lymphoma|Relapsed Disease|Refractory Lymphoma|Refractory Leukemia|Safety|Efficacy, Self",DRUG: BCL2 Inhibitor plus IM2 regimen,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT04732845,Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT04732845,SUSPENDED,Non Hodgkin Lymphoma|Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia,BIOLOGICAL: Fully human anti CD19 CAR-T Cell Dose|DRUG: Fludarabine|DRUG: Cyclophosphamide,Benjamin Tomlinson,,INTERVENTIONAL
NCT06393738,A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.,https://clinicaltrials.gov/study/NCT06393738,RECRUITING,Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)|Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL),DRUG: ARV-393,Arvinas Inc.,,INTERVENTIONAL
NCT05576181,Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05576181,NOT_YET_RECRUITING,"Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited",DRUG: ThisCART19A|DRUG: Fludarabine Oral Tablet|DRUG: Cyclophosphamide|DRUG: VP-16|PROCEDURE: HSCT,"Fundamenta Therapeutics, Ltd.",The First Affiliated Hospital of Zhengzhou University,INTERVENTIONAL
NCT03328104,"Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma",https://clinicaltrials.gov/study/NCT03328104,COMPLETED,Lymphoblastic Leukemia|Lymphoblastic Lymphoma,DRUG: Everolimus|DRUG: Nelarabine|DRUG: Cyclophosphamide|DRUG: Etoposide,Emory University,,INTERVENTIONAL
NCT06961669,"Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma",https://clinicaltrials.gov/study/NCT06961669,RECRUITING,Lymphoblastic Leukemia|Relapsed or Refractory Multiple Myeloma (RRMM),DRUG: Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis,Anhui Provincial Hospital,,INTERVENTIONAL
NCT06256484,A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06256484,TERMINATED,Relapsed/Refractory B-cell Non-Hodgkin Lymphoma,DRUG: ATA3219,Atara Biotherapeutics,,INTERVENTIONAL
NCT00710892,CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene,https://clinicaltrials.gov/study/NCT00710892,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma|Myelodysplastic Syndrome|Chronic Myeloid Leukemia,BIOLOGICAL: Allodepleted T Cells,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT05618041,The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies,https://clinicaltrials.gov/study/NCT05618041,COMPLETED,Acute Lymphoblastic Leukemia|Lymphoma|Multiple Myeloma,BIOLOGICAL: CAR-T Autologous T cell injection,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT02548468,Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT02548468,WITHDRAWN,Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Stage IIB Mycosis Fungoides and Sezary Syndrome|Stage IIIA Mycosis Fungoides and Sezary Syndrome|Stage IIIB Mycosis Fungoides and Sezary Syndrome|Stage IVA Mycosis Fungoides and Sezary Syndrome|Stage IVB Mycosis Fungoides and Sezary Syndrome,DRUG: Fludarabine|RADIATION: Total-Body Irradiation|BIOLOGICAL: T Cell-Depleted Donor Lymphocyte Infusion|DRUG: Cyclophosphamide|PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Mycophenolate mofetil|DRUG: Tacrolimus,Sidney Kimmel Cancer Center at Thomas Jefferson University,,INTERVENTIONAL
NCT02797470,Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant,https://clinicaltrials.gov/study/NCT02797470,ACTIVE_NOT_RECRUITING,HIV Infection|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Plasmablastic Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Follicular Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Carmustine|DRUG: Cytarabine|DRUG: Etoposide|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|DRUG: Melphalan|PROCEDURE: Peripheral Blood Stem Cell Transplantation,AIDS Malignancy Consortium,National Cancer Institute (NCI)|California Institute for Regenerative Medicine (CIRM),INTERVENTIONAL
NCT02961816,Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,https://clinicaltrials.gov/study/NCT02961816,WITHDRAWN,Lymphoma,DRUG: Palifermin|DRUG: Panobinostat|DRUG: Gemcitabine|DRUG: Busulfan|DRUG: Melphalan|DRUG: Rituximab|DRUG: Dexamethasone|DRUG: Caphosol|DRUG: Glutamine|OTHER: Oral Cryotherapy (ice chips)|DRUG: Pyridoxine|BIOLOGICAL: Stem Cell Infusion|DRUG: G-CSF,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT01865617,"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",https://clinicaltrials.gov/study/NCT01865617,COMPLETED,CD19-Positive Neoplastic Cells Present|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma,BIOLOGICAL: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT06393335,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research,https://clinicaltrials.gov/study/NCT06393335,RECRUITING,Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma,DRUG: Metabolically Armed CD19 CAR-T cells,The Children's Hospital of Zhejiang University School of Medicine,"Leman Biotech Co., Ltd.",INTERVENTIONAL
NCT01658319,Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01658319,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Chronic Lymphocytic Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: fludarabine phosphate|DRUG: methoxyamine|OTHER: laboratory biomarker analysis|OTHER: pharmacological study|GENETIC: western blotting|OTHER: mass spectrometry|GENETIC: DNA analysis,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05963217,"Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL",https://clinicaltrials.gov/study/NCT05963217,RECRUITING,Relapsed or Refractory CD19+ B-cell Lymphoma|Relapsed or Refractory Chronic Lymphocytic Leukemia|Relapsed or Refractory Small Lymphocytic Lymphoma,BIOLOGICAL: TBI-2001|DRUG: Cyclophosphamide|DRUG: Fludarabine,"University Health Network, Toronto",Takara Bio Inc.,INTERVENTIONAL
NCT02690545,Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL,https://clinicaltrials.gov/study/NCT02690545,RECRUITING,"Lymphoma|Lymphoma, Non-Hodgkin|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases|Lymphoproliferative Disorders|Neoplasms|Neoplasms by Histologic Type",BIOLOGICAL: ATLCAR.CD30 cells,UNC Lineberger Comprehensive Cancer Center,,INTERVENTIONAL
NCT02848274,ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome,https://clinicaltrials.gov/study/NCT02848274,RECRUITING,Mycosis Fungoides|Non-Hodgkin's Lymphoma,,Stanford University,,OBSERVATIONAL
NCT03833180,A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001),https://clinicaltrials.gov/study/NCT03833180,COMPLETED,Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|Richter Transformation Lymphoma|Burkitt Lymphoma|Lymphoplasmacytoid Lymphoma|T-cell Non-Hodgkin Lymphoma|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Waldenstrom Macroglobulinemia,DRUG: Zilovertamab vedotin,"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",,INTERVENTIONAL
NCT02991898,Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies,https://clinicaltrials.gov/study/NCT02991898,TERMINATED,Acute Lymphoblastic Leukemia|Burkitt Lymphoma|Natural Killer Cell Malignancies|Chronic Myelogenous Leukemia|Myelodysplastic Syndromes|Large-cell Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone B-Cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-Cell Lymphoma|Prolymphocytic Leukemia|Hodgkin Lymphoma|Multiple Myeloma|Acute Myelogenous Leukemia|Biphenotypic Leukemia|Undifferentiated Leukemia,BIOLOGICAL: Infusion of Treg,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT05583149,Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas,https://clinicaltrials.gov/study/NCT05583149,RECRUITING,"Refractory Aggressive B-cell Lymphomas|Refractory B-Cell Non-Hodgkin Lymphoma|Aggressive B-cell NHL|Diffuse Large B-cell Lymphoma (DLBCL)|De Novo or Transformed Indolent B-cell Lymphoma|DLBCL, Nos Genetic Subtypes|T Cell/Histiocyte-rich Large B-cell Lymphoma|EBV-Positive DLBCL, Nos|Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)|High-Grade B-Cell Lymphoma, Nos|C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma|Grade 3b Follicular Lymphoma|C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma",DRUG: ACALABRUTINIB|DRUG: LISOCABTAGENE MARALEUCEL|DRUG: Lymphodepleting chemotherapy,"Patrick C. Johnson, MD",AstraZeneca,INTERVENTIONAL
NCT05106946,Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma,https://clinicaltrials.gov/study/NCT05106946,UNKNOWN,B-cell Malignancy,BIOLOGICAL: ThisCART22 cells,"Fundamenta Therapeutics, Ltd.",The Affiliated Hospital of Xuzhou Medical University,INTERVENTIONAL
NCT05106907,Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma,https://clinicaltrials.gov/study/NCT05106907,UNKNOWN,B-cell Malignancy,BIOLOGICAL: ThisCART19 cells,"Fundamenta Therapeutics, Ltd.",The Affiliated Hospital of Xuzhou Medical University,INTERVENTIONAL
NCT01498484,Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,https://clinicaltrials.gov/study/NCT01498484,COMPLETED,EBV-induced Lymphomas|EBV-associated Malignancies|Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma,BIOLOGICAL: EBV-specific T cells (EBV-CTLs),Atara Biotherapeutics,Memorial Sloan Kettering Cancer Center,INTERVENTIONAL
NCT03228836,Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients,https://clinicaltrials.gov/study/NCT03228836,COMPLETED,Effect of Drugs,DRUG: Sintilimab,Innovent Biologics (Suzhou) Co. Ltd.,,INTERVENTIONAL
NCT06277011,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research,https://clinicaltrials.gov/study/NCT06277011,RECRUITING,Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma,DRUG: Metabolically Armed CD19 CAR-T cells,Anhui Provincial Hospital,"Leman Biotech Co., Ltd.",INTERVENTIONAL
NCT00005985,Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00005985,COMPLETED,Lymphoma,BIOLOGICAL: filgrastim|DRUG: carmustine|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: dexamethasone|DRUG: etoposide|DRUG: mitoxantrone hydrochloride|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT05878184,Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT),https://clinicaltrials.gov/study/NCT05878184,ACTIVE_NOT_RECRUITING,Non Hodgkin Lymphoma|Chronic Lymphocytic Leukemia,DRUG: SC291,Sana Biotechnology,,INTERVENTIONAL
NCT06830031,Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06830031,NOT_YET_RECRUITING,"Diffuse Large B-cell-lymphoma|DLBCL, Nos Genetic Subtypes|Follicular Lymphoma Grade 3B|PMBL|HGBL With MYC and BCL2 and/or BCL6 Rearrangements|HGBL, Nos",BIOLOGICAL: C402-CD19-CAR,Shanghai Exuma Biotechnology Ltd.,"Institute of Hematology & Blood Diseases Hospital, China",INTERVENTIONAL
NCT00882011,"Observational Controlled Clinical Trials, on Adult Patients With T-lymphoblastic Lymphoma Treated With Intensive Chemo/Radiotherapy or Intensive Chemotherapy Followed by Transplant. Evaluation of Clinical, Anatomy -Pathological Parameters",https://clinicaltrials.gov/study/NCT00882011,UNKNOWN,Lymphoblastic Lymphoma,OTHER: Latest generation chemotherapies for T-LBL + transplant,Fondazione Italiana Linfomi - ETS,,OBSERVATIONAL
NCT05694364,Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies,https://clinicaltrials.gov/study/NCT05694364,ACTIVE_NOT_RECRUITING,Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Acute Lymphoblastic Leukemia|Diffuse Large B Cell Lymphoma|Triple Negative Breast Cancer Malignancies,DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: PRGN-3007,H. Lee Moffitt Cancer Center and Research Institute,"Precigen, Inc",INTERVENTIONAL
NCT01435720,"Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)",https://clinicaltrials.gov/study/NCT01435720,UNKNOWN,Multiple Myeloma|Multiple Myeloma in Relapse|Mantle Cell Lymphoma in Relapse|Diffuse Large B Cell Lymphoma in Relapse|Other B Cell Lymphoma in Relapse|Plasma Cell Leukemia,BIOLOGICAL: SNS01-T|BIOLOGICAL: SNS01-T|BIOLOGICAL: SNS01-T|BIOLOGICAL: SNS01-T,"Senesco Technologies, Inc.",,INTERVENTIONAL
NCT03674411,Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy,https://clinicaltrials.gov/study/NCT03674411,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Biphenotypic/Undifferentiated Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia|Relapsed Large Cell Lymphoma|Mantle Cell Lymphoma|Hodgkin Lymphoma|Burkitt Lymphoma|Relapsed T-Cell Lymphoma|Lymphoplasmacytic Lymphoma,DRUG: Fludarabine (FLU)|DRUG: Cyclophosphamide (CY)|DRUG: Total Body Irradiation (TBI)|DRUG: Tacrolimus (Tac)|DRUG: Mycophenolate Mofetil (MMF)|DRUG: Granulocyte Colony-Stimulating Factor (G-CSF)|DRUG: Busulfan (BU)|DRUG: Melphalan|DRUG: MGTA 456 Infusion,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT03754764,A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy,https://clinicaltrials.gov/study/NCT03754764,UNKNOWN,Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI,BIOLOGICAL: Specificity CD38 CAR-T Cells,Chinese PLA General Hospital,,INTERVENTIONAL
NCT00082888,Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma,https://clinicaltrials.gov/study/NCT00082888,COMPLETED,Anaplastic Large Cell Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma,OTHER: Laboratory Biomarker Analysis|DRUG: Tipifarnib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01864889,Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19,https://clinicaltrials.gov/study/NCT01864889,UNKNOWN,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,BIOLOGICAL: anti-CD19-CAR vector-transduced T cells,Chinese PLA General Hospital,,INTERVENTIONAL
NCT00871702,Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease,https://clinicaltrials.gov/study/NCT00871702,COMPLETED,"Leukemia|Lymphoma, Non-Hodgkin|Hodgkin Disease|Myelodysplastic Syndromes|Multiple Myeloma",GENETIC: CD34-TK75 transduced donor lymphocytes|RADIATION: Sub Study - 18 FHBG PET/CT Scans,Washington University School of Medicine,,INTERVENTIONAL
NCT00054171,Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00054171,COMPLETED,Leukemia|Lymphoma,DRUG: aminolevulinic acid hydrochloride,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT03110640,Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma,https://clinicaltrials.gov/study/NCT03110640,UNKNOWN,B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Hematopoietic/Lymphoid Cancer|Refractory Chronic Lymphocytic Leukemia,BIOLOGICAL: anti-CD19 CAR-T|DRUG: Fludarabine|DRUG: Cyclophosphamide,First Affiliated Hospital of Wenzhou Medical University,"Hrain Biotechnology Co., Ltd.|Second Affiliated Hospital of Nanchang University",INTERVENTIONAL
NCT01110135,"Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma",https://clinicaltrials.gov/study/NCT01110135,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,DRUG: bendamustine hydrochloride|DRUG: dexamethasone|BIOLOGICAL: filgrastim|PROCEDURE: leukapheresis|OTHER: laboratory biomarker analysis|OTHER: flow cytometry|DRUG: etoposide,University of Washington,National Cancer Institute (NCI),INTERVENTIONAL
NCT03703050,"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)",https://clinicaltrials.gov/study/NCT03703050,ACTIVE_NOT_RECRUITING,Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma,DRUG: Nivolumab cohort 1|DRUG: Nivolumab cohort 2,"Gustave Roussy, Cancer Campus, Grand Paris",,INTERVENTIONAL
NCT01230983,Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT01230983,COMPLETED,Cardiac Toxicity|Leukemia|Lymphoma,DRUG: asparaginase|DRUG: cytarabine|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: leucovorin calcium|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: prednisone|DRUG: therapeutic hydrocortisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT03207178,Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT03207178,UNKNOWN,Recurrent or Refractory B Cell Malignancy,BIOLOGICAL: Mixed CD19/CD20 CAR-T Transfer,"Shanghai Longyao Biotechnology Inc., Ltd.",Xuzhou Medical University|Shanghai Jiao Tong University School of Medicine,INTERVENTIONAL
NCT00043368,PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909),https://clinicaltrials.gov/study/NCT00043368,COMPLETED,"Melanoma|Breast Neoplasms|Carcinoma, Renal Cell|Lymphoma, T-Cell|Carcinoma, Non-Small-Cell Lung",DRUG: PF-3512676,Pfizer,,INTERVENTIONAL
NCT05779930,Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL,https://clinicaltrials.gov/study/NCT05779930,NOT_YET_RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory|Acute Lymphoblastic Leukemia With Failed Remission|B-cell Non Hodgkin Lymphoma|B Cell Leukemia",BIOLOGICAL: CD19 specific Chimeric Antigen Receptor T Cell,Nationwide Children's Hospital,,INTERVENTIONAL
NCT02705508,"PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma",https://clinicaltrials.gov/study/NCT02705508,UNKNOWN,Treatment Refusal,DRUG: Gemcitabine|DRUG: etoposide|DRUG: Pegaspargase|RADIATION: involved-field radiotherapy,Sun Yat-sen University,China Food and Drug Administration,INTERVENTIONAL
NCT05513612,Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT05513612,WITHDRAWN,"Acute Myeloid Leukemia (AML)|B-cell Non-Hodgkin's Lymphoma (B-NHL)|Multiple Myeloma (MM)|T-Cell Leukemia/Lymphoma, Adult|B-cell Acute Lymphoblastic Leukemia (B-ALL)",BIOLOGICAL: Autologous CAR-T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,Shanghai Pudong Hospital,UTC Therapeutics Inc.,INTERVENTIONAL
NCT04844866,Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients,https://clinicaltrials.gov/study/NCT04844866,ACTIVE_NOT_RECRUITING,Diffuse Large B-cell Lymphoma,GENETIC: MB-CART2019.1|DRUG: R-GemOx or BR plus polatuzumab vedotin,Miltenyi Biomedicine GmbH,ICON plc,INTERVENTIONAL
NCT02772198,T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies,https://clinicaltrials.gov/study/NCT02772198,UNKNOWN,"Acute Lymphoblastic Leukemia, B-precursor|Non-Hodgkin Lymphoma, B-cell",BIOLOGICAL: CD19 CAR T cells,Sheba Medical Center,,INTERVENTIONAL
NCT05424822,"A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",https://clinicaltrials.gov/study/NCT05424822,RECRUITING,"Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, Chronic, B-Cell",DRUG: JNJ-80948543,"Janssen Research & Development, LLC",,INTERVENTIONAL
NCT04989803,Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04989803,RECRUITING,Relapsed and/or Refractory B-cell Lymphoma,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: KITE-363|BIOLOGICAL: KITE-753,"Kite, A Gilead Company",,INTERVENTIONAL
NCT05660967,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05660967,RECRUITING,Diffuse Large B-Cell Lymphoma,BIOLOGICAL: Epcoritamab|DRUG: Lenalidomide,Genmab,AbbVie,INTERVENTIONAL
NCT03704714,Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT03704714,SUSPENDED,Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma,DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|BIOLOGICAL: Nivolumab|DRUG: Prednisone|OTHER: Quality-of-Life Assessment|BIOLOGICAL: Rituximab|DRUG: Vincristine Sulfate,Northwestern University,Bristol-Myers Squibb|National Cancer Institute (NCI),INTERVENTIONAL
NCT00368784,T Cell Repertoire Analysis of Immune Mediated Skin Diseases,https://clinicaltrials.gov/study/NCT00368784,COMPLETED,Psoriasis|Mycosis Fungoides,,"University of California, Davis",,OBSERVATIONAL
NCT06381817,Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients,https://clinicaltrials.gov/study/NCT06381817,RECRUITING,Acute T Cell Lymphoblastic Leukemia|Haploidentical Hematopoietic Stem Cell Transplantation|Cord Blood,BIOLOGICAL: Haplo-cord HCT|BIOLOGICAL: Haplo-HCT,The First Affiliated Hospital of Soochow University,"Children's Hospital of Soochow University|Ruijin Hospital|Nanfang Hospital, Southern Medical University|Fujian Medical University Union Hospital|First Affiliated Hospital Xi'an Jiaotong University|Wuhan Union Hospital, China|Zhejiang University",INTERVENTIONAL
NCT06528301,A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies,https://clinicaltrials.gov/study/NCT06528301,RECRUITING,"Lymphoma, B-Cell|Lymphoma, Non-Hodgkin (NHL)|Lymphoma, Large B-Cell, Diffuse (DLBCL)|Chronic Lymphocytic Leukemia (CLL)",GENETIC: UB-VV111|DRUG: rapamycin,Umoja Biopharma,,INTERVENTIONAL
NCT03035331,"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT03035331,COMPLETED,Aggressive Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma,PROCEDURE: Cryosurgery|BIOLOGICAL: Dendritic Cell Therapy|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Pneumococcal 13-valent Conjugate Vaccine|OTHER: Quality-of-Life Assessment,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT05254899,Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL,https://clinicaltrials.gov/study/NCT05254899,UNKNOWN,"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type|Early-stage|High-Risk Cancer",DRUG: Anti-PD-1 monoclonal antibody|DRUG: Pegaspargase|DRUG: Gemcitabine|DRUG: Oxaliplatin|RADIATION: Involved site radiotherapy,Chinese Academy of Medical Sciences,Peking University Cancer Hospital & Institute|The Affiliated Hospital Of Guizhou Medical University|The First Hospital of Jilin University,INTERVENTIONAL
NCT03984968,CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03984968,RECRUITING,"Acute Lymphoblastic Leukemia, Adult B-Cell",BIOLOGICAL: ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|BIOLOGICAL: ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|BIOLOGICAL: ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion|BIOLOGICAL: ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT02978625,Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,https://clinicaltrials.gov/study/NCT02978625,ACTIVE_NOT_RECRUITING,"Anaplastic Large Cell Lymphoma, ALK-Negative|Anaplastic Large Cell Lymphoma, ALK-Positive|Apocrine Carcinoma|Carcinoma Arising From Cylindroma|Carcinoma Arising From Spiradenoma|Digital Papillary Adenocarcinoma|Endocrine Mucin-Producing Sweat Gland Carcinoma|Extramammary Paget Disease|Extraocular Sebaceous Carcinoma|Hidradenocarcinoma|Malignant Sweat Gland Neoplasm|Merkel Cell Carcinoma|Microcystic Adnexal Carcinoma|NK-Cell Lymphoma, Unclassifiable|Papillary Adenocarcinoma|Porocarcinoma|Primary Cutaneous Mucinous Carcinoma|Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Merkel Cell Carcinoma|Refractory Mycosis Fungoides|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Skin Squamous Cell Carcinoma|Refractory T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|Signet Ring Cell Adenocarcinoma|Skin Adenoid Cystic Carcinoma|Skin Adnexal Carcinoma|Skin Basal Cell Carcinoma|Skin Basosquamous Cell Carcinoma|Skin Keratoacanthoma|Skin Squamous Cell Carcinoma|Squamoid Eccrine Ductal Carcinoma|Squamous Cell Carcinoma of Unknown Primary|Sweat Gland Carcinoma|Trichilemmal Carcinoma|Vulvar Squamous Cell Carcinoma",PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Mammography|BIOLOGICAL: Talimogene Laherparepvec,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06564038,A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies,https://clinicaltrials.gov/study/NCT06564038,RECRUITING,Chronic Lymphocytic Leukaemia|Small Lymphocytic Leukaemia|Mantle-cell Lymphoma|Large B-cell Lymphoma|B-cell Non-Hodgkin Lymphoma,DRUG: AZD0486|DRUG: Acalabrutinib|DRUG: Prednisone|DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Doxorubicin,AstraZeneca,,INTERVENTIONAL
NCT03198234,Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders,https://clinicaltrials.gov/study/NCT03198234,TERMINATED,AML - Acute Myeloid Leukemia|MDS (Myelodysplastic Syndrome)|Mixed Phenotype Acute Leukemia|NHL - Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|ALL,BIOLOGICAL: T-allo10,"Roncarolo, Maria Grazia, MD",National Cancer Institute (NCI),INTERVENTIONAL
NCT03849651,"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",https://clinicaltrials.gov/study/NCT03849651,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myelodysplastic Syndromes (MDS)|NK-Cell Leukemia|Hodgkin Lymphoma|Non Hodgkin Lymphoma (NHL)|Juvenile Myelomonocytic Leukemia (JMML)|Chronic Myeloid Leukemia (CML),DRUG: Cyclophosphamide|BIOLOGICAL: Fludarabine|DRUG: Thiotepa|DRUG: Melphalan|BIOLOGICAL: G-csf|DRUG: Mesna|DEVICE: CliniMACS|BIOLOGICAL: ATG (rabbit)|DRUG: Blinatumomab|BIOLOGICAL: TCRα/β+|BIOLOGICAL: CD19+|BIOLOGICAL: CD45RA-depleted DLI,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT01738594,Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT01738594,TERMINATED,Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome,DRUG: carfilzomib|DRUG: romidepsin|OTHER: laboratory biomarker analysis,Northwestern University,Amgen,INTERVENTIONAL
NCT00918333,"Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT00918333,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|Waldenström Macroglobulinemia,DRUG: panobinostat|DRUG: everolimus|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT00641381,"Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma",https://clinicaltrials.gov/study/NCT00641381,ACTIVE_NOT_RECRUITING,Lymphoma,DRUG: carmustine|DRUG: cyclophosphamide|DRUG: etoposide|OTHER: pharmacological study|PROCEDURE: autologous hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01556035,Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma,https://clinicaltrials.gov/study/NCT01556035,COMPLETED,Refractory Primary-cutaneous Large B-cell Lymphoma (Leg-type),DRUG: Lenalidomide,"University Hospital, Bordeaux",,INTERVENTIONAL
NCT06326463,CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies,https://clinicaltrials.gov/study/NCT06326463,RECRUITING,"Hematologic Malignancy|ALL, Childhood|AML, Childhood|Lymphoma|MDS",DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: CD70-CAR T cell infusion (Autologous)|DRUG: Mesna,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT01676805,Tissue Collection for Studies of Lymph Cancer,https://clinicaltrials.gov/study/NCT01676805,RECRUITING,"Hodgkin Disease|Lymphoma, Non-Hodgkin|Multiple Myeloma|Lymphomatoid Granulomatosis|Leukemia-Lymphoma, Adult T-Cell",,National Cancer Institute (NCI),,OBSERVATIONAL
NCT05476770,Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05476770,RECRUITING,"Hematologic Malignancy|AML|ALL|BPDCN|MDS|Lymphoblastic Lymphoma|Lymphoma, B-Cell|Lymphoma, T-Cell|Hodgkin Lymphoma|Mixed Phenotype Acute Leukemia|Acute Undifferentiated Leukemia",DRUG: Tagraxofusp|DRUG: Fludarabine|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Vincristine|DRUG: Azacitidine|DRUG: Methotrexate|DRUG: Cytarabine IT|DRUG: Hydrocortisone,Therapeutic Advances in Childhood Leukemia Consortium,,INTERVENTIONAL
NCT00333190,CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00333190,COMPLETED,Hematologic Malignancy|AML|ALL|CML|Multiple Myeloma|NHL|Hodgkin's Lymphoma,DEVICE: CD+8 T cell depletion,Dana-Farber Cancer Institute,Brigham and Women's Hospital,INTERVENTIONAL
NCT05105867,CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies,https://clinicaltrials.gov/study/NCT05105867,UNKNOWN,Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|Relapsed or Refractory B-cell Non-hodgkin Lymphoma,BIOLOGICAL: Anti-CD19 Universal CAR-T Cells injection,920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,"Gracell Biotechnologies (Shanghai) Co., Ltd.|Kunming Hope of Health Hospital",INTERVENTIONAL
NCT04204161,A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma,https://clinicaltrials.gov/study/NCT04204161,UNKNOWN,"Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood|Refractory B-cell Acute Lymphoblastic Leukemia, Childhood|Relapsed/Refractory B-cell Lymphoma, Childhood",BIOLOGICAL: CAR-T19/CAR-T22,Shenzhen BinDeBio Ltd.,Xiangya Hospital of Central South University,INTERVENTIONAL
NCT00640796,"Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors",https://clinicaltrials.gov/study/NCT00640796,COMPLETED,"Leukemia, Myeloid, Acute|Leukemia, Lymphocytic, Acute, T-Cell|Juvenile Myelomonocytic Leukemia Lymphoblastic|T-cell Lymphoblastic Lymphoma|Myelodysplastic Syndrome",PROCEDURE: Haploidentical donor derived natural killer cell infusion|DRUG: Chemotherapy|DEVICE: CliniMACS,St. Jude Children's Research Hospital,National Cancer Institute (NCI)|Assisi Foundation,INTERVENTIONAL
NCT04628494,A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL,https://clinicaltrials.gov/study/NCT04628494,ACTIVE_NOT_RECRUITING,Diffuse Large B-cell Lymphoma,BIOLOGICAL: Epcoritamab|DRUG: Investigator's Choice Chemotherapy,Genmab,AbbVie,INTERVENTIONAL
NCT02682667,Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols,https://clinicaltrials.gov/study/NCT02682667,RECRUITING,"Multiple Myeloma|Lymphoma, Non-Hodgkin|Leukemia-Lymphoma, Adult T-Cell|Hodgkin Disease|Non-Small Cell Lung Cancer",,National Cancer Institute (NCI),,OBSERVATIONAL
NCT01735604,Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy,https://clinicaltrials.gov/study/NCT01735604,UNKNOWN,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,BIOLOGICAL: anti-CD20-CAR vector-transduced autologous T cells|OTHER: genetically engineered lymphocyte therapy,Chinese PLA General Hospital,,INTERVENTIONAL
NCT03380026,Mechlorethamine Induced Contact Dermatitis Avoidance Study,https://clinicaltrials.gov/study/NCT03380026,COMPLETED,Cutaneous T-cell Lymphoma|Cutaneous T-cell Lymphoma Stage I|Mycosis Fungoides|Folliculotropic Mycosis Fungoides|Granulomatous Slack Skin|Syringotropic Mycosis Fungoides|Mycosis Fungoides Variant|Transformed Mycosis Fungoides,DRUG: Triamcinolone|DRUG: Valchlor 0.016 % Topical Gel,"Rochester Skin Lymphoma Medical Group, PLLC",Rochester General Hospital,INTERVENTIONAL
NCT04930653,Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT04930653,RECRUITING,Folliculotropic Mycosis Fungoides|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Transformed Mycosis Fungoides,PROCEDURE: Extracorporeal Photopheresis|BIOLOGICAL: Mogamulizumab|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03103971,huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03103971,TERMINATED,"Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory Adult Acute Lymphoblastic Leukemia|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent Transformed Non-Hodgkin Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory B Acute Lymphoblastic Leukemia|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",BIOLOGICAL: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|DRUG: Cyclophosphamide|DRUG: Fludarabine|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Leukapheresis|OTHER: Pharmacological Study,Fred Hutchinson Cancer Center,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",INTERVENTIONAL
NCT00199082,"Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults",https://clinicaltrials.gov/study/NCT00199082,COMPLETED,Burkitt's Lymphoma|Burkitt's Leukemia|Mediastinal Neoplasms|Lymphoblastic Lymphoma|Large Cell Anaplastic Lymphoma,DRUG: Adriamycin|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone/Prednisolone|DRUG: VP16|DRUG: Ifosfamide|DRUG: Methotrexate|DRUG: G-CSF|DRUG: Rituximab|DRUG: Vincristine/Vindesine|PROCEDURE: Irradiation (in specific conditions),Nicola Goekbuget,,INTERVENTIONAL
NCT03423706,Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT03423706,UNKNOWN,CD19-chimeric Antigen Receptor T Cells|Relapsed and/or Refractory Acute Lymphoblastic Leukemia|the Haploidentical Hematopoietic Stem Cell Transplantation,PROCEDURE: the new model of haplo-HSCT for r/r B-ALL,First Affiliated Hospital of Harbin Medical University,,INTERVENTIONAL
NCT02315612,Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies,https://clinicaltrials.gov/study/NCT02315612,COMPLETED,NHL|Large Cell Lymphoma|Follicular Lymphoma|ALL|B-All|B-precursor ALL|Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia|B-Non Hodgkin Lymphoma|B-NHL,BIOLOGICAL: CD22-CAR,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02392039,Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma,https://clinicaltrials.gov/study/NCT02392039,TERMINATED,Lymphoma,DRUG: Pegfilgrastim|DRUG: Loratadine|OTHER: Placebo|BEHAVIORAL: Questionnaires,M.D. Anderson Cancer Center,Amgen,INTERVENTIONAL
NCT04260009,"Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors",https://clinicaltrials.gov/study/NCT04260009,WITHDRAWN,Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma|Inflammatory Myofibroblastic Tumors|Solid Tumors,DRUG: Brigatinib|DRUG: Brigatinib AAF,Takeda,,INTERVENTIONAL
NCT04763083,First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies,https://clinicaltrials.gov/study/NCT04763083,RECRUITING,Chronic Lymphocytic Leukaemia|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma|Non-small Cell Lung Cancer (NSCLC)|Malignant Melanoma,DRUG: NVG-111,NovalGen Ltd.,,INTERVENTIONAL
NCT01164709,Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer,https://clinicaltrials.gov/study/NCT01164709,COMPLETED,Leukemia|Lymphoma|Mature T-cell and Nk-cell Neoplasms|Multiple Myeloma and Plasma Cell Neoplasm,DRUG: bortezomib|DRUG: nelfinavir mesylate,Swiss Group for Clinical Cancer Research,,INTERVENTIONAL
NCT06209671,INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06209671,NOT_YET_RECRUITING,"Leukemia, B-cell",BIOLOGICAL: INS19 CAR-T Cells,"Beijing Immunochina Medical Science & Technology Co., Ltd.",Peking University People's Hospital,INTERVENTIONAL
NCT01523223,Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies,https://clinicaltrials.gov/study/NCT01523223,COMPLETED,Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,BIOLOGICAL: therapeutic allogeneic lymphocytes,Robert Lowsky,National Cancer Institute (NCI),INTERVENTIONAL
NCT01326702,"Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",https://clinicaltrials.gov/study/NCT01326702,COMPLETED,Adult B Acute Lymphoblastic Leukemia|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult Solid Neoplasm|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Plasma Cell Myeloma|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,DRUG: Bendamustine Hydrochloride|OTHER: Pharmacological Study|BIOLOGICAL: Rituximab|DRUG: Veliparib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03061188,Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma,https://clinicaltrials.gov/study/NCT03061188,COMPLETED,Advanced Solid Neoplasm|Aggressive Non-Hodgkin Lymphoma|Recurrent Solid Neoplasm|Refractory Mantle Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma|Unresectable Solid Neoplasm,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|OTHER: Pharmacological Study|DRUG: Veliparib,Northwestern University,Bristol-Myers Squibb|AbbVie|National Cancer Institute (NCI),INTERVENTIONAL
NCT03946878,Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT03946878,ACTIVE_NOT_RECRUITING,Blastoid Variant Mantle Cell Lymphoma|CCND1 Protein Overexpression|CD20 Positive|CD5 Positive|FCER2 Negative|Pleomorphic Variant Mantle Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Mantle Cell Lymphoma|t(11;14)(q13;q32),DRUG: Acalabrutinib|DRUG: Venetoclax,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00052377,Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00052377,TERMINATED,Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome,BIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interleukin-12|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05832125,Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05832125,UNKNOWN,Relapsed/Refractory Acute Lymphoblastic Leukemia|T-cell Acute Lymphoblastic Leukemia,,Versailles Hospital,,OBSERVATIONAL
NCT00003196,"Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma",https://clinicaltrials.gov/study/NCT00003196,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: chemotherapy|RADIATION: total-body irradiation|PROCEDURE: peripheral blood stem cell transplantation|DRUG: cyclosporine|DRUG: mycophenolate mofetil|PROCEDURE: allogeneic hematopoietic stem cell transplantation|BIOLOGICAL: therapeutic allogeneic lymphocytes,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",INTERVENTIONAL
NCT04268706,Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT),https://clinicaltrials.gov/study/NCT04268706,ACTIVE_NOT_RECRUITING,"Hodgkin Lymphoma, Adult|Hodgkin Disease Recurrent|Hodgkin Disease Refractory|Hodgkin Disease, Pediatric",DRUG: CD30.CAR-T|DRUG: Fludarabine|DRUG: Bendamustine,Tessa Therapeutics,,INTERVENTIONAL
NCT00594308,In-Vivo Activated T-Cell Depletion to Prevent GVHD,https://clinicaltrials.gov/study/NCT00594308,TERMINATED,"Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Lymphoma, Non-Hodgkin's|Mantle-Cell Lymphoma|Hodgkin's Disease|Multiple Myeloma|Myelofibrosis",DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Cyclosporine|DRUG: Mycophenolate mofetil|DRUG: Basiliximab,Indiana University,,INTERVENTIONAL
NCT04104776,A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas,https://clinicaltrials.gov/study/NCT04104776,RECRUITING,"Advanced Solid Tumor|Diffuse Large B Cell Lymphoma|Lymphoma, T-Cell|Mesothelioma, Malignant|Prostatic Neoplasms, Castration-Resistant|Endometrial Cancer|Ovarian Clear Cell Carcinoma|Metastatic Castration-resistant Prostate Cancer",DRUG: Tulmimetostat|DRUG: Enzalutamide,Novartis Pharmaceuticals,,INTERVENTIONAL
NCT02757248,Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL,https://clinicaltrials.gov/study/NCT02757248,WITHDRAWN,PTCL|CTCL,DRUG: Volasertib|DRUG: Romidepsin,"Anne Beaven, MD",National Comprehensive Cancer Network|Boehringer Ingelheim,INTERVENTIONAL
NCT00004241,"17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma",https://clinicaltrials.gov/study/NCT00004241,COMPLETED,"AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Chondrosarcoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Metastatic Osteosarcoma|Nodal Marginal Zone B-cell Lymphoma|Ovarian Sarcoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Osteosarcoma|Recurrent Small Lymphocytic Lymphoma|Recurrent Uterine Sarcoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult Soft Tissue Sarcoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Stage IV Uterine Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: tanespimycin|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02475707,Administration of Donor MultiTAA-Specific T Cells for ALL,https://clinicaltrials.gov/study/NCT02475707,COMPLETED,"Leukemia, Lymphoblastic (Acute)",BIOLOGICAL: MultiTAA-specific T cells,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",INTERVENTIONAL
NCT00006383,Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00006383,COMPLETED,Lymphoma,DRUG: liposomal vincristine sulfate,Inex Pharmaceuticals,,INTERVENTIONAL
NCT00038857,Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases,https://clinicaltrials.gov/study/NCT00038857,COMPLETED,Leukemia|Lymphoma,PROCEDURE: Megadose of CD34 Selected Progenitor Cells|DRUG: Melphalan|DRUG: Thiotepa|DRUG: Fludarabine|DRUG: Rabbit ATG,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT04099966,AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion,https://clinicaltrials.gov/study/NCT04099966,RECRUITING,Acute Leukemia|Severe Aplastic Anemia|Non-hodgkin Lymphoma|Hodgkin Lymphoma|Kostmann|Diamond Blackfan Anemia|Amegakaryocytic Thrombocytopenia|Sickle Cell Disease|Beta-Thalassemia,DRUG: alpha beta depletion,Mitchell Cairo,,INTERVENTIONAL
NCT04118868,Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.,https://clinicaltrials.gov/study/NCT04118868,UNKNOWN,Mycosis Fungoides,COMBINATION_PRODUCT: Pembrolizumab administered using the Sofusa® DoseConnect™,"Sorrento Therapeutics, Inc.",,INTERVENTIONAL
NCT01447056,Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases,https://clinicaltrials.gov/study/NCT01447056,COMPLETED,Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Lymphoproliferative Disorder|Nasopharyngeal Carcinoma|Leiomyosarcoma|Severe Chronic Active EBV (SCAEBV),BIOLOGICAL: LMP specific T cells,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT01236586,"RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia",https://clinicaltrials.gov/study/NCT01236586,WITHDRAWN,Lymphoma|Brain Neoplasms|Sarcoma|Osteosarcoma|Wilm's Tumor,DRUG: RO4929097|DRUG: Dexamethasone,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04416984,"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)",https://clinicaltrials.gov/study/NCT04416984,ACTIVE_NOT_RECRUITING,"Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma",GENETIC: ALLO-501A|BIOLOGICAL: ALLO-647|DRUG: Fludarabine|DRUG: Cyclophosphamide,Allogene Therapeutics,,INTERVENTIONAL
NCT03743246,A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL),https://clinicaltrials.gov/study/NCT03743246,TERMINATED,"Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin",DRUG: JCAR017|DRUG: Lymphodepleting|DRUG: Fludarabine|DRUG: Cyclophosphamide,Celgene,,INTERVENTIONAL
NCT02168907,"CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT02168907,TERMINATED,B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,"DRUG: 6,8-bis(benzylthio)octanoic acid|DRUG: bendamustine hydrochloride|BIOLOGICAL: rituximab|OTHER: laboratory biomarker analysis",Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT03734601,Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation,https://clinicaltrials.gov/study/NCT03734601,COMPLETED,Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorder|Chronic Lymphocytic Leukemia|B-cell Lymphoma|T-cell Lymphoma|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Chronic Myelomonocytic Leukemia,RADIATION: Total body irradiation (TBI)|DRUG: Anti-thymocyte globulin (ATG)|DRUG: Tacrolimus|DRUG: Mycophenolate mofetil (MMF)|RADIATION: Total lymphoid irradiation (TLI),Stanford University,,INTERVENTIONAL
NCT06122389,SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma,https://clinicaltrials.gov/study/NCT06122389,RECRUITING,Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy,DRUG: SHR2554; Chidamide analog tablets|DRUG: SHR2554 analog tablets; Chidamide,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL
NCT03638206,Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies,https://clinicaltrials.gov/study/NCT03638206,UNKNOWN,B-cell Acute Lymphoblastic Leukemia|Lymphoma|Myeloid Leukemia|Multiple Myeloma|Hepatoma|Gastric Cancer|Pancreatic Cancer|Mesothelioma|Colorectal Cancer|Esophagus Cancer|Lung Cancer|Glioma|Melanoma|Synovial Sarcoma|Ovarian Cancer|Renal Carcinoma,BIOLOGICAL: CAR-T cell immunotherapy,Shenzhen BinDeBio Ltd.,The First Affiliated Hospital of Zhengzhou University,INTERVENTIONAL
NCT05794880,MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing,https://clinicaltrials.gov/study/NCT05794880,RECRUITING,"Leukemia|Acute Myeloid Leukemia in Remission|Myelodysplasia|Acute Lymphoblastic Leukemia in Remission|Chronic Myelogenous Leukemia - Chronic Phase|Chronic Myelogenous Leukemia, Accelerated Phase|Chronic Myelogenous Leukemia With Crisis of Blast Cells|Biphenotypic Acute Leukemia|Lymphoblastic Lymphoma|Burkitt Lymphoma|Burkitt Leukemia|Lymphoma After Relapse|Other Malignant Hematologic Diseases in Remission","DEVICE: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)",Medical College of Wisconsin,,INTERVENTIONAL
NCT00238368,Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant,https://clinicaltrials.gov/study/NCT00238368,COMPLETED,Lymphoma,BIOLOGICAL: filgrastim|BIOLOGICAL: rituximab|DRUG: busulfan|DRUG: cisplatin|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: methylprednisolone|DRUG: prednisone|DRUG: vincristine sulfate|PROCEDURE: autologous bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: positron emission tomography|RADIATION: fludeoxyglucose F 18|RADIATION: radiation therapy,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT00720135,Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00720135,COMPLETED,Anaplastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,BIOLOGICAL: DI-Leu16-IL2 immunocytokine|BIOLOGICAL: rituximab|OTHER: flow cytometry|OTHER: immunohistochemistry staining method|OTHER: pharmacological study|OTHER: laboratory biomarker analysis|OTHER: enzyme-linked immunosorbent assay|GENETIC: reverse transcriptase-polymerase chain reaction,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05784441,A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL),https://clinicaltrials.gov/study/NCT05784441,RECRUITING,Relapsed or Refractory B Cell Non-Hodgkin Lymphoma,DRUG: JNJ-90009530,"Janssen Research & Development, LLC",,INTERVENTIONAL
NCT03263208,CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.,https://clinicaltrials.gov/study/NCT03263208,UNKNOWN,B-cell Acute Lymphocytic Leukemia,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: CD19 CAR-T,Henan Cancer Hospital,"The Pregene (ShenZhen) Biotechnology Company, Ltd.",INTERVENTIONAL
NCT04400591,Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol,https://clinicaltrials.gov/study/NCT04400591,AVAILABLE,"Lymphoma, Large B-Cell, Diffuse",BIOLOGICAL: Nonconforming Lisocabtagene Maraleucel,"Juno Therapeutics, a Subsidiary of Celgene",,EXPANDED_ACCESS
NCT00625729,"Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT00625729,TERMINATED,Leukemia|Lymphoma,BIOLOGICAL: aldesleukin|BIOLOGICAL: allogeneic natural killer cells|BIOLOGICAL: rituximab|DRUG: cyclophosphamide|DRUG: fludarabine phosphate,"Masonic Cancer Center, University of Minnesota",National Cancer Institute (NCI),INTERVENTIONAL
NCT01581528,Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01581528,COMPLETED,Leukemia,GENETIC: gene expression analysis|OTHER: cell culture procedure|OTHER: flow cytometry|OTHER: laboratory biomarker analysis|OTHER: metabolic assessment,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT00100152,A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013),https://clinicaltrials.gov/study/NCT00100152,TERMINATED,"Leukemia, Lymphoblastic, Acute, T-cell|Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes","DRUG: MK0752, (Notch Inhibitor)",Merck Sharp & Dohme LLC,,INTERVENTIONAL
NCT05747157,Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research,https://clinicaltrials.gov/study/NCT05747157,UNKNOWN,B-cell Acute Lymphoblastic Leukemia,DRUG: Metabolically Armed CD19 CAR-T cells,Anhui Provincial Hospital,"Leman Biotech Co., Ltd.",INTERVENTIONAL
NCT04532281,A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies,https://clinicaltrials.gov/study/NCT04532281,RECRUITING,Acute Lymphoblastic Leukemia|Non-Hodgkin Lymphoma of Soft Tissue,DRUG: Murine CD19 CAR-T cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT03574168,CD19-CAR-T Cells in Patients With R/R B-ALL,https://clinicaltrials.gov/study/NCT03574168,UNKNOWN,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19-CAR-T Cells,"Bioceltech Therapeutics, Ltd.",,INTERVENTIONAL
NCT02520895,Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT02520895,COMPLETED,LYMPHOMA,BIOLOGICAL: blood samplings,Hospices Civils de Lyon,,OBSERVATIONAL
NCT05332054,Long-Term Follow-up Study,https://clinicaltrials.gov/study/NCT05332054,ENROLLING_BY_INVITATION,"Lymphoma, Non-Hodgkin|Relapsed Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Lymphoma|B Cell Lymphoma|B-Cell Non-Hodgkin's Lymphoma|Hematologic Malignancy|Relapsed/Refractory Multiple Myeloma|Relapsed/Refractory Acute Myeloid Leukemia",BIOLOGICAL: Caribou-sponsored investigational therapy,"Caribou Biosciences, Inc.",,OBSERVATIONAL
NCT03570892,Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT03570892,ACTIVE_NOT_RECRUITING,Non-Hodgkin Lymphoma,DRUG: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|DRUG: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT),Novartis Pharmaceuticals,,INTERVENTIONAL
NCT01000753,Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01000753,COMPLETED,Adult Immunoblastic Lymphoma|Central Nervous System Non-Hodgkin Lymphoma|Childhood Immunoblastic Lymphoma|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3 Follicular Lymphoma|Lymphoproliferative Disorder|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Non-Hodgkin Lymphoma|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma,OTHER: Cytology Specimen Collection Procedure,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT05648019,CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol,https://clinicaltrials.gov/study/NCT05648019,RECRUITING,"Lymphoblastic Leukemia|Lymphoblastic Leukemia in Children|Lymphoblastic Leukemia, Acute Adult|B-cell Acute Lymphoblastic Leukemia|Large B-cell Lymphoma|CAR",BIOLOGICAL: Anti-CD19 CAR T-cells,KK Women's and Children's Hospital,Singapore General Hospital,INTERVENTIONAL
NCT01449461,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)",https://clinicaltrials.gov/study/NCT01449461,COMPLETED,"Lymphoma, Large-Cell, Anaplastic|Carcinoma, Non-Small-Cell Lung",DRUG: Brigatinib,Ariad Pharmaceuticals,,INTERVENTIONAL
NCT00038779,Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States,https://clinicaltrials.gov/study/NCT00038779,TERMINATED,Leukemia|Non Hodgkin's Lymphoma|Aplastic Anemia,PROCEDURE: Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT06414148,MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT06414148,RECRUITING,Relapsed/Refractory Large B-cell Lymphoma,"DRUG: Epcoritamab|DRUG: Epcoritamab, lenalidomide and rituximab","Peter MacCallum Cancer Centre, Australia",AbbVie,INTERVENTIONAL
NCT02285062,Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT02285062,COMPLETED,"Lymphoma, Large B-Cell, Diffuse",DRUG: lenalidomide|DRUG: Placebo|DRUG: Rituximab|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: prednisone|DRUG: vincristine,Celgene,,INTERVENTIONAL
NCT04541017,"Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment",https://clinicaltrials.gov/study/NCT04541017,TERMINATED,Mycosis Fungoides|Recurrent Mycosis Fungoides|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Sezary Syndrome|Refractory Mycosis Fungoides|Refractory Mycosis Fungoides and Sezary Syndrome|Refractory Sezary Syndrome|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|BIOLOGICAL: Magrolimab|BIOLOGICAL: Mogamulizumab|PROCEDURE: Positron Emission Tomography|PROCEDURE: Punch Biopsy,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05751044,HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT05751044,NOT_YET_RECRUITING,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory,DRUG: Dasatinib|DRUG: Venetoclax|DRUG: Dexamethasone|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: intrathecal chemotherapy,Princess Maxima Center for Pediatric Oncology,Innovative Therapies For Children with Cancer Consortium|IBFM|Fight Kids Cancer,INTERVENTIONAL
NCT00073918,"Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00073918,COMPLETED,Anaplastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,DRUG: cyclophosphamide|DRUG: etoposide|RADIATION: iodine I 131 tositumomab|PROCEDURE: quality-of-life assessment|PROCEDURE: peripheral blood stem cell transplantation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01853631,"Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",https://clinicaltrials.gov/study/NCT01853631,RECRUITING,Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Acute Lymphocytic Leukemia,GENETIC: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells|GENETIC: Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",INTERVENTIONAL
NCT01029366,CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy,https://clinicaltrials.gov/study/NCT01029366,COMPLETED,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,BIOLOGICAL: CART-19,University of Pennsylvania,,INTERVENTIONAL
NCT04090268,Precision Exercise in Children With Malignant Hemopathies,https://clinicaltrials.gov/study/NCT04090268,RECRUITING,"Leukemia, Myeloid, Acute|Leukemia, B-cell|Leukemia, T Cell|Lymphoma, Hodgkin|Lymphoma, Non-Hodgkin|Drepanocytosis|Thalassemia Major|Adrenoleukodystrophy",OTHER: Sport Therapy,University of Milano Bicocca,"Comitato Maria Letizia Verga,Italy",INTERVENTIONAL
NCT05480449,Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy),https://clinicaltrials.gov/study/NCT05480449,RECRUITING,B Cell Acute Lymphoblastic Leukemia (B-ALL)|B Lineage Lymphoblastic Lymphoma,BIOLOGICAL: Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19),Stephan Grupp MD PhD,Children's Hospital of Philadelphia,INTERVENTIONAL
NCT04227015,A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy,https://clinicaltrials.gov/study/NCT04227015,RECRUITING,Acute Lymphoblastic Leukemia|Non-hodgkin Lymphoma,DRUG: CTA101,He Huang,"Nanjing Bioheng Biotech Co., Ltd.",INTERVENTIONAL
NCT05381181,Safety and Efficacy Evaluation of Next-generation CD19-UCART,https://clinicaltrials.gov/study/NCT05381181,NOT_YET_RECRUITING,Acute Lymphoblastic Leukemia|Non Hodgkin Lymphoma,BIOLOGICAL: CD19-UCART,Bioray Laboratories,The First Affiliated Hospital of Zhengzhou University,INTERVENTIONAL
NCT05538988,BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma,https://clinicaltrials.gov/study/NCT05538988,NOT_YET_RECRUITING,Mycosis Fungoides,DRUG: Cemiplimab,AHS Cancer Control Alberta,,INTERVENTIONAL
NCT03448393,CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies,https://clinicaltrials.gov/study/NCT03448393,COMPLETED,"Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|B-Cell Leukemia|Acute Lymphoid Leukemia|B-Non Hodgkin Lymphoma|B-NHL|B-All|Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia",BIOLOGICAL: CD19/CD22 CAR T-Cells|DRUG: Fludarabine|DRUG: Cyclophosphamide|PROCEDURE: Apheresis|OTHER: Anti-emetic|DRUG: Diphenhydramine|DRUG: Acetaminophen|DIAGNOSTIC_TEST: ECG|DIAGNOSTIC_TEST: ECHO|DIAGNOSTIC_TEST: MRI Brain|PROCEDURE: Bone marrow biopsy|DIAGNOSTIC_TEST: Cardiac MRI,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05535673,"Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma",https://clinicaltrials.gov/study/NCT05535673,NOT_YET_RECRUITING,"Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL",DRUG: ThisCART19A,Zhengzhou University,"Fundamenta Therapeutics, Ltd.",INTERVENTIONAL
NCT00053105,Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00053105,UNKNOWN,Lymphoma,DRUG: cisplatin|DRUG: cytarabine|DRUG: methylprednisolone|DRUG: pixantrone dimaleate,Theradex,,INTERVENTIONAL
NCT06080191,Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL,https://clinicaltrials.gov/study/NCT06080191,RECRUITING,B-cell Acute Lymphoblastic Leukemia,DRUG: CD19-CAR_Lenti_ALLO,Bambino Gesù Hospital and Research Institute,,INTERVENTIONAL
NCT06247501,Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT06247501,RECRUITING,Very High Risk Acute Lymphoblastic Leukemia|CD19 CAR-T Therapy,GENETIC: SNUH-CD19-CAR-T,Seoul National University Hospital,,INTERVENTIONAL
NCT01620736,Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load,https://clinicaltrials.gov/study/NCT01620736,WITHDRAWN,Human T-cell Leukemia Virus Type 1 Infection,DRUG: Raltegravir,Washington University School of Medicine,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT02445248,Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients,https://clinicaltrials.gov/study/NCT02445248,COMPLETED,Diffuse Large B-cell Lymphoma (DLBCL),BIOLOGICAL: Tisagenlecleucel|DRUG: Lymphodepleting chemotherapy,Novartis Pharmaceuticals,,INTERVENTIONAL
NCT00019318,Depsipeptide in Treating Patients With Solid Tumors,https://clinicaltrials.gov/study/NCT00019318,COMPLETED,Lymphoma,DRUG: romidepsin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00602693,T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,https://clinicaltrials.gov/study/NCT00602693,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: umbilical cord blood transplantation|DRUG: Allopurinol|DRUG: fludarabine phosphate|DRUG: Cyclophosphamide|RADIATION: Total body irradiation|BIOLOGICAL: Treg infusion|DRUG: Sirolimus,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT05054257,CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT05054257,RECRUITING,"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma Refractory|Non-Hodgkin's Lymphoma, Relapsed",DRUG: Autologous CAR19 T lymphocytes,"Institute of Hematology and Blood Transfusion, Czech Republic",,INTERVENTIONAL
NCT00006473,Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00006473,COMPLETED,Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia,DRUG: oxaliplatin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00005040,Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00005040,COMPLETED,Lymphoma,DRUG: arsenic trioxide,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05879458,Ritlecitinib in CTCL,https://clinicaltrials.gov/study/NCT05879458,ACTIVE_NOT_RECRUITING,CTCL|Mycosis Fungoides|Sezary Syndrome,DRUG: Ritlecitinib,Icahn School of Medicine at Mount Sinai,Pfizer,INTERVENTIONAL
NCT00589602,"T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases",https://clinicaltrials.gov/study/NCT00589602,TERMINATED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Secondary Myelofibrosis,PROCEDURE: peripheral blood lymphocyte therapy|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: total-body irradiation (TBI),The Cleveland Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT03671460,CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.,https://clinicaltrials.gov/study/NCT03671460,UNKNOWN,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19 CAR-T cells,"Tianjin Mycure Medical Technology Co., Ltd",,INTERVENTIONAL
NCT04129099,A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL,https://clinicaltrials.gov/study/NCT04129099,UNKNOWN,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: GC022F,Hebei Yanda Ludaopei Hospital,Gracell Biotechnology Ltd.|Beijing Lu Daopei Hospital,INTERVENTIONAL
NCT00060112,Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma,https://clinicaltrials.gov/study/NCT00060112,TERMINATED,"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: oblimersen sodium|DRUG: gemcitabine hydrochloride|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04427449,4SCAR-CD44v6 T Cell Therapy Targeting Cancer,https://clinicaltrials.gov/study/NCT04427449,UNKNOWN,Cancers Which Are CD44v6 Positive,BIOLOGICAL: CD44v6-specific CAR gene-engineered T cells,Shenzhen Geno-Immune Medical Institute,Shenzhen Hospital of Southern Medical University|The Seventh Affiliated Hospital of Sun Yat-sen University|Shenzhen Children's Hospital,INTERVENTIONAL
NCT03825731,A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL,https://clinicaltrials.gov/study/NCT03825731,UNKNOWN,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: GC022,Hebei Yanda Ludaopei Hospital,Gracell Biotechnology Ltd.,INTERVENTIONAL
NCT03825718,A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL,https://clinicaltrials.gov/study/NCT03825718,COMPLETED,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: GC007F,Hebei Yanda Ludaopei Hospital,Gracell Biotechnology Ltd.,INTERVENTIONAL
NCT04947618,Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim,https://clinicaltrials.gov/study/NCT04947618,RECRUITING,"Lymphoma, Malignant",,Centre Hospitalier Universitaire de Nīmes,,OBSERVATIONAL
NCT00059995,MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma,https://clinicaltrials.gov/study/NCT00059995,COMPLETED,Lymphoma,BIOLOGICAL: iratumumab,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05391490,Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies,https://clinicaltrials.gov/study/NCT05391490,NOT_YET_RECRUITING,Blood Cancer,GENETIC: KCAT19 T cells,"University College, London",,INTERVENTIONAL
NCT00238433,"Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00238433,COMPLETED,Lymphoma,BIOLOGICAL: filgrastim|DRUG: busulfan|DRUG: melphalan|DRUG: thiotepa|PROCEDURE: bone marrow ablation with stem cell support|PROCEDURE: peripheral blood stem cell transplantation,OHSU Knight Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00458731,"Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma",https://clinicaltrials.gov/study/NCT00458731,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",BIOLOGICAL: bevacizumab|DRUG: cediranib maleate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03768310,CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA),https://clinicaltrials.gov/study/NCT03768310,WITHDRAWN,Non-hodgkin Lymphoma|Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19.CAR-multiVST for Group A|BIOLOGICAL: CD19.CAR-multiVST for Group B,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT03742258,Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma,https://clinicaltrials.gov/study/NCT03742258,ACTIVE_NOT_RECRUITING,"Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|DRUG: Prednisone|BIOLOGICAL: Rituximab|DRUG: Spleen Tyrosine Kinase Inhibitor TAK-659|DRUG: Vincristine Sulfate,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT01307592,"Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01307592,UNKNOWN,Lymphoma,BIOLOGICAL: rituximab|DRUG: gemcitabine hydrochloride|DRUG: lenalidomide|DRUG: oxaliplatin,Auxilio Mutuo Cancer Center,,INTERVENTIONAL
NCT00769288,FAU in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00769288,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: 2'-F-ara-deoxyuridine|OTHER: positron emission tomography|OTHER: laboratory biomarker analysis|OTHER: pharmacological study|OTHER: pharmacogenomic studies,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04764513,Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT,https://clinicaltrials.gov/study/NCT04764513,UNKNOWN,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Lymphoma,BIOLOGICAL: Ex-vivo expanded γδ T cell infusion,Chinese PLA General Hospital,,INTERVENTIONAL
NCT03154775,Study of Safety and Efficacy of C-CAR011 in B-NHL Patients,https://clinicaltrials.gov/study/NCT03154775,UNKNOWN,Refractory or Relapsed Non-Hodgkin Lymphoma,BIOLOGICAL: C-CAR011,Shanghai AbelZeta Ltd.,"Shanghai Tongji Hospital, Tongji University School of Medicine",INTERVENTIONAL
NCT05414162,Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy,https://clinicaltrials.gov/study/NCT05414162,RECRUITING,DLBCL|Multiple Myeloma|Cytokine Release Syndrome|Myocarditis|CAR T-cell Therapy|ALL|PCBCL|Follicular Lymphoma|MCL,DIAGNOSTIC_TEST: Cardiac MRI,"University Hospital, Bonn",,OBSERVATIONAL
NCT00293488,SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma,https://clinicaltrials.gov/study/NCT00293488,COMPLETED,Lymphoma,DRUG: polyamine analogue PG11047,Progen Pharmaceuticals,National Cancer Institute (NCI),INTERVENTIONAL
NCT06793241,Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06793241,RECRUITING,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT05092451,Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances,https://clinicaltrials.gov/study/NCT05092451,RECRUITING,B-Cell Lymphoma|Myelodysplastic Syndromes (MDS)|Acute Myeloid Leukemia (AML)|Multiple Myeloma|Plasma Cell Leukemia|Hodgkin Lymphoma|T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia|Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia|Blastic Transformation of Chronic Myeloid Leukemia|Germ Cell Tumors,DRUG: Cyclophosphamide|DRUG: CAR.70/IL15-transduced CB-NK cells|DRUG: Fludarabine phosphate,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03302403,Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors,https://clinicaltrials.gov/study/NCT03302403,UNKNOWN,B Cell Lymphoma|B Cell Leukemia|Myeloma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Adenocarcinoma of Esophagogastric Junction,GENETIC: CAR-CD19 T cell|GENETIC: CAR-BCMA T cell|GENETIC: CAR-GPC3 T cell|GENETIC: CAR-CLD18 T cell|DRUG: Fludarabine|DRUG: Cyclophosphamide,Kang YU,"CARsgen Therapeutics Co., Ltd.",INTERVENTIONAL
NCT00336063,Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00336063,ACTIVE_NOT_RECRUITING,Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Nasopharyngeal Undifferentiated Carcinoma|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7|Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7,DRUG: Azacitidine|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Vorinostat,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06721598,An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders,https://clinicaltrials.gov/study/NCT06721598,NOT_YET_RECRUITING,"Non-Hodgkin Lymphoma, B-cell|Acute Lymphoblastic Leukemia ALL",,"National Research Center for Hematology, Russia",,OBSERVATIONAL
NCT00748319,Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma,https://clinicaltrials.gov/study/NCT00748319,COMPLETED,"Mycosis Fungicides|Sezary Syndrome|Dermatitis|Dermatitis, Exfoliative",OTHER: Detection of KIR receptor by RT PCR,Assistance Publique - Hôpitaux de Paris,,INTERVENTIONAL
NCT01634217,Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT01634217,COMPLETED,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Non-Hodgkin Lymphoma|Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Multiple Myeloma|Myelodysplastic Syndrome,BIOLOGICAL: iTreg,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT06705530,"A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative Disorders",https://clinicaltrials.gov/study/NCT06705530,RECRUITING,"Non-Hodgkin Lymphoma, B-cell|Acute Lymphoblastic Leukemia ALL",BIOLOGICAL: Hem101,"National Research Center for Hematology, Russia",,INTERVENTIONAL
NCT00671112,Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,https://clinicaltrials.gov/study/NCT00671112,TERMINATED,714leukemia|Lymphoma,DRUG: Bortezomib|DRUG: Everolimus,"Brian Hill, MD, PhD",National Cancer Institute (NCI)|The Leukemia and Lymphoma Society,INTERVENTIONAL
NCT01572493,Continuous Infusion of rhIL-15 for Adults With Advanced Cancer,https://clinicaltrials.gov/study/NCT01572493,COMPLETED,Lymphoma|Carcinoma,BIOLOGICAL: rh IL-15 (10 DAYS)|BIOLOGICAL: rh IL-15 (5 DAYS),National Cancer Institute (NCI),,INTERVENTIONAL
NCT03836690,Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT03836690,UNKNOWN,Lymphoma|Leukemia|Myeloma|Myelodysplastic Syndromes|Severe Aplastic Anemia|Primary Immune Deficiency|Graft Vs Host Disease,BIOLOGICAL: CD62L- Tem,"University College, London",Medical Research Council,INTERVENTIONAL
NCT00561418,Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma,https://clinicaltrials.gov/study/NCT00561418,COMPLETED,Lymphoma|Small Intestine Cancer,DRUG: vorinostat|OTHER: Correlative studies,Ohio State University Comprehensive Cancer Center,Merck Sharp & Dohme LLC,INTERVENTIONAL
NCT02790515,Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,https://clinicaltrials.gov/study/NCT02790515,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Myeloid Sarcoma|Chronic Myeloid Leukemia (CML)|Juvenile Myelomonocytic Leukemia (JMML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL),"DRUG: Anti-thymocyte globulin (rabbit)|DRUG: Blinatumomab|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: G-CSF|DRUG: Melphalan|DRUG: Mesna|DRUG: Rituximab|DRUG: Tacrolimus|DRUG: Thiotepa|BIOLOGICAL: HPC,A Infusion|DEVICE: CliniMACS|DRUG: Sirolimus",St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT05210907,Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05210907,RECRUITING,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: SNUH-CD19-CAR-T,Seoul National University Hospital,,INTERVENTIONAL
NCT01801670,Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study,https://clinicaltrials.gov/study/NCT01801670,WITHDRAWN,Pruritus,PROCEDURE: Biopsy|PROCEDURE: Blood,Boston University,Merck Sharp & Dohme LLC,OBSERVATIONAL
NCT00089076,MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma,https://clinicaltrials.gov/study/NCT00089076,TERMINATED,Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: ipilimumab|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02529813,CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT02529813,COMPLETED,Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|CD19 Positive|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia,DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Tisagenlecleucel,M.D. Anderson Cancer Center,National Cancer Institute (NCI)|Ziopharm Oncology,INTERVENTIONAL
NCT01045928,Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01045928,TERMINATED,Adult Non-Hodgkin Lymphoma|Adult Grade III Lymphomatoid Granulomatosis|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenstrom Macroglobulinemia,DRUG: lenalidomide|BIOLOGICAL: rituximab|GENETIC: polymerase chain reaction|GENETIC: nucleic acid sequencing|GENETIC: polymorphism analysis|OTHER: flow cytometry|OTHER: laboratory biomarker analysis,Case Comprehensive Cancer Center,,INTERVENTIONAL
NCT04603872,CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies,https://clinicaltrials.gov/study/NCT04603872,RECRUITING,"Multiple Myeloma in Relapse|Multiple Myeloma, Refractory|Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphocytic Leukaemia Refractory|Non-Hodgkin's Lymphoma, Relapsed|Non-Hodgkin's Lymphoma Refractory",DRUG: CD19/BCMA Targeted CAR T-cells and dasatinib|DRUG: CD19/BCMA Targeted CAR T-cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT05017337,Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture,https://clinicaltrials.gov/study/NCT05017337,UNKNOWN,"Breast Implant-Associated Anaplastic Large Cell Lymphoma|Capsular Contracture, Implant|Breast Implant; Complications",,Royal Marsden NHS Foundation Trust,,OBSERVATIONAL
NCT02633020,Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease,https://clinicaltrials.gov/study/NCT02633020,COMPLETED,Type II Refractory Celiac Disease (RCD-II)|In-situ Small Bowel T-cell Lymphoma,BIOLOGICAL: AMG 714|BIOLOGICAL: Placebo,Amgen,,INTERVENTIONAL
NCT05740449,HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT05740449,WITHDRAWN,"Acute Lymphoblastic Leukemia, in Relapse|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory",DRUG: Decitabine|DRUG: Venetoclax|DRUG: Navitoclax|DRUG: intrathecal chemotherapy,Princess Maxima Center for Pediatric Oncology,Innovative Therapies For Children with Cancer Consortium|IBFM|Fight Kids Cancer,INTERVENTIONAL
NCT05745714,HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT05745714,NOT_YET_RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory",DRUG: Ruxolitinib|DRUG: Venetoclax|DRUG: Dexamethasone|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: intrathecal chemotherapy,Princess Maxima Center for Pediatric Oncology,Innovative Therapies For Children with Cancer Consortium|IBFM|Fight Kids Cancer,INTERVENTIONAL
NCT01129193,"AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma",https://clinicaltrials.gov/study/NCT01129193,COMPLETED,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,OTHER: Pharmacodynamic Studies|OTHER: Fatigue Inventory|OTHER: Pharmacogenomic studies|DRUG: AR-42,Amir Mortazavi,National Cancer Institute (NCI)|Arno Therapeutics,INTERVENTIONAL
NCT00143559,Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00143559,COMPLETED,Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Paroxysmal Nocturnal Hemoglobinuria|Hodgkin's Lymphoma|Non-Hodgkin Lymphoma,DRUG: Systematic chemotherapy and antibodies|PROCEDURE: Allogeneic stem cell transplantation|DEVICE: Miltenyi CliniMACS,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT00002663,"Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",https://clinicaltrials.gov/study/NCT00002663,COMPLETED,EBV-induced Lymphomas|EBV-associated Malignancies|Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma,BIOLOGICAL: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs),Atara Biotherapeutics,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),INTERVENTIONAL
NCT05658640,HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT05658640,RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent|Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory|Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory",DRUG: Trametinib|DRUG: Dexamethasone|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Intrathecal chemotherapy,Princess Maxima Center for Pediatric Oncology,Innovative Therapies For Children with Cancer Consortium|IBFM|Fight Kids Cancer,INTERVENTIONAL
NCT00243087,"Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)",https://clinicaltrials.gov/study/NCT00243087,COMPLETED,Lymphoma,DRUG: BI 2536,Boehringer Ingelheim,,INTERVENTIONAL
NCT00867529,Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT00867529,COMPLETED,B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: rituximab|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,"American Cancer Society, Inc.|National Cancer Institute (NCI)",INTERVENTIONAL
NCT01959477,Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01959477,COMPLETED,Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: busulfan|DRUG: etoposide|DRUG: cyclophosphamide|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: autologous hematopoietic stem cell transplantation,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01076543,Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01076543,COMPLETED,AIDS-Related Hodgkin Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Waldenstrom Macroglobulinemia,OTHER: Laboratory Biomarker Analysis|DRUG: Lenalidomide|DRUG: Temsirolimus,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04626908,Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04626908,UNKNOWN,Relapsed and Refractory|Lymphoid Hematological Malignancies,DRUG: GC022F CAR-T cells,He Huang,Gracell Biotechnology Ltd.,INTERVENTIONAL
NCT04029038,"Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma",https://clinicaltrials.gov/study/NCT04029038,WITHDRAWN,CD19 Positive|CD22 Positive|Minimal Residual Disease|Progressive Disease|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Non-Hodgkin Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma,BIOLOGICAL: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|DRUG: Cyclophosphamide|DRUG: Fludarabine,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00499811,Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction,https://clinicaltrials.gov/study/NCT00499811,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: vorinostat|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02580539,A Study of the Safety and Efficacy of EBV Specific T-cell Lines,https://clinicaltrials.gov/study/NCT02580539,COMPLETED,Epstein-Barr Virus Infections|Post-Transplant Lymphoproliferative Disorder|Lymphoma,BIOLOGICAL: Group A|BIOLOGICAL: Group B,"Dr. Jean-Sebastien Delisle, MD, PhD",,INTERVENTIONAL
NCT00003056,Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00003056,TERMINATED,Leukemia|Lymphoma|Graft Versus Host Disease,DRUG: cyclosporine|DRUG: cyclosporine and methotrexate,Baxalta now part of Shire,,INTERVENTIONAL
NCT05442515,CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies,https://clinicaltrials.gov/study/NCT05442515,RECRUITING,"B-NHL|B-Non Hodgkin Lymphoma|Acute Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|B-precursor ALL|B-All|Lymphoma, Non-Hodgkin|Leukemia, Lymphocytic, B Cell|B-Cell Lymphoma|B-Cell Leukemia|Acute Lymphoid Leukemia",BIOLOGICAL: CD19/CD22-CAR-transduced T cells|DRUG: cyclophosphamide|DRUG: fludarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00816413,"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer",https://clinicaltrials.gov/study/NCT00816413,WITHDRAWN,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Nonmalignant Neoplasm,DRUG: cyclosporine|DRUG: mycophenolate mofetil|DRUG: pentostatin|GENETIC: cytogenetic analysis|GENETIC: fluorescence in situ hybridization|GENETIC: protein analysis|OTHER: flow cytometry|OTHER: immunoenzyme technique|OTHER: laboratory biomarker analysis|OTHER: reduced-intensity transplant conditioning procedure|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation (PBSC)|RADIATION: total-body irradiation,University of Nebraska,National Cancer Institute (NCI),INTERVENTIONAL
NCT03599375,Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03599375,UNKNOWN,"Leukemia, B-Cell",BIOLOGICAL: CD19-targeted CART cells,jiuwei cui,,INTERVENTIONAL
NCT00354185,PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00354185,TERMINATED,"Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: tanespimycin|DRUG: belinostat|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05470777,CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL,https://clinicaltrials.gov/study/NCT05470777,RECRUITING,B-cell Acute Lymphoblastic Leukemia,"COMBINATION_PRODUCT: CD22/CD19 CAR T and auto-HSCT ""sandwich"" strategy",The First Affiliated Hospital of Soochow University,National Natural Science Foundation of China(Grant No. 81970138)|Jiangsu Province Natural Science Foundation of China (Grant No. BK20210091)|Jining Medical University|The Second People's Hospital of Huai'an|The First Affiliated Hospital of Bengbu Medical University|Northern Jiangsu People's Hospital|Affiliated Hospital of Nantong University|Suzhou Hospital of Traditional Chinese Medicine,INTERVENTIONAL
NCT05571540,Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL,https://clinicaltrials.gov/study/NCT05571540,WITHDRAWN,B-cell Acute Lymphoblastic Leukemia|B-ALL,BIOLOGICAL: U-CAR-T Cells (LstCAR019),Kunming Hope of Health Hospital,,INTERVENTIONAL
NCT03064269,CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT03064269,RECRUITING,B-cell Acute Lymphocytic Leukemia,BIOLOGICAL: CD19 CAR-T cells,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",The First Affiliated Hospital of Soochow University,INTERVENTIONAL
NCT04705090,A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma,https://clinicaltrials.gov/study/NCT04705090,UNKNOWN,PTCL,DRUG: YY-20394 treatment,Shanghai YingLi Pharmaceutical Co. Ltd.,,INTERVENTIONAL
NCT05607420,Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05607420,RECRUITING,B-cell Non-Hodgkin Lymphoma (B-NHL),BIOLOGICAL: UCART20x22|BIOLOGICAL: CLLS52,Cellectis S.A.,,INTERVENTIONAL
NCT01805037,Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas,https://clinicaltrials.gov/study/NCT01805037,TERMINATED,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Epstein-Barr Virus Infection|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia",DRUG: brentuximab vedotin|BIOLOGICAL: rituximab|OTHER: laboratory biomarker analysis,Northwestern University,Seagen Inc.,INTERVENTIONAL
NCT03301168,Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant,https://clinicaltrials.gov/study/NCT03301168,ACTIVE_NOT_RECRUITING,"Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndromes|Primary Immune Deficiency Disorder|Osteopetrosis|Cytopenia|Hemoglobinopathy in Children|Anemia, Aplastic",BIOLOGICAL: BPX-501 T cells|DRUG: Rimiducid,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT00005092,"Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT00005092,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: Cyclophosphamide|DRUG: Psoralen|DRUG: Thiotepa|PROCEDURE: Allogeneic bone marrow transplantation|PROCEDURE: In vitro-treated peripheral blood stem cell transplantation (PBSCT)|RADIATION: Radiation Therapy (RT),M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01994382,"Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL",https://clinicaltrials.gov/study/NCT01994382,COMPLETED,Follicular Lymphoma (FL/Indolent NHL)|Aggressive NHL (a NHL)|Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)|T-cell Lymphoma (PTCL and CTCL)|B-cell Non Hodgkin Lymphoma (NHL),DRUG: Cerdulatinib|BIOLOGICAL: Rituximab,"Alexion Pharmaceuticals, Inc.",Portola Pharmaceuticals,INTERVENTIONAL
NCT00265837,Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT00265837,COMPLETED,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: graft versus host disease prophylaxis/therapy|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: in vitro-treated bone marrow transplantation,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT03614858,CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.,https://clinicaltrials.gov/study/NCT03614858,RECRUITING,"Leukemia, B-cell",BIOLOGICAL: CART-19/22,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",The First Affiliated Hospital of Soochow University,INTERVENTIONAL
NCT05544019,Study of SGR-1505 in Mature B-Cell Neoplasms,https://clinicaltrials.gov/study/NCT05544019,RECRUITING,"Mature B-Cell Neoplasm|Non Hodgkin Lymphoma|DLBCL|Waldenstrom Macroglobulinemia|MALT Lymphoma|Follicular Lymphoma|Pediatric-Type Follicular Lymphoma|IRF4 Gene Rearrangement|EBV-Positive DLBCL, Nos|Burkitt Lymphoma|Plasmablastic Lymphoma|High-grade B-cell Lymphoma|Primary Cutaneous Follicle Center Lymphoma|Primary Effusion Lymphoma|Mantle Cell Lymphoma|DLBCL Germinal Center B-Cell Type|Primary Mediastinal Large B Cell Lymphoma|T-Cell/Histiocyte Rich Lymphoma|ALK-Positive Large B-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma|Splenic Marginal Zone Lymphoma|Chronic Lymphocytic Leukemia|Nodal Marginal Zone Lymphoma|HHV8-Positive DLBCL, Nos|Lymphoplasmacytic Lymphoma|Duodenal-Type Follicular Lymphoma",DRUG: SGR-1505,"Schrödinger, Inc.",,INTERVENTIONAL
NCT00884286,Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00884286,COMPLETED,Leukemia|Lymphoma,DRUG: Aplidin®,PharmaMar,,INTERVENTIONAL
NCT03960840,"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL",https://clinicaltrials.gov/study/NCT03960840,ACTIVE_NOT_RECRUITING,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Diffuse Large B-cell Lymphoma|Acute Lymphoblastic Leukemia|Large B-cell Lymphoma,BIOLOGICAL: Rapcabtagene autoleucel single agent|DRUG: Ibrutinib,Novartis Pharmaceuticals,,INTERVENTIONAL
NCT05836896,A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies,https://clinicaltrials.gov/study/NCT05836896,RECRUITING,"Neoplasms|Relapsed Diffuse Large B-cell Lymphoma (DLBCL)|Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Multiple Myeloma, Refractory|Multiple Myeloma in Relapse",GENETIC: MDC-CAR-BCMA001 (BCMA directed CAR T-cells),Technische Universität Dresden,German Cancer Research Center,INTERVENTIONAL
NCT00047060,Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome,https://clinicaltrials.gov/study/NCT00047060,COMPLETED,Mycosis Fungoides|Sezary Syndrome,OTHER: A matched peripheral donor stem cells|DRUG: cyclosporine|DRUG: fludarabine|DRUG: Campath,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT04975555,Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy,https://clinicaltrials.gov/study/NCT04975555,RECRUITING,"Cytokine Release Syndrome|ICANS|Lymphoma, Non-Hodgkin|Multiple Myeloma|Acute Lymphoblastic Leukemia",DRUG: Siltuximab,University of Alabama at Birmingham,,INTERVENTIONAL
NCT04215016,Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04215016,UNKNOWN,Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive,BIOLOGICAL: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells,Fujian Medical University,,INTERVENTIONAL
NCT00293345,3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00293345,COMPLETED,"Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: gemcitabine hydrochloride|DRUG: triapine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01660607,Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell,https://clinicaltrials.gov/study/NCT01660607,COMPLETED,"Myeloid Leukemia, Chronic|Acute Myelogenous Leukemia|Myelodysplastic Syndromes (MDS)|Lymphoma, Non-Hodgkin|Acute Lymphoblastic Leukemia (ALL)|Myeloproliferative Syndrome|Acute Myeloid Leukemia|Acute Leukemia|Chronic Myelogenous Leukemia",BIOLOGICAL: CD34+ Hematopoietic Progenitor Cells (HSPC)|BIOLOGICAL: Regulatory T-Cells (Treg)|BIOLOGICAL: Conventional T-Cells (Tcon)|PROCEDURE: Myeloablative Conditioning Regimen,Stanford University,"National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL
NCT02296164,"Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma",https://clinicaltrials.gov/study/NCT02296164,COMPLETED,Mycosis Fungoides,DRUG: Valchlor,"Helsinn Therapeutics (U.S.), Inc",,OBSERVATIONAL
NCT05639179,Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL,https://clinicaltrials.gov/study/NCT05639179,RECRUITING,B-cell Acute Lymphoblastic Leukemia|B-ALL,BIOLOGICAL: UCAR-T Cells,920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,,INTERVENTIONAL
NCT00077155,Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00077155,COMPLETED,"AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: cilengitide,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02640209,Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL),https://clinicaltrials.gov/study/NCT02640209,TERMINATED,LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL),BIOLOGICAL: CART 19,University of Pennsylvania,,INTERVENTIONAL
NCT00897923,Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00897923,COMPLETED,Lymphoma|Small Intestine Cancer,PROCEDURE: radionuclide imaging|RADIATION: indium In 111-labeled autologous peripheral blood mononuclear cells|RADIATION: indium In 111-labeled autologous polymorphonuclear leukocytes,Mayo Clinic,National Cancer Institute (NCI),OBSERVATIONAL
NCT06525116,MRD Detection by NGS in Pediatric T-ALL,https://clinicaltrials.gov/study/NCT06525116,COMPLETED,"Acute Lymphoblastic Leukemia, Pediatric",OTHER: MRD,The Children's Hospital of Zhejiang University School of Medicine,,OBSERVATIONAL
NCT01598025,Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor,https://clinicaltrials.gov/study/NCT01598025,TERMINATED,Acute Leukemia|Chronic Leukemia|Myelodysplastic Syndrome|Non-Hodgkins Lymphoma,RADIATION: total-body irradiation (TBI)|DRUG: thiotepa|DRUG: fludarabine phosphate|DRUG: melphalan|BIOLOGICAL: anti-thymocyte globulin|PROCEDURE: allogeneic hematopoietic stem cell transplantation|BIOLOGICAL: peripheral blood stem cell transplantation|OTHER: laboratory biomarker analysis,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT03564704,Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL,https://clinicaltrials.gov/study/NCT03564704,UNKNOWN,"Leukemia|Leukemia, Acute|Adult Lymphoblastic Lymphoma|Leukemia, Lymphoblastic|Leukemia, T Cell|Adult Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Lymphoblastic Leukemia",DRUG: Dexamethasone|DRUG: vincristine|DRUG: Cyclophosphamide|DRUG: Idarubicin|DRUG: Pegaspargase|DRUG: Adriamycin|DRUG: Methotrexate|DRUG: 6-mercaptopurine.|DRUG: Etoposide|DRUG: Cytarabine|PROCEDURE: Bone marrow aspiration|PROCEDURE: Intrathecal injection|RADIATION: Radiation therapy|GENETIC: NGS|PROCEDURE: allogeneic hematopoietic stem cell transplantation|DIAGNOSTIC_TEST: Flow-MRD|DIAGNOSTIC_TEST: FISH|DIAGNOSTIC_TEST: Flow immunophenotyping|DIAGNOSTIC_TEST: Karyotyping|DRUG: Chidamide|DIAGNOSTIC_TEST: PET-CT scan,"Nanfang Hospital, Southern Medical University",,INTERVENTIONAL
NCT01403415,"Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01403415,COMPLETED,Childhood B Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma,DRUG: Dexamethasone|OTHER: Laboratory Biomarker Analysis|DRUG: Methotrexate|DRUG: Mitoxantrone Hydrochloride|DRUG: Pegaspargase|OTHER: Pharmacological Study|DRUG: Temsirolimus|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06542250,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",https://clinicaltrials.gov/study/NCT06542250,RECRUITING,B-cell Malignancies,DRUG: AZD5492,AstraZeneca,,INTERVENTIONAL
NCT00933985,"Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia",https://clinicaltrials.gov/study/NCT00933985,TERMINATED,"Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: obatoclax mesylate|DRUG: liposomal vincristine sulfate|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02477878,Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,https://clinicaltrials.gov/study/NCT02477878,ACTIVE_NOT_RECRUITING,Leukemia|Myelodysplastic Syndromes|Lymphoma|Multiple Myeloma|Hematologic Neoplasms,BIOLOGICAL: BPX-501|DRUG: Rimiducid,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT00047164,Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy,https://clinicaltrials.gov/study/NCT00047164,COMPLETED,Lymphoma,BIOLOGICAL: ipilimumab,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT00376519,Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases,https://clinicaltrials.gov/study/NCT00376519,TERMINATED,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Secondary Myelofibrosis,DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: Treg cell infusion|PROCEDURE: umbilical cord blood transplantation|RADIATION: total-body irradiation,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00961220,O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma,https://clinicaltrials.gov/study/NCT00961220,COMPLETED,Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7,DRUG: Carmustine|OTHER: Laboratory Biomarker Analysis|DRUG: O6-Benzylguanine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06334991,Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT06334991,RECRUITING,Non-Hodgkin Lymphoma Refractory/ Relapsed,BIOLOGICAL: CD19 t-haNK,"ImmunityBio, Inc.",,INTERVENTIONAL
NCT04034446,CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL),https://clinicaltrials.gov/study/NCT04034446,TERMINATED,Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19-CD22 CAR-T cells,"Institute of Hematology & Blood Diseases Hospital, China",Juventas Cell Therapy Ltd.,INTERVENTIONAL
NCT05262673,NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL,https://clinicaltrials.gov/study/NCT05262673,RECRUITING,B-Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: Antigen-specific T cells CART/CTL and DCvac,Shenzhen Geno-Immune Medical Institute,,INTERVENTIONAL
NCT00724984,Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma,https://clinicaltrials.gov/study/NCT00724984,COMPLETED,"Lymphoma|Hodgkin Disease|Lymphoma, Non-Hodgkin",DRUG: PCI-24781,Pharmacyclics LLC.,,INTERVENTIONAL
NCT04437420,"Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90",https://clinicaltrials.gov/study/NCT04437420,UNKNOWN,Acute T Lymphoblastic Leukemia (T-ALL)|Acute B Lymphoblastic Leukemia (B-ALL),DRUG: injection of BEP 800|OTHER: Control,Centre Hospitalier Universitaire Dijon,,OBSERVATIONAL
NCT06765876,CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: a Dose Escalation Phase I Trial,https://clinicaltrials.gov/study/NCT06765876,RECRUITING,"Leukemia, Myeloid, Acute(AML)|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndromes (MDS)|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",BIOLOGICAL: Autologous CAR123 T lymphocytes,"Institute of Hematology and Blood Transfusion, Czech Republic",,INTERVENTIONAL
NCT05157581,Extracorporeal Photopheresis in Sezary Syndrome,https://clinicaltrials.gov/study/NCT05157581,RECRUITING,Sezary Syndrome,DEVICE: Extracorporeal photopheresis (ECP)|DRUG: Methoxsalen Injection,"Oleg E. Akilov, MD, PhD",Mallinckrodt,OBSERVATIONAL
NCT00103246,"Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides",https://clinicaltrials.gov/study/NCT00103246,COMPLETED,Lymphoma|Non-melanomatous Skin Cancer|Precancerous Condition,DRUG: silicon phthalocyanine 4,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003970,Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00003970,COMPLETED,"AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: irinotecan hydrochloride,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04231877,Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04231877,RECRUITING,"Aggressive Non-Hodgkin Lymphoma|ALK-Positive Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Primary Mediastinal Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Gray-Zone Lymphoma",DRUG: Polatuzumab Vedotin|BIOLOGICAL: Rituximab|DRUG: Prednisone|DRUG: Etoposide|DRUG: Doxorubicin|DRUG: Cyclophosphamide|BIOLOGICAL: Glofitamab|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Echocardiography|PROCEDURE: FDG-Positron Emission Tomography|PROCEDURE: Computed Tomography|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration,University of Washington,"Genentech, Inc.",INTERVENTIONAL
NCT01998035,Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT01998035,TERMINATED,Lymphoid Malignancies|Lymphoma|Hodgkin Lymphoma|Non-hodgkin Lymphoma,DRUG: RomiDEPsin 10 MG/M2|DRUG: Oral 5-Azacitidine 100 MG|DRUG: Romidepsin 14 MG/M2|DRUG: Oral 5-Azacitidine 200 MG|DRUG: Oral 5-Azacitidine 300 MG,Columbia University,Celgene,INTERVENTIONAL
NCT02996617,PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia,https://clinicaltrials.gov/study/NCT02996617,UNKNOWN,"Lymphoma,Non-Hodgkin",DRUG: rhG-CSF regimen|DRUG: Pegylated rhG-CSF regimen,Shandong Provincial Hospital,,INTERVENTIONAL
NCT02943642,Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT02943642,UNKNOWN,Mycosis Fungoides,BIOLOGICAL: A-dmDT390-bisFv(UCHT1)|DRUG: Vorinostat,Angimmune LLC,"City of Hope National Medical Center|Columbia University|Dana-Farber Cancer Institute|Northwestern University Feinberg School of Medicine|H. Lee Moffitt Cancer Center and Research Institute|Ohio State University Comprehensive Cancer Center|Rush University Medical Center|Scott and White Hospital & Clinic|Yale University|Stanford University|Thomas Jefferson University|University of Arkansas|University of Colorado, Denver|University of Texas Southwestern Medical Center|University of Washington|Vanderbilt University School of Medicine|Washington University School of Medicine",INTERVENTIONAL
NCT02902874,Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +,https://clinicaltrials.gov/study/NCT02902874,COMPLETED,ALCL,OTHER: Blood sample,"Gustave Roussy, Cancer Campus, Grand Paris",,INTERVENTIONAL
NCT00052936,Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00052936,COMPLETED,Lymphoma,BIOLOGICAL: filgrastim|BIOLOGICAL: rituximab|DRUG: CHOP regimen|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: prednisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,German High-Grade Non-Hodgkin's Lymphoma Study Group,,INTERVENTIONAL
NCT00898872,SWOG-9245 Collecting and Storing Tissue Samples From Patients With Relapsed or Recurrent Non-Hodgkin Lymphoma After Treatment on a Southwest Oncology Group Clinical Trial,https://clinicaltrials.gov/study/NCT00898872,COMPLETED,Lymphoma,OTHER: cryopreservation,SWOG Cancer Research Network,National Cancer Institute (NCI),OBSERVATIONAL
NCT01483690,A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,https://clinicaltrials.gov/study/NCT01483690,TERMINATED,Acute Lymphoblastic Leukemia|Precursor B-Cell Lymphoblastic Leukemia|Precursor T-Cell Lymphoblastic Leukemia,DRUG: Decitabine|DRUG: Vorinostat|DRUG: Vincristine|DRUG: Dexamethasone|DRUG: Mitoxantrone|DRUG: Pegaspargase|DRUG: Methotrexate,Therapeutic Advances in Childhood Leukemia Consortium,,INTERVENTIONAL
NCT03628612,Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells,https://clinicaltrials.gov/study/NCT03628612,ENROLLING_BY_INVITATION,"Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy|Multiple Myeloma|DLBCL|ALL, Adult and Pediatric|T Cell Lymphoma",BIOLOGICAL: AUTO CAR T cell therapy,Autolus Limited,,INTERVENTIONAL
NCT04595162,A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL,https://clinicaltrials.gov/study/NCT04595162,NOT_YET_RECRUITING,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: GC019F,Peking University Third Hospital,Gracell Biotechnology Ltd.,INTERVENTIONAL
NCT00096005,Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas,https://clinicaltrials.gov/study/NCT00096005,TERMINATED,"Adult Grade III Lymphomatoid Granulomatosis|AIDS-related Peripheral/Systemic Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: tanespimycin|DRUG: bortezomib|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00089271,17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas,https://clinicaltrials.gov/study/NCT00089271,COMPLETED,"Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: alvespimycin hydrochloride|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04340167,Study of Anti-CD22 CAR-T Cells Treating Leukemia Children,https://clinicaltrials.gov/study/NCT04340167,COMPLETED,"Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia",BIOLOGICAL: Autologous humanized anti-CD22 chimeric antigen receptor T cells,Beijing Boren Hospital,,INTERVENTIONAL
NCT00098891,MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas,https://clinicaltrials.gov/study/NCT00098891,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: entinostat|DRUG: isotretinoin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00356928,Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00356928,TERMINATED,Leukemia|Myelodysplastic Syndromes,DRUG: Cyclophosphamide|BIOLOGICAL: Donor T cells,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT03373071,Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL,https://clinicaltrials.gov/study/NCT03373071,COMPLETED,CD19-ALL|CD19-LNH,BIOLOGICAL: CD19-CAR T cell,Bambino Gesù Hospital and Research Institute,,INTERVENTIONAL
NCT01683279,A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01683279,ACTIVE_NOT_RECRUITING,B Cell Leukemia,BIOLOGICAL: Autologous CD19 CAR+ EGFTt + T cells,Seattle Children's Hospital,,INTERVENTIONAL
NCT01295476,Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01295476,COMPLETED,Leukemia,GENETIC: gene expression analysis|GENETIC: microarray analysis|OTHER: laboratory biomarker analysis,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT03229876,Safety and Efficacy Evaluation of CD19-UCART,https://clinicaltrials.gov/study/NCT03229876,SUSPENDED,Acute Lymphoblastic Leukemia (ALL)|Non Hodgkin Lymphoma (NHL),BIOLOGICAL: CD19-UCART,Bioray Laboratories,The First Affiliated Hospital of Zhengzhou University|First Affiliated Hospital of Zhejiang University|Second Xiangya Hospital of Central South University,INTERVENTIONAL
NCT04068597,Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies,https://clinicaltrials.gov/study/NCT04068597,RECRUITING,Haematological Malignancy|Acute Myeloid Leukemia|Non Hodgkin Lymphoma|Multiple Myeloma|Higher-risk Myelodysplastic Syndrome|Peripheral T Cell Lymphoma,DRUG: CCS1477|DRUG: Pomalidomide|DRUG: Dexamethasone|DRUG: Azacitidine|DRUG: Venetoclax,CellCentric Ltd.,,INTERVENTIONAL
NCT05037669,Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT05037669,WITHDRAWN,Acute Lymphoblastic Leukemia|Chronic Lymphocytic Leukemia|Non Hodgkin Lymphoma,BIOLOGICAL: PACE CART19,University of Pennsylvania,,INTERVENTIONAL
NCT01746849,Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT01746849,ACTIVE_NOT_RECRUITING,Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,BIOLOGICAL: Palifermin|BIOLOGICAL: Lupron|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: Total-Body Irradiation (TBI)|DRUG: Thiotepa|DRUG: Cyclophosphamide|DRUG: Degarelix,Memorial Sloan Kettering Cancer Center,Swedish Orphan Biovitrum,INTERVENTIONAL
NCT04599556,Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy,https://clinicaltrials.gov/study/NCT04599556,RECRUITING,CD7+ Acute Leukemia|CD7+ Lymphoma,BIOLOGICAL: anti-CD7 CAR-T,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT04609241,CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT04609241,NOT_YET_RECRUITING,Relapsed and/or Refractory Acute Lymphoblastic Leukemia|Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma,DRUG: CD79b CAR-T Cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT02065869,Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant,https://clinicaltrials.gov/study/NCT02065869,TERMINATED,"Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Primary Immunodeficiency|Anemia, Aplastic|Osteopetrosis|Hemoglobinopathies|Cytopenia|Fanconi Anemia|Diamond Blackfan Anemia|Thalassemia|Anemia, Sickle Cell",BIOLOGICAL: BPX-501 T cells|DRUG: Rimiducid,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT04799275,Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma,https://clinicaltrials.gov/study/NCT04799275,SUSPENDED,"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma|Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Grade 3b Follicular Lymphoma|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Intravascular Large B-Cell Lymphoma|Lymphoplasmacytic Lymphoma|Nodular Lymphocyte Predominant B-Cell Lymphoma|Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma",PROCEDURE: Biospecimen Collection|DRUG: Cyclophosphamide|DRUG: Doxorubicin Hydrochloride|DRUG: Oral Azacitidine|DRUG: Prednisone|OTHER: Questionnaire Administration|BIOLOGICAL: Rituximab|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00003210,Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease,https://clinicaltrials.gov/study/NCT00003210,COMPLETED,Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,BIOLOGICAL: recombinant interleukin-12|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04049383,CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL,https://clinicaltrials.gov/study/NCT04049383,SUSPENDED,"Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia With Failed Remission|Acute Lymphoblastic Leukemia Recurrent|Acute Lymphoblastic Leukemia Not Having Achieved Remission|Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia",BIOLOGICAL: CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)|BIOLOGICAL: CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)|BIOLOGICAL: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|BIOLOGICAL: CAR-20/19-T cells,Medical College of Wisconsin,"Children's Hospital and Health System Foundation, Wisconsin",INTERVENTIONAL
NCT04653493,CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL),https://clinicaltrials.gov/study/NCT04653493,UNKNOWN,Relapsed B Cell Acute Lymphoblastic Leukemia (ALL)|Refractory B Cell Acute Lymphoblastic Leukemia (ALL),BIOLOGICAL: CD19 CAR engineered autologous T-cells|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Mesna,Sabz Biomedicals,"Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran|Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran",INTERVENTIONAL
NCT04340154,Study of Sequential CAR-T Cell Treating Leukemia Children,https://clinicaltrials.gov/study/NCT04340154,TERMINATED,"Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoid Leukemia",BIOLOGICAL: chimeric antigen receptor T cell,Beijing Boren Hospital,,INTERVENTIONAL
NCT02037256,Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma,https://clinicaltrials.gov/study/NCT02037256,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Small Lymphocytic Lymphoma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia",DRUG: bortezomib|BIOLOGICAL: filgrastim|PROCEDURE: autologous hematopoietic stem cell transplantation,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT05651191,To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL,https://clinicaltrials.gov/study/NCT05651191,RECRUITING,B-cell Acute Lymphoblastic Leukemia,DRUG: Human CD19 Targeted DASH CAR-T Cells Injection,"Hrain Biotechnology Co., Ltd.",Second Affiliated Hospital of Nanchang University,INTERVENTIONAL
NCT04440436,Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients,https://clinicaltrials.gov/study/NCT04440436,RECRUITING,NHL,DRUG: IM19 CAR-T Cells,"Beijing Immunochina Medical Science & Technology Co., Ltd.","Jiangsu Simcere Pharmaceutical Co., Ltd.",INTERVENTIONAL
NCT01254578,Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers,https://clinicaltrials.gov/study/NCT01254578,COMPLETED,Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With PML-RARA|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Alkylating Agent-Related Acute Myeloid Leukemia|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Post-Transplant Lymphoproliferative Disorder|Primary Cutaneous B-Cell Non-Hodgkin Lymphoma|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Richter Syndrome|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenstrom Macroglobulinemia,OTHER: Laboratory Biomarker Analysis|DRUG: Lenalidomide|OTHER: Pharmacological Study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01990534,A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT01990534,COMPLETED,Hodgkin Lymphoma,DRUG: Brentuximab Vedotin,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT00348985,PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas,https://clinicaltrials.gov/study/NCT00348985,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: belinostat|DRUG: bortezomib|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00112723,Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,https://clinicaltrials.gov/study/NCT00112723,TERMINATED,Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|Waldenström Macroglobulinemia,DRUG: alvocidib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06854653,A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL,https://clinicaltrials.gov/study/NCT06854653,RECRUITING,CTCL,DRUG: PTX-100,"Prescient Therapeutics, Ltd.",,INTERVENTIONAL
NCT00002718,"T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia",https://clinicaltrials.gov/study/NCT00002718,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: methylprednisolone|DRUG: thiotepa|PROCEDURE: in vitro-treated bone marrow transplantation|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation|RADIATION: radiation therapy,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05589896,A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05589896,RECRUITING,Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Biphenotypic Leukemia|Acute Undifferentiated Leukemia|CLL (Chronic Lymphocytic Leukemia)|Chronic Myeloid Leukemia (CML)|MDS (Myelodysplastic Syndrome)|Non-Hodgkin Lymphomas|Hodgkins Lymphoma|Cutaneous T Cell Lymphomas (CTCL),"OTHER: Ossium HPC Marrow, Bone Marrow Transplant|OTHER: Pre-transplant conditioning - Myeloablative (MAC)|OTHER: Pre-transplant conditioning - Reduced Intensity (RIC)|OTHER: Post-transplant treatment","Ossium Health, Inc.",Center for International Blood and Marrow Transplant Research,INTERVENTIONAL
NCT00005854,Bone Marrow Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00005854,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: methotrexate|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: in vitro-treated bone marrow transplantation|RADIATION: radiation therapy,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT06389305,CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction,https://clinicaltrials.gov/study/NCT06389305,NOT_YET_RECRUITING,"B-cell Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoid Leukemia",DRUG: peripheral blood lymphocytes|DRUG: CIK cell,Beijing GoBroad Hospital,,INTERVENTIONAL
NCT03593187,A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma,https://clinicaltrials.gov/study/NCT03593187,COMPLETED,HIV-1 Infection,DRUG: Cal-1 (LVsh5/C46) drug product,Assistance Publique - Hôpitaux de Paris,CSL Behring,INTERVENTIONAL
NCT01494103,Administration of Donor T Cells With the Caspase-9 Suicide Gene,https://clinicaltrials.gov/study/NCT01494103,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia|Non Hodgkin Lymphoma|Hemophagocytic Lymphohistiocytosis|Familial Hemophagocytic Lymphohistiocytosis|Hemophagocytic Syndrome|Epstein Barr Virus Infection|X-linked Lymphoproliferative Disease,BIOLOGICAL: iCaspase9-transduced T cells|DRUG: AP1903,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT03937544,Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL,https://clinicaltrials.gov/study/NCT03937544,RECRUITING,Relapsed B Acute Lymphoblastic Leukaemia|Refractory B Acute Lymphoblastic Leukaemia,BIOLOGICAL: CD19 CAR-T CELLS|DRUG: Cyclophosphamide|DRUG: Fludarabine,National University of Malaysia,Gaia Science,INTERVENTIONAL
NCT00080925,T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00080925,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: filgrastim|BIOLOGICAL: graft-versus-tumor induction therapy|BIOLOGICAL: rituximab|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: cytarabine|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: prednisone|DRUG: vincristine sulfate|PROCEDURE: peripheral blood stem cell transplantation,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT06421571,The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients,https://clinicaltrials.gov/study/NCT06421571,RECRUITING,Mycosis Fungoides,,National and Kapodistrian University of Athens,Recordati Rare Diseases,OBSERVATIONAL
NCT05705570,A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT05705570,NOT_YET_RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia Refractory|B-cell Lymphoma Recurrent|B-cell Lymphoma Refractory|Chronic Lymphocytic Leukemia Recurrent|Chronic Lymphocytic Leukemia Refractory","DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: Chimeric antigen receptor T cells to be implemented in a ""3 + 3"" design on day 0",Hospital Israelita Albert Einstein,"Miltenyi Biotec, Inc.",INTERVENTIONAL
NCT06649812,Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma,https://clinicaltrials.gov/study/NCT06649812,NOT_YET_RECRUITING,"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified|Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|DRUG: Ibrutinib|DRUG: Lenalidomide|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Obinutuzumab|PROCEDURE: Positron Emission Tomography|DRUG: Prednisone|DRUG: Venetoclax,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03925428,"Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas",https://clinicaltrials.gov/study/NCT03925428,WITHDRAWN,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma|Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Pancreatic Carcinoma|Refractory T-Cell Non-Hodgkin Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,DRUG: Entinostat|DRUG: Molibresib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06235281,Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT),https://clinicaltrials.gov/study/NCT06235281,RECRUITING,Mycosis Fungoides,DRUG: Mogamulizumab-Kpkc|DEVICE: Phototherapy,H. Lee Moffitt Cancer Center and Research Institute,"Kyowa Hakko Kirin Pharma, Inc.",INTERVENTIONAL
NCT06207812,Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis,https://clinicaltrials.gov/study/NCT06207812,RECRUITING,Lymphomatoid Papulosis|Mycosis Fungoides,,M.D. Anderson Cancer Center,,OBSERVATIONAL
NCT00168064,Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00168064,COMPLETED,Mycosis Fungoides,DRUG: mechlorethamine-MCH (nitrogen mustard),Yaupon Therapeutics,,INTERVENTIONAL
NCT04684563,huCART19-IL18 in CD19+ Cancers,https://clinicaltrials.gov/study/NCT04684563,RECRUITING,Chronic Lymphocytic Leukemia|Non-hodgkin Lymphoma|Acute Lymphoblastic Leukemia,BIOLOGICAL: huCART19-IL18,University of Pennsylvania,BlueWhale Bio (Cohort D only),INTERVENTIONAL
NCT00058604,Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).,https://clinicaltrials.gov/study/NCT00058604,COMPLETED,Epstein-Barr Virus Infections|Lymphoproliferative Disorders,BIOLOGICAL: Intravenous injection of EBV specific CTLs,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT05321940,Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias,https://clinicaltrials.gov/study/NCT05321940,WITHDRAWN,Refractory Leukemia|Relapsed Leukemia|Acute Myelogenous Leukemia|Acute Lymphoblastic Leukemia|Adult T-Cell Leukemia/Lymphoma,BIOLOGICAL: STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells|BIOLOGICAL: Dendritic Cell Vaccine,"Juan C. Ramos, MD",,INTERVENTIONAL
NCT05904522,Histopathological Changes in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05904522,RECRUITING,Mycosis Fungoides,DIAGNOSTIC_TEST: biopsy,Bezmialem Vakif University,,INTERVENTIONAL
NCT03044743,PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies,https://clinicaltrials.gov/study/NCT03044743,UNKNOWN,Stage IV Gastric Carcinoma|Stage IV Nasopharyngeal Carcinoma|T-Cell Lymphoma Stage IV|Stage IV Adult Hodgkin Lymphoma|Stage IV Diffuse Large B-Cell Lymphoma,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Interleukin-2,Yang Yang,,INTERVENTIONAL
NCT05855460,Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study,https://clinicaltrials.gov/study/NCT05855460,UNKNOWN,Mycosis Fungoides,DIAGNOSTIC_TEST: Skin biopsy,Cairo University,,OBSERVATIONAL
NCT05838599,Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05838599,RECRUITING,Mycosis Fungoides,DRUG: Imiquimod|RADIATION: Radiation Therapy,Northwestern University,,INTERVENTIONAL
NCT01649622,Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL),https://clinicaltrials.gov/study/NCT01649622,WITHDRAWN,Leukemia|Lymphoma,DRUG: Bendamustine,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT04690595,BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL,https://clinicaltrials.gov/study/NCT04690595,RECRUITING,Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: BAFFR-CAR T cells,"PeproMene Bio, Inc.",City of Hope Medical Center,INTERVENTIONAL
NCT02706392,Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies,https://clinicaltrials.gov/study/NCT02706392,TERMINATED,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Recurrent Acute Lymphoblastic Leukemia|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Lung Non-Small Cell Cancer AJCC v7|Unresectable Lung Non-Small Cell Carcinoma,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: ROR1 CAR-specific Autologous T-Lymphocytes,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00040846,"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies",https://clinicaltrials.gov/study/NCT00040846,COMPLETED,"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Progressive Hairy Cell Leukemia, Initial Treatment|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Splenic Marginal Zone Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenström Macroglobulinemia",BIOLOGICAL: alemtuzumab|DRUG: fludarabine phosphate|RADIATION: total-body irradiation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|DRUG: mycophenolate mofetil|DRUG: cyclosporine,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",INTERVENTIONAL
NCT00057954,Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00057954,TERMINATED,Lymphoma,PROCEDURE: Extracorporeal Photopheresis|DRUG: Pentostatin|RADIATION: Total body irradiation (TBI)|PROCEDURE: Allogeneic bone marrow transplantation|DRUG: Cyclosporin (CSA)|DRUG: Mycophenolate mofetil (MMF)|DRUG: Methotrexate (MTX),Eastern Cooperative Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT01050764,Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells,https://clinicaltrials.gov/study/NCT01050764,TERMINATED,"Leukemia, Acute|Chronic Myelogenous Leukemia (CML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin Lymphoma (NHL)|Chronic Lymphocytic Leukemia (CLL)|Acute Myelogenous Leukemia (AML)|Acute Lymphoblastic Leukemia (ALL)","DRUG: Regulatory T-cells|DRUG: Conventional T-cells|DRUG: Melphalan|DRUG: Thiotepa|DEVICE: Fludarabine|DRUG: Anti-thymocyte globulin, rabbit|DRUG: CliniMACS CD34 Reagent System",Everett Meyer,Doris Duke Charitable Foundation,INTERVENTIONAL
NCT04629729,FT819 in Subjects With B-cell Malignancies,https://clinicaltrials.gov/study/NCT04629729,ACTIVE_NOT_RECRUITING,"Lymphoma, B-Cell|Chronic Lymphocytic Leukemia|Precursor B-Cell Acute Lymphoblastic Leukemia",DRUG: FT819|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|DRUG: Bendamustine,Fate Therapeutics,,INTERVENTIONAL
NCT00006251,"Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer",https://clinicaltrials.gov/study/NCT00006251,COMPLETED,"Acute Undifferentiated Leukemia|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Renal Cell Cancer|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia",RADIATION: total-body irradiation|DRUG: fludarabine phosphate|DRUG: cyclosporine|DRUG: mycophenolate mofetil|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|BIOLOGICAL: donor lymphocytes|PROCEDURE: peripheral blood stem cell transplantation|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04788472,Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL,https://clinicaltrials.gov/study/NCT04788472,COMPLETED,"B-Cell Acute Lymphoblastic Leukemia, Adult",DRUG: CAR-T cells targeting CD19 and CD22,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT04325841,Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children,https://clinicaltrials.gov/study/NCT04325841,COMPLETED,"Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia",BIOLOGICAL: Murine autologous anti-CD19 chimeric antigen receptor T cells,Beijing Boren Hospital,,INTERVENTIONAL
NCT05526638,Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05526638,UNKNOWN,Mycosis Fungoides,RADIATION: ultraviolet phototherapy,Cairo University,,INTERVENTIONAL
NCT04191187,Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT04191187,COMPLETED,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Biphenotypic Acute Leukemia|Undifferentiated Leukemia|Prolymphocytic Leukemia|Myelodysplastic Syndromes|Chronic Myelogenous Leukemia|Myeloproliferative Neoplasm|Relapsed Large Cell Lymphoma|Mantle Cell Lymphoma|Hodgkin Lymphoma|Burkitt Lymphoma|Relapsed T-Cell Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Relapsed Small Lymphocytic Lymphoma|Relapsed Marginal B-cell Lymphoma|Relapsed Follicular Lymphoma|Lymphoplasmacytic Lymphoma,DRUG: Fludarabine|DRUG: Melphalan|RADIATION: Total Body Irradiation,H. Lee Moffitt Cancer Center and Research Institute,,INTERVENTIONAL
NCT04740203,Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL,https://clinicaltrials.gov/study/NCT04740203,UNKNOWN,"B-Cell Acute Lymphoblastic Leukemia, Adult",DRUG: CAR-T cells targeting CD19 and CD22,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT03938987,"Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)",https://clinicaltrials.gov/study/NCT03938987,RECRUITING,Relapsed Non Hodgkin Lymphoma|Relapsed Adult ALL|Relapsed Pediatric ALL,BIOLOGICAL: autologous CD19-directed chimeric antigen receptor (CAR) T-cells,University of Alberta,Alberta Cancer Foundation|Canadian Cancer Trials Group,INTERVENTIONAL
NCT05357794,Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT05357794,RECRUITING,Mycosis Fungoides,DRUG: Brentuximab vedotin,M.D. Anderson Cancer Center,Pfizer,INTERVENTIONAL
NCT00101244,SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00101244,TERMINATED,"Adult Grade III Lymphomatoid Granulomatosis|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: ispinesib|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06762431,Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.,https://clinicaltrials.gov/study/NCT06762431,ENROLLING_BY_INVITATION,Chronic Lymphocytic Leukaemia (CLL)|Small Lymphocytic Lymphoma (SLL),DRUG: Lenalidomide|DRUG: Lenalidomide,Vitebsk Regional Clinical Cancer Centre,"Republican Scientific and Practical Center for children's Oncology, Hematology and Immunology",INTERVENTIONAL
NCT06879262,Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL,https://clinicaltrials.gov/study/NCT06879262,NOT_YET_RECRUITING,R/R NHL,BIOLOGICAL: CAR1922T2 T cells（Targeting CD19 and CD22 with CAR-T cells）,Tongji Hospital,,INTERVENTIONAL
NCT04662294,CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases,https://clinicaltrials.gov/study/NCT04662294,RECRUITING,Acute Myeloid Leukemia|Non-hodgkin's Lymphoma|Multiple Myeloma,BIOLOGICAL: CD70 CAR T-cells,Zhejiang University,Yake Biotechnology Ltd.,INTERVENTIONAL
NCT00521430,"Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease",https://clinicaltrials.gov/study/NCT00521430,COMPLETED,"Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: anti-thymocyte globulin|DRUG: busulfan|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: methylprednisolone|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,Asan Medical Center,,INTERVENTIONAL
NCT00837174,Relapsed and/or Refractory Non-Hodgkin Lymphoma Study,https://clinicaltrials.gov/study/NCT00837174,WITHDRAWN,Non-Hodgkin Lymphoma,DRUG: Vorinostat in combination with Bortezomib,The Methodist Hospital Research Institute,,INTERVENTIONAL
NCT05381662,CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment,https://clinicaltrials.gov/study/NCT05381662,RECRUITING,Acute Lymphoblastic Leukemia in Remission,BIOLOGICAL: CD19 CAR-T cells and CD19 positive feeder T cells,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",The First Affiliated Hospital of Soochow University,INTERVENTIONAL
NCT03808610,Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03808610,ACTIVE_NOT_RECRUITING,Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory T Acute Lymphoblastic Leukemia,DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Methotrexate|DRUG: Nelarabine|DRUG: Pegaspargase|DRUG: Prednisone|BIOLOGICAL: Rituximab|DRUG: Venetoclax|DRUG: Vincristine,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05821088,Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE As Salvage Therapy for Transplant Eligible Patients with Relapsed/ Refractory Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05821088,RECRUITING,"Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified|Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma|Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma",PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|DRUG: Etoposide|DRUG: Ifosfamide|DRUG: Lenalidomide|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Tafasitamab,"David Bond, MD",,INTERVENTIONAL
NCT02942173,CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT,https://clinicaltrials.gov/study/NCT02942173,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes|GvHD|Opportunistic Infections|Graft-versus-Host Disease,BIOLOGICAL: CD45RA-depleted peripheral blood mononuclear cells,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",,INTERVENTIONAL
NCT02903810,Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy,https://clinicaltrials.gov/study/NCT02903810,UNKNOWN,Hematopoietic/Lymphoid Cancer,BIOLOGICAL: Mixed CAR-T Transfer,Xuzhou Medical University,,INTERVENTIONAL
NCT05164042,Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05164042,UNKNOWN,Relapse Leukemia|Refractory Leukemia,BIOLOGICAL: Allogeneic CD19 CAR-T cells,Shenzhen University General Hospital,,INTERVENTIONAL
NCT03744676,A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007),https://clinicaltrials.gov/study/NCT03744676,COMPLETED,"Lymphoma, Non-Hodgkin|Lymphoma|Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Neoplasms|Neoplasms by Histologic Type|Lymphoproliferative Disorders|Lymphatic Diseases|Immunoproliferative Disorders|Immune System Disorder",BIOLOGICAL: lisocabtagene maraleucel,"Juno Therapeutics, a Subsidiary of Celgene",Bristol-Myers Squibb,INTERVENTIONAL
NCT01078337,T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis,https://clinicaltrials.gov/study/NCT01078337,COMPLETED,"Leukemia, Lymphocytic, Acute",PROCEDURE: bone marrow aspiration|PROCEDURE: peripheral blood sampling,Stanford University,,OBSERVATIONAL
NCT05043571,CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia,https://clinicaltrials.gov/study/NCT05043571,RECRUITING,"Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Leukemia|Lymphoblastic Leukemia, Acute Adult|Lymphoblastic Leukemia in Children|CAR|CAR T-Cell-Related Encephalopathy Syndrome|Refractory Leukemia",BIOLOGICAL: CAR T-cell therapy,"National University Hospital, Singapore",,INTERVENTIONAL
NCT03398161,Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT03398161,RECRUITING,Localized Skin Lesion|Mycosis Fungoides,OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03288818,Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides,https://clinicaltrials.gov/study/NCT03288818,WITHDRAWN,Mycosis Fungoides,DRUG: Mechlorethamine Hydrochloride Gel|PROCEDURE: Total Skin Electron Beam Radiation Therapy,Sidney Kimmel Cancer Center at Thomas Jefferson University,Actelion,INTERVENTIONAL
NCT03281811,Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides,https://clinicaltrials.gov/study/NCT03281811,COMPLETED,Refractory Mycosis Fungoides,DRUG: Aminolevulinic Acid Hydrochloride|DRUG: Photodynamic Therapy|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT04195633,"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",https://clinicaltrials.gov/study/NCT04195633,RECRUITING,"Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult Diffuse Large Cell Lymphoma|Anaplastic Large Cell Lymphoma|Burkitt Lymphoma|Chronic Myeloid Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Hodgkin Lymphoma|Lymphoblastic Lymphoma|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Small Lymphocytic Lymphoma",PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Cyclophosphamide|DRUG: Cyclosporine|BIOLOGICAL: Filgrastim|DRUG: Fludarabine|DRUG: Mycophenolate Mofetil|DRUG: Mycophenolate Sodium|RADIATION: Total-Body Irradiation|DRUG: Treosulfan|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Echocardiography|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Positron Emission Tomography,Fred Hutchinson Cancer Center,medac GmbH,INTERVENTIONAL
NCT04714593,Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT04714593,UNKNOWN,Acute Lymphocytic Leukemia， B-Cell,BIOLOGICAL: CD19-CD22 CAR-T cells,Shanxi Province Cancer Hospital,Shanghai Ultra-T Immune Therapeutics Co. LTD,INTERVENTIONAL
NCT00712556,PET Study in Patients With Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00712556,COMPLETED,Lymphoma,RADIATION: fluorine 18-fludeoxyglucose positron emission tomography,Vanderbilt-Ingram Cancer Center,,OBSERVATIONAL
NCT04546906,Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04546906,UNKNOWN,B-ALL,BIOLOGICAL: CD22 CAR-T,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT00002765,Immunotoxin in Treating Patients With Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT00002765,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: LMB-2 immunotoxin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02499627,Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting,https://clinicaltrials.gov/study/NCT02499627,TERMINATED,Lymphatic Diseases,DRUG: Brentuximab Vedotin|DRUG: Bendamustine,Fondazione Italiana Linfomi - ETS,,INTERVENTIONAL
NCT06364423,Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL),https://clinicaltrials.gov/study/NCT06364423,RECRUITING,"B-Cell Chronic Lymphocytic Leukemia|Leukemia, Lymphocytic, Chronic, B-Cell|B-Lymphocytic Leukemia, Chronic",BIOLOGICAL: Autologous HuCD19 ( Anti-CD19)CAR T cells|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Rituximab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04925609,"Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors",https://clinicaltrials.gov/study/NCT04925609,RECRUITING,"Anaplastic Large Cell Lymphoma, ALK-Positive|Inflammatory Myofibroblastic Tumor|Other Solid Tumor",DRUG: Brigatinib,Princess Maxima Center for Pediatric Oncology,Takeda,INTERVENTIONAL
NCT06559553,"""Selinexor+Pegaspargase+Dexamethasone""in Ⅰ/Ⅱ NKTCL",https://clinicaltrials.gov/study/NCT06559553,RECRUITING,NKTCL|Selinexor,DRUG: Selinexor+pegaspargase+dexamethasone,Mingzhi Zhang,,INTERVENTIONAL
NCT00648037,Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT,https://clinicaltrials.gov/study/NCT00648037,COMPLETED,Hodgkin's Disease|Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,DRUG: Rituximab,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT02702310,Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides,https://clinicaltrials.gov/study/NCT02702310,RECRUITING,Recurrent Mycosis Fungoides|Refractory Mycosis Fungoides|Stage I Mycosis Fungoides|Stage II Mycosis Fungoides|Stage III Mycosis Fungoides,OTHER: Quality-of-Life Assessment|OTHER: Objective Grading of Skin Findings,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT06173518,A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL),https://clinicaltrials.gov/study/NCT06173518,RECRUITING,Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma,BIOLOGICAL: AUTO1,Autolus Limited,,INTERVENTIONAL
NCT00005580,Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00005580,COMPLETED,Leukemia|Lymphoma,DRUG: bryostatin 1|DRUG: fludarabine phosphate,Virginia Commonwealth University,National Cancer Institute (NCI),INTERVENTIONAL
NCT01652014,Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01652014,WITHDRAWN,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia",DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: umbilical cord blood transplantation|PROCEDURE: double-unit umbilical cord blood transplantation|RADIATION: total-body irradiation|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,University of Medicine and Dentistry of New Jersey,National Cancer Institute (NCI),INTERVENTIONAL
NCT05350163,T-cell Receptor α/β Depleted Donor Lymphocyte Infusion,https://clinicaltrials.gov/study/NCT05350163,TERMINATED,"Lymphoid Leukemia, Acute|Myeloid Malignancy|Plasma Cell Tumor",BIOLOGICAL: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions,Guenther Koehne,,INTERVENTIONAL
NCT00368355,T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts,https://clinicaltrials.gov/study/NCT00368355,COMPLETED,Acute Lymphoblastic Leukemia|Non Hodgkins Lymphoma|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Chronic Myelogenous Leukemia|Hemophagocytic Lymphohistiocytosis (HLH)|Familial Hemophagocytic Lymphohistiocytosis (FLH)|Viral-associated Hemophagocytic Syndrome (VAHS)|X-linked Lymphoproliferative Disease (XLP),DRUG: Ara-C|DRUG: Cyclophosphamide|BIOLOGICAL: Campath-1H|RADIATION: Total Body Irradiation|PROCEDURE: Stem Cell Infusion,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",INTERVENTIONAL
NCT03919240,CAR-T Cell Therapy Targeting to CD19 for R/R ALL,https://clinicaltrials.gov/study/NCT03919240,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia with Failed Remission,BIOLOGICAL: CAR T-cell therapy,The First Affiliated Hospital of Soochow University,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd|The Second People's Hospital of Huai'an|Third Military Medical University",INTERVENTIONAL
NCT00104975,Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT00104975,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: alemtuzumab|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: fludarabine phosphate|DRUG: melphalan|DRUG: tacrolimus|DRUG: thiotepa|PROCEDURE: peripheral blood stem cell transplantation,Yale University,National Cancer Institute (NCI),INTERVENTIONAL
NCT01827579,Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT),https://clinicaltrials.gov/study/NCT01827579,COMPLETED,Haematological Malignancies,BIOLOGICAL: CD25/71 allodepleted donor T-cells,"University College, London",Medical Research Council,INTERVENTIONAL
NCT05316701,Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05316701,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Mixed Phenotype Acute Leukemia|Undifferentiated Leukemia|Myelodysplastic Syndrome|Acute Leukemia|Therapy-Related Myelodysplastic Syndrome,BIOLOGICAL: Orca-T|BIOLOGICAL: Standard-of-Care,"Orca Biosystems, Inc.",,INTERVENTIONAL
NCT00539695,"Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD",https://clinicaltrials.gov/study/NCT00539695,COMPLETED,Acute Lymphoblastic Leukemia|ALL|Acute Myelogenous Leukemia|AML|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorder|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Non-malignant Diseases Requiring Allogeneic HSCT,BIOLOGICAL: IL-2,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT02975687,CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02975687,COMPLETED,"Acute Lymphoblastic Leukemia, Adult B-Cell|Acute Lymphoblastic Leukaemia Recurrent",BIOLOGICAL: CD19 CAR T cells,"Institute of Hematology & Blood Diseases Hospital, China",Juventas Cell Therapy Ltd.,INTERVENTIONAL
NCT05519527,STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis,https://clinicaltrials.gov/study/NCT05519527,WITHDRAWN,Refractory T Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia (AML),DRUG: Part 1 (STI-6129)|DRUG: Part 2 (STI-6129),M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT05809284,Determining the Mechanisms of Loss of CAR T Cell Persistence,https://clinicaltrials.gov/study/NCT05809284,RECRUITING,"Acute Lymphoblastic Leukemia With Failed Remission|Acute Lymphoblastic Leukemia Not Having Achieved Remission|Acute Lymphoblastic Leukemia, Pediatric|Acute Lymphoblastic Leukemia, Adult|Acute Lymphoblastic Leukemia, in Relapse",,"University College, London",,OBSERVATIONAL
NCT03091933,Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion),https://clinicaltrials.gov/study/NCT03091933,UNKNOWN,Hematologic Cancer|Relapse Leukemia|Relapsed Adult ALL|Relapsed Adult AML|Relapsed CLL|Relapsed Non Hodgkin Lymphoma|Relapsed Hodgkin's Lymphoma|Relapsed Myelodysplastic Syndromes|Relapsed Multiple Myeloma,BIOLOGICAL: GLIDE,Ciusss de L'Est de l'Île de Montréal,,INTERVENTIONAL
NCT04209829,Response to Chimeric Antigen Receptor (CAR)-T Cells Therapy in Patients With Hematologic Malignancies Depending on Tumor Characteristics,https://clinicaltrials.gov/study/NCT04209829,NOT_YET_RECRUITING,Hematologic Diseases,,Assistance Publique - Hôpitaux de Paris,,OBSERVATIONAL
NCT01686594,PUVA Maintenance Therapy in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT01686594,COMPLETED,Patch/Plaque Stage Mycosis Fungoides,DRUG: 8-methoxypsoralen,Medical University of Graz,,INTERVENTIONAL
NCT03733249,Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study,https://clinicaltrials.gov/study/NCT03733249,TERMINATED,"Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndromes|Primary Immunodeficiency|Anemia, Aplastic|Hemoglobinopathies|Cytopenia|Fanconi Anemia|Diamond Blackfan Anemia|Thalassemia|Anemia, Sickle Cell",DRUG: Rimiducid|BIOLOGICAL: rivogenlecleucel,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT00725062,Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00725062,TERMINATED,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: CD4+CD25+ regulatory T cells|PROCEDURE: allogeneic hematopoietic stem cell transplantation,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT04013685,Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT04013685,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Myelodysplastic Syndromes|Acute Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Chronic Myeloid Leukemia,BIOLOGICAL: Orca-T,"Orca Biosystems, Inc.",,INTERVENTIONAL
NCT01158274,RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors,https://clinicaltrials.gov/study/NCT01158274,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|HER2-negative Breast Cancer|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Male Breast Cancer|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Breast Cancer|Recurrent Colon Cancer|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Rectal Cancer|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Colon Cancer|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Rectal Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Rectal Cancer|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097|DRUG: capecitabine|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04904146,Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome.,https://clinicaltrials.gov/study/NCT04904146,RECRUITING,Mycosis Fungoides|Sezary Syndrome,"DIAGNOSTIC_TEST: Blood tests and testing of analysis of the lymphoma microenvironment in skin, skin barrier and skin microbiology profile.",Lund University Hospital,,OBSERVATIONAL
NCT00891072,"Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",https://clinicaltrials.gov/study/NCT00891072,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: R-(-)-gossypol acetic acid|DRUG: paclitaxel|DRUG: carboplatin|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00416312,Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00416312,COMPLETED,Lymphoma,DEVICE: Patient-specific dosimetry|DEVICE: conventional dosimetry,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),OBSERVATIONAL
NCT04534634,Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）,https://clinicaltrials.gov/study/NCT04534634,RECRUITING,B-cell Acute Lymphoblastic Leukemia,COMBINATION_PRODUCT: IFN-α combined with CAR-T cell therapy,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT06357988,Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T),https://clinicaltrials.gov/study/NCT06357988,ACTIVE_NOT_RECRUITING,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Hematopoietic and Lymphatic System Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|PROCEDURE: Echocardiography Test|PROCEDURE: Radionuclide Imaging|DRUG: Vismodegib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00118352,"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer",https://clinicaltrials.gov/study/NCT00118352,COMPLETED,"Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia",BIOLOGICAL: alemtuzumab|RADIATION: total-body irradiation|DRUG: fludarabine phosphate|DRUG: cyclosporine|DRUG: mycophenolate mofetil|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|BIOLOGICAL: graft versus host disease prophylaxis/therapy|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00873093,Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT00873093,COMPLETED,B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia,DRUG: L-asparaginase|DRUG: doxorubicin hydrochloride|DRUG: therapeutic hydrocortisone|DRUG: vincristine sulfate|DRUG: cytarabine|DRUG: prednisone|DRUG: bortezomib|DRUG: pegaspargase|DRUG: methotrexate|DRUG: etoposide phosphate|DRUG: cyclophosphamide|BIOLOGICAL: filgrastim|DRUG: leucovorin calcium|OTHER: laboratory biomarker analysis|DRUG: High Dose MTX,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04746209,Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT,https://clinicaltrials.gov/study/NCT04746209,RECRUITING,"B-cell Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|B-Cell ALL, Childhood",DEVICE: Alpha/Beta T-cell and B-cell depleted HCT|DRUG: Blinatumomab,Medical College of Wisconsin,"Amgen|University of Wisconsin, Madison",INTERVENTIONAL
NCT02337595,Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT02337595,COMPLETED,"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Myeloid, Acute|Immune Deficiency Disease|Bone Marrow Failure Syndromes|Opportunistic Infections|Graft vs Host Disease",BIOLOGICAL: CD45RA-depleted peripheral blood mononuclear cells,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",,INTERVENTIONAL
NCT05944562,Tulmimetostat (CPI-0209) in Patients With Mycosis Fungoides and Sézary Syndrome,https://clinicaltrials.gov/study/NCT05944562,RECRUITING,Mycosis Fungoides|Sezary Syndrome|Mycosis Fungoides/Sezary Syndrome,DRUG: Tulmimetostat,Washington University School of Medicine,MorphoSys AG|The Foundation for Barnes-Jewish Hospital|Swim Across America|Daniel E. Corbin Jr. Lymphoma Fund,INTERVENTIONAL
NCT05822050,"An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL",https://clinicaltrials.gov/study/NCT05822050,RECRUITING,PTCL Patients Who Achieved Complete Response From Frontline Treatment,DRUG: Selinexor,The First Hospital of Jilin University,,INTERVENTIONAL
NCT06635330,Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL,https://clinicaltrials.gov/study/NCT06635330,RECRUITING,Relapse/Refractory B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: anti-CD19 CAR T cell therapy,Kara Yakhteh Tajhiz Azma Company,,INTERVENTIONAL
NCT02369653,A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase,https://clinicaltrials.gov/study/NCT02369653,COMPLETED,Lymphoma|Acute Lymphoblastic Leukemia,DRUG: Apixaban|OTHER: No systemic anticoagulant prophylaxis,Bristol-Myers Squibb,Pfizer,INTERVENTIONAL
NCT00535470,An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00535470,COMPLETED,Mycosis Fungoides,DRUG: 0.04% Mechlorethamine gel,Yaupon Therapeutics,,INTERVENTIONAL
NCT00939770,Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT00939770,COMPLETED,Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma,DRUG: Crizotinib|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|OTHER: Questionnaire Administration,Children's Oncology Group,National Cancer Institute (NCI)|Pfizer,INTERVENTIONAL
NCT00496743,Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides,https://clinicaltrials.gov/study/NCT00496743,TERMINATED,Mycosis Fungoides,DEVICE: Low-dose total skin electron beam therapy (4 Gy),Bispebjerg Hospital,,INTERVENTIONAL
NCT01008462,"Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT01008462,COMPLETED,B-Cell Prolymphocytic Leukemia|Hypodiploidy|Loss of Chromosome 17p|Plasma Cell Leukemia|Progression of Multiple Myeloma or Plasma Cell Leukemia|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Non-Hodgkin Lymphoma|Refractory Plasma Cell Myeloma|Refractory Small Lymphocytic Lymphoma|t(14;16)|t(4;14)|T-Cell Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia,PROCEDURE: Allogeneic Bone Marrow Transplantation|PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|PROCEDURE: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|DRUG: Carmustine|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Etoposide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Melphalan|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Tacrolimus|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01518153,Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT),https://clinicaltrials.gov/study/NCT01518153,TERMINATED,Leukemia|Lymphoma|Myeloma|Myeloproliferative Diseases,DRUG: Fludarabine|DRUG: Melphalan|DRUG: Alemtuzumab|PROCEDURE: Stem Cell Infusion|DRUG: Tacrolimus|DRUG: Methotrexate|DRUG: G-CSF|PROCEDURE: Low Dose Donor T-Cells|PROCEDURE: High Dose Donor T-Cells,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT05455931,Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER),https://clinicaltrials.gov/study/NCT05455931,ACTIVE_NOT_RECRUITING,Mycosis Fungoides and Sézary Syndrome,DRUG: Poteligeo,Kyowa Kirin Pharmaceutical Development Ltd,,OBSERVATIONAL
NCT06207123,"A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)",https://clinicaltrials.gov/study/NCT06207123,RECRUITING,Acute Leukemia|Lymphoblastic Leukemia|Lymphoblastic Lymphoma,DRUG: LP-118|DRUG: Ponatinib|DRUG: Vincristine|DRUG: Dexamethasone|DRUG: Methotrexate,University of Chicago,,INTERVENTIONAL
NCT00226993,"Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.",https://clinicaltrials.gov/study/NCT00226993,WITHDRAWN,Mycosis Fungoides,DRUG: CPG 7909,Stanford University,National Institutes of Health (NIH),INTERVENTIONAL
NCT00085150,LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT00085150,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: LMB-2 immunotoxin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03884205,GDPE/CEOPE Compared With CEOPE for Newly Diagnosed Patients With PTCL,https://clinicaltrials.gov/study/NCT03884205,UNKNOWN,PTCL|Gemcitabine,,Shandong Provincial Hospital,,OBSERVATIONAL
NCT02228772,Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults,https://clinicaltrials.gov/study/NCT02228772,COMPLETED,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia,DRUG: MLN 9708|DRUG: Vincristine|DRUG: Cytarabine|DRUG: Doxorubicin|DRUG: Mercaptopurine|DRUG: Cyclophosphamide|DRUG: Methotrexate,Massachusetts General Hospital,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT00899366,DNA Analysis of Tissue From Patients With T-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00899366,COMPLETED,Leukemia,GENETIC: microarray analysis|GENETIC: mutation analysis|OTHER: immunologic technique,ECOG-ACRIN Cancer Research Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT04960618,Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome,https://clinicaltrials.gov/study/NCT04960618,RECRUITING,Mycosis Fungoides|Mycosis Fungoides/Sezary Syndrome|Sezary Syndrome|Sézary|Advanced Mycosis Fungoides,DRUG: Gemcitabine|DRUG: Pembrolizumab,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT05507541,TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma,https://clinicaltrials.gov/study/NCT05507541,RECRUITING,"Recurrent ALK Positive Large B-Cell Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Recurrent Grade 3b Follicular Lymphoma|Recurrent High Grade B-Cell Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent Intravascular Large B-Cell Lymphoma|Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma|Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Refractory ALK Positive Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|Refractory Grade 3b Follicular Lymphoma|Refractory High Grade B-Cell Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified|Refractory Intravascular Large B-Cell Lymphoma|Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Refractory Primary Mediastinal Large B-Cell Lymphoma|Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Recurrent Gray Zone Lymphoma",PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Ontorpacept|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography|DRUG: Maplirpacept|PROCEDURE: Biopsy,Mayo Clinic,,INTERVENTIONAL
NCT01016990,"Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT01016990,UNKNOWN,Leukemia|Lymphoma,DRUG: valproic acid|GENETIC: western blotting|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,Auxilio Mutuo Cancer Center,,INTERVENTIONAL
NCT04850560,Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma,https://clinicaltrials.gov/study/NCT04850560,UNKNOWN,Objective Response Rate,BIOLOGICAL: CD19 PD-1/CD28 CAR-T Plus Low Dose Decitabine,"Second Affiliated Hospital, School of Medicine, Zhejiang University",,INTERVENTIONAL
NCT03775525,Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer,https://clinicaltrials.gov/study/NCT03775525,UNKNOWN,Advanced Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer|Prostate Cancer Metastatic|Colo-rectal Cancer|Solid Tumor|Solid Carcinoma|Solid Carcinoma of Stomach|Cancer of Stomach|Lymphoma|Sarcoma|Cutaneous T Cell Lymphoma|Head and Neck Squamous Cell Carcinoma|Basal Cell Carcinoma|Cutaneous T-cell Lymphoma|Cutaneous Squamous Cell Carcinoma,DRUG: GZ17-6.02|DRUG: Capecitabine,"Genzada Pharmaceuticals USA, Inc.",Translational Drug Development,INTERVENTIONAL
NCT04652960,Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome,https://clinicaltrials.gov/study/NCT04652960,ACTIVE_NOT_RECRUITING,Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8,PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|DRUG: Duvelisib|BIOLOGICAL: Nivolumab|PROCEDURE: Positron Emission Tomography|PROCEDURE: Punch Biopsy,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00996359,Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation,https://clinicaltrials.gov/study/NCT00996359,TERMINATED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: Irradiated haploidentical allogeneic lymphocytes|RADIATION: total-body irradiation,University of Medicine and Dentistry of New Jersey,National Cancer Institute (NCI),INTERVENTIONAL
NCT01240525,Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers,https://clinicaltrials.gov/study/NCT01240525,UNKNOWN,Graft Versus Host Disease|Leukemia|Lymphoma|Myeloma|Myelodysplastic Syndrome,OTHER: CD4 DLI|OTHER: No DLI,"University College, London",,INTERVENTIONAL
NCT05965505,Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas,https://clinicaltrials.gov/study/NCT05965505,TERMINATED,Relapsed or Refractory Non-Hodgkin's Lymphoma,DRUG: AXT-1003,"Axter Therapeutics (Beijing) Co., Ltd",,INTERVENTIONAL
NCT00840853,"Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT",https://clinicaltrials.gov/study/NCT00840853,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia (ALL)|Chronic Lymphocytic Leukemia (CLL)|Non Hodgkin's Lymphoma,GENETIC: CD19CAR/virus specific T cells|DRUG: Benadryl and Tylenol,Baylor College of Medicine,"The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine",INTERVENTIONAL
NCT00608361,Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00608361,COMPLETED,Adult Acute Lymphoblastic Leukemia in Remission|Adult B Acute Lymphoblastic Leukemia|Adult Hepatocellular Carcinoma|Adult Nasal Type Extranodal NK/T-Cell Lymphoma|Adult Solid Neoplasm|Adult T Acute Lymphoblastic Leukemia|Advanced Adult Hepatocellular Carcinoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-Cell Lymphoma|Chronic Lymphocytic Leukemia|Cutaneous B-Cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Hepatosplenic T-Cell Lymphoma|Intraocular Lymphoma|Localized Non-Resectable Adult Liver Carcinoma|Localized Resectable Adult Liver Carcinoma|Lymphomatous Involvement of Non-Cutaneous Extranodal Site|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Nodal Marginal Zone Lymphoma|Progressive Hairy Cell Leukemia Initial Treatment|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Liver Carcinoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-Cell Leukemia/Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Small Intestinal Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Small Lymphocytic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-Cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides and Sezary Syndrome|Stage IIIB Mycosis Fungoides and Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-Cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides and Sezary Syndrome|Stage IVB Mycosis Fungoides and Sezary Syndrome|T-Cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Hairy Cell Leukemia|Waldenstrom Macroglobulinemia,DRUG: Dasatinib|OTHER: Pharmacological Study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05967949,A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.,https://clinicaltrials.gov/study/NCT05967949,RECRUITING,PTCL,DRUG: chidamide,The First Affiliated Hospital with Nanjing Medical University,,OBSERVATIONAL
NCT04256018,Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome,https://clinicaltrials.gov/study/NCT04256018,RECRUITING,Sezary Syndrome|Mycosis Fungoides,DRUG: Mogamulizumab|RADIATION: LD TSEBT,Stanford University,,INTERVENTIONAL
NCT00651716,T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00651716,TERMINATED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,OTHER: flow cytometry|OTHER: laboratory biomarker analysis|OTHER: Data Collection,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI)|National Institutes of Health (NIH),OBSERVATIONAL
NCT00127881,Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome,https://clinicaltrials.gov/study/NCT00127881,TERMINATED,Mycosis Fungoides|Sezary Syndrome,DRUG: HuMax-CD4 (zanolimumab),Emergent Product Development Seattle LLC,,INTERVENTIONAL
NCT00096161,Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00096161,COMPLETED,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Graft Versus Host Disease|Hodgkin Lymphoma|Myelodysplastic/Myeloproliferative Neoplasm|Non-Hodgkin Lymphoma|Plasma Cell Myeloma|Waldenstrom Macroglobulinemia",DRUG: Cyclosporine|DRUG: Mycophenolate Mofetil|DRUG: Pentostatin|BIOLOGICAL: Therapeutic Allogeneic Lymphocytes,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05225831,Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05225831,UNKNOWN,CD19+ and CD 22+ B-ALL,"BIOLOGICAL: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|DRUG: Cyclophosphamide,Fludarabine","Hebei Senlang Biotechnology Inc., Ltd.",Hebei Yanda Ludaopei Hospital,INTERVENTIONAL
NCT03695471,Pembrolizumab in Treating Patients with Stage IB-IV Mycosis Fungoides,https://clinicaltrials.gov/study/NCT03695471,COMPLETED,Mycosis Fungoides|Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage II Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC V8|Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC V8,BIOLOGICAL: Pembrolizumab,Mayo Clinic,,INTERVENTIONAL
NCT01860937,T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01860937,ACTIVE_NOT_RECRUITING,Relapsed B-Cell Acute Lymphoblastic Leukemia,PROCEDURE: leukapheresis or collection of PBMCs|DRUG: cyclophosphamide based chemotherapy regimens|BIOLOGICAL: modified T cells,Memorial Sloan Kettering Cancer Center,Dana-Farber Cancer Institute,INTERVENTIONAL
NCT07003100,"A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab",https://clinicaltrials.gov/study/NCT07003100,RECRUITING,Recurrent Mycosis Fungoides|Recurrent Sezary Syndrome|Refractory Mycosis Fungoides|Refractory Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8,OTHER: Non-Interventional Study,City of Hope Medical Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT03038672,Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,https://clinicaltrials.gov/study/NCT03038672,ACTIVE_NOT_RECRUITING,"ALK-Positive Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|EBV-Positive Mucocutaneous Ulcer|HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Intravascular Large B-Cell Lymphoma|Large B-Cell Lymphoma With 11q Aberration|Large B-Cell Lymphoma With IRF4 Rearrangement|Plasmablastic Lymphoma|Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System|Primary Effusion Lymphoma|Recurrent B-Cell Non-Hodgkin Lymphoma|Recurrent Burkitt Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Gray-Zone Lymphoma|Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Recurrent Lymphomatoid Granulomatosis|Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Recurrent Primary Mediastinal Large B-Cell Lymphoma|Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Burkitt Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Gray-Zone Lymphoma|Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements|Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type|Refractory Primary Mediastinal Large B-Cell Lymphoma|Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",BIOLOGICAL: Nivolumab|DRUG: Varlilumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT03587844,"Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients",https://clinicaltrials.gov/study/NCT03587844,RECRUITING,Mycosis Fungoides|Lymphomatoid Papulosis|Sezary Syndrome,DRUG: brentuximab vedotin|DRUG: brentuximab vedotin|DRUG: brentuximab vedotin,Memorial Sloan Kettering Cancer Center,Seagen Inc.,INTERVENTIONAL
NCT00054483,Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction,https://clinicaltrials.gov/study/NCT00054483,COMPLETED,"Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Splenic Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: bortezomib|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05238064,Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL,https://clinicaltrials.gov/study/NCT05238064,NOT_YET_RECRUITING,PI3Kδ Inhibitor|Parsaclisib|CHOP|PTCL,DRUG: Parsaclisib|DRUG: CHOP,Fudan University,,INTERVENTIONAL
NCT01625455,Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome,https://clinicaltrials.gov/study/NCT01625455,TERMINATED,Sezary Syndrome|Pruritus,DRUG: Aprepitant|DRUG: Placebo,Vanderbilt University Medical Center,,INTERVENTIONAL
NCT06641024,Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL,https://clinicaltrials.gov/study/NCT06641024,NOT_YET_RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia",BIOLOGICAL: MC-1-50,"Chongqing Precision Biotech Co., Ltd",Ruijin Hospital,INTERVENTIONAL
NCT03128359,"High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant",https://clinicaltrials.gov/study/NCT03128359,COMPLETED,"Acute Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Graft Versus Host Disease|Hodgkin Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Myelodysplastic Syndrome",DRUG: Busulfan|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|PROCEDURE: Hematopoietic Cell Transplantation|OTHER: Laboratory Biomarker Analysis|DRUG: Melphalan Hydrochloride|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|OTHER: Quality-of-Life Assessment|DRUG: Tacrolimus|RADIATION: Total-Body Irradiation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT06343090,Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients,https://clinicaltrials.gov/study/NCT06343090,RECRUITING,"B-cell Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoid Leukemia",DRUG: CD19 CAR T-cell|DRUG: CD22 CAR T cells|PROCEDURE: hematopoietic stem-cell transplantation,Beijing GoBroad Hospital,,INTERVENTIONAL
NCT03239392,A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL,https://clinicaltrials.gov/study/NCT03239392,COMPLETED,LGL Leukemia|CTCL,DRUG: BNZ132-1-40,Bioniz Therapeutics,,INTERVENTIONAL
NCT02822586,TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome,https://clinicaltrials.gov/study/NCT02822586,COMPLETED,Mycosis Fungoides|Sézary Syndrome,RADIATION: TSEB Therapy|DRUG: Brentuximab vedotin,Virginia Commonwealth University,Seagen Inc.,INTERVENTIONAL
NCT04553393,Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden,https://clinicaltrials.gov/study/NCT04553393,UNKNOWN,Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden,DRUG: Chidamide|DRUG: Decitabine|DRUG: Chidamide and Decitabine|BIOLOGICAL: Decitabine-primed Tandem CAR19/20 engineered T cells,Chinese PLA General Hospital,,INTERVENTIONAL
NCT02243579,Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome,https://clinicaltrials.gov/study/NCT02243579,COMPLETED,Recurrent Mycosis Fungoides and Sezary Syndrome|Refractory Mycosis Fungoides and Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06738368,"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia",https://clinicaltrials.gov/study/NCT06738368,NOT_YET_RECRUITING,"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|T Acute Lymphoblastic Leukemia",DRUG: Asparaginase Erwinia chrysanthemi|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Collection|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Etoposide|BIOLOGICAL: Filgrastim|BIOLOGICAL: Pegfilgrastim|PROCEDURE: Positron Emission Tomography|DRUG: Prednisone|BIOLOGICAL: Rituximab|DRUG: Vincristine,University of Washington,Jazz Pharmaceuticals,INTERVENTIONAL
NCT05905328,Study of CTO1681 for the Prevention and Treatment of CRS in DLBCL Patients Receiving CAR T-Cell Therapy,https://clinicaltrials.gov/study/NCT05905328,RECRUITING,Cytokine Release Syndrome,DRUG: CTO1681 10 μg|DRUG: CTO1681 20 μg|DRUG: CTO1681 30 μg,"CytoAgents, Inc.",,INTERVENTIONAL
NCT00723099,Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00723099,COMPLETED,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Myelogenous Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Indolent Non-Hodgkin Lymphoma|Lymphoma|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Recurrent Chronic Lymphocytic Leukemia|Recurrent Follicular Lymphoma|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Small Lymphocytic Lymphoma|Recurrent T-Cell Non-Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia|Refractory Follicular Lymphoma|Refractory Hodgkin Lymphoma|Refractory Lymphoplasmacytic Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Small Lymphocytic Lymphoma|T-Cell Non-Hodgkin Lymphoma,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Cyclophosphamide|DRUG: Cyclosporine|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Mycophenolate Mofetil|RADIATION: Total-Body Irradiation|PROCEDURE: Umbilical Cord Blood Transplantation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05433727,Dermoscopic Findings of Small Plaque Parapsoriasis and Patch Stage Mycosis Fungoides and Histopathological Correlation,https://clinicaltrials.gov/study/NCT05433727,COMPLETED,Mycosis Fungoides of Skin,"DIAGNOSTIC_TEST: videodermoscopy, lesional capillaroscopy",Istanbul Training and Research Hospital,,OBSERVATIONAL
NCT03275493,CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03275493,RECRUITING,Acute Lymphoblastic Leukemia|CD19 Positive|Relapse|Refractory,BIOLOGICAL: CD19 CAR-T cells|BIOLOGICAL: CD19 CAR-T cells with CRS suppression technology,"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd",The First Affiliated Hospital of Soochow University,INTERVENTIONAL
NCT00016302,Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00016302,COMPLETED,T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia,DRUG: prednisone|DRUG: vincristine sulfate|DRUG: daunorubicin hydrochloride|DRUG: asparaginase|DRUG: methotrexate|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: mercaptopurine|DRUG: leucovorin calcium|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: thioguanine|RADIATION: radiation therapy|DRUG: nelarabine|DRUG: pegaspargase|RADIATION: radiation therapy|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04154709,CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04154709,UNKNOWN,Acute Lymphoblastic Leukemia,BIOLOGICAL: CTA101,Kai Lin Xu; Jun Nian Zheng,"Nanjing Bioheng Biotech Co., Ltd.",INTERVENTIONAL
NCT00962507,Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,https://clinicaltrials.gov/study/NCT00962507,COMPLETED,Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,DRUG: everolimus|DRUG: panobinostat|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01350258,Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps,https://clinicaltrials.gov/study/NCT01350258,TERMINATED,Hematologic Malignancies|Acute Leukemia|Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes|Hodgkin's Lymphoma|Non-Hodgkin's Lymphoma|Myeloma|Chronic Myelogenous (or Myeloid) Leukemia (CML) Resistant to STI Therapy,DRUG: Fludarabine|DRUG: Thiotepa|RADIATION: Total Body Irradiation (TBI)|BIOLOGICAL: Donor Lymphocyte Infusion (DLI)|DRUG: Melphalan|DEVICE: Hematopoietic stem cell transplantation (HSCT),Sidney Kimmel Cancer Center at Thomas Jefferson University,,INTERVENTIONAL
NCT02146924,Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02146924,ACTIVE_NOT_RECRUITING,B Acute Lymphoblastic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|OTHER: Laboratory Biomarker Analysis,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05053971,"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas",https://clinicaltrials.gov/study/NCT05053971,RECRUITING,Advanced Lymphoma|Advanced Malignant Solid Neoplasm|Advanced Pancreatic Carcinoma|B-Cell Non-Hodgkin Lymphoma|Metastatic Pancreatic Carcinoma|Refractory B-Cell Non-Hodgkin Lymphoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Pancreatic Carcinoma|Refractory T-Cell Non-Hodgkin Lymphoma|Stage II Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Unresectable Pancreatic Carcinoma,DRUG: BET Bromodomain Inhibitor ZEN-3694|PROCEDURE: Core Biopsy|DRUG: Entinostat,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01071226,Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device,https://clinicaltrials.gov/study/NCT01071226,COMPLETED,"Malignant Diseases (ie, Leukemia, MDS, Lymphoma)|Non-malignant Diseases (ie, Bone Marrow Failure Syndromes)","DEVICE: CliniMACS (CD+3, CD+19 depletion)|DEVICE: CliniMACS (CD 34+ positive selection)|OTHER: HSCT",Medical College of Wisconsin,Children's Hospital of Philadelphia,INTERVENTIONAL
NCT03117751,Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT03117751,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma,DRUG: Prednisone|DRUG: Vincristine|DRUG: Daunorubicin|DRUG: Pegaspargase|DRUG: Erwinase®|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Mercaptopurine|DRUG: Dasatinib|DRUG: Methotrexate|DRUG: Blinatumomab|DRUG: Ruxolitinib|DRUG: Bortezomib|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Etoposide|DRUG: Clofarabine|DRUG: Vorinostat|DRUG: Idarubicin|DRUG: Nelarabine|DRUG: Thioguanine|DRUG: Asparaginase Erwinia chrysanthemi (recombinant)-rywn|DRUG: Calaspargase Pegol,St. Jude Children's Research Hospital,Incyte Corporation|Amgen|Servier,INTERVENTIONAL
NCT01626183,Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01626183,COMPLETED,Leukemia,GENETIC: RNA analysis|GENETIC: proteomic profiling|OTHER: laboratory biomarker analysis,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT00073944,BCX-1777 in Treating Patients With Refractory Cancer,https://clinicaltrials.gov/study/NCT00073944,COMPLETED,Cancer,DRUG: forodesine hydrochloride,BioCryst Pharmaceuticals,,INTERVENTIONAL
NCT04423926,Lenalidomide in Combination With CHOP in Patients With Untreated PTCL,https://clinicaltrials.gov/study/NCT04423926,UNKNOWN,"PTCL, NOS|AITL|ALK- ALCL|Phase III-IV ALK+ ALCL|EATL",DRUG: Lenalidomide|DRUG: Cyclophosphamide|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Prednisolone,The First Affiliated Hospital with Nanjing Medical University,,INTERVENTIONAL
NCT04158011,A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells,https://clinicaltrials.gov/study/NCT04158011,UNKNOWN,Acute Lymphoblastic Leukemia,,Sheba Medical Center,,OBSERVATIONAL
NCT03902197,CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients,https://clinicaltrials.gov/study/NCT03902197,UNKNOWN,Acute Lymphoblastic Leukemia,BIOLOGICAL: CD19 hsCAR-T,"Xuanwu Hospital, Beijing",Beijing Children's Hospital,INTERVENTIONAL
NCT03272633,Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT03272633,TERMINATED,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia in Remission|Hematopoietic Cell Transplantation Recipient|JAK2 Gene Mutation|Loss of Chromosome 17p|Mantle Cell Lymphoma|Minimal Residual Disease|Myelodysplastic Syndrome|Non-Hodgkin Lymphoma|Plasma Cell Myeloma|RAS Family Gene Mutation|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hematologic Malignancy|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome|TP53 Gene Mutation,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Irradiated Allogeneic Cells,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI),INTERVENTIONAL
NCT03107663,⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT03107663,COMPLETED,Positron-Emission Tomography|Immunomodulation|Metastatic Solid Malignancies|Hodgkin Lymphoma,DRUG: ⁸⁹Zr-Df-IAB22M2C Infusion,"ImaginAb, Inc.",,INTERVENTIONAL
NCT02118311,Treg Cells for AGVHD in Non-myeloablative UCB Transplant,https://clinicaltrials.gov/study/NCT02118311,WITHDRAWN,Hematologic Malignancies,BIOLOGICAL: T Regulatory cells|DRUG: Fludarabine|DRUG: Cyclophosphamide|RADIATION: Total Body Irradiation,"Masonic Cancer Center, University of Minnesota",National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL
NCT07008885,BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL,https://clinicaltrials.gov/study/NCT07008885,NOT_YET_RECRUITING,Acute Lymphocytic Leukemia,BIOLOGICAL: CAR19TIF cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,Chinese PLA General Hospital,,INTERVENTIONAL
NCT00002766,Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT00002766,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: dactinomycin|BIOLOGICAL: sargramostim|DRUG: carmustine|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: mitoxantrone hydrochloride|DRUG: pegaspargase|DRUG: prednisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00001432,The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00001432,COMPLETED,Chronic Myeloid Leukemia|Healthy|Hematologic Neoplasm|Lymphoma,,National Cancer Institute (NCI),,OBSERVATIONAL
NCT05727683,CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05727683,RECRUITING,Acute Lymphocytic Leukemia,BIOLOGICAL: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells,"Shanghai Ming Ju Biotechnology Co., Ltd.",,INTERVENTIONAL
NCT00049504,Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer,https://clinicaltrials.gov/study/NCT00049504,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hematopoietic/Lymphoid Cancer|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: tacrolimus|DRUG: mycophenolate mofetil|GENETIC: polymerase chain reaction|GENETIC: fluorescence in situ hybridization|GENETIC: polymorphism analysis|GENETIC: gene expression analysis|RADIATION: total-body irradiation|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02287311,"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)",https://clinicaltrials.gov/study/NCT02287311,ACTIVE_NOT_RECRUITING,Hodgkin Disease|Non-Hodgkin Lymphoma|Severe Chronic Active Epstein Barr Virus|T/NK-lymphoproliferative Disease|Nasopharyngeal Carcinoma|Smooth Muscle Tumor,BIOLOGICAL: MABEL CTLs|DRUG: Cyclophosphamide|DRUG: Fludarabine,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",INTERVENTIONAL
NCT00157274,Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome,https://clinicaltrials.gov/study/NCT00157274,UNKNOWN,Mycosis Fungoides|Sezary Syndrome,DRUG: alemtuzumab,Latin American Cooperative Onco-Haematology Group - Peru,,INTERVENTIONAL
NCT05602194,Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT05602194,RECRUITING,"B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, BCR-ABL1-Like|Lymphoblastic Lymphoma|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia",PROCEDURE: Biospecimen Collection|DRUG: Calaspargase Pegol|DIETARY_SUPPLEMENT: Levocarnitine|DRUG: Pegaspargase|OTHER: Quality-of-Life Assessment,Children's Oncology Group,,INTERVENTIONAL
NCT00078858,Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00078858,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Childhood Renal Cell Carcinoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Clear Cell Renal Cell Carcinoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Renal Cell Cancer|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Renal Cell Cancer|T-cell Large Granular Lymphocyte Leukemia|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies|Waldenström Macroglobulinemia",DRUG: fludarabine phosphate|RADIATION: total-body irradiation|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|DRUG: cyclosporine|DRUG: mycophenolate mofetil|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",INTERVENTIONAL
NCT01273766,Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01273766,COMPLETED,"Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Langerhans Cell Histiocytosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Mast Cell Leukemia|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelofibrosis|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenstrom Macroglobulinemia",DRUG: deferasirox|OTHER: laboratory biomarker analysis|OTHER: enzyme-linked immunosorbent assay,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT01231919,MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia,https://clinicaltrials.gov/study/NCT01231919,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Leukemias of Ambiguous Lineage|Acute Myeloid Leukemia/Transient Myeloproliferative Disorder|Acute Undifferentiated Leukemia|Aggressive NK-cell Leukemia|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myeloid/NK-cell Acute Leukemia|Noncutaneous Extranodal Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: Akt inhibitor MK2206|OTHER: diagnostic laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05348889,First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05348889,TERMINATED,"Non-Hodgkin's Lymphoma (disorder)|Acute Lymphoid Leukemia, Disease (disorder)",DRUG: 1A46 Injection,"Chimagen Biosciences, Ltd",,INTERVENTIONAL
NCT01044745,Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT01044745,TERMINATED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Waldenström Macroglobulinemia,DRUG: rituximab|DRUG: mycophenolate mofetil|DRUG: tacrolimus|DRUG: anti-thymocyte globulin|PROCEDURE: allogeneic hematopoietic stem cell transplantation|OTHER: laboratory biomarker analysis|BIOLOGICAL: graft versus host disease prophylaxis/therapy|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: busulfan|RADIATION: total-body irradiation|BIOLOGICAL: graft-versus-tumor induction therapy|BIOLOGICAL: immunosuppressive therapy,University of Nebraska,National Cancer Institute (NCI),INTERVENTIONAL
NCT05429905,Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia,https://clinicaltrials.gov/study/NCT05429905,RECRUITING,"Lymphoblastic Leukemia|Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Leukemia in Children|Lymphoblastic Leukemia, Acute Adult|CAR",BIOLOGICAL: Phase I|BIOLOGICAL: Phase II,KK Women's and Children's Hospital,"Singapore General Hospital|National University Hospital, Singapore",INTERVENTIONAL
NCT03798509,Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia,https://clinicaltrials.gov/study/NCT03798509,UNKNOWN,CD19-positive|Acute Lymphoblastic Leukemia,DRUG: Human CD19 targeted T Cells Injection,"Hrain Biotechnology Co., Ltd.","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",INTERVENTIONAL
NCT00002970,506U78 in Treating Patients With Refractory Hematologic Cancer,https://clinicaltrials.gov/study/NCT00002970,COMPLETED,Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Childhood Acute Lymphoblastic Leukemia,DRUG: nelarabine|DRUG: methotrexate|DRUG: cytarabine|DRUG: therapeutic hydrocortisone,National Cancer Institute (NCI),Children's Cancer Group,INTERVENTIONAL
NCT03624686,Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies,https://clinicaltrials.gov/study/NCT03624686,UNKNOWN,Leukemia,OTHER: peripheral blood,National Taiwan University Hospital,,OBSERVATIONAL
NCT03755414,Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation,https://clinicaltrials.gov/study/NCT03755414,COMPLETED,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndromes|Non-Hodgkin Lymphoma|Hodgkin Disease,PROCEDURE: Stem cell transplantation|DRUG: Itacitinib|OTHER: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|OTHER: Human Activity Profile,Washington University School of Medicine,Incyte Corporation|American Society of Hematology|National Cancer Institute (NCI),INTERVENTIONAL
NCT01606878,Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,https://clinicaltrials.gov/study/NCT01606878,COMPLETED,Childhood Solid Neoplasm|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Neuroblastoma,DRUG: Crizotinib|DRUG: Cyclophosphamide|DRUG: Dexrazoxane Hydrochloride|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|OTHER: Questionnaire Administration|DRUG: Topotecan Hydrochloride|DRUG: Vincristine Sulfate,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT05032183,Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT05032183,TERMINATED,Recurrent Adult Lymphoblastic Lymphoma|Recurrent B Acute Lymphoblastic Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Lymphoblastic Lymphoma|Refractory T Acute Lymphoblastic Leukemia,DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|BIOLOGICAL: Filgrastim-sndz|DRUG: Leucovorin|DRUG: Mercaptopurine|DRUG: Mesna|DRUG: Methotrexate|BIOLOGICAL: Pegfilgrastim|DRUG: Prednisone|BIOLOGICAL: Rituximab|BIOLOGICAL: Tagraxofusp-erzs|DRUG: Vincristine,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT01789255,"Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies",https://clinicaltrials.gov/study/NCT01789255,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|B-cell Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Intraocular Lymphoma|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Post-transplant Lymphoproliferative Disorder|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ringed Sideroblasts|Refractory Chronic Lymphocytic Leukemia|Refractory Cytopenia With Multilineage Dysplasia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Central Nervous System Hodgkin Lymphoma|Secondary Central Nervous System Non-Hodgkin Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia",DRUG: vorinostat|DRUG: tacrolimus|DRUG: cyclosporine|DRUG: methotrexate|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00898612,Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant,https://clinicaltrials.gov/study/NCT00898612,WITHDRAWN,Lymphoma,,Mayo Clinic,National Cancer Institute (NCI),OBSERVATIONAL
NCT02588456,Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02588456,TERMINATED,Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: CART22 cells,University of Pennsylvania,,INTERVENTIONAL
NCT01200017,Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01200017,NO_LONGER_AVAILABLE,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Lymphomas|Bone Marrow Failure|Hemoglobinopathy|Immune Deficiency|Osteopetrosis|Cytopenias|Leukocyte Disorders|Anemia Due to Intrinsic Red Cell Abnormality,"BIOLOGICAL: CD34+ enriched, T Cell Depleted donor stem cell product",Christopher Dvorak,,EXPANDED_ACCESS
NCT06581081,Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06581081,RECRUITING,Relapsed Adult ALL|B-cell Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|Relapsed Pediatric ALL,BIOLOGICAL: Senl_B19 autologous CAR-T (S1904) treatment,Peking University People's Hospital,"The First Affiliated Hospital of Soochow University|Nanfang Hospital, Southern Medical University",INTERVENTIONAL
NCT02487459,Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,https://clinicaltrials.gov/study/NCT02487459,WITHDRAWN,Hematologic Malignancies,BIOLOGICAL: BPX-501|DRUG: AP1903,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT04150497,Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01),https://clinicaltrials.gov/study/NCT04150497,RECRUITING,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: UCART22|BIOLOGICAL: CLLS52,Cellectis S.A.,,INTERVENTIONAL
NCT02443831,CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia,https://clinicaltrials.gov/study/NCT02443831,RECRUITING,Acute Lymphoblastic Leukemia,PROCEDURE: Leukapheresis|RADIATION: Total Body Irradiation (TBI)|DRUG: Lymphodepletion with Fludarabine|DRUG: Lymphodepletion with Cyclophosphamide|BIOLOGICAL: CD19+CD22 CAR T-cells,"University College, London",,INTERVENTIONAL
NCT00004114,Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer,https://clinicaltrials.gov/study/NCT00004114,WITHDRAWN,Leukemia|Lymphoma|Myelodysplastic Syndromes,BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: fludarabine phosphate|PROCEDURE: peripheral blood stem cell transplantation,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL
NCT02881086,"Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment",https://clinicaltrials.gov/study/NCT02881086,COMPLETED,Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma,DRUG: Rituximab|DRUG: Nelarabine|DRUG: PEG-Asparaginase|PROCEDURE: Cranial irradiation|DRUG: Imatinib|DRUG: Idarubicin|DRUG: Dexamethasone|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Vincristine|DRUG: Mercaptopurine|DRUG: VP16|DRUG: Daunorubicin (DNR)|DRUG: Methotrexate|PROCEDURE: Stem cell transplantation|DRUG: Cytarabine|DRUG: Vindesine|DRUG: Adriamycin|DRUG: Prednisolone,Goethe University,,INTERVENTIONAL
NCT00585195,"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",https://clinicaltrials.gov/study/NCT00585195,COMPLETED,Non-Small Cell Lung Cancer ALK-positive|Non-Small Cell Lung Cancer c-Met Dependent|Non-Small Cell Lung Cancer ROS Marker Positive|Systemic Anaplastic Large-Cell Lymphoma|Advanced Malignancies Except Leukemia,DRUG: PF-02341066|DRUG: Rifampin|DRUG: Itraconazole,Pfizer,,INTERVENTIONAL
NCT03467256,CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL,https://clinicaltrials.gov/study/NCT03467256,ACTIVE_NOT_RECRUITING,"B-cell Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia, Pediatric",BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Tocilizumab|DRUG: Cytarabine|DRUG: Etoposide|DRUG: Dexamethasone,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",,INTERVENTIONAL
NCT00571662,Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00571662,COMPLETED,Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplastic Syndromes|Multiple Myeloma|Non-Hodgkins Lymphoma|Hodgkins Disease|Peripheral T-cell Lymphoma,DRUG: Pentostatin|RADIATION: Total-body irradiation (TBI)|DRUG: Cyclosporine A (CsA)|DRUG: Mycophenolate Mofetil (MMF)|DRUG: G-CSF,University of Nebraska,"Astex Pharmaceuticals, Inc.",INTERVENTIONAL
NCT03226119,MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study,https://clinicaltrials.gov/study/NCT03226119,COMPLETED,HTLV-I Infections|HTLV-II Infections|Human T-lymphotropic Virus 1|Human T-lymphotropic Virus 2|HTLV I Associated T Cell Leukemia Lymphoma|HTLV I Associated Myelopathies,DIAGNOSTIC_TEST: MP Diagnostics HTLV Blot 2.4,"MP Biomedicals, LLC",MP Biomedicals Asia Pacific Pte. Ltd.,INTERVENTIONAL
NCT00340821,"A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis",https://clinicaltrials.gov/study/NCT00340821,COMPLETED,HTLV-I,,National Cancer Institute (NCI),,OBSERVATIONAL
NCT03146013,Dual Algorithm Post Market Clinical Study,https://clinicaltrials.gov/study/NCT03146013,COMPLETED,HTLV-I Infections|HTLV-II Infections|Human T-lymphotropic Virus 1|Human T-lymphotropic Virus 2|HTLV I Associated T Cell Leukemia Lymphoma|HTLV I Associated Myelopathies,DIAGNOSTIC_TEST: MP Diagnostics HTLV Blot 2.4,"MP Biomedicals, LLC",MP Biomedicals Asia Pacific Pte. Ltd.,OBSERVATIONAL
NCT03289455,CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL),https://clinicaltrials.gov/study/NCT03289455,COMPLETED,B Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia|B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: AUTO3 (CD19/22 CAR T cells,Autolus Limited,,INTERVENTIONAL
NCT00003728,Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00003728,UNKNOWN,Leukemia|Lymphoma,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: leucovorin calcium|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: mitoxantrone hydrochloride|DRUG: prednisolone|DRUG: therapeutic hydrocortisone|DRUG: thioguanine|DRUG: vincristine sulfate|DRUG: vindesine|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT00785330,Allo-hNHL (FluBuCy),https://clinicaltrials.gov/study/NCT00785330,COMPLETED,Non-Hodgkin's Lymphoma,DRUG: standard GVHD prophylaxis|DRUG: rituximab,Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH,University Hospital Goettingen|German High-Grade Non-Hodgkin's Lymphoma Study Group,INTERVENTIONAL
NCT03765177,CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies,https://clinicaltrials.gov/study/NCT03765177,RECRUITING,Acute Lymphoblastic Leukemia|Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia,BIOLOGICAL: CLIC-1901,Ottawa Hospital Research Institute,,INTERVENTIONAL
NCT06783816,A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors,https://clinicaltrials.gov/study/NCT06783816,RECRUITING,"Acute Lymphocytic Leukemia|Lymphoma,Non-Hodgkin|Relapsed Refractory Multiple Myeloma",DRUG: chimeric antigen receptor gene modified T cells,Shanxi Bethune Hospital,,INTERVENTIONAL
NCT00547196,AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders,https://clinicaltrials.gov/study/NCT00547196,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes,BIOLOGICAL: filgrastim|DRUG: Busulfan|DRUG: Cyclophosphamide|DRUG: Cyclosporine|DRUG: Fludarabine phosphate|DRUG: Melphalan|DRUG: Mycophenolate Mofetil|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: umbilical cord blood transplantation|RADIATION: total-body irradiation|RADIATION: Fractionated total body irradiation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01185886,Study of Blood and Tissue Samples in Children With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01185886,UNKNOWN,Leukemia|Lymphoma,GENETIC: gene expression analysis|GENETIC: mutation analysis|GENETIC: polymorphism analysis|OTHER: biologic sample preservation procedure|OTHER: laboratory biomarker analysis|OTHER: pharmacogenomic studies,European Organisation for Research and Treatment of Cancer - EORTC,,OBSERVATIONAL
NCT03432741,"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",https://clinicaltrials.gov/study/NCT03432741,TERMINATED,Breast Adenocarcinoma|Metastatic Breast Carcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Breast Carcinoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7,DRUG: Belinostat|DRUG: Carfilzomib|DRUG: Copanlisib Hydrochloride|BIOLOGICAL: Daratumumab|DRUG: Fludeoxyglucose F-18|DRUG: Gemcitabine Hydrochloride|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|BIOLOGICAL: Obinutuzumab|BIOLOGICAL: Pembrolizumab|PROCEDURE: Positron Emission Tomography|BIOLOGICAL: Rituximab|DRUG: Romidepsin|OTHER: Saline|BIOLOGICAL: Trastuzumab,Mayo Clinic,,INTERVENTIONAL
NCT00897767,Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial,https://clinicaltrials.gov/study/NCT00897767,COMPLETED,Leukemia|Lymphoma,OTHER: biologic sample preservation procedure,Eastern Cooperative Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT05329792,L19IL2/L19TNF in Skin Cancer Patients,https://clinicaltrials.gov/study/NCT05329792,RECRUITING,BCC - Basal Cell Carcinoma|SCC - Squamous Cell Carcinoma|Merkel Cell Carcinoma|Keratoacanthoma of Skin|Malignant Adnexal Tumors of the Skin (MATS)|Tumors From Cutaneous T-cell Lymphoma (CTCL)|Kaposi Sarcoma,DRUG: L19IL2/L19TNF,Philogen S.p.A.,,INTERVENTIONAL
NCT05255601,"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT05255601,RECRUITING,"Lymphoma, Non-Hodgkin|Hodgkin Disease",DRUG: Relatlimab|DRUG: Nivolumab,Bristol-Myers Squibb,,INTERVENTIONAL
NCT05665530,A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05665530,ACTIVE_NOT_RECRUITING,Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Mantle Cell Lymphoma (MCL)|Richter's Syndrome|T-cell Lymphoma|Diffuse Large B-cell Lymphoma (DLBCL)|Marginal Zone Lymphoma|Myeloid Malignancies|Acute Myeloid Leukemia (AML)|Chronic Myelomonocytic Leukemia (CMML)|Myelodysplastic Syndrome (MDS)|MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome,DRUG: PRT2527|DRUG: Zanubrutinib|DRUG: Venetoclax,Prelude Therapeutics,BeiGene,INTERVENTIONAL
NCT00889408,"DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",https://clinicaltrials.gov/study/NCT00889408,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: DT2219ARL,"Masonic Cancer Center, University of Minnesota",National Cancer Institute (NCI),INTERVENTIONAL
NCT05907603,Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML),https://clinicaltrials.gov/study/NCT05907603,COMPLETED,Neoplasms|Hematologic Neoplasms|Hematologic Diseases,DRUG: RD13-02 cell infusion,Kai Lin Xu，MD,"Nanjing Bioheng Biotech Co., Ltd.",INTERVENTIONAL
NCT01621477,T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,https://clinicaltrials.gov/study/NCT01621477,TERMINATED,"Acute Lymphoblastic Leukemia|Acute Myelocytic Leukemia|Chronic Myelocytic Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hodgkin or Non-Hodgkin Lymphoma|Sarcoma, Myeloid",DRUG: clofarabine|DRUG: cytarabine|DRUG: busulfan|DRUG: Plerixafor|DRUG: cyclophosphamide|DRUG: antithymocyte globulin (rabbit)|BIOLOGICAL: stem cells|DRUG: Tacrolimus|DRUG: mycophenolate mofetil,St. Jude Children's Research Hospital,Assisi Foundation,INTERVENTIONAL
NCT00185692,Allogeneic Transplantation From Related Haploidentical Donors,https://clinicaltrials.gov/study/NCT00185692,COMPLETED,Blood Cancer|Leukemia|Graft Versus Host Disease|Malignancy|CLL|NHL|Hodgkin's Disease|MDS,PROCEDURE: non-myeloablative hematopoietic cell transplantation|DRUG: Anti-Thymocyte Globulin|DRUG: Cyclosporine|DRUG: Mycophenolate Mofetil|DRUG: G-CSF|DRUG: Solumedrol|DRUG: Acetaminophen|DRUG: Diphenydramine|DRUG: Hydrocortisone,Stanford University,,INTERVENTIONAL
NCT00466531,Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19,https://clinicaltrials.gov/study/NCT00466531,ACTIVE_NOT_RECRUITING,Leukemia,BIOLOGICAL: therapeutic autologous lymphocytes|DRUG: cyclophosphamide,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03620058,CART22 Alone or in Combination With huCART19 for ALL,https://clinicaltrials.gov/study/NCT03620058,ACTIVE_NOT_RECRUITING,Chemotherapy Resistant Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: CART22-65s cells|BIOLOGICAL: huCART19 Cells,University of Pennsylvania,,INTERVENTIONAL
NCT00716911,Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00716911,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonneoplastic Condition,DRUG: ganciclovir|GENETIC: polymerase chain reaction|OTHER: flow cytometry|OTHER: immunologic technique|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: assessment of therapy complications|PROCEDURE: peripheral blood stem cell transplantation,City of Hope Medical Center,National Cancer Institute (NCI)|National Institute of Allergy and Infectious Diseases (NIAID),INTERVENTIONAL
NCT01467024,Evaluation of the MP Diagnostics HTLV Blot 2.4,https://clinicaltrials.gov/study/NCT01467024,UNKNOWN,HTLV-I Infections|HTLV-II Infections|Human T-lymphotropic Virus 1|Human T-lymphotropic Virus 2|HTLV I Associated T Cell Leukemia Lymphoma|HTLV I Associated Myelopathies,OTHER: CDPHL Algorithm,"MP Biomedicals, LLC",Vital Systems Inc.,OBSERVATIONAL
NCT01427881,Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies,https://clinicaltrials.gov/study/NCT01427881,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Myeloid Leukemia in Remission|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Multiple Myeloma|Testicular Lymphoma|Waldenström Macroglobulinemia,DRUG: cyclophosphamide|DRUG: cyclosporine|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: total-body irradiation|DRUG: fludarabine phosphate|DRUG: busulfan|PROCEDURE: allogeneic hematopoietic stem cell transplantation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04162353,BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma,https://clinicaltrials.gov/study/NCT04162353,UNKNOWN,Multiple Myeloma in Relapse|Refractory Multiple Myeloma|Plasmacytoid; Lymphoma,BIOLOGICAL: BCMA-CD19 cCAR T cells,iCell Gene Therapeutics,iCAR Bio Therapeutics Ltd.|Peking University Shenzhen Hospital,INTERVENTIONAL
NCT04136756,NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT04136756,COMPLETED,Multiple Myeloma|Non-Hodgkin Lymphoma|Indolent Non-Hodgkin Lymphoma,DRUG: NKTR-255|DRUG: NKTR-255 Q21|DRUG: Rituximab|DRUG: Daratumumab,Nektar Therapeutics,,INTERVENTIONAL
NCT00769613,Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections,https://clinicaltrials.gov/study/NCT00769613,UNKNOWN,Cancer,BIOLOGICAL: cytomegalovirus IE-1-specific cytotoxic T lymphocytes|BIOLOGICAL: cytomegalovirus pp65-specific cytotoxic T lymphocytes|BIOLOGICAL: therapeutic allogeneic lymphocytes|GENETIC: polymerase chain reaction|OTHER: flow cytometry|OTHER: immunological diagnostic method|OTHER: laboratory biomarker analysis,Milton S. Hershey Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03779854,Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT03779854,RECRUITING,Acute Biphenotypic Leukemia|Acute Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Lymphoblastic Leukemia|Acute Undifferentiated Leukemia|Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Blastic Plasmacytoid Dendritic Cell Neoplasm|Blasts Under 25 Percent of Bone Marrow Nucleated Cells|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome/Acute Myeloid Leukemia|Burkitt Leukemia|Chronic Monocytic Leukemia|Lymphoblastic Lymphoma|Mast Cell Leukemia|Myeloproliferative Neoplasm,RADIATION: Total-Body Irradiation|DRUG: Thiotepa|DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Busulfan|PROCEDURE: Allogeneic Bone Marrow Transplantation|DRUG: Tacrolimus|DRUG: Methotrexate|PROCEDURE: Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation|PROCEDURE: Echocardiography|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05038696,ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.,https://clinicaltrials.gov/study/NCT05038696,RECRUITING,"Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Leukemia|Lymphoblastic Leukemia, Acute Adult|Lymphoblastic Leukemia in Children|CAR|CAR T-Cell-Related Encephalopathy Syndrome",BIOLOGICAL: CAR T-cell therapy,"National University Hospital, Singapore",,INTERVENTIONAL
NCT04557436,TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL),https://clinicaltrials.gov/study/NCT04557436,COMPLETED,B Acute Lymphoblastic Leukemia,DRUG: PBLTT52CAR19,Great Ormond Street Hospital for Children NHS Foundation Trust,"University College, London",INTERVENTIONAL
NCT04792593,Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04792593,UNKNOWN,B-ALL,BIOLOGICAL: Senl-h19 CAR-T,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT00787761,"Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer",https://clinicaltrials.gov/study/NCT00787761,COMPLETED,Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: anti-thymocyte globulin|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: tacrolimus|PROCEDURE: nonmyeloablative allogeneic HSCT,"Northside Hospital, Inc.",Blood and Marrow Transplant Group of Georgia,INTERVENTIONAL
NCT01044069,Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19,https://clinicaltrials.gov/study/NCT01044069,ACTIVE_NOT_RECRUITING,Leukemia|Acute Lymphoblastic Leukemia,BIOLOGICAL: gene-modified T cells targeted,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT02186860,Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02186860,UNKNOWN,Acute Lymphoblastic Leukemia,BIOLOGICAL: CAR-T cells,Affiliated Hospital to Academy of Military Medical Sciences,,INTERVENTIONAL
NCT04881240,Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia,https://clinicaltrials.gov/study/NCT04881240,RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory|Pediatric ALL",BIOLOGICAL: CD19-CAR(Mem) T-cells|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Mesna|DEVICE: CliniMACS|PROCEDURE: Leukapheresis,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT02071888,Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors,https://clinicaltrials.gov/study/NCT02071888,COMPLETED,"Non-Hodgkin's Lymphoma (NHL)|Multiple Myeloma|Waldenstrom's Macroglobulinemia (WM)|Other B-cell NHL Subtypes, Including WM|T-cell NHL","DRUG: CB-839|DRUG: CB-839 and low dose dexamethasone|DRUG: CB-839, pomalidomide, and low dose dexamethasone","Calithera Biosciences, Inc",,INTERVENTIONAL
NCT00534118,Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00534118,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: donor lymphocytes,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT03533816,Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide,https://clinicaltrials.gov/study/NCT03533816,UNKNOWN,Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes,DRUG: EAGD T-cell infusion (Phase I)|DRUG: EAGD T-cell infusion (Expansion),University of Kansas Medical Center,In8bio Inc.,INTERVENTIONAL
NCT01588015,Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01588015,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Promyelocytic Leukemia (M3)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma|B-cell Adult Acute Lymphoblastic Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cytomegalovirus Infection|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Isolated Plasmacytoma of Bone|Monoclonal Gammopathy of Undetermined Significance|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Central Nervous System Hodgkin Lymphoma|Primary Central Nervous System Non-Hodgkin Lymphoma|Primary Myelofibrosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Multiple Myeloma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia",BIOLOGICAL: tetanus-CMV fusion peptide vaccine|OTHER: laboratory biomarker analysis,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00570999,Palifermin After Haploidentical PBSCT,https://clinicaltrials.gov/study/NCT00570999,WITHDRAWN,Non-Hodgkin's Lymphoma or Hodgkin's Disease|Acute Leukaemia|Myelodysplastic Syndrome|Chronic Myeloid Leukemia|Osteomyelofibrosis,DRUG: Palifermin|OTHER: Placebo,European Society for Blood and Marrow Transplantation,Amgen,INTERVENTIONAL
NCT00378534,Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants,https://clinicaltrials.gov/study/NCT00378534,COMPLETED,Chronic Myelogenous Leukemia|Acute Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome,DEVICE: Miltenyi reagent system|DRUG: Fludarabine|DRUG: Cyclosporine|DRUG: Cyclophosphamide|OTHER: FILGRASTIM (G-CSF),"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT04254107,A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer,https://clinicaltrials.gov/study/NCT04254107,TERMINATED,Non-small Cell Lung Cancer|Gastric Carcinoma|Gastroesophageal Junction Carcinoma|Classical Hodgkin Lymphoma|Diffuse Large B-cell Lymphoma|Peripheral T-cell Lymphoma|Cutaneous Melanoma|Head and Neck Squamous Cell Carcinoma|Bladder Cancer|Ovarian Cancer|Triple Negative Breast Cancer|Cervical Cancer,DRUG: SEA-TGT|DRUG: sasanlimab|DRUG: brentuximab vedotin,Seagen Inc.,,INTERVENTIONAL
NCT01199562,Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01199562,COMPLETED,"Hematopoietic/Lymphoid Cancer|Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Aplastic Anemia|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Cytomegalovirus Infection|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia",PROCEDURE: infection prophylaxis and management|OTHER: laboratory biomarker analysis|OTHER: flow cytometry|GENETIC: DNA analysis|GENETIC: RNA analysis|PROCEDURE: management of therapy complications|DRUG: ganciclovir|DRUG: valganciclovir|DRUG: foscarnet sodium|PROCEDURE: antiviral therapy|GENETIC: polymerase chain reaction|GENETIC: protein expression analysis,City of Hope Medical Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00782379,"Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT00782379,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes,DRUG: busulfan|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,"Northside Hospital, Inc.",,INTERVENTIONAL
NCT01088763,"Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia",https://clinicaltrials.gov/study/NCT01088763,TERMINATED,"Childhood Atypical Teratoid/Rhabdoid Tumor|Childhood Central Nervous System Choriocarcinoma|Childhood Central Nervous System Germinoma|Childhood Central Nervous System Mixed Germ Cell Tumor|Childhood Central Nervous System Teratoma|Childhood Central Nervous System Yolk Sac Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood Infratentorial Ependymoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Gonadotroph Adenoma|Pituitary Basophilic Adenoma|Pituitary Chromophobe Adenoma|Pituitary Eosinophilic Adenoma|Prolactin Secreting Adenoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Central Nervous System Embryonal Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Childhood Spinal Cord Neoplasm|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Childhood Visual Pathway Glioma|Recurrent Pituitary Tumor|Recurrent/Refractory Childhood Hodgkin Lymphoma|T-cell Childhood Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|TSH Secreting Adenoma|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: gamma-secretase/Notch signalling pathway inhibitor RO4929097|OTHER: diagnostic laboratory biomarker analysis|OTHER: pharmacological study|DRUG: dexamethasone,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00967343,"Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor",https://clinicaltrials.gov/study/NCT00967343,TERMINATED,Myeloid Leukemia|Lymphoblastic Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome|Myeloproliferative Disorders,BIOLOGICAL: Donor lymphocyte preparation depleted of host functional alloreactive T-cells,Kiadis Pharma,,INTERVENTIONAL
NCT03244306,A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma,https://clinicaltrials.gov/study/NCT03244306,ACTIVE_NOT_RECRUITING,Leukemia,BIOLOGICAL: Patient-derived CD22-specific CAR T-cells also expressing an EGFRt,Seattle Children's Hospital,,INTERVENTIONAL
NCT06659653,Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease.,https://clinicaltrials.gov/study/NCT06659653,RECRUITING,Acute Lymphoblastic Leukemia,DRUG: PRG2302,Tan Jie,"Shenzhen Pregene Biopharma Co., Ltd.",INTERVENTIONAL
NCT03326921,HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT03326921,SUSPENDED,"Juvenile Myelomonocytic Leukemia|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Undifferentiated Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Myelodysplastic Syndrome|Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm|Refractory Myelodysplastic Syndrome|Acute Undifferentiated Leukemia|Mixed Phenotype Acute Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Acute Biphenotypic Leukemia|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Minimal Residual Disease|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Leukemia",BIOLOGICAL: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|OTHER: Laboratory Biomarker Analysis,Fred Hutchinson Cancer Center,"HighPass Bio, Inc.|PromiCell Therapeutics, Inc.",INTERVENTIONAL
NCT00145613,Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT00145613,COMPLETED,"Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Secondary AML|Myelodysplastic Syndrome (MDS)|Secondary MDS|Chronic Myeloid Leukemia|Juvenile Myelomonocytic Leukemia (JMML)|Paroxysmal Nocturnal Hemoglobinuria (PNH)|Lymphoma, Non-Hodgkin|Hodgkin Disease",PROCEDURE: Stem Cell Transplantation|DEVICE: Miltenyi Biotec CliniMACS|DRUG: Systemic chemotherapy and antibodies,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,https://clinicaltrials.gov/study/NCT00474929,COMPLETED,Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,DRUG: RAD001|DRUG: Sorafenib,Mayo Clinic,University of Iowa,INTERVENTIONAL
NCT04404660,A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL),https://clinicaltrials.gov/study/NCT04404660,ACTIVE_NOT_RECRUITING,Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia,BIOLOGICAL: AUTO1,Autolus Limited,,INTERVENTIONAL
NCT00421213,Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers,https://clinicaltrials.gov/study/NCT00421213,COMPLETED,Hematologic Neoplasms|Bone Marrow Neoplasms|Non-Hodgkin's Lymphoma,DRUG: Darinaparsin,Alaunos Therapeutics,,INTERVENTIONAL
NCT00089011,Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT00089011,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies|Waldenström Macroglobulinemia,DRUG: fludarabine phosphate|RADIATION: total-body irradiation|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00105001,Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT00105001,COMPLETED,"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndrome|Refractory Chronic Lymphocytic Leukemia|Refractory Plasma Cell Myeloma|Waldenstrom Macroglobulinemia|Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Lymphoma|Childhood Myelodysplastic Syndrome|Stage II Contiguous Adult Burkitt Lymphoma|Stage II Contiguous Adult Diffuse Large Cell Lymphoma|Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma|Stage II Contiguous Adult Diffuse Small Cleaved Cell Lymphoma|Stage II Adult Contiguous Immunoblastic Lymphoma|Stage II Contiguous Adult Lymphoblastic Lymphoma|Stage II Grade 1 Contiguous Follicular Lymphoma|Stage II Grade 2 Contiguous Follicular Lymphoma|Stage II Grade 3 Contiguous Follicular Lymphoma|Stage II Contiguous Mantle Cell Lymphoma|Stage II Non-Contiguous Adult Burkitt Lymphoma|Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma|Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma|Stage II Non-Contiguous Adult Diffuse Small Cleaved Cell Lymphoma|Stage II Adult Non-Contiguous Immunoblastic Lymphoma|Stage II Non-Contiguous Adult Lymphoblastic Lymphoma|Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Stage II Grade 3 Non-Contiguous Follicular Lymphoma|Stage II Non-Contiguous Mantle Cell Lymphoma|Stage II Small Lymphocytic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Burkitt Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Recurrent Childhood Hodgkin Lymphoma|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Myelodysplastic Syndrome|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Burkitt Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Small Lymphocytic Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Burkitt Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Burkitt Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Burkitt Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma",DRUG: Fludarabine Phosphate|RADIATION: Total-Body Irradiation|PROCEDURE: Peripheral Blood Stem Cell Transplantation|PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Tacrolimus|DRUG: Mycophenolate Mofetil|DRUG: Sirolimus,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00028730,Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00028730,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: thiotepa|PROCEDURE: allogeneic bone marrow transplantation|RADIATION: radiation therapy,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00047021,Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma,https://clinicaltrials.gov/study/NCT00047021,COMPLETED,Leukemia|Lymphoma,BIOLOGICAL: sargramostim|DRUG: cytarabine|DRUG: mitoxantrone hydrochloride,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01643603,Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01643603,TERMINATED,Non-Hodgkin's Lymphoma|Hodgkin's Lymphoma|Myeloid Leukemia|Multiple Myeloma|Myelodysplastic Syndrome|Lymphoid Leukemia,DRUG: Dasatinib|OTHER: laboratory biomarker analysis,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT03291444,CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS,https://clinicaltrials.gov/study/NCT03291444,RECRUITING,"Leukemia, Acute Lymphocytic (ALL)|Leukemia, Acute Myelogenous (AML)|Myelodysplastic Syndromes",BIOLOGICAL: Chimeric antigen receptor T cells|BIOLOGICAL: peptide specific dendritic cell,Zhujiang Hospital,Shenzhen Geno-Immune Medical Institute|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,INTERVENTIONAL
NCT02520479,"""Sandwich"" Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL",https://clinicaltrials.gov/study/NCT02520479,TERMINATED,Treatment Refusal,DRUG: P-CHOP|RADIATION: Radiotherapy|DRUG: P-CHOP,Sun Yat-sen University,,INTERVENTIONAL
NCT05770037,"DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers",https://clinicaltrials.gov/study/NCT05770037,RECRUITING,Haematological Malignancy|Malignant Neoplasm|Lymphoproliferative Disorders|Neoplasms by Histologic Type|Neoplasms by Site|Cancer|Anaplastic Large Cell Lymphoma|Lymphoma|Renal Cell Carcinoma|Neuroblastoma|Solid Tumour,DRUG: Alectinib,Cancer Research UK,University of Manchester|University of Birmingham|Royal Marsden NHS Foundation Trust|Hoffmann-La Roche,INTERVENTIONAL
NCT00878189,A Trial In Patients With Advanced Cancer And Leukemia,https://clinicaltrials.gov/study/NCT00878189,COMPLETED,Neoplasms by Histologic Type,DRUG: PF-03084014,Pfizer,,INTERVENTIONAL
NCT02978235,A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma,https://clinicaltrials.gov/study/NCT02978235,TERMINATED,Multiple Myeloma|NonHodgkin Lymphoma,DRUG: TAS4464,"Taiho Oncology, Inc.",,INTERVENTIONAL
NCT00014235,Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00014235,COMPLETED,"Acute Myeloid Leukemia/Transient Myeloproliferative Disorder|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Plasmacytoid Dendritic Cell Neoplasm|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage II Multiple Myeloma|Stage III Multiple Myeloma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies|Waldenström Macroglobulinemia",DRUG: fludarabine phosphate|RADIATION: total-body irradiation|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|DRUG: cyclosporine|DRUG: mycophenolate mofetil|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",INTERVENTIONAL
NCT01460134,A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers,https://clinicaltrials.gov/study/NCT01460134,COMPLETED,"CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Marginal Zone B Cell Lymphoma)|Any T-cell Malignancy|Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma|Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer|Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)|Burkett's Lymphoma|Primary Lymphoma of the Central Nervous System",DRUG: CDX-1127|DRUG: CDX-1127|DRUG: CDX-1127,Celldex Therapeutics,,INTERVENTIONAL
NCT05707273,CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission,https://clinicaltrials.gov/study/NCT05707273,ACTIVE_NOT_RECRUITING,B Acute Lymphoblastic Leukemia,DRUG: Autologous Anti-CD19 CAR-expressing T Lymphocytes|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration and Biopsy|DRUG: Cyclophosphamide|DRUG: Fludarabine|PROCEDURE: Leukapheresis|OTHER: Questionnaire Administration,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02722668,UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep,https://clinicaltrials.gov/study/NCT02722668,ACTIVE_NOT_RECRUITING,Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia/Lymphoma|Burkitt's Lymphoma|Natural Killer Cell Malignancies|Chronic Myelogenous Leukemia|Myelodysplastic Syndrome|Large-cell Lymphoma|Hodgkin Lymphoma|Multiple Myeloma|Relapsed Chronic Lymphocytic Leukemia|Relapsed Small Lymphocytic Lymphoma|Marginal Zone B-cell Lymphoma|Follicular Lymphoma|Lymphoplasmacytic Lymphoma|Mantle-cell Lymphoma|Prolymphocytic Leukemia|Bone Marrow Failure Syndromes|Myeloproliferative Neoplasms/Myelofibrosis|Biphenotypic/Undifferentiated/Prolymphocytic Leukemias|MRD Positive Leukemia|Leukemia or MDS in Aplasia|Relapsed T-Cell Lymphoma|Relapsed Multiple Myeloma|Plasma Cell Leukemia,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: MMF|DRUG: Sirolimus|RADIATION: TBI|BIOLOGICAL: Umbilical cord blood cell infusion|BIOLOGICAL: ATG,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT03012620,Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types,https://clinicaltrials.gov/study/NCT03012620,COMPLETED,"Sarcoma|Ovarian Neoplasm|Central Nervous System Neoplasm|Thyroid Neoplasm|Carcinoma, Neuroendocrine|Neoplasms, Germ Cell and Embryonal|NK/T-cell Lymphoma",DRUG: Pembrolizumab,UNICANCER,"National Cancer Institute, France|Ligue contre le cancer, France|Merck Sharp & Dohme LLC",INTERVENTIONAL
NCT04994210,Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL,https://clinicaltrials.gov/study/NCT04994210,RECRUITING,Safety and Efficacy,DRUG: Sintilimab|DRUG: Chidamide,Sun Yat-sen University,,INTERVENTIONAL
NCT05223686,To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.,https://clinicaltrials.gov/study/NCT05223686,UNKNOWN,Acute Lymphoblastic Leukemia,DRUG: Human CD19-CD22 Targeted T Cells Injection,"Hrain Biotechnology Co., Ltd.",Ruijin Hospital,INTERVENTIONAL
NCT00582933,"Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor",https://clinicaltrials.gov/study/NCT00582933,COMPLETED,Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma|Allogeneic Marrow Transplant,"DRUG: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|DRUG: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|DRUG: BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF",Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT01162031,Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia,https://clinicaltrials.gov/study/NCT01162031,WITHDRAWN,Leukemia|Acute Lymphocytic Leukemia,DRUG: Velcade,Stanford University,"Millennium Pharmaceuticals, Inc.",INTERVENTIONAL
NCT03573700,Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03573700,ACTIVE_NOT_RECRUITING,"Acute Lymphoblastic Leukemia, in Relapse|Acute Lymphoblastic Leukemia, Refractory",DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Mesna|DEVICE: CliniMACS|BIOLOGICAL: CD19- specific CAR engineered autologous T-cells (SJCAR19 product),St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT00112593,Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer,https://clinicaltrials.gov/study/NCT00112593,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aggressive NK-cell Leukemia|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|HIV Infection|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Central Nervous System Lymphoma|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage 0 Chronic Lymphocytic Leukemia|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Small Lymphocytic Lymphoma|Stage IA Mycosis Fungoides/Sezary Syndrome|Stage IB Mycosis Fungoides/Sezary Syndrome|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage IIA Mycosis Fungoides/Sezary Syndrome|Stage IIB Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IIIA Mycosis Fungoides/Sezary Syndrome|Stage IIIB Mycosis Fungoides/Sezary Syndrome|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Stage IVA Mycosis Fungoides/Sezary Syndrome|Stage IVB Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: fludarabine phosphate|RADIATION: total-body irradiation|PROCEDURE: peripheral blood stem cell transplantation|DRUG: cyclosporine|DRUG: mycophenolate mofetil|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05464836,Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL,https://clinicaltrials.gov/study/NCT05464836,TERMINATED,"Leukemia, Lymphoblastic|Leukemia",DRUG: CB-103|DRUG: Venetoclax,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT03594162,Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch,https://clinicaltrials.gov/study/NCT03594162,NO_LONGER_AVAILABLE,Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders,DRUG: iC9-CAR19 cells|DRUG: AP1903|DRUG: Cyclophosphamide|DRUG: Fludarabine,UNC Lineberger Comprehensive Cancer Center,Bellicum Pharmaceuticals,EXPANDED_ACCESS
NCT06847269,"CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia",https://clinicaltrials.gov/study/NCT06847269,RECRUITING,Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Mesna|BIOLOGICAL: CD19-CAR T cell Infusion,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT04747236,Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL,https://clinicaltrials.gov/study/NCT04747236,RECRUITING,PTCL,DRUG: Azacytidine|DRUG: Romidepsin|DRUG: Belinostat|DRUG: Pralatrexate|DRUG: Gemcitabine,University of Virginia,Celgene,INTERVENTIONAL
NCT00005606,Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation,https://clinicaltrials.gov/study/NCT00005606,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,BIOLOGICAL: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|BIOLOGICAL: autologous Epstein-Barr virus-specific cytotoxic T lymphocytes,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT04626726,Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT04626726,UNKNOWN,Adult B Acute Lymphoblastic Leukemia,DRUG: CD19 CAR-T|DRUG: CD22 CAR-T|DRUG: CD19+CD22 CAR-T|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Hebei Senlang Biotechnology Inc., Ltd.",,INTERVENTIONAL
NCT04000698,Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias,https://clinicaltrials.gov/study/NCT04000698,UNKNOWN,Refractory Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia,DRUG: Preparative regimen,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",,INTERVENTIONAL
NCT02746952,Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia,https://clinicaltrials.gov/study/NCT02746952,COMPLETED,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: UCART19,Institut de Recherches Internationales Servier,"ADIR, a Servier Group company",INTERVENTIONAL
NCT00322296,Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis,https://clinicaltrials.gov/study/NCT00322296,TERMINATED,Parapsoriasis,DRUG: Bexarotene 1% gel,Fox Chase Cancer Center,Ligand Pharmaceuticals,INTERVENTIONAL
NCT02030847,Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02030847,COMPLETED,"Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options",BIOLOGICAL: CART-19|BIOLOGICAL: CART-19|BIOLOGICAL: CART-19|BIOLOGICAL: CART-19,University of Pennsylvania,,INTERVENTIONAL
NCT00093704,Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma,https://clinicaltrials.gov/study/NCT00093704,TERMINATED,Lymphoma|Lymphoproliferative Disorder,DRUG: bortezomib + ganciclovir,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL
NCT06481228,Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL,https://clinicaltrials.gov/study/NCT06481228,RECRUITING,"Philadelphia Positive Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia, Adult",COMBINATION_PRODUCT: CAR-T cells|DRUG: Venetoclax|DRUG: Olverembatinib,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT06752785,CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.,https://clinicaltrials.gov/study/NCT06752785,RECRUITING,Acute Lymphoblastic Leukemia,DRUG: CAR-T Therapy,Guangzhou Women and Children's Medical Center,,INTERVENTIONAL
NCT03340155,Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases,https://clinicaltrials.gov/study/NCT03340155,UNKNOWN,Psoriasis|Cutaneous T Cell Lymphoma|Lymphoproliferative Disorders|Eczema|Lichen Planus|Prurigo|Pruritus|Polymorphic Light Eruption|Graft Vs Host Disease|Mastocytosis|Vitiligo,OTHER: Photo(chemo)therapy,Medical University of Graz,,INTERVENTIONAL
NCT05168748,CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05168748,WITHDRAWN,Acute Lymphoblastic Leukemia,DRUG: IMJ995 single agent,Novartis Pharmaceuticals,,INTERVENTIONAL
NCT00003398,Bone Marrow Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00003398,COMPLETED,Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: thiotepa|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: bone marrow ablation with stem cell support|RADIATION: radiation therapy,"University of Maryland, Baltimore",University of Maryland Greenebaum Cancer Center,INTERVENTIONAL
NCT00506948,"Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)",https://clinicaltrials.gov/study/NCT00506948,TERMINATED,Hematological Malignancies|Myelodysplastic Syndrome|Leukemia|Lymphoma,DRUG: Mycophenolate Mofetil (MMF)|DRUG: Thymoglobulin|DRUG: Sirolimus|PROCEDURE: Stem Cell Transplant,M.D. Anderson Cancer Center,"Genzyme, a Sanofi Company",INTERVENTIONAL
NCT00612716,"Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT00612716,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,DRUG: busulfan|DRUG: cyclophosphamide|BIOLOGICAL: Stem cell infusion|RADIATION: Total body irradiation,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00470405,Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00470405,COMPLETED,Lymphoma|Solid Tumor,DRUG: oxaliplatin|DRUG: pemetrexed disodium,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00079391,Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies,https://clinicaltrials.gov/study/NCT00079391,COMPLETED,Hematologic Malignancies|Bone Marrow Transplant Rejection,DEVICE: allogeneic hematopoietic stem cell transplantation,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT06777264,Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1,https://clinicaltrials.gov/study/NCT06777264,NOT_YET_RECRUITING,Acute Lymphoblastic Leukemia|B Cell ALL,BIOLOGICAL: Biological: single dose of Inaticabtagene autoleucel,First Affiliated Hospital of Zhejiang University,,INTERVENTIONAL
NCT00104858,"Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",https://clinicaltrials.gov/study/NCT00104858,COMPLETED,Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma|T-Cell Large Granular Lymphocyte Leukemia,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Cyclosporine|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|OTHER: Pharmacological Study|BIOLOGICAL: Rituximab|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02465528,Ceritinib Rare Indications Study in ALK+ Tumors,https://clinicaltrials.gov/study/NCT02465528,TERMINATED,Tumors With Aberrations in ALK|Anaplastic Large Cell Lymphoma|Inflammatory Myofibroblastic Tumor|Glioblastoma,DRUG: Ceritinib (LDK378),Novartis Pharmaceuticals,,INTERVENTIONAL
NCT05805605,Allo HSCT Using RIC and PTCy for Hematological Diseases,https://clinicaltrials.gov/study/NCT05805605,RECRUITING,"Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Biphenotypic Acute Leukemia|Undifferentiated Leukemia|Prolymphocytic Leukemia|Chronic Myelogenous Leukemia|Plasma Cell Leukemia|Myelodysplastic Syndromes|Leukemia, Myeloid|Myelodysplastic Syndrome With Excess Blasts-1|Burkitt Lymphoma|Relapsed T-Cell Lymphoma|Relapsed Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Marginal Zone Lymphoma|Follicular Lymphoma|Myeloproliferative Neoplasm|Myelofibrosis",BIOLOGICAL: Peripheral Blood Stem Cell Transplant|DRUG: Allopurinol 300 MG|DRUG: Fludarabine|DRUG: Cyclophosphamide|BIOLOGICAL: Bone Marrow Cell Transplant|RADIATION: Total Body Irradiation|DRUG: Sirolimus Pill|DRUG: Mycophenolate Mofetil,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00557193,Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00557193,COMPLETED,Acute Lymphoblastic Leukemia|Acute Undifferentiated Leukemia|Childhood T Acute Lymphoblastic Leukemia,DRUG: Asparaginase|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Biopsy|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin Hydrochloride|DRUG: Dexamethasone|PROCEDURE: Echocardiography|DRUG: Etoposide|BIOLOGICAL: Filgrastim|OTHER: Laboratory Biomarker Analysis|DRUG: Lestaurtinib|DRUG: Leucovorin Calcium|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Methylprednisolone|PROCEDURE: Multigated Acquisition Scan|DRUG: Pegaspargase|OTHER: Pharmacological Study|DRUG: Prednisone|DRUG: Therapeutic Hydrocortisone|DRUG: Vincristine Sulfate,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT02890368,Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides,https://clinicaltrials.gov/study/NCT02890368,TERMINATED,Solid Tumors|Mycosis Fungoides|Melanoma|Merkel-cell Carcinoma|Squamous Cell Carcinoma|Breast Carcinoma|Human Papillomavirus-Related Malignant Neoplasm|Soft Tissue Sarcoma,DRUG: TTI-621 Monotherapy|DRUG: TTI-621 + PD-1/PD-L1 Inhibitor|DRUG: TTI-621 + pegylated interferon-α2a|OTHER: TTI-621 + T-Vec|OTHER: TTI-621 + radiation,Pfizer,,INTERVENTIONAL
NCT01529827,"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",https://clinicaltrials.gov/study/NCT01529827,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Aplastic Anemia|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Congenital Amegakaryocytic Thrombocytopenia|Diamond-Blackfan Anemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Paroxysmal Nocturnal Hemoglobinuria|Peripheral T-cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Severe Combined Immunodeficiency|Severe Congenital Neutropenia|Shwachman-Diamond Syndrome|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome",DRUG: fludarabine phosphate|DRUG: melphalan|RADIATION: total-body irradiation|DRUG: tacrolimus|DRUG: mycophenolate mofetil|DRUG: methotrexate|OTHER: laboratory biomarker analysis|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT05480501,Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05480501,UNKNOWN,Leukemia,BIOLOGICAL: IM19 CAR-T cells,"Beijing Immunochina Medical Science & Technology Co., Ltd.",,INTERVENTIONAL
NCT06481241,Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL,https://clinicaltrials.gov/study/NCT06481241,RECRUITING,"Philadelphia Chromosome Negative ALL|Acute Lymphoblastic Leukemia, Adult",COMBINATION_PRODUCT: CAR-T cells|DRUG: Venetoclax,"Institute of Hematology & Blood Diseases Hospital, China",,INTERVENTIONAL
NCT05535855,UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1,https://clinicaltrials.gov/study/NCT05535855,RECRUITING,Acute Lymphoid Leukemia|Acute Lymphoblastic Leukemia,DRUG: CD19 Directed CAR T Cell,"University of Colorado, Denver",,INTERVENTIONAL
NCT05066958,Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT,https://clinicaltrials.gov/study/NCT05066958,UNKNOWN,"Acute Myeloid Leukemia|High Risk Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia, in Relapse|High Risk Acute Lymphoblastic Leukemia|Acute Biphenotypic Leukemia in Relapse|Non-hodgkin Lymphoma|Myelodysplastic Syndromes",BIOLOGICAL: boost anti-viral immunity after T-cell depleted HSCT,"Federal Research Institute of Pediatric Hematology, Oncology and Immunology",,INTERVENTIONAL
NCT00489203,Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT00489203,COMPLETED,"Hematopoietic/Lymphoid Cancer|Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 1 Follicular Lymphoma|Contiguous Stage II Grade 2 Follicular Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|Contiguous Stage II Marginal Zone Lymphoma|Contiguous Stage II Small Lymphocytic Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Isolated Plasmacytoma of Bone|Juvenile Myelomonocytic Leukemia|Meningeal Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Disease, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Diffuse Small Cleaved Cell Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Adult T-cell Leukemia/Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage I Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage I Small Lymphocytic Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage II Adult T-cell Leukemia/Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma",DRUG: beclomethasone dipropionate|DRUG: placebo|DRUG: tacrolimus|DRUG: methotrexate|PROCEDURE: allogeneic hematopoietic stem cell transplantation,Fred Hutchinson Cancer Center,,INTERVENTIONAL
NCT04137900,"Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies",https://clinicaltrials.gov/study/NCT04137900,RECRUITING,Advanced Unresectable Solid Tumor|Metastatic Solid Tumor,DRUG: TAB004|DRUG: Toripalimab,TopAlliance Biosciences,"Shanghai Junshi Bioscience Co., Ltd.|CTI Clinical Trial and Consulting Services",INTERVENTIONAL
NCT05260203,MargheRITA (Remote Intelligence for Therapeutic Adherence),https://clinicaltrials.gov/study/NCT05260203,COMPLETED,Multiple Myeloma|Solitary Plasmacytoma|Amyloidosis|Chronic Myeloid Leukemia|Chronic Lymphocytic Leukemia|T Cell Non-Hodgkin Lymphoma|Lymphocytic Lymphoma|Hodgkin Lymphoma|B-cell Non Hodgkin Lymphoma|Acute Myeloid Leukemia|Myelodysplasia|Chronic Myeloproliferative Disorder|Treatment Adherence|Treatment Adherence and Compliance,DEVICE: RITA (App),Advice Pharma Group srl,,INTERVENTIONAL
NCT06447987,Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06447987,RECRUITING,Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|BIOLOGICAL: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|BIOLOGICAL: Cetuximab|PROCEDURE: Computed Tomography|DRUG: Cyclophosphamide|PROCEDURE: Echocardiography|DRUG: Fludarabine|PROCEDURE: Leukapheresis|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Positron Emission Tomography,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03063632,Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma,https://clinicaltrials.gov/study/NCT03063632,COMPLETED,Metastatic Myxoid Liposarcoma|Metastatic Round Cell Liposarcoma|Metastatic Synovial Sarcoma|Recurrent Mycosis Fungoides and Sezary Syndrome|Refractory Mycosis Fungoides and Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7|Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7|Unresectable Synovial Sarcoma,BIOLOGICAL: Interferon Gamma-1b|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00317785,Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases,https://clinicaltrials.gov/study/NCT00317785,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes,DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: methotrexate|DRUG: mycophenolate mofetil|DRUG: sirolimus|DRUG: tacrolimus|OTHER: pharmacological study|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: total-body irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00856388,"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders",https://clinicaltrials.gov/study/NCT00856388,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Aplastic Anemia|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Fanconi Anemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Paroxysmal Nocturnal Hemoglobinuria|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Waldenström Macroglobulinemia",DRUG: fludarabine phosphate|DRUG: melphalan|RADIATION: total-body irradiation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|BIOLOGICAL: anti-thymocyte globulin,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT06481735,TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL,https://clinicaltrials.gov/study/NCT06481735,RECRUITING,Acute Lymphocytic Leukemia,BIOLOGICAL: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell|DRUG: Fludarabine|DRUG: Cyclophosphamide,Chinese PLA General Hospital,Peking University,INTERVENTIONAL
NCT00004904,Stem Cell Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00004904,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|DRUG: cladribine|DRUG: cyclophosphamide|DRUG: etoposide|DRUG: methylprednisolone|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT03018093,A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL,https://clinicaltrials.gov/study/NCT03018093,UNKNOWN,Relapsed or Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: C-CAR-011,Shanghai AbelZeta Ltd.,Chinese PLA General Hospital,INTERVENTIONAL
NCT01076270,Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01076270,TERMINATED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma",DRUG: plerixafor|BIOLOGICAL: filgrastim|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03977103,Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT,https://clinicaltrials.gov/study/NCT03977103,UNKNOWN,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Myeloproliferative Disorders|Lymphoma|Multiple Myeloma|Other Hematologic Malignant Neoplasms,BIOLOGICAL: High dose irradiation conditioning + Treg/Tcon,University Of Perugia,,INTERVENTIONAL
NCT00536601,High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors,https://clinicaltrials.gov/study/NCT00536601,COMPLETED,"Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Plasma Cell Neoplasm|Primary Systemic Amyloidosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Neuroblastoma|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Regional Neuroblastoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: etoposide|DRUG: cyclophosphamide|DRUG: carmustine|DRUG: melphalan|DRUG: busulfan|DRUG: carboplatin|DRUG: thiotepa|RADIATION: total-body irradiation|PROCEDURE: autologous hematopoietic stem cell transplantation|PROCEDURE: autologous-autologous tandem hematopoietic stem cell transplantation,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT02497131,Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients,https://clinicaltrials.gov/study/NCT02497131,COMPLETED,Lymphatic Diseases,DRUG: Brentuximab Vedotin,Fondazione Italiana Linfomi - ETS,,INTERVENTIONAL
NCT06334835,Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.,https://clinicaltrials.gov/study/NCT06334835,RECRUITING,"Acute Lymphoblastic Leukemia, Pediatric",DIAGNOSTIC_TEST: lncRNA signature analyses,IRCCS SYNLAB SDN,Fondazione Santobono Pausilipon,OBSERVATIONAL
NCT01251575,"Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant",https://clinicaltrials.gov/study/NCT01251575,COMPLETED,"Adult Acute Lymphoblastic Leukemia|Adult Acute Myeloid Leukemia|Adult Diffuse Large B-Cell Lymphoma|Adult Myelodysplastic Syndrome|Adult Non-Hodgkin Lymphoma|Aggressive Non-Hodgkin Lymphoma|Childhood Acute Lymphoblastic Leukemia|Childhood Acute Myeloid Leukemia|Childhood Diffuse Large B-Cell Lymphoma|Childhood Myelodysplastic Syndrome|Childhood Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia in Remission|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematopoietic and Lymphoid Cell Neoplasm|Mantle Cell Lymphoma|Plasma Cell Myeloma|Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Hodgkin Lymphoma",PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Cyclosporine|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Sirolimus|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03954106,A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity,https://clinicaltrials.gov/study/NCT03954106,TERMINATED,DLBCL|Neurotoxicity Syndromes,DRUG: Defibrotide,Jazz Pharmaceuticals,,INTERVENTIONAL
NCT00413075,Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00413075,COMPLETED,Solid Tumor|Lymphoma,DRUG: oral belinostat,Valerio Therapeutics,"Spectrum Pharmaceuticals, Inc",INTERVENTIONAL
NCT05968170,TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant,https://clinicaltrials.gov/study/NCT05968170,NOT_YET_RECRUITING,Graft Vs Host Disease|Graft-versus-host-disease|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Non-hematologic Malignancy|Hematologic Malignancy,DEVICE: CliniMACS® device,"Neena Kapoor, M.D.",,INTERVENTIONAL
NCT02597387,Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs,https://clinicaltrials.gov/study/NCT02597387,UNKNOWN,Relapsed DLBCL and PT/NKCLs,DRUG: Mitoxantrone HCL Liposome Injection,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",,INTERVENTIONAL
NCT06777979,CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06777979,RECRUITING,Acute Lymphoblastic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Recurrent B Acute Lymphoblastic Leukemia,DRUG: Fludarabine|DRUG: Cyclophosphamide|DRUG: Mesna|DEVICE: CD19-CD22 CAR T cell infusion,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT06703216,Pre-emptive Anakinra for Cytokine Event Reduction,https://clinicaltrials.gov/study/NCT06703216,NOT_YET_RECRUITING,B-Acute Lymphoblastic Leukemia|CAR-T Cell Therapy|Cytokine Release Syndrome|Immune Effector Cell Associated Neurotoxicity Syndrome|Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome,DRUG: Anakinra (Kineret®),Ann & Robert H Lurie Children's Hospital of Chicago,National Center for Advancing Translational Sciences (NCATS),INTERVENTIONAL
NCT00275080,"Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia",https://clinicaltrials.gov/study/NCT00275080,COMPLETED,"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Secondary Acute Myeloid Leukemia|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia",DRUG: vorinostat|DRUG: decitabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01186328,EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL),https://clinicaltrials.gov/study/NCT01186328,TERMINATED,"Lymphoblastic Leukemia, Acute|Lymphoblastic Leukemia, Acute, Childhood|Leukemia, Lymphoblastic, Acute, T Cell|Leukemia, Lymphoblastic, Acute",DRUG: EZN-3042|DRUG: Cytarabine|DRUG: Doxorubicin|DRUG: Prednisone|DRUG: Vincristine|DRUG: PEG-asparaginase|DRUG: Methotrexate|DRUG: Hydrocortisone,Therapeutic Advances in Childhood Leukemia Consortium,"Enzon Pharmaceuticals, Inc.",INTERVENTIONAL
NCT03601442,CTL019 Out of Specification MAP for ALL or DLBCL Patients,https://clinicaltrials.gov/study/NCT03601442,AVAILABLE,Acute Lymphoblastic Leukemia (ALL)|Diffuse Large B-cell Lymphoma (DLBCL),BIOLOGICAL: CTL019,Novartis Pharmaceuticals,,EXPANDED_ACCESS
NCT03820596,Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL,https://clinicaltrials.gov/study/NCT03820596,COMPLETED,Safety and Efficacy,DRUG: Sintilimab|DRUG: Chidamide,Huiqiang Huang,,INTERVENTIONAL
NCT00436618,Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment,https://clinicaltrials.gov/study/NCT00436618,COMPLETED,Leukemia|Lymphoma|Lymphoproliferative Disorder,DRUG: Everolimus,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT01053494,Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer,https://clinicaltrials.gov/study/NCT01053494,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Mantle Cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Essential Thrombocythemia|Extramedullary Plasmacytoma|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Noncontiguous Stage II Mantle Cell Lymphoma|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Stage 0 Chronic Lymphocytic Leukemia|Stage I Childhood Anaplastic Large Cell Lymphoma|Stage I Childhood Hodgkin Lymphoma|Stage I Childhood Large Cell Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Childhood Small Noncleaved Cell Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma|Stage I Multiple Myeloma|Stage I Mycosis Fungoides/Sezary Syndrome|Stage II Childhood Anaplastic Large Cell Lymphoma|Stage II Childhood Hodgkin Lymphoma|Stage II Childhood Large Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage II Childhood Small Noncleaved Cell Lymphoma|Stage II Chronic Lymphocytic Leukemia|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma|Stage II Multiple Myeloma|Stage II Mycosis Fungoides/Sezary Syndrome|Stage III Childhood Anaplastic Large Cell Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage III Childhood Large Cell Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Childhood Small Noncleaved Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Multiple Myeloma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage IV Childhood Anaplastic Large Cell Lymphoma|Stage IV Childhood Hodgkin Lymphoma|Stage IV Childhood Large Cell Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Childhood Small Noncleaved Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|T-cell Large Granular Lymphocyte Leukemia|Unspecified Childhood Solid Tumor, Protocol Specific",PROCEDURE: massage therapy|OTHER: questionnaire administration|PROCEDURE: quality-of-life assessment|OTHER: intervention by caregiver|PROCEDURE: standard follow-up care,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT03207542,Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL),https://clinicaltrials.gov/study/NCT03207542,WITHDRAWN,Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic,DRUG: Daratumumab,M.D. Anderson Cancer Center,"Janssen Scientific Affairs, LLC",INTERVENTIONAL
NCT05667506,A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric),https://clinicaltrials.gov/study/NCT05667506,RECRUITING,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: single dose of CNCT19,Juventas Cell Therapy Ltd.,,INTERVENTIONAL
NCT01794299,Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor,https://clinicaltrials.gov/study/NCT01794299,COMPLETED,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome,BIOLOGICAL: ATIR,Kiadis Pharma,,INTERVENTIONAL
NCT00818961,Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer,https://clinicaltrials.gov/study/NCT00818961,TERMINATED,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: alemtuzumab|BIOLOGICAL: graft-versus-tumor induction therapy|BIOLOGICAL: rituximab|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation,"Northside Hospital, Inc.",Blood and Marrow Transplant Group of Georgia,INTERVENTIONAL
NCT00054327,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00054327,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cytarabine|RADIATION: radiation therapy|DRUG: Etoposide|PROCEDURE: Stem Cell Transfusion,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03919526,Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL,https://clinicaltrials.gov/study/NCT03919526,COMPLETED,MRD-positive|Acute Lymphoblastic Leukemia,BIOLOGICAL: anti-CD19/CD22 CAR-T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL
NCT00003406,Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer,https://clinicaltrials.gov/study/NCT00003406,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: carboplatin|DRUG: docetaxel|DRUG: ifosfamide|PROCEDURE: autologous bone marrow transplantation|PROCEDURE: bone marrow ablation with stem cell support|PROCEDURE: peripheral blood stem cell transplantation,Cancer Treatment Centers of America,,INTERVENTIONAL
NCT05309213,Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05309213,UNKNOWN,Leukemia,BIOLOGICAL: IM19 CAR-T cells,"Beijing Immunochina Medical Science & Technology Co., Ltd.",,INTERVENTIONAL
NCT00343798,A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00343798,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|Contiguous Stage II Adult Diffuse Large Cell Lymphoma|Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Contiguous Stage II Adult Lymphoblastic Lymphoma|Contiguous Stage II Grade 3 Follicular Lymphoma|Contiguous Stage II Mantle Cell Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Adult Burkitt Lymphoma|Stage I Adult Diffuse Large Cell Lymphoma|Stage I Adult Diffuse Mixed Cell Lymphoma|Stage I Adult Immunoblastic Large Cell Lymphoma|Stage I Adult Lymphoblastic Lymphoma|Stage I Childhood Lymphoblastic Lymphoma|Stage I Grade 3 Follicular Lymphoma|Stage I Mantle Cell Lymphoma|Stage II Childhood Lymphoblastic Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Childhood Lymphoblastic Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Childhood Lymphoblastic Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: cyclosporine|DRUG: mycophenolate mofetil|OTHER: ex-vivo umbilical cord blood expansion|PROCEDURE: double-unit umbilical cord blood transplantation|PROCEDURE: biopsy|OTHER: immunologic technique|OTHER: diagnostic laboratory biomarker analysis,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Damon Runyon Cancer Research Foundation",INTERVENTIONAL
NCT01875237,Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene,https://clinicaltrials.gov/study/NCT01875237,TERMINATED,Leukemia|Myeloma|Myeloproliferative Diseases,DRUG: Fludarabine|DRUG: Melphalan|DRUG: Alemtuzumab|PROCEDURE: Stem Cell infusion|DRUG: Tacrolimus|DRUG: Mini Methotrexate|DRUG: G-CSF|PROCEDURE: Donor Lymphocyte Infusion (DLI)|DRUG: AP1903|DRUG: Methylprednisolone|BEHAVIORAL: Questionnaire,M.D. Anderson Cancer Center,Bellicum Pharmaceuticals,INTERVENTIONAL
NCT01256398,Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01256398,COMPLETED,Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,BIOLOGICAL: Alemtuzumab|PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dasatinib|DRUG: Daunorubicin Hydrochloride|DRUG: Dexamethasone|DRUG: Etoposide Phosphate|BIOLOGICAL: Filgrastim|DRUG: Fludarabine Phosphate|PROCEDURE: In Vitro-Treated Peripheral Blood Stem Cell Transplantation|OTHER: Laboratory Biomarker Analysis|DRUG: Leucovorin Calcium|DRUG: Melphalan|DRUG: Mercaptopurine|DRUG: Methotrexate|BIOLOGICAL: Pegfilgrastim|OTHER: Pharmacological Study|DRUG: Tacrolimus|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06865352,Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT06865352,COMPLETED,Acute Lymphoblastic Leukemia ALL|Acute Myeloid Leukemia (AML),BIOLOGICAL: HSCT donor leukemia-specific cytotoxic T-cells,Fondazione IRCCS Policlinico San Matteo di Pavia,,INTERVENTIONAL
NCT02924402,Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies,https://clinicaltrials.gov/study/NCT02924402,COMPLETED,B-cell Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukemia,BIOLOGICAL: XmAb13676,"Xencor, Inc.",ICON Clinical Research,INTERVENTIONAL
NCT04626765,CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04626765,UNKNOWN,Childhood Acute Lymphoblastic Leukemia,DRUG: CD19 CAR-T|DRUG: CD22 CAR-T|DRUG: CD 19+22|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Hebei Senlang Biotechnology Inc., Ltd.",The Second Hospital of Hebei Medical University,INTERVENTIONAL
NCT02643303,A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers,https://clinicaltrials.gov/study/NCT02643303,COMPLETED,Head and Neck Squamous Cell Carcinoma|Breast Cancer|Sarcoma|Merkel Cell Carcinoma|Cutaneous T-Cell Lymphoma|Melanoma|Renal Cancer|Bladder Cancer|Prostate Cancer|Testicular Cancer|Solid Tumor,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Poly-ICLC,Ludwig Institute for Cancer Research,"MedImmune LLC|Cancer Research Institute, New York City",INTERVENTIONAL
NCT03233854,CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT03233854,ACTIVE_NOT_RECRUITING,B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|OTHER: Questionnaire Administration|DRUG: NKTR-255,"Crystal Mackall, MD",California Institute for Regenerative Medicine (CIRM),INTERVENTIONAL
NCT04530565,Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults,https://clinicaltrials.gov/study/NCT04530565,RECRUITING,B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Blinatumomab|PROCEDURE: Bone Marrow Aspiration and Biopsy|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dasatinib|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|PROCEDURE: Echocardiography Test|PROCEDURE: Electrocardiography|PROCEDURE: Lumbar Puncture|DRUG: Mesna|DRUG: Methotrexate|PROCEDURE: Multigated Acquisition Scan|DRUG: Ponatinib Hydrochloride|DRUG: Prednisone|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04094766,Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04094766,WITHDRAWN,Refractory B Acute Lymphoblastic Leukemia|Relapse B Acute Lymphoblastic Leukemia,DRUG: Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy,Second Affiliated Hospital of Xi'an Jiaotong University,Nanjing Legend Biotech Co.,INTERVENTIONAL
NCT00890747,Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy,https://clinicaltrials.gov/study/NCT00890747,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Grade III Lymphomatoid Granulomatosis|Adult Langerhans Cell Histiocytosis|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aggressive NK-cell Leukemia|AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Malignancies|AIDS-related Small Noncleaved Cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Clear Cell Renal Cell Carcinoma|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|HIV Infection|HIV-associated Hodgkin Lymphoma|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Light Chain Deposition Disease|Mast Cell Leukemia|Myelodysplastic Syndrome With Isolated Del(5q)|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Myeloid/NK-cell Acute Leukemia|Nodal Marginal Zone B-cell Lymphoma|Noncutaneous Extranodal Lymphoma|Osteolytic Lesions of Multiple Myeloma|Peripheral T-cell Lymphoma|Plasma Cell Neoplasm|Polycythemia Vera|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Renal Cell Cancer|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Stage IV Renal Cell Cancer|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia",DRUG: sunitinib malate|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00001873,The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers,https://clinicaltrials.gov/study/NCT00001873,COMPLETED,Chronic Lymphocytic Leukemia|Graft vs Host Disease|Hematologic Neoplasm|Multiple Myeloma|Myelodysplastic Syndrome,DEVICE: Isolex 300i plus MoAbs,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT04209621,Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,https://clinicaltrials.gov/study/NCT04209621,TERMINATED,Small Lymphocytic Leukemia (SLL)|Chronic Lymphocytic Leukemia (CLL),DRUG: Duvelisib|DRUG: Ibrutinib,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT05391295,Mapping Emotional Dynamics During Corticosteroid Treatment,https://clinicaltrials.gov/study/NCT05391295,RECRUITING,Emotions|Corticosteroids,OTHER: Short daily questionnaire,Leiden University Medical Center,,OBSERVATIONAL
NCT06904066,Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06904066,NOT_YET_RECRUITING,"Malignancy, Hematologic|Neoplasms, Hematologic|Neoplasms, Hematopoietic|Blood Cancer|Hematological Neoplasms|Hematopoietic Malignancies|Dysmyelopoietic Syndromes|Hematopoetic Myelodysplasia|Myeloid Leukemia, Acute|Nonlymphoblastic Leukemia, Acute|Leukemia, Lymphocytic, Acute",DRUG: aldesleukin|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|BIOLOGICAL: Individual Patient TCR-Transduced PBL|DEVICE: TruSight Oncology (TSO) 500,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06695013,Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL,https://clinicaltrials.gov/study/NCT06695013,RECRUITING,B-NHL|CART Therapy,DRUG: zanubrutinib|DRUG: CAR-T|RADIATION: Bridging radiotherapy|DRUG: Tislelizumab,Ruijin Hospital,,INTERVENTIONAL
NCT00001586,Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis,https://clinicaltrials.gov/study/NCT00001586,COMPLETED,Chronic Lymphocytic Leukemia,BIOLOGICAL: Rituximab|DRUG: Fludarabine phosphate|OTHER: Leukemic or stroma cells,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00792948,Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00792948,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Adult L1 Acute Lymphoblastic Leukemia|Adult L2 Acute Lymphoblastic Leukemia|Adult T Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dasatinib|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|DRUG: Etoposide|BIOLOGICAL: Filgrastim|OTHER: Laboratory Biomarker Analysis|DRUG: Leucovorin Calcium|DRUG: Methotrexate|DRUG: Methylprednisolone|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Prednisone|DRUG: Sirolimus|DRUG: Tacrolimus|RADIATION: Total-Body Irradiation|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00975975,Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer,https://clinicaltrials.gov/study/NCT00975975,COMPLETED,"Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Non-Hodgkin's Lymphoma|Hodgkin's Disease|Multiple Myeloma|Myelofibrosis|Anemia, Aplastic|Hemoglobinuria, Paroxysmal",DRUG: Basiliximab,Indiana University School of Medicine,,INTERVENTIONAL
NCT00795769,Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00795769,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Small Lymphocytic Lymphoma",DRUG: ondansetron|OTHER: survey administration|PROCEDURE: management of therapy complications,Fred Hutchinson Cancer Center,,INTERVENTIONAL
NCT00003395,Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer,https://clinicaltrials.gov/study/NCT00003395,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,DRUG: arsenic trioxide,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00569309,Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma,https://clinicaltrials.gov/study/NCT00569309,COMPLETED,Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Small Intestine Cancer,BIOLOGICAL: Streptococcus pneumoniae|OTHER: laboratory correlative studies|OTHER: quality-of-life assessment,Ohio State University Comprehensive Cancer Center,,INTERVENTIONAL
NCT00079261,"Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00079261,COMPLETED,Lymphoma|Small Intestine Cancer,DRUG: CHOP regimen|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: gemcitabine hydrochloride|DRUG: prednisone|DRUG: vincristine sulfate,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT03397706,Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT03397706,COMPLETED,Epstein-Barr Virus-Associated Lymphoma|Lymphoproliferative Disorders,COMBINATION_PRODUCT: VRx-3996 and valganciclovir,"Viracta Therapeutics, Inc.",,INTERVENTIONAL
NCT00587054,"Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders",https://clinicaltrials.gov/study/NCT00587054,COMPLETED,Allogeneic Stem Cell Transplant|Leukemia|Non-Hodgkins|Lymphoblastic Lymphoma|Myelodysplastic Syndrome|Paroxysmal Nocturnal Hemoglobinuria (PNH),DRUG: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02159495,Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm,https://clinicaltrials.gov/study/NCT02159495,ACTIVE_NOT_RECRUITING,Adult Acute Myeloid Leukemia in Remission|Acute Biphenotypic Leukemia|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Blastic Plasmacytoid Dendritic Cell Neoplasm|Acute Myeloid Leukemia|Adult Acute Lymphoblastic Leukemia|Interleukin-3 Receptor Subunit Alpha Positive|Minimal Residual Disease|Refractory Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: cyclophosphamide|BIOLOGICAL: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|OTHER: laboratory biomarker analysis|BIOLOGICAL: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|DRUG: Fludarabine Phosphate,City of Hope Medical Center,"National Cancer Institute (NCI)|Mustang Bio, Inc.",INTERVENTIONAL
NCT01093586,Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01093586,COMPLETED,"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Blastic Phase Chronic Myelogenous Leukemia|Burkitt Lymphoma|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Myelodysplastic Syndromes|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Secondary Myelofibrosis|Splenic Marginal Zone Lymphoma|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Waldenstrom Macroglobulinemia",PROCEDURE: double-unit umbilical cord blood transplantation|OTHER: cytogenetic analysis|PROCEDURE: bone marrow aspiration|OTHER: fluorescence in situ hybridization|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: anti-thymocyte globulin|DRUG: methylprednisolone|DRUG: cyclosporine|DRUG: mycophenolate mofetil|OTHER: flow cytometry|PROCEDURE: allogeneic hematopoietic stem cell transplantation,Case Comprehensive Cancer Center,,INTERVENTIONAL
NCT06735690,Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT06735690,RECRUITING,Acute Lymphoblastic Leukemia,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|BIOLOGICAL: Anti-CD19-CAR CMV-specific T-lymphocytes|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Echocardiography|PROCEDURE: Leukapheresis|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Positron Emission Tomography|OTHER: Transplant Conditioning|PROCEDURE: X-Ray Imaging,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT06712810,Q702 for the Treatment of Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06712810,NOT_YET_RECRUITING,"Central Nervous System Lymphoma|Hematopoietic and Lymphatic System Neoplasm|Histiocytic Sarcoma|Malignant Histiocytosis|Peripheral T-Cell Lymphoma, Not Otherwise Specified|Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Follicular Lymphoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Lymphoplasmacytic Lymphoma|Recurrent Myelodysplastic Syndrome|Recurrent Primary Myelofibrosis|Recurrent Small Lymphocytic Lymphoma|Recurrent Waldenstrom Macroglobulinemia|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Erdheim-Chester Disease|Refractory Follicular Lymphoma|Refractory Langerhans Cell Histiocytosis|Refractory Lymphoplasmacytic Lymphoma|Refractory Myelodysplastic Syndrome|Refractory Primary Myelofibrosis|Refractory Small Lymphocytic Lymphoma|Refractory Waldenstrom Macroglobulinemia|Rosai-Dorfman-Destombes Disease",DRUG: Axl/Mer/CSF1R Inhibitor Q702|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography|OTHER: Survey Administration,Mayo Clinic,,INTERVENTIONAL
NCT06009107,A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL),https://clinicaltrials.gov/study/NCT06009107,NOT_YET_RECRUITING,B-cell Acute Lymphoblastic Leukemia,BIOLOGICAL: HY004|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate,Juventas Cell Therapy Ltd.,,INTERVENTIONAL
NCT00994500,"Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma",https://clinicaltrials.gov/study/NCT00994500,COMPLETED,"Childhood Burkitt Lymphoma|Childhood Central Nervous System Choriocarcinoma|Childhood Central Nervous System Germ Cell Tumor|Childhood Central Nervous System Germinoma|Childhood Central Nervous System Mixed Germ Cell Tumor|Childhood Central Nervous System Teratoma|Childhood Central Nervous System Yolk Sac Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Medulloepithelioma|Childhood Meningioma|Childhood Mixed Glioma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Childhood Oligodendroglioma|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Central Nervous System Embryonal Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma|Recurrent Childhood Visual Pathway Glioma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: vorinostat|DRUG: bortezomib|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05588440,A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies,https://clinicaltrials.gov/study/NCT05588440,TERMINATED,Relapsed/Refractory Aggressive B-Cell Malignancies,BIOLOGICAL: ONCT-808|DRUG: Bridging Therapy,"Oncternal Therapeutics, Inc",,INTERVENTIONAL
NCT00799461,Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications,https://clinicaltrials.gov/study/NCT00799461,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Cancer Survivor|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Depression|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Fatigue|Long-term Effects Secondary to Cancer Therapy in Adults|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Psychosocial Effects of Cancer and Its Treatment|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma",OTHER: internet-based intervention|OTHER: questionnaire administration|PROCEDURE: psychosocial assessment and care|PROCEDURE: assessment of therapy complications|PROCEDURE: management of therapy complications|PROCEDURE: fatigue assessment and management|OTHER: counseling intervention,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium,National Cancer Institute (NCI),INTERVENTIONAL
NCT03016377,Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL,https://clinicaltrials.gov/study/NCT03016377,RECRUITING,Acute Lymphoblastic Leukemia|Immune System Diseases|Immunoproliferative Disorders,BIOLOGICAL: iC9-CAR19 cells|DRUG: Rimiducid|DRUG: Cyclophosphamide|DRUG: Fludarabine,UNC Lineberger Comprehensive Cancer Center,Bellicum Pharmaceuticals|The Leukemia and Lymphoma Society,INTERVENTIONAL
NCT01484015,Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia,https://clinicaltrials.gov/study/NCT01484015,COMPLETED,"Adult Acute Lymphoblastic Leukemia|Adult Acute Myeloid Leukemia|Adult Burkitt Lymphoma|Adult Diffuse Large Cell Lymphoma|Adult Diffuse Mixed Cell Lymphoma|Adult Diffuse Small Cleaved Cell Lymphoma|Adult Hodgkin Lymphoma|Adult Immunoblastic Large Cell Lymphoma|Adult Lymphoblastic Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Breast Cancer|Chronic Eosinophilic Leukemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Cutaneous T-cell Non-Hodgkin Lymphoma|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Grade 1 Follicular Lymphoma|Grade 2 Follicular Lymphoma|Grade 3 Follicular Lymphoma|Malignant Testicular Germ Cell Tumor|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Multiple Myeloma|Mycosis Fungoides/Sezary Syndrome|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neutropenia|Nodal Marginal Zone B-cell Lymphoma|Ovarian Epithelial Cancer|Ovarian Germ Cell Tumor|Plasma Cell Neoplasm|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Primary Myelofibrosis|Prolymphocytic Leukemia|Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma",DRUG: cefepime hydrochloride,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT00006020,S0010 506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00006020,COMPLETED,Leukemia,DRUG: nelarabine,SWOG Cancer Research Network,National Cancer Institute (NCI),INTERVENTIONAL
NCT00060424,Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00060424,COMPLETED,B-Cell Prolymphocytic Leukemia|Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|T-Cell Prolymphocytic Leukemia,DRUG: Cyclosporine|DRUG: Fludarabine Phosphate|PROCEDURE: Hematopoietic Cell Transplantation|OTHER: Laboratory Biomarker Analysis|DRUG: Mycophenolate Mofetil|PROCEDURE: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00509691,Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy,https://clinicaltrials.gov/study/NCT00509691,COMPLETED,Cancer,BIOLOGICAL: cytomegalovirus pp65-specific cytotoxic T lymphocytes|GENETIC: polymerase chain reaction|OTHER: diagnostic laboratory biomarker analysis|OTHER: flow cytometry|OTHER: immunologic technique,University of Louisville,Penn State University,INTERVENTIONAL
NCT06462365,Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT),https://clinicaltrials.gov/study/NCT06462365,RECRUITING,"Hematologic Malignancy|GvHD|GVHD,Acute|GVHD, Chronic|Hematopoietic Stem Cell Transplant|Acute Lymphoblastic Leukemia, Adult B-Cell|Acute Lymphoblastic Leukemia, Adult T-Cell|Acute Myeloid Leukemia in Remission|Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia, in Remission|Cancer Remission",BIOLOGICAL: TRX103,"Tr1X, Inc.",,INTERVENTIONAL
NCT02231853,Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections,https://clinicaltrials.gov/study/NCT02231853,TERMINATED,Chronic Lymphocytic Leukemia|CML (Chronic Myelogenous Leukemia)|MDS (Myelodysplastic Syndrome)|Acute Lymphoblastic Leukemia|AML (Acute Myelogenous Leukemia),BIOLOGICAL: MVST|BIOLOGICAL: MVSTr,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT00003962,Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00003962,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,BIOLOGICAL: aldesleukin,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT02500550,"Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor",https://clinicaltrials.gov/study/NCT02500550,COMPLETED,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome,BIOLOGICAL: ATIR101|PROCEDURE: Haploidentical hematopoietic stem cell transplantation (HSCT)|PROCEDURE: TBI regime|PROCEDURE: Non-TBI regime,Kiadis Pharma,,INTERVENTIONAL
NCT01551043,Allo CART-19 Protocol,https://clinicaltrials.gov/study/NCT01551043,TERMINATED,Acute Lymphocytic Leukemia,BIOLOGICAL: CART-19,University of Pennsylvania,,INTERVENTIONAL
NCT00053131,Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00053131,COMPLETED,Leukemia,BIOLOGICAL: filgrastim|BIOLOGICAL: sargramostim|DRUG: cytarabine|DRUG: mitoxantrone hydrochloride,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT02999854,Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer,https://clinicaltrials.gov/study/NCT02999854,TERMINATED,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome,"BIOLOGICAL: ATIR101|DRUG: Cyclophosphamide|PROCEDURE: T-cell depleted HSCT from a related, haploidentical donor|PROCEDURE: T-cell replete HSCT from a related, haploidentical donor",Kiadis Pharma,,INTERVENTIONAL
NCT03792633,Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL,https://clinicaltrials.gov/study/NCT03792633,COMPLETED,Acute Lymphoblastic Leukemia,BIOLOGICAL: huCART19,University of Pennsylvania,Children's Hospital of Philadelphia,INTERVENTIONAL
NCT00101270,Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas,https://clinicaltrials.gov/study/NCT00101270,COMPLETED,"Childhood Burkitt Lymphoma|Childhood Central Nervous System Germ Cell Tumor|Childhood Diffuse Large Cell Lymphoma|Childhood Grade III Lymphomatoid Granulomatosis|Childhood Immunoblastic Large Cell Lymphoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Liver Cancer|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Medulloblastoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway Glioma|Recurrent Colon Cancer|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Melanoma|Recurrent Nasopharyngeal Cancer|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Recurrent Wilms Tumor and Other Childhood Kidney Tumors|Recurrent/Refractory Childhood Hodgkin Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: irinotecan hydrochloride|DRUG: oxaliplatin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01858740,Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children,https://clinicaltrials.gov/study/NCT01858740,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia",PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Methotrexate|PROCEDURE: Peripheral Blood Stem Cell Transplantation|BIOLOGICAL: T Cell-Depleted Hematopoietic Stem Cell Transplantation|DRUG: Tacrolimus|DRUG: Thiotepa|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,"National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL
NCT05268003,A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05268003,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Leukemia,DRUG: Ponatinib|DRUG: Venetoclax|DRUG: Mini-hyper CVD,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT05679687,ThisCART19A Bridging to alloHSCT for R/R B-ALL,https://clinicaltrials.gov/study/NCT05679687,RECRUITING,CAR|Refractory Acute Lymphoblastic Leukemia|Relapsed Adult ALL,DRUG: Treatment,The First Affiliated Hospital of Soochow University,"Fundamenta Therapeutics, Ltd.",INTERVENTIONAL
NCT01558778,Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01558778,WITHDRAWN,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Plasma Cell Neoplasm|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage II Ovarian Epithelial Cancer|Stage II Ovarian Germ Cell Tumor|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Ovarian Epithelial Cancer|Stage III Ovarian Germ Cell Tumor|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Small Lymphocytic Lymphoma",PROCEDURE: management of therapy complications|PROCEDURE: musculoskeletal complications management/prevention,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT00776373,Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT00776373,TERMINATED,ALL|Burkitt's Lymphoma|Lymphoblastic Leukemia|CML,DRUG: Rapamycin + high dose etoposide and cytarabine,Abramson Cancer Center at Penn Medicine,,INTERVENTIONAL
NCT05031897,Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant,https://clinicaltrials.gov/study/NCT05031897,RECRUITING,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Adult T-Cell Leukemia/Lymphoma|Aplastic Anemia|Chronic Lymphocytic Leukemia|Chronic Myeloid Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Hematopoietic and Lymphatic System Neoplasm|Hodgkin Lymphoma|Multiple Myeloma|Myelodysplastic Syndrome|Myelofibrosis|Myeloid Neoplasm|Non-Hodgkin Lymphoma|Polycythemia Vera|Small Lymphocytic Lymphoma",DRUG: Fludarabine|RADIATION: Total-Body Irradiation|PROCEDURE: Donor Lymphocyte Infusion|DRUG: Cyclophosphamide|DRUG: Tacrolimus|DRUG: Mycophenolate Mofetil|PROCEDURE: Hematopoietic Cell Transplantation|DRUG: Melphalan|PROCEDURE: Bone Marrow Aspiration and Biopsy|PROCEDURE: Diagnostic Imaging|PROCEDURE: Biospecimen Collection,Thomas Jefferson University,,INTERVENTIONAL
NCT03327285,C-CAR011 Treatment in Subjects With ALL After HSCT,https://clinicaltrials.gov/study/NCT03327285,UNKNOWN,Acute Lymphoblastic Leukemia(ALL),BIOLOGICAL: C-CAR011,Peking University People's Hospital,Shanghai AbelZeta Ltd.,INTERVENTIONAL
NCT00025415,Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction,https://clinicaltrials.gov/study/NCT00025415,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Extramedullary Plasmacytoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Gastrointestinal Stromal Tumor|Intraocular Lymphoma|Isolated Plasmacytoma of Bone|Meningeal Chronic Myelogenous Leukemia|Monoclonal Gammopathy of Undetermined Significance|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Central Nervous System Non-Hodgkin Lymphoma|Primary Myelofibrosis|Primary Systemic Amyloidosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Unspecified Adult Solid Tumor, Protocol Specific|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Hairy Cell Leukemia|Waldenström Macroglobulinemia",DRUG: imatinib mesylate|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT06845592,Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia,https://clinicaltrials.gov/study/NCT06845592,RECRUITING,Acute Myeloid Leukaemia (AML)|Acute Lymphoblastic Leukemia ALL|High Risk Leukaemia|Leukaemia Relapse,RADIATION: total marrow/lymphoid irradiation,University Of Perugia,,INTERVENTIONAL
NCT05621291,A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...,https://clinicaltrials.gov/study/NCT05621291,RECRUITING,B-All|Acute Lymphoblastic Leukemia,DIAGNOSTIC_TEST: NGS testing,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01231412,Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01231412,COMPLETED,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Aggressive Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Diffuse Large B-Cell Lymphoma|Hematopoietic and Lymphoid Cell Neoplasm|Indolent Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Prolymphocytic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Refractory Chronic Lymphocytic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Hodgkin Lymphoma|Small Lymphocytic Lymphoma|T-Cell Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia",PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Cyclosporine|DRUG: Fludarabine Phosphate|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Sirolimus|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03263637,"Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies",https://clinicaltrials.gov/study/NCT03263637,COMPLETED,Relapsed or Refractory Haematological Malignancies Including|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Chronic Lymphocytic Leukemia|High Risk Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Richter's Syndrome|B-cell Non-Hodgkin Lymphoma|T-cell Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma|Multiple Myeloma,DRUG: AZD4573,AstraZeneca,,INTERVENTIONAL
NCT05440409,CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL,https://clinicaltrials.gov/study/NCT05440409,COMPLETED,"Leukemia, Acute Lymphoblastic|Lymphoblastic Leukemia, Acute, Childhood",,National Cancer Institute (NCI),,OBSERVATIONAL
NCT00062140,"Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT00062140,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,DRUG: cyclophosphamide|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00008307,Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders,https://clinicaltrials.gov/study/NCT00008307,UNKNOWN,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: melphalan|DRUG: methylprednisolone|DRUG: mycophenolate mofetil|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: syngeneic bone marrow transplantation,Herbert Irving Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03241940,Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies,https://clinicaltrials.gov/study/NCT03241940,ACTIVE_NOT_RECRUITING,B Acute Lymphoblastic Leukemia|CD19 Positive|Minimal Residual Disease|Philadelphia Chromosome Positive|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: Chimeric Antigen Receptor T-Cell Therapy|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|OTHER: Questionnaire Administration,"Crystal Mackall, MD",,INTERVENTIONAL
NCT06559644,Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia,https://clinicaltrials.gov/study/NCT06559644,NOT_YET_RECRUITING,"Leukemia, Myeloid, Acute|B-cell Acute Lymphoblastic Leukemia",BIOLOGICAL: Hema-NeoTIL01,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT00002625,Topotecan and Radiation Therapy in Treating Patients With Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00002625,COMPLETED,Esophageal Cancer|Lung Cancer|Lymphoma,DRUG: topotecan hydrochloride|RADIATION: low-LET electron therapy|RADIATION: low-LET photon therapy,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02129062,Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02129062,TERMINATED,Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia,DRUG: Ibrutinib|OTHER: Laboratory Biomarker Analysis,National Cancer Institute (NCI),M.D. Anderson Cancer Center,INTERVENTIONAL
NCT00891137,Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy,https://clinicaltrials.gov/study/NCT00891137,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: human myeloid progenitor cells,Cellerant Therapeutics,Department of Health and Human Services,INTERVENTIONAL
NCT01159067,Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload,https://clinicaltrials.gov/study/NCT01159067,TERMINATED,"Iron Overload|Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Small Lymphocytic Lymphoma",DRUG: deferasirox,City of Hope Medical Center,,INTERVENTIONAL
NCT01233921,Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT01233921,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Graft Versus Host Disease|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Small Lymphocytic Lymphoma",BIOLOGICAL: palifermin|OTHER: flow cytometry|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,"Martin, Paul",National Cancer Institute (NCI),INTERVENTIONAL
NCT00304018,Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer,https://clinicaltrials.gov/study/NCT00304018,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: sargramostim|DRUG: busulfan|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: prednisone|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: umbilical cord blood transplantation,"University of California, San Francisco",National Cancer Institute (NCI),INTERVENTIONAL
NCT00720109,Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00720109,COMPLETED,Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,DRUG: Asparaginase|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dasatinib|DRUG: Daunorubicin Hydrochloride|DRUG: Dexamethasone|DRUG: Etoposide|BIOLOGICAL: Filgrastim|DRUG: Hydrocortisone Sodium Succinate|DRUG: Ifosfamide|OTHER: Laboratory Biomarker Analysis|DRUG: Leucovorin Calcium|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Methylprednisolone|DRUG: Pegaspargase|DRUG: Prednisone|RADIATION: Radiation Therapy|DRUG: Vincristine Sulfate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04771572,"Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.",https://clinicaltrials.gov/study/NCT04771572,RECRUITING,Non Hodgkin Lymphoma|Richter Transformation|Multiple Myeloma|T-cell-prolymphocytic Leukemia|Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myeodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm|Myelofibrosis|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Chronic Myelomonocytic Leukemia-2|Myelodysplastic Neoplasm in Blast Phase,DRUG: LP-118,Newave Pharmaceutical Inc,,INTERVENTIONAL
NCT05011058,"An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas",https://clinicaltrials.gov/study/NCT05011058,TERMINATED,"Epstein-Barr Virus Associated Lymphoproliferative Disorder|EBV-Related PTLD|EBV Related Non-Hodgkin's Lymphoma|EBV-Positive DLBCL, NOS|EBV Associated Lymphoma|EBV Related PTCL, NOS",DRUG: Nanatinostat in combination with valganciclovir,"Viracta Therapeutics, Inc.",,INTERVENTIONAL
NCT00025129,VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas,https://clinicaltrials.gov/study/NCT00025129,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: laromustine,Vion Pharmaceuticals,,INTERVENTIONAL
NCT00301951,"Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer",https://clinicaltrials.gov/study/NCT00301951,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: sargramostim|DRUG: busulfan|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: umbilical cord blood transplantation,"University of California, San Francisco",National Cancer Institute (NCI),INTERVENTIONAL
NCT00003993,Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00003993,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: aldesleukin|DRUG: bryostatin 1,National Institute on Aging (NIA),National Cancer Institute (NCI),INTERVENTIONAL
NCT00577798,Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin,https://clinicaltrials.gov/study/NCT00577798,COMPLETED,Cardiac Toxicity|Chemotherapeutic Agent Toxicity|Lymphoma,PROCEDURE: contrast-enhanced magnetic resonance imaging,University of Nebraska,National Cancer Institute (NCI),OBSERVATIONAL
NCT03007147,Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03007147,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia,PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Calaspargase Pegol|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Daunorubicin Hydrochloride|DRUG: Dexamethasone|DRUG: Dexrazoxane Hydrochloride|DRUG: Doxorubicin|DRUG: Etoposide|BIOLOGICAL: Filgrastim|DRUG: Ifosfamide|DRUG: Imatinib Mesylate|OTHER: Laboratory Biomarker Analysis|DRUG: Leucovorin Calcium|DRUG: Levoleucovorin|DRUG: Mercaptopurine|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Methylprednisolone|DRUG: Pegaspargase|DRUG: Prednisolone|OTHER: Questionnaire Administration|DRUG: Therapeutic Hydrocortisone|DRUG: Thioguanine|DRUG: Vincristine Sulfate,Children's Oncology Group,EsPhALL|National Cancer Institute (NCI),INTERVENTIONAL
NCT02638922,Evaluation and Treatment of Tall Statured Girls,https://clinicaltrials.gov/study/NCT02638922,UNKNOWN,Constitutional Tall Stature,DRUG: Estradiol,"Rigshospitalet, Denmark",,OBSERVATIONAL
NCT03840317,Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT03840317,UNKNOWN,Acute Lymphocytic Leukemia,BIOLOGICAL: Autologous CD19-targeting CAR T cells,"Hebei Senlang Biotechnology Inc., Ltd.",Hebei Yanda Ludaopei Hospital,INTERVENTIONAL
NCT02767934,Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02767934,TERMINATED,B Acute Lymphoblastic Leukemia|Minimal Residual Disease|Recurrent Acute Lymphoblastic Leukemia|T Acute Lymphoblastic Leukemia,OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab,University of Washington,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003885,"Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma",https://clinicaltrials.gov/study/NCT00003885,UNKNOWN,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: arsenic trioxide,Our Lady of Mercy Medical Center,,INTERVENTIONAL
NCT00898404,Response or Resistance to Chemotherapy in Young Patients With Acute Lymphoblastic Leukemia Treated With Methotrexate,https://clinicaltrials.gov/study/NCT00898404,COMPLETED,B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia,OTHER: laboratory biomarker analysis,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT02935543,CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL,https://clinicaltrials.gov/study/NCT02935543,TERMINATED,"Leukemia, Acute Lymphoblastic",BIOLOGICAL: CART 19,University of Pennsylvania,,INTERVENTIONAL
NCT00589381,Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00589381,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: fenretinide lipid matrix,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT00891592,Umbilical Cord Blood Transplant for Hematological Malignancies,https://clinicaltrials.gov/study/NCT00891592,COMPLETED,CML|AML|MDS|ALL|NHL|Multiple Myeloma|Hodgkin's Disease,BIOLOGICAL: Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|OTHER: Observation Arm,University of Pennsylvania,,INTERVENTIONAL
NCT03459170,Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant,https://clinicaltrials.gov/study/NCT03459170,ACTIVE_NOT_RECRUITING,Hematologic Malignancy,BIOLOGICAL: BPX-501 T cells|DRUG: rimiducid,Bellicum Pharmaceuticals,,INTERVENTIONAL
NCT01028716,Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01028716,TERMINATED,Acute Biphenotypic Leukemia|Acute Erythroid Leukemia in Remission|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome|Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1|Acute Myeloid Leukemia With Multilineage Dysplasia|Acute Myeloid Leukemia With t(6;9)|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1)|Ph+ ALL|Burkitt Lymphoma|Childhood Acute Lymphoblastic Leukemia in Complete Remission|DS Stage II Plasma Cell Myeloma|DS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Recurrent Anaplastic Large Cell Lymphoma|Blasts Under 5 Percent of Bone Marrow Nucleated Cells|Recurrent Follicular Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma|Secondary Acute Myeloid Leukemia|T Lymphoblastic Lymphoma|Hematopoietic Cell Transplant Recipient,DRUG: Cyclophosphamide|BIOLOGICAL: Filgrastim|DRUG: Fludarabine Phosphate|DRUG: Mycophenolate Mofetil|PROCEDURE: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Tacrolimus|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,,INTERVENTIONAL
NCT00964821,Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00964821,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm,BIOLOGICAL: trivalent influenza vaccine|OTHER: Immunoenzyme technique|OTHER: Laboratory biomarker analysis,City of Hope Medical Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT06287528,A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL),https://clinicaltrials.gov/study/NCT06287528,RECRUITING,"Philadelphia-Negative ALL|Philadelphia-Positive ALL|Relapsed ALL, Adult|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia (ALL)|Refractory Acute Lymphoid Leukemia in Relapse",BIOLOGICAL: 19-28z/IL-18 CAR T cells,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT01177371,"High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma",https://clinicaltrials.gov/study/NCT01177371,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With T(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With T(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Burkitt Lymphoma|Childhood Acute Erythroleukemia (M6)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myeloid Leukemia in Remission|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Acute Promyelocytic Leukemia (M3)|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|Cutaneous B-cell Non-Hodgkin Lymphoma|De Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-Cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult Non-Hodgkin Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenstrom Macroglobulinemia,DRUG: busulfan|DRUG: cyclophosphamide|PROCEDURE: allogeneic bone marrow transplantation|DRUG: methylprednisolone|DRUG: methotrexate|DRUG: cyclosporine,Case Comprehensive Cancer Center,,INTERVENTIONAL
NCT00049569,Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00049569,COMPLETED,"L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Non-T, Non-B Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia",DRUG: cytarabine|DRUG: methotrexate|DRUG: vincristine sulfate|DRUG: prednisone|DRUG: pegaspargase|DRUG: doxorubicin hydrochloride|DRUG: imatinib mesylate|DRUG: cyclophosphamide|DRUG: etoposide|BIOLOGICAL: filgrastim|DRUG: leucovorin calcium|DRUG: asparaginase|DRUG: therapeutic hydrocortisone,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00103272,17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer,https://clinicaltrials.gov/study/NCT00103272,TERMINATED,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,DRUG: tanespimycin|DRUG: bortezomib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04778579,Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy,https://clinicaltrials.gov/study/NCT04778579,ACTIVE_NOT_RECRUITING,Acute Lymphoid Leukemia,DRUG: ARI-0001 cells,Sara V. Latorre,Institut d'Investigacions Biomèdiques August Pi i Sunyer|Instituto de Salud Carlos III,INTERVENTIONAL
NCT00467961,Stem Cell Transplantation for Patients With Cancers of the Blood,https://clinicaltrials.gov/study/NCT00467961,COMPLETED,CML (Chronic Myelogenous Leukemia)|CLL (Chronic Lymphocytic Leukemia)|AML (Acute Myelogenous Leukemia)|Acute Lymphocytic Leukemia|MDS (Myelodysplastic Syndrome),COMBINATION_PRODUCT: Miltenyi system,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT06839456,Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT,https://clinicaltrials.gov/study/NCT06839456,RECRUITING,Leukemia|High Risk Acute Lymphoblastic Leukemia|High Risk Acute Myeloid Leukemia|Relapse Leukemia|MDS (Myelodysplastic Syndrome)|Relapsed Non-Hodgkin Lymphoma|Acquired Aplastic Anemia|Inherited BMF Syndrome|Immunodeficiency|Primary Immune Regulatory Disorder|Hemoglobinopathies|Bone Marrow Failure|Inborn Errors of Metabolism|HLH,"DEVICE: Phase 1 Dose Level 1|DEVICE: Phase 1 Dose Level 2|DEVICE: Phase 1 Dose Level 3|DEVICE: Phase 2 Maximum Tolerated Dose determined in Phase 1|DEVICE: Phase 2 Established Dose from prior study, NCT03810196",Children's Hospital of Philadelphia,,INTERVENTIONAL
NCT00045500,UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00045500,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: 7-hydroxystaurosporine|DRUG: prednisone,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00129415,Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions,https://clinicaltrials.gov/study/NCT00129415,TERMINATED,Atopic Dermatitis|Psoriasis|Alopecia|Mycosis Fungoides|Urticaria|Dermatoses|Stretch Marks,PROCEDURE: UVA1 Irradiation|PROCEDURE: UVB Irradiation,University of Michigan,,INTERVENTIONAL
NCT00005799,"Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer",https://clinicaltrials.gov/study/NCT00005799,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|B-cell Chronic Lymphocytic Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Childhood Renal Cell Carcinoma|Chronic Phase Chronic Myelogenous Leukemia|Clear Cell Renal Cell Carcinoma|de Novo Myelodysplastic Syndromes|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Splenic Marginal Zone Lymphoma|Stage III Renal Cell Cancer|Stage IV Renal Cell Cancer|T-cell Large Granular Lymphocyte Leukemia|Type 1 Papillary Renal Cell Carcinoma|Type 2 Papillary Renal Cell Carcinoma|Waldenström Macroglobulinemia,DRUG: fludarabine phosphate|RADIATION: total-body irradiation|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: cyclosporine|DRUG: mycophenolate mofetil|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",INTERVENTIONAL
NCT03203369,Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN,https://clinicaltrials.gov/study/NCT03203369,TERMINATED,Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN),BIOLOGICAL: UCART123,Cellectis S.A.,,INTERVENTIONAL
NCT04012879,Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT04012879,UNKNOWN,Relapsed Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,COMBINATION_PRODUCT: CD19 CART,Chinese PLA General Hospital,Shenzhen University General Hospital,INTERVENTIONAL
NCT04128501,Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting,https://clinicaltrials.gov/study/NCT04128501,RECRUITING,Acute Bilineal Leukemia|Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Mixed Phenotype Acute Leukemia|T Acute Lymphoblastic Leukemia|Therapy-Related Acute Myeloid Leukemia,DRUG: Azacitidine|DRUG: Venetoclax,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT06220487,"A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL",https://clinicaltrials.gov/study/NCT06220487,RECRUITING,Acute Lymphoblastic Leukemia|Philadelphia Chromosome|Philadelphia-Positive ALL|Adult ALL|IKZF1 Gene Mutation,"DRUG: Prednisone, Olverembatinib, Blinatumomab, Chidamide","Nanfang Hospital, Southern Medical University",,INTERVENTIONAL
NCT01384513,A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies,https://clinicaltrials.gov/study/NCT01384513,COMPLETED,"Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Nasal Type Extranodal NK/T-cell Lymphoma|Aplastic Anemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Essential Thrombocythemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Juvenile Myelomonocytic Leukemia|Mastocytosis|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Anemia|Refractory Anemia With Ringed Sideroblasts|Refractory Hairy Cell Leukemia|Refractory Multiple Myeloma|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Waldenström Macroglobulinemia",DRUG: Fludarabine|DRUG: Busulfan|RADIATION: Total Body Irradiation (TBI)|BIOLOGICAL: Donor Lymphocyte Infusion (DLI)|DRUG: Cyclophosphamide (CY)|DRUG: Tacrolimus|DRUG: Mycophenolate mofetil|DEVICE: Allogeneic hematopoietic stem cell transplantation|PROCEDURE: Peripheral blood stem cell transplantation (PBSCT),Sidney Kimmel Cancer Center at Thomas Jefferson University,,INTERVENTIONAL
NCT00053196,Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer,https://clinicaltrials.gov/study/NCT00053196,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma|Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myeloproliferative Neoplasms,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: G-CSF|DRUG: busulfan|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic cell transplantation|DRUG: allopurinol,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT00619645,"Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers",https://clinicaltrials.gov/study/NCT00619645,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: busulfan|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,"University of California, Davis",,INTERVENTIONAL
NCT03544021,CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）,https://clinicaltrials.gov/study/NCT03544021,UNKNOWN,"Leukemia, Lymphocytic, Acute",BIOLOGICAL: CART-19 cells,The Affiliated Hospital of the Chinese Academy of Military Medical Sciences,,INTERVENTIONAL
NCT06078306,CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).,https://clinicaltrials.gov/study/NCT06078306,RECRUITING,B Acute Lymphoblastic Leukemia|Ph-Negative ALL|High Risk Acute Lymphoblastic Leukemia,DRUG: Azacitidine Injection|DRUG: Venetoclax|DRUG: CD19CD22 CAR-T,The First Affiliated Hospital of Soochow University,,INTERVENTIONAL
NCT03389035,Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT,https://clinicaltrials.gov/study/NCT03389035,COMPLETED,"Acute Lymphoblastic Leukemia, in Relapse",BIOLOGICAL: CARCIK-CD19,Fondazione Matilde Tettamanti Menotti De Marchi Onlus,,INTERVENTIONAL
NCT04151706,"CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML",https://clinicaltrials.gov/study/NCT04151706,COMPLETED,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Acute Leukemia|Chronic Myeloid Leukemia,DRUG: CD8+ Memory T Cell Infusion|DRUG: Thiotepa|DRUG: Fludarabine|RADIATION: Hyperfractionated TBI|DRUG: Busulfan|DRUG: Cyclophosphamide,Robert Lowsky,National Institutes of Health (NIH)|National Cancer Institute (NCI),INTERVENTIONAL
NCT00740467,Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders,https://clinicaltrials.gov/study/NCT00740467,UNKNOWN,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition,BIOLOGICAL: anti-thymocyte globulin|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation,Institut Paoli-Calmettes,,INTERVENTIONAL
NCT05216835,Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT05216835,ACTIVE_NOT_RECRUITING,Relapsed or Refractory Classical Hodgkin Lymphoma,DRUG: Sabestomig (AZD7789),AstraZeneca,Parexel,INTERVENTIONAL
NCT02508038,Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors,https://clinicaltrials.gov/study/NCT02508038,RECRUITING,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Hodgkin Lymphoma|Non-Hodgkin Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Syndrome|Rhabdomyosarcoma|Ewing Sarcoma|Primitive Neuroectodermal Tumor|Osteosarcoma|Neuroblastoma,PROCEDURE: TCRαβ+/CD19+ depleted Haploidentical HSCT|DRUG: Zoledronate,"University of Wisconsin, Madison",,INTERVENTIONAL
NCT00004057,"Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas",https://clinicaltrials.gov/study/NCT00004057,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific","DRUG: L-778,123|DRUG: paclitaxel",Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00061581,Experimental Bone Marrow Transplant Protocol,https://clinicaltrials.gov/study/NCT00061581,COMPLETED,Acute Lymphocytic Leukemia|Chronic Myeloid Leukemia|Acute Myelocytic Leukemia|Myelodysplastic Syndromes|Myeloproliferative Disorders,DEVICE: Isolex 300i Stem Cell Selection,"National Heart, Lung, and Blood Institute (NHLBI)",,INTERVENTIONAL
NCT00079378,Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,https://clinicaltrials.gov/study/NCT00079378,COMPLETED,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: decitabine|DRUG: valproic acid|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00049400,S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction,https://clinicaltrials.gov/study/NCT00049400,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: BMS-247550,SWOG Cancer Research Network,National Cancer Institute (NCI),INTERVENTIONAL
NCT06551584,Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT,https://clinicaltrials.gov/study/NCT06551584,NOT_YET_RECRUITING,Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndromes,DRUG: ORCA-T,Lori Muffly,"Orca Biosystems, Inc.",INTERVENTIONAL
NCT02484430,Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02484430,COMPLETED,"B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Recurrent Adult Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|T Acute Lymphoblastic Leukemia",OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Sapanisertib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT05107674,A Study of NX-1607 in Adults With Advanced Malignancies,https://clinicaltrials.gov/study/NCT05107674,RECRUITING,"Ovarian Cancer, Epithelial|Gastric Cancer|GastroEsophageal Junction (GEJ) Cancer|Head and Neck Squamous Cell Carcinoma|Metastatic or Unresectable Melanoma|Non-small Cell Lung Cancer (NSCLC)|Metastatic Castration-resistant Prostate Cancer (mCRPC)|Malignant Pleural Mesothelioma (MPM)|Triple Negative Breast Cancer (TNBC)|Metastatic Urothelial Carcinoma|Cervical Cancer|Diffuse Large B Cell Lymphoma (DLBCL)|Richter Transformation|Microsatellite Stable Colorectal Carcinoma",DRUG: NX-1607|DRUG: Paclitaxel,"Nurix Therapeutics, Inc.",,INTERVENTIONAL
NCT00678275,Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia,https://clinicaltrials.gov/study/NCT00678275,COMPLETED,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia,DRUG: ATG FRESENIUS (Anti-Lymphocyte-Globulin)|DRUG: ATG FRESENIUS (Anti-Lymphocyte-Globulin),Universitätsklinikum Hamburg-Eppendorf,,INTERVENTIONAL
NCT00002502,Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT00002502,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cytarabine|PROCEDURE: allogeneic bone marrow transplantation,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05236764,Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion,https://clinicaltrials.gov/study/NCT05236764,TERMINATED,Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission|Myelodysplastic Syndromes|Chronic Myeloid Leukemia|Hemophagocytic Lymphohistiocytoses|Primary Immunodeficiency Diseases|Hemoglobinopathies|Severe Aplastic Anemia|Cytopenia|Bone Marrow Failure Syndrome|Severe Chronic Active Epstein-Barr Virus Infection,DEVICE: CliniMACS,Baylor College of Medicine,"Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital Research Institute",INTERVENTIONAL
NCT00408681,Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00408681,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Disseminated Neuroblastoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Gastrointestinal Complications|Juvenile Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Nodal Marginal Zone B-cell Lymphoma|Noncontiguous Stage II Adult Burkitt Lymphoma|Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma|Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma|Noncontiguous Stage II Adult Lymphoblastic Lymphoma|Noncontiguous Stage II Grade 1 Follicular Lymphoma|Noncontiguous Stage II Grade 2 Follicular Lymphoma|Noncontiguous Stage II Grade 3 Follicular Lymphoma|Noncontiguous Stage II Mantle Cell Lymphoma|Noncontiguous Stage II Marginal Zone Lymphoma|Noncontiguous Stage II Small Lymphocytic Lymphoma|Poor Prognosis Metastatic Gestational Trophoblastic Tumor|Previously Treated Childhood Rhabdomyosarcoma|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Small Lymphocytic Lymphoma|Recurrent Wilms Tumor and Other Childhood Kidney Tumors|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Splenic Marginal Zone Lymphoma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Malignant Testicular Germ Cell Tumor|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage III Small Lymphocytic Lymphoma|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Breast Cancer|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Ovarian Epithelial Cancer|Stage IV Small Lymphocytic Lymphoma",DRUG: lithium carbonate|OTHER: laboratory biomarker analysis,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05735717,MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies,https://clinicaltrials.gov/study/NCT05735717,RECRUITING,Hematologic Malignancy|Acute Leukemia|Remission|Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|AML|TP53|Intrachromosomal Amplification of Chromosome 21|Cytogenetic Abnormality|CNS Leukemia|Minimal Residual Disease|Myelodysplasia|Juvenile Myelomonocytic Leukemia|Somatic Mutation|PTPN11 Gene Mutation|N-RAS Gene Amplification|Neurofibromatosis 1|NF1 Mutation|CBL Gene Mutation|Monosomy 7|Chromosome Abnormality|Fetal Hemoglobin,DRUG: Fludarabine|DRUG: Busulfan|DRUG: Melphalan|DRUG: Rituximab|DRUG: Levetiracetam,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00088868,17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma,https://clinicaltrials.gov/study/NCT00088868,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: alvespimycin hydrochloride,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT05054465,A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL,https://clinicaltrials.gov/study/NCT05054465,NOT_YET_RECRUITING,Acute Lymphoblastic Leukemia,DRUG: Navitoclax|DRUG: Venetoclax,Israeli Medical Association,Rabin Medical Center|Sheba Medical Center|Rambam Health Care Campus|Tel Aviv Medical Center|Soroka University Medical Center|Shaare Zedek Medical Center|Hadassah Medical Organization,INTERVENTIONAL
NCT00448357,Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen,https://clinicaltrials.gov/study/NCT00448357,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: rabbit anti-thymocyte globulin (ATG)|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: busulfan|DRUG: fludarabine phosphate|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|DRUG: methotrexate,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI)|Otsuka America Pharmaceutical,INTERVENTIONAL
NCT05170828,Cryopreserved MMUD BM With PTCy for Hematologic Malignancies,https://clinicaltrials.gov/study/NCT05170828,WITHDRAWN,Acute Leukemia|Myelodysplastic Syndromes|T-lymphoblastic Lymphoma|Acute Lymphocytic Leukemia|Acute Myeloid Leukemia|Acute Biphenotypic Leukemia|Acute Undifferentiated Leukemia,DRUG: Cyclophosphamide|DRUG: Fludarabine|RADIATION: Total Body Irradiation|DRUG: Busulfan|DRUG: Mesna|DRUG: Sirolimus|DRUG: Mycophenolate Mofetil|DRUG: Filgrastim|DRUG: Cyclophosphamide|PROCEDURE: Bone Marrow Transplant,"Ossium Health, Inc.",Center for International Blood and Marrow Transplant Research,INTERVENTIONAL
NCT01881334,Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants,https://clinicaltrials.gov/study/NCT01881334,AVAILABLE,Hematologic Malignancies|Inborn Errors of Metabolism Disorders|Immune Deficiencies,BIOLOGICAL: CliniMACS CD34 Reagent System,"Joanne Kurtzberg, MD","Duke University|Miltenyi Biotec, Inc.",EXPANDED_ACCESS
NCT00008216,Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00008216,TERMINATED,Adult Langerhans Cell Histiocytosis|Childhood Langerhans Cell Histiocytosis|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,PROCEDURE: Peripheral Blood Stem Cell Transplantation,Columbia University,National Cancer Institute (NCI),OBSERVATIONAL
NCT00827099,"Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT00827099,TERMINATED,Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|DRUG: fludarabine phosphate|DRUG: Melphalan|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: umbilical cord blood transplantation,"Northside Hospital, Inc.",,INTERVENTIONAL
NCT01810120,Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT,https://clinicaltrials.gov/study/NCT01810120,COMPLETED,Acute Lymphoblastic Leukemia|Leukemia Acute Myeloid - AML|Non-Hodgkin Lymphoma|Myelodysplastic Syndromes,BIOLOGICAL: TCR alfa beta T cell depletion,Mariella Enoc,,INTERVENTIONAL
NCT05987605,Phase I/II Clinical Study of 1A46 Drug Substance,https://clinicaltrials.gov/study/NCT05987605,TERMINATED,Advanced Malignancies,DRUG: 1A46 Drug Substance,"BioRay Pharmaceutical Co., Ltd.",,INTERVENTIONAL
NCT01769209,Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01769209,COMPLETED,B-cell Adult Acute Lymphoblastic Leukemia (ALL)|Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)|Recurrent Adult Acute Lymphoblastic Leukemia (ALL)|T-cell Adult Acute Lymphoblastic Leukemia (ALL),DRUG: Bortezomib|DRUG: Doxorubicin hydrochloride (HCl)|DRUG: PEG-Asparaginase|DRUG: Vincristine sulfate|DRUG: Dexamethasone|DRUG: Cytarabine|DRUG: Methotrexate,Stanford University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00005590,Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00005590,COMPLETED,"Brain and Central Nervous System Tumors|Breast Cancer|Extragonadal Germ Cell Tumor|Infection|Lung Cancer|Lymphoma|Ovarian Cancer|Small Intestine Cancer|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: levofloxacin,Cancer Research Campaign Clinical Trials Centre,,INTERVENTIONAL
NCT02535364,Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL),https://clinicaltrials.gov/study/NCT02535364,TERMINATED,Acute Lymphoblastic Leukemia,BIOLOGICAL: JCAR015 (CD19-targeted CAR T cells),"Juno Therapeutics, a Subsidiary of Celgene",,INTERVENTIONAL
NCT05334823,A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents,https://clinicaltrials.gov/study/NCT05334823,RECRUITING,Acute Lymphoblastic Leukemia|Relapsed Pediatric ALL|Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: pCAR-19B cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT00104923,Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer,https://clinicaltrials.gov/study/NCT00104923,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,DRUG: fenretinide,California Cancer Consortium,National Cancer Institute (NCI),INTERVENTIONAL
NCT04888468,Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents,https://clinicaltrials.gov/study/NCT04888468,COMPLETED,Acute Lymphoblastic Leukemia|Relapsed Pediatric ALL|Refractory Acute Lymphoblastic Leukemia,BIOLOGICAL: pCAR-19B cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT02220985,Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD,https://clinicaltrials.gov/study/NCT02220985,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Leukemia of Ambiguous Lineage|Acute Undifferentiated Leukemia|Allogeneic Hematopoietic Stem Cell Transplant Recipient|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blastic Plasmacytoid Dendritic Cell Neoplasm|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Donor|Lymphoblastic Lymphoma|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia in Remission",PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Methotrexate|DRUG: Mycophenolate Mofetil|PROCEDURE: Peripheral Blood Stem Cell Transplantation|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Tacrolimus|DRUG: Thiotepa|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,"National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL
NCT04888442,Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL,https://clinicaltrials.gov/study/NCT04888442,UNKNOWN,"Acute Lymphoblastic Leukemia, in Relapse|Refractory Acute Lymphoblastic Leukemia",BIOLOGICAL: pCAR-19B cells,"Chongqing Precision Biotech Co., Ltd",,INTERVENTIONAL
NCT00504205,MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma,https://clinicaltrials.gov/study/NCT00504205,TERMINATED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: multitargeted receptor tyrosine kinase inhibitor MP470|OTHER: laboratory biomarker analysis|OTHER: pharmacological study|PROCEDURE: positron emission tomography,"Astex Pharmaceuticals, Inc.",,INTERVENTIONAL
NCT00023816,Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00023816,UNKNOWN,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: carbendazim,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00085449,"Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT00085449,WITHDRAWN,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: alemtuzumab|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: melphalan|DRUG: mycophenolate mofetil|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT01273090,Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT01273090,COMPLETED,"Brain and Central Nervous System Tumors|Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: imetelstat sodium|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT00006225,Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer,https://clinicaltrials.gov/study/NCT00006225,COMPLETED,Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: filgrastim|BIOLOGICAL: recombinant flt3 ligand|BIOLOGICAL: recombinant human thrombopoietin|BIOLOGICAL: recombinant interleukin-3|PROCEDURE: in vitro-treated peripheral blood stem cell transplantation,Northwestern University,,INTERVENTIONAL
NCT00004075,17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery,https://clinicaltrials.gov/study/NCT00004075,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: tanespimycin,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT00866671,Observational Study of Nelarabine in Children and Young Adults,https://clinicaltrials.gov/study/NCT00866671,COMPLETED,"Leukaemia, Lymphoblastic, Acute",DRUG: nelarabine,GlaxoSmithKline,,OBSERVATIONAL
NCT01118013,Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01118013,TERMINATED,Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: donor lymphocytes|BIOLOGICAL: filgrastim|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: busulfan|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|OTHER: reduced-intensity transplant conditioning procedure|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT02793544,HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,https://clinicaltrials.gov/study/NCT02793544,COMPLETED,Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL),"DRUG: Fludarabine|DRUG: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|RADIATION: Total Body Irradiation (TBI) 200cGy on Day -1|PROCEDURE: Infusion of non-T-cell depleted bone marrow on Day 0|DRUG: Busulfan|DRUG: Cyclophosphamide 50mg/kg/day IV on Days -2,-1|DRUG: Cyclophosphamide 50mg/kg/day IV on Days -5,-4|RADIATION: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|DRUG: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|DRUG: Sirolimus|DRUG: Mycophenolate mofetil|DRUG: G-CSF|DRUG: Pre-HCT Mesna on Days -6 and -5|DRUG: Pre-HCT Mesna on Days -2 and -1|DRUG: Pre-HCT Mesna on Days -5 and -4|DRUG: Post-HCT Mesna",Center for International Blood and Marrow Transplant Research,National Marrow Donor Program,INTERVENTIONAL
NCT00003116,High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00003116,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: filgrastim|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cyclosporine|PROCEDURE: bone marrow ablation with stem cell support|PROCEDURE: peripheral blood stem cell transplantation,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00044954,"Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT00044954,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,University of Texas Southwestern Medical Center,,INTERVENTIONAL
NCT03195010,Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia,https://clinicaltrials.gov/study/NCT03195010,TERMINATED,"Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|B-Cell Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Hematologic and Lymphocytic Disorder|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome|Primary Myelofibrosis|Secondary Myelofibrosis|T-Cell Non-Hodgkin Lymphoma|Thrombocytopenia|Venous Thromboembolism",BIOLOGICAL: Platelet Transfusion|BIOLOGICAL: Platelet Transfusion,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01638533,"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",https://clinicaltrials.gov/study/NCT01638533,COMPLETED,Glioma|Hematopoietic and Lymphoid Cell Neoplasm|Lymphoma|Metastatic Malignant Solid Neoplasm|Neuroendocrine Neoplasm|Recurrent Adult Soft Tissue Sarcoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Chronic Lymphocytic Leukemia|Recurrent Colorectal Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Pancreatic Carcinoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Chronic Lymphocytic Leukemia|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage III Breast Cancer AJCC v7|Stage III Colorectal Cancer AJCC v7|Stage III Cutaneous Melanoma AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage III Prostate Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IV Prostate Cancer AJCC v7|Stage IV Renal Cell Cancer AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Solid Neoplasm,OTHER: Pharmacological Study|DRUG: Romidepsin,National Cancer Institute (NCI),Celgene Corporation,INTERVENTIONAL
NCT00453206,Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases,https://clinicaltrials.gov/study/NCT00453206,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,Wake Forest University Health Sciences,,INTERVENTIONAL
NCT00019019,Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas,https://clinicaltrials.gov/study/NCT00019019,COMPLETED,"Brain and Central Nervous System Tumors|Breast Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Melanoma (Skin)|Ovarian Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: carboxyamidotriazole|DRUG: paclitaxel,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT00621036,Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,https://clinicaltrials.gov/study/NCT00621036,WITHDRAWN,Brain and Central Nervous System Tumors|Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer,BIOLOGICAL: autologous immunoglobulin idiotype-KLH conjugate vaccine|BIOLOGICAL: sargramostim|DRUG: methotrexate|DRUG: thiotepa|RADIATION: radiation therapy,University of Texas Southwestern Medical Center,,INTERVENTIONAL
NCT00003956,Combination Chemotherapy in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00003956,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: fluorouracil|DRUG: leucovorin calcium|DRUG: lonafarnib,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00002862,Perillyl Alcohol in Treating Patients With Refractory Cancer,https://clinicaltrials.gov/study/NCT00002862,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: perillyl alcohol,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00352443,S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00352443,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: everolimus|DRUG: lapatinib ditosylate,SWOG Cancer Research Network,National Cancer Institute (NCI),INTERVENTIONAL
NCT03970096,Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS),https://clinicaltrials.gov/study/NCT03970096,RECRUITING,Acute Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Myeloproliferative Neoplasm,RADIATION: Total-Body Irradiation|DRUG: Thiotepa|DRUG: Fludarabine|DRUG: Tacrolimus|BIOLOGICAL: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|DRUG: Methotrexate|DRUG: Cyclophosphamide|BIOLOGICAL: Peripheral Blood Stem Cell|DRUG: Cyclosporine|DRUG: Sirolimus|DRUG: Busulfan|PROCEDURE: Bone Marrow Aspiration and Biopsy|PROCEDURE: Echocardiography|PROCEDURE: Multigated Acquisition Scan|PROCEDURE: Biospecimen Collection,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00002909,Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00002909,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: chemotherapy|DRUG: oral sodium phenylbutyrate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00390117,AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT00390117,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: CDKI AT7519|OTHER: laboratory biomarker analysis,NCIC Clinical Trials Group,,INTERVENTIONAL
NCT03628053,Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03628053,WITHDRAWN,Acute Lymphoblastic Leukemia,BIOLOGICAL: Tisagenlecleucel|DRUG: Blinatumomab|DRUG: Inotuzumab,Novartis Pharmaceuticals,,INTERVENTIONAL
NCT00004002,PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00004002,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: bortezomib,NYU Langone Health,National Cancer Institute (NCI),INTERVENTIONAL
NCT00296023,Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00296023,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: busulfan|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: tacrolimus|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,"University of California, San Francisco",National Cancer Institute (NCI),INTERVENTIONAL
NCT06718244,Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1,https://clinicaltrials.gov/study/NCT06718244,RECRUITING,Acute Lymphoblastic Leukemia,BIOLOGICAL: single dose of Inaticabtagene autoleucel,Ruijin Hospital,,INTERVENTIONAL
NCT00002946,Penclomedine in Treating Patients With Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00002946,COMPLETED,"Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: penclomedine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00006340,Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus,https://clinicaltrials.gov/study/NCT00006340,COMPLETED,Leukemia|Lymphoma|Precancerous Condition|Small Intestine Cancer,DRUG: arginine butyrate|DRUG: ganciclovir,Boston Medical Center,,INTERVENTIONAL
NCT01010217,Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide,https://clinicaltrials.gov/study/NCT01010217,COMPLETED,Blood Stem Cell Transplant Failure|Leukemia|Hematologic Malignancies,DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Mesna|DRUG: Rituximab|PROCEDURE: Stem Cell Transplantation|DRUG: Thiotepa|DRUG: Tacrolimus|DRUG: Mycofenolate mofetil|DRUG: G-CSF,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT00734890,Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00734890,COMPLETED,"Lung Cancer|Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: bevacizumab|DRUG: vandetanib|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT00562380,AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma,https://clinicaltrials.gov/study/NCT00562380,COMPLETED,"Lymphoma|Prostate Cancer|Sarcoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: ganitumab|OTHER: laboratory biomarker analysis|OTHER: pharmacological study|PROCEDURE: biopsy,Amgen,National Cancer Institute (NCI),INTERVENTIONAL
NCT00107354,"Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant",https://clinicaltrials.gov/study/NCT00107354,COMPLETED,Leukemia|Myelodysplastic Syndromes,BIOLOGICAL: aldesleukin|BIOLOGICAL: therapeutic allogeneic lymphocytes|BIOLOGICAL: therapeutic autologous lymphocytes|DRUG: cytarabine|DRUG: etoposide|DRUG: mitoxantrone hydrochloride|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation,Fred Hutchinson Cancer Center,,INTERVENTIONAL
NCT05320380,A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat,https://clinicaltrials.gov/study/NCT05320380,WITHDRAWN,Recurrent Acute Myeloid Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Mixed Phenotype Acute Leukemia|Recurrent T Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory T Acute Lymphoblastic Leukemia,DRUG: Anti-CD123 ADC IMGN632|PROCEDURE: Bone Marrow Aspiration and Biopsy|DRUG: Cytarabine|DRUG: Fludarabine Phosphate|DRUG: Hydrocortisone Sodium Succinate|DRUG: Liposome-encapsulated Daunorubicin-Cytarabine|DRUG: Methotrexate|DRUG: Prednisolone,Children's Oncology Group,"ImmunoGen, Inc.|National Cancer Institute (NCI)",INTERVENTIONAL
NCT00019513,"Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas",https://clinicaltrials.gov/study/NCT00019513,COMPLETED,"Colorectal Cancer|Esophageal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Liver Cancer|Lung Cancer|Lymphoma|Pancreatic Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: fluorouracil|DRUG: gemcitabine hydrochloride|DRUG: leucovorin calcium,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT01371630,Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01371630,RECRUITING,"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|Burkitt-Like Lymphoma With 11q Aberration|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma, Not Otherwise Specified|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Burkitt Lymphoma|Refractory B Acute Lymphoblastic Leukemia|Refractory Burkitt Lymphoma",BIOLOGICAL: Blinatumomab|DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|BIOLOGICAL: Inotuzumab Ozogamicin|OTHER: Laboratory Biomarker Analysis|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Prednisone|BIOLOGICAL: Rituximab|DRUG: Vincristine,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00068523,Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00068523,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: anti-thymocyte globulin|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: methylprednisolone|PROCEDURE: UV light therapy|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation,Case Comprehensive Cancer Center,,INTERVENTIONAL
NCT00020579,MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00020579,COMPLETED,Cancer,DRUG: entinostat,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT00566696,Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies,https://clinicaltrials.gov/study/NCT00566696,COMPLETED,"Leukemia, Acute Lymphocytic (ALL)|Leukemia, Myeloid, Acute(AML)|Leukemia, Myeloid, Chronic(CML)|Juvenile Myelomonocytic Leukemia (JMML)|Hemoglobinuria, Paroxysmal Nocturnal (PNH)|Hodgkin Lymphoma|Lymphoma, Non-Hodgkin (NHL)|Myelodysplastic Syndrome (MDS)",DEVICE: CliniMACS|PROCEDURE: Stem cell transplantation|DRUG: Fludarabine|DRUG: Thioplex®|DRUG: L-phenylalanine mustard|DRUG: Mycophenolate mofetil|DRUG: Rituxan™|DRUG: Alemtuzumab|DRUG: Cyclophosphamide|DRUG: Anti-thymocyte globulin (Rabbit)|DRUG: G-CSF|DRUG: Muromonab,St. Jude Children's Research Hospital,,INTERVENTIONAL
NCT02813252,Long-Term Follow-up Study for Patients Previously Treated With JCAR015,https://clinicaltrials.gov/study/NCT02813252,COMPLETED,Acute Lymphoblastic Leukemia,GENETIC: JCAR015,"Juno Therapeutics, a Subsidiary of Celgene",,OBSERVATIONAL
NCT00956475,Quality of Life in Younger Leukemia and Lymphoma Survivors,https://clinicaltrials.gov/study/NCT00956475,COMPLETED,Anxiety Disorder|Cancer Survivor|Fatigue|Leukemia|Long-term Effects Secondary to Cancer Therapy in Adults|Lymphoma|Lymphoproliferative Disorder|Pain|Psychosocial Effects of Cancer and Its Treatment|Small Intestine Cancer,BEHAVIORAL: telephone-based intervention|OTHER: questionnaire administration|PROCEDURE: assessment of therapy complications|PROCEDURE: fatigue assessment and management|PROCEDURE: psychosocial assessment and care|PROCEDURE: quality-of-life assessment,Case Comprehensive Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00423826,Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease,https://clinicaltrials.gov/study/NCT00423826,NO_LONGER_AVAILABLE,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Secondary Myelofibrosis,DRUG: Busulfan|DRUG: Cytarabine|DRUG: Fludarabine phosphate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: umbilical cord blood transplantation|RADIATION: total-body irradiation,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),EXPANDED_ACCESS
NCT00008164,Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia,https://clinicaltrials.gov/study/NCT00008164,UNKNOWN,Childhood Langerhans Cell Histiocytosis|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,PROCEDURE: umbilical cord blood transplantation,Herbert Irving Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01524926,CREATE: Cross-tumoral Phase 2 With Crizotinib,https://clinicaltrials.gov/study/NCT01524926,COMPLETED,Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma|Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor|Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1|Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma|Locally Advanced and/or Metastatic Clear Cell Sarcoma|Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma,DRUG: Crizotinib (PF-02341066),European Organisation for Research and Treatment of Cancer - EORTC,Pfizer,INTERVENTIONAL
NCT00281879,Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00281879,TERMINATED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unusual Cancers of Childhood,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|DRUG: busulfan|DRUG: carmustine|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: cytarabine|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: melphalan|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: umbilical cord blood transplantation|RADIATION: radiation therapy,OHSU Knight Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT03267407,Vietnam Cryptococcal Retention in Care Study - Version 2.1,https://clinicaltrials.gov/study/NCT03267407,UNKNOWN,"HIV/AIDS|Cryptococcal Meningitis|Opportunistic Infections, HIV Related|Cryptococcosis|Mycosis; Opportunistic|Mycosis Fungoides",OTHER: Preemptive high-dose Fluconazole,"National Hospital for Tropical Diseases, Hanoi, Vietnam","Centers for Disease Control and Prevention|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",OBSERVATIONAL
NCT01119066,"HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies",https://clinicaltrials.gov/study/NCT01119066,COMPLETED,Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome|Multiple Myeloma,RADIATION: total body irradiation|DRUG: Thiotepa|DRUG: Cyclophosphamide|DRUG: Busulfan|DRUG: Melphalan|DRUG: Fludarabine|DRUG: Clofarabine|PROCEDURE: (CliniMACS) T-cell depleted PBSC Transplant,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT00016172,ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00016172,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: pegylated liposomal doxorubicin hydrochloride|DRUG: picoplatin,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00002673,Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00002673,COMPLETED,Cancer,PROCEDURE: infection prophylaxis and management,Fred Hutchinson Cancer Center,,INTERVENTIONAL
NCT00448201,Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease,https://clinicaltrials.gov/study/NCT00448201,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: sargramostim|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: busulfan|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: tacrolimus|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00608517,Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil,https://clinicaltrials.gov/study/NCT00608517,TERMINATED,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: methylprednisolone|RADIATION: total-body irradiation,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00469820,"Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant",https://clinicaltrials.gov/study/NCT00469820,TERMINATED,Leukemia|Multiple Myeloma and Plasma Cell Neoplasm,BIOLOGICAL: autologous tumor cell vaccine|BIOLOGICAL: peripheral blood lymphocyte therapy,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT00005622,"Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders",https://clinicaltrials.gov/study/NCT00005622,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Multiple Myeloma and Malignant Plasma Cell Neoplasms|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,DRUG: cyclophosphamide|RADIATION: TBI,H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00004239,506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment,https://clinicaltrials.gov/study/NCT00004239,TERMINATED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: Compound 506U78,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT00049712,Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00049712,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: etaracizumab,"University of Wisconsin, Madison",National Cancer Institute (NCI),INTERVENTIONAL
NCT00324597,AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00324597,UNKNOWN,"Lung Cancer|Lymphoma|Lymphoproliferative Disorder|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: gemcitabine hydrochloride|DRUG: motesanib diphosphate|OTHER: pharmacological study,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00295997,"Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia",https://clinicaltrials.gov/study/NCT00295997,UNKNOWN,Chronic Myeloproliferative Disorders|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|BIOLOGICAL: graft-versus-tumor induction therapy|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,"University of California, San Francisco",National Cancer Institute (NCI),INTERVENTIONAL
NCT00053989,NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders,https://clinicaltrials.gov/study/NCT00053989,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Fanconi Anemia|Aplastic Anemia,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: graft-versus-tumor induction therapy|BIOLOGICAL: sargramostim|BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: methylprednisolone|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: umbilical cord blood transplantation,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT00382109,Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission,https://clinicaltrials.gov/study/NCT00382109,COMPLETED,B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Graft Versus Host Disease|L1 Childhood Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia,DRUG: thiotepa|DRUG: cyclophosphamide|DRUG: tacrolimus|DRUG: methotrexate|DRUG: sirolimus|RADIATION: total body irradiation,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT00560794,Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL),https://clinicaltrials.gov/study/NCT00560794,COMPLETED,Acute Lymphoblastic Leukemia,BIOLOGICAL: Blinatumomab (MT103),Amgen Research (Munich) GmbH,,INTERVENTIONAL
NCT00611351,"Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer",https://clinicaltrials.gov/study/NCT00611351,COMPLETED,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Secondary Myelofibrosis,BIOLOGICAL: anti-thymocyte globulin|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: mycophenolate mofetil|DRUG: tacrolimus|GENETIC: polymerase chain reaction|GENETIC: polymorphism analysis|OTHER: flow cytometry|OTHER: laboratory biomarker analysis|OTHER: pharmacogenomic studies|OTHER: pharmacological study|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,University of Nebraska,National Cancer Institute (NCI),INTERVENTIONAL
NCT00005021,Combination Chemotherapy With or Without Biological Therapy in Treating Patients With Refractory Solid Tumor or Lymphoma,https://clinicaltrials.gov/study/NCT00005021,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: filgrastim|DRUG: carboplatin|DRUG: paclitaxel|DRUG: topotecan hydrochloride,Fox Chase Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00002759,Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma,https://clinicaltrials.gov/study/NCT00002759,COMPLETED,"Drug/Agent Toxicity by Tissue/Organ|Lymphoma|Neutropenia|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: cyclosporine|DRUG: irinotecan hydrochloride|DRUG: phenobarbital,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01564277,Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01564277,TERMINATED,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Contiguous Stage II Adult Burkitt Lymphoma|de Novo Myelodysplastic Syndromes|Noncontiguous Stage II Adult Burkitt Lymphoma|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Stage I Adult Burkitt Lymphoma|Stage III Adult Burkitt Lymphoma|Stage IV Adult Burkitt Lymphoma|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: rasburicase|DRUG: allopurinol,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00800150,"Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment",https://clinicaltrials.gov/study/NCT00800150,TERMINATED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,DRUG: fludarabine phosphate|DRUG: melphalan|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|RADIATION: intensity-modulated radiation therapy|RADIATION: tomotherapy|RADIATION: total marrow irradiation|RADIATION: total nodal irradiation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00042822,"FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma",https://clinicaltrials.gov/study/NCT00042822,COMPLETED,Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,DRUG: romidepsin,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003294,Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer,https://clinicaltrials.gov/study/NCT00003294,COMPLETED,"Leukemia|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: filgrastim|DRUG: amifostine trihydrate|DRUG: carboplatin|DRUG: paclitaxel,Roswell Park Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT01190930,Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma,https://clinicaltrials.gov/study/NCT01190930,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Adult B Lymphoblastic Lymphoma|Ann Arbor Stage I B Lymphoblastic Lymphoma|Ann Arbor Stage II B Lymphoblastic Lymphoma|Childhood B Acute Lymphoblastic Leukemia|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Childhood B Lymphoblastic Lymphoma|Down Syndrome|Hypodiploid B Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive,DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Leucovorin Calcium|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Pegaspargase|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|DRUG: Thioguanine|DRUG: Vincristine Sulfate,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT00823524,Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00823524,COMPLETED,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: donor natural killer cell infusion,Asan Medical Center,Korea Research Institute of Bioscience & Biotechnology,INTERVENTIONAL
NCT00003368,Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis,https://clinicaltrials.gov/study/NCT00003368,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: irinotecan hydrochloride,National Cancer Institute (NCI),Alliance for Clinical Trials in Oncology,INTERVENTIONAL
NCT00327678,Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults,https://clinicaltrials.gov/study/NCT00327678,COMPLETED,"Leukemia, Lymphocytic",DRUG: Rituximab|DRUG: Imatinib Mesylate,Assistance Publique - Hôpitaux de Paris,Group for Research in Adult Acute Lymphoblastic Leukemia,INTERVENTIONAL
NCT00290641,"Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT00290641,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes,BIOLOGICAL: filgrastim|BIOLOGICAL: graft-versus-tumor induction therapy|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: umbilical cord blood transplantation|RADIATION: radiation therapy,"Masonic Cancer Center, University of Minnesota",National Cancer Institute (NCI),INTERVENTIONAL
NCT00365768,"Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors",https://clinicaltrials.gov/study/NCT00365768,COMPLETED,Kidney Cancer|Leukemia|Lymphoma|Neurotoxicity|Peripheral Neuropathy|Sarcoma,DRUG: Glutamine|OTHER: Placebo,Columbia University,,INTERVENTIONAL
NCT00806767,"Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer",https://clinicaltrials.gov/study/NCT00806767,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: therapeutic immune globulin|DRUG: busulfan|DRUG: fludarabine phosphate|PROCEDURE: allogeneic hematopoietic stem cell transplantation,Institut Paoli-Calmettes,,INTERVENTIONAL
NCT00014482,Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00014482,COMPLETED,Anxiety Disorder|Chronic Myeloproliferative Disorders|Depression|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Pain,PROCEDURE: pain therapy|PROCEDURE: psychosocial assessment and care,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00006042,Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00006042,COMPLETED,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|RADIATION: radiation therapy,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT02122081,Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,https://clinicaltrials.gov/study/NCT02122081,COMPLETED,Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia,RADIATION: radiation therapy|DRUG: cyclophosphamide|BIOLOGICAL: anti-thymocyte globulin|DRUG: tacrolimus|DRUG: methotrexate|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|OTHER: laboratory biomarker analysis,Sumithira Vasu,,INTERVENTIONAL
NCT00659568,Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma,https://clinicaltrials.gov/study/NCT00659568,COMPLETED,"Breast Cancer|Endometrial Cancer|Kidney Cancer|Lung Cancer|Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: metformin hydrochloride|DRUG: temsirolimus,London Health Sciences Centre,,INTERVENTIONAL
NCT00134004,"Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer",https://clinicaltrials.gov/study/NCT00134004,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|RADIATION: radiation therapy,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT00004232,Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00004232,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition,BIOLOGICAL: filgrastim|DRUG: cyclosporine|DRUG: methylprednisolone|DRUG: prednisone|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00031941,CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy,https://clinicaltrials.gov/study/NCT00031941,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: lenalidomide,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT00134017,"Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer",https://clinicaltrials.gov/study/NCT00134017,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: Busulfan|DRUG: Cyclophosphamide,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT00049699,VNP40101M in Treating Patients With Advanced or Metastatic Cancer,https://clinicaltrials.gov/study/NCT00049699,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: laromustine,Vion Pharmaceuticals,,INTERVENTIONAL
NCT00053157,Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia,https://clinicaltrials.gov/study/NCT00053157,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: sargramostim,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT00004189,Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00004189,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: filgrastim|DRUG: becatecarin|DRUG: cisplatin,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00005639,Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment,https://clinicaltrials.gov/study/NCT00005639,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: Azacitidine Injection|DRUG: sodium phenylbutyrate,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT04681105,Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies,https://clinicaltrials.gov/study/NCT04681105,ACTIVE_NOT_RECRUITING,"Recurrent Acute Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Hairy Cell Leukemia|Recurrent Hematologic Malignancy|Recurrent Hodgkin Lymphoma|Recurrent T Acute Lymphoblastic Leukemia|Refractory Acute Leukemia|Refractory B Acute Lymphoblastic Leukemia|Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Hairy Cell Leukemia|Refractory Hematologic Malignancy|Refractory Hodgkin Lymphoma|Refractory T Acute Lymphoblastic Leukemia|Systemic Mastocytosis",DRUG: Acetaminophen|DRUG: Dexamethasone|DRUG: Diphenhydramine|BIOLOGICAL: Flotetuzumab|DRUG: Ibuprofen|DRUG: Ranitidine,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05753501,"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",https://clinicaltrials.gov/study/NCT05753501,RECRUITING,Hematologic Cancer,DRUG: ABBV-101,AbbVie,,INTERVENTIONAL
NCT00006221,BMS-247550 in Treating Patients With Advanced Cancers,https://clinicaltrials.gov/study/NCT00006221,COMPLETED,"Lymphoma|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: ixabepilone,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00301912,Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00301912,WITHDRAWN,Anemia|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: filgrastim|DRUG: busulfan|DRUG: fludarabine phosphate|DRUG: methotrexate|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation,"University of California, San Francisco",National Cancer Institute (NCI),INTERVENTIONAL
NCT00646139,KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment,https://clinicaltrials.gov/study/NCT00646139,COMPLETED,"Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: Src kinase inhibitor KX2-391|OTHER: immunoenzyme technique|OTHER: pharmacological study,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT00438958,Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases,https://clinicaltrials.gov/study/NCT00438958,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Secondary Myelofibrosis,BIOLOGICAL: filgrastim|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation,The Canadian Blood and Marrow Transplant Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT00004036,Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00004036,UNKNOWN,"Chronic Myeloproliferative Disorders|Drug/Agent Toxicity by Tissue/Organ|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: sargramostim|DRUG: amifostine trihydrate|DRUG: carboplatin|DRUG: cyclophosphamide,The Cleveland Clinic,,INTERVENTIONAL
NCT03333486,"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer",https://clinicaltrials.gov/study/NCT03333486,ACTIVE_NOT_RECRUITING,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Leukemia in Remission|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Aplastic Anemia|B-Cell Non-Hodgkin Lymphoma|CD40 Ligand Deficiency|Chronic Granulomatous Disease|Chronic Leukemia in Remission|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Congenital Amegakaryocytic Thrombocytopenia|Congenital Neutropenia|Congenital Pure Red Cell Aplasia|Glanzmann Thrombasthenia|Immunodeficiency Syndrome|Myelodysplastic Syndrome|Myelofibrosis|Myeloproliferative Neoplasm|Paroxysmal Nocturnal Hemoglobinuria|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Non-Hodgkin Lymphoma|Refractory Non-Hodgkin Lymphoma|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome|Severe Aplastic Anemia|Shwachman-Diamond Syndrome|Sickle Cell Disease|T-Cell Non-Hodgkin Lymphoma|Thalassemia|Waldenstrom Macroglobulinemia|Wiskott-Aldrich Syndrome",DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Peripheral Blood Stem Cell Transplantation|RADIATION: Total-Body Irradiation,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT00544115,Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders,https://clinicaltrials.gov/study/NCT00544115,ACTIVE_NOT_RECRUITING,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition,DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: melphalan|DRUG: methotrexate|DRUG: mycophenolate mofetil|DRUG: sirolimus|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: total-body irradiation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00036738,"Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib",https://clinicaltrials.gov/study/NCT00036738,COMPLETED,"Adult Acute Lymphoblastic Leukemia in Remission|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blastic Phase|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Phase of Disease|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Disease",DRUG: Cyclosporine|DRUG: Dasatinib|DRUG: Fludarabine Phosphate|DRUG: Imatinib Mesylate|DRUG: Mycophenolate Mofetil|DRUG: Nilotinib|PROCEDURE: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Peripheral Blood Stem Cell Transplantation|BIOLOGICAL: Therapeutic Allogeneic Lymphocytes|RADIATION: Total-Body Irradiation,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01139970,Veliparib and Temozolomide in Treating Patients With Acute Leukemia,https://clinicaltrials.gov/study/NCT01139970,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Adult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA|Adult B Acute Lymphoblastic Leukemia|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Adult T Acute Lymphoblastic Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia,OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Temozolomide|DRUG: Veliparib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01005914,Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01005914,TERMINATED,Leukemia,DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: imatinib mesylate|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: pegaspargase|DRUG: vincristine sulfate,OHSU Knight Cancer Institute,,INTERVENTIONAL
NCT02727803,Personalized NK Cell Therapy in CBT,https://clinicaltrials.gov/study/NCT02727803,RECRUITING,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Biphenotypic Leukemia|Acute Lymphoblastic Leukemia|Acute Lymphoblastic Leukemia in Remission|Acute Myeloid Leukemia With Myelodysplasia-Related Changes|Acute Myeloid Leukemia With Variant MLL Translocations|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Chemotherapy-Related Leukemia|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements|ISS Stage II Plasma Cell Myeloma|ISS Stage III Plasma Cell Myeloma|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Gene Mutation|Myelodysplastic/Myeloproliferative Neoplasm|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome",BIOLOGICAL: Allogeneic Natural Killer Cell Line NK-92|BIOLOGICAL: Anti-Thymocyte Globulin|DRUG: Busulfan|DRUG: Clofarabine|DRUG: Cyclophosphamide|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Melphalan|BIOLOGICAL: Rituximab|RADIATION: Total-Body Irradiation|PROCEDURE: Umbilical Cord Blood Transplantation,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02988466,Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT,https://clinicaltrials.gov/study/NCT02988466,COMPLETED,Hematologic Malignancies,BIOLOGICAL: Haplo HCT <55 years old|BIOLOGICAL: Haplo HCT ≥55 years old|DRUG: GVHD Prophylaxis|BIOLOGICAL: Haplo HCT ≥55 and < 65 years old|BIOLOGICAL: Haplo HCT ≥65 and ≤75 years old,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00004105,Combination Chemotherapy in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00004105,COMPLETED,"Leukemia|Lymphoma|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: estramustine phosphate sodium|DRUG: paclitaxel|DRUG: vinorelbine ditartrate,NYU Langone Health,National Cancer Institute (NCI),INTERVENTIONAL
NCT01869777,Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia,https://clinicaltrials.gov/study/NCT01869777,COMPLETED,Acute Undifferentiated Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Mast Cell Leukemia|Myeloid/NK-cell Acute Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia,PROCEDURE: bioelectric impedance analysis,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT00365287,"Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer",https://clinicaltrials.gov/study/NCT00365287,COMPLETED,Breast Cancer|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,DRUG: anti-thymocyte globulin|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: radiation therapy|PROCEDURE: umbilical cord blood transplantation,"Masonic Cancer Center, University of Minnesota",National Cancer Institute (NCI),INTERVENTIONAL
NCT00004875,Heparin or Enoxaparin in Patients With Cancer,https://clinicaltrials.gov/study/NCT00004875,COMPLETED,"Lymphoma|Thromboembolism|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: enoxaparin|DRUG: heparin,Northwestern University,National Cancer Institute (NCI),OBSERVATIONAL
NCT01077440,Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT01077440,TERMINATED,Cancer Survivor|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Testicular Germ Cell Tumor,GENETIC: DNA analysis|GENETIC: polymerase chain reaction|OTHER: flow cytometry|OTHER: laboratory biomarker analysis,Vanderbilt University,National Cancer Institute (NCI),OBSERVATIONAL
NCT00813501,Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases,https://clinicaltrials.gov/study/NCT00813501,TERMINATED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic-Myeloproliferative Diseases|Neuroblastoma|Therapy-related Toxicity,BIOLOGICAL: immunosuppressive therapy|OTHER: immunological diagnostic method|PROCEDURE: allogeneic hematopoietic stem cell transplantation,City of Hope Medical Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT03575325,Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03575325,COMPLETED,Lymphoid Leukemia|Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia,DRUG: CPX-351,H. Lee Moffitt Cancer Center and Research Institute,Jazz Pharmaceuticals,INTERVENTIONAL
NCT00513474,Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00513474,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cyclosporin-A|DRUG: etoposide|DRUG: methotrexate|DRUG: rasburicase|DRUG: sirolimus|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: total-body irradiation|DRUG: fludarabine|DRUG: allopurinol,Massachusetts General Hospital,,INTERVENTIONAL
NCT00060372,Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer,https://clinicaltrials.gov/study/NCT00060372,COMPLETED,"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Childhood Myelodysplastic Syndromes|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Disseminated Neuroblastoma|Malignant Neoplasm|Ovarian Choriocarcinoma|Ovarian Embryonal Carcinoma|Ovarian Immature Teratoma|Ovarian Mature Teratoma|Ovarian Mixed Germ Cell Tumor|Ovarian Monodermal and Highly Specialized Teratoma|Ovarian Polyembryoma|Ovarian Yolk Sac Tumor|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Malignant Testicular Germ Cell Tumor|Recurrent Mantle Cell Lymphoma|Recurrent Neuroblastoma|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Refractory Chronic Lymphocytic Leukemia|Refractory Multiple Myeloma|Relapsing Chronic Myelogenous Leukemia|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage II Ovarian Epithelial Cancer|Stage III Malignant Testicular Germ Cell Tumor|Stage III Multiple Myeloma|Stage III Ovarian Epithelial Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Ovarian Epithelial Cancer|Testicular Choriocarcinoma|Testicular Choriocarcinoma and Embryonal Carcinoma|Testicular Choriocarcinoma and Seminoma|Testicular Choriocarcinoma and Teratoma|Testicular Choriocarcinoma and Yolk Sac Tumor|Testicular Embryonal Carcinoma|Testicular Embryonal Carcinoma and Seminoma|Testicular Embryonal Carcinoma and Teratoma|Testicular Embryonal Carcinoma and Teratoma With Seminoma|Testicular Embryonal Carcinoma and Yolk Sac Tumor|Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma|Testicular Teratoma|Testicular Yolk Sac Tumor|Testicular Yolk Sac Tumor and Teratoma|Testicular Yolk Sac Tumor and Teratoma With Seminoma",DRUG: ipilimumab|DRUG: therapeutic allogeneic lymphocytes,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00387530,Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer,https://clinicaltrials.gov/study/NCT00387530,WITHDRAWN,Gastric Cancer|Head and Neck Cancer|Lymphoma|Lymphoproliferative Disorder,DRUG: oral sodium phenylbutyrate|DRUG: valganciclovir|GENETIC: polymerase chain reaction|GENETIC: protein expression analysis|PROCEDURE: biopsy,"University of California, San Diego",National Cancer Institute (NCI),INTERVENTIONAL
NCT01147991,Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer,https://clinicaltrials.gov/study/NCT01147991,COMPLETED,Gastric Cancer|Head and Neck Cancer|Lymphoma|Lymphoproliferative Disorder|Nonneoplastic Condition,BIOLOGICAL: EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,Cancer Research UK,,INTERVENTIONAL
NCT01298388,"Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998",https://clinicaltrials.gov/study/NCT01298388,UNKNOWN,Cancer Survivor|Leukemia|Long-term Effects Secondary to Cancer Therapy in Children,OTHER: medical chart review|OTHER: questionnaire administration|OTHER: study of socioeconomic and demographic variables,European Organisation for Research and Treatment of Cancer - EORTC,,OBSERVATIONAL
NCT05993949,Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT05993949,RECRUITING,Lymphoblastic Leukemia,DRUG: Dasatinib,Stanford University,"Kite, A Gilead Company",INTERVENTIONAL
NCT00019344,Flavopiridol in Treating Patients With Refractory Cancer,https://clinicaltrials.gov/study/NCT00019344,COMPLETED,"Lymphoma|Prostate Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: alvocidib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT02551289,MAgnetic Resonance Imaging in COeliac Disease,https://clinicaltrials.gov/study/NCT02551289,COMPLETED,Celiac Disease|Coeliac Disease|Celiac Sprue|Gluten Enteropathy,OTHER: Gluten free diet,University of Nottingham,Nottingham University Hospitals NHS Trust|University of Salerno,OBSERVATIONAL
NCT00064311,Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00064311,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,DRUG: ravuconazole,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),INTERVENTIONAL
NCT00082654,Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients,https://clinicaltrials.gov/study/NCT00082654,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Neuroblastoma|Ovarian Cancer|Psychosocial Effects of Cancer and Its Treatment|Testicular Germ Cell Tumor,PROCEDURE: psychosocial assessment and care,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00437060,Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00437060,COMPLETED,Childhood B Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Cognitive Side Effects of Cancer Therapy|Long-Term Effects Secondary to Cancer Therapy in Children|Neurotoxicity Syndrome|Psychological Impact of Cancer|Untreated Childhood Acute Lymphoblastic Leukemia,PROCEDURE: Cognitive Assessment|PROCEDURE: Diffusion Tensor Imaging|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|PROCEDURE: Psychosocial Assessment and Care,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT00691015,"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",https://clinicaltrials.gov/study/NCT00691015,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: rituximab|DRUG: busulfan|DRUG: carmustine|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: melphalan|RADIATION: total body irradiation (TBI)|DRUG: anti-thymocyte globulin IV,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00952185,Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers,https://clinicaltrials.gov/study/NCT00952185,TERMINATED,Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm|Viral Infection,OTHER: cytology specimen collection procedure|OTHER: fluorescent antibody technique|PROCEDURE: assessment of therapy complications,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00589563,"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer",https://clinicaltrials.gov/study/NCT00589563,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Precancerous Condition|Secondary Myelofibrosis|Small Intestine Cancer,BIOLOGICAL: anti-thymocyte globulin|DRUG: cyclophosphamide|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: melphalan|DRUG: methotrexate|DRUG: sirolimus|DRUG: tacrolimus|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: hematopoietic stem cell transplantation|PROCEDURE: nonmyeloablative allogeneic hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: total-body irradiation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02143414,"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia",https://clinicaltrials.gov/study/NCT02143414,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia,PROCEDURE: Biopsy Procedure|PROCEDURE: Biospecimen Collection|BIOLOGICAL: Blinatumomab|PROCEDURE: Bone Marrow Aspiration and Biopsy|PROCEDURE: Computed Tomography|DRUG: Dasatinib|PROCEDURE: Echocardiography Test|PROCEDURE: Lumbar Puncture|PROCEDURE: Magnetic Resonance Imaging|DRUG: Mercaptopurine|DRUG: Methotrexate|DRUG: Methotrexate Sodium|DRUG: Prednisone|DRUG: Vincristine|DRUG: Vincristine Sulfate|PROCEDURE: X-Ray Imaging,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00052520,"Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation",https://clinicaltrials.gov/study/NCT00052520,COMPLETED,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia,BIOLOGICAL: therapeutic allogeneic lymphocytes|BIOLOGICAL: aldesleukin|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: allogeneic bone marrow transplantation|OTHER: laboratory biomarker analysis|GENETIC: gene expression analysis|OTHER: immunologic technique|OTHER: flow cytometry|GENETIC: polymerase chain reaction|GENETIC: cytogenetic analysis|OTHER: staining method,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00053053,Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer,https://clinicaltrials.gov/study/NCT00053053,COMPLETED,"Cachexia|Lymphoma|Lymphoproliferative Disorder|Unspecified Adult Solid Tumor, Protocol Specific",DIETARY_SUPPLEMENT: Juven|DIETARY_SUPPLEMENT: Non-Juven Supplement,Radiation Therapy Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT03678883,9-ING-41 in Patients with Advanced Cancers,https://clinicaltrials.gov/study/NCT03678883,ACTIVE_NOT_RECRUITING,"Cancer|Pancreatic Cancer|Sarcoma|Renal Cancer|Refractory Cancer|Refractory Neoplasm|Refractory Non-Hodgkin Lymphoma|Pancreatic Adenocarcinoma|Resistant Cancer|Neoplasm Metastasis|Neoplasm of Bone|Neoplasm, Breast|Neoplasm of Lung|Neoplasms,Colorectal|Neoplasms Pancreatic|Malignant Glioma|Malignancies|Malignancies Multiple|Bone Metastases|Bone Neoplasm|Bone Cancer|Pancreas Cancer|Pancreatic Neoplasms|Breast Neoplasms|Acute T Cell Leukemia Lymphoma",DRUG: 9-ING-41|DRUG: Gemcitabine - 21 day cycle|DRUG: Doxorubicin.|DRUG: Lomustine|DRUG: Carboplatin.|DRUG: Nab paclitaxel.|DRUG: Paclitaxel.|DRUG: Gemcitabine - 28 day cycle|DRUG: Irinotecan,Actuate Therapeutics Inc.,,INTERVENTIONAL
NCT01760655,Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01760655,COMPLETED,"Acute Myeloid Leukemia With FLT3/ITD Mutation|Acute Myeloid Leukemia With Gene Mutations|Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM|Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214|Aplastic Anemia|Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Follicular Lymphoma|Hodgkin Lymphoma|Myelodysplastic Syndrome|Myelofibrosis|Myeloid Leukemia|Non-Hodgkin Lymphoma|Plasma Cell Myeloma|Polycythemia Vera|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia",DRUG: Fludarabine phosphate|DRUG: Busulfan|RADIATION: Total-Body Irradiation|BIOLOGICAL: Therapeutic Allogeneic Lymphocytes|DRUG: Cyclophosphamide|PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation|PROCEDURE: Peripheral Blood Stem Cell Transplantation|DRUG: Tacrolimus|DRUG: Mycophenolate Mofetil|OTHER: Laboratory Biomarker Analysis,Sidney Kimmel Cancer Center at Thomas Jefferson University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00458848,Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00458848,COMPLETED,Leukemia,DRUG: asparaginase|DRUG: daunorubicin hydrochloride|DRUG: etoposide|DRUG: idarubicin|DRUG: imatinib mesylate|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: mitoxantrone hydrochloride|DRUG: prednisone|DRUG: vincristine sulfate|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: autologous hematopoietic stem cell transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Gruppo Italiano Malattie EMatologiche dell'Adulto,,INTERVENTIONAL
NCT00237627,Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00237627,COMPLETED,"Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: PS-341|DRUG: Doxil|DRUG: Velcade,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04526795,"Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia",https://clinicaltrials.gov/study/NCT04526795,TERMINATED,"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Recurrent T-Cell Prolymphocytic Leukemia|Refractory Acute Biphenotypic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory T-Cell Prolymphocytic Leukemia",DRUG: Cytarabine|DRUG: Fludarabine|DRUG: Pegcrisantaspase,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003538,Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation,https://clinicaltrials.gov/study/NCT00003538,COMPLETED,Cancer,BIOLOGICAL: graft versus host disease prophylaxis/therapy|PROCEDURE: allogeneic bone marrow transplantation,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT00361049,Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00361049,COMPLETED,Cancer,BIOLOGICAL: graft versus host disease prophylaxis/therapy|GENETIC: fluorescence in situ hybridization|OTHER: immunoenzyme technique|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis|PROCEDURE: in vitro-treated bone marrow transplantation|PROCEDURE: management of therapy complications,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01116232,"Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",https://clinicaltrials.gov/study/NCT01116232,TERMINATED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: rituximab|DRUG: sirolimus|DRUG: tacrolimus|OTHER: laboratory biomarker analysis|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: management of therapy complications|PROCEDURE: peripheral blood stem cell transplantation,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003805,Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count,https://clinicaltrials.gov/study/NCT00003805,COMPLETED,"Bone Marrow Suppression|Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: piperacillin sodium|DRUG: piperacillin-tazobactam|DRUG: tazobactam sodium|DRUG: vancomycin,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT00066599,Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy,https://clinicaltrials.gov/study/NCT00066599,COMPLETED,Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Neutropenia|Sarcoma,DRUG: voriconazole,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00245037,"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer",https://clinicaltrials.gov/study/NCT00245037,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Precancerous Condition,BIOLOGICAL: therapeutic allogeneic lymphocytes|DRUG: busulfan|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: Total Body Irradiation (TBI)|DRUG: Granulocyte colony-stimulating factor (G-CSF)|DRUG: Phenytoin|DRUG: Methotrexate,OHSU Knight Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT01175785,Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT01175785,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes,PROCEDURE: umbilical cord blood transplantation|DRUG: fludarabine phosphate|DRUG: cyclophosphamide|BIOLOGICAL: ex vivo-expanded cord blood progenitor cell infusion|RADIATION: total-body irradiation|DRUG: cyclosporine|DRUG: mycophenolate mofetil|OTHER: laboratory biomarker analysis,"Nohla Therapeutics, Inc.","National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Fred Hutchinson Cancer Center",INTERVENTIONAL
NCT00006379,Non-Ablative Allo HSCT For Hematologic Malignancies or SAA,https://clinicaltrials.gov/study/NCT00006379,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition|Small Intestine Cancer,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: graft-versus-tumor induction therapy|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|PROCEDURE: peripheral blood stem cell transplantation,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00324324,Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00324324,TERMINATED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,DRUG: moxifloxacin hydrochloride|DRUG: Placebo,OHSU Knight Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00061945,Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00061945,COMPLETED,Acute Undifferentiated Leukemia|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|L1 Adult Acute Lymphoblastic Leukemia|L1 Childhood Acute Lymphoblastic Leukemia|L2 Adult Acute Lymphoblastic Leukemia|L2 Childhood Acute Lymphoblastic Leukemia|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia,DRUG: allopurinol|DRUG: cyclophosphamide|DRUG: daunorubicin hydrochloride|DRUG: vincristine sulfate|DRUG: dexamethasone|DRUG: asparaginase|BIOLOGICAL: filgrastim|DRUG: imatinib mesylate|DRUG: methotrexate|DRUG: cytarabine|DRUG: trimethoprim-sulfamethoxazole|DRUG: mercaptopurine|DRUG: leucovorin calcium|BIOLOGICAL: alemtuzumab|DRUG: acyclovir|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00003816,Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer,https://clinicaltrials.gov/study/NCT00003816,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",BIOLOGICAL: anti-thymocyte globulin|DRUG: busulfan|DRUG: carboplatin|DRUG: cyclophosphamide|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: melphalan|DRUG: thiotepa|RADIATION: total-body irradiation,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT00004058,12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder,https://clinicaltrials.gov/study/NCT00004058,TERMINATED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition,DRUG: tetradecanoylphorbol acetate,University of Medicine and Dentistry of New Jersey,National Cancer Institute (NCI),INTERVENTIONAL
NCT06195891,"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome",https://clinicaltrials.gov/study/NCT06195891,RECRUITING,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome,PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Marrow Aspiration|PROCEDURE: Bone Marrow Biopsy|PROCEDURE: Dual-Energy Computed Tomography|PROCEDURE: Echocardiography|DRUG: Fludarabine|PROCEDURE: Magnetic Resonance Imaging|DRUG: Melphalan|PROCEDURE: Multigated Acquisition Scan|BIOLOGICAL: Partially Engineered T-regulatory Cell Donor Graft TRGFT-201|DRUG: Tacrolimus|DRUG: Thiotepa|RADIATION: Total Marrow and Lymphoid Irradiation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02094794,Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML,https://clinicaltrials.gov/study/NCT02094794,ACTIVE_NOT_RECRUITING,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia,DRUG: etoposide|DRUG: cyclophosphamide|RADIATION: total marrow irradiation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: allogeneic bone marrow transplantation,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00499668,Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer,https://clinicaltrials.gov/study/NCT00499668,WITHDRAWN,Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Nausea and Vomiting|Solid Tumor,DRUG: aprepitant|DRUG: ondansetron hydrochloride,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00054236,Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia,https://clinicaltrials.gov/study/NCT00054236,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|PROCEDURE: umbilical cord blood transplantation|DRUG: methylprednisolone,Case Comprehensive Cancer Center,,INTERVENTIONAL
NCT00946283,Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT00946283,TERMINATED,Breast Cancer|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,DIETARY_SUPPLEMENT: Lactobacillus rhamnosus GG,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey,INTERVENTIONAL
NCT00003408,Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer,https://clinicaltrials.gov/study/NCT00003408,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor,BIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa|BIOLOGICAL: sargramostim,Cancer Treatment Centers of America,,INTERVENTIONAL
NCT00713505,Educational and Skills Training Program for Parents of Childhood Cancer Survivors Who Have Neurobehavioral Dysfunction,https://clinicaltrials.gov/study/NCT00713505,COMPLETED,Cancer Survivor|Cognitive/Functional Effects|Leukemia|Long-term Effects Secondary to Cancer Therapy in Children|Lymphoma|Psychosocial Effects of Cancer and Its Treatment,OTHER: educational intervention|PROCEDURE: psychosocial assessment and care,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00755040,Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder,https://clinicaltrials.gov/study/NCT00755040,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,DRUG: cyclosporine ophthalmic emulsion|OTHER: placebo,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00293384,"Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant",https://clinicaltrials.gov/study/NCT00293384,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nausea and Vomiting|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,DRUG: Aprepitant|DRUG: Cyclophosphamide|DRUG: Dexamethasone|DRUG: Granisetron hydrochloride,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00661999,Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer,https://clinicaltrials.gov/study/NCT00661999,COMPLETED,"Anemia|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: darbepoetin alfa|DIETARY_SUPPLEMENT: ferrous sulfate|DRUG: sodium ferric gluconate complex in sucrose|OTHER: placebo,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT00070382,Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer,https://clinicaltrials.gov/study/NCT00070382,COMPLETED,"Anemia|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: darbepoetin alfa|DRUG: epoetin alfa,Jonsson Comprehensive Cancer Center,Amgen,INTERVENTIONAL
NCT00255749,Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer,https://clinicaltrials.gov/study/NCT00255749,COMPLETED,"Anemia|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: epoetin alfa,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT05008666,Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH,https://clinicaltrials.gov/study/NCT05008666,UNKNOWN,Safety and Efficacy,DRUG: Sintilimab|DRUG: Chidamide|DRUG: Azacitidine|DRUG: L-DEP,Sun Yat-sen University,,INTERVENTIONAL
NCT02663518,A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors,https://clinicaltrials.gov/study/NCT02663518,TERMINATED,Hematologic Malignancies|Solid Tumor,DRUG: PF-0791800 (TTI-621)|DRUG: PF-07901800 (TTI-621) plus Rituximab|DRUG: PF-07901800 (TTI-621) plus Nivolumab,Pfizer,,INTERVENTIONAL
NCT01156883,Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01156883,COMPLETED,Leukemia,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: ifosfamide|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: prednisone|DRUG: thioguanine|DRUG: vincristine sulfate|DRUG: vindesine,Gruppo Italiano Malattie EMatologiche dell'Adulto,,INTERVENTIONAL
NCT01607892,Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer,https://clinicaltrials.gov/study/NCT01607892,COMPLETED,Hematological Malignancies,DRUG: KPT-330,Karyopharm Therapeutics Inc,,INTERVENTIONAL
NCT00416624,Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy,https://clinicaltrials.gov/study/NCT00416624,COMPLETED,"Anemia|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: darbepoetin alfa|DRUG: epoetin alfa|PROCEDURE: fatigue assessment and management|PROCEDURE: quality-of-life assessment,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL
NCT00060255,"High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors",https://clinicaltrials.gov/study/NCT00060255,COMPLETED,"Breast Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Testicular Germ Cell Tumor|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: busulfan|DRUG: carboplatin|DRUG: carmustine|DRUG: cyclophosphamide|DRUG: etoposide|DRUG: melphalan|DRUG: thiotepa|PROCEDURE: autologous bone marrow transplantation|PROCEDURE: bone marrow ablation with stem cell support|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Roswell Park Cancer Institute,,INTERVENTIONAL
NCT00110045,Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00110045,COMPLETED,Cancer,DRUG: caspofungin acetate,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT00967057,Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00967057,COMPLETED,Leukemia,DRUG: asparaginase|DRUG: dexamethasone|DRUG: idarubicin|DRUG: methotrexate|DRUG: mitoxantrone hydrochloride|DRUG: pegaspargase|DRUG: vincristine sulfate,Children's Cancer and Leukaemia Group,,INTERVENTIONAL
NCT00004230,Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00004230,COMPLETED,Cancer,DRUG: captopril|DRUG: cyclophosphamide|PROCEDURE: autologous bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT01225874,Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL,https://clinicaltrials.gov/study/NCT01225874,COMPLETED,Leukemia,DRUG: SC-PEG E. coli L-asparaginase|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: methotrexate|DRUG: pegaspargase|DRUG: prednisone|DRUG: vincristine sulfate,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT02238522,Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML,https://clinicaltrials.gov/study/NCT02238522,WITHDRAWN,Lymphoproliferative Malignancies|Acute Myeloid Leukemia,DRUG: ZEN003365,Zenith Epigenetics,,INTERVENTIONAL
NCT02568267,"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)",https://clinicaltrials.gov/study/NCT02568267,ACTIVE_NOT_RECRUITING,"Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor",DRUG: Entrectinib,Hoffmann-La Roche,,INTERVENTIONAL
NCT00005852,Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant,https://clinicaltrials.gov/study/NCT00005852,TERMINATED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes,BIOLOGICAL: anti-thymocyte globulin|BIOLOGICAL: filgrastim|BIOLOGICAL: muromonab-CD3|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: methylprednisolone|PROCEDURE: allogeneic bone marrow transplantation,H. Lee Moffitt Cancer Center and Research Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT01137643,"Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer",https://clinicaltrials.gov/study/NCT01137643,RECRUITING,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm,OTHER: biologic sample preservation procedure|OTHER: cytology specimen collection procedure,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00248547,Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00248547,COMPLETED,Cancer,DRUG: aprepitant|DRUG: dexamethasone|DRUG: ondansetron|DRUG: placebo,OHSU Knight Cancer Institute,,INTERVENTIONAL
NCT02819804,Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT02819804,TERMINATED,B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Adult Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia,DRUG: Dasatinib|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Nivolumab|OTHER: Pharmacological Study,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00301769,"SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia",https://clinicaltrials.gov/study/NCT00301769,TERMINATED,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes,DRUG: SJG-136,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00093678,"Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer",https://clinicaltrials.gov/study/NCT00093678,WITHDRAWN,"Cachexia|Lymphoma|Melanoma (Skin)|Ovarian Cancer|Pain|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: celecoxib|PROCEDURE: anticachectic therapy|PROCEDURE: nutritional support|PROCEDURE: pain therapy|PROCEDURE: supportive care/therapy,Eastern Cooperative Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT00005634,Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy,https://clinicaltrials.gov/study/NCT00005634,COMPLETED,"Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Prostate Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: vorinostat,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00898079,"Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer",https://clinicaltrials.gov/study/NCT00898079,COMPLETED,"Acute Undifferentiated Leukemia|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Childhood Acute Lymphoblastic Leukemia|Childhood Acute Myeloid Leukemia|Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Childhood Solid Neoplasm|Chronic Lymphocytic Leukemia|Hairy Cell Leukemia|Juvenile Myelomonocytic Leukemia|Mast Cell Leukemia|Neoplasm of Uncertain Malignant Potential|Prolymphocytic Leukemia|Secondary Acute Myeloid Leukemia|T-Cell Large Granular Lymphocyte Leukemia",OTHER: Cytology Specimen Collection Procedure,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT00957736,Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00957736,TERMINATED,Cancer,GENETIC: polymorphism analysis|OTHER: laboratory biomarker analysis,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00003887,Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00003887,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor,BIOLOGICAL: peripheral blood lymphocyte therapy,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04872790,"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",https://clinicaltrials.gov/study/NCT04872790,RECRUITING,B Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Mixed Phenotype Acute Leukemia|Recurrent B Acute Lymphoblastic Leukemia|Recurrent Mixed Phenotype Acute Leukemia,DRUG: Dasatinib|DRUG: Methotrexate|DRUG: Prednisone|BIOLOGICAL: Rituximab|DRUG: Venetoclax|BIOLOGICAL: Blinatumomab|PROCEDURE: Bone Marrow Aspiration and Biopsy|PROCEDURE: Lumbar Puncture|PROCEDURE: Biospecimen Collection,OHSU Knight Cancer Institute,AbbVie|Oregon Health and Science University,INTERVENTIONAL
NCT01005758,Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01005758,UNKNOWN,Leukemia,DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: etoposide phosphate|DRUG: hydrocortisone sodium succinate|DRUG: imatinib mesylate|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: pegaspargase|DRUG: prednisolone|DRUG: prednisone|DRUG: vincristine sulfate|OTHER: laboratory biomarker analysis|RADIATION: radiation therapy,Ohio State University Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00045292,Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00045292,COMPLETED,Cancer,DRUG: acyclovir|DRUG: acyclovir sodium|DRUG: valacyclovir,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00005804,Bone Marrow Transplantation in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00005804,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer,DRUG: cyclophosphamide|PROCEDURE: allogeneic bone marrow transplantation|RADIATION: radiation therapy,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00387426,Sunitinib in Treating Patients With Idiopathic Myelofibrosis,https://clinicaltrials.gov/study/NCT00387426,TERMINATED,"Accelerated Phase Chronic Myelogenous Leukemia|Acute Undifferentiated Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia|Mast Cell Leukemia|Meningeal Chronic Myelogenous Leukemia|Primary Myelofibrosis|Progressive Hairy Cell Leukemia, Initial Treatment|Prolymphocytic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Stage I Chronic Lymphocytic Leukemia|Stage II Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia|T-cell Large Granular Lymphocyte Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Hairy Cell Leukemia",DRUG: sunitinib malate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00900068,Blood Samples From Patients on a Clinical Trial to CINV During HSCT,https://clinicaltrials.gov/study/NCT00900068,TERMINATED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nausea and Vomiting|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,OTHER: immunoenzyme technique|OTHER: laboratory biomarker analysis|OTHER: medical chart review,OHSU Knight Cancer Institute,National Cancer Institute (NCI),OBSERVATIONAL
NCT00255710,Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer,https://clinicaltrials.gov/study/NCT00255710,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: peripheral blood stem cell transplantation|RADIATION: radiation therapy,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003107,Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors,https://clinicaltrials.gov/study/NCT00003107,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,BIOLOGICAL: recombinant interleukin-12,Indiana University School of Medicine,National Cancer Institute (NCI),INTERVENTIONAL
NCT00096096,Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00096096,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,DRUG: mycophenolate mofetil|DRUG: tacrolimus,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00004258,EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer,https://clinicaltrials.gov/study/NCT00004258,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: cilengitide,Indiana University School of Medicine,National Cancer Institute (NCI),INTERVENTIONAL
NCT00664677,Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia,https://clinicaltrials.gov/study/NCT00664677,TERMINATED,Leukemias|Acute Myeloid Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Adult T Cell Leukemia (ATL)|Chronic Myeloid Leukemia (CML-BP)|Chronic Lymphocytic Leukemia (CLL)|Myelodysplastic Syndrome (MDS)|Chronic Myelomonocytic Leukemia (CMML),DRUG: Terameprocol (EM-1421),Erimos Pharmaceuticals,,INTERVENTIONAL
NCT01094860,Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT01094860,COMPLETED,Leukemia,DRUG: Nelarabine,M.D. Anderson Cancer Center,GlaxoSmithKline,INTERVENTIONAL
NCT00079222,Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00079222,COMPLETED,Cancer,DRUG: itraconazole|DRUG: voriconazole,Jonsson Comprehensive Cancer Center,,INTERVENTIONAL
NCT00390793,Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.,https://clinicaltrials.gov/study/NCT00390793,COMPLETED,"Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|t(9;22)",DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dasatinib|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Methotrexate|DRUG: Prednisone|DRUG: Vincristine,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00788125,"Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors",https://clinicaltrials.gov/study/NCT00788125,TERMINATED,"Brain and Central Nervous System Tumors|Childhood Germ Cell Tumor|Extragonadal Germ Cell Tumor|Kidney Cancer|Liver Cancer|Lymphoma|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: carboplatin|DRUG: dasatinib|DRUG: etoposide phosphate|DRUG: ifosfamide|GENETIC: microarray analysis|GENETIC: western blotting|OTHER: immunohistochemistry staining method|OTHER: laboratory biomarker analysis|PROCEDURE: therapeutic conventional surgery|RADIATION: radiation therapy,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00357084,Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00357084,COMPLETED,Cancer,DRUG: methotrexate|DRUG: methylprednisolone|DRUG: prednisone,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00445952,Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00445952,COMPLETED,Cancer,OTHER: clinical observation|PROCEDURE: management of therapy complications,European Organisation for Research and Treatment of Cancer - EORTC,,OBSERVATIONAL
NCT00764907,Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00764907,UNKNOWN,Leukemia,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: ifosfamide|DRUG: leucovorin calcium|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: prednisone|DRUG: thioguanine|DRUG: vincristine sulfate|DRUG: vindesine,"University Hospital, Motol",,INTERVENTIONAL
NCT00558519,Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00558519,UNKNOWN,Leukemia,DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: pegaspargase|DRUG: thioguanine|DRUG: vincristine sulfate|RADIATION: radiation therapy,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT00089037,"Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation",https://clinicaltrials.gov/study/NCT00089037,COMPLETED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,DRUG: methotrexate|DRUG: sirolimus|DRUG: tacrolimus,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00060021,Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00060021,COMPLETED,Cancer,PROCEDURE: acupuncture therapy|PROCEDURE: management of therapy complications|PROCEDURE: pain therapy,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00006213,"BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia",https://clinicaltrials.gov/study/NCT00006213,COMPLETED,Adult Acute Promyelocytic Leukemia (M3)|Blastic Phase Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia,DRUG: BMS-214662|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00077181,3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies,https://clinicaltrials.gov/study/NCT00077181,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia,DRUG: cytarabine|DRUG: triapine|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00949117,Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer,https://clinicaltrials.gov/study/NCT00949117,TERMINATED,"Leukemia|Lymphoma|Malnutrition|Myelodysplastic Syndromes|Unspecified Childhood Solid Tumor, Protocol Specific|Weight Changes",DIETARY_SUPPLEMENT: Ensure|DIETARY_SUPPLEMENT: PediaSure|DRUG: cyproheptadine hydrochloride,University of South Florida,National Cancer Institute (NCI),INTERVENTIONAL
NCT03394365,Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy,https://clinicaltrials.gov/study/NCT03394365,RECRUITING,Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)|Solid Organ Transplant Complications|Lymphoproliferative Disorders|Allogeneic Hematopoietic Cell Transplant|Stem Cell Transplant Complications,BIOLOGICAL: tabelecleucel,Atara Biotherapeutics,,INTERVENTIONAL
NCT00993694,Methemoglobinemia in Young Patients With Hematologic Cancer or Aplastic Anemia Treated With Dapsone,https://clinicaltrials.gov/study/NCT00993694,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Methemoglobinemia|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm,DRUG: chemotherapy|DRUG: dapsone|OTHER: medical chart review|PROCEDURE: assessment of therapy complications,Vanderbilt University,National Cancer Institute (NCI),OBSERVATIONAL
NCT00005805,St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer,https://clinicaltrials.gov/study/NCT00005805,COMPLETED,"Chronic Myeloproliferative Disorders|Fatigue|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DIETARY_SUPPLEMENT: St. John's wort,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00020865,Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia,https://clinicaltrials.gov/study/NCT00020865,UNKNOWN,"Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Neutropenia|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: cefepime hydrochloride|DRUG: levofloxacin,Jonsson Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00949052,Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer,https://clinicaltrials.gov/study/NCT00949052,TERMINATED,Cancer,GENETIC: DNA analysis|GENETIC: polymorphism analysis|OTHER: laboratory biomarker analysis|OTHER: medical chart review|OTHER: questionnaire administration|PROCEDURE: assessment of therapy complications|PROCEDURE: evaluation of cancer risk factors,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00410657,Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00410657,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,BIOLOGICAL: alemtuzumab|DRUG: methylprednisolone|DRUG: prednisone|OTHER: flow cytometry|OTHER: immunologic technique|OTHER: pharmacological study,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003335,Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer,https://clinicaltrials.gov/study/NCT00003335,COMPLETED,Graft Versus Host Disease|Leukemia|Lymphoma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,BIOLOGICAL: anti-thymocyte globulin|DRUG: busulfan|DRUG: cyclosporine|DRUG: melphalan|DRUG: methylprednisolone|PROCEDURE: umbilical cord blood transplantation|RADIATION: radiation therapy,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00109993,Campath-1H + FK506 and Methylprednisolone for GVHD,https://clinicaltrials.gov/study/NCT00109993,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,BIOLOGICAL: alemtuzumab|DRUG: methylprednisolone|DRUG: tacrolimus,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT02311998,Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML,https://clinicaltrials.gov/study/NCT02311998,COMPLETED,"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|CD22 Positive|Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",DRUG: Bosutinib|BIOLOGICAL: Inotuzumab Ozogamicin,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT03860844,Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT03860844,TERMINATED,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia,DRUG: Isatuximab|DRUG: Dexamethasone or equivalent|DRUG: Fludarabine|DRUG: Cytarabine|DRUG: Liposomal daunorubicin|DRUG: Daunorubicin (nonliposomal)|DRUG: Idarubicin|DRUG: Filgrastim or equivalent|DRUG: Mitoxantrone|DRUG: Doxorubicin|DRUG: Vincristine|DRUG: Pegaspargase (PEG) Asparaginase|DRUG: Cyclophosphamide|DRUG: Etoposide|DRUG: Methotrexate|DRUG: L - Asparginase|DRUG: Hydroxyurea|DRUG: L - Asparaginase (Erwinase),Sanofi,,INTERVENTIONAL
NCT00569283,Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant,https://clinicaltrials.gov/study/NCT00569283,COMPLETED,Cancer,BIOLOGICAL: therapeutic allogeneic lymphocytes,Asan Medical Center,,INTERVENTIONAL
NCT00003331,Combination Chemotherapy in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00003331,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: fluorouracil|DRUG: leucovorin calcium|DRUG: topotecan hydrochloride,NYU Langone Health,National Cancer Institute (NCI),INTERVENTIONAL
NCT00002980,Decitabine in Treating Patients With Melanoma or Other Advanced Cancer,https://clinicaltrials.gov/study/NCT00002980,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: decitabine,California Cancer Consortium,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003451,Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00003451,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: recombinant interferon alfa|BIOLOGICAL: recombinant interleukin-12,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00003883,Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation,https://clinicaltrials.gov/study/NCT00003883,COMPLETED,Cancer,DRUG: fluconazole|DRUG: itraconazole,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00042900,Pyroxamide in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00042900,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: pyroxamide,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00010283,"Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon",https://clinicaltrials.gov/study/NCT00010283,COMPLETED,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Graft Versus Host Disease|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Testicular Germ Cell Tumor,DRUG: beclomethasone dipropionate,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00430118,Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00430118,COMPLETED,Leukemia,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: ifosfamide|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: prednisone|DRUG: thioguanine|DRUG: vincristine sulfate|DRUG: vindesine|RADIATION: radiation therapy,University Hospital Schleswig-Holstein,,INTERVENTIONAL
NCT00343369,Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00343369,UNKNOWN,Leukemia,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: doxorubicin hydrochloride|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: pegaspargase|DRUG: prednisolone|DRUG: teniposide|DRUG: thioguanine|DRUG: vincristine sulfate|RADIATION: radiation therapy,Universitätsklinikum Hamburg-Eppendorf,,INTERVENTIONAL
NCT00719563,American Ginseng in Treating Patients With Fatigue Caused by Cancer,https://clinicaltrials.gov/study/NCT00719563,COMPLETED,"Chronic Myeloproliferative Disorders|Fatigue|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: American ginseng|OTHER: placebo,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT00023790,Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin,https://clinicaltrials.gov/study/NCT00023790,TERMINATED,Breast Cancer|Head and Neck Cancer|Lymphoma|Metastatic Cancer|Non-melanomatous Skin Cancer|Sarcoma,DRUG: silicon phthalocyanine 4,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003082,Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00003082,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: monoclonal antibody A27.15|BIOLOGICAL: monoclonal antibody E2.3,University of Arizona,National Cancer Institute (NCI),INTERVENTIONAL
NCT04817761,SPARK-ALL: Calaspargase Pegol in Adults with ALL,https://clinicaltrials.gov/study/NCT04817761,ACTIVE_NOT_RECRUITING,Acute Lymphoblastic Leukemia,DRUG: Calaspargase pegol (S95015),Institut de Recherches Internationales Servier,"ADIR, a Servier Group company",INTERVENTIONAL
NCT01101412,Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies,https://clinicaltrials.gov/study/NCT01101412,WITHDRAWN,"Chronic Myeloproliferative Disorders|Infection|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: Edetate Calcium Disodium|DRUG: Ethanol|DRUG: Trimethoprim-sulfamethoxazole|OTHER: Hypertonic Saline,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00707083,Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00707083,COMPLETED,Leukemia,DRUG: dexamethasone|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: vincristine sulfate,"Prince of Wales Hospital, Shatin, Hong Kong",,INTERVENTIONAL
NCT00445497,Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia,https://clinicaltrials.gov/study/NCT00445497,UNKNOWN,"Brain and Central Nervous System Tumors|Lymphoma|Neutropenia|Psychosocial Effects of Cancer and Its Treatment|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: amoxicillin-clavulanate potassium|DRUG: ciprofloxacin|PROCEDURE: psychosocial assessment and care|PROCEDURE: quality-of-life assessment,Clatterbridge Centre for Oncology,,INTERVENTIONAL
NCT00096135,Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes,https://clinicaltrials.gov/study/NCT00096135,COMPLETED,Leukemia,BIOLOGICAL: filgrastim|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: etoposide|DRUG: leucovorin calcium|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: pegaspargase|DRUG: therapeutic hydrocortisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT00002704,Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00002704,COMPLETED,Leukemia,BIOLOGICAL: filgrastim|DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: daunorubicin hydrochloride|DRUG: dexamethasone|DRUG: etoposide|DRUG: leucovorin calcium|DRUG: liposomal cytarabine|DRUG: mercaptopurine|DRUG: mesna|DRUG: methotrexate|DRUG: therapeutic hydrocortisone|DRUG: thiotepa|DRUG: vincristine sulfate|RADIATION: low-LET electron therapy|RADIATION: low-LET photon therapy,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00006083,Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter,https://clinicaltrials.gov/study/NCT00006083,COMPLETED,"Cervical Cancer|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific|Veno-occlusive Disease",DRUG: Fragmin|OTHER: placebo,Jonsson Comprehensive Cancer Center,Upjohn,INTERVENTIONAL
NCT03095573,Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease,https://clinicaltrials.gov/study/NCT03095573,UNKNOWN,Celiac Disease,DEVICE: Lateral-viewing CapsoCam device|DEVICE: Axial-viewing capsule,"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico",IRCCS Policlinico S. Donato,INTERVENTIONAL
NCT03519984,EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia,https://clinicaltrials.gov/study/NCT03519984,TERMINATED,"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Myelodysplastic/Myeloproliferative Neoplasm|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|T Acute Lymphoblastic Leukemia",DRUG: Cytarabine|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Recombinant EphB4-HSA Fusion Protein|DRUG: Vincristine Liposomal,University of Southern California,"National Cancer Institute (NCI)|Vasgene Therapeutics, Inc|Whittier Foundation",INTERVENTIONAL
NCT00002504,Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer,https://clinicaltrials.gov/study/NCT00002504,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous/Nonmalignant Condition|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: aldesleukin|BIOLOGICAL: recombinant interferon alfa,Hoag Memorial Hospital Presbyterian,Cancer Biotherapy Research Group,INTERVENTIONAL
NCT01137825,Registry of Older Patients With Cancer,https://clinicaltrials.gov/study/NCT01137825,RECRUITING,"Chronic Myeloproliferative Disorders|Cognitive/Functional Effects|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific",,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00088543,Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant,https://clinicaltrials.gov/study/NCT00088543,COMPLETED,Acute Myelogenous Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Graft vs. Host Disease (GvHD),BIOLOGICAL: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|BIOLOGICAL: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)],"Genzyme, a Sanofi Company",,INTERVENTIONAL
NCT00376922,Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases,https://clinicaltrials.gov/study/NCT00376922,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Psychosocial Effects of Cancer and Its Treatment,PROCEDURE: music therapy,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003687,Treatment for Chronic Pain in Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00003687,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Pain|Precancerous/Nonmalignant Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: dextromethorphan hydrobromide|DRUG: morphine sulfate,NCIC Clinical Trials Group,,INTERVENTIONAL
NCT00499759,Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00499759,COMPLETED,Depression|Fatigue|Leukemia|Musculoskeletal Complications|Psychosocial Effects of Cancer and Its Treatment,BEHAVIORAL: Resting vitals|BEHAVIORAL: Body Composition|BEHAVIORAL: Timed Get-up and Go test (TGUG).|BEHAVIORAL: Cardiorespiratory assessment|BEHAVIORAL: Handgrip evaluation|BEHAVIORAL: Dynamic muscular endurance,UNC Lineberger Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04329728,The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies,https://clinicaltrials.gov/study/NCT04329728,RECRUITING,Lymphoid Malignancies,DRUG: AVM0703,AVM Biotechnology Inc,"Medpace, Inc.",INTERVENTIONAL
NCT03155191,Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT03155191,ACTIVE_NOT_RECRUITING,"Lymphoblastic Leukemia, Acute Adult",BIOLOGICAL: TBI-1501,Takara Bio Inc.,,INTERVENTIONAL
NCT00337168,S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00337168,COMPLETED,Leukemia,DRUG: clofarabine|DRUG: cytarabine,SWOG Cancer Research Network,National Cancer Institute (NCI),INTERVENTIONAL
NCT00253552,G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders,https://clinicaltrials.gov/study/NCT00253552,TERMINATED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Sarcoma,BIOLOGICAL: filgrastim|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: etoposide|DRUG: methotrexate|PROCEDURE: allogeneic bone marrow transplantation|RADIATION: radiation therapy,OHSU Knight Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00750009,Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial,https://clinicaltrials.gov/study/NCT00750009,COMPLETED,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific",OTHER: educational intervention,Case Comprehensive Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT04506086,Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL),https://clinicaltrials.gov/study/NCT04506086,TERMINATED,B-precursor Acute Lymphoblastic Leukemia,DRUG: Blinatumomab|DEVICE: Current Wearable Heatlth Monitoring System (CWHMS),Amgen,,INTERVENTIONAL
NCT00049465,Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer,https://clinicaltrials.gov/study/NCT00049465,COMPLETED,Cancer,PROCEDURE: fatigue assessment and management|PROCEDURE: management of therapy complications|PROCEDURE: psychosocial assessment and care,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00003269,Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors,https://clinicaltrials.gov/study/NCT00003269,COMPLETED,"Breast Cancer|Drug/Agent Toxicity by Tissue/Organ|Lung Cancer|Lymphoma|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific",BIOLOGICAL: sargramostim|DRUG: amifostine trihydrate|DRUG: cisplatin|DRUG: cyclophosphamide|DRUG: etoposide,Scripps Health,,INTERVENTIONAL
NCT00459212,"GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia",https://clinicaltrials.gov/study/NCT00459212,COMPLETED,Acute Undifferentiated Leukemia|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: GTI-2040|PROCEDURE: pharmacological study|PROCEDURE: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00281814,Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant,https://clinicaltrials.gov/study/NCT00281814,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Psychosocial Effects of Cancer and Its Treatment,PROCEDURE: psychosocial assessment and care,The Cleveland Clinic,National Cancer Institute (NCI),OBSERVATIONAL
NCT00281801,Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation,https://clinicaltrials.gov/study/NCT00281801,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Psychosocial Effects of Cancer and Its Treatment,PROCEDURE: psychosocial assessment and care|PROCEDURE: Quality of Life Assessments,Case Comprehensive Cancer Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00014391,Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation,https://clinicaltrials.gov/study/NCT00014391,COMPLETED,Cancer,BIOLOGICAL: palivizumab|DRUG: ribavirin,Fred Hutchinson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00860574,"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia",https://clinicaltrials.gov/study/NCT00860574,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia in Remission|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia,DRUG: treosulfan|DRUG: fludarabine phosphate|RADIATION: total-body irradiation|PROCEDURE: peripheral blood stem cell transplantation|DRUG: tacrolimus|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|DRUG: methotrexate,Fred Hutchinson Cancer Center,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",INTERVENTIONAL
NCT00935090,3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer,https://clinicaltrials.gov/study/NCT00935090,RECRUITING,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Adult Solid Tumor, Protocol Specific",DEVICE: 3'-deoxy-3'-[18F]fluorothymidine,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00666211,Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain,https://clinicaltrials.gov/study/NCT00666211,COMPLETED,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",OTHER: educational intervention|OTHER: Titrated pain management|OTHER: questionnaire administration,Vanderbilt-Ingram Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00062231,Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer,https://clinicaltrials.gov/study/NCT00062231,TERMINATED,"Chronic Myeloproliferative Disorders|Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Neutropenia|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: amoxicillin-clavulanate potassium|DRUG: ciprofloxacin|DRUG: moxifloxacin hydrochloride|PROCEDURE: management of therapy complications,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT00900120,Collecting and Storing Blood Samples From Patients With Cancer,https://clinicaltrials.gov/study/NCT00900120,WITHDRAWN,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Nonmalignant Neoplasm|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",,University of Medicine and Dentistry of New Jersey,National Cancer Institute (NCI),OBSERVATIONAL
NCT03576547,"Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",https://clinicaltrials.gov/study/NCT03576547,TERMINATED,"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Refractory Acute Lymphoblastic Leukemia|Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive|t(9;22)",DRUG: Dexamethasone|DRUG: Ponatinib Hydrochloride|BIOLOGICAL: Rituximab|DRUG: Venetoclax,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01295710,Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD),https://clinicaltrials.gov/study/NCT01295710,COMPLETED,GVHD|Adult Acute Myeloid Leukemia|Adult Acute Lymphoid Leukemia|Myelodysplastic Syndrome,BIOLOGICAL: US-ATG-F|BIOLOGICAL: Placebo,Neovii Biotech,,INTERVENTIONAL
NCT00424242,Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases,https://clinicaltrials.gov/study/NCT00424242,COMPLETED,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Metastatic Cancer|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Precancerous Condition|Secondary Myelofibrosis|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: Pemetrexed,Northwestern University,National Cancer Institute (NCI),INTERVENTIONAL
NCT00899951,Studying Fentanyl in Patients With Cancer,https://clinicaltrials.gov/study/NCT00899951,TERMINATED,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: fentanyl citrate|OTHER: pharmacological study,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,National Cancer Institute (NCI),OBSERVATIONAL
NCT00331513,Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes,https://clinicaltrials.gov/study/NCT00331513,COMPLETED,"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Promyelocytic Leukemia (M3)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes",DRUG: vorinostat|DRUG: idarubicin|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00951626,A Standardized Nursing Intervention Protocol for HCT Patients,https://clinicaltrials.gov/study/NCT00951626,COMPLETED,Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Psychosocial Effects of Cancer and Its Treatment|Therapy-related Toxicity,BEHAVIORAL: exercise intervention|BEHAVIORAL: telephone-based intervention|DIETARY_SUPPLEMENT: dietary intervention|OTHER: educational intervention|OTHER: questionnaire administration|PROCEDURE: allogeneic bone marrow transplantation|PROCEDURE: allogeneic hematopoietic stem cell transplantation|PROCEDURE: assessment of therapy complications|PROCEDURE: peripheral blood stem cell transplantation|PROCEDURE: psychosocial assessment and care|PROCEDURE: quality-of-life assessment|PROCEDURE: standard follow-up care,City of Hope Medical Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00726830,"Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer",https://clinicaltrials.gov/study/NCT00726830,TERMINATED,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Lymphoproliferative Disorder|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Pain|Precancerous Condition|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: methadone hydrochloride|DRUG: morphine sulfate|DRUG: oxycodone hydrochloride,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01085617,Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01085617,COMPLETED,Leukemia|Mucositis|Oral Complications,BIOLOGICAL: palifermin|BIOLOGICAL: rituximab|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: daunorubicin hydrochloride|DRUG: etoposide|DRUG: fludarabine phosphate|DRUG: imatinib mesylate|DRUG: melphalan|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: nelarabine|DRUG: pegaspargase|DRUG: vincristine sulfate|PROCEDURE: allogeneic hematopoietic stem cell transplantation|RADIATION: total-body irradiation,"University College, London",,INTERVENTIONAL
NCT00290628,Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer,https://clinicaltrials.gov/study/NCT00290628,TERMINATED,Chronic Myeloproliferative Disorders|Diamond-blackfan Anemia|Fanconi Anemia|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases,DRUG: anti-thymocyte globulin|DRUG: busulfan|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: filgrastim|DRUG: melphalan|DRUG: methylprednisolone|DRUG: mycophenolate mofetil|PROCEDURE: radiation therapy|PROCEDURE: umbilical cord blood transplantation,"Masonic Cancer Center, University of Minnesota",National Cancer Institute (NCI),INTERVENTIONAL
NCT00255684,"Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer",https://clinicaltrials.gov/study/NCT00255684,TERMINATED,Chronic Myeloproliferative Disorders|Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms,BIOLOGICAL: graft-versus-tumor induction therapy|DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: fludarabine phosphate|DRUG: mycophenolate mofetil|PROCEDURE: umbilical cord blood transplantation|RADIATION: radiation therapy,University of Rochester,,INTERVENTIONAL
NCT00770419,Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers,https://clinicaltrials.gov/study/NCT00770419,WITHDRAWN,"Brain and Central Nervous System Tumors|Chronic Myeloproliferative Disorders|Depression|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Psychosocial Effects of Cancer and Its Treatment|Unspecified Adult Solid Tumor, Protocol Specific",OTHER: medical chart review|OTHER: questionnaire administration|PROCEDURE: psychosocial assessment and care,"Rutgers, The State University of New Jersey",National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey,OBSERVATIONAL
NCT00886496,Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia,https://clinicaltrials.gov/study/NCT00886496,WITHDRAWN,"Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Myelodysplastic Syndromes|Neutropenia|Unspecified Childhood Solid Tumor, Protocol Specific",BIOLOGICAL: recombinant human mannose-binding lectin,"Enzon Pharmaceuticals, Inc.",National Cancer Institute (NCI),INTERVENTIONAL
NCT01316744,Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain,https://clinicaltrials.gov/study/NCT01316744,UNKNOWN,Cancer,DRUG: ketamine hydrochloride|OTHER: pharmacogenomic studies|OTHER: questionnaire administration|PROCEDURE: assessment of therapy complications|PROCEDURE: quality-of-life assessment,University of Glasgow,,INTERVENTIONAL
NCT00084916,"CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase",https://clinicaltrials.gov/study/NCT00084916,COMPLETED,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes,DRUG: temsirolimus|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00899496,Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants,https://clinicaltrials.gov/study/NCT00899496,COMPLETED,Cancer,OTHER: immunological diagnostic method|OTHER: physiologic testing,Wake Forest University Health Sciences,National Cancer Institute (NCI),OBSERVATIONAL
NCT00458744,Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment,https://clinicaltrials.gov/study/NCT00458744,WITHDRAWN,"Brain and Central Nervous System Tumors|Leukemia|Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: talotrexin|PROCEDURE: chemotherapy,Children's Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT03263572,"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",https://clinicaltrials.gov/study/NCT03263572,RECRUITING,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Recurrent Acute Lymphoblastic Leukemia|Refractory Acute Lymphoblastic Leukemia|t(9;22)",BIOLOGICAL: Blinatumomab|DRUG: Cytarabine|DRUG: Methotrexate|DRUG: Ponatinib,M.D. Anderson Cancer Center,National Cancer Institute (NCI)|Amgen|Takeda,INTERVENTIONAL
NCT00087204,"Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia",https://clinicaltrials.gov/study/NCT00087204,COMPLETED,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes,DRUG: becatecarin|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00686556,Total Marrow Irradiation for Refractory Acute Leukemia,https://clinicaltrials.gov/study/NCT00686556,COMPLETED,Acute Lymphoblastic Leukemia|Myelodysplastic Syndrome|Multiple Myeloma,DRUG: cyclophosphamide|DRUG: cyclosporine|DRUG: Fludarabine|DRUG: mycophenolate mofetil|RADIATION: total marrow irradiation|PROCEDURE: umbilical cord blood transplantation|BIOLOGICAL: Granulocyte colony-stimulating factor|BIOLOGICAL: HLA-matched related donor bone marrow,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL
NCT00295841,Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT00295841,COMPLETED,Leukemia,DRUG: clofarabine|DRUG: cytarabine,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT00006348,Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment,https://clinicaltrials.gov/study/NCT00006348,COMPLETED,"Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Nausea and Vomiting|Precancerous Condition|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific",DRUG: ondansetron|OTHER: placebo,Alliance for Clinical Trials in Oncology,National Cancer Institute (NCI),INTERVENTIONAL
NCT04644315,A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors,https://clinicaltrials.gov/study/NCT04644315,TERMINATED,"Neoplasms|Colorectal Neoplasms|Melanoma|Pancreatic Neoplasms|Sarcoma|Ovarian Neoplasms|Brain Neoplasms|Thyroid Neoplasms|Neuroendocrine Tumors|Cholangiocarcinoma|Salivary Gland Neoplasms|Head and Neck Neoplasms|Thyroid Cancer, Papillary|Lymphoma, Large-Cell, Anaplastic|Neoplasms by Site|Respiratory Tract Neoplasms|Thoracic Neoplasms|Respiratory Tract Diseases|Carcinoma, Bronchogenic|Bronchial Neoplasms|Intestinal Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Digestive System Diseases|Gastrointestinal Diseases|Colonic Diseases|Intestinal Diseases|Central Nervous System",DRUG: Alectinib,Hoffmann-La Roche,,INTERVENTIONAL
NCT00002520,Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer,https://clinicaltrials.gov/study/NCT00002520,COMPLETED,"Bladder Cancer|Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Lung Cancer|Lymphoma|Prostate Cancer|Testicular Germ Cell Tumor|Tobacco Use Disorder|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: nicotine|BEHAVIORAL: Usual Care,Eastern Cooperative Oncology Group,National Cancer Institute (NCI),INTERVENTIONAL
NCT02822495,Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies,https://clinicaltrials.gov/study/NCT02822495,NO_LONGER_AVAILABLE,"Epstein-Barr Virus (EBV) Infections|Lymphoproliferative Disorders|EBV+ Associated Lymphoma|EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)|Epstein-Barr Viremia|Lymphoma, AIDS-related|Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID)|Leiomyosarcoma (LMS)|Nasopharyngeal Carcinoma (NPC)|Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID)|Solid Organ Transplant Complications|Stem Cell Transplant Complications",BIOLOGICAL: tabelecleucel,Atara Biotherapeutics,,EXPANDED_ACCESS
NCT00036790,Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00036790,COMPLETED,"Breast Cancer|Chronic Myeloproliferative Disorders|Colorectal Cancer|Head and Neck Cancer|Leukemia|Lung Cancer|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic/Myeloproliferative Diseases|Prostate Cancer|Small Intestine Cancer|Unspecified Adult Solid Tumor, Protocol Specific",DRUG: doxorubicin hydrochloride|DRUG: motexafin gadolinium,"University of Wisconsin, Madison",National Cancer Institute (NCI),INTERVENTIONAL
NCT00801346,Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission,https://clinicaltrials.gov/study/NCT00801346,COMPLETED,Fatigue|Leukemia|Long-term Effects Secondary to Cancer Therapy in Children,OTHER: laboratory biomarker analysis|OTHER: metabolic assessment|OTHER: questionnaire administration|PROCEDURE: assessment of therapy complications|PROCEDURE: fatigue assessment and management|PROCEDURE: quality-of-life assessment,Vanderbilt University Medical Center,National Cancer Institute (NCI),OBSERVATIONAL
NCT00757614,"Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom",https://clinicaltrials.gov/study/NCT00757614,UNKNOWN,Bladder Cancer|Brain and Central Nervous System Tumors|Esophageal Cancer|Intraocular Melanoma|Kidney Cancer|Lymphoma|Melanoma (Skin)|Pancreatic Cancer|Transitional Cell Cancer of the Renal Pelvis and Ureter,GENETIC: DNA analysis|GENETIC: polymorphism analysis|OTHER: laboratory biomarker analysis|OTHER: questionnaire administration,Cancer Research UK,,OBSERVATIONAL
NCT00357708,"Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases",https://clinicaltrials.gov/study/NCT00357708,COMPLETED,"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Chronic Myelomonocytic Leukemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Philadelphia Chromosome Negative Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia",DRUG: decitabine|DRUG: vorinostat|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT04872595,A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant,https://clinicaltrials.gov/study/NCT04872595,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia (AML)|Acute Lymphoid Leukemia (ALL)|Myelodysplastic Syndromes (MDS),OTHER: Personalized rATG (P-rATG)|RADIATION: Hyper fractionated total body irradiation|DRUG: Thiotepa|DRUG: Cyclophosphamide|DRUG: GCSF|DRUG: Busulfan|DRUG: Melphalan|DRUG: Fludarabine,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL
NCT00301938,"7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes",https://clinicaltrials.gov/study/NCT00301938,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: 7-hydroxystaurosporine|DRUG: perifosine|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00217646,"Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia",https://clinicaltrials.gov/study/NCT00217646,COMPLETED,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Blastic Phase|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome,DRUG: Sorafenib Tosylate,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00003938,Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients,https://clinicaltrials.gov/study/NCT00003938,COMPLETED,Cancer,DRUG: liposomal amphotericin B,European Organisation for Research and Treatment of Cancer - EORTC,,INTERVENTIONAL
NCT01424982,Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01424982,ACTIVE_NOT_RECRUITING,"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Acute Lymphoblastic Leukemia|Adult Acute Lymphoblastic Leukemia in Complete Remission|B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Philadelphia Chromosome Positive|Untreated Adult Acute Lymphoblastic Leukemia",DRUG: Cyclophosphamide|DRUG: Cytarabine|DRUG: Dexamethasone|DRUG: Doxorubicin|DRUG: Doxorubicin Hydrochloride|OTHER: Laboratory Biomarker Analysis|DRUG: Methotrexate|DRUG: Ponatinib|DRUG: Ponatinib Hydrochloride|DRUG: Prednisone|BIOLOGICAL: Rituximab|DRUG: Vincristine|DRUG: Vincristine Sulfate,M.D. Anderson Cancer Center,,INTERVENTIONAL
NCT00008359,Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment,https://clinicaltrials.gov/study/NCT00008359,COMPLETED,Cancer,DRUG: caspofungin acetate|DRUG: liposomal amphotericin B,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01295463,Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer,https://clinicaltrials.gov/study/NCT01295463,UNKNOWN,Cancer,OTHER: questionnaire administration|OTHER: study of socioeconomic and demographic variables|PROCEDURE: assessment of therapy complications|PROCEDURE: fertility assessment and management|PROCEDURE: psychosocial assessment and care|PROCEDURE: quality-of-life assessment,Institut Català d'Oncologia,,OBSERVATIONAL
NCT00378781,Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection,https://clinicaltrials.gov/study/NCT00378781,WITHDRAWN,Cancer,DRUG: Heparin|DRUG: Minocycline-EDTA,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT01005277,Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT01005277,COMPLETED,Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Promyelocytic Leukemia With PML-RARA|Childhood Acute Lymphoblastic Leukemia in Remission|Childhood Acute Myeloid Leukemia|Childhood Acute Myeloid Leukemia in Remission|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia,OTHER: Laboratory Biomarker Analysis,Children's Oncology Group,National Cancer Institute (NCI),OBSERVATIONAL
NCT00351975,Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases,https://clinicaltrials.gov/study/NCT00351975,COMPLETED,"Accelerated Phase of Disease|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase|Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia|Previously Treated Myelodysplastic Syndrome|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Disease|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome",DRUG: Belinostat|DRUG: Azacitidine|OTHER: Laboratory Biomarker Analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00445731,A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant,https://clinicaltrials.gov/study/NCT00445731,COMPLETED,Cancer,BEHAVIORAL: exercise intervention|PROCEDURE: management of therapy complications|PROCEDURE: observation,University of Minnesota,,INTERVENTIONAL
NCT00400946,Treatment of Acute Lymphoblastic Leukemia in Children,https://clinicaltrials.gov/study/NCT00400946,COMPLETED,Drug/Agent Toxicity by Tissue/Organ|Leukemia,DRUG: asparaginase|DRUG: cyclophosphamide|DRUG: cytarabine|DRUG: dexamethasone|DRUG: dexrazoxane hydrochloride|DRUG: doxorubicin hydrochloride|DRUG: etoposide|DRUG: leucovorin calcium|DRUG: mercaptopurine|DRUG: methotrexate|DRUG: methylprednisolone|DRUG: pegaspargase|DRUG: prednisolone|DRUG: therapeutic hydrocortisone|DRUG: vincristine sulfate|RADIATION: radiation therapy,Dana-Farber Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL
NCT00131989,"Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia",https://clinicaltrials.gov/study/NCT00131989,COMPLETED,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia,DRUG: sorafenib tosylate|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT01656031,A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia,https://clinicaltrials.gov/study/NCT01656031,COMPLETED,Leukemia,DRUG: clofarabine|DRUG: cytarabine,Wake Forest University Health Sciences,National Cancer Institute (NCI),INTERVENTIONAL
NCT00101231,"Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia",https://clinicaltrials.gov/study/NCT00101231,TERMINATED,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia,DRUG: alvocidib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00904514,Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial,https://clinicaltrials.gov/study/NCT00904514,TERMINATED,Cancer,GENETIC: gene expression analysis|GENETIC: microarray analysis|GENETIC: mutation analysis|GENETIC: polymerase chain reaction|OTHER: flow cytometry|OTHER: immunoenzyme technique|OTHER: laboratory biomarker analysis,National Institutes of Health Clinical Center (CC),National Cancer Institute (NCI),OBSERVATIONAL
NCT00383474,Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase,https://clinicaltrials.gov/study/NCT00383474,COMPLETED,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Blastic Phase|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Disease|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: Bortezomib|OTHER: Laboratory Biomarker Analysis|DRUG: Tipifarnib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00470197,"Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia",https://clinicaltrials.gov/study/NCT00470197,COMPLETED,Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Malignant Neoplasm|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia,DRUG: alvocidib|DRUG: cytarabine|DRUG: mitoxantrone hydrochloride|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00098826,"SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes",https://clinicaltrials.gov/study/NCT00098826,COMPLETED,Acute Undifferentiated Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Myeloid Leukemia,DRUG: ispinesib|OTHER: laboratory biomarker analysis|OTHER: pharmacological study,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00095797,XK469R in Treating Patients With Refractory Hematologic Cancer,https://clinicaltrials.gov/study/NCT00095797,COMPLETED,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Refractory Chronic Lymphocytic Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Myelodysplastic Syndromes|Stage III Chronic Lymphocytic Leukemia|Stage IV Chronic Lymphocytic Leukemia|Untreated Adult Acute Myeloid Leukemia,DRUG: R(+)XK469|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00161187,Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor,https://clinicaltrials.gov/study/NCT00161187,COMPLETED,Cancer,BIOLOGICAL: therapeutic allogeneic lymphocytes,University of Medicine and Dentistry of New Jersey,National Cancer Institute (NCI),INTERVENTIONAL
NCT00588991,"Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders",https://clinicaltrials.gov/study/NCT00588991,COMPLETED,"Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|De Novo Myelodysplastic Syndrome|Essential Thrombocythemia|Hematopoietic and Lymphoid Cell Neoplasm|Myelodysplastic Syndrome|Polycythemia Vera|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Myelodysplastic Syndrome",DRUG: Carboplatin|OTHER: Laboratory Biomarker Analysis|DRUG: Topotecan Hydrochloride|DRUG: Veliparib,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00098423,"Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes",https://clinicaltrials.gov/study/NCT00098423,COMPLETED,Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes,DRUG: tanespimycin|DRUG: cytarabine,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00357305,"Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders",https://clinicaltrials.gov/study/NCT00357305,COMPLETED,"Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Blastic Phase Chronic Myelogenous Leukemia|Chronic Eosinophilic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|de Novo Myelodysplastic Syndromes|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Primary Myelofibrosis|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes",DRUG: vorinostat|DRUG: cytarabine|DRUG: etoposide|OTHER: pharmacological study|OTHER: laboratory biomarker analysis,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00045006,Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer,https://clinicaltrials.gov/study/NCT00045006,COMPLETED,Cancer,DRUG: vorinostat,Memorial Sloan Kettering Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL
NCT00538850,Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain,https://clinicaltrials.gov/study/NCT00538850,COMPLETED,Cancer,DRUG: Fentanyl sublingual spray|DRUG: Placebo,INSYS Therapeutics Inc,National Cancer Institute (NCI),INTERVENTIONAL
NCT00637637,External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases,https://clinicaltrials.gov/study/NCT00637637,UNKNOWN,Cancer,DRUG: indinavir sulfate|DRUG: ritonavir|RADIATION: radiation therapy,Oncology Institute of Southern Switzerland,,INTERVENTIONAL
NCT00462605,MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia,https://clinicaltrials.gov/study/NCT00462605,COMPLETED,"Adult Acute Lymphoblastic Leukemia in Remission|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Ringed Sideroblasts|Refractory Cytopenia With Multilineage Dysplasia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia",DRUG: entinostat|DRUG: sargramostim,National Cancer Institute (NCI),,INTERVENTIONAL
NCT00496860,Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies,https://clinicaltrials.gov/study/NCT00496860,COMPLETED,Progressive Metastatic Malignancies,BIOLOGICAL: ALT-801,Altor BioScience,,INTERVENTIONAL
NCT01793168,Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford,https://clinicaltrials.gov/study/NCT01793168,RECRUITING,"Rare Disorders|Undiagnosed Disorders|Disorders of Unknown Prevalence|Cornelia De Lange Syndrome|Prenatal Benign Hypophosphatasia|Perinatal Lethal Hypophosphatasia|Odontohypophosphatasia|Adult Hypophosphatasia|Childhood-onset Hypophosphatasia|Infantile Hypophosphatasia|Hypophosphatasia|Kabuki Syndrome|Bohring-Opitz Syndrome|Narcolepsy Without Cataplexy|Narcolepsy-cataplexy|Hypersomnolence Disorder|Idiopathic Hypersomnia Without Long Sleep Time|Idiopathic Hypersomnia With Long Sleep Time|Idiopathic Hypersomnia|Kleine-Levin Syndrome|Kawasaki Disease|Leiomyosarcoma|Leiomyosarcoma of the Corpus Uteri|Leiomyosarcoma of the Cervix Uteri|Leiomyosarcoma of Small Intestine|Acquired Myasthenia Gravis|Addison Disease|Hyperacusis (Hyperacousis)|Juvenile Myasthenia Gravis|Transient Neonatal Myasthenia Gravis|Williams Syndrome|Lyme Disease|Myasthenia Gravis|Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome)|Isolated Klippel-Feil Syndrome|Frasier Syndrome|Denys-Drash Syndrome|Beckwith-Wiedemann Syndrome|Emanuel Syndrome|Isolated Aniridia|Axenfeld-Rieger Syndrome|Aniridia-intellectual Disability Syndrome|Aniridia - Renal Agenesis - Psychomotor Retardation|Aniridia - Ptosis - Intellectual Disability - Familial Obesity|Aniridia - Cerebellar Ataxia - Intellectual Disability|Aniridia - Absent Patella|Aniridia|Peters Anomaly - Cataract|Peters Anomaly|Potocki-Shaffer Syndrome|Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11|Silver-Russell Syndrome Due to Imprinting Defect of 11p15|Silver-Russell Syndrome Due to 11p15 Microduplication|Syndromic Aniridia|WAGR Syndrome|Wolf-Hirschhorn Syndrome|4p16.3 Microduplication Syndrome|4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome|Autosomal Recessive Stickler Syndrome|Stickler Syndrome Type 2|Stickler Syndrome Type 1|Stickler Syndrome|Mucolipidosis Type 4|X-linked Spinocerebellar Ataxia Type 4|X-linked Spinocerebellar Ataxia Type 3|X-linked Intellectual Disability - Ataxia - Apraxia|X-linked Progressive Cerebellar Ataxia|X-linked Non Progressive Cerebellar Ataxia|X-linked Cerebellar Ataxia|Vitamin B12 Deficiency Ataxia|Toxic Exposure Ataxia|Unclassified Autosomal Dominant Spinocerebellar Ataxia|Thyroid Antibody Ataxia|Sporadic Adult-onset Ataxia of Unknown Etiology|Spinocerebellar Ataxia With Oculomotor Anomaly|Spinocerebellar Ataxia With Epilepsy|Spinocerebellar Ataxia With Axonal Neuropathy Type 2|Spinocerebellar Ataxia Type 8|Spinocerebellar Ataxia Type 7|Spinocerebellar Ataxia Type 6|Spinocerebellar Ataxia Type 5|Spinocerebellar Ataxia Type 4|Spinocerebellar Ataxia Type 37|Spinocerebellar Ataxia Type 36|Spinocerebellar Ataxia Type 35|Spinocerebellar Ataxia Type 34|Spinocerebellar Ataxia Type 32|Spinocerebellar Ataxia Type 31|Spinocerebellar Ataxia Type 30|Spinocerebellar Ataxia Type 3|Spinocerebellar Ataxia Type 29|Spinocerebellar Ataxia Type 28|Spinocerebellar Ataxia Type 27|Spinocerebellar Ataxia Type 26|Spinocerebellar Ataxia Type 25|Spinocerebellar Ataxia Type 23|Spinocerebellar Ataxia Type 22|Spinocerebellar Ataxia Type 21|Spinocerebellar Ataxia Type 20|Spinocerebellar Ataxia Type 2|Spinocerebellar Ataxia Type 19/22|Spinocerebellar Ataxia Type 18|Spinocerebellar Ataxia Type 17|Spinocerebellar Ataxia Type 16|Spinocerebellar Ataxia Type 15/16|Spinocerebellar Ataxia Type 14|Spinocerebellar Ataxia Type 13|Spinocerebellar Ataxia Type 12|Spinocerebellar Ataxia Type 11|Spinocerebellar Ataxia Type 10|Spinocerebellar Ataxia Type 1 With Axonal Neuropathy|Spinocerebellar Ataxia Type 1|Spinocerebellar Ataxia - Unknown|Spinocerebellar Ataxia - Dysmorphism|Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature|Spasticity-ataxia-gait Anomalies Syndrome|Spastic Ataxia With Congenital Miosis|Spastic Ataxia - Corneal Dystrophy|Spastic Ataxia|Rare Hereditary Ataxia|Rare Ataxia|Recessive Mitochondrial Ataxia Syndrome|Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature|Posterior Column Ataxia - Retinitis Pigmentosa|Post-Stroke Ataxia|Post-Head Injury Ataxia|Post Vaccination Ataxia|Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract|Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus|Non-hereditary Degenerative Ataxia|Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity|Olivopontocerebellar Atrophy - Deafness|NARP Syndrome|Myoclonus - Cerebellar Ataxia - Deafness|Multiple System Atrophy, Parkinsonian Type|Multiple System Atrophy, Cerebellar Type|Multiple System Atrophy|Maternally-inherited Leigh Syndrome|Machado-Joseph Disease Type 3|Machado-Joseph Disease Type 2|Machado-Joseph Disease Type 1|Leigh Syndrome|Late-onset Ataxia With Dementia|Infection or Post Infection Ataxia|GAD Ataxia|Hereditary Episodic Ataxia|Gliadin/Gluten Ataxia|Friedreich Ataxia|Fragile X-associated Tremor/Ataxia Syndrome|Familial Paroxysmal Ataxia|Exposure to Medications Ataxia|Episodic Ataxia With Slurred Speech|Episodic Ataxia Unknown Type|Episodic Ataxia Type 7|Episodic Ataxia Type 6|Episodic Ataxia Type 5|Episodic Ataxia Type 4|Episodic Ataxia Type 3|Episodic Ataxia Type 1|Epilepsy and/or Ataxia With Myoclonus as Major Feature|Early-onset Spastic Ataxia-neuropathy Syndrome|Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity|Early-onset Cerebellar Ataxia With Retained Tendon Reflexes|Early-onset Ataxia With Dementia|Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia|Dilated Cardiomyopathy With Ataxia|Cataract - Ataxia - Deafness|Cerebellar Ataxia, Cayman Type|Cerebellar Ataxia With Peripheral Neuropathy|Cerebellar Ataxia - Hypogonadism|Cerebellar Ataxia - Ectodermal Dysplasia|Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss|Brain Tumor Ataxia|Brachydactyly - Nystagmus - Cerebellar Ataxia|Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia|Autosomal Recessive Syndromic Cerebellar Ataxia|Autosomal Recessive Spastic Ataxia With Leukoencephalopathy|Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay|Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria|Autosomal Recessive Spastic Ataxia|Autosomal Recessive Metabolic Cerebellar Ataxia|Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine|Autosomal Recessive Ataxia, Beauce Type|Autosomal Recessive Ataxia Due to Ubiquinone Deficiency|Autosomal Recessive Ataxia Due to PEX10 Deficiency|Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia|Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency|Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency|Autosomal Recessive Congenital Cerebellar Ataxia|Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency|Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome|Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity|Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency|Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect|Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion|Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation|Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness|Autosomal Recessive Cerebellar Ataxia|Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly|Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation|Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy|Autosomal Dominant Spastic Ataxia Type 1|Autosomal Dominant Spastic Ataxia|Autosomal Dominant Optic Atrophy|Ataxia-telangiectasia Variant|Ataxia-telangiectasia|Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy|Autosomal Dominant Cerebellar Ataxia Type 4|Autosomal Dominant Cerebellar Ataxia Type 3|Autosomal Dominant Cerebellar Ataxia Type 2|Autosomal Dominant Cerebellar Ataxia Type 1|Autosomal Dominant Cerebellar Ataxia|Ataxia-telangiectasia-like Disorder|Ataxia With Vitamin E Deficiency|Ataxia With Dementia|Ataxia - Oculomotor Apraxia Type 1|Ataxia - Other|Ataxia - Genetic Diagnosis - Unknown|Acquired Ataxia|Adult-onset Autosomal Recessive Cerebellar Ataxia|Alcohol Related Ataxia|Multiple Endocrine Neoplasia|Multiple Endocrine Neoplasia Type II|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2|Multiple Endocrine Neoplasia, Type IV|Multiple Endocrine Neoplasia, Type 3|Multiple Endocrine Neoplasia (MEN) Syndrome|Multiple Endocrine Neoplasia Type 2B|Multiple Endocrine Neoplasia Type 2A|Atypical Hemolytic Uremic Syndrome|Atypical HUS|Wiedemann-Steiner Syndrome|Breast Implant-Associated Anaplastic Large Cell Lymphoma|Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)|Hemophagocytic Lymphohistiocytosis|Behcet&#39;s Disease|Alagille Syndrome|Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD)|Lowe Syndrome|Pitt Hopkins Syndrome|1p36 Deletion Syndrome|Jansen Type Metaphyseal Chondrodysplasia|Cockayne Syndrome|Chronic Recurrent Multifocal Osteomyelitis|CRMO|Malan Syndrome|Hereditary Sensory and Autonomic Neuropathy Type Ie|VCP Disease|Hypnic Jerking|Sleep Myoclonus|Mollaret Meningitis|Recurrent Viral Meningitis|CRB1|Leber Congenital Amaurosis|Retinitis Pigmentosa|Rare Retinal Disorder|KCNMA1-Channelopathy|Primary Biliary Cirrhosis|ZMYND11|Transient Global Amnesia|Glycogen Storage Disease|Alstrom Syndrome|White Sutton Syndrome|DNM1|EIEE31|Myhre Syndrome|Recurrent Respiratory Papillomatosis|Laryngeal Papillomatosis|Tracheal Papillomatosis|Refsum Disease|Nicolaides Baraitser Syndrome|Leukodystrophy|Tango2|Cauda Equina Syndrome|Rare Gastrointestinal Disorders|Achalasia-Addisonian Syndrome|Achalasia Cardia|Achalasia Icrocephaly Syndrome|Anal Fistula|Congenital Sucrase-Isomaltase Deficiency|Eosinophilic Gastroenteritis|Idiopathic Gastroparesis|Hirschsprung Disease|Rare Inflammatory Bowel Disease|Intestinal Pseudo-Obstruction|Scleroderma|Short Bowel Syndrome|Sacral Agenesis|Sacral Agenesis Syndrome|Caudal Regression|Scheuermann Disease|SMC1A Truncated Mutations (Causing Loss of Gene Function)|Cystinosis|Juvenile Nephropathic Cystinosis|Nephropathic Cystinosis|Kennedy Disease|Spinal Bulbar Muscular Atrophy|Warburg Micro Syndrome|Mucolipidoses|Mitochondrial Diseases|Mitochondrial Aminoacyl-tRNA Synthetases|Mt-aaRS Disorders|Hypertrophic Olivary Degeneration|Non-Ketotic Hyperglycinemia|Fish Odor Syndrome|Halitosis|Isolated Congenital Asplenia|Lambert Eaton (LEMS)|Biliary Atresia|STAG1 Gene Mutation|Coffin Lowry Syndrome|Borjeson-Forssman-Lehman Syndrome|Blau Syndrome|Arginase 1 Deficiency|HSPB8 Myopathy|Beta-Mannosidosis|TBX4 Syndrome|DHDDS Gene Mutations|MAND-MBD5-Associated Neurodevelopmental Disorder|Constitutional Mismatch Repair Deficiency (CMMRD)|SPATA5 Disorder|SPATA5L1 Related Disorder|Acrodysostosis|Multi-systematic Smooth Muscle Dysfunction Syndrome|CRELD1 (Cysteine Rich With EGF Like Domains 1)|GNB1 Syndrome|Pyruvate Dehydrogenase Complex Deficiency Disease|Beta Mannosidosis|Kbg Syndrome|Labrune Syndrome|Metachromatic Leukodystrophy (MLD)|Moyamoya Disease|OPHN1 Syndrome|Oculopharyngeal Muscular Dystrophy (OPMD)|TUBB3 Mutation|WOREE (WWOX-related Epileptic Encephalopathy|SCAR12|Skraban-Deardorff Syndrome|Hereditary Myopathy With Early Respiratory Failure",,Sanford Health,"National Ataxia Foundation|International WAGR Syndrome Association|4p- Support Group|ML4 Foundation|Cornelia de Lange Syndrome Foundation|Stickler Involved People|Kawasaki Disease Foundation|Klippel-Feil Syndrome Alliance|Klippel-Feil Syndrome Freedom|Hyperacusis Research Limited|Hypersomnia Foundation|Kabuki Syndrome Network|Kleine-Levin Syndrome Foundation|Leiomyosarcoma Direct Research Foundation|Marinesco-Sjogren Syndrome Support Group - NORD|Mucolipidosis Type IV (ML4) Foundation|People with Narcolepsy 4 People with Narcolepsy (PWN4PWN)|Soft Bones Incorporated|American Multiple Endocrine Neoplasia Support|Atypical Hemolytic Uremic Syndrome Foundation|All Things Kabuki|Wiedemann-Steiner Syndrome Foundation|Breast Implant Victim Advocates|PROS Foundation|American Behcet's Disease Association|Alstrom United Kingdom|Athymia|Curing Retinal Blindness Foundation|HSAN1E Society|1p36 Deletion Support and Awareness|The Alagille Syndrome Alliance|Autoinflammatory Alliance|Beyond Batten Disease Foundation|Bohring-Opitz Syndrome Foundation, INC|Cockayne Syndrome Network (Share and Care)|CRMO Foundation|Cure VCP Disease,INC|FOD Support|Cystinosis Research Foundation|Global DARE Foundation|Hypnic Jerk-Sleep Myoclonus Support Group|Jansen's Foundation|KCNMA1 Channelopathy International Advocacy Foundation|Kawasaki Disease Foundation Australia|Life with LEMS Foundation|Lowe Syndrome Association|The Malan Syndrome Foundation|Maple Syrup Urine Disease Family Support Group|International Association for Muscle Glycogen Storage Disease (IamGSD)|Myhre Syndrome Foundation|DNM1 Families|Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation|The PBCers Organization|Pitt Hopkins Research Foundation|Recurrent Meningitis Association|Recurrent Respiratory Papillomatosis Foundation|Remember the Girls|Smith-Kingsmore Syndrome Foundation|SPG Research Foundation|Team Telomere|Transient Global Amnesia Project|The Charlotte & Gwenyth Gray Foundation|The Cute Syndrome Foundation|The Maddi Foundation|White Sutton Syndrome Foundation|Zmynd11 Gene Disorder|Cauda Equina Foundation, Inc|Tango2 Research Foundation|Noah's Hope - Hope4Bridget Foundation|Project Sebastian|SMC1A Epilepsy Foundation|International Foundation for Gastrointestinal Disorders|Endosalpingiosis Foundation, Inc|International Sacral Agenesis/Caudal Regression Association (ISACRA)|Scheuermann's Disease Fund|Batten Disease Support and Research Association|Kennedy's Disease Association|Cure Mito Foundation|Warburg Micro Research Foundation|Cure Mucolipidosis|Riaan Research Initiative|CureARS A NJ Nonprofit Corporation|CACNA1H Alliance|IMBS Alliance|SHINE-Syndrome Foundaion|Non- Ketotic Hyperglycinemia (NKH) Crusaders|Hypertrophic Olivary Degeneration Association (HODA)|National Organization for Disorders of the Corpus Callosum (NODCC)|Team4Travis|Taylor's Tale Foundation|Lambert Eaton (LEMS) Family Association|BARE Inc|STAG1 Gene Foundation|Coffin Lowry Syndrome Foundation|BLFS Incorporate|Aniridia North America|Cure Blau Syndrome Foundation|ARG1D Foundation|CURE HSPB8 Myopathy|International Society of Mannosidosis and Related Disorders|TBX4Life|Cure DHDDS|MANDKind Foundation|Krishnan Family Foundation|SPATA Foundation|Acrodysostosis Support and Research|ACTA2 Alliance|ANA-Aniridia North America|CRELD1 Warriors|GNB1 Advocacy Group|Hope for PDCD Foundation|ISMRD - Beta Mannosidosis|KBG Syndrome Association|The LCC Foundation|MLD Foundation|MSA United Research Consortium|Moyamoya Foundation|OPMD Association|SKDEAS Foundation|The Foundation for Casey's Cure|TUBB3 Foundation|WWOX Foundation",OBSERVATIONAL
NCT04723602,"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults",https://clinicaltrials.gov/study/NCT04723602,COMPLETED,Ebola Virus Disease|Marburg Virus Disease,BIOLOGICAL: cAd3-Marburg|BIOLOGICAL: cAd3-EBO-S,Albert B. Sabin Vaccine Institute,ICON plc|Oklahoma Blood Institute,INTERVENTIONAL
